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The increased prevalence of obesity in our society is a cause for serious concern. Although                           
lifestyle and diet changes are successful ways to lose weight, a high percentage of people                           
weight cycle, also known as “yoyo” dieting. Evidence suggests weight cycling is no more                         
detrimental to a person’s health than remaining obese, but there still remains speculation over                         
the mechanisms involved in weight regain. One such model proposes the “food addiction”                       
model, whereby a deficit in reward function can lead to a blunted reward response to eating,                             
leading to over consumption.
In this thesis, I aim to clarify the role of mesolimbic dopamine signalling. Firstly, a short, medium                               
and chronic high fat (HF) feeding study was used to assess the development of changes in                             
dopamine signalling. Secondly, to assess the effects of a single weight cycle on dopamine                         
signalling, mice were fed control or HF diets, and swapped diet every 6 weeks. Finally, to assess                               
the effect of rapid weight change, lean and DIO mice swapped to a HF diet or control diet for a                                     
week, respectively.
Chronic HF diet increased dopamine­related gene expression and showed a similar expression                     
profile as short term HF feeding. Medium term HF feeding on the other hand showed a decrease                               
in dopamine related gene expression. Weight cycling appeared to have no clear uniform effect                         
on dopamine­related gene expression.
Rapid weight gain showed little change in dopamine­related gene expression in the reward                       
areas. Conversely, rapid weight loss induced a decrease in tyrosine hydroxylase (TH) and                       
dopamine receptor 2 (D2R) mRNA in the VTA, but with little change elsewhere.
In conclusion, my data does not support the “food addiction” model of changes in dopamine                           




Firstly, I would like to thank my supervisor, Professor Jimmy Bell, who gave me a great amount                               
of freedom to pursue my interests. Jimmy was also great support for when things didn’t go                             
according to plan, and was always available for a chat.
I would also like to thank everyone in the Metabolic and Molecular Imaging Group, including Áine,                             
Gina, Leigh, Louise, Jelena, Jim, Meliz, Mo and Tony. I really couldn’t have done my work without                               
everyone’s help.
Thanks also to everyone who helped me with my studies from the BIC, Jordi and Marzena.







Table of Contents 5
Table of Figures, Tables and Equations 10
Abbreviations 23
{1.} Introduction 29
{1.1} Definition of obesity 29
{1.2} Neural control of appetite 31
{1.2.1} The hypothalamus 31
{1.2.1.1} The periventricular zone 31
{1.2.1.2} The medial zone 32
{1.2.1.3} The lateral zone 32
{1.2.1.4} Arcuate nucleus 35
{1.2.1.5} Ventromedial nucleus of the hypothalamus (VMH) 35
{1.2.1.6} Dorsomedial nucleus of the hypothalamus (DMH) 36
{1.2.1.7} Paraventricular nucleus of the hypothalamus (PVN) 37
{1.2.1.8} Lateral hypothalamus (LH) 37
{1.2.2} The brainstem 38
{1.2.3} The vagus nerve 39
{1.2.4} Neurotransmitters of the hypothalamus 40
{1.2.4.1} Neuropeptide Y (NPY) 41
{1.2.4.2} Agouti-related peptide (AgRP) 44
{1.2.4.3} γ-Aminobutyric acid (GABA) and glutamate 47
{1.2.4.4} Orexins 47
{1.2.4.5} Melanin concentrating hormone (MCH) 48
{1.2.4.6} Endogenous opioids 49
{1.2.4.7} Endocannabinoids 50
{1.2.4.8} Melanocortins 51
{1.2.4.9} Cocaine- and amphetamine-regulated transcript (CART) 54
{1.2.4.10} Brain derived neurotrophic factor (BDNF) 57
{1.2.4.11} Corticotropin releasing hormone (CRH) 58
{1.2.4.12} Thyrotropin releasing hormone (TRH) 58
{1.2.4.13} Serotonin 59
{1.2.5} Mesolimbic dopamine system 61
{1.2.5.1} Dopamine signalling 61
{1.2.5.2} The mesolimbic dopamine pathway 66
{1.2.5.3} The effects of central and peripheral signals on dopamine signalling 70
{1.2.5.4} The mesolimbic dopamine pathway and obesity: a result of food addiction? 74
{1.3} External signals of energy balance 80
{1.3.1} Long-term modulation of energy balance 80
{1.3.1.1} Leptin 80
{1.3.1.2} Insulin 83
{1.3.2} Short-term modulation of energy balance 85
{1.3.2.1} Glucagon 85
{1.3.2.2} Ghrelin 86
{1.3.2.3} Peptide YY (PYY) 87
{1.3.2.4} Pancreatic polypeptide (PP) 87
{1.3.2.5} Glucagon-Like Peptide 1 and 2 (GLP-1 and GLP-2) 88
{1.3.2.6} Oxyntomodulin (OXM) 89
{1.3.2.7} Cholecystokinin (CCK) 89
{1.3.2.8} Glucose and lipid sensing 90
{1.4} Development and treatment of obesity 91
{1.4.1} Origins of obesity 91
{1.4.2} Mechanisms involved in the development of obesity 92
{1.4.3} Weight loss strategies 94
{1.4.3.1} Anti-obesity drugs 94
{1.4.3.2} Gut hormone therapy 96
{1.4.3.3} Bariatric surgery 97
5
{1.4.3.4} Diet and lifestyle changes 99
{1.5} Hypothesis and Aims of Thesis 107
{1.5.1} Hypothesis 107
{1.5.2} AIms of this thesis 107
{2.} Materials and Methods 108
{2.1} Experiment 1: The Effects of Rapid Weight Change on Metabolism and Appetite 108
{2.1.1} Animals and Treatment 108
{2.1.2} Diet Composition 108
{2.1.3} Experimental Protocol 110
{2.1.4} Methods 110
{2.2} Experiment 2: The Effects of a Single Weight Cycle on Metabolism and Appetite 112
{2.2.1} Animals and Treatment 112
{2.2.2} Experimental Model 112
{2.2.3} Methods 113
{2.3} Experiment 3: The Effects of Multiple Episodes of Weight Cycling on Metabolism and
Appetite
116
{2.3.1} Animals and Treatment 116
{2.3.2} Experimental Model 116
{2.3.3} Methods 119
{2.4} Methods used to Study the Effects of Weight Cycling on Metabolism and Appetite 120
{2.4.1} Whole Body MRI and 1H MRS 120
{2.4.1.1} Whole Body MRI 120
{2.4.1.2} Whole Body and Localised 1H MRS 123
{2.4.2} Intraperitoneal Glucose Tolerance Test (IPGTT) 126
{2.4.3} Indirect Calorimetry 126
{2.4.4} Acute Exercise 128
{2.4.5} Whole Body NMR 128
{2.4.6} Tissue Collection 128
{2.4.7} Metabolic Hormone Assay 129
{2.4.8} Gene Expression Analysis 129
{2.4.8.1} RNA  and DNA Extraction 129
{2.4.8.2} cDNA Synthesis 131
{2.4.8.3} Quantitative RT-PCR Analysis 131
{2.4.9} Statistical Analysis 131
{3.} The Effects of Rapid Weight Change on Metabolism and Appetite 135
{3.1} The Effect of Rapid Weight Change on Body weight 135
{3.1.1} Before diet swap 135
{3.1.2} Weight gain 136
{3.1.3} Weight loss 140
{3.2} The Effect of Rapid Weight Change on Food Intake 144
{3.2.1} Before diet swap 144
{3.2.2} Weight gain 145
{3.2.3} Weight loss 147
{3.3} The Effect of Rapid Weight Change on Calorie intake 149
{3.3.1} Before diet swap 149
{3.3.2} Weight gain 150
{3.3.3} Weight loss 152
{3.4} The Effect of Rapid Weight Change on Whole Body and Localised Adiposity 154
{3.4.1} Before diet swap 154
{3.4.2} Weight gain 156
{3.4.3} Weight loss 157
{3.5} The Effect of Rapid Weight Change on Hepatic Lipid Content 158
{3.5.1} Before diet swap 158
{3.5.2} Weight gain 159
{3.5.3} Weight loss 160
{3.6} The Effect of Rapid Weight Change on Adipose Tissue Content and Distribution 161
{3.6.1} Before diet swap 161
{3.6.2} Weight gain 164
{3.6.3} Weight loss 167
{3.7} The Effect of Rapid Weight Change on Glucose Tolerance 170
6
{3.7.1} Before diet swap 170
{3.7.2} Weight gain 173
{3.7.3} Weight loss 176
{3.8}The Effect of Rapid Weight Change on Indirect Calorimetry 179
{3.8.1} Before diet swap 179
{3.8.2} Weight gain 179
{3.8.3} Weight loss 189
{3.9} The effect of rapid weight change on acute exercise 198
{3.9.1} Before diet swap 198
{3.9.2} Weight gain 198
{3.9.3} Weight loss 206
{3.10} The effect of rapid weight change on metabolic hormones 213
{3.10.1} Before weight swap 213
{3.10.2} Weight gain 213
{3.10.3} Weight loss 220
{3.11} The effect of rapid weight change on organ mass 226
{3.11.1} Before diet swap 226
{3.11.2} Weight gain 226
{3.11.3} Weight loss 230
{3.12} The effect of rapid weight change on white adipose tissue mass 234
{3.12.1} Before diet swap 234
{3.12.2} Weight gain 234
{3.12.3} Weight loss 239
{3.13} The effect of rapid weight change on neuronal gene expression 244
{3.13.1} Before diet swap 244
{3.13.2} Weight gain 245
{3.13.3} Weight loss 251
{4.} The Effects of a Single Weight Cycle on Metabolism and Appetite. 257
{4.1} The Effect of a Single Weight Cycle on Body Weight 257
{4.1.1} Time point 1: 6 weeks of feeding, no diet swaps 257
{4.1.2} Time point 2: 12 weeks of feeding, one diet swap 259
{4.1.3} Time point 3: 18 weeks of feeding, two diet swaps 267
{4.2} The Effect of a Single Weight Cycle on Food Intake 278
{4.2.1} Time point 1: 6 weeks of feeding, no diet swaps 278
{4.2.2} Time point 2: 12 weeks of feeding, 1 diet swap 280
{4.2.3} Time point 3: 18 weeks of feeding, 2 diet swaps 288
{4.3} The effect of a single weight cycle on calorie intake 300
{4.3.1} Time point 1: 6 weeks of feeding, no diet swaps 300
{4.3.2} Time point 2: 12 weeks of feeding, 1 diet swap 302
{4.3.3} Time point: 18 weeks of feeding, 2 diet swaps 310
{4.4}The Effect of a Single Weight Cycle on Whole Body Adiposity 322
{4.4.1} Time point 1: 4 weeks of feeding, no diet swaps 322
{4.4.2} Time point 2: 10 weeks of feeding, 1 diet swap 323
{4.4.3} Time point 3: 6 weeks of feeding, 2 diet swaps 325
{4.5} The Effect of a Single Weight Cycle on Hepatic Lipid Content 327
{4.5.1} Time point 1: 4 weeks of feeding, no diet swaps 327
{4.5.2} Time point 2: 10 weeks of feeding, 1 diet swap 328
{4.5.3} Time point 3: 16 weeks of feeding, 2 diet swaps 329
{4.6} The Effect of a Single Weight Cycle on Muscle Lipid Content 330
{4.7} The Effect of a Single Weight Cycle on Adipose Tissue Content and Distribution 332
{4.7.1} Time point 1: 4 weeks of feeding, no diet swaps 332
{4.7.2} Time point 2: 10 weeks of feeding, 1 diet swap 336
{4.7.3} Time point 3: 16 weeks of feeding, 2 siet swaps 341
{4.8} The Effect of a Single Weight Cycle on Glucose Tolerance 347
{4.8.1} Time point 1: 5 weeks of feeding, no diet swaps 347
{4.8.2} Time point 2: 11 weeks of feeding, 1 diet swap 350
{4.8.3} Time point 3: 17 weeks of feeding, 2 diet swaps 352
{4.9} The Effect of a Single Weight Cycle on Indirect Calorimetry 355
{4.9.1} Time point 1: 6 weeks of feeding, no diet swaps 355
{4.9.2} Time point 2: 12 weeks of feeding, 1 diet swap 363
7
{4.9.3} Time point 3: 18 weeks of feeding, 2 diet swaps 378
{4.10} The Effect of a Single Weight Cycle on Acute Exercise 393
{4.10.1} Time point 1: 6 weeks of feeding, no diet swaps 393
{4.10.2} Time point 2: 12 weeks of feeding, 1 diet swap 399
{4.10.3} Time point 3: 18 weeks of feeding, 2 diet swaps 402
{4.11} The Effect of a Single Weight Cycle on Metabolic Hormones 410
{4.11.1} Time point 1: 6 weeks of feeding, no diet swaps 410
{4.11.2} Time point 2: 12 weeks of feeding, 1 diet swap 416
{4.11.3} Time point 2: 18 weeks of feeding, 2 diet swaps 422
{4.12} The Effect of a Single Weight Cycle on Organ Mass 429
{4.12.1} Time point 1: 6 weeks of feeding, no diet swaps 429
{4.12.2} Time point 2: 12 weeks of feeding, 1 diet swap 433
{4.12.3} Time point 3: 18 weeks of feeding, 2 diet swaps 437
{4.13} The Effect of a Single Weight Cycle on White Adipose Tissue Mass 441
{4.13.1} Time point 1: 6 weeks of feeding, no diet swaps 441
{4.13.2} Time point 2: 12 weeks of feeding, 1 diet swap 446
{4.13.3} Time point 3: 18 weeks of feeding, 2 diet swaps 454
{4.14} The effect of a single weight cycle on neuronal gene expression 462
{4.14.1} Time point 1: 6 weeks of feeding, no diet swaps 462
{4.14.2} Time point 2: 12 weeks of feeding, 1 diet swap 469
{4.14.3} Time point 3: 18 weeks of feeding, 2 diet swaps 478
{5.} The Effects of Multiple Weight Cycles on Metabolism and Appetite 485
{5.1} The Effect of Multiple Weight Cycles on Body Weight 485
{5.1.1} Time point 1: 12 weeks of feeding, 1 weight cycle 485
{5.1.2} Time point 2: 28 weeks of feeding, 3 weight cycles 493
{5.2} The Effect of Multiple Weight Cycles on Food Intake 510
{5.2.1} Time point 1: 12 weeks of feeding, 1 weight cycle 510
{5.2.2} Time point 2: 28 weeks of feeding, 3 weight cycles 521
{5.3} The Effect of Multiple Weight Cycles on Calorie Intake 541
{5.3.1} Time point 1: 12 weeks of feeding, 1 weight cycle 541
{5.3.2} Time point 2: 28 weeks of feeding, 3 weight cycles 551
{5.4} The Effect of Multiple Weight Cycles on Whole Body Adiposity 571
{5.4.1} Time point 1: 11 weeks of feeding, 1 weight cycle 571
{5.4.2} Time point 2: 27 weeks of feeding, 3 weight cycles 573
{5.5} The Effect of Multiple Weight Cycles on Hepatic Lipid Content 575
{5.5.1} Time point 1: 11 weeks of feeding, 1 weight cycle 575
{5.5.2} Time point 2: 27 weeks of feeding, 3 weight cycles 576
{5.6} The Effect of Multiple Weight Cycles on Adipose Tissue Content and Distribution 577
{5.6.1} Time point 1: 11 weeks of feeding, 1 weight cycle 577
{5.6.2} Time point 2: 27 weeks of feeding, 3 weight cycles 584
{5.7} The Effect of Multiple Weight Cycles on Glucose Tolerance 591
{5.7.1} Time point 1: 11 weeks of feeding, 1 weight cycle 591
{5.7.2} Time point 2: 27 weeks of feeding, 3 weight cycles 595
{5.8} The Effect of Multiple Weight Cycles on Indirect Calorimetry 599
{5.8.1} Time point 1: 12 weeks of feeding, 1 weight cycle 599
{5.8.2} Time point 2: 28 weeks of feeding, 3 weight cycles 615
{5.9} The Effect of Multiple Weight Cycles on Acute Exercise 631
{5.9.1} Time point 1: 12 weeks of feeding, 1 weight cycle 631
{5.9.2} Time point 2: 28 weeks of feeding, 3 weight cycles 634
{5.10} The Effect of Multiple Weight Cycles on Metabolic Hormones 643
{5.10.1} Time point 1: 12 weeks of feeding, 1 weight cycle 643
{5.10.2} Time point 2: 28 weeks of feeding, 3 weight cycles 651
{5.11} The Effect of Multiple Weight Cycles on Organ Mass 657
{5.11.1} Time point 1: 12 weeks of feeding, 1 weight cycle 657
{5.11.2} Time point 2: 28 weeks of feeding, 3 weight cycles 663
{5.12} The Effect of Multiple Weight Cycles on White Adipose Tissue Mass 669
{5.12.1} Time point 1: 12 weeks of feeding, 1 weight cycle 669
{5.12.2} Time point 2: 28 weeks of feeding, 3 weight cycles 678
{6.} Discussion 689
{6.1} Summary of results 689
8
{6.2} Overview of Literature 691
{6.3} The Effects of Weight Cycling on Body Weight and Food Intake 694
{6.4} The Effects of Weight Cycling on Fat Content and Body Composition 695
{6.5} The Effects of Weight Cycling on Glucose Tolerance and Metabolic Hormones 698
{6.6} The Effects of Weight Cycling on Energy expenditure and Motor Activity 702
{6.7} The Effects of Weight Cycling on Neuronal Gene Expression 705
{6.7.1} Homeostatic signalling in the hypothalamus 705
{6.7.2} Dopamine signalling in the brain 708
{6.7.2.1} Hypothalamus 709
{6.7.2.2} Reward areas 711
{6.8} Limitations of the study 718




Table of Figures, Tables and Equations
Figure {1.2.1.3.1}. Organisation of the hypothalamus 33
Figure {1.2.1.3.2}. Three-dimensional view of the rat hypothalamus showing the
major nuclei.
34
Table {1.2.4.0.1}. The major neurotransmitters involved with appetite regulation 40
Figure {1.2.4.8.1} POMC precursor peptide and major cleavage products in the
hypothalamus
52
Figure {1.2.4.9.1} Reciprocal regulation of arcuate neurons 57
Figure {1.2.5.1.1} Turnover of catecholamine neurotransmitters 61
Figure {1.2.5.1.2} DARPP-32 signalling cascade 64
Figure {1.2.5.2.1} Schematic of reward circuitry 66
Figure {1.2.5.4.1} Schematic diagram of the relationship between homeostatic and
hedonic systems for food intake.
79
Table {1.4.3.1.1} Mechanisms underlying obesity drugs 94
Table {2.1.2.0.1} Nutrient composition of control and high fat diets 109
Figure {2.1.4.0.1} Schematic of protocol used to study the effects of rapid weight
change on metabolism and appetite
111
Figure {2.2.3.0.1} Schematic of protocol used to study the effects of a single weight
cycle on metabolism and appetite
114
Figure {2.3.2.0.1} Schematic of protocol used to study the effects of multiple
episodes of weight cycling on metabolism and appetite
118
Figure {2.4.1.1.1} Piloting of the transverse MR images across the body 121
Equation {2.4.1.1.2} Equations for calculating tissue mass 122
Figure {2.4.1.2.1} Voxel localization on MR image in liver 123
Equation {2.4.1.2.2} Equation to calculate whole body adiposity 124
Figure {2.4.1.2.3} Whole body spectrum of a mouse 125
Equation {2.4.3.0.1} Equations for indirect calorimetry 127
Figure {2.4.8.1.1} Regions of interest used for gene expression analysis 130
Table {2.4.9.0.1} List of TaqMan probes used for gene expression assays (Applied
Biosystems, USA).
#N/A
Table {2.4.9.0.2} List of primer sequences used for gene expression assays (Stütz
et al., 2007. Supplied by Invitrogen, UK).
#N/A
Figure {3.1.2.0.1} The effect of one week of high fat feeding on body weight of lean
mice
136
Table {3.1.2.0.2} The effect of one week of high fat feeding on body weight of lean
mice
137
Figure {3.1.2.0.3} The effect of one week of high fat feeding on weekly body weight
change of lean mice
138
Figure {3.1.2.0.4} The effect of one week of high fat feeding on weekly body weight
change of lean mice
139
Figure {3.1.3.0.1} The effect of one week of normal fat feeding on body weight of
DIO mice
140
Table {3.1.3.0.2} The effect of one week of normal fat feeding on body weight of
DIO mice
141
Figure {3.1.3.0.3} The effect of one week of normal fat feeding on weekly body
weight change of DIO mice
142
Table {3.1.3.0.4} The effect of one week of normal fat feeding on weekly body
weight change of DIO mice
143
Figure {3.2.2.0.1} The effect of one week of high fat feeding on food intake of lean
mice
145
Table {3.2.2.0.2} The effect of one week of high fat feeding on food intake of lean
mice
146
Figure {3.2.3.0.1} The effect of one week of normal fat feeding on food intake of
DIO mice
147
Table {3.2.3.0.2} The effect of one week of normal fat feeding on food intake of
DIO mice
148
Figure {3.3.2.0.1} The effect of one week of high fat feeding on calorie intake of
lean mice
150




Figure {3.3.3.0.1} The effect of one week of normal fat feeding on calorie intake of
DIO mice
152
Figure {3.3.3.0.2} The effect of one week of normal fat feeding on calorie intake of
DIO mice
153
Figure {3.4.1.0.1} The effect of six weeks of high fat feeding on adiposity 155
Figure {3.4.2.0.1} The effect of one week of high fat feeding on adiposity of lean
mice
156
Figure {3.4.3.0.1} The effect of one week of normal fat feeding on adiposity of DIO
mice
157
Figure {3.5.1.0.1} The effect of six weeks of high fat feeding on IHCL content 158
Figure {3.5.2.0.1} The effect of one week of high fat feeding on IHCL content of
lean mice
159
Figure {3.5.3.0.1} The effect of one week of normal fat feeding on IHCL content of
DIO mice
160
Figure {3.6.1.0.1} The effect of six weeks of high fat feeding on total body WAT 161
Figure {3.6.1.0.2} The effect of six weeks of high fat feeding on subcutaneous and
internal WAT
162
Figure {3.6.1.0.3} The effect of six weeks of high fat feeding on internal:
subcutaneous WAT ratio
163
Figure {3.6.2.0.1} The effect of one week of high fat feeding on total body WAT of
lean mice
164
Figure {3.6.2.0.2} The effect of one week of high fat feeding on subcutaneous and
internal WAT of lean mice
165
Figure {3.6.2.0.3} The effect of one week of high fat feeding on internal:
subcutaneous WAT ratio of lean mice
166
Figure {3.6.3.0.1} The effect of one week of normal fat feeding on total body WAT
of DIO mice
167
Figure {3.6.3.0.2} The effect of one week of normal fat feeding on subcutaneous
and internal WAT of DIO mice
168
Figure {3.6.3.0.3} The effect of one week of normal fat feeding on internal:
subcutaneous WAT ratio of DIO mice
169
Figure {3.7.1.0.1} The effect of six weeks of high fat feeding glucose tolerance 171
Table {3.7.1.0.2} The effect of six weeks of high fat feeding glucose tolerance 172
Figure {3.7.2.0.1} The effect of one week of high fat feeding on glucose tolerance
of lean mice
174
Table {3.7.2.0.2} The effect of one week of high fat feeding on glucose tolerance of
lean mice
175
Figure {3.7.3.0.1} The effect of one week of normal fat feeding on glucose
tolerance of DIO mice
177
Figure {3.7.3.0.2} The effect of one week of normal fat feeding on glucose
tolerance of DIO mice
178
Figure {3.8.2.0.1} The effect of one week of high fat feeding on water intake of lean
mice measured using CLAMS metabolic cages
180
Figure {3.8.2.0.2} The effect of one week of high fat feeding on O2 consumption
and CO2 production of lean mice measured using CLAMS metabolic cages
182
Figure {3.8.2.0.3} The effect of one week of high fat feeding on RER and heat
production of lean mice measured using CLAMS metabolic cages
184
Table {3.8.2.0.4} The effect of one week of high fat feeding on indirect calorimetry
measurements in lean mice
185
Figure {3.8.2.0.5} The effect of one week of high fat feeding on activity of lean mice
measured using CLAMS metabolic cages
187
Table {3.8.2.0.6} The effect of one week of high fat feeding on activity in lean mice 188
Figure {3.8.3.0.1} The effect of one week of normal fat feeding on water intake of
DIO mice measured using CLAMS metabolic cages
189
Figure {3.8.3.0.2} The effect of one week of normal fat feeding on O2 consumption
and CO2 production of DIO mice measured using CLAMS metabolic cages
191
Figure {3.8.3.0.3} The effect of one week of normal fat feeding on RER and heat
production of DIO mice measured using CLAMS metabolic cages
193
Table {3.8.3.0.4} The effect of one week of normal fat feeding on indirect
calorimetry measurements in DIO mice
194
11
Figure {3.8.3.0.5} The effect of one week of normal fat feeding on activity of DIO
mice measured using CLAMS metabolic cages
196
Table {3.8.3.0.6} The effect of one week of high fat feeding on activity in lean mice 197
Figure {3.9.2.0.1} The effect of one week of high fat feeding on distance ran on a
treadmill of lean mice
199
Figure {3.9.2.0.2} The effect of one week of high fat feeding on distance ran on a
treadmill of lean mice correlated with body weight
200
Table {3.9.2.0.3} The effect of one week of high fat feeding on distance ran on a
treadmill of lean mice correlated with body weight
200
Table {3.9.2.0.4} The effect of one week of high fat feeding on lean mass and fat
mass in lean mice
201
Figure {3.9.2.0.5} The effect of one week of high fat feeding on lean mass and fat
mass in lean mice
202
Figure {3.9.2.0.6} The effect of one week of high fat feeding on correlation between
distance ran on a treadmill with lean mass and fat mass of lean mice
204
Table {3.9.2.0.7} The effect of one week of high fat feeding on correlation between
distance ran on a treadmill with lean mass and fat mass of lean mice
205
Figure {3.9.3.0.1} The effect of one week of normal fat feeding on distance ran on a
treadmill of DIO mice
206
Figure {3.9.3.0.2} The effect of one week of normal fat feeding on distance ran on a
treadmill of DIO mice correlated with body weight
207
Table {3.9.3.0.3} The effect of one week of normal fat feeding on distance ran on a
treadmill of DIO mice correlated with body weight
207
Table {3.9.3.0.4} The effect of one week of normal fat feeding on lean mass and fat
mass in DIO mice
208
Figure {3.9.3.0.5} The effect of one week of normal fat feeding on lean mass and
fat mass in DIO mice
209
Figure {3.9.3.0.6} The effect of one week of normal fat feeding on correlation
between distance ran on a treadmill with lean mass and fat mass of DIO mice
211
Table {3.9.3.0.7} The effect of one week of normal fat feeding on correlation
between distance ran on a treadmill with lean mass and fat mass of DIO mice
212
Figure {3.10.2.0.1} The effect of one week of high fat feeding on blood glucose and
β-ketone concentration of lean mice
214
Figure {3.10.2.0.2} The effect of one week of high fat feeding on plasma leptin and
resistin concentration of lean mice
215
Figure {3.10.2.0.3} The effect of one week of high fat feeding on plasma insulin, c-
peptide and GIP concentration of lean mice
216
Figure {3.10.2.0.4} The effect of one week of high fat feeding on plasma glucagon
and ghrelin concentration of lean mice
217
Figure {3.10.2.0.5} The effect of one week of high fat feeding on plasma
inflammatory cytokine concentration of lean mice
218
Table {3.10.2.0.6} The effect of one week of high fat feeding on blood and plasma
measurements of lean mice
219
Figure {3.10.3.0.1} The effect of one week of normal fat feeding on blood glucose
and β-ketone concentration of DIO mice
220
Figure {3.10.3.0.2} The effect of one week of normal fat feeding on plasma leptin
and resistin concentration of DIO mice
221
Figure {3.10.3.0.3} The effect of one week of normal fat feeding on plasma insulin,
c-peptide and GIP concentration of DIO mice
222
Figure {3.10.3.0.4} The effect of one week of normal fat feeding on plasma
glucagon and ghrelin concentration of DIO mice
223
Figure {3.10.3.0.5} The effect of one week of high fat feeding on plasma
inflammatory cytokine concentration of lean mice
224
Table {3.10.3.0.6} The effect of one week of normal fat feeding on blood and
plasma measurements of DIO mice
225
Figure {3.11.2.0.1} Effect of one week of high fat feeding on organ mass of lean
mice
227
Figure {3.11.2.0.2} Effect of one week of high fat feeding on organ weight as a
percentage of body weight of lean mice
228
12
Table {3.11.2.0.3} Effect of one week of high fat feeding on organ weight in gram
and as a percentage of body weight of lean mice
229
Figure {3.11.3.0.1} Effect of one week of normal fat feeding on organ mass of DIO
mice
231
Figure {3.11.3.0.2} Effect of one week of normal fat feeding on organ weight as a
percentage of body weight of DIO mice
232
Table {3.11.3.0.3} Effect of one week of normal fat feeding on organ weight in
grams and as a percentage of body weight of DIO mice
233
Figure {3.12.2.0.1} Effect of one week of high fat feeding on total WAT mass of
lean mice
235
Table {3.12.2.0.2} Effect of one week of high fat feeding on WAT of lean mice 235
Figure {3.12.2.0.3} Effect of one week of high fat feeding on WAT mass of lean
mice
236
Figure {3.12.2.0.4} Effect of one week of high fat feeding on WAT mass as a
percentage of body weight of lean mice
237
Figure {3.12.2.0.5} Effect of one week of high fat feeding on WAT distribution of
lean mice
238
Table {3.12.2.0.6} Effect of one week of high fat feeding on WAT distribution of
lean mice
238
Figure {3.12.3.0.1} Effect of one week of normal fat feeding on total WAT mass of
DIO mice
239
Table {3.12.3.0.2} Effect of one week of normal fat feeding on WAT of DIO mice 240
Figure {3.12.3.0.3} Effect of one week of normal fat feeding on WAT mass of DIO
mice
241
Figure {3.12.3.0.4} Effect of one week of normal fat feeding on WAT mass of DIO
mice
242
Figure {3.12.3.0.5} Effect of one week of normal fat feeding on WAT distribution of
DIO mice
243
Table {3.12.3.0.6} Effect of one week of normal fat feeding on WAT distribution of
DIO mice
243
Figure {3.13.2.0.1} The effect of one week of high fat feeding on neuronal gene
expression in the hypothalamus of lean mice
245
Figure {3.13.2.0.2} The effect of one week of high fat feeding on dopamine-related
gene expression in the hypothalamus and reward areas of lean mice
247
Figure {3.13.2.0.3} The effect of one week of high fat feeding on leptin receptor
gene expression in the hypothalamus and VTA, and MC4R gene expression in the
hypothalamus of lean mice
248
Table {3.13.2.0.4} The effect of one week of high fat feeding on gene expression in
the hypothalamus and VTA of lean mice
249
Table {3.13.2.0.5} The effect of one week of high fat feeding on gene expression in
the NAc and PFC of lean mice
250
Figure {3.13.3.0.1} The effect of one week of normal fat feeding on neuronal gene
expression in the hypothalamus of DIO mice
251
Figure {3.13.3.0.2} The effect of one week of normal fat feeding on dopamine-
related gene expression in the hypothalamus and reward areas of DIO mice
253
Figure {3.13.3.0.3} The effect of one week of normal fat feeding on leptin receptor
gene expression in the hypothalamus and VTA, and MC4R gene expression in the
hypothalamus of lean mice
254
Table {3.13.3.0.4} The effect of one week of normal fat feeding on gene expression
in the hypothalamus and VTA of DIO mice
255
Table {3.13.3.0.5} The effect of one week of normal fat feeding on gene expression
in the NAc and PFC of DIO mice
256
Figure {4.1.1.0.1} The effect of 6 weeks of high fat feeding on body weight 257
Figure {4.1.1.0.2} The effect of 6 weeks of high fat feeding on weekly body weight
change
258
Figure {4.1.2.0.1} The effect of maintained weight change on body weight 261
Figure {4.1.2.0.2} The effect of 12 weeks of high fat feeding on weekly body weight
change
262




Figure {4.1.2.0.4} The effect of maintained weight loss on weekly body weight
change
266
Figure {4.1.3.0.1} The effect of a single weight cycle on body weight 269
Table {4.1.3.0.2} The effect of a single weight cycle on body weight 270
Figure {4.1.3.0.3} The effect of 18 weeks of high fat feeding on weekly body weight
change
271
Figure {4.1.3.0.4} The effect of a single weight cycle ending with weight loss on
weekly body weight change
273
Figure {4.1.3.0.5} The effect of a single weight cycle ending with weight gain on
weekly body weight change
275
Table {4.1.3.0.6} The effect of a single weight cycle on weekly body weight change 276
Table {4.1.3.0.7} The effect of a single weight cycle on weekly percentage body
weight change
277
Figure {4.2.1.0.1} The effect of six weeks high fat feeding on weekly food intake 278
Figure {4.2.1.0.2} The effect of six weeks high fat feeding on cumulative food
intake
279
Figure {4.2.2.0.1} The effect of 12 weeks high fat feeding on weekly food intake 280
Figure {4.2.2.0.2} The effect of maintained weight gain weekly food intake 282
Figure {4.2.2.0.3} The effect of maintained weight gain on weekly food intake 283
Figure {4.2.2.0.4} The effect of six weeks high fat feeding from week 7 to 12 on
cumulative food intake
284
Figure {4.2.2.0.5} The effect of six weeks high fat feeding after normal fat feeding
from week seven to twelve on cumulative food intake
286
Figure {4.2.2.0.6} The effect of six weeks normal fat feeding after high fat fat
feeding from week seven to twelve on cumulative food intake
287
Figure {4.2.3.0.1} The effect of six weeks high fat feeding from week thirteen to
eighteen on weekly food intake
288
Figure {4.2.3.0.2} The effect of a single weight cycle ending with weight loss on
weekly food intake
290
Figure {4.2.3.0.3} The effect of a single weight cycle ending with weight gain on
weekly food intake
291
Table {4.2.3.0.4} The effect of a single weight cycle on weekly food intake 292
Table {4.2.3.0.5} The effect of a single weight cycle on weekly food intake
normalised to total cage weight0.75
293
Figure {4.2.3.0.6} The effect of six weeks high fat feeding from week thirteen to
eighteen on cumulative food intake
294
Figure {4.2.3.0.7} The effect of a single weight cycle ending with weight loss on
cumulative food intake
296
Figure {4.2.3.0.8} The effect of a single weight cycle ending with weight gain on
cumulative food intake
297
Table {4.2.3.0.9} The effect of a single weight cycle on periodic cumulative food
intake
298
Table {4.2.3.0.10} The effect of a single weight cycle on periodic cumulative food
intake normalised to total cage weight0.75
299
Figure {4.3.1.0.1} The effect of six weeks high fat feeding from week one to six on
weekly calorie intake
300
Figure {4.3.1.0.2} The effect of six weeks high fat feeding from week one to six on
cumulative calorie intake
301
Figure {4.3.2.0.1} The effect of 12 weeks high fat feeding on weekly calorie intake 302
Figure {4.3.2.0.2} The effect of maintained weight gain on weekly calorie intake 304
Figure {4.3.2.0.3} The effect maintained weight loss on weekly calorie intake 305
Figure {4.3.2.0.4} The effect of six weeks high fat feeding from week 7 to 12 on
cumulative calorie intake
306
Figure {4.3.2.0.5} The effect of six weeks high fat feeding after normal fat feeding
from week seven to twelve on cumulative calorie intake
308
Figure {4.3.2.0.6} The effect of six weeks normal fat feeding after high fat feeding
from week seven to twelve on cumulative calorie intake
309
Figure {4.3.3.0.1} The effect of 18 weeks high fat feeding on weekly calorie intake 310




Figure {4.3.3.0.3} The effect of a single weight cycle ending with weight gain on
weekly calorie intake
313
Table {4.3.3.0.4} The effect of a single weight cycle on weekly calorie intake 314
Table {4.3.3.0.5} The effect of a single weight cycle on weekly calorie intake 315
Figure {4.3.3.0.6} The effect of six weeks high fat feeding from week thirteen to
eighteen on cumulative calorie intake
316
Figure {4.3.3.0.7} The effect of a single weight cycle ending with weight loss on
cumulative calorie intake
318
Figure {4.3.3.0.8} The effect of a single weight cycle ending with weight gain on
cumulative calorie intake
319
Table {4.3.3.0.9} The effect of a single weight cycle on periodic cumulative calorie
intake
320
Table {4.3.3.0.10} The effect of a single weight cycle on periodic cumulative calorie
intake normalised to total cage weight0.75
321
Figure {4.4.1.0.1} The effect of four weeks of high fat feeding on adiposity 322
Figure {4.4.2.0.1} The effect of maintained weight loss and gain on adiposity 324
Figure {4.4.3.0.1} The effect of a single weight cycle on adiposity 326
Figure {4.5.1.0.1} The effect of four weeks of high fat feeding on IHCL content 327
Figure {4.5.2.0.1} The effect of maintained weight loss and gain on IHCL content 328
Figure {4.5.3.0.1} The effect of a single weight cycle on IHCL content 329
Figure {4.6.0.0.1} The effect of a single weight cycle on IMCL content 330
Table {4.6.0.0.2} The effect of a single weight cycle on IMCL content 331
Figure {4.7.1.0.1} The effect of four weeks of high fat feeding on total body WAT 332
Figure {4.7.1.0.2} The effect of four weeks of high fat feeding on subcutaneous
WAT
333
Figure {4.7.1.0.3} The effect of four weeks of high fat feeding on internal WAT 334
Figure {4.7.1.0.4} The effect of four weeks of high fat feeding on internal:
subcutaneous WAT ratio
335
Figure {4.7.2.0.1} The effect of maintained weight loss and gain on total body WAT 336
Figure {4.7.2.0.2} The effect of maintained weight loss and gain on subcutaneous
WAT
337
Figure {4.7.2.0.3} The effect of maintained weight loss and gain on internal WAT 339
Figure {4.7.2.0.4} The effect of maintained weight loss and gain on internal:
subcutaneous WAT ratio
340
Figure {4.7.3.0.1} The effect of a single weight cycle on total body WAT 342
Figure {4.7.3.0.2} The effect of a single weight cycle on subcutaneous WAT 344
Figure {4.7.3.0.3} The effect of a single weight cycle on internal WAT 345
Figure {4.7.3.0.4} The effect of a single weight cycle on internal:subcutaneous
WAT ratio
346
Figure {4.8.1.0.1} The effect of five weeks of high fat feeding glucose tolerance 348
Table {4.8.1.0.2} The effect of five weeks of high fat feeding glucose tolerance 349
Figure {4.8.2.0.1} The effect of maintained weight loss and gain on glucose
tolerance
350
Table {4.8.2.0.2} The effect of maintained weight loss and gain on glucose
tolerance
350
Figure {4.8.2.0.3} The effect of maintained weight loss and gain on glucose
tolerance
351
Figure {4.8.3.0.1} The effect of a single weight cycle on glucose tolerance 353
Table {4.8.3.0.2} The effect of a single weight cycle on glucose tolerance 353
Figure {4.8.3.0.3} The effect of a single weight cycle on glucose tolerance 354
Figure {4.9.1.0.1} The effect of 6 weeks of high fat feeding on cumulative water
intake measured using CLAMS metabolic cages
355
Figure {4.9.1.0.2} The effect of 6 weeks of high fat feeding on O2 consumption and
CO2 production measured using CLAMS metabolic cages
357
Figure {4.9.1.0.3} The effect of 6 weeks of high fat feeding on RER and heat
production measured using CLAMS metabolic cages
358
Table {4.9.1.0.4} The effect of 6 weeks of high fat feeding on indirect calorimetry
measurements
359
Figure {4.9.1.0.5} The effect of 6 weeks of high fat feeding on activity measured
using CLAMS metabolic cages
361
15
Table {4.9.1.0.6} The effect of 6 weeks of high fat feeding on activity 362
Figure {4.9.2.0.1} The effect of maintained weight change on cumulative water
intake measured using CLAMS metabolic cages
364
Figure {4.9.2.0.2} The effect of maintained weight change on O2 consumption
measured using CLAMS metabolic cages
366
Figure {4.9.2.0.3} The effect of maintained weight change on CO2 consumption
measured using CLAMS metabolic cages
367
Figure {4.9.2.0.4} The effect of maintained weight change on RER measured using
CLAMS metabolic cages
369
Figure {4.9.2.0.5} The effect of maintained weight change on heat production
measured using CLAMS metabolic cages
370
Table {4.9.2.0.6} The effect of maintained weight change on indirect calorimetry
measurements
371
Figure {4.9.2.0.7} The effect of maintained weight change on ambulatory activity
using CLAMS metabolic cages
374
Figure {4.9.2.0.8} The effect of maintained weight change on rearing activity using
CLAMS metabolic cages
375
Figure {4.9.2.0.9} The effect of maintained weight change on activity using CLAMS
metabolic cages
376
Table {4.9.2.0.10}  The effect of maintained weight change on activity 377
Figure {4.9.3.0.1} The effect of a single weight cycle on cumulative water intake
measured using CLAMS metabolic cages
379
Figure {4.9.3.0.2} The effect of a single weight cycle on O2 consumption measured
using CLAMS metabolic cages
381
Figure {4.9.3.0.3} The effect of a single weight cycle on CO2 consumption
measured using CLAMS metabolic cages
382
Figure {4.9.3.0.4} The effect of maintained weight change on RER measured using
CLAMS metabolic cages
384
Figure {4.9.3.0.5} The effect of a single weight cycle on heat production measured
using CLAMS metabolic cages
385
Table {4.9.3.0.6} The effect of a single weight cycle on indirect calorimetry
measurements
386
Figure {4.9.3.0.7} The effect of a single weight cycle on ambulatory activity using
CLAMS metabolic cages
389
Figure {4.9.3.0.8} The effect of a single weight cycle on rearing activity using
CLAMS metabolic cages
390
Figure {4.9.3.0.9} The effect of a single weight cycle on activity using CLAMS
metabolic cages
391
Table {4.9.3.0.10}  The effect of a single weight cycle on activity 392
Figure {4.10.1.0.1} The effect of 6 weeks of high fat feeding on distance ran on a
treadmill of lean mice
393
Figure {4.10.1.0.2} The effect of 6 weeks of high fat feeding on distance ran on a
treadmill correlated with body weight
394
Figure {4.10.1.0.3} The effect of 6 weeks of high fat feeding on lean mass and fat
mass assessed using EchoMRI
396
Figure {4.10.1.0.4} The effect of 6 weeks of high fat feeding on correlation between
distance ran on a treadmill with lean mass and fat mass
398
Figure {4.10.2.0.1} The effect of maintained weight change on distance ran on a
treadmill of lean mice
399
Figure {4.10.2.0.2} The effect of maintained weight change on distance ran on a
treadmill correlated with body weight
401
Table {4.10.2.0.3} The effect of maintained weight change on distance ran on a
treadmill correlated with body weight
401
Figure {4.10.3.0.1} The effect of a single weight cycle on distance ran on a
treadmill of lean mice
402
Figure {4.10.3.0.2} The effect of a single weight cycle on distance ran on a
treadmill correlated with body weight
404
Table {4.10.3.0.3} The effect of single weight cycle on distance ran on a treadmill
correlated with body weight
404
16
Table {4.10.3.0.4} The effect of a single weight cycle on lean mass and fat mass
assessed using EchoMRI
405
Figure {4.10.3.0.5} The effect of three weight cycles on lean mass and fat mass
assessed using EchoMRI
406
Figure {4.10.3.0.6} The effect of a single weight cycle on correlation between
distance ran on a treadmill with lean mass and fat mass
408
Table {4.10.3.0.7} The effect of a single weight cycle on correlation between
distance ran on a treadmill with lean mass and fat mass
409
Figure {4.11.1.0.1} The effect of a 6 weeks of high fat feeding on blood glucose
and β-ketone concentration
410
Figure {4.11.1.0.2} The effect of 6 weeks of high fat on plasma leptin and resistin
concentration
411
Figure {4.11.1.0.3} The effect of 6 weeks of high fat feeding on plasma insulin, c-
peptide and GIP concentration
412
Figure {4.11.1.0.4} The effect of 6 weeks of high fat feeding on plasma glucagon
and ghrelin concentration
413
Figure {4.11.1.0.5} The effect of 6 weeks of high fat feeding on plasma cytokines 414
Table {4.11.1.0.6} The effect of 6 weeks of high fat feeding on blood and plasma
measurements
415
Figure {4.11.2.0.1} The effect of maintained weight change on blood glucose and
β-ketone concentration
416
Figure {4.11.2.0.2} The effect of maintained weight change on plasma leptin and
resistin concentration
417
Figure {4.11.2.0.3} The effect of maintained weight change on plasma insulin, c-
peptide and GIP concentration
418
Figure {4.11.2.0.4} The effect of maintained weight change on plasma glucagon
and ghrelin concentration
419
Figure {4.11.2.0.5} The effect of maintained weight change on plasma cytokines 420
Table {4.11.2.0.6} The effect of maintained weight change on blood and plasma
measurements
421
Figure {4.11.3.0.1} The effect of a single weight cycle on blood glucose and β-
ketone concentration
422
Figure {4.11.3.0.2} The effect of a single weight cycle on plasma leptin and resistin
concentration
423
Figure {4.11.3.0.3} The effect of a single weight cycle on plasma insulin, c-peptide
and GIP concentration
425
Figure {4.11.3.0.4} The effect of a single weight cycle on plasma glucagon and
ghrelin concentration
426
Figure {4.11.3.0.5} The effect of a single weight cycle on plasma cytokines 427
Table {4.11.3.0.6} The effect of a single weight cycle on blood and plasma
measurements
428
Figure {4.12.1.0.1} The effect of 6 weeks of high fat feeding on organ weight 430
Figure {4.12.1.0.2} The effect of 6 weeks of high fat feeding on organ weight as a
percentage of body weight
431
Table {4.12.1.0.3} The effect of 6 weeks of high fat feeding on organ weight 432
Figure {4.12.2.0.1} The effect of maintained weight change on organ weight 434
Figure {4.12.2.0.2} The effect of maintained weight change on organ weight as a
percentage of body weight
435
Table {4.12.2.0.3} The effect of maintained weight change on organ weight 436
Figure {4.12.3.0.1} The effect of a single weight cycle on organ weight 438
Figure {4.12.3.0.2} The effect of a single weight cycle on organ weight as a
percentage of body weight
439
Table {4.12.3.0.3} The effect of a single weight cycle on organ weight 440
Figure {4.13.1.0.1} The effect of 6 weeks of high fat feeding on total WAT mass 441
Figure {4.13.1.0.2} The effect of 6 weeks of high fat feeding on WAT mass 442
Figure {4.13.1.0.3} The effect of 6 weeks of high fat feeding on WAT mass as a
percentage of body weight
443
Figure {4.13.1.0.4} The effect of 6 weeks of high fat feeding on WAT mass 444




Table {4.13.1.0.6} The effect of 6 weeks of high fat feeding on WAT distribution 445
Figure {4.13.2.0.1} The effect of maintained weight change on total WAT mass 446
Figure {4.13.2.0.2} The effect of maintained weight change on WAT mass 448
Figure {4.13.2.0.3} The effect of maintained weight change on WAT mass as a
percentage of body weight
449
Figure {4.13.2.0.4} The effect of maintained weight change on WAT mass 450
Figure {4.13.2.0.5} The effect of maintained weight change on internal:
subcutaneous WAT ratio
451
Figure {4.13.2.0.6} The effect of maintained weight change on WAT distribution 453
Table {4.13.2.0.7} The effect of maintained weight change on WAT distribution 453
Figure {4.13.3.0.1} The effect of a single weight cycle on total WAT mass 454
Figure {4.13.3.0.2} The effect of a single weight cycle on WAT mass 456
Figure {4.13.3.0.3} The effect of a single weight cycle on WAT mass as a
percentage of body weight
457
Figure {4.13.3.0.4} The effect of a single weight cycle on WAT mass 458
Figure {4.13.3.0.5} The effect of a single weight cycle on internal:subcutaneous
WAT ratio
459
Figure {4.13.3.0.6} The effect of a single weight cycle on WAT distribution 461
Table {4.13.3.0.7} The effect of a single weight cycle on WAT distribution 461
Figure {4.14.1.0.1} The effect of 6 weeks of high fat feeding on neuronal gene
expression in the hypothalamus
463
Figure {4.14.1.0.2} The effect of 6 weeks of high fat feeding on dopamine-related
gene expression in the hypothalamus and reward areas
465
Figure {4.14.1.0.3} The effect of 6 weeks of high fat feeding on LepR gene
expression in the hypothalamus and VTA, and MC4R gene expression in the
hypothalamus of lean mice
466
Table {4.14.1.0.4} The effect of 6 weeks of high fat feeding on gene expression in
the hypothalamus and VTA
467
Table {4.14.1.0.5} The effect of 6 weeks of high fat feeding on gene expression in
the NAc and PFC
468
Figure {4.14.2.0.1} The effect of maintained weight change on neuronal gene
expression in the hypothalamus
470
Figure {4.14.2.0.2} The effect of maintained weight change on dopamine-related
gene expression in the hypothalamus and reward areas
473
Figure {4.14.2.0.3} The effect of maintained weight change on LepR gene
expression in the hypothalamus and VTA, and MC4R gene expression in the
hypothalamus of lean mice
475
Table {4.14.2.0.4} The effect of maintained weight change on gene expression in
the hypothalamus and VTA
476
Table {4.14.2.0.5} The effect of maintained weight change on gene expression in
the NAc and PFC
477
Figure {4.14.3.0.1} The effect of a single weight cycle on neuronal gene expression
in the hypothalamus
478
Figure {4.14.3.0.2} The effect of a single weight cycle on dopamine-related gene
expression in the hypothalamus and reward areas
481
Figure {4.14.3.0.3} The effect of a single weight cycle on LepR gene expression in
the hypothalamus and VTA, and MC4R gene expression in the hypothalamus of
lean mice
482
Table {4.14.3.0.4} The effect of a single weight cycle on gene expression in the
hypothalamus and VTA
483
Table {4.14.3.0.5} The effect of a single weight cycle on gene expression in the
NAc and PFC
484
Figure {5.1.1.0.1} The effect of a single weight cycle on body weight 487
Figure {5.1.1.0.2} The effect of 12 weeks of high fat feeding on weekly body weight
change
488
Figure {5.1.1.0.3} The effect of a single weight cycle ending with weight loss on
weekly body weight change
490
Figure {5.1.1.0.4} The effect of a single weight cycle ending with weight gain on
weekly body weight change
492
Figure {5.1.2.0.1} The effect of three weight cycles on body weight 496
18
Table {5.1.2.0.2} The effect of three weight cycles on body weight 497
Figure {5.1.2.0.3} The effect of 28 weeks of high fat feeding on weekly body weight
change
499
Figure {5.1.2.0.4} The effect of three weight cycles ending with weight loss on
weekly body weight change
502
Figure {5.1.2.0.5} The effect of three weight cycles ending with weight gain on
weekly body weight change
505
Table {5.1.2.0.6} The effect of three weight cycles on weekly body weight change 506
Table {5.1.2.0.7} The effect of three weight cycles on weekly percentage body
weight change
509
Figure {5.2.1.0.1} The effect of 12 weeks of high fat feeding on weekly food intake 510
Figure {5.2.1.0.2} The effect of a single weight cycle ending with weight loss on
weekly food intake
512
Figure {5.2.1.0.3} The effect of a single weight cycle ending with weight gain on
weekly food intake
515
Figure {5.2.1.0.4} The effect of 12 weeks of high fat feeding on cumulative food
intake for 4 week periods
516
Figure {5.2.1.0.5} The effect of a single weight cycle ending with weight loss on
cumulative food intake for 4 week periods
518
Figure {5.2.1.0.6} The effect of a single weight cycle ending with weight gain on
cumulative food intake for 4 week periods
520
Figure {5.2.2.0.1} The effect of 28 weeks of high fat feeding on weekly food intake 521
Figure {5.2.2.0.2} The effect of three weight cycles ending with weight loss on
weekly food intake
524
Figure {5.2.2.0.3} The effect of three weight cycles ending with weight gain on
weekly food intake
527
Table {5.2.2.0.4} The effect of three weight cycles on weekly food intake 528
Table {5.2.2.0.5} The effect of three weight cycles on weekly food intake
normalised to cage weight0.75.
531
Figure {5.2.2.0.6} The effect of 28 weeks of high fat feeding on cumulative food
intake for 4 week periods
532
Figure {5.2.2.0.7} The effect of three weight cycles ending with weight loss on
cumulative food intake for 4 week periods
534
Figure {5.2.2.0.8} The effect of three weight cycles ending with weight gain on
cumulative food intake for 4 week periods
536
Table {5.2.2.0.9} The effect of three weight cycles on cumulative food intake for 4
week periods
537
Table {5.2.2.0.10} The effect of three weight cycles on cumulative food intake for 4
week periods normalised to cage weight0.75
539
Figure {5.3.1.0.1} The effect of 12 weeks of high fat feeding on weekly calorie
intake
541
Figure {5.3.1.0.2} The effect of a single weight cycle ending with weight loss on
weekly calorie intake
543
Figure {5.3.1.0.3} The effect of a single weight cycle ending with weight gain on
weekly calorie intake
545
Figure {5.3.1.0.4} The effect of 12 weeks of high fat feeding on cumulative calorie
intake for 4 week periods
546
Figure {5.3.1.0.5} The effect of a single weight cycle ending with weight loss on
cumulative calorie intake for 4 week periods
548
Figure {5.3.1.0.6} The effect of a single weight cycle ending with weight gain on
cumulative calorie intake for 4 week periods
550
Figure {5.3.2.0.1} The effect of 28 weeks of high fat feeding on weekly calorie
intake
551
Figure {5.3.2.0.2} The effect of three weight cycles ending with weight loss on
weekly calorie intake
554
Figure {5.3.2.0.3} The effect of three weight cycles ending with weight gain on
weekly calorie intake
556
Table {5.3.2.0.4} The effect of three weight cycles on weekly calorie intake 557
Table {5.3.2.0.5} The effect of three weight cycles on weekly calorie intake
normalised to total cage weight0.75
559
19
Figure {5.3.2.0.6} The effect of 28 weeks of high fat feeding on cumulative calorie
intake for 4 week periods
561
Figure {5.3.2.0.7} The effect of three weight cycles ending with weight loss on
cumulative calorie intake for 4 week periods
564
Figure {5.3.2.0.8} The effect of three weight cycles ending with weight gain on
cumulative calorie intake for 4 week periods
566
Table {5.3.2.0.9} The effect of three weight cycle ending on cumulative calorie
intake for 4 week periods
567
Table {5.3.2.0.10} The effect of three weight cycle on cumulative calorie intake for
4 week periods  normalised to total cage weight0.75 (kcal/g0.75)
569
Figure {5.4.1.0.1} The effect of a single weight cycle on whole body adiposity 572
Figure {5.4.2.0.1} The effect of three weight cycles on whole body adiposity 574
Figure {5.5.1.0.1} The effect of a single weight cycle on IHCL content 575
Figure {5.5.2.0.1} The effect of three weight cycles on IHCL content 576
Figure {5.6.1.0.1} The effect of a single weight cycle on total body WAT 578
Figure 5.6.1.2] The effect of a single weight cycle on subcutaneous WAT 580
Figure {5.6.1.0.2} The effect of a single weight cycle on internal WAT 582
Figure {5.6.1.0.3} The effect of a single weight cycle on internal:subcutaneous
WAT ratio
583
Figure {5.6.2.0.1} The effect of three weight cycles on total body WAT 585
Figure {5.6.2.0.2} The effect of three weight cycles on subcutaneous WAT 587
Figure {5.6.2.0.3} The effect of three weight cycles on internal WAT 589
Figure {5.6.2.0.4} The effect of three weight cycles on internal:subcutaneous WAT
ratio
590
Figure {5.7.1.0.1} The effect of a single weight cycle on glucose tolerance 593
Table {5.7.1.0.2} The effect of a single weight cycle on glucose tolerance 593
Figure {5.7.1.0.3} The effect of a single weight cycle on glucose tolerance 594
Figure {5.7.2.0.1} The effect of three weight cycles on glucose tolerance 597
Table {5.7.2.0.2} The effect of three weight cycles on glucose tolerance 597
Figure {5.7.2.0.3} The effect of three weight cycles on glucose tolerance 598
Figure {5.8.1.0.1} The effect of a single weight cycle on cumulative water intake 600
Figure {5.8.1.0.2} The effect of a single weight cycle on O2 consumption 602
Figure {5.8.1.0.3} The effect of a single weight cycle on CO2 production 603
Figure {5.8.1.0.4} The effect of a single weight cycle on respiratory exchange ratio
(RER)
605
Figure {5.8.1.0.5} The effect of a single weight cycle on heat production 606
Table {5.8.1.0.6} The effect of a single weight cycle on indirect calorimetry
measurements
607
Figure {5.8.1.0.7} The effect of a single weight cycle on ambulatory activity 609
Figure {5.8.1.0.8} The effect of a single weight cycle on rearing activity 611
Figure {5.8.1.0.9} The effect of a single weight cycle on activity 613
Table {5.8.1.0.10}  The effect of a single weight cycle on activity 614
Figure {5.8.2.0.1} The effect of three weight cycles on cumulative water intake 616
Figure {5.8.2.0.2} The effect of three weight cycles on O2 consumption 618
Figure {5.8.2.0.3} The effect of three weight cycles on CO2 consumption 619
Figure {5.8.2.0.4} The effect of three weight cycles on respiratory exchange ratio
(RER)
621
Figure {5.8.2.0.5} The effect of three weight cycles on heat production 622
Table {5.8.2.0.6} The effect of three weight cycles on indirect calorimetry
measurements
623
Figure {5.8.2.0.7} The effect of three weight cycles on ambulatory activity 625
Figure {5.8.2.0.8} The effect of three weight cycles on rearing activity 627
Figure {5.8.2.0.9} The effect of three weight cycles on activity 629
Table {5.8.2.0.10} The effect of three weight cycles on activity 630
Figure {5.9.1.0.1} The effect of a single weight cycle on distance ran on a treadmill 631
Figure {5.9.1.0.2} The effect of a single weight cycle on distance ran on a treadmill
correlated with body weight
633
Table {5.9.1.0.3} The effect of a single weight cycle on distance ran on a treadmill
correlated with body weight
633
Figure {5.9.2.0.1} The effect of three weight cycles on distance ran on a treadmill 634
20
Figure {5.9.2.0.2} The effect of three weight cycles on distance ran on a treadmill
correlated with body weight
636
Table {5.9.2.0.3} The effect of three weight cycles on distance ran on a treadmill
correlated with body weight
636
Figure {5.9.2.0.4} The effect of three weight cycles on lean mass and fat mass
assessed using EchoMRI
638
Table {5.9.2.0.5} The effect of three weight cycles on lean mass and fat mass
assessed using EchoMRI
639
Figure {5.9.2.0.6} The effect of three weight cycles on correlation between distance
ran on a treadmill with lean mass and fat mass
641
Table {5.9.2.0.7} The effect of three weight cycles on correlation between distance
ran on a treadmill with lean mass and fat mass
642
Figure {5.10.1.0.1} The effect of a single weight cycle on blood glucose and β-
ketone concentration
643
Figure {5.10.1.0.2} The effect of a single weight cycle on plasma leptin and resistin
concentration
644
Figure {5.10.1.0.3} The effect of a single weight cycle on plasma insulin, c-peptide
and GIP concentration
646
Figure {5.10.1.0.4} The effect of a single weight cycle on plasma glucagon and
ghrelin concentration
647
Figure {5.10.1.0.5} The effect of a single weight cycle on plasma cytokines
concentration
649
Table {5.10.1.0.6} The effect of a single weight cycle on blood and plasma
measurements
650
Figure {5.10.2.0.1} The effect of a three weight cycles on blood glucose and β-
ketone concentration
651
Figure {5.10.2.0.2} The effect of three weight cycles on plasma leptin and resistin
concentration
652
Figure {5.10.2.0.3} The effect of three weight cycles on plasma insulin, c-peptide
and GIP concentration
653
Figure {5.10.2.0.4} The effect of three weight cycles on plasma glucagon and
ghrelin concentration
654
Figure {5.10.2.0.5} The effect of three weight cycles on plasma cytokines
concentration
655
Table {5.10.2.0.6} The effect of three weight cycles on blood and plasma
measurements
656
Figure {5.11.1.0.1} The effect of a single weight cycle on organ weight 658
Table {5.11.1.0.2} The effect of a single weight cycle on organ weight 659
Figure {5.11.1.0.3} The effect of a single weight cycle on organ weight as a
percentage of body weight
661
Table {5.11.1.0.4} The effect of a single weight cycle on organ weight as a
percentage of body weight
662
Figure {5.11.2.0.1} The effect of three weight cycles on organ weight 664
Figure {5.11.2.0.2} The effect of three weight cycles on organ weight 665
Table {5.11.2.0.3} The effect of three weight cycles on organ weight as a
percentage of body weight
667
Figure {5.11.2.0.4} The effect of three weight cycles on organ weight as a
percentage of body weight
668
Figure {5.12.1.0.1} The effect of a single weight cycle on total WAT mass 669
Figure {5.12.1.0.2} The effect of a single weight cycle on WAT mass 671
Figure {5.12.1.0.3} The effect of a single weight cycle on WAT mass as a
percentage of body weight
672
Figure {5.12.1.0.4} The effect of a single weight cycle on WAT mass 673
Figure {5.12.1.0.5} The effect of a single weight cycle on internal:subcutaneous
WAT ratio
674
Figure {5.12.1.0.6} The effect of a single weight cycle on WAT distribution 676
Table {5.12.1.0.7} The effect of a single weight cycle on WAT distribution 677
Figure {5.12.2.0.1} The effect of three weight cycles on total WAT mass 679
Figure {5.12.2.0.2} The effect of three weight cycles on WAT mass 681
21
Figure {5.12.2.0.3} The effect of three weight cycles on WAT mass as a
percentage of body weight
683
Table {5.12.2.0.4} The effect of three weight cycles on WAT mass 684
Figure {5.12.2.0.5} The effect of three weight cycles on internal:subcutaneous WAT
ratio
685
Figure {5.12.2.0.6} The effect of three weight cycles on WAT distribution 687





5-HT(1-7)R 5-hydroxytryptamine(1-7)Receptors (Serotonin Receptors)
α/β/γ MSH α/β/γ Melanocyte stimulating hormone
ACTH Adrenocorticotrophin
Acyl CoA Acyl Coenzyme A
AEBSF 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride
AgRP Agouti Related Peptide
AHA Anterior hypothalamic area
AMPA alpha- amino-3-hydroxy-5-methyl-4-isoxazolepropionic
AMPK 5' adenosine monophosphate-activated protein kinase
AP Area Postrema
ARC Arcuate Nucleus
ATPD Acute tyrosine/phenylalanine depletion
AUC Area under the Curve
AV3V Anteroventral area of third ventricle
BAT Brown adipose tissue
BBB Blood Brain Barrier
BDNF Brain derived neurotrophic factor
BED Binge Eating Disorder
BMI Body mass index
BNST Bed nucleus of the stria terminalis
cAMP cyclic adenosine monophosphate
CART Cocaine- and amphetamine-regulated transcript
CB (1-2) R Cannabinoid (1-2) receptor
CCK (1-2) R Cholecystokinin (1-2) receptor
CCK Cholecystokinin
CI capsula interna
CLAMS Comprehensive Lab Animal Monitoring System
23




CRH Corticotropin releasing hormone
D(1-5)R Dopamine (1-5) receptor
DA Dopamine
D-Fen D-Fenfluramine
DARPP-32 Dopamine and cAMP-regulated phosphoprotein of 32 kDa
DAT Dopamine reuptake transporter
DREADD Designer receptors exclusively activated by designer drugs
DIO Diet induced obese
DMH Dorsomedial Hypothalamus
DMN Dorsomedial Nucleus
DMV Dorsal motor nucleus of the Vagus
DOPAC 3,4-dihydroxyphenylacetic Acid
DP, Dorsal parvocellular subnucleus of paraventricular nucleus
DPPIV Dipeptidyl Peptidase
DSM-V Diagnostic and Statistical Manual of Mental Disorder




ERK 1/2 Extracellular-signal-regulated kinases 1/2
F Fornix
FE Feeding Efficiency
fMRI Functional Magnetic Resonance Imaging
FOV Field of View
FOXO1 Forkhead box protein O1
GABA γ amino butyric acid
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GHSR 1 Growth hormone secretagogue receptor 1
GHRH Growth hormone-releasing hormone
24
GIP Gastric inhibitory Protein
GnRH Gonadotropin-releasing hormone
GLP-(1-2) R Glucagon-like Peptide (1-2) receptor
GLP-1/2 Glucagon-like Peptide 1/2
GluT Glucose transporter
GOAT Ghrelin-O-acyltransferase
GPCR G-protein coupled receptor
5-HT 5-hydroxytryptamine




IHCL Intrahepatocellular lipid content
IP (1-2) Intervening peptide (1-2)
IPGTT Intraperitoneal glucose tolerance test
IMCL Intramyocellcular lipid content
IRS Insulin receptor substrate
i.v. Intravenous









LH Lateral Hypothalamic Area
LHA Lateral Hypothalamic Area
LM Lateral magnocellular subnucleus of paraventricular nucleus
LPOA Lateral preoptic area
LRb Long form of leptin receptor
MAO Monoamine oxidase
25
MAPK Mitogen-activated protein kinase
MBH Mediobasal hypothalamus
MC (1-4) R Melanocortin (1-4) receptors
MCH (1-2) R Melanocortin concentrating hormone (1-2) receptor
MCH Melanocortin Concentrating Hormone
MCP-1 Monocyte Chemotactic protein-1
ME Median Eminence
Mes Mesenteric
MP Medial parvocellular PVN
MPO Medial preoptic area
MRI Magnetic Resonance Imaging
mRNA Messenger Ribonucleic Acid
MRS Magnetic Resonance Spectroscopy





NTS Nucleus tractus solitarius
OFC Orbitofrontal cortex
OT Optic tract
OX(1-2)R Orexin (1-2) receptor
OXM Oxyntomodulin
p75NTR p75 neurotrophin receptor
PeN Periventricular Nucleus
PET Positron Emission Tomography
PI3K Phosphatidylinositide 3-kinases
PFC Prefrontal cortex
PKA Protein Kinase A
POMC Pro-opiomelanocortin
PP Pancreatic Polypeptide
PP1 Protein phosphatase 1





REE Resting energy expenditure




RT-qPCR Real time-quantitative polymerase chain reaction




SEM Standard error of the mean
SERT Serotonin Transporter
SF-1 Steroidogenic Factor 1
SI Substantia inominata
Sim1 Single minded 1
Sirt Sirtuin
SNAC Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate
S.Nigra Substantia Nigra
SNP Single Nucleotide Polymorphism
SNS Sympathetic Nervous System
SOCS3 Suppressor of cytokine signaling 3
SON Supraoptic Nucleus










TNF-A Tumour Necrosis Factor Alpha
TR Repetition Time
TRH Thyrotropin releasing hormone
TrkB Tyrosine receptor kinase B
UCP-1-3 Uncoupling Protein 1-3
VGAT Vesicular GABA transporter
VMAT Vesicular monoamine transporter
VIP Vasoactive intestinal peptide
VMH Ventromedial Hypothalamus
VMN Ventromedial Nucleus
VP Ventral parvocellular subnucleus of paraventricular nucleus
VTA Ventral Tegmental Area
WAT White Adipose Tissue
Y (1-5) R Neuropeptide Y (1-5) receptor
YFAS Yale Food Addiction Scale





Obesity is defined as an excess accumulation of fat, resulting from an imbalance of energy input                             
and energy output [Wardle, 2007]. BMI (body mass index) is a commonly used measurement to                           
classify individuals as overweight or obese. BMI is defined as body mass divided by the square                             
of height (units kg/m2). The World Health Organisation defined an individual as overweight with a                           
BMI over 25 kg/m2 and obese with a BMI over 30 kg/m2.
Obesity has become a major concern throughout the world, with estimates suggesting 1.4 billion                         
adults classified as overweight and approximately 500 million people classified as obese [WHO,                       
2012]. Once considered a disease of the developed world, there has been a striking increase in                             
the prevalence of overweight and obese individuals in low­ and middle­income countries, where                       
levels of obesity have tripled in the last 20 years [Hossain et al., 2007]. In fact, 65% of the world’s                                     
population now live in countries where being overweight or obese leads to more deaths than                           
being underweight [WHO, 2012].
Statistics published in 2012 by the NHS Information Centre for England showed 24% of men and                             
26% women were classified as obese, whilst 42% of men and 36% of women were considered                             
overweight. An increase in the rate of childhood (age 2 to 15) overweight and obesity has also                               
been observed since 1995 to 2010, from 11.1% to 17.1% in boys, and 12.2 to 14.8% in girls                                 
[NHS, 2012].
Obesity is a major health concern as it is associated with a number of comorbidities, including                             
diabetes, cardiovascular disease, musculoskeletal diseases and certain types of cancer [Guh et                     
al., 2009]. Alongside decreased life expectancy and quality of life, obesity is a huge economic                           
burden on society, and is set to rise in the future alongside increased projections of                           
obesity­related diseases [McCormick & Stone, 2007; Wang et al., 2011].
The most common method to lose weight is through calorie restriction and exercise. However,                         
weight loss through dieting is frequently unsuccessful as a long­term method to maintain a lower                           
weight. Turk et al. suggested a third of the body weight lost is usually regained within a year,                                 
whilst the majority of weight is regained within 3 to 5 years of the initial reduction in body weight                                   
[Turk et al., 2009]. Multiple instances of weight fluctuation results in weight cycling, or                         
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“yoyo”dieting, which will be discussed in more detail in Section 1.4.3.4. This in turn has led to the                                 
development of more invasive but effective treatments, such as bariatric surgery. Therefore, it is                         
crucial to fully understand the mechanisms underlying appetite control, particularly after weight                     






An indication of the importance of the hypothalamus in appetite control and obesity was first                           
described in 1901 by Alfred Fröhlich, who observed pituitary tumours that caused damage to the                           
adjacent hypothalamus and resulted in an obese phenotype. This became known as Fröhlich's                       
syndrome, or now more commonly known as adiposogenital dystrophy [Fröhlich, 1901]. Further                     
advances in the understanding of the neural control of feeding was demonstrated in early                         
experiments using gross lesions. As a result, the "dual­centre" hypothesis was formed, where                       
ablation of the lateral hypothalamus (LH) resulted in hypophagia and ablation of the ventromedial                         
hypothalamus (VMH) resulted in hyperphagia. This led to the conclusion that the LH controls                         
hunger and the VMH controls satiety (Hetherington & Ranson, 1940; Anand & Brobeck, 1951;                         
Stellar, 1954). Although this model is not entirely correct (due to the use of non­specific                           
lesioning, [Rolls, 1981]), this was a starting point to understanding the wide variety of central                           
mechanisms that are involved in regulating food intake and energy balance.
The hypothalamus can be divided into three longitudinal sections, based on both anatomy and                         
functionality [Crosby & Woodburne, 1940]. These are the periventricular, medial and lateral                     
zones. Based on the functional structure of the medial zone, further subdivisions can be made                           
along the rostral­caudal axis. These are the pre­optic, anterior, tuberal and mamillary regions [Le                         
Gros Clark, 1938].
{1.2.1.1} The periventricular zone
The periventricular zone contains the vast majority of neurons that project to the pituitary gland                           
and is heavily involved in the integration of blood­borne signals and the control of endocrine                           
responses [Simerly & Paxinos, 2004]. There are two types of cell present in the periventricular                           
zone: parvocellular and magnocellular neurosecretory cells.
Parvocellular neurosecretory cells project from the median eminence (ME) and paraventricular                   
nucleus (PVN) at the base of the hypothalamus and top of the third ventricle, respectively, where                             
hypophysiotropic hormones are released which act upon five hormone­secreting cells in the                     
anterior pituitary gland (adenohypophysis). The most widely documented neuropeptides released                 
by the parvocellular neurosecretory cells from the periventricular zone are thyrotropin­releasing                   
hormone (TRH) and corticotropin­releasing hormone (CRH), whilst growth hormone­releasing               
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hormone (GHRH), somatostatin (SS), gonadotropin­releasing hormone (GnRH) and dopamine               
(DA) are released from the periventricular nucleus [Markakis & Swanson, 2002; Simmons &                       
Swanson, 2009].
Magnocellular neurosecretory cells have continuous projections from the supraoptic and                 
accessory supraoptic nuclei to the posterior pituitary gland (neurohypophysis) and releases                   
vasopressin and oxytocin [Swanson, 2000].
{1.2.1.2} The medial zone
The functional structure of the medial zone allows further regional classification of hypothalamic                       
nuclei along the rostral­caudal axis. The nuclei in the medial zone receive many sensory inputs                           
and have major connections to other areas of the hypothalamus and limbic areas, such as the                             
amygdala. A major function of the medial zone is the control of a number of adaptive behaviours,                               
such as aggression and reproduction [Berthoud, 2002]. More recently, it appears the medial                       
zone of the hypothalamus is part of a behavioural control column, which extends from the medial                             
zone of the hypothalamus to the midbrain [Swanson, 2000; Swanson, 2005]. The rostral part of                           
the column is important in goal­directed behaviours, such as ingestive, reproductive, and                     
defensive behaviour, whilst the caudal part of the column is important in foraging and other                           
exploratory behaviour.
{1.2.1.3} The lateral zone
In contrast, the lateral zone lacks a clear nuclear division and the connections are dominated by                             
the medial forebrain bundle and the fornix [Berthoud, 2002]. Although there appears to be a lack                             
of structural differentiation, work has identified groups of cells definable through their                     
neurochemistry [Sawchenko, 1998]. One of the key areas of the lateral zone is the lateral                           
hypothalamus (LH). The LH has an extensive network of intra­ and inter­hypothalamic                     
connections, including the amygdala, hippocampus, midbrain, thalamus and brainstem, as well                   
as other hypothalamic nuclei [Elias et al., 1998; Rempel­Clower & Barbas, 1998].
One of the key roles of the LH that has emerged is the control of wakefulness, with the discovery                                   
of orexins [de Lacea et al., 1998; Sakurai et al., 1998; Adamantidis et al., 2007]. Other roles of                                 
the LH include respiratory control, cardiovascular control, stress, addiction and thirst [Samson et                       









Figure {1.2.1.3.2}. Three­dimensional view of the rat hypothalamus showing the major                   
nuclei.
AHA, anterior hypothalamic area; ARC, arcuate nucleus; AV3V, anteroventral area of third                     
ventricle; CI, capsula interna; DP, dorsal parvocellular subnucleus of paraventricular nucleus                   
(PVN); DMN, dorsomedial nucleus; F, fornix; LHA, lateral hypothalamic area; LM, lateral                     
magnocellular subnucleus of paraventricular nucleus; LPOA, lateral preoptic area; ME, median                   
eminence; MP, medial parvocellular PVN; MPO, medial preoptic area; OT, optic tract; SCh,                       
suprachiasmatic nucleus; SON, supraoptic nucleus; SI, substantia innominata; ST, subthalamic                 





The arcuate nucleus is located in the mediobasal hypothalamus along both sides of the third                           
ventricle and at a site where the blood brain barrier (BBB) is incomplete [Ciofi, 2011].                           
Additionally, the arcuate nucleus is directly above the median eminence, which is one of the few                             
areas of the brain which lies outside the BBB and contains fenestrated capillaries. The ME is an                               
integral part of the connection between the pituitary gland and the hypothalamus, known as the                           
hypophyseal portal system [Hawkins et al., 2006]. Together, the ME and arcuate nucleus is a                           
circumventricular organ, and allows the arcuate nucleus to be an ideal integrator of peripheral                         
signals, such as circulating nutrients and hormonal signals of energy status. These include                       
leptin, insulin, glucose, sex hormones and glucocorticoids [Glaum et al., 1996; Sato et al., 2005;                           
Muroya et al., 1999; Tong et al., 1990; Hisano et al., 1988; Blouet & Schwartz, 2010].
Other than circulating hormonal inputs, there are also many neuronal inputs to the arcuate                         
nucleus. Using retrograde tracing, the arcuate nucleus shows a substantial number of inputs                       
from a wide variety of areas, including other hypothalamic nuclei, the hindbrain, limbic areas and                           
cortical areas [DeFalco et al., 2001].
The arcuate nucleus contains two key populations of neurons. These are parvocellular cells                       
(discussed above) and centrally projecting neurons. Centrally projecting neurons have been                   
shown to have an essential role in appetite regulation and can be broadly classified into two                             
types of neurons. Neurons expressing neuropeptide Y (NPY) and agouti­related peptide (AgRP)                     
increase food intake, whilst neurons expressing pro­opiomelanocortin (POMC) and cocaine­ and                   
amphetamine­regulated transcript (CART) suppress appetite. These neurons are referred to as                   
first order neurons, as they are the initial site of interaction within the hypothalamus to a number                               
of circulating metabolic signals described above. These neuropeptides will be discussed in more                       
detail in Section 1.2.6.
{1.2.1.5} Ventromedial nucleus of the hypothalamus (VMH)
The VMH is located above the arcuate nucleus and was commonly associated with satiety [King,                           
2006]. However, early lesion experiments proved to be unreliable due to unspecific damage.                       
More recent studies using knockouts have again shown the VMH appears to have a key role in                               
food intake and energy expenditure [Elmquist et al., 1999; Kim et al., 2002]. Specifically, the role                             
of a transcription factor, steroidogenic factor 1 (SF­1), had been been shown to be essential for                             




High fat diet has been shown to inhibit SF­1 neurons via insulin receptors and PI3K signalling                             
[Klöckener et al., 2011]. Additionally, removing PI3K signalling from SF­1 neurons has been                       
shown to disrupt energy expenditure [Yong et al., 2010]. Similarly, removal of FOXO1 or SIRT1                           
signalling from SF­1 VMH neurons shows a disruption in energy expenditure [Ramadori et al.,                         
2011; Kim et al., 2012]. Both leptin and diet­induced thermogenesis have also been shown to be                             
dependent on functional SF­1 [Kim et al., 2011].
VMH neurons have also been shown to respond to glucose, a short term energy signal [Routh,                             
2010]. There appear to be neurons the are excited by glucose and others which are inhibited by                               
glucose [Parton et al., 2007; Williams & Burdakov, 2009]. Loss of glucose sensing VMH neurons                           
has shown a reduction in food intake and a loss of glucagon secretion in response to                             
hypoglycemia [Miki et al., 2001; McCrimmon, 2009].
{1.2.1.6} Dorsomedial nucleus of the hypothalamus (DMH)
The DMH receives the majority of neuronal inputs from other hypothalamic nuclei, including the                         
arcuate nucleus, VMH, paraventricular nucleus (PVN) and lateral hypothalamus (LH). The                   
majority of efferent projections connect to the PVN, whilst other connections are observed within                         
the periventricular zone of the hypothalamus [Thompson & Swanson, 1998].
Neurons in the DMH also respond to external signals. Leptin receptors are expressed in the                           
DMH, many of which form projections to the PVN [Bjørbæk & Kahn, 2004; Elmquist et al., 1998].                               
A group of DMH neurons express CCK­A receptors, which respond to cholecystokinin, most of                         
which are colocalized with NPY expression [Bi et al., 2001]. Knockouts of CCK­A receptors                         
result in hyperphagia and obesity, suggesting CCK may act upon NPY neurons to reduce food                           
intake [Moran et al., 1998]. Estrogen receptors are also present on NPY DMH neurons, which                           
may explain the observation NPY expression is increased during lactation [Smith, 1993;                     
Shughrue et al., 1997].
The DMH has also been shown to play an essential role in food­entrainable circadian rhythms                           
[Mieda et al., 2006]. In one study, c­Fos expression was observed to increase in the DMH at                               
scheduled meal times. When these neurons were lesioned, preprandial responses to scheduled                     
meal times were abolished [Gooley et al., 2006]. Similarly, the intensity of meal anticipation has                           
been shown to be a result of the interaction between the DMH and suprachiasmatic nucleus                           
(SCN) [Acosta­Galvan et al., 2011]
It has also been suggested the DMH may mediate autonomic responses from the preoptic area                           
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[Hunt et al., 2010]. These include heart rate, blood pressure, thermoregulation and locomotor                       
activity [Hunt et al., 2010; Zhang et al., 2011; DiMicco & Zaretsky, 2006]. Additionally, knockdown                           
of NPY expressing neurons in the DMH has been shown to increase the development of brown                             
adipocytes and reduce the incidence of obesity [Chao et al., 2011].
{1.2.1.7} Paraventricular nucleus of the hypothalamus (PVN)
The PVN plays a key role in the neuroendocrine response and energy homeostasis. Many inputs                           
to the PVN originate from other hypothalamic nuclei, but also the brainstem, forebrain and limbic                           
areas [Spencer et al., 2005; Herman et al., 2005; Berthoud 2002; Sawchenko & Swanson, 1982;                           
Sawchenko & Swanson, 1983].
The PVN is a major site of second order neurons, to which many first order neurons in the                                 
arcuate nucleus terminate [Schwartz et al., 2000]. Many of these neurons are parvocellular                       
neurosecretory cells that project to the ME and produce CRH and TRH, both of which reduce                             
food intake [Uchoa et al., 2009; Dhillo et al., 2011]. The PVN also has a autonomic function,                               
involved in both sympathetic and vagal­parasympathetic preganglionic projections that innervate                 
the pancreas [Jansen et al., 1997]. The PVN is also involved in a number of other autonomic                               
nervous processes, including stress, immune, gastrointestinal, renal and cardiovascular               
responses [Buller et al., 2003; Coote, 2005; Ferguson et al., 2008].
Another major output from the PVN are the magnocellular neurosecretory cells that project to the                           
posterior pituitary gland involved in the secretion of oxytocin and vasopressin [Berthoud, 2002].
Although the PVN appears to be a site of termination for many primary neurons, leptin receptors                             
have been found in the PVN [Mercer et al., 1996; Håkansson et al., 1998]. Leptin administration                             
both intravenously and through the third ventricle have been shown to induce c­Fos activation                         
[Van Dijk et al., 1996; Elmquist et al., 1998]. Electrophysiology experiments have also shown                         
leptin depolarises the majority of PVN neurons [Powis et al., 1998]. Additionally, it has been                           
shown this direct inhibitory effect of leptin on PVN neurons is the primary mechanism for leptin’s                             
effect, in contrast to modulation by NPY neurons. This in turn increased melanocortin 4 receptor                           
(MC4R) expression in these neurons, thereby increasing satiety [Ghamari­Langroudi et al.,                   
2011].
{1.2.1.8} Lateral hypothalamus (LH)
The LH was first identified as a feeding centre through gross lesion experiments, where                         
destruction of the LH suppresses appetite [Hetherington & Ranson 1940; Anand & Brobeck                       
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1951]. Since then, the LH has been identified as a key nuclei involved with arousal, after the                               
discovery of orexins and melanin concentrating hormone (MCH) [de Lacea et al., 1998; Sakurai                         
et al., 1998; Broberger et al., 1998; Gerashchenko & Shiromani, 2004; Ohno, K & Sakurai. 2008].
Connections between the LH and limbic system have been shown to be important for                         
maintaining attention during emotional stimuli [Kayaba et al., 2003; Zhang et al., 2006].                       
Food­induced cataplexy observed in narcoleptic dogs indicate the importance of cholinergic                   
signals in the forebrain with emotion and reward­related behaviours, which are required for                       
maintaining attention and feeding [Reid et al., 1998]. LH orexin neurons have also been                         
implicated in morphine addiction [Georgescu et al., 2003]. In addition, leptin has been shown to                           
alter mesolimbic dopamine signalling via the LH [Leinninger et al., 2009].
Similarly, energy homeostasis signals, such as glucose and leptin, have been shown to affect                         
orexin neurons in the LH, again suggesting the importance of these neurons in maintaining                         
attention with regards to altering homeostasis [Yamanaka et al., 2003; Tsujino & Sakurai, 2009].
Other processes linked with maintenance of vigilance are respiratory and cardiovascular control,                     
and thirst [Samson et al., 2005; Badami et al., 2010; Samson et al., 1999; Watts et al., 1999].
{1.2.2} The brainstem
The hypothalamus is clearly an important mediator of energy balance through integration of                       
central and peripheral signals. In addition to this, the brainstem has not only been shown to                             
respond to hypothalamic modulation, but also responds directly to a number of peripheral signals                         
[Suzuki et al., 2010]. This is most clearly illustrated in experiments where behavioural responses                         
to peripheral stimulation are observed in chronically decerebrate animals [Grill & Norgen, 1978].
The dorsal vagal complex in the brainstem represents a group of nuclei that have been shown to                               
influence appetite and respond to signals of energy balance. This comprises of the nucleus                         
tractus solitarius (NTS), area postrema (AP) and the dorsal motor nucleus of the vagus nerve                           
(DMV) [Bailey et al., 2008].
The AP is a circumventricular organ that lies outside the blood brain barrier [Murabe et al., 1981].                               
The NTS lies below the AP, so similar to the arcuate nucleus and ME, the NTS is ideally                                 
positioned to be exposed to peripheral signals. Leptin receptors are expressed in the NTS and is                             
thought to amplify the response of gastric distention [Huo et al., 2007]. Leptin has also been                             
observed to directly inhibit neurons in the NTS and DMV [Williams & Smith, 2006; Williams et al.,                               
2007]. Specific deletion of leptin receptors in the NTS/AP and from hindbrain GLP­1 neurons                         
results in hyperphagia and weight gain in mice [Hayes et al., 2010; Scott et al., 2011].                             
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Melanocortin receptor agonists and antagonist also affect feeding when directly administered to                     
the fourth ventricle and are implicated in CCK­induced feeding and sympathetic signalling [Grill et                         
al., 1998; Williams et al., 2003; Fan et al., 2004; Skibicka & Grill, 2008]
{1.2.3} The vagus nerve
The vagus nerve is part of the parasympathetic nervous system and is involved in a number of                               
autonomic functions. Vagal afferents from the gastrointestinal tract convey information to the                     
brain and terminate in the NTS [Sawchenko, 1983]. This then transmits to the hypothalamus,                         
providing another route for information about the gut and energy homeostasis to be received by                           
the hypothalamus [Suzuki et al., 2011]. Vagal afferents from the stomach are stimulated by                         
gastric distension, and transection of these afferents results in increased meal size and duration                         
[Mathis et al., 1998; Schwartz et al., 1999; Schwartz, 2000; Berthoud, 2008]. Vagal afferents                         
express leptin receptors, ghrelin receptors, CCK­1 and 2 receptors, 5­HT3 receptors and Y2                       
receptors and a number of gastrointestinal hormones that directly affect vagal firing [Burdyga et                         
al., 2002; Burdyga et al., 2006; Moriarty et al., 1997; Morales et al., 2002; Koda et al., 2005;                                 
Iwasaki & Yada, 2012]. The vagus nerve appears crucial in mediating the feeding response of                           
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NPY is a 36 amino acid peptide that is one of the most potent orexigenic neurotransmitters in the                                 
hypothalamus [Mercer et al., 2011]. It is mainly synthesised in neurons that also coexpress                         
agouti­related peptide (AgRP), another orexigenic neurotransmitter [Chronwall et al., 1985; Hahn                   
et al., 1998]. NPY is also expressed in the DMH, though only expressed during specific periods                             
of negative energy balance, such as early postnatal growth and lactation [Grove et al., 2003;                           
Chen & Smith, 2003]. NPY is highly expressed in the brainstem and hippocampus, although the                           
role of NPY in these regions towards feeding and energy expenditure is less well known                           
compared to hypothalamic NPY [De Quidt, M., & Emson. 1986; Tseng et al., 1989; Decressac et                             
al., 2011].
NPY neurons project to a number of nuclei in the hypothalamus. The PVN shows a large number                               
of NPY terminals [Chronwell et al., 1985]. Fasting results in an increase in NPY release into the                               
PVN, whilst an acute injection of NPY stimulates food intake [Dube et al., 1992; Stanley &                             
Leibowitz, 1985]. Overexpression of NPY in the PVN leads to hyperphagia and obesity [Tiesjema                         
et al., 2007; Tiesjema et al., 2009]. Conversely, administration of anti­NPY antibodies into the                         
PVN reduces food intake [Shibasaki et al., 1993]. Within the PVN, NPY inhibits GABA release                           
onto a subpopulation of PVN neurons and also hyperpolarises neurons expressing MC4R                     
[Cowley et al., 1999]. Similarly, NPY has been shown to inhibit VMH glutamatergic neurons, a                           
high proportion of which express the Y1 receptor [Kumarnsit et al., 2003; Chee et al., 2010].                             
Arcuate nucleus NPY neurons also project to the LH, where NPY inhibits both orexin and MCH                             
neurons, whilst orexin and MCH increase NPY expression in the arcuate nucleus, perhaps                       
showing an orexigenic feedback loop [Fu et al., 2004; van den Pol et al., 2004; Muroya et al.,                                 
2004; Della­Zuana et al., 2002].
Acute intracerebroventricular (i.c.v) administration of NPY dose­dependently increases food               
intake, whilst chronic central administration of NPY induces long­term hyperphagia and obesity                     
[Clarke et al., 1985; Zarjevski et al., 1993]. Diet induced obese models and several genetic                           
models of obesity show increased expression of NPY, whilst obesity resistant rats show                       
decreased NPY mRNA expression [Guan et al., 1998; Kesterson et al., 1997; Wilding et al.,                           
1993; Huang et al., 2003]. Chronic high fat feeding (9­17 weeks) increased the feeding response                           
to i.c.v. NPY administration, whilst immunohistochemical expression and efflux of NPY was                     
decreased, suggesting a compensatory mechanism coupled with upregulation of Y2                 
autoreceptors [Hansen et al., 2004; Widdowson et al., 1997]. In contrast, obesity resistance and                         
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food restriction decreased expression of Y2 and Y5 receptor mRNA in the arcuate nucleus                         
[Widdowson et al., 1997; Huang et al., 2003]. NPY neurons have been shown to terminate on                             
arcuate nucleus POMC neurons, which are inhibited by NPY through expression of Y1 and Y2                           
receptors [Cowley et al., 2001; Roseberry et al., 2004; Acuna­Goycolea et al., 2005]. NPY                         
neurons also express MC3R and MC4R, indicating mutual regulation of orexigenic and                     
anorexigenic neurons within the arcuate nucleus [Mounien et al., 2005]. A more recent                       
optogenetic study showed photostimulation of NPY neurons induced feeding in direct response                     
to firing rate within NPY/AgRP neurons [Aponte et al., 2011].
An initial attempt to investigate the role of NPY through animal knockout models showed no                           
phenotypic change, although use of this model has shown a reduced response to fasting                         
[Erickson et al., 1996a]. However, when crossed with leptin­deficient ob/ob mice, hyperphagia                     
and reduced energy expenditure were abolished [Erickson et al., 1996b]. Postnatal ablation of                       
NPY neurons induced starvation in adult mice, but again, ablation of NPY neurons in neonates                           
showed a normal phenotype, suggesting neuronal compensation within appetite regulating                 
circuits during early life [Luquet et al., 2005]. Similarly, studies attempting to induce NPY                         
overexpression produce some surprising results given the clear effects of NPY when injected                       
centrally. No change was observed in food intake or body weight with a modest overexpression                           
of NPY [Inui et al., 1998]. When presented with a high sugar diet, these mice showed a major                                 
increase in food intake resulting in obesity [Kaga et al., 2001]. Another mouse model                         
successfully increased NPY expression four times the normal amount in the arcuate nucleus,                       
however no differences in food intake or major changes in body weight were observed [Marie et                             
al., 2005]. A rat model of NPY overexpression showed PVN­specific overexpression increased                     
meal frequency and reduced locomotor activity, leading to obesity [Tiesjema et al., 2007;                       
Tiesjema et al., 2009]. LH overexpression of NPY shows an increase in food intake by increasing                             
meal frequency [Tiesjema et al., 2007]. Alterations in NPY signalling show different results for                         
acute and chronic food restriction, indicating a difference in signalling to initial and sustained                         
weight loss. Both restrictions show increased NPY and decreased POMC mRNA expression in                       
the arcuate nucleus, whilst AgRP was only increased in acute food restriction rats. However,                         
chronic food restriction increased NPY mRNA expression in the DMH but not with acute food                           
restriction [Bi et al., 2003].
There are 8 subtypes of NPY receptors, named Y1 to Y8. These are G protein­coupled receptors                             
which have been shown to bind to peptide YY (PYY) and pancreatic polypeptide (PP). Some of                             
these receptors, such as Y3, Y6­8 are not well characterised, whilst Y1,Y2 and Y5 receptors                           
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have a strong affinity for NPY and are the most well defined with regards to regulating energy                               
balance [Mercer et al., 2011]. Y1 receptor agonists show an increase in food intake and weight                             
gain, whilst Y1 receptor antagonists reduce food intake [Mullins et al., 2001; Fekete et al., 2002;                             
Ishihara et al., 1998; Kanatani et al., 1999]. Y1 receptor knockouts have been shown to reduce                             
food intake, although the effect of this deletion appears to differ according to genetic background                           
[Kanatani et al., 2000; Kushi et al., 1998]. Crossing Y1 receptor knockouts with ob/ob mice                           
reduces food intake and obesity in these mice [Pralong et al., 2002]. NPY signalling has also                             
been shown to decrease UCP1 expression in BAT through activation of Y1 receptors on TH                           
neurons in the PVN, thereby inducing a positive energy balance [Shi et al., 2013].
The Y2 receptor has been implicated as an inhibitory autoreceptor, which also preferentially                       
binds the satiety gut hormone PYY3­36 [Chen et al., 1997; Batterham et al., 2002].                         
Pharmacological agonists of Y2 receptors also reduce food intake and increase fat metabolism                       
[Balasubramaniam et al., 2007; Lumb et al., 2007]. Conversely, Y2 receptor antagonists                     
increase food intake and reduce PYY­induced hypophagia [Abbott et al., 2004; Shoblock et al.,                         
2010]. Similarly, knockout of Y2 receptors in NPY neurons lead to an increase in food intake,                             
body weight and increased NPY expression, again suggesting Y2 receptors negatively regulate                     
NPY expression [Naveilhan et al., 1999].
Y5 receptor agonists increase food intake, whilst two Y5 receptor antagonists indicate only                       
minimal to modest weight loss in the clinic [Criscione et al., 1998; Erondu et al, 2006]. NPY                               
receptor Y2 and Y5 binding was significantly reduced in food­restricted mice, whilst increased in                         
HFD fed mice [Widdowson et al., 1997]. This may reduce inhibition of NPY signalling (via                           
downregulation of autoreceptor Y2) and Y5 downregulation may reduce thermogenesis [Beck,                   
2006].
Given the crucial role NPY plays in appetite control, it is not surprising NPY neurons express a                               
number of receptors for peripheral signals of energy status. Arcuate nucleus NPY neurons                       
express insulin receptors, where central administration of insulin results in a reduction in NPY                         
expression [Brief & Davis, 1984; Obici et al., 2002]. Diet induced obese (DIO) mice show a                             
limited anorexigenic response to insulin, both behaviourally and in terms of NPY expression,                       
indicating a site of insulin resistance [Ikeda et al., 1986; Davidowa & Plagemann, 2007].                         
Similarly, administration of peripheral insulin reduces NPY expression in LH NPY neurons,                     
although this appears to be mediated by glucose directly, as addition of insulin to patched cells                             
does not alter electrical activity [Marston et al., 2011].
Leptin receptors are widely expressed within the hypothalamus, including a population of NPY                       
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neurons stimulated by fasting [Elmquist et al., 1998; Baskin et al., 1999]. NPY expression                         
increases with low levels of leptin, and decreases with higher circulating levels of leptin [Korner                           
et al., 2008]. Leptin directly inhibits NPY neurons, which in turn removes inhibition of                         
neighbouring POMC neurons [Takahashi & Cone, 2005]. Within NPY neurons, AMPK and PI3K                       
signalling has been implicated in the leptin­induced decrease in NPY expression, which is                       
disrupted upon pre­treatment of hypothalamic cells with leptin, indicating a possible mechanism                     
for leptin resistance in NPY neurons [Dhillon et al., 2011].
NPY neurons also express ghrelin receptors and are shown to be involved in mediating the                           
orexigenic response [Kamegai et al., 2001; Asakawa et al., 2001; Mondal et al., 2005]. In DIO                             
mice, NPY/AgRP neurons show limited response to ghrelin, indicating the development of ghrelin                       
resistance in orexigenic neurons may exacerbate obesity [Briggs et al., 2010].
{1.2.4.2} Agouti­related peptide (AgRP)
AgRP was first identified by comparing sequence homology with Agouti protein, a 131 amino                         
acid paracrine peptide expressed in melanocytes. Ectopic expression of Agouti occurs in the                       
lethal yellow Ay mouse, resulting in hyperphagia, hyperinsulinemia, obesity and a yellow coat                       
[Bultman et al., 1992; Stütz et al., 2005]. AgRP is also a 131 amino acid neurotransmitter                             
coexpressed in the arcuate nucleus with NPY [Ilnytska & Argyropoulos, 2008].
I.c.v. administration of AgRP stimulates hyperphagia which can last for 7 days, unlike a single                           
injection of NPY or orexin [Olmann et al., 1997; Rossi et al., 1998]. Similarly, overexpression of                             
AgRP also increases food intake and results in obesity [Graham et al., 1997]. Recent                         
experiments using cutting edge techniques, including optogenetics and designer receptors                 
exclusively activated by designer drugs (DREADD), have illustrated rapid activation of arcuate                     
nucleus AgRP neurons is sufficient to induce feeding [Aponte et al., 2011; Krashes et al., 2011].
Similar to NPY, genetic knockout models of AgRP show no effect on feeding or phenotype [Qian                             
et al., 2002]. Postnatal ablation of AgRP expression results in hypophagia and reduced body                         
weight, again suggesting the neural system compensates for a lack of AgRP or NPY [Bewick et                             
al., 2005; Gropp et al., 2005; Luquet et al., 2005].
AgRP neurons project to other hypothalamic areas and other brain areas, such as the nucleus                           
accumbens, amygdala, and brainstem [Broberger et al., 1998; Haskell­Luevano et al., 1999].                     
Activity in these areas differ according to the length of time after AgRP administration, again                           
suggesting other areas may mediate the prolonged effects of AgRP on food intake [Hagen et al.,                             
2001]. Direct injection of AgRP into the VMH, LH or arcuate nucleus has no effect on food intake,                                 
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whilst direct injection of AgRP into the PVN significantly increased food intake in rats.                         
Administration of an α­MSH analogue decreased food intake when administered into the arcuate                       
nucleus and LH [Kim et al., 2000]. More recently, optogenetic and pharmacological techniques                       
were used to show a prominent population of inhibitory neurons present in the PVN, which in turn                               
project to a group of oxytocin neurons traditionally absent in Prader­Willi syndrome [Atasoy et al.,                           
2012]. Disruption of AgRP neurons, through targeted Sirt1 knockdown or early AgRP ablation,                       
increased exploratory behaviour and enhanced the locomotor response to cocaine, indicating                   
increased reward seeking and sensitivity. VTA dopamine neurons showed altered electrical firing                     
and increased basal dopamine levels in the forebrain. This suggests a role of AgRP neurons in                             
reward circuitry development [Dietrich et al., 2012].
AgRP does not bind to an AgRP­specific receptor, but is highly selective for MC3R and MC4R                             
and is considered a melanocortin receptor inverse agonist. This is demonstrated by the ability of                           
AgRP to abolish the effects of α­MSH and melanocortin agonists on food intake [Rossi et al.,                             
1998]. However, AgRP is also considered an inverse agonist of the MC4R [Haskell­Luevano &                         
Monck. 2001; Nijenhuis et al., 2001]. It was observed MC4R are constitutively active, due to the                             
observation of constitutive adenyl cyclase activity, which is abolished with the administration of                       
AgRP.
A single i.c.v injection of AgRP not only resulted in an immediate increase in food intake, but also                                 
persisted for a week, unlike other appetite­related neurotransmitters [Hagen et al., 2000; Lu et al.,                           
2001]. Similarly, these effects outlast those induced by α­MSH or MC4R agonists and                       
antagonists [Kim et al., 2002]. Injection of AgRP immediately before giving MC3/4R agonist (MTII)                         
blocked MTII­induced hypophagia, suggesting AgRP acts as a melanocortin receptor antagonist.                   
However, an injection of AgRP made 24 hours before MTII administration showed an                       
MTII­induced decrease in food intake, which increased once the effects of MTII expired [Hagen et                           
al., 2000]. This effect was also observed in MC4R knockout mice, suggesting the long­lasting                         
effects of AgRP on food intake are not entirely mediated by MC4R [Marsh et al., 1999]. In                               
addition, this feeding response does not appear to be mediated by MC3R either, as MC3R                           
agonism or knockouts does not any effect of food intake [Abbott et al., 2000; Chen et al., 2000].                                 
MTII has no effect on food intake in MC4R knockout mice, indicating MC3R signalling has no                             
effect on food intake [Chen et al., 2000].
AgRP also decreases energy expenditure, which alongside increased food intake, results in a                       
positive energy balance. I.c.v. administration of AgRP decreased UCP­1 expression and BAT                     
temperature [Yasuda et al., 2004]. A 50% reduction of AgRP expression using RNA interference                         
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increases energy expenditure and a reduction in body weight without altering food intake                       
[Makimura et al., 2002]. AgRP also has a suggested role in pituitary function and may also be                               
involved in inflammatory responses [Xiao et al., 2003; Scarlett et al., 2008]. Using a postnatal                           
AgRP ablation model, it has been shown AgRP is involved in the autonomic output onto the liver,                               
pancreas and muscle. This can alter the the ratio of fat and carbohydrate metabolism, indicated                           
by the development of obesity and hyperinsulinemia on a chow diet, whilst a HFD improves                           
glucose tolerance and reduces weight gain [Joly­Amado, 2012].
Traditionally, the C­terminal fragment has been assumed to be the active part of AgRP, but it                             
was unclear how exactly AgRP was processed, and whether the N­terminal fragments produced                       
by peptide cleavage has a role in energy homeostasis, as they do not bind to the melanocortin                               
receptors [Rossi et al., 1998; Pritchard & White, 2005]. The production of functional AgRP                         
appears to involve cleavage of the peptide before release as a C­terminal product and two                           
N­terminal fragments. Recently, Proprotein Convertase 1 has been shown to play a key role in                           
the production of AgRP fragments. The C­terminal fragment AgRP83­132 appears to be the                       
primary mediator of orexigenic signalling, and is a more potent orexigenic signal compared to full                           
length AgRP. This suggests processing of the peptide before release from the neurons,                       
contradicting the hypothesis that intact AgRP signalling involved the binding of both the                       
C­terminal and N­terminal with a coreceptor, syndecan­3 [Pritchard & White, 2005; Creemers et                       
al., 2006]. Another study showed separate administration of C­terminal and N­terminal fragments                     
increased adiposity and body weight without inducing hyperphagia [Goto et al., 2003]. However,                       
this result has not been replicated, perhaps due to the different techniques involved in generating                           
the N­terminal fragments [Creemers et al., 2006].
AgRP neurons respond to both leptin and insulin, showing a decrease in activity due to a                             
decrease in resting membrane potential [Könner et al., 2007; Takahashi et al., 2005].                       
Additionally, the change in AgRP neuronal activity induced by an insulin­related decrease                     
glucose production in the liver. However, removal of insulin receptors has no effect on                         
phenotype, whilst removal of leptin receptors in AgRP neurons results in modest weight gain                         
without altering food intake or energy expenditure [Könner et al., 2007; van de Wall et al., 2008].                               
AgRP­specific removal of FOXO1, involved in leptin and insulin signalling, shows mice are                       
hypophagic, lean and show improved responsiveness to insulin and leptin. A pharmacological                     
agonist of a downstream target of FOXO1, Gpr17, results in an increase in food intake, whilst                             
antagonism decreases food intake. Knockout of FOXO1 in AgRP neurons abolished these                     





GABA is an amino acid transmitter coexpressed in the arcuate nucleus with AgRP and NPY                           
[Horvath et al,. 1997]. Selective deletion of vesicular GABA transporter (VGAT) from NPY/AGRP                       
neurons results in a decrease in body weight, whilst deletion of VGAT from leptin expressing                           
neurons results in hyperphagia and obesity [Tong et al., 2008; Xu et al., 2012]. Additionally, it                             
appears GABA may mediate the effect of leptin on food intake by responding to leptin and altering                               
inhibitory signalling onto POMC neurons [Vong et al., 2011]. Conversely, loss of GABA signalling                         
in AgRP neurons in the parabrachial nucleus leads to starvation [Wu et al., 2009]. Glutamate,                           
another amino acid transmitter, has also been shown to be an important neurotransmitter in the                           
VMH that inhibits hypoglycemia [Tong et al., 2007]. POMC neurons have been shown to express                           
both glutamate and GABA, which has been confirmed using optogenetic [Hentges et al., 2009;                         
Dicken et al., 2012]. Release of GABA and glutamate within the arcuate nucleus suggests this                           
signalling could affect other first order neurons in the arcuate nucleus and act as a feedback                             
mechanism for POMC neurons, as these neurons express GABA and glutamate receptors                     
[Wang et al., 2001; Reyes et al., 2006]. Glutamate and GABA release was decreased when μ                             
and κ opioid receptor agonists were applied, as well as a GABA agonist [Dicken et al. 2012].
A recent discussion regarding the importance of neurons in the hypothalamus expressing                     
multiple neuropeptides suggest fast acting amino acids, such as glutamate and GABA, are not                         
merely modulatory neuropeptides. A range of fast and slow acting neurotransmitters may allow a                         
broader range of responses, whereby a signal can be maintained using a slow acting                         
neuropeptide, whilst fast acting neurotransmitters can be used for immediate response without                     
being exhausted for long­term signalling [Schöne & Burdakov, 2012].
{1.2.4.4} Orexins
Orexins are neuropeptides derived from a 131 amino acid precursor prepro­orexin that form two                         
functional peptides, orexin A and orexin B. Orexin A is a 33 amino acid peptide with an N­terminal                                 
pyroglutamyl residue and two intrachain disulphide bonds. Orexin B is linear peptide 28 amino                         
acids in length [Martynska et al., 2005]. The actions of orexins are mediated through two G                             
protein­coupled receptors. Ox1R is highly selective for orexin A, whilst Ox2R will bind to both                           
orexin peptide [Sakurai et al., 1998]. Orexins were discovered as endogenous ligands for two                         
orphan G protein coupled receptors using a cell­based reporter system [Sakurai et al., 1998].                         
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Orexins were found to be exclusively produced in the LH, and i.c.v. administration of orexins                           
increased food intake [Sakurai et al., 1998; Fadel et al., 2008]. Simultaneously, another research                         
group discovered orexins and called these proteins hypocretins [de Lecea et al., 1998; Fadel et                           
al., 2008]. Due to its accumulation within the dorsal­lateral hypothalamus, and projections to                       
other hypothalamic nuclei and areas such as the brainstem, thalamus and forebrain, it was                         
suggested these neurons may mediate food intake.
Since these initial findings, orexins are now more widely known for their role in sleep and                             
wakefulness [Sakurai, 2007]. A lack of orexin expression in mice and a spontaneous mutation in                           
the Ox2R in dogs show both models are narcoleptic [Chemelli et al., 1999; Lin et al., 1999].                               
Post­mortem analysis of human narcoleptics also show a large decrease in the number of                         
orexin­producing neurons [Nishino et al., 2000; Thannickal et al., 2000; Peyron et al., 2000].                         
Using optogenetics, it has been demonstrated stimulation of orexin neurons can rapidly alter                       
arousal in mice [Adamantidis et al., 2007].
With regards to food intake, there are obvious implications for altering arousal with regards to                           
appetite control. As described above, i.c.v. infusion of orexin stimulated feeding in mice [Sakurai                         
et al., 1998]. Ox1R antagonists reduce food intake in both wild type mice and ob/ob mice                             
[Haynes et al., 2000; Haynes et al., 2002]. Orexins have been shown to stimulate NPY neurons                             
and hyperpolarise POMC neurons [Yamanaka et al., 2000; Muroya et al., 2003]. Orexins are also                           
required during long periods of food deprivation, which normally disrupts circadian activity                     
[Yamanaka et al., 2003]. Similarly, food anticipation response induced by food restriction is                       
impaired when orexin neurons are ablated [Akiyama et al., 2004; Mieda et al., 2004]. Orexin                           
neurons have also been shown to respond to peripheral cues of energy status, such as glucose,                             
leptin, ghrelin and amino acids [Diano et al., 2003; Yamanaka et al., 2003; Williams et al., 2008;                               
Karnani et al., 2011].
Orexins may also alter reward signalling, again indicating a link between arousal and feeding.                         
Orexin neurons project to reward areas and have been shown to directly stimulate VTA                         
dopamine neurons via Ox1R [Nakamura et al., 2000]. Orexins have been implicated in inducing                         
place preference with both addictive drugs and food, and i.c.v. or VTA infusions of orexin can                             
reinstate reward­seeking behaviour [Boutrel et al., 2005; Harris et al., 2005]. Place preference                       





MCH is a 19 amino acid peptide which is predominantly expressed in the LH in mammals                             
alongside orexin neurons [Bittencourt, 2011]. MCH expression is increased in fasting lean mice                       
and ob/ob mice, whilst an i.c.v. injection of MCH increased food intake [Qu et al., 1996; Rossi et                                 
al., 1997; Ludwig et al., 1998]. Chronic central infusion of MCH led to an increased in food intake,                                 
which showed an increase in body weight in mice, but not in rats [Ito et al., 2003; Della­Zuana et                                   
al., 2002]. Additionally, lipogenic activity in the liver and BAT was increased, along with a                           
decrease in thermogenesis in BAT [Ito et al., 2003]. Coadministration of MCH and NPY showed                           
an additive effect of the two treatments on NPY expression, suggesting MCH­induced food intake                         
may be mediated by another pathway [Della­Zuana et al., 2002].
Mice lacking the MCH gene are hypophagic, resulting in a lower body weight and an increase in                               
energy expenditure, regardless of reduced circulating leptin levels. Reduced POMC expression                   
in the arcuate nucleus was also observed[Shimada et al., 1998]. Knockout of MCH in ob/ob mice                             
showed a dramatic reduction in body fat and an improvement in insulin signalling, but no change                             
in hyperphagia. This appeared to be a result of increased basal energy expenditure and                         
increased locomotor activity [Segal­Lieberman et al., 2003; Alon & Friedman, 2006]. Similarly,                     
ablation of MCH neurons led to late­onset leanness which was also characterised by hypophagia                         
and increased energy expenditure. MCH abated mice showed a normal feeding response to                       
fasting and leptin administration, suggesting MCH is not involved with leptin­mediated satiety                     
[Alon & Friedman, 2006]. Conversely, overexpression of MCH led to hyperphagia and mild                       
obesity [Ludwig et al., 2001].
There are two receptors that mediate the effects of MCH on food intake and energy expenditure.                             
MCH1 and MCH2 receptors are both expressed in the appetite­related areas of the brain,                         
although MCH2 has not been identified in rats or mice [Chambers et al., 1999; Saito et al., 2000;                                 
Sailer et al., 2001., An et al., 2001]. Mice lacking MCH1 receptors are hyperphagic, show                           
increased motor activity and have a lean phenotype [Marsh et al., 2002].
{1.2.4.6} Endogenous opioids
Opioid receptors have been implicated in feeding and food reward. There are three subtypes of                           
opioid receptor found in the CNS: μ, κ, and δ opioid receptors. These respond to endogenous                             
opioid peptides β­endorphin, dynorphin and enkephalins, respectively [Bodnar, 2004; Gosnell &                   
Levine, 2009]. Experiments in the early 1980s showed μ­opioid receptor agonists (morphine)                     
increased the selection of high fat foods and decreased carbohydrate selection in rats, whilst a                           
non­specific antagonist (naloxone) decreased fat intake [Marks­Kaufman & Kanarek, 1981;                 
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Marks­Kaufman, 1982]. Other experiments dispute the effect of opioids on macronutrient                   
selection, suggesting food was selected as a result of individual preference, rather than                       
macronutrient composition, whilst others agree macronutrient composition is key [Gosnell et al.,                     
1990; Woolley et al., 2006; Zhang et al., 1998].
With regards to food intake, a large proportion of the literature suggests opioids lead to an                             
increase in food intake, and this link with food reward is a cause in the overconsumption of                               
palatable foods [Levine et al., 1995; Olszewski & Levine, 2007]. Because of the involvement of                           
food reward, parallels between the opioid system have been drawn with drug addiction [Herz,                         
1997; Gosnell & Levine, 2009; Vuong et al., 2010]. Within the hypothalamus, it has been                           
observed opioids may interact within the melanocortin system. Naxolone (an antagonist) has                     
been shown to reduce the orexigenic effect of AgRP injection into the third ventricle whilst                           
peripheral administration of naxolone increased activation of POMC neurons in the arcuate                     
nucleus [Olszewski et al., 2001]. This suggests opioids increase food intake by suppressing the                         
melanocortin system. However, a study using knockout of β­endorphin, which is found                     
coexpressed in POMC hypothalamic neurons, induced hyperphagia and obesity, suggesting the                   
effects of β­endorphin release are independent from POMC signalling. Both wildtype and                     
knockout mice showed the same orexigenic response to external opioids and an anorexigenic                       
response with an opioid antagonist (naxolone). Together, this data suggests β­endorphin plays a                       
role in food intake similar to that of POMC and in fact decreases food intake [Appleyard et al.,                                 
2003]. However, it was suggested perhaps rewiring within the orexigenic pathways may have                       
occured, or that there could be a difference in the short­ and long­term effects of opioids on food                                 
intake. Given these results, further research is needed to clarify the roles of opioids within                           
different systems to give a coherent picture with regards to all aspects of food intake [Glass et                               
al., 1999]. This can be further illustrated by a study using optogenetics, indicating β­endorphin                         
released by POMC neurons can reduce excitatory synaptic inputs onto AgRP neurons, resulting                       
in a decrease in AgRP activity [Yang et al., 2011].
{1.2.4.7} Endocannabinoids
Marijuana smoking has been shown to increase food intake and body weight in human subjects                           
in laboratory conditions, which appeared to be a result of increased calorie intake between                         
meals, rather than increased meal size [Foltin et al., 1986]. Interestingly, body weight increased                         
beyond that expected as a result of calorie intake alone [Foltin et al., 1988]. Additionally, the                             




The effects of THC are mediated through G protein­coupled cannabinoid receptors, CB1 and                       
CB2 [Matsuda et al., 1990; Munro et al., 1993]. CB1 receptors are found primarily in the brain,                               
whilst CB2 receptors are mainly expressed in the periphery, although CB2 receptors have been                         
shown to be expressed in microglial cells in the brain and may play a role in immune function                                 
[Cabral et al., 2009].
Upon discovery of the cannabinoid receptors, a family of endogenous neuromodulatory                   
cannabinoids ­ endocannabinoids ­ were identified. These are small lipid molecules derived from                       
arachidonic acid, anandamide (arachidonoylethanolamide) and 2­arachidonoylglycerol which           
bind preferentially to CB1 receptors [Rodríguez de Fonseca et al., 2004]. The synthesis,                       
transport, and degradation processes involved in the endocannabinoid system have been well                     
documented [DiMarzo et al., 1994; Cadas et al., 1996; Cravatt et al., 1996; Beltramo et al.,                             
1997].
The hypothalamus has been shown to be an important area for mediating the effects of                           
endocannabinoids on appetite [Bellocchio et al., 2008]. CB1 knockout mice show reduced food                       
intake after fasting, and CB1 antagonists reduce food intake. Leptin knockouts show elevated                       
levels of endocannabinoids in the hypothalamus but not other areas of the brain, and upon leptin                             
treatment, these mice showed normalised endocannabinoid levels [Di Marzo et al., 2001].                     
Endocannabinoids also appear to have a role with the rewarding elements of food and contribute                           
to increased food intake [Williams & Kirkham, 1999; Kirkham, 2003], as well as other emotive                           
processes, including addiction and stress [Navarro et al., 2001; Navarro et al., 1997; Ledent et                           
al., 1999; Sanchis­Segura et al., 2004]. Additionally, endocannabinoids are involved in energy                     
metabolism in other organs, including adipose tissue, pancreas, liver and muscle [Gómez et al.,                         
2002; Bellochio et al., 2009].
{1.2.4.8} Melanocortins
The melanocortin system plays a fundamental role in food intake and energy homeostasis. This                         
large circuit is made up of neurons which contain one of the following features: express                           
melanocortin receptors (G protein­coupled receptors, MC1­MC5); express pro­opiomelanocortin             
(POMC) or its cleavage products; or express the MCR antagonist/inverse agonist AgRP (See                       
Section 1.2.6.2) [Garfield et al., 2009]. POMC is a 32kDa precursor prohormone polypeptide                       
found in the pituitary gland, skin and hypothalamus, predominantly in the arcuate nucleus                       
[Pritchard et al., 2002; Shimzu et al., 2007]. The breakdown of POMC into active components is                             
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specific for different tissues [Raffin­Sanson et al., 2003]. Figure 1.2.4.8.1 shows the breakdown                       
process of POMC in the hypothalamus, showing the productions of α­MSH, γ­MSH and β­MSH                         
(the latter has only been identified in humans), which have been shown to activate MCR                           
[Wardlaw, 2011]. β­endorphin is also a product of POMC cleavage, which has been shown to                           
have a role in food intake and reward (See Section 1.2.6.6). Patients identified with POMC                           
deficiency show early­onset obesity [Krude et al., 1998; Krude et al., 2003; Mountjoy, 2010].                         
Similarly, deletion of the POMC gene in mice results in hyperphagia and obesity, which can be                             
attenuated with α­MSH treatment [Yaswen et al., 1999]. A decrease in oxygen consumption has                         
also been observed with POMC deletion, suggested a role of POMC on energy efficiency                         
[Challiss et al., 2004]. Heterozygous POMC mutants show an increase in obesity, but only with                           
HFD [Challiss et al., 2004].
Figure {1.2.4.8.1} POMC precursor peptide and major cleavage products in the                   
hypothalamus
Pro­opiomelanocortin, POMC; adrenocorticotropic hormone, ACTH; lipoprotein, LPH; N­terminal             
fragment, N­POC; junction peptide, JP; deactyl melanocyte stimulating hormone, DA­MSH;                 
corticotropin­like intermediate lobe peptide, CLIP; endorphin, END. * only present in humans.
MC3/4R have been shown to play a dominant role within the melanocortin system. MC3R                         
knockouts do not show hyperphagic behaviour and only show modest obesity, however they                       
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have reduced lean mass and increased fat mass. This suggests a role of MC3R in altering                             
energy utilisation. When fed a HFD, MC3R knockouts showed a rapid increase in body weight                           
and developed hyperinsulinemia, similar to that observed with MC4R [Butler et al., 2000; Chen et                           
al., 2000]. Deletion of both receptors causes an even greater level of obesity and metabolic                           
problems than deletion of each receptor individually [Chen et al., 2000]. Another suggested role                         
of MC3R is circadian control of glucose and energy homeostasis. This is due to the observation                             
MC3R knockouts subjected to a restricted feeding paradigm do not develop normal meal                       
anticipatory responses [Sutton et al., 2008]. These mice also showed hyperinsulinemia, glucose                     
intolerance, increased expression of lipogenic genes and increased ketogenesis. A number of                     
rhythmically controlled metabolic transcription factors, such as FOXO1, were also disrupted                   
[Sutton et al., 2010].
Global knockout of MC4R results in hyperphagia, severe obesity, hyperleptinemia,                 
hyperinsulinemia and reduced locomotion [Huszar et al., 1997; Marie et al., 2000]. The onset of                           
obesity due to MC4R knockout appears to be mediated by increased food intake, rather than                           
hypometabolism [Weide et al., 2003]. Similarly, patients identified with a dominantly inherited                     
monogenic mutation in the MC4R gene results in obesity [Vaisse et al., 1998; Yeo et al., 1998].                               
Recent research suggests the metabolic effects observed may be independent from changes in                       
food intake and these features may be controlled separately by MC4R in different nuclei.                         
Reexpression of MC4R in single minded 1 (Sim1) cells present only in the PVN and amygdala                             
showed a restoration of food intake, whilst energy expenditure was still reduced, and                       
hyperglycemia and hyperinsulinemia remained [Balthasar et al., 2005]. Similarly, restoration of                   
MC4R in all cholinergic neurons, which includes sympathetic and parasympathetic preganglionic                   
cells, or just in parasympathetic preganglionic cells showed sympathetic and parasympathetic                   
signalling increased energy expenditure and partially reduced body weight, whilst                 
parasympathetic signalling alone had no effect. Reexpression of MC4R in all cholinergic neurons                       
improved insulin and glucose sensitivity in mice, whilst reexpression of MC4R in                     
parasympathetic cholinergic neurons reduced hyperinsulinemia, but had no effect on glucose                   
tolerance [Rossi et al., 2011].
The melanocortin system reduces energy intake by promoting hypophagia, but also increasing                     
energy expenditure. I.c.v. administration of MC3/4R agonist MTII increased UCP­1 expression in                     
BAT and increased BAT temperature, which can be abolished by severing sympathetic neurons                       
[Williams et al., 2003; Brito et al., 2007; Nogueiras et al., 2007]. I.c.v. infusion of MTII increased                               
lipid mobilisation and decreased lipid accumulation in white adipose tissue (WAT). This is                       
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concurrent with increased sympathetic signalling to WAT and BAT [Nogueiras et al., 2007].                       
Similarly, i.c.v. administration of MCR antagonist reduced expression of UCP­1 and ­3 in BAT                         
and increased the expression of lipogenic genes, triglyceride synthesis and triglyceride content                     
in WAT [Nogueiras et al., 2007].
POMC neurons are directly depolarised by leptin [Cowley et al., 2001]. ob/ob mice and fasted                           
lean mice show decreased POMC expression, which is restored with peripheral leptin                     
administration or transgenic overexpression [Schwartz et al., 1997; Thornton et al., 1997; Mizuno                       
et al., 1998; Mizuno et al., 2003]. POMC­specific deletion of leptin receptors results in a mild                             
obese phenotype, due to decreased energy expenditure with no significant change in food intake                         
[Balthasar et al., 2004]. Similarly, reexpression of leptin receptors in POMC neurons in db/db                         
mice lacking leptin receptors show a mild reduction in body weight, although they also show a                             
reduction in food intake [Huo et al., 2009]. The direct effects of leptin on POMC neurons also                               
appears to be important in glucose homeostasis and hepatic glucose tolerance [Berglund et al.,                         
2012].
{1.2.4.9} Cocaine­ and amphetamine­regulated transcript (CART)
CART was first described as a somatostatin­like peptide, originally isolated from the                     
hypothalamus, and later characterised as being regulated by cocaine and amphetamine [Spiess                     
et al., 1988; Douglass et al., 1995]. Within the rat hypothalamus, CART is the third most                             
abundant mRNA and is present in the arcuate nucleus, VMH, DMH, PVN, LH and supraoptic                           
nucleus [Gautvik et al., 1996; Elias et al., 2001]. CART is also expressed in other areas of the                                 
brain including the frontal cortex, amygdala, midbrain, nucleus accumbens and the NTS [Koylu                       
et al., 1997; Koylu et al., 1998; Smith et al., 1999]. The CART propeptide is spliced to produce                                 
four fragments [Murphy, 2005]. The most commonly researched peptide fragment is called                     
CART (55­102) and is found in the hypothalamus and nucleus accumbens [Kuhar et al., 1999;                           
Thim et al., 1999]. Other than CART­mediated processes involved with energy homeostasis,                     
CART has also been shown to influence pain perception, blood pressure and pancreatic function                         
[Hsun et al., 2005; Hwang et al., 2004; Cowles et al., 2001] and is expressed in the adrenal                                 
medulla, pancreas and ileum [Jenson et al., 1999; Koylu et al., 1997; Couceyro et al., 1998].
Traditionally, CART has been regarded as an anorexigenic neurotransmitter, as i.c.v. injection of                       
CART (55­102) dose dependently inhibits feeding in normal and fasted rats, and inhibits                       
NPY­induced feeding [Kristensen et al., 1998; Vrang et al., 1999]. Similarly, chronic i.c.v.                       
injections of CART (55­102) was shown to reduce body weight in normal rats and also obese                             
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Zucker rats [Larsen et al., 2000]. Analysis of changes within the hypothalamus upon i.c.v.                         
injections of CART (55­102) show neuronal activation in the arcuate nucleus, DMH and PVN                         
[Vrang et al., 1999]. A number of hypothalamic neurons show CART coexpression with other                         
appetite regulating neurotransmitters, such as POMC, MCH, CRH and TRH [Vrang et al., 1999;                         
Broberger, 1999]. However, CART knockouts do not show a dramatic change in body weight or                           
food intake, as observed with knockout models of satiety [Asnicar et al., 2001]. Unfortunately, a                           
CART receptor has still yet to be identified and characterised [Murphy, 2005].
In contrast to i.c.v. administration, injection of CART (55­102) into specific nuclei of the                         
hypothalamus has been shown to increase food intake [Abbott et al., 2001]. Although CART is                           
highly coexpressed with POMC neurons, CART has been shown to reduce α­MSH release from                         
explants of the hypothalamus [Stanley et al., 2001]. CART­induced hypophagia is not affected by                         
blocking MC3/MC4R along with an i.c.v. injection of AgRP, indicating the melanocortin system is                         
not involved in CART signalling [Edwards et al., 2000]. The role of AgRP and NPY neurons with                               
regards to CART signalling are also contradictory. In hypothalamic explants, AgRP is released                       
with CART stimulation, whilst AgRP decreased CART release [Dhillo et al., 2002]. With an i.c.v.                           
injection of AgRP, CART expression was increased in the arcuate nucleus [Zheng et al., 2002a].                           
With regards to NPY neurons, CART has not been found to coexpress with NPY neurons, whilst                             
NPY administration leads to an increase in CART expression, and CART similarly increases                       
NPY expression [Stanley et al., 2001; Dhillo et al., 2002].
Blocking the connection between the third and fourth ventricle abolishes the effect of an ic.v.                           
injection of CART reducing food intake, suggesting mediation by the brainstem [Aja et al., 2001].                           
Third and fourth ventricle administration of CART showed neuronal activation in the brainstem,                       
including the NTS [Zheng et al., 2001]. Similarly, CART expressing vagal nerves terminate in the                           
NTS, however direct injection of CART (55­102) into the NTS shows no significant change in                           
food intake [Zheng et al., 2002b].
Given CART appears to be an orexigenic and anorexigenic neurotransmitter, there has been a                         
suggestion CART may mediate heat stress, whereby cold temperatures can lead to increased                       
food intake and increased energy expenditure. Chronic arcuate nucleus injections of CART show                       
an increase in food intake, and an increase in UCP­1 expression in BAT, and increased heat                             
production in response to a β­3 agonist. Similarly, overexpression of CART induced through                       
gene transfer into the arcuate nucleus results in hyperphagia, but reduced body weight gain. This                           
seems to be a result of increased energy expenditure, again shown through increased UCP­1                         
expression in BAT. Chronic cold exposure increased arcuate nucleus expression of CART                     
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[Kong et al., 2003]. PVN injections of CART also increased UCP­1 expression in BAT, but also                             
UCP­2 expression in white adipose tissue and UCP­3 expression in muscle [Wang et al., 2001].
Genetic studies investigating the effect of CART polymorphisms in humans are limited, but there                         
is a suggestion CART is involved in altering fat distribution and may be associated with obesity                             
[Challis et al., 2000]. In animals, fasting reduces CART expression in the arcuate nucleus, which                           
is restored with leptin administration. In ob/ob mice, CART expression is negligible in the arcuate                           
nucleus, and is restored with leptin treatment [Kristensen et al., 1998; McAlister & Van Vugt,                           
2004]. CART also appears to mediate leptin­induced changes in fat accumulation                   
[Rohner­Jeanrenaud et al., 2002]. Chronic i.c.v. injections of CART (55­102) increased lipid                     
oxidation and circulating non­esterified fatty acids, whilst decreasing lipoprotein lipase activity in                     
white adipose tissue [Wortley et al., 2004].
It has been suggested hypophagia induced by i.c.v. CART (55­102) administration may be a                         
result of changes in behaviour. It has been noted i.c.v. administration of CART (55­102) induces                           
anxiety or unusual behaviour in rodents [Kask et al., 2000; Aja et al., 2001; Chaki et al., 2003]. A                                   
tremor has also been observed after administration with no accompanying change in locomotor                       
activity, whilst chronic i.c.v. CART (55­102) administration induced a major reduction in                     





Neuropeptide Y, NPY(N, red); agouti­related peptide (A, orange); gamma­aminobutyric acid,                 
GABA; pro­opiomelanocortin (POMC, blue); CART, cocaine­ and amphetamine­regulated             
transcript (CART). Image taken from Mercer et al., 2011.
{1.2.4.10} Brain derived neurotrophic factor (BDNF)
BDNF is a member of the neurotrophin family, small proteins that have been shown to be                             
important during the development of the CNS and PNS. Two functional classes of BDNF cell                           
surface receptors are present in the the CNS: p75 neurotrophin receptor (p75NTR) and tyrosine                         
kinase receptor B (TrkB). Pro­BDNF preferentially binds to p75NTR, whilst BDNF binds                     
preferentially to TrkB. BDNF binding to TrkB shows a key role in regulating synaptic activity,                           
neurotransmission and neuronal plasticity [Rosas­Vargas et al., 2011]. In the adult CNS, BDNF                       
and TrkB are widely expressed in the hippocampus, amygdala, cortical areas and the                       
hypothalamus [Hofer et al., 1990; Yan et al., 1997].
Other than it’s role in development and synaptic plasticity, BDNF appears to have a role in the                               
regulation of food intake and energy metabolism [Noble et al., 2011]. Injection of BDNF into the                             
third ventricle has shown to inhibit weight gain and food intake in rats [Lapchak & Hefti 1992;                               
Pelleymounter et al., 1995]. Heterozygous knockout of BDNF in mice results in hyperphagia and                         
age­dependent obesity, which can be reversed with third ventricle injections of BDNF [Kernie et                         
al., 2000; Fox & Bryerly, 2004]. Additionally, heterozygous knockout of BDNF causes                     
abnormalities in serotonin neurons in the hypothalamus, hippocampus and frontal cortex,                   
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thereby also altering food intake by disrupting serotonin signalling (See Section 1.2.6.13; Lyons                       
et al., 1999).
It has been suggested BDNF expression in the VMH is important with regards to regulating food                             
intake. BDNF is highly expressed in the VMH and leptin administration increases BDNF in the                           
VMH [Kernie et al., 2000; Komori et al., 2006] It has also been suggested that melanocortin                             
expression controls BDNF signalling [Xu et al., 2003; Unger et al., 2007]. BDNF administration to                           
the VMH has been shown to attenuate NPY­induced feeding [Wang et al., 2007]. Additionally,                         
BDNF has been shown to increase energy expenditure by increasing spontaneous activity and                       
resting metabolic rate, but had no effect on BAT thermogenesis [Wang et al., 2010]. The PVN                             
has also been implicated in the BDNF­related decrease in food intake, and may act through                           
increasing corticotropin­releasing hormone (CRH) [Toriya et al., 2010].
{1.2.4.11} Corticotropin releasing hormone (CRH)
CRH is a 41 amino acid neuropeptide found in the parvocellular neurosecretory cells in the                           
medial part of the PVN [Sawchenko & Swanson, 1985; Richard et al., 2000]. CRH is mostly                             
associated with adrenocorticotropic hormone (ACTH) secretion in the pituitary gland and is                     
released in response to stress [O'Connor et al., 2000]. Additionally, administration of CRH has                         
been shown to reduce food intake and increase movement and grooming [Krahn et al., 1988].                           
Leptin has also been shown to increase the expression of CRH2 receptors in the VMH, and CRH                               
antagonists were able to abolish the anorexigenic effect of leptin [Huang et al., 1998; Uehara et                             
al., 1998].
CRH has been shown to induce thermogenesis, which appears to be mediated by the PVN and                             
medial preoptic area, although lesions to the PVN do not abolish the anorexigenic effects of                           
exercise, suggesting other areas of the brain which may be involved in altering energy balance                           
[Egawa et al, 1990; Rivest & Richard, 1990]. The VMH has been excluded as a candidate area,                               
as VMH­specific CRH injection do not alter food intake or BAT activity [Krahn et al., 1988; Arase                               
et al.,1989].
{1.2.4.12} Thyrotropin releasing hormone (TRH)
TRH is a tripeptide hormone released by parvocellular neurosecretory cells in the PVN that                         
stimulates pituitary production of thyrotropin [Ishiwaka et al., 1988]. This in turn stimulates the                         
production of thyroxine, a thyroid hormone involved in metabolic regulation. However, the                     
distribution of TRH­expressing neurons in the PVN appears to be different between rats and                         
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mice, as well as the structure of the PVN as a whole [Kádár et la., 2010]. Using food restriction                                   
and dehydration­induced anorexia in rats, it has been suggested different parts of the PVN                         
releasing TRH may react in different ways to a negative energy balance depending on the source                             
of energy deprivation [Alvarez­Salas et la., 2012].
Thyroid hormones have been shown to have an effect on appetite [Amin et al., 2011]. Central                             
administration of TRH has been shown to reduce food intake in fed mice and fasted mice                             
[Vijayan & McCann, 1977; Suzuki et al., 1982]. Physical activity is also increased with TRH                           
administration, increasing energy expenditure and thereby reducing energy intake [Vogel, 1979;                   
Wei et al., 1975].
TRH have been shown to excite orexin neurons in the LH, but hyperpolarises MCH neurons                           
[Hara et al., 2009; González et al., 2009; Zhang & van den Pol, 2012]. In the same study, TRH                                   
did not alter NPY or POMC activity, suggesting TRH may reduce food intake by decreasing MCH                             
activation. A significant number of TRH neurons coexpress leptin receptors and show a                       
dose­dependent increase in TRH expression in response to leptin. Additionally, α­MSH increased                     
TRH expression in addition to leptin stimulation, whilst an MCR antagonist suppressed                     
leptin­induced TRH expression. Alongside increased TRH expression in response to                 
anorexigenic neuronal signaling, NPY was shown to inhibit TRH synthesis [Nillni et al., 2000].
{1.2.4.13} Serotonin
Serotonin is a monoamine neurotransmitter commonly associated with mood and anxiety                   
[Nordquist & Oreland, 2010]. It is synthesised throughout the enteric nervous system and CNS.                         
Serotonin is derived from the essential amino acid tryptophan, which is acquired from the diet.                           
Within the CNS, serotonin is synthesised by serotonin neurons in the Raphe nucleus of the                           
brainstem, which form 9 distinct neuronal populations. Neuronal projections from the Raphe                     
nucleus include the midbrain, cerebellum, other areas of the brainstem, cortex, hypothalamus                     
and amygdala [Lam et al., 2010]. There are 7 groups of serotonin receptors, 5­HT1R­5­HT7R, all                           
except 5­HT3R are G protein­coupled receptors [Nichols & Nichols, 2008].
Early experiments suggested serotonin’s role in regulating food intake, where inhibition of                     
serotonin synthesis induced pharmacologically specifically within the brain resulted in                 
hyperphagia and weight gain [Breisch et al., 1976]. One of the most successful weight loss                           
drugs released was D­fenfluramine (D­Fen), which induces the release of serotonin and blocks                       




Animal knockout models suggest 5­HT2CR plays a crucial role for mediating serotonin’s effect on                         
food intake, whereby knockout of the receptor leads to increased food intake and meal frequency                           
[Tecott et al., 1995; Nonogaki et al., 1998; Vickers et al., 1999]. Blocking the function of 5­HT2CR                               
pharmacologically also affects food intake, whereby agonists reduce food intake and antagonists                     
result in hyperphagia [Martin et al., 1998; Schreiber & De Vry, 2002; Lam et al., 2008].
Within the hypothalamus, serotonin appears to enhance satiety by stimulating POMC neurons,                     
whilst simultaneously inhibiting AgRP neurons [Heisler et al., 2006]. Knockouts of the MC4R,                       
which acts downstream of POMC signalling, abolish hypophagia normally induced by D­Fen or                       
serotonin receptor agonist administration [Heiser et al., 2006; Lam et al.,2008]. Re­expression of                       
5­HT2CR on POMC neurons is sufficient to recover the obese phenotype observed in full                         
5­HT2CR knockouts, demonstrating the crucial role of POMC function mediating the effect of                       
serotonin [Xu et al., 2008]. Similarly, serotonin appears to induce satiety by also inhibiting an                           
orexigenic response. NPY neurons have been shown to be hyperpolarised by 5­HT1BR agonists,                       
whilst NPY mRNA expression is reduced when serotonin production is increased, whilst a                       






Dopamine is a catecholamine neurotransmitter derived from the amino acid tyrosine. The rate                       
limiting enzyme for dopamine synthesis is tyrosine hydroxylase (TH), which catalyses the                     
hydroxylation of tyrosine into L­3,4­dihydroxyphenylalanine (L­DOPA). This undergoes             
decarboxylation to produce dopamine in the presynaptic neurons, which is then transferred into                       
synaptic vesicles by vesicular monoamine transporter (VMAT), where further processing is                   
undertaken to produce noradrenaline and adrenaline (norepinephrine and epinephrine) (Figure                 
1.2.5.1.1.A) [Daubner et al., 2011]. A rare deletion in the TH gene has been implicated in the                               
development in Parkinson’s disease, whilst polymorphisms in the gene may be associated with                       
mood disorders and hyperactivity [Bademci et al., 2010; Kubinyi et al., 2012].
Dopaminergic neurons are located in the ventral midbrain and can be subdivided into three main                           
groups. Lateral A9 dopamine neurons are located in the substantia nigra (S.Nigra). The medial                         






Dopamine signalling is predominantly terminated by removing dopamine from the synapse                   
through the dopamine reuptake transporter, a sodium­dependent transporter (DAT) [Torres et                   
al., 2003]. Another mechanism for terminating dopamine signalling is through enzymatic                   
degradation. Two enzymes are involved in the breakdown of dopamine: monoamine oxidase                     
(MAO) and catechol­O­methyltransferase (COMT). MAO converts dopamine to             
3,4­dihydroxyphenylacetic acid (DOPAC), which is converted to homovanillic acid (HVA) by                   
COMT. Alternatively, dopamine can be converted to 3­methoxytyramine (3­MT) by COMT, then                     
degraded further to HVA by MAO (Figure 1.2.5.1.1.B). Both enzymes are highly expressed in the                           
hypothalamus [Myöhänen et al., 2010; Tong et al., 2013]. Polymorphisms in MAO and COMT                         
genes have been linked schizophrenia and other psychiatric illnesses in humans [Craddock et                       
al., 2006; Matsumoto et al., 2004; Volavka et al., 2006.
DAT is involved in mediating a number of drug responses, such as cocaine and amphetamines                           
[Kalivas, 2007; Beuming et al., 2008]. However, global knockout models are accompanied by a                         
number of phenotypic abnormalities, such as dwarfism [Bossé et al., 1997]. Unexpectedly, these                       
mice still exhibit a reward response to cocaine [Rocha et al., 1998; Sora et al., 1998; Medvedev                               
et al., 2005]. This may be due to compensatory mechanisms from serotonin and noradrenaline                         
transporters (SERT and NET). SERT and NET inhibitors show no effect on reward response in                           
wild type mice, whilst an alteration is exhibited with global DAT knockout mice [Carboni et al.,                             
2001; Shen et al., 2004; Budygin et al., 2004]. A knock­in DAT model that is insensitive to                               
cocaine (DAT­CI) produces mice which show no reward response to cocaine [Chen et al.,                         
2006]. DAT knockdown models, where DAT expression is reduced by 90% also show a reduced                           
response to amphetamine and cocaine [Zhuang et al., 2001; Tilley et al., 2007]. Similarly, there is                             
an altered response to sweet rewards which appear to indicate elevated dopamine increases                       
“wanting” and motivation learning in motivation tasks, but has no effect on “liking”, as there is no                               
behavioural change to sweet tasting food [Peciña et al., 2003; Cagniard et al., 2005].
Dopamine binds to five different dopamine receptors, D1­D5. The D1 family of receptors (D1                         
and D5) are coupled to Gαs, which increases cAMP concentration upon stimulation. Conversely,                       
the D2 family of receptors (D2­D4) are coupled to Gαi, which inhibits the production of cAMP in                               
response to dopamine binding [Beaulieu & Gainetdinov, 2011]. D1 receptors (D1R) are                     
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expressed through the nigrostriatal and mesolimbic and mesocortical areas, including the                   
hypothalamus, striatum (caudate putamen, CPu), nucleus accumbens (NAc), amygdala and                 
prefrontal cortex (PFC). D2 receptors (D2R) are highly expressed in the NAc, striatum and                         
olfactory bulb. They are also expressed in the S.Nigra, VTA, hypothalamus, and amygdala. Using                         
promoter­specific fluorescent reporters, the receptor profile of dopaminergic projections can be                   
determined. For example, medial spiny neurons that project to the medial globus pallidus and                         
S.Nigra show a direct nigrostriatal pathway that express D1R specifically. Projection­specific                   
receptor expression could show pathway functionality. Additionally, D1R are exclusively                 
postsynaptically expressed, whilst both D2R and D3R are expressed in the presynaptic and                       
postsynaptic terminal, indicating presynaptic autoreceptors that provide a feedback mechanism                 
for dopamine transmission [Beaulieu & Gainetdinov, 2011]. In a diet preference study, D1R                       
agonists increased the preference of high fat and high sugar food in rats, whilst a D2R/D3R                             
agonist reduced this preference [Cooper & Al­Naser, 2006]. Knockdown of D1R and D2R is                         
lethal, but this appears to be due to a gastrointestinal defect [Kobayashi et al., 2004]. However,                             
chronic D2R blockade increases obesity and down regulation of D2R is commonly linked to                         
obesity [Cope et al., 2005; Palmiter, 2007; Vucetic & Reyes, 2010].
An increase in cAMP leads to the activation of cAMP­dependent protein kinase (PKA), which in                           
turn phosphorylates dopamine and cAMP­regulated phosphoprotein of 32 kDa (DARPP­32) at                   
residue Thr34. Phosphorylated DARPP­32 inhibits protein phosphatase 1 (PP1), which in turn                     
alters expression of AMPA and NMDA glutamate receptors, GABAA receptors, other transcription                     
factors, voltage­gated ion channels and some kinases. Alternatively, DARPP­32 can be                   
phosphorylated at residue Thr75 which inhibits PKA, in turn altering activation of other                       
downstream molecules [Svenningsson et al., 2000]. In addition to being able to respond to                         
alterations in cAMP in response to glutamate, serotonin, opioids and other substances, such as                         





A) Activity in response to D1 receptor stimulation; B) activity in response to D2 receptor                           
stimulation. Taken from Fernandez et al., 2006.
There are three pathways associated with dopamine signalling. The nigrostriatal pathway is                     
mostly associated with motor control and dopamine projections originate from the S.Nigra and                       
project to the dorsal striatum. The tuberoinfundibular pathway originates from parvocellular                   
neurosecretory cells in the PVN and arcuate nucleus which project to the anterior pituitary gland.                           
The mesolimbic and mesocortical pathways originate from dopamine neurons in the VTA and                       
project to the NAc and PFC, respectively. Signalling in this pathway is associated with motivation                           
for food and mediating the rewarding properties of food [Wise, 2006]. Initial findings suggested a                           
role of dopamine in feeding behaviour, as observed in dopamine deficient­mice, which are                       
aphagic and adipsic [Szczypka et al., 1999; Palmiter, 2008]. However, dopamine has many roles                         
in neuronal signalling, including movement control. This has led to research attempting to                       
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decipher the exact role of dopamine within the context of feeding, and determining the relative                           
importance of it’s projections
The tuberoinfundibular pathway appears to be primarily involved in prolactin secretion [Gudelsky,                     
1981; Ben­Jonathan & Hnasko, 2001]. This pathway has had minimal research with regards to                         
reward signalling.
Degeneration of the nigrostriatal pathway is commonly associated with Parkinson’s disease,                   
who show decreased body weight. However, this could be the result of motor and cognitive                           
degeneration [Hornykiewicz, 2008]. In rat models, food and water intake is decreased with                       
lesions to the S.Nigra [Ungerstedt, 1971; Smith et al., 1972]. Similar to human patients, these                           
rats also show alterations in movement [Pioli et al., 2008]. Interestingly, re­expression of TH in                           
the dorsal striatum (caudate putamen, CPu) but not in the ventral striatum (nucleus accumbens,                         
NAc) in TH knockout mice showed restoration of feeding behaviour for palatable food, but this                           
was not able to sustain long­term feeding behaviour [Zhou & Palmiter, 1995; Szczypka et al.,                           
1999]. Although difficult to dissociate with the motor functions of this pathway, there is evidence                           
to suggest nigrostriatal dopamine signalling is involved in goal­directed behaviour [Palmiter,                   
2008]. Imaging studies have shown activation in the striatal regions towards visual cues and can                           
be correlated with meal pleasantness [Volkow et al., 2002; Small et al., 2003].
The mesolimbic and mesocortical dopamine system is commonly associated with reward and                     
addiction, as well as resilience, memory, stress and mood disorders [Tye et al., 2012]. Food                           
intake is commonly in excess of what is homeostatically necessary. Additionally, food is                       
considered pleasurable or a reward, and can be treated as so in scientific experiments where                           
humans and animals will work for palatable food. This suggests feeding can be separated into                           
homeostatic feeding and hedonic feeding [Zheng & Berthoud, 2007]. The role of the mesolimbic                         





Figure 1.2.5.2.1 shows some of the signalling pathways involved in reward signalling. Additional                       
pathways include serotonin, opioid and endocannabinoid signalling, some of which directly alter                     
dopamine signalling [Olijslagers et al., 2006; Britt & McGehee, 2008; Melis & Pistis, 2007].                         
Dopaminergic neurons project from the VTA to the amygdala, nucleus accumbens and                     
prefrontal cortex (Figure 1.2.5.2.1).
Figure {1.2.5.2.1} Schematic of reward circuitry
Dopamine neurons (blue) project from ventral tegmental area (VTA) to the nucleus accumbens                       
(NAc), medial prefrontal cortex (mPFC), amygdala and hippocampus. This forms the                   
mesolimbic pathway. GABAergic neurons project from the NAc to VTA and hypothalamus.                     
Glutamatergic afferents from the mPFC, amygdala and hippocampus project to the NAc, whilst                       
glutamatergic projections are observed in the amygdala to the VTA. Afferents from the                       
hypothalamus (shown as ARC and LH) project VTA and NAc, such as orexins and other                           
neuropeptides.
CP, caudate­putamen; DMT, dorsomedial thalamus; SC, superior colliculus; IC, inferior                 




The VTA is the source of dopaminergic projections within the mesolimbic and mesocortical                       
pathways. The majority of neurons in the VTA are dopaminergic whilst approximately 20% are                         
GABAergic, which have also been shown to project to the striatum and PFC [Margolis et al.,                             
2012]. Direct optogenetic stimulation of VTA dopamine neurons has been shown to be sufficient                         
to reinstate food seeking behaviour [Adamantidis et al., 2011]. Similarly, dopamine stimulation                     
using this method can also reinforce operant feeding, and dopamine efflux in the limbic areas is                             
necessary to induce appetitive behaviour [Gambarana et al., 2003; Kim et al., 2012]. The VTA                           
has been shown to respond to more specific regional effects and also respond a number of                             
feeding­related signals, such as leptin, ghrelin and insulin [Fulton et al., 2006; Hommel et al.,                           
2006; Domingos et al., 2011; Abizaid et al., 2006; Könner et al., 2011]. In normal mice, leptin is                                 
shown to inhibit VTA dopamine neurons, whilst studies in ob/ob mice showed decreased VTA                         
dopamine, which were normalised upon leptin administration [Hommel et al., 2006; Fulton et al.,                         
2006; Roseberry et al., 2007]. However, another study in ob/ob mice showed no effect of leptin                             
on VTA dopamine expression when injected directly into the VTA, but did normalise when                         
injected into the LH, suggesting leptin signalling affects VTA dopamine activity indirectly via the                         
LH [Leinninger et al., 2009].
An important projection site involved in reward and hedonic feeding is the ventral striatum, which                           
contains the NAc [Salamone et al., 2003]. An increase in dopamine is observed during feeding                           
and hypothalamic stimulation [Church et al., 1987; Hernandez & Hoebel, 1988]. Similarly, high fat                         
food and sucrose increase dopamine released in the NAc [Hajnal & Norgren, 2001; Hajnal et al.,                             
2004; Liang et al., 2006]. The shell and core of the NAc appear to have different roles in feeding,                                   
with the shell showing increased dopamine levels in anticipation of food presentation, whilst the                         
core showed increased dopamine efflux when presented with food [Bassareo & Di Chiara,                       
1999]. The level of dopamine efflux in the NAc has also been correlated with motivational                           
behaviour [Wilson et al., 1995]. Dopamine release appears to be extremely rapid in the NAc, with                             
transient increases observed in subsecond times, which peak at the point of operant behaviour                         
(e.g. lever press for sucrose) [Roitman et al., 2004]. This has also been observed in response to                               
operant training for cocaine [Phillips et al., 2003]. However, pharmacological reduction of                     
dopamine in the NAc or lesions do not alter food intake, rather altering the effort to obtain food,                                 
indicating a role of the NAc in motivation for food [Salamone et al., 1997; Salamone et al., 2002;                                 
Kelley et al., 2005]. An increase in dopamine concentration in the NAc enhances operant                         
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responding for food or food­cues, but again doe not alter food intake [Kelley et al., 2005; Baldo et                                 
al., 2007]. Some studies have suggested dopamine signalling within the NAc encodes “wanting”                       
of food. For example, knockout of DAT in the NAc results in an increase in food intake and body                                   
weight in mice [Peciña, et al., 2003]. Another study showed increased calorie consumption                       
induced by intragastric fat infusion decreased ventral striatal dopamine release, indicating an                     
increase in dopamine in this area would results in an increase in food intake [Ferreira et al.,                               
2012].
Another projection site within the striatum is the dorsal striatum, which contains the CPu. Mice                           
deficient in TH show aphagia and adipsia, but will consume food and water when assisted. Free                             
feeding and drinking is restored with restoration of TH production in the dorsal striatum                         
[Szczypka et al., 2001; Palmiter, 2008]. This indicates the importance of dorsal striatal dopamine                         
signalling in the goal­directed behaviours. A study in humans using PET showed dorsal striatum                         
D2R binding correlated with ratings of meal pleasantness. Additionally, this study did not show a                           
correlation between D2R binding and meal rating in the ventral striatum. This indicates an                         
increase in dorsal striatal dopamine signalling correlated with the increased pleasure                   
experienced [Volkow et al., 2002; Small et al., 2003]. Increased activity in the dorsal striatum has                             
been shown to mediate abnormal anticipatory activity in response to food cues in humans, and                           
appears to be associated with increased connectivity to the insula and amygdala, and reduced                         
inhibitory control from prefrontal regions [Nummenmaa, et al., 2012]. Taken together, results                     
from numerous studies suggest dopamine signalling within the dorsal striatum encode “wanting”                     
of food [Volkow et al., 2011]. In contrast, other studies suggest decreased dopamine signalling in                           
the dorsal striatum may increase feeding. Ferreira et al showed dorsal striatal dopamine                       
increased with increased calorie intake (via intragastric fat infusion), and disruption of D2R                       
increased calorie consumption [Ferreira et al., 2012]. Similarly, decreased D2R expression has                     
been observed in “junk food” fed obese rats. Viral knockdown of D2R increased compulsivity, a                           
trait associated with binge eating, but did not alter food intake after two weeks of feeding                             
[Johnson & Kenny, 2010].
Ablation of the central nucleus of the amygdala increased food intake and dopamine release has                           
been observed in the amygdala in response to food [Holland et al., 2002; Hajnal et al., 1997].                               




The PFC can mediate top­down control of the VTA, NAc and amygdala [Gabbott et al., 2005].                             
Food intake has been shown to increase dopamine release in the PFC [Hernandez & Hoebel,                           
1990]. However, lesions to the PFC do not significantly alter self­administration (SA) of cocaine                         
[Martin­Iverson et al., 1986]. Ventromedial PFC lesions do not alter free­feeding behaviour but do                         
reduce cue­driven food consumption, although this may be a defect in learning [Petrovich et al.,                           
2007]. Interestingly, a study utilising optogenetics has shown two types of projections from the                         
VTA: one to the NAc and one to the PFC. It appears projections to the NAc encode                               
reward­related behaviour, whilst projections to the PFC promote aversive­like behaviour                 
[Lammel et al., 2012].
The exact contributions of dopamine signalling at a neuronal level and at a system level towards                             
reward behaviour can be interpreted in a number of ways. Studies indicate a difference between                           
“liking” and “wanting” in terms of reward response. It has been suggested dopamine mediates                         
the wanting response, meaning the motivation to acquire a reward, whilst the opioid system                         
regulates the liking response. Sensitisation of reward circuits to either drugs or palatable foods                         
may alter “wanting”, leading to compulsive behaviour, without necessarily altering the perceived                     
pleasure of the reward. This is discussed in further detail by Berridge, 2009. Similarly, although                           
the dopaminergic system has been neuroanatomically characterised, the functional and                 
molecular properties of different dopaminergic projections are unknown. Fast phasic firing in VTA                       
dopamine neurons has been suggested to encode reward prediction errors. Firing rate                     
significantly increased to novel or unpredicted rewards, whilst a decrease in firing rate is                         
observed when a predicted reward is omitted [Schultz, 2007]. In line with this, it has also been                               
shown D1R and D2R can behave differently to encode persistent reinforcement and transient                       
punishment [Kravitz et al., 2012]. However, slow tonic firing has also been observed in these                           
neurons, with a suggested role in salience or working memory [Stefan & Moghaddam, 2006].                         
Along these lines, two different types of dopaminergic projections were characterised by firing                       
pattern. One set of dopaminergic neurons projected to the PFC, NAc core and medial shell, and                             
the basolateral amygdala. These neurons showed fast­ﬁring patterns and small DAT/TH mRNA                     
expression ratios. Another set of neurons projected only to the NAc lateral shell and dorsolateral                           




With regards to feeding, dopamine can be considered more as a modulator of feeding signals,                           
rather than necessary for actual feeding [Palmiter, 2007; Narayanan et al., 2010]. In turn, these                           
circuits can be affected by peripheral state and alter motivation for feeding, again another                         
mechanism in which the periphery can influence food intake.
{1.2.5.3} The effects of central and peripheral signals on dopamine signalling
Reward related behaviours can be altered according to energy status. Food deprivation and                       
calorie restriction results in an increase in SA of a psychoactive drugs, and appears to be related                               
to weight loss [da Vaca & Carr, 1998; Carr, 2002; Fulton et al, 2004; Fulton et al., 2006b]. In                                   
contrast, obese rats decrease cocaine SA, and obesity and HFD decreased                   
amphetamine­induced place preference and operant responding for sucrose [Wellman et al.,                   
2007; Davis et al., 2008].
However, obesity still seems to induce reward responses to palatable food. Obese patients                       
show altered neural activation to food­related cues and show increased craving for high calorie                         
food compared to lean controls [Stice et al., 2009]. Similarly, high calorie diet enhanced the                           
response to food rewards in animals, whilst the absence of satiety signalling in rats via CCK­1                             
receptors show more sucrose SA compared to lean rats [Hajnal et al., 2007].
Centrally derived signals have also been shown to modulate dopamine signalling. Dopaminergic                     
neurons in the hypothalamus and VTA express NPY receptors. NPY appears to enhance the                         
release of dopamine from striatal neurons via Y2 receptors and increases food reward via Y1                           
receptors, whilst dopamine appears to inhibit both dopaminergic and GABAergic neurons in the                       
VTA [Ault et al., 1998; Adewale et al., 2005; Korotkova et al., 2006; Sørensen et al., 2009;                               
Skibicka et al., 2012]. To counterbalance this, D2R activation inhibits NPY release and chronic                         
treatment with a D2 agonist or antagonist increased or decreased NPY mRNA expression,                       
respectively [Pelletier & Simard, 1991; Cao et al., 2007]. In the amygdala, acute D1R/D2R                         
antagonist administration decreased NPY mRNA expression, whilst chronic administration               
increased NPY mRNA expression [Smialowska et al., 2001].
As with orexigenic signalling, the melanocortin and dopaminergic systems interact. Melanocortin                   
receptor agonist MTII stimulated the production of a dopamine metabolite, whilst a melanocortin                       
antagonist inhibits its production in the NAc and CPu [Yang & Shieh, 2005]. α­MSH stimulates                           
dopamine efflux in the NAc when injected into the VTA and is mediated by MC4R [Lindblom et al.,                                 
2001]. Interestingly, chronic administration of MTII showed different effects in reward areas,                     
where D1R binding increased in the NAc core and CPu, whilst D2R binding increased in the VTA                               
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but decreased in the CPu [Lindblom et al., 2002]. In the hypothalamus, D2R agonists decreased                           
the response of neurons to α­MSH, whilst a D2R antagonist increased the release of α­MSH                           
[Tiligada et al., 1989]. A global increase in dopamine levels through cocaine administration                       
increased MC4R expression in the striatum and downregulated POMC mRNA in the arcuate                       
nucleus [Alvaro et al., 2003]. However, chronic treatment with a D2R agonist increased arcuate                         
nucleus POMC mRNA expression, whilst a dopamine antagonist decreased POMC mRNA                   
expression [Tiligada et al., 1989].
Orexin neurons in the LH project to the VTA and has shown to stimulate VTA dopamine neuron,                               
where orexin receptors are expressed by dopaminergic neurons [Korotkova et al., 2003].                     
Additionally, orexin VTA signalling is necessary for behavioural sensitisation to cocaine [Borgland                     
et al., 2006]. Orexin injected into the VTA increase dopamine release in the NAc but does not                               
alter feeding [Narita et al., 2006]. However, orexin signaling in the VTA is also required for                             
opioid­induced preference for high fat diet [Zheng et al., 2007]. Dopamine can also affect orexin                           
signalling in the LH, where D1 and D2 receptor agonists increase c­Fos expression in LH orexin                             
neurons. Similarly, a combined dopamine receptors antagonist decreased activation in orexin                   
neurons, but separate D1 and D2 receptor antagonists did not. Additionally, these effects were                         
unaltered by NAc lesions, indicating dopamine­induced activity in the LH is not mediated by the                           
NAc [Bubser et al., 2005]. Leptin receptors in the VTA are not expressed either orexin­ or                             
MCH­expressing neurons, instead they appear to be expressed in a subpopulation of GABAergic                       
neurons [Leinninger et al., 2009].
Also within the lateral hypothalamus, MCH neurons project to the NAc and coexpress D1 and D2                             
receptors with MCH receptors. MCH injection into the NAc medial shell increases dopamine                       
releases and induced feeding. In line with this, a MCH receptor antagonist decreased dopamine                         
release and reduced feeding [Pissios et al., 2006; Chung et al., 2009]. DAT expression is                           
significantly elevated in MCH knockout mice, indicating MCH prevents reuptake of dopamine.                     
These mice also showed no hyperphagia when presented with a palatable diet [Pissios et al.,                           
2008].
There is also a theory that cotransmission of dopamine and glutamate may play in reward and                             
addictive behaviour [Lapish et al., 2006]. This can be observed in the fast transient signalling                           
observed in the NAc and PFC, whilst glutamate receptors are expressed in the VTA suggesting                           
a feedback mechanism [Chuhma et al., 2004; Lavin et al., 2005; Mendez et al., 2008].                           
Additionally, glutamate modulation in the NAc can have a profound effect on feeding [Kelley,                         




Due to the interaction of energy state and reward response, the role of satiety signals,                           
particularly signals directly linked with adiposity such as leptin and insulin, have been studied as                           
a potential modulatory mechanism. As discussed in Section 1.3, obesity alters the expression of                         
a number of these satiety signals, which in turn can alter feeding through indirect neuronal                           
modulation of appetite circuits. This hypothesis is further strengthened by the observation leptin                       
and insulin receptors are expressed in the VTA, whilst connections between the dopaminergic                       
system and the hypothalamus have also been suggested to modulate dopaminergic signalling                     
[Nakamura et al., 2000; Fadel et al., 2002; Figlewicz et al., 2003; Korotkova et al., 2003].                             
Examples include fasting decreases DAT mRNA expression, suggesting an increase in                   
sensitivity to dopamine, whilst feeding evoked dopamine release is attenuated by leptin                     
administration [Patterson et al., 1998; Krügel et al., 2003].
High levels of insulin have been shown to reduce SA, whilst i.c.v administration of insulin and                             
leptin reduce the rewarding properties of LH self stimulation for an extended period of time                           
[Bruijnzeel et al., 2011]. Similarly, SA of cocaine in rats was reduced with abnormally high levels                             
of circulating insulin, whilst i.c.v. leptin administration reduced food deprivation­induced heroin                   
SA [Galici et al., 2003]. Similar to addictive drugs, i.c.v. administration of insulin and leptin                           
reduced SA of sucrose [Figlewicz et al., 2006]. Further investigation showed the effects of insulin                           
on SA behaviour appeared to be mediated by the arcuate nucleus, [Figlewicz et al., 2008].
Interestingly, direct administration of insulin to the VTA does not affect food SA, although it does                             
appear to decrease opioid­induced sucrose intake in rats and decreases intake of palatable food                         
[Sipols et al., 2002; Figlewicz et al., 2008; Mebel et al., 2012]. I.c.v administration of insulin                             
coupled with i.p. injections of D2 receptor antagonist showed a reduction in sucrose                       
consumption [Sipols et al., 2000]. Continuous i.c.v. administration of insulin and hyperinsulinemic                     
Fa/Fa Zucker rats show decreased self stimulation, correlated with increased expression of DAT                       
mRNA in the VTA and S.Nigra [Figlewicz et al., 1994; Figlewicz et al., 1998]. Insulin has been                               
shown to directly increased dopamine neuronal firing in the VTA and S.Nigra. Knockdown of                         
insulin receptors in dopamine neurons abolished this response and resulted in hyperphagia and                       
obesity, whilst cocaine­induced locomotion was decreased in these mice [Könner et al., 2011].                       
Functional DAT is also required to mediate these effects, as DAT antagonism or DAT knockout                           
mice abolishes this reaction. Together with the observation insulin upregulates DAT, it appears                       
DAT is essential in mediating the insulin response, by removing dopamine from the synapse                         
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[Figlewicz et al. 1994; Mebel et al., 2012]. It has recently been shown insulin dose­dependently                           
induces long­term depression in neurons that synapse onto VTA dopamine neurons, and this                       
process requires activation of Akt and mTOR signalling. Endocannabinoids also appear to                     
mediate presynaptic inhibition of glutamate release via the CB1 receptor [Labouèbe et al., 2013].                         
Normal insulin response in appetite and reward areas in humans was attenuated in insulin                         
resistant patients, indicating reduced response to peripheral energy signals could facilitate                   
overeating [Anthony et al., 2006].
Direct administration of leptin to the VTA decreased food intake [Hommel et al., 2006; Figlewicz                           
et al., 2008]. Similarly, RNAi­mediated knockdown of leptin receptors in the VTA led to an                           
increase in food intake and increased sensitivity to palatable food [Hommel et al., 2006]. Using                           
retrograde tracers, these leptin receptor­expressing dopamine neurons in the VTA project to the                       
nucleus accumbens. ob/ob mice show decreased amphetamine­induced locomotion and also                 
show decrease dopamine expression and release in the nucleus accumbens [Fulton et al.,                       
2006]. Additionally, ob/ob mice show a reduction in the amount of dopamine that can be released                             
due to decreased somatodendritic vesicular stores, indicating another mechanism ob/ob mice a                     
attenuated locomotor response to cocaine [Roseberry et al., 2007]. Similar to insulin, leptin also                         
stimulates the expression of DAT in the nucleus accumbens, but also stimulates dopamine                       
activity in the nucleus accumbens. Amphetamine­induced efflux of dopamine was enhanced by                     
leptin pretreatment, suggesting leptin induces leptin sensitivity, which can results in a reduction                       
in amphetamine­induced locomotion [Perry et al., 2010]. Leptin signalling in the VTA may also                         
play a role in the amygdala, where projections from the VTA have been shown to terminate on                               
CART neurons in the amygdala, whilst leptin receptor knockout increases dopamine release in                       
the amygdala and is associated with anxiety [Leshan et al., 2010; Liu et al., 2011]. The actions of                                 
leptin within the mesolimbic systems may be ineffective during obesity due to the development of                           
leptin resistance in the VTA, as demonstrated by an attenuated response to leptin administration                         
centrally and directly in the VTA [Matheny et al., 2011; Bruijnzeel et al., 2012].
Both insulin and leptin receptor stimulation activates insulin receptor substrate (IRS) and has                       
been shown to regulate exposure to psychostimulant exposure. IRS mediates the effects of                       
morphine on cell morphology in the mesolimbic system, whilst IRS overexpression in the VTA                         
enhances reward and locomotor responses to cocaine and blockade of IRS attenuates this                       
response [Russo et al., 2007; Iñiguez et al., 2008]. Additionally, there appears to be regional                           
differences in leptin signalling. VTA leptin signalling does not appear to involve IRS­PI3K                       
signalling or mTOR signalling but is still dependent on Jak­2 signalling, whilst the hypothalamus                         
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involves IRS­PI3K signalling [Morton et al., 2009]. Leptin signalling also involves phosphorylation                     
of ERK1/2, which has been shown to be critical for VTA leptin signalling in mediating the                             
anorexigenic effects of leptin administered to the VTA [Trinko et al., 2011]. Leptin has been                           
shown to directly reduce dopaminergic signalling via presynaptic inhibition, and this is dependent                       
on Jak­2 and PI3K signalling [Thompson et al., 2013]. A suggestion for the differences in                           
leptin­induced VTA signalling are leptin­induced presynaptic suppression requires PI3K               
signalling, whilst suppression of firing rate by leptin is dependent on ERK1/2 signalling.
Ghrelin has also been shown to influence the rewarding properties of food and ghrelin receptors                           
GHSR are expressed in areas other than the hypothalamus, including VTA, S.Nigra, raphe                       
nuclei, hippocampus and brainstem [van Zessen et al., 2012]. Ghrelin receptor expression is not                         
commonly reported in the nucleus accumbens, but there does appear to be low level expression                           
[Guan et al., 1997; Katayama et al., 2000; Skibicka et al., 2011]. Direct injection of ghrelin to the                                 
VTA increased food intake, whilst direct injection into the nucleus accumbens elicited a smaller                         
but significant increase in food intake. Opioid antagonists injected into the nucleus accumbens                       
did not affect feeding after ghrelin injection to the VTA, and similarly, opioid antagonism in the                             
VTA did not alter ghrelin­induced feeding when injected into the nucleus accumbens [Naleid et                         
al., 2005; Skibicka et al., 2011]. The action of ghrelin in the VTA appears to reliant on glutamate                                 
signalling, whilst this study also showed orexin signalling was not necessary in mediating the                         
ghrelin­induced feeding in the VTA [Jerlhag et al., 2010]. The release of dopamine in response to                             
ghrelin in the VTA appears to be dependent on the feeding state of the mouse, whereby food                               
removal after peripheral ghrelin administration was decreased in the nucleus accumbens, which                     
is mediated by GABA and glutamatergic signalling in the VTA. If food was given after a peripheral                               
ghrelin injection, dopamine release in the nucleus accumbens increased and was dependent on                       
glutamatergic signalling in the VTA only [Kawahara et al., 2009]. Ghrelin also modifies motivation                         
for food reward, where direct injection of ghrelin to the VTA, but not the nucleus accumbens,                             
increased operant behaviour for sucrose reward. GHSR1 antagonism reduced the operant                   
behaviour response for sucrose after fasting, but did not alter hyperphagia, indicating the role of                           
ghrelin signalling in the mesolimbic system in motivation, but not reward [Skibicka et al., 2011;                           
Skibicka et al., 2012]. Additionally, chronic central treatment of ghrelin alter dopamine receptor                       
expression and acetylcholinergic gene expression [Skibicka et al., 2012].
{1.2.5.4} The mesolimbic dopamine pathway and obesity: a result of food addiction?
Human genetic studies assessing polymorphisms in dopaminergic genes, including DAT, D2                   
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and D4 receptors and MAO can be linked to changes in BMI and food intake [Kaplan et al., 2007;                                   
Fuemmeler et al., 2008; Heber & Carpenter, 2011]. Binge eating disorder (BED) has also shown                           
a combination of alleles for D2D2 and μ­opioid receptor are overrepresented [Davis et al., 2009].                           
fMRI studies have shown Prader­Willi syndrome (PWS) patients have increased ventromedial                   
prefrontal cortex activation compared to controls in response to pictures of food, indicating                       
increased reward value to food, which may contribute to obesity [Miller et al., 2007]. Similarly,                           
compared to simple obesity, PWS individuals showed increased activation in subcortical reward                     
circuitry, whilst also showing decreased activation cortical inhibitory areas, such as the                     
orbitofrontal cortex and dorsolateral prefrontal cortex, indicating the importance of inhibitory                   
circuits in feeding [Holsen et al., 2011]. This has also been demonstrated in simple obese                           
patients using fMRI, which has proved to be a useful tool in understanding a whole brain system                               
with regards to feeding and obesity in humans [De Silva et al., 2012; Martens et al., 2013].
A landmark paper published in 2001 showed a direct inverse correlation between BMI and D2                           
receptor availability using PET in humans [Wang et al., 2001]. This could be associated with                           
reduced activity in the prefrontal circuitry in obese patients but not in controls, and is an                             
association also made in alcohol abusers [Volkow et al., 2006; Volkow et al., 2008a]. This                           
suggested obesity may a result of a reward deficit, whereby a reduction in reward signalling                           
results in overeating to compensate leading to obesity. This in turn has led to the development of                               
the food addiction model as a result of reward­deficiency, due to similarities between reward                         
signalling and drug addiction [Volkow et al., 2008b]. In support of this, a decreases striatal                           
response has been shown to predict weight gain in obese patients over 6 to 12 months [Stice et                                 
al., 2008; Stice et al., 2010]. It is a compelling argument that could alter how obesity is treated,                                 
both by the medical profession and society as a whole [Puhl & Heuer, 2012]. Although there is                               
much evidence to support this model, there are also a number of weaknesses which may                           
prevent obesity being classed as substance dependency [Ziauddeen et al., 2012].
Obesity prone rats shown reduced D2 receptor expression compared to lean controls and                       
obesity resistant rats fed a high fat diet [Huang et al., 2006]. High fat diet and obesity prone                                 
animals have also shown reduced basal dopamine levels in the nucleus accumbens [Geiger et                         
al., 2008; Davis et al., 2008; Geiger et al., 2009; Rada et al., 2010]. Another study found being fed                                   
a high fat diet for 6 weeks, regardless of body weight reduced the expression of dopaminergic                             
markers, whilst swapping to a control diet increased dopaminergic signalling [Li et al., 2009].                         
Both decreased striatal dopamine levels and decreased D1 receptor expression in the nucleus                       
accumbens is demonstrated in the diet induced obese rats [Geiger et al., 2009; Alsiö et al.,                             
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2010]. Obese rats fed a “junk food” diet increases compulsive feeding behaviour and is also                           
associated with decreases striatal D2 receptor expression. Knockdown of striatal D2 receptors                     
in lean rats increased the threshold for SA and increased compulsive­food seeking behaviour.                       
These rats also showed decreased SA to the LH, indicating a reduced response to reward,                           
reminiscent of rats who are dependent on cocaine or heroin [Ahmed et al., 2002; Kenny et al.,                               
2006; Johnson & Kenny, 2010]. Similarly, 8 weeks of high fat diet decreased striatal D2 receptor                             
density and decreased DAT expression and function, which in turn increased extracellular                     
dopamine concentration. However this study showed no increase in impulsive behaviour, but did                       
demonstrate increased motivation for food, which was shown to be an accurate predictor of                         
obesity development. Interestingly, this study also demonstrates changes in striatal D2 receptor                     
and DAT expression were observed after the onset of obesity and did not accurately predict the                             
onset of obesity [Narayanaswam et al., 2012]. Chronic high fat diet exposure has been shown to                             
decreased tyrosine hydroxylase and DAT mRNA in the VTA, whilst increasing mRNA expression                       
in the hypothalamus. This suggests dopamine hyposensitivity can induce increase dopamine                   
signalling in the hypothalamus to increase food intake. D1 receptor mRNA was significantly                       
reduced in the PFC, NAc and VTA, and D2 receptor mRNA was decreased in the VTA. A                               
possible mechanism for this modification could be alterations in DNA methylation, whereby                     
increased methyl enrichment can decreases mRNA expression [Vucetic et al., 2012]. Microarray                     
data also shows an increase in tyrosine hydroxylase and DAT expression, with no changes in                           
receptor expression [Lee et la., 2010]. Short term exposure to high fat diet does not appear to                               
induce compulsive eating or changes in dopaminergic mRNA expression, although 4 weeks of                       
high fat diet was enough to induce insulin resistance [Johnson & Kenny, 2010; de Leeuw van                             
Weenen et al., 2009].
With regards to whether food addiction is convincing model, there are a number reviews                         
discussing the evidence of its validity [Kenny, 2011; Peters, 2012; Ziauddeen et al., 2012].                         
Ziauddeen et al discuss the features of obesity that may classify obesity as a mental disorder                             
with the same criteria drug dependency is characterised by the Diagnostic and Statistical                       
Manual of Mental Disorder (DSM­V) and also by the newly developed Yale Food Addiction Scale                           
(YFAS). Some traits between obesity and drug­dependence are observed, such as cravings and                       
continued use despite negative consequences, others do not. A key point is tolerance and                         
withdrawal are not well­observed in human studies, whilst food is also essential for survival and                           
is easily accessible [Gearhardt et al., 2009]. Animal studies have suggested sugar can be                         
addictive and withdrawal symptoms similar to drug withdrawal, such as tremors and                     
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increased­substance seeking is observed despite adverse stimuli [Rada et al., 2005; Avena et                       
al., 2008; Avena et al., 2009]. This is well documented in binge­eating models, however these                           
models have very strict regimes to induce this type of behaviour, which may not be applicable to                               
humans [Corwin et al., 2011]. Additionally, sucrose bingeing does not increase food intake or                         
weight gain, whilst fat by itself does not increase food intake or weight gain, plus no addictive                               
behaviour in developed. However, in combination, hyperphagia and weight gain are apparent,                     
suggesting the sucrose element is the addictive element of the diet, whilst the caloric content of                             
the high fat results in obesity [Avena et al., 2009; Lomba et al., 2009; Dimitriou et al., 2000;                                 
Zilberter, 2012]. Indeed, withdrawal symptoms have not been documented in animals with just                       
high fat diets, or combination diets of high sugar and high fat [Bocarsly et al., 2011]. However,                               
some studies with high fat diet showed animals with endure adverse stimuli to eat palatable                           
food, similar to rats that have developed cocaine dependence [Teegarden & Bale, 2007; Johnson                         
& Kenny, 2010; Vanderschuren & Everitt, 2004; Belin et al., 2008].
As described above, genetic linkage studies have identified some polymorphisms in dopamine                     
genes which can be associated with obesity. The Taq1A minor (A1) allele of the dopamine                           
receptor D2 (DRD2) has been associated with obesity and a number of addictive habits, such                           
as smoking , alcoholism, cocaine and opioid use [Stice et al., 2008; Zuo et al., 2009; Munafo et                                 
al., 2007; Noble et al., 1993; Doehring et al., 2009]. However, other linkage studies have not                             
found these associations [Gelernter et al., 1999; Smith et al., 2008; Munafo et al., 2009]. This                             
polymorphism has also been associated with impulsivity, a trait associated with addiction.                     
Additionally, impulsivity appears to be increased in patients with BED and obesity, and has                         
shown weak correlation with food intake [Eisenberg et al., 2007; Davis et al., 2008; Galanti et al.,                               
2007; Guerrieri et al., 2007].
Interestingly, although the first PET studies indicating reduced striatal D2R binding and reduced                       
prefrontal inhibitory control in obese patients brought the idea of reward hypofunction contributing                       
to obesity, many studies performed since then have shown contradictory data. For example,                       
food consumption was associated with reduced dopamine binding in the striatum, whilst another                       
study showed food in the mouth did not show any changes in dopamine binding [Small et al.,                               
2003; Volkow et al., 2003]. Additionally, food did not alter striatal dopamine binding, whilst ritalin                           
does have an effect on striatal binding [Volkow et al., 2002]. This highlights the diversity of                             
experimental paradigms all attempting to answer the same question, which leads to uncertainty.                       
Other studies which do not support the addiction model include BMI­matched comparisons                     
between BED and controls, which show no striatal binding correlations, whilst gastric bypass                       
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patients have been shown to both increased and decreased D2 receptor binding after surgery                         
[Steele et al., 2010; Dunn et al., 2010]. Similarly, a large number of fMRI studies have not                               
provided a consistent representation of obesity and associated reward signalling. A concise                     
summary detailing the main findings of a number of clinical studies with regards to reward                           
signalling can be found in Ziauddeen et al., 2012.
Obesity is an extremely complex disease, with significant contributions from a number of                       
different systems which are interconnected, directly and indirectly (Figure 1.2.9.4.1). Additionally,                   
there is a large variety of obese phenotypes in the human population, it is difficult to characterise                               
for a generic patient. There is a danger of attributing much importance to one network without                             
considering the whole system, therefore the future of developing an overall mechanism for the                         
development has to consider all these components, from epigenetic modifications and molecular                     




Figure {1.2.5.4.1} Schematic diagram of the relationship between homeostatic and                 
hedonic systems for food intake.
Dark gray boxes are homeostatic elements of the feeding, and light gray boxes are hedonic                           





Peripheral signals are integrated by the CNS, such as circulating nutrients, gut hormones and                         




Leptin is a 167 amino acid peptide hormone that is synthesised and secreted by white adipose                             
tissue and is correlated with fat mass in mice and humans [Frederich et al.,1995; Maffei et al.,                               
1995]. Leptin also responds acutely, increasing after feeding and decreasing after fasting [De                       
Vos et al., 1995]. Mutations in the gene encoding leptin and the leptin receptor result in severe                               
hyperphagia and obesity [Zhang et al., 1994; Chen et al., 1996; Clément et al., 1998]. Parabiosis                             
studies involving ob/ob and db/db mice showed a circulating factor in db/db mice was sufficient                           
to reduce body weight in ob/ob and lean mice, whilst db/db mice were unaffected by attachment                             
to either ob/ob or lean mice. Once the leptin gene and leptin receptor were cloned, it was shown                                 
the circulating factor was leptin, the gene for which was absent in ob/ob mice, whilst db/db mice                               
could produce leptin but could not respond to it, indicating they lacked the gene for the leptin                               
receptor [Coleman, 1973; Coleman, 2010]. Similarly, injecting leptin into ob/ob mice could return                       
feeding to normal, whilst expressing the leptin receptor in db/db mice normalised feeding [Halaas                         
et al., 1995; Pelleymounter, et al., 1995; Campfield et al., 1995; Kowalski, et al., 2001]. From                             
these early experiments, it was clear leptin acts to reduce energy intake, in part, by promoting                             
satiety.
The are multiple isoforms of the leptin receptor, all originating from the Lepr gene. and can be                               
classified as secreted, short or long forms of the receptor [Cottrell & Mercer, 2012]. The long                             
form (LRb) has been shown to be crucial for leptin signalling. The LRb is the absent form of                                 
leptin receptor in db/db mice, whilst the other forms are still expressed. Mice which have a                             
complete absence of leptin receptors (db3J/db3J) show a very similar phenotype to db/db and                         
ob/ob mice [Tartaglia, 1997; Chua et al., 1997]. The role of the other forms are unclear, but may                                 
be involved in transporting leptin across the blood brain barrier and the production of LR                           
extracellular domains which attach to leptin [Ge et al., 2002; Uotani et al., 1999]. The LRb is part                                 
of the interleukin (IL)­6 receptor family of class 1 cytokine receptors. These contain an                         
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extracellular ligand­binding domain, a single transmembrane domain and a cytoplasmic                 
signalling domain. LRb signalling is not a self­contained enzymatic reaction, instead signaling                     
through tyrosine kinase signalling pathway, Jak kinase A tyrosine phosphorylation cascade in                     
turn recruits the transcription factor STAT3, which has led to the leptin signalling pathway being                           
named as the JAK/STAT3 pathway [Myers et al., 2008; Cottrell & Mercer, 2012]. LRb activation                           
also appears to regulate mTOR, AMPK and PI3K pathways, as well as phosphorylation of IRS                           
proteins [Cota et al., 2006; Minokoshi et al., 2004; Xu et al., 2005; Hill et al., 2008; Hennige et al.,                                     
2006].
The role of the hypothalamus in altering food intake in response to circulating leptin was first                             
illustrated by gross lesioning of the hypothalamus [Hervey, 1959]. This showed, again through                       
parabiosis, that the circulating factor, leptin, was sufficient to reduce food intake in intact rats, but                             
was ineffective in rats with lesioned hypothalami. Recent studies have built from these early                         
experiments to elucidate the roles of each neuronal population in mediating the effects of leptin                           
on energy balance. In the hypothalamus, the arcuate nucleus, VMH, DMH, LH and ventral                         
premammillary (PMv) nuclei all express LRb, whilst extrahypothalamic areas, such as the VTA                       
and brainstem also express LRb [Elmquist et al., 1998; Baskin et al., 1999; Fulton et al., 2006;                               
Hommel et al., 2006; Grill et al., 2002]. Within the arcuate nucleus, leptin stimulate POMC                           
neurons, increasing the production of POMC and α­MSH. Conversely, leptin inhibits the                     
NPY/AgRP neurons, leading to a decrease in the production of NPY and AgRP, thereby reducing                           
the inhibitory tone of AgRP on POMC neurons [Coley et al., 2001; Enriori et al., 2007]. As a                                 
result, there is an increase in anorexigenic signalling and a decrease in orexigenic signalling.
Although there is clearly an important role for the arcuate nucleus in mediating feeding response,                           
the anorexigenic response of leptin does not appear to mediated entirely by the arcuate nucleus.                           
Deletion of LRb from POMC neurons or expression of LRb in the arcuate nucleus in db/db mice                               
results only in a mild change in body weight [Balthasar et al., 2004; Huo et al., 2009]. Additive                                 
obesity results when leptin receptor knockouts occur in both the ARC POMC and VMH neurons,                           
although this is still not to the extent observed in global leptin receptor knockouts, suggesting                           
additional targets of leptin [Morton et al., 2003; Balthasar et al., 2004; Dhillon et al., 2006].                             
Similarly, total disruption of STAT3 signalling results in severe hyperphagia and obesity, whilst                       
arcuate nucleus disruption of STAT3 again only results in a modest change in food intake and                             
body weight [Bates et al., 2003; Kaelin et al., 2006; Xu et al., 2007]. Disruption of leptin signalling                                 
in the VMH appears to be crucial for mediating thermogenesis induced by leptin signalling, whilst                           
leptin signalling in the mesolimbic dopamine pathway are necessary for motivational behaviour                     
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[Dhillon et al., 2006; Fulton et al., 2006; Hommel et al., 2006]. Intact PI3K signalling has been                               
shown to be necessary for the acute effects of leptin on POMC neurons, but did not appear to be                                   
necessary for long term control of body weight. The same study also showed PI3K signalling is                             
necessary to mediate the activation of POMC neurons by leptin, but also necessary for the                           
inhibition of POMC neurons by insulin, indicating possible subpopulations of POMC neurons that                       
respond to leptin and insulin [Hill et al., 2008]. Additionally, the effects of leptin on NPY signalling                               
do not appear to be mediated via the same mechanisms as the effects on POMC neurons,                             
instead acting through the MAPK signalling cascade as opposed to PI3K signalling [Wang et al.,                           
2008]
Leptin signalling has been shown to alter the perception of rewarding properties of food, as well                             
as other addictive substances [Figlewicz et al., 2007; Carr, 2007]. This could be through direct                           
interaction with dopamine signalling. LRb­expressing VTA dopamine neurons have shown leptin                   
is able to alter their activity, whereby a knockdown of LRb in VTA neurons results in an increase                                 
in food intake, but with change in body weight [Fulton et al., 2006; Hommel et al., 2006]. Within                                 
these neurons, the leptin­mediated reduction in dopamine neuron firing appears to pERK1/2                     
signaling, whilst other studies have excluded PI3K signalling as a mediator of this response                         
[Trinko et al., 2011; Morten et al., 2009]. Additionally, LRb neurons in the LH project to VTA                               
dopamine neurons, a pathway that appears to be mediate alterations in self stimulation of the LH                             
with leptin administration [Fulton et al., 2000].
In addition to the well documented changes in food intake, leptin signalling also affects energy                           
expenditure and glucose homeostasis. Deletion of leptin receptor expression in VMH neurons (by                       
targeting VMH specific SF1) showed impaired thermogenesis when fed a high fat diet, again                         
indicating regional specific functions of the hypothalamus [Dhillon et al., 2006].                   
Melanocortin­mediated leptin signalling appears to have an effects of glucose and insulin                     
regulation, whereby i.c.v administration of leptin inhibits glycogenolysis in the liver and                     
suppresses glucose production, and has been shown to be mediated by leptin’s direct action on                           
POMC neurons [Pocai et al., 2005; Berglund et al., 2012]. Similarly, this direct action on POMC                             
neurons is required for leptin and insulin signalling on maintaining normal glucose homeostasis                       
[Hill et al., 2010]. Reexpression of leptin receptors in the arcuate nucleus in long­form leptin                           
receptor knockout mice show a mild decrease in body weight, but a significant improvement in                           
hyperinsulinemia and hyperglycemia [Coppari et al., 2005]. Deletion of leptin receptors in VMH                       
neurons show insulin resistance develops before any observable change in body weight                     
[Bingham et al., 2008]. Additionally, deletion of PI3K signalling in the VMH shows an attenuated                           
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response to leptin [Xu et al., 2010]. A downstream transcription factor of PI3K, FOXO1, is also                             
involved in leptin and insulin signalling in the brain, whereby FOXO1 expression is decreased in                           
the hypothalamus with leptin or insulin administration, and activation of FOXO1 in the                       
hypothalamus decreases food intake and body weight [Kim et al., 2006]. FOXO1 stimulated the                         
production of NPY and AgRP and is necessary for the mediation of leptin’s effects on AgRP                             
neurons Kim et al., 2006; Kitamura et al., 2006]. NTS specific deletion of leptin receptors                           
increase the instance of obesity, by increasing food intake but without alterations in energy                         
expenditure [Hayes et al., 2010; Scott et al., 2011].
Although leptin effectively reduces food intake and body weight in lean mice and ob/ob mice, DIO                             
mice do not show the same feeding response to leptin administration. Additionally, DIO mice                         
show high levels of circulating leptin, similar to db/db mice, but express LRb, indicating leptin                           
resistance [Enriori et al., 2007; Olofsson et al., 2013]. This appears to be a result of alterations in                                 
LRb signalling. Interestingly, this alteration remains when tissue from DIO mice is explanted into                         
lean mice, indicating resistance within the cells persists regardless of the environment [Enriori et                         
al., 2007]. Candidate molecules in the pathway include Try985 and SOCS3 [Bjørbæk et al., 2000;                           
You et al., 2010; Howard et al., 2004; Olofsson et al., 2013]. Other pathways which increase                             
SOCS3 production include other metabolic signalling pathways and inflammatory pathways,                 
which could in turn increase leptin resistance and exaggerate the obese state [Ozcan et al.,                           
2009; Reed et al., 2010].
The arcuate nucleus seems particularly susceptible to leptin resistance [Münzberg et al., 2004;                       
Enriori et al., 2007]. This may be a result of the arcuate nucleus being more exposed to                               
circulating factors due to the incomplete blood brain barrier, whilst other areas of the                         
hypothalamus a reliant on other transport mechanisms. Similarly, there is increased LRb                     
signalling in the arcuate nucleus compared to other areas of the hypothalamus, whilst the the                           
LRb response is similar across all areas if leptin is administered via an i.c.v injection [Faouzi et                               
al., 2007; Myers et al., 2008]. A detailed review of the cellular mechanisms thought to be involved                               
in the development of leptin resistance are described by Myers et al., 2008, and Morton &                             
Schwartz, 2011.
{1.3.1.2} Insulin
Insulin is secreted by β cells in the pancreas and is classically associated with glucose                           
homeostasis [Saltiel & Kahn, 2001]. Similar to leptin, insulin is considered an adiposity signal, as                           
the circulating concentration is proportional to fat content, thus acting as a long term signal of                             
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energy state [Benoit et al., 2004; Schwartz & Porte Jr, 2005]. As well as it’s role mediating                               
glucose concentration, insulin has been shown to act within the CNS to directly regulated food                           
intake and energy homeostasis, showing a decrease in food intake, regulating normal glucose                       
homeostasis and control of lipolysis [Wood et al., 1979; Brief & Davis, 1984; Cusin et al., 1998;                               
Scherer et al., 2011]. Insulin receptors are expressed within the CNS [Plum et al., 2005; Plum et                               
al., 2006]. A significant reduction in insulin receptors in the arcuate nucleus results in                         
hyperphagia, increased fat content and an attenuated response in hepatic glucose production                     
[Obici et al., 2002]. Insulin signalling within the CNS regardless of peripheral state has been                           
shown to reduce hepatic glucose production, which can be inhibited by blocking K+ channels in                           
the hypothalamus, but not with a melanocortin receptor antagonist [Obici et al., 2002; Pocai et                           
al., 2005b]. Similarly, selective deletion of insulin receptors in POMC neurons does not alter                         
energy homeostasis, whilst deletion with leptin receptor deletion had a severe effect of glucose                         
homeostasis [Könner et al., 2007; Hill et al., 2010]. In addition to this, POMC neurons expressing                             
leptin receptors or insulin receptors occur in two separate population [Williams et al., 2010].                         
Restoration of insulin receptors in POMC neurons in arcuate nucleus insulin receptor                     
knockdowns in fact further decreased hepatic insulin resistance, but restored locomotor activity,                     
suggesting a role in energy expenditure [Lin et al., 2010]. In normal circuits, insulin decreases                           
POMC mRNA expression, via K+ dependent hyperpolarisation and is mediated by PI3K and                       
FOXO1 signalling. This is also true for AgRP neurons, however this action results in a n                             
increased in AgRP mRNA expression [Kitamura et al., 2006; Spanswick et al., 2000; Plum et al.,                             
2006]. AgRP neurons have also been shown to be essential for the central actions of insulin in                               
suppressing hepatic glucose production, but appear to have no effect on feeding behaviour                       
[Könner et al., 2007]. Reexpression of insulin receptors in AgRP neurons after selective                       
knockdown in the arcuate nucleus restores normal glucose levels [Lin et al., 2010]. Central                         
insulin administration decreases NPY mRNA expression and inhibits NPY neuronal firing                   
[Schwartz et al., 1992; Sipols et al., 1995; Davidowa & Plagemann, 2007].
Insulin signalling with the VMH has also been shown to be a crucial area in energy regulation.                               
Infusion of insulin directly into the VMH decreases food intake and body weight [McGowen et al.,                             
1990]. A subpopulation of these neurons are depolarised via K+ channels which also project                         
glutamate neurons to POMC neurons in the arcuate nucleus [Sternson et al., 2005; Klöckener et                           
al., 2011]. Knockout of VMH insulin receptors had no effect in mice fed a chow diet, but these                                 
mice appeared to be protected from the effects of a high fat diet. Disruption of PI3K signalling                               
resulted in an increase in food intake and body weight on chow diet [Klöckener et al., 2011]. In                                 
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contrast, lentiviral­mediated knockdown of insulin receptors in the VMH led to a disruption of                         
glucose metabolism and pancreatic function [Paranjape et al., 2011].
Within reward circuitry, insulin receptors have been shown to coexpress with tyrosine                     
hydroxylase­expressing neurons in the VTA and S.Nigra [Figlewicz et al., 2003; Figlewicz et al.,                         
2009]. Insulin increases the firing rate in a subset of dopamine neurons, and knockout of insulin                             
receptors in TH neurons led to hyperphagia and an increase in fat mass and body weight. There                               
was also an increased sensitivity to sucrose. Additionally, administration of cocaine in fasted                       
mice showed an attenuated locomotor response with additional insulin administration [Könner et                     
al., 2011]. Central administration of insulin decreases acute sucrose intake and reduces                     
conditioned place preference for high fat food, indicating insulin can alter rewarding properties of                         
food [Figlewicz et al., 2008; Figlewicz et al., 2004]. Direct administration of insulin to the VTA                             
also reduced palatable food intake, which appears to be mediated by upregulation of DAT,                         
resulting in a decrease in synaptic dopamine concentration [Mebel et al., 2012].
In addition to the hypothalamus, the vagal nerves and brainstem have been shown to mediate                           
hepatic glucose production [Pocai et al., 2005c].
Similar to leptin, insulin resistance can occur with obesity, which can in turn lead to the                             
development of type 2 diabetes [Samuel & Shulman., 2012]. Insulin resistance has been                       
observed at the neuronal level, where central administration of insulin in obese models show no                           
change in food intake, K+ channel activation or NPY activity [Ikeda et al., 1986; Schwartz et al.,                               
1991; Spanswick et al., 2000; Davidowa & Plagemann, 2007]. A detailed review of the                         




Glucagon is a cleavage product of proglucagon and is secreted by α­cells in the pancreas.                           
Unlike the other products of proglucagon cleavage, GLP­1 and 2 and oxyntomodulin,                     
hypoglycemia stimulates the production of glucagon, which stimulates glycogenolysis in the liver                     
[Suzuki et al., 2011]. Peripheral administration of glucagon decreases food intake and body                       
weight in rodents and humans [Holloway & Stevenson, 1964; Geary et al., 1993; Schulman et al.,                             
1957]. Energy expenditure is also increased with glucagon administration [Hepner et al., 2010].                       
Vagotomy or brainstem­hypothalamus transection attenuates the effects of glucagon on feeding,                   
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indicating the importance of the brainstem in glucagon signalling [Weatherford & Ritter; Geary et                         
al., 1993]. Peripheral administration of glucagon has been shown to increase c­Fos expression                       
in the AP and amygdala, but showed no effect on c­Fos expression in hypothalamic nuclei,                           
despite previous reports of low levels of glucagon mRNA expression in the hypothalamus                       
[Parker et al., 2013; Hoosein & Gurd, 1984].
{1.3.2.2} Ghrelin
Ghrelin is a 28 amino acid peptide produced by the stomach and is the only known gut hormone                                 
that stimulates appetite. It is mainly secreted by oxyntic gland cells in the mucosa of the                             
stomach when it is empty, and rapidly suppressed when food is present. An active and inactive                             
form of ghrelin is present in circulation [Sakata & Sakai, 2010]. Acyl ghrelin is the active form                               
which can stimulate the ghrelin receptor growth hormone secretagogue receptor (GHSR), which                     
undergoes octanoylation by ghrelin­O­acyltransferase (GOAT), produced by the stomach and                 
pancreas [Yang et al., 2008; Gutierrez et al., 2008]. The non­active form of ghrelin is known as                               
desacyl ghrelin, which does not bind to GHSR1a, but may shown GHSR­independent effects                       
which may counteract the effects of acyl­ghrelin [Inhoff et al., 2008]. Fenestrated capillaries have                         
been shown to enable rapid binding of ghrelin to appetite regulating neurons in the hypothalamus                           
[Schaeffer et al., 2013].
Both central and peripheral administration of ghrelin results in increased food intake [Nakazato et                         
al., 2001; Tschöp et al., 2000]. GHSR1a is expressed in the arcuate nucleus and VMH, but also                               
in other areas of the CNS including the VTA, hippocampus and brainstem. Within the arcuate                           
nucleus, GHSR are expressed in NPY/AgRP, POMC/CART, somatostatin, growth hormone and                   
dopamine neurons [Zigman et al., 2005].
Peripheral administration increased c­Fos expression in NPY/AgRP neurons in the arcuate                   
nucleus, whilst the orexigenic effects is abolished with ablation of these neurons [Wang et al.,                           
2002; Chen et al., 2004]. I.c.v. administration of ghrelin induces activity in the PVN, DMH and                             
brainstem [Lawrence et al., 2002].
Ghrelin levels are increased after fasting and during weight loss, and a negative correlation is                           
observed between BMI and circulating ghrelin [Toshinai et al., 2001; Cummings et al., 2002;                         
Shiiya et al., 2002]. Anorexic patients show particularly high levels of ghrelin after fasting, whilst                           
high levels of ghrelin are observed with PWS [Otto et al., 2001; Cummings et al., 2002].                             
However, the decrease in ghrelin after feeding is attenuated in obese patients [Le Roux et al.,                             
2005]. Using fMRI, an increase in neural activation was observed in the amygdala, orbitofrontal                         
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cortex, anterior insula and striatum were correlated with hunger ratings after an infusion of                         
ghrelin in fed patients, mimicking the response given by fasted patients. This indicates ghrelin                         
may enhance hedonic perception of food [Malik et al., 2008].
Vagal afferents have been shown to be involved with ghrelin­mediate feeding. Central                     
administration increased cFos activity in the NTS and AP, and vagotomy inhibits ghrelin­induced                       
feeding and prevents an increase in cFos activity in the arcuate nucleus [Lawrence et al., 2002;                             
Date et al., 2002]. Ghrelin receptors are present in vagal afferents, where stimulation of these                           
receptors inhibits vagal afferent activity [Asakawa et al., 2001]. Additionally, a number of                       
gastric­load sensitive neurons express ghrelin receptors and have been implicated in the                     
vago­vagal reflex in the gastrointestinal tract [Arnold et al., 2006]. Other roles for ghrelin within                           
neuronal signalling include arousal state, memory and nociception [Ferrini et al., 2009].
{1.3.2.3} Peptide YY (PYY)
PYY is secreted by L cells in the intestine and circulates in two forms: PYY (1­36) and PYY                                 
(3­36). PYY (1­36) has an affinity to all Y receptor subtypes, whilst PYY (3­36) has a high affinity                                 
towards Y2 receptors in the hypothalamus [Eberlein et al., 1989; Suzuki et al., 2011]. Circulating                           
PYY levels are low during fasting, and peak between 1­2 hours after feeding [Adrian et al., 1985].                               
Peripheral administration of PYY decreased food intake and weight gain in rodents, and reduced                         
food intake and appetite in lean and obese humans [Batterham et al., 2002; Batterham et al.,                             
2003]. It is thought the effects of PYY (3­36) on food intake are mediated through direct action in                                 
the arcuate nucleus, as peripheral administration increased c­Fos expression in the arcuate                     
nucleus, and direct arcuate administration inhibits food intake. This effect is abolished with Y2                         
receptor knockout models [Batterham et al., 2002]. However, vagal and brainstem control may                       
also contribute to this effects, as vagotomy or brainstem­hypothalamic transection abolishes the                     
effects of peripheral PYY administration [Abbott et al., 2005; Koda et al., 2005]. I.c.v. or PVN                             
administration of PYY (3­36) increases food intake, perhaps due to signaling via Y1 or Y5                           
receptors [Morley et al., 1985; Stanley et al., 1985; Kanatani et al., 2000]. Peripheral PYY (3­36)                             
administration has also been shown to alter reward signalling and higher neural functions in                         
humans, indicating PYY may play a role in altering reward processing of food [Batterham et al.,                             





PP is secreted by PP cells in the pancreas, and increase in proportion to calorie intake [Suzuki                               
et al., 2011]. PP administration has been shown to reduce food intake in humans and rodents                             
[Batterham et al., 2003; Asakawa et al., 1999]. Some studies have observed reduced circulating                         
levels of PP in obese patients [Reinehr et al., 2006]. Chronic PP administration in ob/ob mice                             
showed a reduction in body weight gain and an improvement in insulin sensitivity [Asakawa et al.,                             
2003]. PP administration has been shown to decrease NPY expression in the hypothalamus,                       
whilst vagotomy abolishes the anorexigenic actions of PP [Asakawa et al., 2003]. The                       
anorexigenic effects of PP are thought to signal via the Y4 receptor, as a reduction in food intake                                 
with PP administration is abolished in Y4 receptor knockout models [Lin et al., 2009]. Y4                           
receptors are expressed in the brainstem and hypothalamus, with the greatest number of                       
binding sites in the brainstem, suggesting the brainstem as the major site of PP action on satiety                               
[Parker & Herzog, 1999; Whitcomb et al., 1990]. Central administration of PP has been shown to                             
induce an orexigenic response, in contrast to peripheral administration, suggesting PP may act                       
via other mechanisms unknown [Clark et al., 1984].
{1.3.2.5} Glucagon­Like Peptide 1 and 2 (GLP­1 and GLP­2)
GLP­1 and GLP­2 are cleavage products of proglucagon and are secreted by L cells in the                             
intestine [Tang­Christensen et al., 2001]. Both are secreted in response to nutrient intake,                       
however they appear to have different roles in energy expenditure. GLP­2 has no effect on food                             
intake but has been shown to stimulate the production of crypt cells in the intestine [Drucker,                             
2001; Schmidt et al., 2003]. Both GLP­1 and GLP­2 have been shown to reduce gastric                           
emptying, with GLP­1 showing a more potent response [Nagell et al., 2004].
GLP­1 reduces food intake dose dependently, however this response is attenuated in obese                       
patients [Verdich et al., 2001; Holst, 2007]. GLP­1 receptors are expressed in the brain, digestive                           
tract and pancreas [Holst, 2007]. GLP­1 suppresses glucagon secretion and stimulated insulin                     
secretion according to glucose concentration [Cummings & Joost Overduin, 2007]. Chronic                   
GLP­1 administration in type 2 diabetes patients shows a decrease in appetite, body weight and                           
an improvement in glucose tolerance [Zander et al., 2002]. Other effects include increased                       
proliferation of β­cells in the pancreas, reduces oxygen consumption and respiratory quotient,                     
and as a potential neuroprotective agent in degenerative models [Egan et al., 2003; Baggio et al.,                             
2004; Harkavyi & Whitton, 2010]. With regards to neural control, i.c.v. administration of GLP­1                         
shows an increase in c­Fos expression in the PVN, SON, NTS and AP [Larsen et al., 1997]. The                                 
majority of GLP­1 receptor expressing PVN neurons also express CRH, whilst a smaller                       
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population coexpress oxytocin [Larsen et al., 1997]. GLP­1 neurons in the NTS have been shown                           
to project to the VTA and NAc, suggesting a direct alteration in reward signalling [Alhadeff et al.,                               
2012]. Using manganese­enhanced MRI (MEMRI), GLP­1 signalling closely resembled the neural                   
signalling pattern induced by lithium chloride, suggesting GLP­1 may reduce food intake via                       
circuits involved in nausea [Parkinson et al., 2009]. A fasting­induced decrease in GLP­1 was                         
prevented by leptin administration, suggesting suppression of food intake by leptin may involve a                         
decrease in GLP­1 signalling in the brain [Goldstone et al., 2000]. GLP­1 stimulates                       
ghrelin­inhibited neurons in the hypothalamus, and also suppressed ghrelin­excited neurons                 
[Riediger et al., 2010].
{1.3.2.6} Oxyntomodulin (OXM)
OXM is secreted by L cells in the intestine, and like GLP, is a cleavage product of proglucagon                                 
[Bataille et al., 1982]. It is released in proportion to calorie consumed and has been shown to                               
decrease food intake and increased energy expenditure in humans and rodents [Cohen et al.,                         
2003; Dakin et al., 2001; Wynne et al., 2006]. One mechanism of signalling is through the GLP­1                               
receptor, as the anorexigenic effect of OXM is blocked by GLP­1 receptor antagonists and                         
GLP­1 receptor knockout mice [Baggio et al., 2004; Dakin et al., 2004]. However, another                         
receptor with an affinity for OXM may be present, as other effects of OXM, such as an increase                                 
in heart rate, is still present in GLP­1 receptor knockout mice [Sowden et al., 2007]. Although                             
OXM can signal via the GLP­1 receptor, OXM and GLP­1 have some different effects on energy                             
homeostasis, such as gastric emptying and energy expenditure [Maida et al., 2008; Baggio et al.,                           
2004]. OXM administration has been shown to alter activity in the brainstem and hypothalamus,                         
whilst GLP­1 appears to excite ghrelin­inhibited neurons in the hypothalamus, and inhibits                     
ghrelin­excitable neurons [Parkinson et al., 2009; Riediger et al., 2010].
{1.3.2.7} Cholecystokinin (CCK)
CCK is secreted by I cells in the small intestine, and increased within 15 minutes of feeding                               
[Liddle et al., 1985]. There are two CCK receptors, CCK1 and CCK2, which are expressed in the                               
hypothalamus and brainstem [Wank et al., 1995]. CCK1 receptors in the vagal nerve have been                           
shown to mediate the anorexigenic effect of CCK, whereby lesion to the vagal nerve attenuates                           
CCK­induced satiation and this pathway has been suggested to mediate meal termination                     
[Moran et al., 1997; Moran et al., 1998; Moran et al., 2004]. CCK has been shown to reduce food                                   
intake in both humans and rodents [Liddle et al., 1985; Kissileff et al., 1981; Gibbs et al., 1973;                                 
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Smith, 2006]. Periodic CCK infusion in rats shows a decrease in meal size, but also increased                             
meal frequency, whilst a continuous CCK infusion does not alter food intake [West et al., 1984;                             
Crawley & Beinfeld, 1983]. CCK has also been implicated in leptin’s action on central neural                           
pathways, by increasing the accessibility of leptin, possibly by increasing barriers to the brain                         
more permeable [Merino et al., 2008; Cano et al., 2008].
{1.3.2.8} Glucose and lipid sensing
The central nervous system has been shown to be affected directly by circulating nutrients, as                           
well other hormones indirectly signalling energy status.
Two separate population of glucose sensing neurons exist, whereby one population is excited by                         
an increase in extracellular glucose whilst the other set is inhibited by an increase in extracellular                             
glucose. A large number of these neurons are present in the hypothalamus, but are also present                             
in the brainstem [Jordan et al., 2010]. In the arcuate nucleus, an increase in glucose                           
concentration inhibits NPY/AgRP neurons, whilst stimulating POMC neurons [Ibrahim et al.,                   
2003; Muroya et al., 1999; Mountjoy et al., 2007; Fioramonti et al., 2007]. In addition, it has been                                 
suggested glucose sensing within the lateral hypothalamus acts to mediate goal­orientated                   
behaviour with regards to glucose concentration [Karnani & Burdakov, 2011]. Orexin neurons are                       
inhibited by glucose, whilst MCH neurons are excited by glucose [Burdakov et al., 2005;                         
Broberger et al., 1998]. A detailed description of glucose sensing neurons is reviewed by Jordan                           
et al., 2010, and Karnani & Burdakov, 2011.
Neurons in the hypothalamus have also been shown to respond to long­chain fatty acids, up to                             
70% of which, also respond to glucose in the arcuate nucleus and VMH [Le Poll et al., 2009].                                 
Lipids have been shown to increase c­Fos expression neurons in the LH, whilst inhibit c­Fos                           
expression in the arcuate nucleus, DMH, VMH and PVN, which appears to be dependent on                           
extracellular glucose concentration [Cruciani­Guglielmacci et al., 2004; Wang et al., 2006]. I.c.v.                     
of a long­chain fatty acid reduced food intake and hepatic glucose production, and appeared to                           
be partly a result of a decreased in AgRP and NPY signalling [Obici et al., 2002; Morgan et al.,                                   






The increased prevalence of obesity in recent years has led to suggestion that an “obesogenic”                           
environment [Swinburn & Egger, 2004] ­ cheap, available high calorie food and a sedentary                         
lifestyle ­ coupled with our genetic background, is responsible. This is commonly known as the                           
“thrifty genotype” hypothesis, whereby an evolutionary pressure was present selecting for traits                     
which were advantageous in a nutrient­deprived environment, but now pose a risk to individuals                         
of developing obesity and type 2 diabetes [Gluckman & Hanson, 2004a].
However, it has been suggested that the rate of increase in obesity observed can not be                             
accounted for by genetics alone. This led to the development of the “thrifty phenotype”                         
hypothesis. Epidemiological evidence discussed by Hales & Barker (1992) showed offspring                   
who were exposed to poor fetal and early postnatal nutrition were more likely to develop type 2                               
diabetes and was a landmark study suggesting the developmental programming of metabolic                     
syndrome [Hales & Barker, 2001; Gluckman & Hanson, 2004b].
It has since been observed not only do offspring born during periods of undernutrition exhibit                           
signs of metabolic syndrome, but also offspring born from an environment of maternal                       
overnutrition [Armitage et al., 2005]. One example shows a U­shaped curve exists indicating low­                         
and high­birth weight offspring are more likely to suffer from cardiovascular disease and insulin                         
resistance in later life [Osmund & Barker, 2000, Pettitt & Jovanovic, 2001]. However, birth weight                           
alone does not always predict developmental outcome of the offspring, as demonstrated by                       
offspring born during the Dutch Winter famine, where birth weight was normal although these                         
individuals showed an increased prevalence of type 2 diabetes [de Rooij et al., 2006]. This has                             
led to an updated hypothesis known as the “predictive adaptive response” [Gluckman & Hanson,                         
2004c].
Building on epidemiological studies, animal studies also suggest early life programming during                     
the fetal and early postnatal period can have an effect on the development of disease during                             
adulthood (Bertram & Hanson, 2001; Tarry­Adkins & Ozanne, 2011). Of particular interest are                       
the changes observed in the central nervous system due to developmental programming [Cripps                       
et al., 2005; McMillen et al., 2005; Grayson et al., 2010]. The effects of protein restriction as a                                 
model of undernutrition has been shown to increase the risk of developing obesity and metabolic                           
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syndrome in adulthood [de Oliveira et al., 2012]. Similarly, maternal overfeeding has been shown                         
to increase the risk of developing obesity in later life. For example, a maternal HF diet in rats,                                 
associated with increased circulating levels of leptin, produced offspring expressing higher levels                     
of orexigenic peptides and an increased density of these peptide­expressing neurons. These                     
neuronal changes also persisted during postnatal return to control diet and led to long­term                         
changes, such as increased feeding and body weight (Chang et al., 2008). Another study also                           
showed an increase in food intake in offspring exposed to a maternal HF diet, but also an                               
increase in NPY, POMC and LepR mRNA expression, whilst also showing a decrease in Y1                           
receptor mRNA expression [Page et al., 2009]. One study suggests that simple exposure to a                           
HF diet during pregnancy and lactation is sufficient to cause these changes in the offspring,                           
whilst a different study claims maternal obesity, rather than just maternal high fat diet exposure,                           
is required for adverse early life programming [Howie et al., 2009; White et al., 2009]. Similar                             
changes in orexigenic neuropeptide expression were also observed with overnutrition due to a                       
small litter size, indicating the effects of intrauterine and early postnatal programming (Chen et                         
al., 2009).
In addition to changes in hypothalamic circuitry, mesolimbic dopamine circuitry has also been                       
shown to be affected in developmental programming (Vucetic & Reyes, 2010a). A study                       
investigating the effects of early postnatal HF diet resulted in a significant preference for HF                           
foods that could not be attributed to familiarity (Teegarden et al. 2009). HF diet exposure during                             
pregnancy was shown to increase dopamine levels in the NAc and VTA, and these mice showed                             
a decreased locomotor response to amphetamine administration and increased motivation for                   
HF food [Naef et al., 2008; Naef et al., 2011]. These mice also showed altered expression of                               
central dopamine markers in the striatum suggesting reduced dopaminergic signalling. In a                     
separate study, it was found offspring from mothers fed a HF diet during pregnancy and lactation                             
showed increased DAT and μ­opioid receptor mRNA expression in reward areas, accompanied                     
with global and gene specific hypermethylation (Vucetic et al. 2010b). Another study showed                       
offspring born to mothers fed on a “junk food“ diet showed decreased DAT and increased                           
μ­opioid receptor mRNA expression at 6 weeks of age, whilst the reverse was observed at 3                             
months of age [Ong & Muhlhausler, 2011]. Overall, these studies suggest early life nutrition can                           
have profound effects on the dopamine­reward system and could produce long­term effects.
{1.4.2} Mechanisms involved in the development of obesity
Genetic predispositions to obesity have been observed in animal (e.g. ob/ob and db/db mice)                         
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and within the human population [Yeo & Heisler, 2012]. Although monogenic forms of obesity                         
have a very large influence on the development of obesity, these account for a small proportion                             
of the population, and the mechanisms contributing to the development of “simple” obesity                       
appear more complex [Yeo & Heisler, 2012].
A number of different mechanisms have been shown to influence the development of obesity.                         
The study of epigenetic modifications have received much attention in recent years, including in                         
the field of nutrition, obesity and early life programming. These include alterations in methylation                         
of the DNA and histones, acetylation states of histones, and small and long non­coding RNA                           
[Slomko et al., 2012; Youngson & Morris, 2013; Pham & Lee et al., 2012; Ortega et al., 2013].                                 
Changes in DNA methylation have been shown with regards to dopaminergic and opioid circuits                         
in mice as a result of chronic adult high HF diet and early life programming [Vucetic et al., 2010b;                                   
Vucetic et al., 2011; Vucetic et al., 2012]. Decreased methylation of the MC4R gene has also                             
been shown, but only demonstrated a marginal effect of MC4R gene expression [Widiker et al,                           
2010]. Similarly, the effect of changes in methylation alone has not been shown to induce                           
obesity, questioning the relative importance of these alterations in the development of obesity                       
[Youngson & Morris, 2013].
Obesity has been shown to induce inflammation and could affect neural signalling, particularly                       
the hypothalamus, which is exposed to a multiple circulating factors [Lumeng & Saltiel, 2011;                         
Thaler et al., 2012]. Chronic inflammation has also been linked to neurodegeneration [Whitman                       
et al., 2008; Susaki & Nakayama., 2010; Doherty, 2011]. Adult stem cells in the median                           
eminence have been shown to decrease in number with exposure to HF diet, and have also                             
been shown to be mediated by inflammatory pathways [Zhang et al., 2008; Li et al., 2012; Cai,                               
2012]. However, short term HF diet has been shown to increase proliferation of adult stem cells                             
in the median eminence. Targeted destruction of the median eminence decreased weight gain                       
and fat mass, accompanied by an increase in oxygen consumption, energy expenditure and total                         
activity, although the relative contribution of destroyed adult stem cells and mature neurons was                         
not clear [Lee et al., 2012]. Autophagy dysfunction has also been linked to obesity, and a                             
decrease in autophagy has been associated with insulin resistance [Codogno & Meijer., 2010;                       
Yang et al., 2010]. However, another study suggested decreased autophagy in muscle protects                       
against the effects of obesity, with a knockdown of skeletal muscle autophagy reducing fat mass                           
and improved insulin sensitivity [Kim et al., 2012]. In the hypothalamus, starvation­induced                     
autophagy increased AgRP protein expression, whilst inhibition of autophagy failed to increase                     
AgRP protein expression in response to fasting. This in turn increased POMC and α­MSH                         
93
1. Introduction
production, thereby enhancing satiety and producing a lean phenotype. This autophagy process                     
involved the production of free fatty acids in the brain, which stimulated AgRP expression                         
[Kaushik et al., 2011]. Synaptic plasticity has also been shown to be affected by energy signals,                             




A drug which induces weight loss without side effects would be a perfect result of much of the                                 
work attempting to elucidate the many mechanisms involved in energy balance. However, most                       
anti­obesity drugs that have been released usually induce a number of side effects, resulting is a                             
few of these to be withdrawn from the market [Adan, 2013]. Most of these modern drugs target                               
energy intake, either by reducing appetite or reducing absorption of nutrients (Table 1.4.3.1.1).                       
Past drugs altering energy expenditure, such as thyroid hormone treatment and dinitrophenol (a                       






A number of these drugs target central systems involved in appetite regulation, particularly the                         
serotonergic system. There are seven families of receptors and at least eighteen receptor                       
subtypes which show a wide distribution of expression within the CNS and periphery [Marston et                           
al., 2011]. For this reason, targeting central serotonergic signalling has led to problems                       
[Connolley et al., 1997]. Fenfluramine and sibrutramine, both effective weight loss drugs that act                         
as indirect serotonin agonists, also activated 5­HT2b receptors expressed in the heart, which led                         
to the development of valvular heart disease and increased the risk of stroke [Weintraub et al.,                             
1992; Connolly et al., 1997; James et al., 2000; James et al., 2010]. Locraserin is a selective                               
5­HT2c receptor agonist which is successful in reducing body weight without associated heart                       
problems, as the 5­HT2c receptor in not expressed in the heart [Smith et al., 2010; O’Neil et al.,                                 
2012]. However, Locraserin is a less effective weight loss drug compared to more non­selective                         
5­HT agonists, suggested other receptor targets for treatment. [Thomson et al., 2008]. As well                         
as acting to increase serotonin production by targeting the vesicular monoamine transporter                     
(VMAT2), fenfluramine also acts as a selective­serotonin reuptake inhibitor (SSRI) [Cooke &                     
Bloom, 2006]. However, other SSRIs such as paroxetine increase body weight, suggesting                     
increased serotonin production induced by VMAT2 is required for weight loss [Marks et al., 2008].
Another target which can alter serotonergic signalling is noradrenaline, which are stimulated by                       
noradrenaline and α1­adrenoreceptor agonists in the brainstem, which in turn leads to a                       
decrease in food intake [Mansur et al., 2011]. Noradrenaline also induces weight loss via the                           
PVN, although the type of neurons that express α1­adrenoreceptors are unknown [Wellman,                     
2000]. Peripheral noradrenaline signalling induces lipolysis in WAT through activation of                   
α3­adrenoreceptors, specifically expressed in adipocytes [Mansur et al., 2011]. However,                 
α3­adrenoreceptors have not been shown to alter weight loss long term [Redman et al., 2007].                           
Unfortunately, drugs which increase noradrenaline release tend to mimic amphetamines, so are                     
only available for short­term prescriptions. In addition to their addictive nature, there are also                         
associated cardiac problems [Derosa & Maffioli, 2012].
Rimonabant is a CB1 receptor antagonist that has a significant effects on CNS signalling, but                           
also affects peripheral systems [Kunos & Tam, 2011]. Like the peripheral noradrenaline                     
signalling, CB1 receptors antagonists increase lipolysis in WAT [Jbilo et al., 2005]. Unfortunately,                       
rimonabant use not only led to weight loss but also resulted in anxiety and depression                           
[Christensen et al., 2007]. Peripheral inverse agonists that do not affect CNS endocannabinoid                       
signalling showed a reduction in body weight without mental health effects, whilst neutral CB1                         
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antagonists were as effective as inverse agonists at reducing body weight, again with no                         
adverse psychological effects [Tam et al., 2011; Meye et al., 2012]. It has been suggested the                             
depressive­symptoms are a result of the inverse antagonism in the VTA and amygdala, whilst                         
the weight loss effects were mediated by hypothalamic CB1 receptor antagonism, with an                       
additional effect on the periphery due to inverse agonists.
Similar to serotonin­target drugs, vanoxerine, a reuptake inhibition of dopamine results in a                       
decrease in food intake and increased locomotor activity [van der Hoek & Cooper, 1994].                         
Bupropion is a noradrenaline and dopamine reuptake inhibitor which has been shown to increase                         
POMC signalling and shows enhanced weight loss than targeting just noradrenaline or dopamine                       
[Billes & Cowley, 2006; Plodkowski et al., 2009; Billes & Greenway, 2011]. A current drug in                             
development, tesofensine, also has multiple targets, being a combination of noradrenaline,                   
dopamine and serotonin reuptake inhibitors [Astrup et al., 2008]. Other combination drugs in                       
developed recently include contrave, which consists of bupropion and naltrexone, a μ/κ opioid                       
receptor antagonist [Greenway et al., 2009;]. Empatic is a combination of bupropion and                       
zonisamide, an antiepileptic drug which increases GABA signalling and reduced AMPA receptor                     
signalling [Gadde et al., 2007]. Qsymia is a recently FDA­approved weight loss drug which                         
combines phentermine and a extended­release version of topiramate, another antiepileptic drug                   
[Garvey et al., 2012].
{1.4.3.2} Gut hormone therapy
As shown above, a number of anti­obesity drugs target parts of the nervous system to                           
predominantly alter food intake. Many of these drugs are accompanied with a number of adverse                           
side effects, meaning in the UK, only orlistat is currently available as a weight loss drug                             
[McGavigan & Murphy, 2012]. Orlistat is a gastric and pancreatic lipase inhibitor which reduces                         
the absorption of fat from the diet. Unfortunately, only 30% of patients achieve a weight reduction                             
of 5% or more, possibly due to unpleasant side effects [Powell et al., 2011].
The discovery of leptin was thought to be the end of obesity, with the proposition this could be                                 
used as an anti­obesity drug [Halaas et al., 1995]. Although peripheral administration of leptin                         
reduces food intake in lean animals and patients, obesity results in leptin resistance, thereby                         
removing the efficacy of leptin treatment [Heymsfield et al., 1999; Hukshorn et al., 2003a; Myers                           
et al., 2008]. More recently, a number of satiety gut hormones have been investigated as                           
potential therapies for obesity, including amylin, GLP­1, PP, PYY and oxyntomodulin [Chaudhri et                       
al., 2008; MCGavigan & Murphy, 2012]. Although all these gut hormones significantly reduce food                         
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intake, they all suffer as potential therapies due to their short half­lives in vivo as a result of                                 
hormone degradation by DPP­IV and/or neutral endopeptidases. A focus of gut hormone therapy                       
is to produce long­lasting analogues of these hormones, many of which show promising results                         
[McGavigan & Murphy, 2012]. In particular, combination administration of a low dose GLP­17­36                       
and PYY3­36 shows an additive anorexigenic effect, whereas separate administration of the low                       
dose does not alter food intake. This is also an attractive treatment as these low doses would                               
reduce the incidence of nausea which can occur with high doses of individual administration of                           
these hormones [Neary et al., 2005; Steinert et al., 2010].
Another challenge to overcome for gut hormone therapy to be a standard treatment for obesity is                             
effective drug delivery. This is intimately linked to the ability to generate long­lasting stable                         
analogues. Many of these analogues are administered multiple times a day with subcutaneous                       
injections [Naslund et al., 2004; Wynne et al., 2005]. A suggested method is the use of                             
nanoparticles formulated to reliably cross the intestinal mucosa, whilst carrying an effective and                       
stable dose [des Rieux et al., 2006]. A promising new method of oral administration of GLP­17­37                             
and PYY3­36 has shown significant effects on food intake and glucose tolerance in healthy adult                           
males [Steinert et al., 2009; Steinert et al., 2010]. This is achieved by combining the hormone                             
analogue with sodium N­[8­(2­hydroxybenzoyl) amino] caprylate (SNAC), a hydrophobic               
molecule that forms non­covalent bonds with the peptide. This increases their lipophilicity and                       
improves their absorption in the small intestine, whereafter the peptide is released into the blood                           
[Kidron et al., 2004].
{1.4.3.3} Bariatric surgery
Bariatric surgery is considered the most effective treatment for obesity and type 2 diabetes,                         
achieving considerable weight loss which, most importantly, is maintained [Beckman et al.,                     
2010]. Interestingly, weight loss surgery induced the patient to reduce their calorie input, similar                         
to any low calorie diet, however, patient reports indicate surgery­induced calorie reduction is not                         
accompanied with hunger or the body compensating against weight loss, as observed from                       
lifestyle changes and dieting [Schultes et al., 2010; Miras et al., 2012; Ullrich et al., 2012]. The                               
mechanisms involved in this response are not entirely clear, but may result from changes in gut                             
hormone release and vagal afferents as a result of the surgery [Berthoud, 2008; Beckman et al.,                             
2010]. In turn, these peripheral changes could alter central signalling of appetite control, resulting                         




There are several types of bariatric surgery, including vertical banded gastroplasty, gastric                     
banding, sleeve gastrectomy, biliopancreatic diversion duodenal switch and Roux­en­Y gastric                 
bypass (RYGB). RYGB accounts for 70­75% of bariatric surgeries, as it one of the safest and                             
most effective surgeries that can now also be performed using laparoscopic techniques                     
[Beckman et al., 2010]. For this reason, the effects of RYGB will be discussed in further detail.
RYGB involves making a small pouch created from the distal part of the mid­jejunum, whilst the                             
proximal end if the jejunum is connected to the ileum to allow the drainage of bile and pancreatic                                 
juices (biliopancreatic limb). The result is food moves straight from the pouch to the distal parts                             
of the jejunum (Roux limb) [Shin & Berthoud, 2013. The obvious result of this modification is a                               
restriction of food intake due to reduced capacity of the digestive system. However, even if meal                             
sizes are smaller as a result of surgery, one might expect a large increase in the number of                                 
meals eaten to compensate if the body was defending a past set­point. This does not occur,                             
suggesting there are other effects of surgery that contribute to significant weight loss [Laurenius                         
et al., 2011]. Weight loss significantly improves insulin secretion and action, and this appears                         
proportional to the amount of weight lost, and is a common positive side effect of bariatric                             
surgery [Weyer et al., 2000; Polyzogopoulou et al., 2003].
One of the most studied alterations after surgery is the changes observed in gut hormone                           
circulation, in particular GLP­1 and PYY. Both GLP­1 and PYY levels are significantly higher after                           
RYGB surgery compared to lean controls, unoperated obese, overweight patients and patients                     
who have undergone other weight loss surgeries [Borg et al., 2006; Korner et al., 2007; le Roux                               
et al., 2007; Rodieux et al., 2008]. The changes in hormone levels appear within a few days of                                 
the surgery and appear to be long term changes. This change is probably a result of the rapid                                 
increase in nutrient delivery to the lower parts of the small intestine where these hormones are                             
produced by L cells [Cummings et al., 2007]. Changes in ghrelin levels are also implicated in the                               
weight loss responses. RYGB patients show reduced plasma ghrelin compared to lean controls,                       
unoperated obese, overweight and patients who have undergone a different method of weight                       
loss surgery. Similar to GLP­1 and PYY, changes in ghrelin expression occur rapidly after                         
surgery and remain decreased one year after the surgery [Leonetti et al., 2003; Lin et al., 2004;                               
Engström et al., 2006; Rodieux et al., 2008]. Again, this is likely to be a result of the almost                                   
complete removal of the stomach from the flow of food in the gastrointestinal tract. Surgeries                           
which do not bypass the stomach to such an extent as RYGB do not achieve such an effective                                 
weight loss, indicating the importance of changing circulating ghrelin concentration in significant                     
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and sustained weight loss [Leonetti et al., 2003; Lin et al., 2004; Korner et al., 2006]. There have                                 
also been observations of altered circulation of bile acids after surgery, which has been shown to                             
improve glucose homeostasis and increase fatty acid oxidation, and may result in an increase in                           
BAT thermogenesis and an increase the release of GLP­1 [Patti et al., 2009; Simonen et al.,                             
2012; Watanabe et al., 2006; Knop et al., 2010].
These changes in peripheral signals may lead to the reported changes in hedonic processing                         
observed in RYGB patients. Several studies have reported a preference switch from high­calorie                       
food to low­calorie food [Kenlar et al., 1990; Olbers et al., 2006; Thirlby et al., 2006; Ochner et al.,                                   
2011]. Similarly, it has also been observed a decrease in the threshold for detecting sweetness                           
[Burge et al., 1995]. fMRI and PET data suggest these preference changes could be a result of                               
altered dopamine signalling in reward areas [Ochner et al., 2011; Steele et al., 2010; Dunn et al.,                               
2010].
{1.4.3.4} Diet and lifestyle changes
The least invasive method of reducing weight is through reduced calorie intake and increased                         
energy expenditure in the form of exercise. However, as demonstrated by the development of                         
drug and hormone administration and ultimately surgery, these lifestyle changes are often not                       
successful as a long­term method of weight reduction. There are multiple factors which                       
determine whether weight loss can be maintained, including types of food consumed, exercise,                       
sedentary behaviours (e.g. sleep duration, television watching, internet usage), alcohol                 
consumption and smoking [Mozaffarian et al., 2011]. Different behavioural strategies have also                     
shown to be a variable in successful weight loss and maintenance [Unick et al., 2013]. By                             
defining successful weight loss as a maintaining a 10% reduction in body weight for a year,                             
around 20% of dieters are successful [Kraschnewski et al., 2010]. A third of the body weight lost                               
is usually regained within a year, whilst the majority of weight is regained within 3 to 5 years of                                   
the initial reduction in body weight [Turk et al., 2009]. This can lead to multiple dieting                             
unsuccessful dieting attempts, resulting in weight cycling, or “yoyo dieting”. A Finnish study                       
showed within a population, weight cycling occured within 29% of women and 18% of men,                           
indicating the high prevalence of weight fluctuation, especially in women [Lahti‐Koski et al.,                       
2005]. Additionally, weight cycling is not limited to the overweight or obese, but underweight and                           
normal weight individuals [Bendixen et al., 2002].
Although weight cycling is undesirable, as it means a failure to lose weight effectively, there are                             
conflicting accounts on the long term effects of weight cycling. A recent study showed no effect                             
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of weight cycling on mortality, independent from BMI and weight gain [Stevens et al., 2012].                           
Another study showed weight cycling itself could increase the risk of metabolic syndrome, such                         
as increased blood pressure and increased waist:hip ratio [Vergnaud et al., 2007]. Another                       
common condition which has received attention is the risk of cardiovascular disease with weight                         
cycling, again with conflicting results [Graci et al., 2003; Montani et al., 2006]. A recent study also                               
showed patients with a history of weight cycling did not show any difficulty in dieting or                             
maintaining an exercise regime compared to non­weight cyclers, and still showed the same                       
metabolic and body composition benefits from dieting for 1 year [Mason et al., 2012]. However,                           
longer­term studies have shown a history of weight cycling can predict future weight gain                         
[Korkeila et al., 1999; Field et al., 2004; Hill et al., 2004; Savage et al., 2010]. In a cohort of weight                                       
cycling athletes, there appeared to be a predisposition to weight gain due to weight cycling at a                               
young age [Saarni et al., 2006]. There are also contradictory results assessing differences in fat                           
distribution as a result of weight cycling. An increased waist:hip ratio has been observed in                           
women with a history of weight cycling when BMI matched to controls, which also positively                           
correlates with an increased risk of hypertension [Rodin et al., 1990; Guagnano et al., 1999;                           
Guagnano et al., 2000]. Another study showed changes in fat distribution due to weight cycling,                           
shifting subcutaneous tissue towards the upper body depots, as opposed to the thighs [Wallner                         
et al., 2004]. Other studies found no effect of weight cycling on body composition, fat distribution,                             
resting energy expenditure (REE) or lipolytic activity [Brownell et al., 1986; Jebb et al., 1991;                           
Hainer et al., 1992; Prentice et al 1992; Wadden et al., 1996; Heitmann et al., 2002; Lien et al,.                                   
2009]. Additionally, some studies have shown no difference in visceral fat in obese or non­obese                           
weight cyclers [van der Kooy et al., 1993; Rebuffé­Serive et al., 1994; Zamboni et al., 1996].
A weight cycle study in rats showed weight cycling did not predispose rats to weight gain with a                                 
high fat diet compared to non­weight cyclers [Graham et al., 1990]. In contrast, another study                           
showed weight cycling reduced the rate of weight regain but not weight loss, whilst there was an                               
increased tendency towards fat deposition at the expense of fat free mass [Jen et al., 1995].                             
Another study showed an increase in internal adipose tissue as a result of weight cycling, which                             
was also accompanied by hypertension [Ernsberger et al., 1996]. Lim et al. showed four weight                           
cycles, consisting of of 7 days of food restriction and 7 days of ad libitum feeding, resulted in an                                   
increase in fat content in rats. Additionally, this study showed treadmill exercise could prevent                         
the increase in fat content observed with weight cycling [Lim et al., 1996]. However, other studies                             
which consisted of short periods of weight cycling (3 days fasting, followed by 7 days ad libitum                               
feeding) showed no difference on body composition after multiple weight cycles in rats [Hill et al.,                             
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1987; Hill et al., 1988; Graham et al., 1990; Wheeler et al., 1990]. Lu et al. showed no change in                                     
fat content, hypertension or hyperglycemia as a result of weight cycling, but did show a degree of                               
insulin resistance and hyperinsulinemia [Lu et al., 1995]. However, a study in humans showed                         
weight cycled women showed an improvement in insulin sensitivity in a weight reduced state,                         
but this could predict future weight gain [Yost et al., 1995]. Other studies have shown an                             
increase in insulin resistance in normal weight people, with a suggestion this may induce weight                           
gain, whilst other studies have found no association [Yatsuya et al., 2003; Zhang et al., 2005;                             
Field et al., 2004]. Another study showed no effect in of weight cycling on rats on body                               
composition, fat content, total energy efficiency or weight gain after the weight cycling period                         
[Lauer et al., 1999]. When energy efficiency was analysed for each weight cycle, energy                         
efficiency was increased during each weight regain period compared to obese controls [Brownell                       
et al., 1986]. Similarly, another short­term weight cycling study showed no differences in fat                         
distribution, but observed weight loss became more difficult and weight gain became easier over                         
time [Pellizzon et al., 2000]. Another study assessing changes in fatty acid metabolism showed                         
a decrease in unsaturated:saturated fat ratio in weight cycled mice who cycled onto a fat diet,                             
accompanied with an increase in lipogenic gene expression and an increase in adipocyte size                         
and retroperitoneal and epididymal fat pads [Sea et al., 2000]. Other studies have also showed a                             
decrease unsaturated fats with weight cycling, both total body content and liver content [Chen et                           
al., 1995; Chen et al., 1996; Chen et al., 1997]. Increased lipogenic activity has also been                             
observed in WAT with weight cycling, which may become amplified with each cycle [Kochan et                           
al., 2003; Stelmanska et al., 2004; Karbowska et al., 2001].
Changes in leptin levels may contribute to weight regain after weight loss. Leptin levels were                           
significantly lower during weight loss compared to weight maintenance, even when matched for                       
body composition. Additionally, no correlation between leptin concentration or energy expenditure                   
was observed, and appeared to be independent of post­absorptive plasma insulin concentration                     
[Rosenbaum et al., 1997]. Another study showed increased leptin concentration in weight cycling                       
women independent of fat content [Benini et al., 2001]. Interestingly, a study in humans                         
assessing changes in metabolic hormones after a hypocaloric diet showed increased plasma                     
leptin levels and lower ghrelin levels, which could be used to predict weight regain, opposite to                             
what would be expected [Crujeiras et al., 2010]. In contrast to this, a study assessing hormonal                             
changes with successful weight maintenance still showed significant alterations in hormone                   
concentrations as measured after the initial weight loss. This includes decreased leptin                     
concentration corrected to fat mass, increased plasma ghrelin concentration, and insulin, PYY                     
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and GLP­1 plasma concentrations were also significantly lower compared to before weight loss.                       
Rating of hunger and the amount of time spent thinking about food was also significantly                           
increased after initial weight loss and one year after compared to ratings before weight loss                           
[Sumithran et al., 2011].
Much of the research on diet and lifestyle changes focuses on the drivers for weight regain,                             
either after acute weight loss or with prolonged calorie restriction [MacLean et al., 2011;                         
Sumithran & Proietto, 2013]. Multiple systems appear to contribute to weight regain, including                       
central neural signalling, alterations in gut hormone circulation, altered adipose tissue                   
composition, lipid metabolism and muscle metabolism.
As expected, the hypothalamus, particularly the arcuate nucleus alters signalling to increase                     
food intake and inhibit satiety [Sainsbury & Zhang, 2010]. In mice, fasting increased NPY and                           
AgRP peptide concentration and mRNA content in the arcuate nucleus. In contrast, POMC and                         
CART expression in decreased during fasting in mice [Brady et al., 1990; Mizuno et al., 1999;                             
Swart et al., 2002]. This signalling pattern is also observed in genetic models of obesity, whereby                             
a lack of hormonal satiety signalling creates an effective energy deficit accompanied by obesity                         
[Sainsbury & Zhang, 2010]. Alterations in hypothalamic structure upon HF feeding has been                       
shown to reduce arcuate nucleus cell proliferation [McNay et al., 2012]. This change can persist                           
after successful weight loss, suggesting the new set­point induced by HF feeding is retained                         
after dieting, which means short­term weight loss does not predict weight maintenance.                     
Additionally, weight loss induced by calorie restriction on a HF diet does not result in successful                             
long­term weight loss, whilst calorie restriction with a normal fat diet showed an increase in                           
hypothalamic cell proliferation and an attenuation in weight rebound [McNay & Speakman, 2012].
Food intake was significantly increased after a 48 hour fast, where a 18% reduction in body                             
weight was accompanied with a 65% increase in food intake upon refeeding which lasted for 5                             
days [Erickson et al., 1996a]. Two weeks of food restriction resulted in a 15% weight loss, and                               
energy intake was significantly increased when refed a chow diet compared to HF feeding before                           
food restriction [MacLean et al., 2004a; MacLean et al., 2004b]. This appeared to be a result of                               
increased energy intake as opposed to decreased energy expenditure, as continued energy                     
restriction was able to maintain a lower weight [MacLean et al., 2004a; MacLean et al., 2004b].                             
Similar results have been shown in humans, whereby a 24 week energy restriction programme                         
resulted in a 25% reduction in body weight, but was followed by a 160% increase in energy                               
intake relative to pre­restriction energy intake [Keys et al., 1950]. 48 hours of food restriction also                             
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significantly increased energy intake when given free access to food, and was correlated with an                           
increase in reported hunger and desire to eat [Mars et al., 2005; Hukshorn et al., 2003b].
Different reports on physical activity exist on the effects of food restriction. Both an increase,                           
decrease and no effect on physical activity has been reported [Overton et al., 2001; Williams et                             
al., 2000; Nagashima et al.,2003]. Age may also affect activity in response to energy restriction,                           
where wheel running activity in mice was lower during early life energy restriction, whereas                         
activity was increased in the same set of mice later in life [Goodrick et al., 1983]. An increase in                                   
activity could indicate increased food­seeking behaviour, whilst a decrease in activity would                     
reduce energy expenditure during energy deficit [Gutierrez et al., 2002]. Similarly, some reports                       
in humans show decreased physical activity in response to calorie restriction, whilst another                       
study showed reduced physiological stress in dieting patients in response to exercise, which                       
resulted in an increased tendency to be more activity compared to pre­dieting [Martin et al., 2007;                             
Weinsier et al., 2000a]. Rhesus monkeys showed a decrease in physical activity after 70%                         
energy restriction for 1 year, but no difference in activity was observed when this restriction was                             
prolonged for 5 to 6 years [Kemnitz et al., 1993; Ramsey et al., 1997]. Another study showed                               
aged monkeys who had been energy restricted for 5 to 10 years showed both similar or                             
increased levels of physical activity compared to controls [Moscrip et al., 2000; DeLany et al.,                           
1999]. Similar to mice, young monkeys showed a decrease in physical activity after 5 to 6 years                               
of energy restriction [Weed et al., 1997; Moscrip et al., 2000].
In line with a drive to increase energy intake, energy expenditure has been shown to decrease                             
with energy deficit. In mice, fasting decreased resting metabolic rate, reduced oxygen                     
consumption and decreased body temperature [Williams et al., 2000; Bézaire et al., 2001;                       
Nagashima et al., 2003]. The reduction in oxygen consumption has been shown to decrease                         
independently of physical activity [Nagashima et al., 2003]. A 2 week energy restriction                       
programme in rats showed decreased energy expenditure during the initial weeks and                     
afterwards, when rats had ad libitum access to food [MacLean et al., 2004; MacLean et al.,                             
2006]. Alongside an increase in food intake after the 24 week food restriction programme,                         
humans also showed a decrease in metabolic rate compared to pre­programme rates [Keys et                         
al., 1950]. Similarly, obese and overweight patients showed decreased metabolic rate and                     
energy expenditure after weight loss, and appeared to correlate with the amount lost [Weinsier et                           
al., 2000; Rosenbaum et al., 1997; Leibel et al., 1995]. The decrease in energy expenditure could                             
be used to predict subsequent weight regain [Pasman et al., 1999; Goran, 2000]. However, this                           
decrease in energy expenditure appeared to be transient, as this change was not observed                         
103
1. Introduction
during weight maintenance [Weinsier et al., 2000; Westerterp­Plantenga et al., 2004;                   
Rosenbaum et al., 2000].
Other non­homeostatic areas of the brain have shown altered signalling in response to weight                         
loss [Rosenbaum et al., 2008; Yu et al., 2009]. In particular, much focus on non­homeostatic                           
signalling with regards to weight has been conducted in humans, due to the complex interactions                           
of cognition and emotion [Cornier et al., 2009; Lemmens et al., 2009; Joseph et al., 2011;                             
Jasinska et al., 2012]. Subjective appetite is reported to increase with weight loss, alongside an                           
increase in the perceived reward of food [Doucet et al., 2000; Cameron et al., 2008; Sumithran et                               
al., 2011]. Taste preference appears to also be altered depending on weight state, whereby                         
obese patients show an increased preference for HF solutions, whilst weight loss patients show                         
a preference for high sugar and HF solutions [Drewnowski et al., 1985]. An overnight fast biases                             
food selection towards high calorie food, where an increase in activation is observed in the                           
ventral striatum, amygdala, insula and orbitofrontal cortex [Goldstone et al., 2009]. Weight loss                       
patients also show an increased activity in reward areas of the brain, and reduced activity in                             
areas associated with emotional control [Rosenbaum et al., 2008]. 2 days of overfeeding has                         
shown a decrease in activation in the hypothalamus and insula in lean controls, whilst                         
reduced­obese patients showed a change in response to an increase in energy [Cornier et al.,                           
2009]. The insula can be stimulated by ghrelin or inhibited with leptin in reduced­obese patients                           
[Malik et al., 2008; Rosenbaum et al., 2008; Baicy et al., 2007].
After 5 days of L­DOPA infusion, weight gain was significantly increased after withdrawal of                         
L­DOPA infusions compared to vehicle infusion. This overstimulation for a short period of time is                           
suggested to reduce receptor expression, therefore inducing hyposensitivity to dopamine.                 
However, this study does not indicate how the L­DOPA infusion compared to dopamine release                         
in relation to food [Reinholz et al., 2008]. However, a study in humans to assess the effect of                                 
dopamine signalling using acute tyrosine/phenylalanine depletion (ATPD) had no effect on                   
motivation, as measured by willingness to pay for food or alcohol, whilst there was a decrease in                               
hunger, indicating dopamine depletion reduces the desire to eat [Hardman et al., 2011]. This                         
method has previously shown an increase in reward intensity for smoking [Montgomery et al.,                         
2003]. However, this may be a result of using healthy individuals, suggesting dopamine signalling                         
deficiency by itself does not cause overeating, but in the context of a number of perturbed                             
regulatory mechanisms (e.g. leptin, insulin resistance), may contribute to its development. In                     




Other central signalling pathways appear to be altered after weight loss. These include                       
hypothalamic­pituitary­thyroid, adrenal, gonadal and somatotropic axis [Sainsbury & Zhang,               
2012]. In summary, an energy deficit decreases thyroid, gonadal and growth hormone                     
production, whilst glucocorticoid production is increased. These changes in turn can alter food                       
intake, body weight, body composition and fat distribution.
Stress has been shown to increase food intake and obesity increases stress­related                     
glucocorticoids [la Fleur, 2006; Habhab et al., 2009; Born et al., 2010]. Drugs which induce                           
stress can reinstate operant behaviour for palatable food, which can be attenuated by a CRF­1                           
receptor antagonist [Ghitza et al., 2006]. In mice, a palatable diet shows decreased CRF mRNA                           
expression in the central nucleus of the amygdala (CeA), but the stress of calorie restriction                           
increases CRF mRNA expression [Teegarden & Bale, 2007]. Similarly, cyclic access to HF diet                         
(5 days chow, 2 day high fat) showed a CRF­1 receptor antagonist decreased the consumption                           
of HF food in favour of chow. CRF expression increased when moving from HF diet to a chow                                 
diet, which normalised when reexposed to the HF diet. CRF­1 receptor antagonist also                       
increased GABAergic signalling in the CeA, resulting in cycled rats having comparable levels of                         
transmission compared to controls, indicating increased CeA signalling lacks sufficient inhibition                   
during the stress response when diet cycling [Cottone et al., 2009]. A similar response has been                             
observed during alcohol withdrawal [Roberto et al., 2010]. Additionally, a stress response                     
measured as an increase in CRF release can be induced by NPY stimulation, which is shown to                               
increase during diet restriction [Wahlestedt et al., 1987; Suda et al., 1993; Widdowson et al.,                           
1997]. CRF expression has shown to be decreased in the bed nucleus of the stria terminalis                             
(BNST) with HF diet exposure after calorie restriction, which was associated with decreased                       
methylation of the CRH promoter region. This was correlated with an increase in orexin and                           
MCH neuropeptides, and an MCH receptor antagonist was able to reduce HF refeeding                       
[Pankevich et al., 2010]. Intact ghrelin signalling has been shown to be essential for                         
stress­induced reward seeking behaviour, and ghrelin receptor signalling within dopaminergic                 
neurons alone was sufficient in mediating this response [Chuang et al., 2011].
Improved metabolic flexibility is induced after weight loss, which included a shift towards                       
carbohydrate oxidation over fat oxidation and improved insulin sensitivity [Froidevaux et al., 1993;                       
Yost et al., 1995; McLaughlin et al., 2008; Rabøl et al., 2009]. However, this improved sensitivity                             
and increased nutrient clearance has been suggested to prime the body towards weight regain                         
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[Tremblay et al., 2005; MacLean et al., 2006]. There is also an increased preference towards fat                             
deposition due to the reduction in fat oxidation, coupled with the lower energetic costs of fat                             
deposition versus carbohydrate deposition [Flatt et al., 1985; Schutz, 2004; Jackman et al.,                       
2008]. An increased efficiency in weight gain can be predicted by insulin sensitivity, glucose                         
sensitivity, and preference for carbohydrate oxidation [Yost et al., 1995; Froidevaux et al., 1993;                         
Boulé et al., 2008]. Upon weight loss, hepatic regulation of carbohydrate and fat is improved,                           
accompanied by a decrease in hepatic lipid and glucose production [James et al., 2003; Kirk et                             
al., 2009]. Dark and light cycle changes in nutrient metabolism is restored with weight loss,                           
indicating an improved ability in nutrient clearance in the liver. Additionally, there appeared to be                           
an increase in lipogenic activity in the liver, where newly formed fat was retained by the liver                               
[Jackman et al., 2008]. Humans show an increase in fat deposition as opposed to glycogen                           
stores when fed a low fat, high carbohydrate diet after weight loss [Minehira et al., 2003; Minehira                               
et al., 2004].
Assessment of adipose tissue showed a decrease in metabolic gene expression after weight                       
loss, favouring energy conservation and repletion of fat stores during meals and overfeeding                       
[Kern et al., 1995; Levin et al.,2002; Bergman et al., 2004; Capel et al., 2009]. This correlated                               
with a decrease in inflammatory markers which are known to decrease appetite and increase                         
energy expenditure [Kern et al., 1995; Palming et al., 2007; Huang et al., 2010]. Cell size but not                                 
cell number were decreased after weight loss, which could contribute to improved tissue                       
metabolism due to an effective increase in surface area [MacLean et al., 2006 MacLean et al.,                             
2009]. Smaller adipocytes also appear to exhibit lower lipolysis, lipid turnover and exhibit a gene                           
expression favouring lipid storage [Löfgren et al., 2005a; Svensson et al., 2008]. There was an                           
increased number of these small adipocytes in weight­reduced DIO rats during the first stages                         
of weight regain, with these cells preferentially increasing in size. Additionally, animals who                       
underwent weight relapse still showed an increased number of small adipocytes compared to                       
obese rats that had not undergone weight loss [Jackman et al.,2008]. This cell distribution has                           
also been observed in post obese humans [Löfgren et al., 2005b]. However, this hypercellular                         






Exposure to a high fat diet causes long term alterations in dopaminergic gene expression that                           
persists after weight loss. These changes decrease dopamine sensitivity, which in turn leads to                         
overeating to compensate and encourages weight regain.
{1.5.2} AIms of this thesis
● To assess the effects of rapid weight change and weight cycling on neural gene                         
expression. Dopaminergic gene expression will be assessed in reward areas (VTA, NAc                     
and PFC) and the hypothalamus to determine the effects the treatment on reward                       
signalling. Additionally, changes in gene expression of homeostatic markers will be                   
assessed in the hypothalamus, including NPY, AgRP and POMC.
● To assess the phenotypic changes as result of rapid weight change and weight cycling.                         
This includes body weight and food intake monitoring, assessment of fat content and                       









under the project licence 70/6656 and 70/7502. Unless specified, all mice were acclimatised for                         
a week and housed in ventilated cages in groups of 4 under a 12h:12h light cycle (lights on at                                   
7am) at 21­23°C with ad libitum access to food and water.
{2.1.2} Diet Composition
The composition of the diets used for this study are shown in table 2.1.2.0.1. The two diets used                                 








































A) Nutrient composition of the diets used for the documented experiments. Units g/kg. The                         
variables altered which defined whether the diet was a control or high fat diet were predominantly                             
corn starch or lard content.
B) The control diet contained 4.2% fat as a percentage of ingredients whilst the HFD contained                             
34.3% fat as a percentage of ingredients. In terms of fat as a caloric percentage, the control diet                                 





The protocol for this experiment is shown in Figure 2.1.4.0.1. The diets used for this experiment                             
are described above (Table 2.1.2.0.1). C57Bl6 males (Harlan UK) aged 8­10 weeks were caged                         
in groups of 4 and fed either a HFD (TD.06414, 60% by kcal intake) or a control diet (TD.08806,                                   
10% by kcal intake, Harlan, USA). The entire experiment lasted 7 weeks.
● Rapid weight gain
After 6 weeks of feeding, half the mice fed a control diet continued feeding on the control                               
diet for another week, whilst half the control mice swapped to a HFD for one week. These                               
two groups were labelled CC (control­control) and CF (control­high fat), where the CC                       
group acts as a control group for the rapid weight gain group CF.
● Rapid weight loss
Half the mice fed a HFD for 6 weeks continued feeding on the HFD for another week. The                                 
remaining half of HFD fed mice swapped to a control diet for a week after 6 weeks of                                 
HFD. The two groups were labelled FF (high fat­high fat) and FC (high fat­control), where                           
the FF group was a control group for the rapid weight loss group FC.
{2.1.4} Methods
Body weight and food intake was monitored weekly. Whole body MRI and MRS, and localised                           
liver MRS was performed after 7 weeks of feeding. An IPGTT was performed after 7 weeks of                               
feeding to assess glucose tolerance. Indirect calorimetry and an acute exercise study assessed                       
changes in metabolism and endurance. Finally, tissue samples were collected after 7 weeks of                         
feeding and neural signalling was assessed using RT­qPCR. Different subsets of animals were                       




Figure {2.1.4.0.1} Schematic of protocol used to study the effects of rapid weight change                         
on metabolism and appetite
C57Bl6 males aged 8­10 weeks were used for the experiment, which lasted 7 weeks in total.                             
After 6 weeks of feeding, half the mice fed a control diet continued feeding on the control diet for                                   
another week, whilst half the control mice swapped to the HFD for one week. These two groups                               
are labelled CC (control­control) and CF (control­high fat), where the CC group acts as a control                             
group for the rapid weight gain group CF. Similarly, half the mice fed a HFD for 6 weeks                                 
continued feeding on a HFD for another week. The remaining half of high fat fed mice swapped                               
to the control diet for a week after 6 weeks of HFD feeding. The two groups were labelled FF                                   
(high fat­high fat) and FC (high fat­control), where the FF group was a control group for the rapid                                 
weight loss group FC.
MRI/MRS, an IPGTT, indirect calorimetry and acute exercise studies were performed after 6 and                         
7 weeks of feeding (n=8/group). Finally, tissue samples were collected after 6 and 7 weeks of                             
feeding and neural signalling was assessed using RT­qPCR (n=6­8/group). Different subsets of                     








under the project licence 70/6656 and 70/7502. Unless specified, all mice were acclimatised for                         
a week and housed in ventilated cages in groups of 4 under a 12h:12h light cycle (lights on at                                   
7am) at 21­23°C with ad libitum access to food and water.
{2.2.2} Experimental Model
The protocol for this experiment is shown in Figure 2.2.3.0.1. C57Bl6 male mice (Harlan, UK)                           
aged 8­10 weeks were caged in groups of 4 and fed either on a HFD or a control diet (Table                                     
2.1.2.0.1). This experiment ran for a total of 18 weeks, with 3 time points for diet swapping in 6                                   
week periods (6, 12 and 18 weeks of feeding). There was a total of 10 separate groups, each                                 
containing 28 mice (total number=280).
● Time Point 1: 6 weeks of feeding, no diet swaps
For the first two groups, mice were fed either a normal fat control diet or HFD for 6 weeks                                   
(C and Fa).
● Time Point 2: 12 weeks of feeding, 1 diet swap
After feeding for 12 weeks, there were 4 groups of mice. Two of the groups were control                               
groups, being fed either a control diet or a HFD for 12 weeks (CC and FaFa) and two                                 
experimental groups. The first of these groups was fed a control diet for 6 weeks, then                             
swapped to a HFD for 6 weeks and is known as CFa. The second experimental group                             
was fed a HFD for 6 weeks, then swapped to a control diet for 6 weeks and is known as                                     
FaC.
● Time Point 3: 18 weeks of feeding, 2 diet swaps
After 18 weeks of feeding, another 4 groups of mice were examined. Again, two of these                             
groups were control groups, being fed either a normal fat control diet or a HFD for 18                               
weeks (CCC and FaFaFa), and a further two experimental groups. One of these groups                         
was fed a control diet for 6 weeks, swapped to a HFD for 6 weeks, then swapped back to                                   
the control diet for a further 6 weeks and is known as CFaC. The second experimental                             
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group was fed a high fat diet for 6 weeks, swapped to a control diet for 6 weeks then                                   
swapped back to a HFD for a further 6 weeks and is known as FaCFa.
{2.2.3} Methods
Body weight and food intake was monitored weekly. Separate subsets of mice underwent whole                         
body MRI and 1H MRS, and localised 1H liver and muscle MRS after 4 weeks, 10 weeks and 16                                   
weeks of their assigned diet regime (n=10­12/group). An IPGTT was performed on separate                       
subsets of mice after 5 weeks, 11 weeks and 17 weeks on their assigned diet regime                             
(n=10­12/group). Indirect calorimetry and acute exercise experiments were carried out at 6                     
weeks, 12 weeks and 18 weeks on a separate group of mice (n=8/group). Finally, half the mice                               
that underwent MRI/MRS and half the mice that underwent an IPGTT were fully dissected at the                             




Figure {2.2.3.0.1} Schematic of protocol used to study the effects of a single weight cycle                           
on metabolism and appetite
C57Bl6 males aged 8­10 weeks were fed a control diet or a HFD for a period of 6 weeks. Mice                                     
fed a control diet are represented in the top half of the diagram, with the control group shown as                                   
the black line at the top of the diagram. Mice fed a HFD are represented in the bottom half of the                                       
diagram, with the mice fed a HFD only shown as the black line at the bottom of the diagram.                                   
After 6 weeks of feeding, a subset of mice from each group were dissected resulting in two                               
groups, C and Fa (control and high fat). Mice that continued feeding after the first 6 weeks were                                 
either kept on their originally assigned diet for a further 6 and 12 weeks (CC, FaFa and CCC,                                 
FaFaFa), whilst subsets of mice were swapped onto the opposing diet for 6 weeks (control to                             
high fat, and high fat to control). The red line represents mice fed a control diet for the first 6                                     
weeks, then swapped to a HFD for 6 weeks before swapping back to the control diet for a further                                   
6 weeks. The blue line represents animals fed a HFD for the first 6 weeks, then swapped to a                                   
control diet for 6 weeks, then moving back to a HFD for a further 6 weeks. As before, subsets of                                     
mice were dissected after a total of 6 weeks on the opposing diet resulting in the two                               
experimental groups (CFa and FaC) together with two control groups fed for 12 weeks (CC and                             
FaFa). After a total of 18 weeks of feeding, the final subsets of mice were dissected, producing                               
two control groups and two experimental groups (CCC, FaFaFa, CFaC and FaCFa). Before                       
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each time point (6, 12 and 18 weeks), MRI/MRS experiments were performed 2 weeks prior to                             
dissection and an IPGTT was performed one week prior to dissection on separate subsets of                           








under the project licence 70/6656 and 70/7502. Unless specified, all mice were acclimatised for                         
a week and housed in ventilated cages in groups of 4 under a 12h:12h light cycle (lights on at                                   
7am) at 21­23°C with ad libitum access to food and water.
{2.3.2} Experimental Model
The protocol for this experiment is shown in Figure 2.3.2.0.1. The diets used for this experiment                             
are described above (Table 2.1.2.0.1). C57Bl6 males (Harlan UK) aged 8­10 weeks were caged                         
in groups of 4 and fed either a HFD (TD.06414, 60% by kcal intake) or a control diet (TD.08806,                                   
10% by kcal intake. Harlan, USA). This experiment ran for a total of 28 weeks, where diets were                                 
swapped every 4 weeks and tissue samples were collected at 2 time points (12 weeks and 28                               
weeks of feeding). There was a total of 8 separate groups, each containing 28 mice (total                             
number=224).
● Time Point 1: 12 weeks of feeding, 2 diet swaps
Mice were fed either a control diet or a HFD. Again there were two control groups, one                               
group of mice fed a normal fat control diet and another group fed a HFD for 12 weeks.                                 
There were two experimental groups, one group fed a control diet and another group fed                           
a HFD. After 4 weeks of feeding, the experimental group on a control diet swapped to a                               
HFD, whilst the experimental group starting on a HFD swapped to a control diet. After a                             
further 4 weeks, mice that had been fed a control diet for the first 4 weeks then swapped                                 
to a HFD for 4 weeks were placed back onto the original control diet. Similarly, mice that                               
had been fed a HFD for the first 4 weeks then swapped to control diet for 4 weeks were                                   
swapped on to the original HFD.
This resulted in two control groups and two experimental groups for time point 1: CT                           





The experimental design for this time point follows the same cycling schedule as the 2                           
swap cohort (time point 1) feeding for 12 weeks as described above. Two control groups                           
were fed for 28 weeks either on a normal fat control diet or a HFD. There were two                                 
swapping groups, fed either a normal fat control diet or a HFD for 4 weeks (n=20/group).                             
After 4 weeks of feeding, mice fed the control diet were swapped to a HFD, whilst mice                               
fed the HFD were swapped to the control group. After a further 4 weeks, mice were                             
returned to their original assigned diet. This swapping procedure was repeated another 2                       
times, resulting in a total of 6 swaps in 28 weeks.
This resulted in 2 control groups and 2 swapping groups for time point 2: LTC (long term                               




Figure {2.3.2.0.1} Schematic of protocol used to study the effects of multiple episodes of                         
weight cycling on metabolism and appetite
C57Bl6 males aged 8­10 weeks were fed a control diet or a HFD. Mice fed the control diet are                                   
represented at the top of the diagram, with the control group shown as the black line at the top of                                     
the diagram. Mice were fed for 12 weeks (control throughout, CT) or 28 weeks (long term                             
control, LTC). Mice fed a HFD are represented at the bottom of the diagram, with the mice fed a                                   
HFD only shown as the black line at the bottom. Mice were fed for 12 weeks (HFD throughout,                                 
FT) or for 28 weeks (long term HFD, LTF). Two experimental swapping groups were collected at                             
12 weeks and 28 weeks, swapping diets at 4 week intervals. The red line represents mice that                               
start and finish feeding on a control diet, either for 12 weeks (control­HFD­control, CFC) or 28                             
weeks (long term control­HFD swapping, LTCF). The blue line represents mice that start and                         
finish feeding on a HFD, either for 12 weeks (high fat­control­high fat, FCF) or 28 weeks (long                               
term HFD­control swapping, LTFC). One week before each time point (11 and 27 weeks),                         
MRI/MRS experiments and an IPGTT were performed on separate groups of mice (n=10/group).                       
Tissues were collected at 12 and 28 weeks (n=10/group). Indirect calorimetry and acute                       





Body weight and food intake was monitored weekly. Separate subsets of mice underwent whole                         
body MRI and 1H MRS, and localised 1H liver after 11 weeks and 27 weeks of feeding                               
(n=10/group). An IPGTT was also performed after 11 weeks and 27 weeks of feeding on                           
separate subsets of mice (n=10/group). Indirect calorimetry and acute exercise experiments                   
were carried out at 12 weeks and 28 weeks on a separate group of mice (n=8/group). Finally,                               
half the mice that underwent MRI/MRS and half the mice that underwent an IPGTT were fully                             




{2.4} Methods used to Study the Effects of Weight Cycling on                   
Metabolism and Appetite
{2.4.1} Whole Body MRI and 1H MRS
Adiposity was assessed using whole body MRI and 1H MRS, and localised 1H liver. Mice were                             
fasted overnight for 16­18 hours, after which anaesthesia was induced with a 3%                       
oxygen­isofluorane mix. The mix was maintained at 1.5­2% according to respiration and body                       
temperature monitoring during the scan (SA Instruments Inc. USA). Temperature was                   
maintained at 37°C and respiration was maintained at 60­80 breaths per minute. Mice were                         
placed in a whole body birdcage coil and scanned in a 4.7T Unity Inova MR scanner (Varian Inc,                                 
USA)
{2.4.1.1} Whole Body MRI
Following an appropriate pilot image, consecutive transverse MR images of the whole body were                         
collected using a T1­weighted spin echo sequence with the following parameters: repetition time                       
(TR) 2.2s, echo time (TE) 20ms, field of view (FOV) 45mm x 45mm, matrix size 256 x 192, 2                                   
averages, slice thickness 2mm and 50 slices.
The images collected were converted into a stack using ImageJ (Rasband) and image                       
segmentation analysis was performed using SliceOmaticTM (Tomovision®) to provide volumes                 
and mass of internal and subcutaneous adipose tissue deposits. Analysis was performed by a                         
trained analyst blinded to the animal treatment. Adipose tissue appears brighter compared to                       
other tissues, due to the chemical properties of adipose tissue shortening the T1 recovery curve.                           





A) A sagittal pilot image through the whole mouse body (head to tail, left to right) including slices                                 
(in yellow) placed in the location where they were acquired
B) A representative image of a transverse slice acquired in the abdominal region




To calculate the volume of adipose tissue, equation 2.4.1.1.2 was used. The imaging                       
parameters described above for FOV, matrix size and slice thickness were used along with the                           
number of pixels highlighted for a particular depot of adipose tissue to calculate the volume of                             
that depot of adipose tissue.
Calculated volumes of adipose tissue were converted into adipose tissue mass by using the                         
density value of adipose tissue (0.92 g/mm3) as shown in equation 2.4.1.1.2.





1. Equation to calculate adipose tissue volume (mm3). Field of view (FOV) = 45mm x                         
45mm; matrix size = 256mm x 192mm; slice thickness = 2mm.
2. Equation to calculate adipose tissue mass (g). Adipose tissue volume calculated using                     





Whole body 1H MRS was performed using a single pulse sequence (SPULS) with the following                           
parameters:  TR 10s, pulse angle 45°, 4 averages and spectral width 20,000Hz.
Localised 1H liver MRS was performed using a Point Resolved Spectroscopy (PRESS)                     
sequence with a voxel 2x2x2mm3 placed using the images generated from whole body MRI                         
(Figure 2.4.1.3.1) with the following parameters: TR 10s, TE 9ms, averages 64 and spectral                         
width 20,000Hz.
Figure {2.4.1.2.1} Voxel localization on MR image in liver
A transverse MR image slice through the liver, with a 2x2x2 mm3 voxel placed on the top left of                                   
the liver. Attention was paid to the placement of the voxel to ensure 1H MR spectra were acquired                                 
from the same location each time. Figure kindly provided by Jelena Anastasovska.
The spectra obtained were analysed using MestRe­C (Santiago de Compostela, Spain). An                     
exponential line broadening of 1.5Hz was applied before phasing and baseline correction. The                       
water peak was referenced at 4.8ppm and the combined water and lipid peak referenced at                           




To calculate whole body adiposity, equation 2.4.1.3.2 was used with the lipid and water integrals                           




Whole body adiposity (%) was calculated using the lipid and water integrals obtained with                         





A representative whole body spectrum of a mouse obtained using MestRe­C software. The                       
integrals of water and lipid peaks are highlighted above. The lipid content is 50% of the water                               





Mice were fasted overnight for 16­18 hours. Fasting blood glucose levels were determined using                         
a commercially available glucose meter (Boots Stores, UK). Mice were injected i.p. with a                         
D­glucose 2g/kg bolus. Blood glucose levels were detected after 15, 30, 60 and 120 minutes.                           
Glucose tolerance was assessed by calculating the area under the curve (AUC) using the                         
trapezoidal rule.
{2.4.3} Indirect Calorimetry
A comprehensive laboratory animal monitoring system (CLAMS) was used to make indirect                     
calorimetry measurements. All measurements were recorded for 5 seconds after a cage settle                       
time of 55 seconds, 6 times an hour. Mice were individually housed in plexiglass cages                           
maintained on a 12h:12h light cycle (lights on at 7am) at 21­23°C. All animals were housed in the                                 
system for 2 days in total, with the first day for acclimatisation and the second day data used for                                   
indirect calorimetry measurements, movement and water intake.
Mice also had ad libitum access to water, which was measured using a volumetric drinking                           
monitor (Columbus Instruments, USA).
Locomotor activity was assessed individually using dual axis infrared photocell technology. One                     
beam break resulted in one count of movement. A beam across the x­axis measured horizontal                           
movement (XAMB) and a z­axis beam measuring rearing movements (ZTOT).
Indirect open­circuit calorimetry was used to assess the exchange of oxygen and carbon dioxide                         
(Oxymax System, Columbus Instruments, USA). Oxygen and carbon dioxide sensors were                   
calibrated using an OxyVal system and a pure gas standard (5000ppm CO2, 20.5% O2).                         
Accurate readings were maintained by re­recording background gas levels after every 8 cages.                       
Background measurements were taken for 5 seconds after an 85 second settle time, and were                           
calculated by assessing ambient air compared to the gas standard. During indirect calorimetry                       
measurements, sensors assessing oxygen and carbon dioxide levels in each cage were                     
compared to this reference, which enabled the calculation of oxygen consumption and carbon                       
dioxide production (Equation 2.4.3.0.1 1­2). A respiratory exchange ratio (RER) and heat                     
production could be calculated using VO2 and VCO2 measurements (Equation 2.4.3.0.1 3­6).                     











1. Oxygen consumption (VO2). Vi and Vo are the input and output ventilation rates,                       
respectively. O2i and O2o are oxygen fractions in the input and output, respectively. Units                         
are ml/hour.
2. Carbon dioxide production (VCO2). Vi and Vo are the input and output ventilation rates,                         
respectively. CO2i and CO2o are carbon dioxide fractions in the input and output,                       
respectively. Units are m/hour.
3. Respiratory exchange ratio (RER). Ratio of carbon dioxide production (VCO2) and                   
oxygen consumption (VO2).
4. Heat for each animal is calculated using the calorific value (CV) from equation 5 and                           
oxygen production (VO2) from equation 1.
5. Calorific value (CV). Constants 3.815 and 1.232 are derived from observed oxidation                     
from known mixture of fat and carbohydrate (Lusk, 1928.), and the Respiratory exchange                       
ratio (RER) from equation 5.






To assess changes in the ability to exercise, an acute exercise study was performed as                           
described previously (He et al., 2012). Mice were acclimatised on a 10° uphill Exer 3/6 open                             
treadmill for 2 days (Columbus Instruments, USA). On day 1, mice ran at 8m/minute for 5                             
minutes. On day 2, mice ran 8m/minute for 5 minutes, followed by 10m/minute for 10 minutes.                             
On day 3, mice ran for single session starting at 10m/minute for 40 minutes. After this, the                               
treadmill speed was increased at a rate of 1m/minutes every 10 minutes for 30 minutes, and                             
then increased at a rate of 1m/minute every 5 minutes until the mouse was exhausted.                           
Exhaustion was defined as the point at which mice spent more than 5 seconds on the electric                               
shock pad without attempting to run. Total running time and distance was recorded for each                           
mouse.
{2.4.5} Whole Body NMR
To assess adiposity in mice undergoing acute exercise studies, an EchoMRI­100 was used                       
(Echo Medical Systems, Houston, TX, USA). Mice were placed in a plastic holding tube                         
unanaesthetised and inserted into the scanner. 3 acquisitions were used to quantify lean mass                         
and fat mass. Total scan time was 168 seconds. Scans took place one day before indirect                             
calorimetry or the first day of running for the acute exercise study.
{2.4.6} Tissue Collection
Tissue collection occured between 11:00 and 13:00, with mice dissected in a fed state.                         
Anaesthesia was induced with a 3% oxygen­isofluorane mix before the animal was decapitated                       
and approximately 1ml of blood was collected by torso inversion. EDTA­coated vacutainers were                       
used to collect blood containing 100μl AEBSF (Pefabloc Sc, Roche), 10μl protease inhibitor                       
cocktail (Sigma, UK) and 10μl of DPPIV inhibitor (Millipore, USA). Blood was gently inverted to                           
mix then centrifuged for 15 minutes at 2500rpm at 4°C. Plasma was collected and stored at                             
­80°C until assessment for metabolic hormones.
White adipose tissue was collected (subcutaneous, epididymal, retroperitoneal and mesenteric),                 
along with brown adipose tissue, liver, pancreas, kidneys, heart and gastrocnemeus muscle.                     
Tissue samples were frozen on dry ice then stored at ­80°C. Brains were cut coronally on an ice                                 
cold brain matrix into 3 sections (forebrain, midbrain and hindbrain) and stored in RNAlater                         





A MILLIPLEX MAP Mouse Metabolic Hormone Magnetic Bead Panel was used to assess                       
metabolic hormone levels in the plasma (Millipore, USA). The assay was performed according to                         
the manufacturer’s protocol using undiluted plasma. The plate was run on a MAGPIX system                         
with xPonent software (Luminex Corp, US). Hormones assessed include leptin, resistin, insulin,                     




Brain RNA was extracted using a combination of Trizol treatment and an AllPrep DNA/RNA                         
micro kit (Bettscheider et al., 2011). Brains preserved in RNAlater were sectioned coronally at                         
500µm on an ice cold brain matrix using double edged razor blades. Specific regions of interest                             
were dissected from 2 slices using a mouse brain atlas as a reference (Figure 2.4.9.1.1,                           
Franklin & Paxinos, 2007). Approximately 4µg of tissue was placed in a 2ml eppendorf with 350µl                             
of RLT Buffer Plus (Qiagen, USA), 1% 2­Mercaptoethanol and 0.5% Reagent DX (Qiagen). The                         
tissue was lysed and disrupted by placing a 5mm steel bead (Qiagen) in the eppendorf and                             
placing in a TissueLyser II (Qiagen) for 4 minutes at 20Hz. The lysate was removed and added                               
to an AllPrep DNA column and centrifuged at 13,500rpm for 3 minutes at 4°C. The columns                             
were then placed in new collection tubes on ice for DNA elution after RNA extraction was                             
completed (as DNA is more stable than RNA). The flow through was added to a new 1.5ml                               
eppendorf, along with 100µl of Trizol reagent (Ambion, USA) and incubated at room temperature                         
for 5 minutes. 20µl of chloroform was added and the tube was vigorously shaken by hand for 15                                 
seconds, before being left a further 2 minutes at room temperature. The sample was then                           
centrifuged at 13,500rpm for 15 minutes at 4 °C, after which the aqueous phase (containing                           
RNA) was removed and added to a new 1.5ml eppendorf. 70% ethanol was added to the sample                               
to precipitate the RNA, then added to an RNeasy MinElute spin column (Qiagen). The columns                           
were centrifuged at 13,500rpm for 3 minutes at 4°C and flow through discarded. The spin                           
column membrane underwent a series of washes as described in the manufacturer’s protocol,                       
along with on­column DNAse digestion using RNase­free DNase (Qiagen). RNA was eluted                     
using 12µl of THE RNA storage solution (Ambion) and stored at ­80°C until further use. AllPrep                             
129
2. Materials and Methods
DNA columns also underwent a series of washes as described in the manufacturer’s protocol                         
and eluted twice using 30µl of EB buffer preheated to 70°C, then stored at ­80°C.
Figure {2.4.8.1.1} Regions of interest used for gene expression analysis
Mouse brain atlas images showing ROI locations in the mouse brain (Franklin & Paxinos, 2007).                           
A) Medial Prefrontal Cortex (mPFC, Bregma 1.70mm); B) Nucleus Accumbens (NAc, Bregma                     















Using the cDNA template generated, a master mix of Platinum SYBR Green qPCR                       
superMix­UDG, primer, ROX reference dye, DEPC­treated water (Invitrogen) and cDNA template                   
were prepared for qRT­PCR analysis. Each sample was added in triplicate to a MicroAmp Fast                           
96­well reaction plate (Applied Biosystems, USA), including a 1:5 serial dilution of the cDNA                         
templates used for each primer. Expression of all genes undergoing investigation were                     
normalised to a control gene (GAPDH) (Table 2.4.10.0.1, 2.4.10.0.2). The plate was sealed with                         
a PCR­specific seal (Invitrogen) then placed in a pre­heated (Applied Biosystems 7500 Fast                       
Real­Time PCR System) at a cycling program of 50°C for 2 minutes, 94°C for 2 minutes, 40                               
cycles of 95°C for 15 seconds, 65°C for 30 seconds, then a dissociation step of 95°C for 15                                 
seconds, 60°C for 60 seconds and 95°C for 15 seconds. Gene expression analysis was                         
performed using delta Ct values as described previously (Bookout & Mangelsdorf 2003, Bookout                       
et al., 2006).
{2.4.9} Statistical Analysis
All data is presented as mean ± standard error of mean (SEM) unless specified. All statistical                             
tests were performed using GraphPad Software (USA). In each instance, data normality was                       
assessed using a Kolmogorov­Smirnov test. A p­value below 0.05 was an indication a particular                         
comparison was significantly different.
A number of different statistical tests were employed to aid interpretation of the data presented.                           
The tests used were selected on the type of data used.
For continuous data analysis, a two­way ANOVA with Bonferroni correction was used. This                       




For single factor analysis between two groups only, an unpaired t­test was used to assess                           
statistical significance. This includes analysis for adiposity (MRS and MRI measurements),                   
comparison between AUC values from the IPGTT, total distance travelled on a treadmill,                       
metabolic hormone measurements in plasma, organ weight measurements and RT­qPCR                 
measurements.
For single factor analysis between multiple groups, a one­way ANOVA was performed with                       
Tukey correction for multiple comparisons. This test was performed for all data collected in the                           
experiments described above that were assessed using an unpaired t­test.
To assess the relationship between distance ran on a treadmill and basic phenotypic                       
measurements, correlation analysis was performed using a Pearson’s correlation test. Although                   
correlation analysis does not provide a definitive answer on the cause of a particular variable, it                             




Gene Symbol Gene Name RefSeq mRNA Taqman Assay ID






































C57Bl6 male mice aged 8­10 weeks of age were fed a control diet (10% kcal fat) for 6 weeks or                                     
a high fat diet (HFD, 60% kcal fat) for 6 weeks.
To assess whether rapid weight loss or gain would have an effect on phenotype, a phenotype at                               
the time of swapping was established. Therefore, two separate groups of mice were fed either a                             
control normal fat diet (C) of a HFD (F) for 6 weeks. 6 weeks was chosen as suitable period of                                     
time to produce diet induced obesity (DIO) in HF fed adult mice.
A detailed description of body weight measurements in mice fed a control diet or HF diet can be                                 
found in Section 4.1.1. In summary, body weight was significantly higher in F mice from week 1                               
to 6 (Figure 4.1.1.0.1. Table 4.1.3.0.2).
Weight change was significantly higher in F mice from week 1 to 6, whilst percentage weight                             





The protocol for this experiment is described in Section 2.1. C57Bl6 male mice aged 8­10 weeks                             
of age were fed a control diet (10% kcal fat) for 6 weeks. At week 6, half the mice continued to                                       
feed on the control diet for one more week (CC group), whilst the other half were fed a HFD                                   
(60% kcal fat) for one week (CF group).
Body weight between the two groups was comparable for the first 6 weeks of feeding. One week                               
of high fat feeding was sufficient to significantly increase body weight in the CF group (Figure                             
3.1.2.0.1. Table 3.1.2.0.2. p<0.001, n=48/group).
Figure {3.1.2.0.1} The effect of one week of high fat feeding on body weight of lean mice
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group).




Week CC (g) CF (g) p value
0 25.3 ± 0.2 25.3 ± 0.3 n.s
1 26.5 ± 0.2 26.4 ± 0.3 n.s
2 27.3 ± 0.3 27.6 ± 0.3 n.s
3 28.5 ± 0.3 28.8 ± 0.3 n.s
4 29.1 ± 0.3 29.5 ± 0.4 n.s
5 30.2 ± 0.3 30.6 ± 0.4 n.s
6 30.8 ± 0.3 31.2 ± 0.4 n.s
7 31.6 ± 0.4 34.5 ± 0.4 <0.001
Table {3.1.2.0.2} The effect of one week of high fat feeding on body weight of lean mice
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group).
Body weight measured in grams (g). Data presented as mean ± sem. n=48/group. n.s=not                         




There was also a fairly constant change in body weight in both groups for the first 6 weeks of                                   
feeding. One week of high fat feeding significantly increased the amount of body weight gained                           
and the percentage weight change in the CF group (Figure 3.1.2.0.3.A­B. Table 3.1.2.0.4.A­B.                       
p<0.001, n=48/group).
Figure {3.1.2.0.3} The effect of one week of high fat feeding on weekly body weight                           
change of lean mice
A) Weight change in grams (g); B) Percentage weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group).




Week CC (g) CF (g) p value
1 1.2 ± 0.1 1.1 ± 0.1 n.s
2 0.8 ± 0.1 1.2 ± 0.2 n.s
3 1.2 ± 0.1 1.2 ± 0.2 n.s
4 0.6 ± 0.1 0.8 ± 0.2 n.s
5 1.1 ± 0.1 1.1 ± 0.1 n.s
6 0.7 ± 0.2 0.6 ± 0.2 n.s
7 0.7 ± 0.2 3.3 ± 0.2 <0.001
Week CC (%) CF (%) p value
1 4.99 ± 0.38 4.54 ± 0.32 n.s
2 2.86 ± 0.34 4.54 ± 0.60 n.s
3 4.43 ± 0.31 4.35 ± 0.59 n.s
4 2.29 ± 0.46 2.29 ± 0.52 n.s
5 3.61 ± 0.49 3.77 ± 0.51 n.s
6 2.25 ± 0.50 2.067 ± 0.52 n.s
7 2.47 ± 0.57 10.68 ± 0.61 <0.001
Figure {3.1.2.0.4} The effect of one week of high fat feeding on weekly body weight                           
change of lean mice
A) Weight change in grams (g); B) Percentage weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group).
Data presented as mean ± sem. n=48/group. n.s=not significant. Yellow highlight indicates a                       





The protocol for this experiment is described in Section 2.1. C57Bl6 male mice aged 8­10 weeks                             
of age were fed a HFD (60% kcal fat) for 6 weeks. At week 6, half the mice continued to feed on                                         
the HFD for one more week (FF group), whilst the other half were fed a normal fat control diet                                   
(10% kcal fat) for one week (FC group).
Body weight between the two groups was comparable for the first 6 weeks of feeding. One week                               
of normal fat feeding was sufficient to significantly reduce body weight in the FC group (Figure                             
3.1.3.0.1. Table 3.1.3.0.2. p<0.001, n=48/group).
Figure {3.1.3.0.1} The effect of one week of normal fat feeding on body weight of DIO                             
mice
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   




Week FF (g) FC (g) p value
0 25.1 ± 0.3 25.4 ± 0.3 n.s
1 28.2 ± 0.3 28.3 ± 0.3 n.s
2 30.1 ± 0.3 30.2 ± 0.4 n.s
3 32.7 ± 0.4 32.6 ± 0.4 n.s
4 34.7 ± 0.4 34.9 ± 0.4 n.s
5 37.3 ± 0.5 37.7 ± 0.5 n.s
6 39.5 ± 0.5 39.8 ± 0.5 n.s
7 40.9 ± 0.5 37.2 ± 0.5 <0.001
Table {3.1.3.0.2} The effect of one week of normal fat feeding on body weight of DIO                             
mice
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   
normal fat control diet (FC group).
Body weight measured in grams (g). Data presented as mean ± sem. n=48/group. n.s=not                         




Body weight change was comparable between the two groups during the first 6 weeks of HF                             
feeding. One week of normal fat feeding led to a significant negative decrease in weight change                             
in FC mice compared to FF mice, both in measurements of grams and as a percentage (Figure                               
3.1.3.0.3.A­B. Table 3.1.3.0.4.A­B. p<0.001, n=48/group).
Figure {3.1.3.0.3} The effect of one week of normal fat feeding on weekly body weight                           
change of DIO mice
A) Weight change in grams (g); B) Percentage weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   
normal fat  control diet (FC group).




Week FF (g) FC (g) p value
1 3.1 ± 0.2 2.9 ± 0.2 n.s
2 1.9 ± 0.1 1.9 ± 0.1 n.s
3 2.5 ± 0.2 2.4 ± 0.1 n.s
4 2.1 ± 0.2 2.2 ± 0.1 n.s
5 2.6 ± 0.1 2.8 ± 0.1 n.s
6 2.2 ± 0.2 2.1 ± 0.1 n.s
7 1.5 ± 0.1 ­2.6 ± 0.3 <0.001
Week FF (%) FC (%) p value
1 12.29 ± 0.65 11.64 ± 0.77 n.s
2 6.87 ± 0.45 6.77 ± 0.45 n.s
3 8.42 ± 0.52 8.09 ± 0.43 n.s
4 6.32 ± 0.50 6.87 ± 0.38 n.s
5 7.44 ± 0.36 8.02 ± 0.35 n.s
6 5.76 ± 0.42 5.58 ± 0.30 n.s
7 3.85 ± 0.31 ­6.45 ± 0.74 <0.001
Table {3.1.3.0.4} The effect of one week of normal fat feeding on weekly body weight                           
change of DIO mice
A) Weight change in grams (g); B) Percentage weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   
normal fat control diet (FC group).
Data presented as mean ± sem. n=48/group. n.s=not significant. Yellow highlight indicates a                       






A detailed description of food intake measurements in mice fed a control diet or HF diet can be                                 
found in Section 3.1.2.1. In summary, food intake, both measured in grams and gram intake                           
normalised to cage weight0.75 was significantly lower in F mice from week 1 to 6 compared to C                                 
mice (Figure 4.2.1.0.1.A­B.Table 3.1.1.2.2.A­B).
Cumulative food intake was also significantly lower in F mice compared to C mice from week 2                               





For the first 6 weeks of feeding, food intake per cage of 4 mice was comparable between both                                 
groups. Food intake significantly decreased when mice were moved from the control diet to HFD                           
between weeks 6 and 7 (Figure 3.2.2.0.1.A. Table 3.2.2.0.2.A. p<0.05, n=26/group).
However when food intake was normalised to the cage weight0.75, this decrease was no longer                           
significant (Figure 3.2.2.0.1.B. Table 3.2.2.0.2.B. n=26/group).
Figure {3.2.2.0.1} The effect of one week of high fat feeding on food intake of lean mice
A) Food intake measured in grams per cage of 4 mice (g); B) Food intake measured in grams                                 
per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group) for a week.




Week CC (g) CF (g) p value
1 92.6 ± 1.9 93.2 ± 1.6 n.s
2 89.4 ± 2.8 90.7 ± 2.7 n.s
3 86.9 ± 2.8 87.4 ± 2.4 n.s
4 88.6 ± 2.4 91.1 ± 3.1 n.s
5 88.7 ± 1.6 89.0 ± 1.7 n.s
6 87.5 ± 1.7 88.0 ± 1.6 n.s
7 85.3 ± 2.0 77.4 ± 2.0 <0.05
Week CC (g/g0.75) CF (g/g0.75) p value
1 2.96 ± 0.06 2.97 ± 0.06 n.s
2 2.72 ± 0.08 2.73 ± 0.09 n.s
3 2.58 ± 0.09 2.60 ± 0.08 n.s
4 2.53 ± 0.07 2.57 ± 0.09 n.s
5 2.48 ± 0.04 2.47 ± 0.05 n.s
6 2.38 ± 0.05 2.39 ± 0.04 n.s
7 2.28 ± 0.05 2.09 ± 0.04 n.s
Table {3.2.2.0.2} The effect of one week of high fat feeding on food intake of lean mice
A) Food intake measured in grams per cage of 4 mice (g); B) Food intake measured in grams                                 
per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group) for a week.
Data presented as mean ± sem. n=26/group. n.s=not significant. Yellow highlight indicates a                       





For the first 6 weeks of feeding, food intake per cage of 4 mice was comparable between both                                 
groups. Food intake significantly decreased when mice were moved from the HFD to the normal                           
fat control diet between weeks 6 and 7 (Figure 3.2.3.0.1.A. Table 3.2.3.0.2.A. p<0.001,                       
n=26/group).
This decrease was still significant when food intake was normalised to cage weight0.75 (Figure                         
3.2.3.0.1.B. Table 3.2.3.0.2.B. p<0.001, n=26/group).
Figure {3.2.3.0.1} The effect of one week of normal fat feeding on food intake of DIO                             
mice
A) Food intake measured in grams per cage of 4 mice (g); B) Food intake measured in grams                                 
per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   
normal fat diet (FC group) for a week.




Week FF (g) FC (g) p value
1 82.0 ± 2.8 83.6 ± 2.6 n.s
2 79.9 ± 2.8 82.4 ± 3.1 n.s
3 75.8 ± 2.4 76.0 ± 2.1 n.s
4 76.8 ± 2.1 77.7 ± 2.3 n.s
5 77.9 ± 1.5 77.9 ± 1.9 n.s
6 76.5 ± 2.5 73.9 ± 3.0 n.s
7 76.3 ± 2.5 56.9 ± 2.9 <0.001
Week FF (g/g0.75) FC (g/g0.75) p value
1 2.61 ± 0.09 2.66 ± 0.08 n.s
2 2.31 ± 0.08 2.37 ± 0.09 n.s
3 2.07 ± 0.07 2.07 ± 0.06 n.s
4 1.97 ± 0.05 1.99 ± 0.06 n.s
5 1.90 ± 0.04 1.89 ± 0.05 n.s
6 1.77 ± 0.06 1.70 ± 0.07 n.s
7 1.70 ± 0.06 1.26 ± 0.07 <0.001
Table {3.2.3.0.2} The effect of one week of normal fat feeding on food intake of DIO mice
A) Food intake measured in grams per cage of 4 mice (g); B) Food intake measured in grams                                 
per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   
normal fat diet (FC group) for a week.
Data presented as mean ± sem. n=26/group. n.s=not significant. Yellow highlight indicates a                       






A detailed description of calorie intake measurements in mice fed a control diet or HF diet can be                                 
found in Section 4.3.1. In summary, calorie intake was significantly higher from week 1 to 6 in F                                 
mice compared to C mice (Figure 4.3.1.0.1.A]. Table 4.3.3.0.4). However, when calorie intake                       
was normalised to cage weight, calorie intake was only significantly higher in F mice compared                           
to C mice from week 1 to 4 (Figure 4.3.1.0.1.B. Table 4.3.3.0.5)
Cumulative calorie intake was significantly higher in F mice compared to C mice from week 1 to                               





For the first 6 weeks of feeding, calorie intake per cage of 4 mice was comparable between both                                 
groups. Calorie intake significantly increased when mice were moved from the control diet to                         
HFD between weeks 6 and 7 (Figure 3.3.2.0.1.A. Table 3.3.2.0.2.A. p<0.001, n=26/group).
This increase was still significant when calorie intake was normalised to cage weight0.75 (Figure                         
3.3.2.0.2.B. Table 3.3.2.0.2.B. p<0.001, n=26/group).
Figure {3.3.2.0.1} The effect of one week of high fat feeding on calorie intake of lean                             
mice
A) Calorie intake measured in grams per cage of 4 mice (kcal); B) Calorie intake measured in                               
grams per cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group) for a week. Data presented as mean ± sem. n=26/group. ***                               




Week CC (kcal) CF (kcal) p value
1 333.2 ± 6.9 335.5 ± 5.6 n.s
2 321.7 ± 10.2 326.7 ± 9.8 n.s
3 312.9 ± 10.0 314.5 ± 8.6 n.s
4 318.9 ± 8.6 327.9 ± 11.1 n.s
5 319.3 ± 5.7 320.3 ± 6.1 n.s
6 314.9 ± 6.0 316.6 ±  5.6 n.s
7 307.2 ± 7.2 394.5 ± 10.1 <0.001
Week CC (kcal/g0.75) CF (kcal/g0.75) p value
1 10.81 ± 0.29 10.81 ± 0.31 n.s
2 9.89 ± 0.27 10.03 ± 0.29 n.s
3 9.44 ± 0.39 9.56 ± 0.37 n.s
4 9.24 ± 0.27 9.36 ± 0.33 n.s
5 9.06 ± 0.18 9.05 ± 0.22 n.s
6 8.73 ± 0.23 8.78 ± 0.24 n.s
7 8.22 ± 0.19 9.90 ± 0.41 <0.001
Table {3.3.2.0.2} The effect of one week of high fat feeding on calorie intake of lean mice
A) Calorie intake measured in grams per cage of 4 mice (kcal); B) Calorie intake measured in                               
grams per cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet for 6 weeks. At this point, half                                     
the mice continued to feed on the control diet for another week (CC group) whilst the other half                                 
were fed a HFD (CF group) for a week.
Data presented as mean ± sem. n=26/group. n.s=not significant. Yellow highlight indicates a                       





For the first 6 weeks of feeding, calorie intake per cage of 4 mice was comparable between both                                 
groups. Calorie intake significantly decreased when mice were moved from the HFD to the                         
normal fat control diet between weeks 6 and 7 (Figure 3.3.3.0.1.A. Table 3.3.3.0.2.A. p<0.001,                         
n=26/group).
This decrease was still significant when calorie intake was normalised to cage weight0.75 (Figure                         
3.3.3.0.1.B. Table 3.3.3.0.2.B. p<0.001, n=26/group).
Figure {3.3.3.0.1} The effect of one week of normal fat feeding on calorie intake of DIO                             
mice
A) Calorie intake measured in grams per cage of 4 mic (kcal); B) Calorie intake measured in                               
grams per cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   
normal fat diet (FC group) for a week.




Week FF (kcal) FC (kcal) p value
1 418.0 ± 14.4 426.4 ± 13.0 n.s
2 407.5 ± 14.4 420.2 ± 15.9 n.s
3 386.4 ± 12.1 387.6 ± 10.6 n.s
4 391.8 ± 10.8 396.4 ± 11.6 n.s
5 397.4 ± 7.9 397.1 ± 9.9 n.s
6 390.3 ± 12.5 376.7 ± 15.2 n.s
7 389.0 ± 12.7 204.8 ± 10.6 <0.001
Week FF (kcal/g0.75) FC (kcal/g0.75) p value
1 13.30 ± 0.45 13.57 ± 0.42 n.s
2 11.79 ± 0.43 12.08 ± 0.44 n.s
3 10.57 ± 0.37 10.55 ± 0.32 n.s
4 10.05 ± 0.27 10.15 ± 0.29 n.s
5 9.70 ± 0.21 9.65 ± 0.26 n.s
6 9.04 ± 0.30 8.66 ± 0.37 n.s
7 8.54 ± 0.30 4.80 ± 0.26 <0.001
Figure {3.3.3.0.2} The effect of one week of normal fat feeding on calorie intake of DIO                             
mice
A) Calorie intake measured in grams per cage of 4 mice (kcal); B) Calorie intake measured in                               
grams per cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75)
C57Bl6 male mice aged 8­10 weeks of age were fed a HFD for 6 weeks. At this point, half the                                     
mice continued to feed on the HFD for another week (FF group) whilst the other half were fed a                                   
normal fat diet (FC group) for a week.
Data presented as mean ± sem. n=26/group. n.s=not significant. Yellow highlight indicates a                       




{3.4} The Effect of Rapid Weight Change on Whole Body and                   
Localised Adiposity
Mice were fasted overnight for 16­18 hours before assessing whole body and localised lipid                         
content using MRI and MRS. Mice were anaesthetised with a 3% oxygen­isofluorane mix. The                         
mix was maintained at 1.5­2% according to respiration and body temperature monitoring during                       
the scan (SA Instruments Inc. USA). Mice were placed in a whole body birdcage coil and                             
scanned in a 4.7T Unity Inova MR scanner (Varian Inc, USA).
Using whole body 1H MRS, whole body adiposity could be assessed in these mice                         
non­invasively. Localised liver 1H MRS was also used to assess intrahepatic cellular lipid (IHCL)                         
content.
{3.4.1} Before diet swap
To assess the phenotype exhibited before a diet change, two separate groups of mice were                           
used to compare differences between 6 weeks of high fat and normal fat feeding.
At the time of the scan, mice fed a HFD for 6 weeks were significantly heavier compared to                                 
control fed mice (Figure 3.4.1.0.1.A. C: 28.98 ± 0.62 g; F: 38.46 ± 1.48 g. p<0.0001,                             
n=7­8/group).
Whole body 1H MRS showed whole body adiposity was significantly higher in mice fed a HFD for                               
6 weeks, closely matching the increase in body weight observed (Figure 3.4.1.0.1.B. C: 11.74 ±                           











At the time of the scan, CF mice were significantly heavier compared to CC mice (Figure                             
3.4.2.0.1.A. CC: 30.83 ± 0.45 g; CF: 33.76 ± 0.53 g. p=0.0004, n=7­8/group).
Whole body 1H MRS showed whole body adiposity was significantly higher in CF mice compared                           
to CC mice (Figure 3.4.2.0.1.B]. CC: 11.73 ± 1.26 %; CF: 16.24 ± 0.83 %. p=0.0107,                             




Whole body adiposity was assessed using whole body 1H MRS. Data presented as mean ±                           





At the time of the scan, FC mice were significantly lighter compared to FF mice (Figure                             
3.4.3.0.1.A. FF: 40.49 ± 0.88 g; 34.65 ± 0.99 g. p=0.0006, n=7­8/group).
Whole body 1H MRS showed FC mice had significantly lower whole body adiposity compared to                           
FF mice (Figure 3.4.3.0.1.B. FF: 32.27 ± 1.75 %; FC: 26.54 ± 1.42 %. p=0.0261, n=7­8/group).                             




Whole body adiposity was assessed using whole body 1H MRS. Data presented as mean ±                           






Localised 1H liver MRS showed there was no significant difference in IHCL content between                         
mice fed a HFD 6 weeks compared to mice fed a normal fat diet (Figure 3.5.1.0.1]. C: 14.25 ±                                   
1.49 %; F: 14.29 ± 0.84 %. p=0.9843, n=7­8/group). This contrasts with whole body 1H liver MRS                               
measurements of adiposity and what would be expected with a higher body weight.
Figure {3.5.1.0.1} The effect of six weeks of high fat feeding on IHCL content





Localised 1H liver MRS showed there was no significant difference in IHCL content between CF                           
and CC mice, although there was a trend towards an increase in IHCL content in CF mice                               
compared to CC mice (Figure 3.5.2.0.1. CC: 17.50 ± 1.06 %; CF: 17.57 ± 1.54 %. p=0.9712,                               
n=7­8/group).
Figure {3.5.2.0.1} The effect of one week of high fat feeding on IHCL content of lean                             
mice





Localised 1H liver MRS showed there was no significant difference in IHCL content between FC                           
and FF mice, although there was a trend towards an increase in IHCL content in FC mice                               
compared to FF mice (Figure 3.5.3.0.1. FF: 24.00 ± 3.00 %; FC: 23.83 ± 1.58 %. p=0.9653,                               
n=7­8/group).
Figure {3.5.3.0.1} The effect of one week of normal fat feeding on IHCL content of DIO                             
mice




{3.6} The Effect of Rapid Weight Change on Adipose Tissue Content                   
and Distribution
{3.6.1} Before diet swap
6 weeks of high fat feeding significantly increased the amount of total WAT in F mice compared                               
to C mice (Figure 3.6.1.0.1.A. C: 5.04 ± 0.29 g; F: 10.96 ± 0.82 g. p<0.0001, n=7­8/group). This                                 
remained true when normalising total WAT to body weight (Figure 3.6.1.0.1.B. C: 17.36 ± 0.88                           
%; F: 28.33 ± 1.43 %. p<0.0001, n=10/group). This strongly correlates the results obtained using                           
whole body MRS above (Figure 3.4.1.0.1).
Figure {3.6.1.0.1} The effect of six weeks of high fat feeding on total body WAT
A) Total body WAT measured in grams (g); B) Total body WAT as a percentage of body weight                                 
(%).




A comparison of subcutaneous WAT showed F mice had significantly more subcutaneous WAT                       
compared to C mice, both in total and as a percentage of body weight (Figure 3.6.1.0.2:A­B]                             
Total: C: 3.12 ± 0.13 g; F: 5.87 ± 0.38 g. p<0.0001. Normalised: C: 10.75 ± 0.39 %; F: 15.21 ±                                       
0.67 %; Fa: 16.79 ± 0.34 %. p<0.0001, n=7­8/group).
Assessment of internal WAT also showed Fa mice had significantly more internal WAT                       
compared to C mice, both in total and as a percentage of body weight (Figure 3.6.1.0.2:C­D]                             
Total: C: 1.92 ± 0.16 g; F: 5.10 ± 0.45 g. p<0.0001. Normalised: C: 6.61 ± 0.51 %; F: 13.12 ± 0.82                                         
%. p<0.0001, n=7­8/group).
Figure {3.6.1.0.2} The effect of six weeks of high fat feeding on subcutaneous and                         
internal WAT
A) Subcutaneous WAT measured in grams (g); B) Subcutaneous WAT as a percentage of body                           
weight (%); C) Internal WAT measured in grams (g); D) Internal WAT as a percentage of body                               
weight (%).




Comparing the internal:subcutaneous WAT ratio indicates the relative distribution of WAT. F                     
mice showed a significantly higher internal:subcutaneous ratio compared to C mice, indicating 6                       
weeks of HF feeding increases the proportion of fat around the internal organs (Figure 3.6.1.0.3.                           
C: 0.609 ± 0.030; F: 0.861 ± 0.031. p<0.0001, n=7­8/group).
Figure {3.6.1.0.3} The effect of six weeks of high fat feeding on internal:subcutaneous                       
WAT ratio





After swapping to the HFD for 1 week after 6 weeks of control diet feeding, no significant                               
difference was observed in total body WAT in CF mice compared to CC mice, although a trend                               
showing an increase total body WAT was observed in CF mice (Figure 3.6.2.0.1:A]. CC: 6.14 ±                             
0.44 g F: 16 ± 0.29 g. p=0.0716, n=7­8/group). Similarly, no significant difference was observed                           
between groups when normalising total WAT to body weight (Figure 3.6.2.0.1:B. CC: 19.80 ±                         
1.33 %; CF: 21.08 ± 0.55 %. p=0.3678, n=7­8/group). This contrasts with the results obtained                           
using whole body MRS presented above, indicating significantly lower adiposity in CF mice                       
(Figure 3.4.2.0.1).
Figure {3.6.2.0.1} The effect of one week of high fat feeding on total body WAT of lean                               
mice
A) Total body WAT measured in grams (g); B) Total body WAT as a percentage of body weight                                 
(%).
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




A comparison of subcutaneous WAT showed no significant differences in CF mice compared to                         
CC mice when measured in grams or as a percentage of body weight (Figure 3.6.2.0.2:A­B.                           
Total: CC: 3.55 ± 0.16 g; CF: 3.90 ± 0.19 g. p=0.1790. Normalised: CC: 11.44 ± 0.43 %; CF:                                   
11.48 ± 0.41 %. p=0.9392, n=7­8/group).
A trend was observed showing an increased in internal WAT in CF mice compared to CC mice,                               
although this was not a significant difference (Figure 3.6.2.0.2:C. CC: 2.60 ± 0.31 g; CF: 3.26 ±                               
0.15 g. p=0.0665, n=7­8/group). However this trend wa much reduced when internal WAT was                         
normalised to body weight (Figure 3.6.2.0.2:D. CC: 8.36 ± 0.98 %; CF: 9.60 ± 0.34 %. p=0.2319,                               
n=7­8/group).
Figure {3.6.2.0.2} The effect of one week of high fat feeding on subcutaneous and                         
internal WAT of lean mice
A) Subcutaneous WAT measured in grams (g); B) Subcutaneous WAT as a percentage of body                           
weight (%); C) Internal WAT measured in grams (g); D) Internal WAT as a percentage of body                               
weight (%). Quantification of WAT was assessed using whole body MRI. Data presented as                         




No significant difference was observed when comparing internal:subcutaneous WAT ratio                 
between CC mice and CF mice (Figure 3.6.2.0.3. CC: 0.724 ± 0.067; CF: 0.841 ± 0.040.                             
p=0.1512, n=7­8/group).
Figure {3.6.2.0.3} The effect of one week of high fat feeding on internal:subcutaneous                       
WAT ratio of lean mice





After swapping to control diet for 1 week after 6 weeks of HF feeding, a significant decreased in                                 
total body WAT was observed in FC mice compared to FF mice (Figure 3.6.3.0.1:A. FF: 13.19 ±                               
0.77 g; FC: 9.96 ± 0.66 g. p=0.0080, n=7­8/group). However when total body WAT was                           
normalised to body weight, only a nonsignificant trend was observed in FC mice compared to FF                             
mice (Figure 3.6.3.0.1.B. FF: 32.17 ± 1.46 %; FC: 28.69 ± 1.11 %. p=0.0819, n=7­8/group).                           
Similar to weight gain mice presented above, this contrasts with whole body adiposity                       
measurements using MRS, which showed significant decreased in adiposity in FT mice (Figure                       
3.4.3.0.1).
Figure {3.6.3.0.1} The effect of one week of normal fat feeding on total body WAT of DIO                               
mice
A) Total body WAT measured in grams (g); B) Total body WAT as a percentage of body weight                                 
(%).
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




A comparison of subcutaneous WAT showed a significant reduction in subcutaneous WAT                     
mass in FC mice compared to FF mice, whilst again, a trend was observed when subcutaneous                             
WAT was normalised to body weight (Figure 3.6.3.0.2:A­B. Total: FF: 7.18 ± 0.46 g; FC: 5.54 ±                               
0.31 g. p=0.0124. Normalised: FF: 17.51 ± 0.93 %; FC: 16.00 ± 0.50 %. p=0.1813, n=7­8/group).
Similarly, FC mice showed significantly lower internal WAT mass compared to FF mice, but                         
upon normalisation this was no longer significant, although showed a strong trend (Figure                       
3.6.3.0.2:C. FF: 6.02 ± 0.33 g; FC: 4.42 ± 0.37 g. p=0.0072, n=7­8/group). However this trend                             
was much reduced when internal WAT was normalised to body weight (Figure 3.6.3.0.2:D. FF:                         
14.66 ± 0.58 %; FC: 12.69 ± 0.70 %. p=0.0508, n=7­8/group).
Figure {3.6.3.0.2} The effect of one week of normal fat feeding on subcutaneous and                         
internal WAT of DIO mice
A) Subcutaneous WAT measured in grams (g); B) Subcutaneous WAT as a percentage of body                           
weight (%); C) Internal WAT measured in grams (g); D) Internal WAT as a percentage of body                               
weight (%). Quantification of WAT was assessed using whole body MRI. Data presented as                         




No significant difference was observed when comparing internal:subcutaneous WAT ratio                 
between FF mice and FC mice (Figure 3.6.3.0.3. FF: 0.843 ± 0.026; FC: 0.792 ± 0.034.                             
p=0.2526, n=7­8/group).
Figure {3.6.3.0.3} The effect of one week of normal fat feeding on internal:subcutaneous                       
WAT ratio of DIO mice





To assess changes in glucose tolerance due to rapid weight changes, an intraperitoneal glucose                         
tolerance test (IPGTT) was performed. Mice were fasted overnight for 16­18 hours prior to the                           
IPGTT. Fasting glucose was determined with a commercially available glucose metre before                     
injecting a 2g/kg D­glucose bolus i.p. Blood glucose concentration was determined 15, 30, 60                         
and 120 minutes after the glucose injection.
{3.7.1} Before diet swap
As above, mice fed a HFD for 6 weeks who underwent an IPGTT were significantly heavier                             
compared to mice fed a control diet for 6 weeks (Figure 3.7.1.0.1:A]. C: 30.29 ± 0.86 g; F: 36.74                                   
± 1.43 g. p=0.0018, n=8/group).
During the IPGTT, blood glucose levels were elevated at all time points in high fat fed mice                               
compared to controls (Figure 3.7.1.0.1:B. Table 3.7.1.0.2. n=8/group). However, glucose levels                   
were only significantly higher 60 and 120 minutes after the glucose injection (p<0.001).
Area under the curve analysis indicates mice fed a HFD for 6 weeks are significantly more                             
glucose intolerant compared to control fed mice (Figure 3.7.1.0.1:C. C: 1990 ± 120.0 mmol/L x                           





A) Body weight of mice at the time of the IPGTT (g); B) Blood glucose measurements during the                                 
IPGTT (mmol/L). C) Area under the curve analysis of the IPGTT (mmol/L x 120 mins).




Time (mins) C (mmol/L) F (mmol/L) p value
0 6.3 ± 0.4 9.3 ± 0.7 n.s
15 20.2 ± 1.3 23.8 ± 0.8 n.s
30 22.8 ± 1.2 25.7 ± 0.8 n.s
60 16.2 ± 1.3 22.9 ± 1.8 <0.001
120 13.2 ± 1.4 20.5 ± 1.4 <0.001
Table {3.7.1.0.2} The effect of six weeks of high fat feeding glucose tolerance
Blood glucose measurements (mmol/L) assessed during the IPGTT at 0, 15, 30, 60 and 120                           
minutes after a glucose injection.
Data presented as mean ± sem. n=8/group. n.s=not significant. Yellow highlight indicates a                       





As above, CF mice who underwent an IPGTT were significantly heavier compared to FF mice                           
fed a normal fat control diet for 7 weeks (Figure 3.7.2.0.1:A. CC: 27.56 ± 0.57 g; CF: 31.19 ± 0.74                                     
g. p=0.0017, n=8/group).
During the IPGTT, fasting blood glucose levels was slightly elevated in CF mice compared to CC                             
mice (Figure 3.7.2.0.1:B. Table 3.7.2.0.2. n=8/group). This was also true 60 and 120 minutes                         
after the glucose injection, however none of these measurements were significantly different.
Area under the curve analysis also indicates CF mice fed a HFD for 1 week did not have altered                                   
glucose tolerance compared to CC mice (Figure 3.7.2.0.1:C. CC: 2085 ± 92.5 mmol/L x 120                           
mins; CF: 2304 ± 101.9 mmol/L x 120 mins. p=0.1339, n=8/group). A trend towards a decrease                             




Figure {3.7.2.0.1} The effect of one week of high fat feeding on glucose tolerance of lean                             
mice
A) Body weight of mice at the time of the IPGTT (g); B) Blood glucose measurements during the                                 
IPGTT (mmol/L). C) Area under the curve analysis of the IPGTT (mmol/L x 120 mins).




Time (mins) CC (mmol/L) CF (mmol/L) p value
0 9.7 ± 1.5 8.2 ± 0.6 n.s
15 24.4 ± 1.0 21.6 ± 1.7 n.s
30 23.2 ± 0.8 23.6 ± 1.4 n.s
60 17.9 ± 1.1 21.5 ± 1.2 n.s
120 10.7 ± 0.9 14.1 ± 1.2 n.s
Table {3.7.2.0.2} The effect of one week of high fat feeding on glucose tolerance of lean                             
mice
Blood glucose measurements (mmol/L) assessed during the IPGTT at 0, 15, 30, 60 and 120                           
minutes after a glucose injection.
Data presented as mean ± sem. n=8/group. n.s=not significant. Yellow highlight indicates a                       





As above, FC mice who underwent an IPGTT were significantly lighter compared to FF mice fed                             
a HFD for 7 weeks (Figure 3.7.3.0.1:A. FF: 39.48 ± 0.79 g; FC: 34.33 ± 1.72 g. p=0.0164,                                 
n=8/group).
During the IPGTT, blood glucose levels were slightly decreased in FC mice compared to FF                           
mice throughout (Figure 3.7.3.0.1:B, Table 3.7.3.0.2), but this was only significantly lower 120                       
minutes after the glucose injection (p<0.05, n=8/group).
Area under the curve analysis indicates FC mice fed a normal fat control diet for 1 week do not                                   
have altered glucose tolerance compared to FF mice, however a trend towards an improvement                         




Figure {3.7.3.0.1} The effect of one week of normal fat feeding on glucose tolerance of                           
DIO mice
A) Body weight of mice at the time of the IPGTT (g); B) Blood glucose measurements during the                                 
IPGTT (mmol/L). C) Area under the curve analysis of the IPGTT (mmol/L x 120 mins).




Time (mins) FF (mmol/L) FC (mmol/L) p value
0 9.6 ± 1.0 7.7 ± 1.4 n.s
15 25.2 ± 1.5 22.7 ± 1.2 n.s
30 25.6 ± 1.2 23.6 ± 1.0 n.s
60 24.6 ± 1.2 22.3 ± 1.3 n.s
120 21.8 ± 2.0 16.3 ± 1.61 <0.05
Figure {3.7.3.0.2} The effect of one week of normal fat feeding on glucose tolerance of                           
DIO mice
Blood glucose measurements (mmol/L) assessed during the IPGTT at 0, 15, 30, 60 and 120                           
minutes after a glucose injection.
Data presented as mean ± sem. n=8/group. n.s=not significant. Yellow highlight indicates a                       





Mice were housed individually in CLAMS metabolic cages to assess changes in food intake,                         
water intake, O2 consumption, CO2 production and movement.
{3.8.1} Before diet swap
An assessment of mouse metabolism and behaviour using indirect calorimetry after 6 weeks of                         
control diet or HFD feeding was discussed in detail in Section 4.9.1.
In summary, cumulative water intake was higher in control fed animals. Oxygen consumption                       
and carbon dioxide production was also increased in control fed mice compared to HF fed mice,                             
which in turn led to a high respiratory exchange ratio in control fed mice, indicating the higher                               
carbohydrate content of the diet, compared to HF diet. Heat production was increased in HF fed                             
mice compared to control fed mice.
No significant differences were observed in ambulatory activity between the two groups, whilst                       
ZTOT activity was increased in control fed mice.
{3.8.2} Weight gain
Water intake was measured during a full light cycle and shows a slight increase in water intake                               
in CC mice compared to CF mice (Figure 3.8.2.0.1:A). This slight increase in water intake                           




Figure {3.8.2.0.1} The effect of one week of high fat feeding on water intake of lean mice                               
measured using CLAMS metabolic cages
A) Water intake over 24 hour light cycle; B) Total water intake during light phase and dark phase                                 
of the light cycle.
Shaded area on the graph represents the dark phase of the light cycle. Data presented as mean                               




Oxygen consumption and carbon dioxide production show a slight reduction in both                     
measurements in CF mice compared to CC mice, particularly at the onset of the dark phase                             
(Figure 3.8.2.0.2:A,C). No significant difference in O2 production was detected between groups,                     
and only one measurement at 20:00hr showed a significant reduction in CO2 production in CF                           
mice compared to CC mice (p<0.05). Similarly, a slight reduction in O2 consumption and CO2                           




Figure {3.8.2.0.2} The effect of one week of high fat feeding on O2 consumption and CO2                             
production of lean mice measured using CLAMS metabolic cages
A) O2 consumption over 24 hour light cycle; B) O2 consumption during light phase and dark                             
phase of the light cycle; C) CO2 over 24 hour light cycle; D) CO2 production during light and dark                                   
phase of the light cycle.
Shaded area on the graph represents the dark phase of the light cycle. Data presented as mean                               




Following measurements made in O2 consumption and CO2 production, the respiratory                   
exchange ratio (RER) and heat production could be calculated (Equation 2.4.3.0.1).
A significant decrease in the RER of CF mice compared to CC mice was observed between                             
10:00­3:00hrs (Figure 3.8.2.0.3:A, p<0.05­0.001). Similarly, a significant decrease in RER in CF                     
mice compared to CC mice was observed when comparing RER during the light and dark                           
phase of the light cycle (Figure 3.8.2.0.3:B. Table 3.8.2.0.4). An RER between 0.7 and 0.8                           
indicates fat is the dominant source being utilised by these mice, whilst an RER closer to 1.0                               
indicates carbohydrate as the dominant energy source. Given CF mice are feeding on a HFD, an                             
RER close to 0.7 would be expected, whilst CC mice feeding on a diet higher in carbohydrates                               
have an RER mostly between 0.8 and 1, indicating carbohydrate and protein are being utilised.                           
An RER between 0.7 and 0.8 indicates fat is the dominant source being utilised by these mice,                               
whilst an RER closer to 1.0 indicates carbohydrate as the dominant energy source. Given Fa                           
mice are feeding on a HFD, an RER close to 0.7 would be expected, whilst C mice feeding on a                                     
diet higher in carbohydrates have an RER mostly between 0.8 and 1, indicating carbohydrate                         
and protein are being utilised.




Figure {3.8.2.0.3} The effect of one week of high fat feeding on RER and heat production                             
of lean mice measured using CLAMS metabolic cages
A) Respiratory exchange ratio (RER) over 24 hour light cycle; B) RER during light phase and                             
dark phase of the light cycle; C) Heat production over 24 hour light cycle; D) Heat production                               
during light and dark phase of the light cycle.
Shaded area on the graph represents the dark phase of the light cycle. Data presented as mean                               





Water intake (ml) Light 0.379 ± 0.073 1.027 ± 0.268 n.s
Dark 0.393 ± 0.065 0.830 ± 0.137 n.s
VO2 (ml/kg0.75/hr) Light 3692 ± 164.1 4268 ± 168.7 n.s
Dark 3511 ± 132.7 4087 ± 146.6 n.s
VCO2 (ml/kg0.75/hr) Light 3428 ± 163.7 3954 ± 163.4 n.s
Dark 3061 ± 152.8 3550 ± 201.1 n.s
RER Light 0.8573 ± 0.0201 0.8735 ± 0.0271 <0.001
Dark 0.7548 ± 0.0073 0.7547 ± 0.0070 <0.001
Heat (kcal/hr) Light 0.5605 ± 0.0233 0.6510 ± 0.0251 n.s
Dark 0.5836 ± 0.0170 0.6779 ± 0.0229 n.s
Table {3.8.2.0.4} The effect of one week of high fat feeding on indirect calorimetry                         
measurements in lean mice
Total water intake (ml), average O2 consumption (ml/kg0.75/hr), CO2 production (ml/kg0.75/hr),                   
RER (arbitrary unit) and heat production (kcal/hr) measured during the light and dark phase of a                             
24 hour light cycle using CLAMS metabolic cages. RER and heat production calculated using                         
equations 2.4.3.0.1. Data presented as mean ± sem, n=7­8/group. n.s=not significant. Yellow                     




Movement was assessed using infrared beams, with a beam crossing given as one count of                           
movement. XAMB counts measured ambulatory activity on a horizontal axis. CF mice showed a                         
significant increase in ambulatory activity at the onset of the dark phase of the light cycle (Figure                               
3.8.2.0.5:A, p<0.05, n=7­8/group), However, total ambulatory activity was not significantly                 
different during the light or dark phase of the light cycle (Figure 3.8.2.0.5:B. Table 3.8.2.0.6.                           
n=7­8/group). Total movement over the 24 hour light cycle showed increase ambulatory activity,                       
but again this was not significantly different (Figure 3.8.2.0.5:B. Table 3.8.2.0.6. n=7­8/group).
In contrast, ZTOT counts, which measures movement in the vertical axis (e.g. rearing), showed                         
CC mice were more active in this plane of movement compared to CF mice. This was                             
significant at 20:00­22:00hr (Figure 3.8.2.0.5:C. p<0.05­0.001, n=7­8/group), and as a sum                   
during the entire dark phase of the light cycle (p<0.01). Total vertical movement over the 24 hour                               
light cycle was also significantly decreased in FC mice compared to CC mice (Figure                         
3.8.2.0.5:D. Table 3.8.2.0.6. n=7­8/group).
XTOT counts measure all movement in the horizontal axis, including fine movements like                       
grooming. These was no significant difference in XTOT counts, indicating perhaps CC mice                       
make more finer movements than CF mice. As the difference in XTOT movements appears to                           
be much smaller in comparison to XAMB movements, where CF mice appear to make more                           
ambulatory movements, it seems finer movements in CC mice have therefore reduced the                       
difference in XAMB counts (Figure 3.8.2.0.5:E. n=7­8/group). No significant difference between                   




Figure {3.8.2.0.5} The effect of one week of high fat feeding on activity of lean mice                             
measured using CLAMS metabolic cages
A) Ambulatory activity counts (XAMB) over 24 hour light cycle; B) Total XAMB counts during light                             
phase, dark phase and entire light cycle; C) Rearing activity counts (ZTOT) over 24 hour light                             
cycle; D) Total ZTOT counts during light phase, dark phase and entire light cycle; E) All                             
movement along the horizontal plane (XTOT), including ambulatory and fine movements (such                     
as grooming) over 24 hour cycle; F) Total XTOT counts during light phase, dark phase and entire                               
light cycle. Shaded area on the graph represents the dark phase of the light cycle. Data                             





Light CC 2126.8 ± 273.1 286.0 ± 50.2 5726.5 ± 647.8
CF 4515.8 ± 684.4 206.8 ± 34.8 7045.4 ± 1153.1
Dark CC 10005.3 ± 1797.7 2827.4 ± 441.5 19415.8 ± 2936.8
CF 13402.7 ± 1884.7 1254.7 ± 285.3 18686.3 ± 1976.4
Total CC 17918.5 ± 2484.6 3113.4 ± 443.7 25142.3 ± 3084.0
CF 12132.1 ± 1813.8 1461.5 ± 297.8 25731.7 ± 2994.3
Table {3.8.2.0.6} The effect of one week of high fat feeding on activity in lean mice
Total number of XAMB, ZTOT and XTOT counts during the light phase, dark phase and over a                               
whole 24 hour light cycle. Data presented as mean ± sem, n=7­8/group. Yellow highlight                         





A significant increase in water consumption in FC mice compared to FF mice was observed                           
during the 24hr period measured from 01:00 hr to 09:00 hr (Figure 3.8.3.0.1:A]. 01:00­02:00hrs:                         
p<0.05; 03:00­09:00hr: p<0.01, n=6­8/group). Both light and dark phases of the light cycle show                         
FC mice consume more water, which was significant in the dark phase (Figure 3.8.3.0.1:B.                         
Table 3.8.3.0.4. p<0.05, n=6­8/group).
Figure {3.8.3.0.1} The effect of one week of normal fat feeding on water intake of DIO                             
mice measured using CLAMS metabolic cages
A) Water intake over 24 hour light cycle; B) Total water intake during light phase and dark phase                                 
of the light cycle.
Shaded area on the graph represents the dark phase of the light cycle. Data presented as mean                               




Oxygen consumption and carbon dioxide production show a slight increase in both                     
measurements in FC mice compared to FF mice, except at the onset of the dark phase, where                               
FF mice show increased O2 consumption but equal CO2 production (Figure 3.8.3.0.2:A,C).                     
However, none of these measurements show a significant difference between groups. Similarly,                     
a slight increase in O2 consumption and CO2 production were observed in FC mice compared to                             




Figure {3.8.3.0.2} The effect of one week of normal fat feeding on O2 consumption and                           
CO2 production of DIO mice measured using CLAMS metabolic cages
A) O2 consumption over 24 hour light cycle; B) O2 consumption during light phase and dark                             
phase of the light cycle; C) CO2 over 24 hour light cycle; D) CO2 production during light and dark                                   
phase of the light cycle.
Shaded area on the graph represents the dark phase of the light cycle. Data presented as mean                               




A significant increase in the RER of FC mice was observed compared to FF mice between                             
11:00­5:00hrs (Figure 3.8.3.0.3:A. p<0.05­0.001, n=8/group). Similarly, there was a significant                 
increase in RER in FC mice compared to FF mice during the light and dark phase of the light                                   
cycle (Figure 3.8.3.0.3:B. Table 3.8.3.0.4, n=8/group). As above, this indicated FC mice are                       
using more carbohydrate and protein as an energy source since moving to a normal fat                           
carbohydrate­rich diet, whilst FF mice are still using fat as their main energy source, since they                             
are feeding on a HFD.
Heat production was slightly decreased in FC mice compared to FF mice, particularly at the                           
onset of the dark phase of the light cycle. However, no difference in heat production was                             




Figure {3.8.3.0.3} The effect of one week of normal fat feeding on RER and heat                           
production of DIO mice measured using CLAMS metabolic cages
A) Respiratory exchange ratio (RER) over 24 hour light cycle; B) RER during light phase and                             
dark phase of the light cycle; C) Heat production over 24 hour light cycle; D) Heat production                               
during light and dark phase of the light cycle.
Shaded area on the graph represents the dark phase of the light cycle. Data presented as mean                               





Water intake (ml) Light 0.302 ± 0.040 0.771 ± 0.102 n.s
Dark 0.467 ± 0.090 0.905 ± 0.198 <0.005
VO2 (ml/kg0.75/hr) Light 3298 ± 180.9 3812 ± 220.3 n.s
Dark 3434 ± 106.3 3922 ± 152.4 n.s
VCO2 (ml/kg0.75/hr) Light 2850 ± 229.7 3286 ± 254.1 n.s
Dark 3095 ± 161.3 3621 ± 151.3 n.s
RER Light 0.7334 ± 0.0046 0.7329 ± 0.0052 <0.001
Dark 0.8113 ± 0.0124 0.8545 ± 0.0170 <0.001
Heat (kcal/hr) Light 0.589 ± 0.0272 0.6786 ± 0.0297 n.s
Dark 0.5600 ± 0.0207 0.6450 ± 0.0181 n.s
Table {3.8.3.0.4} The effect of one week of normal fat feeding on indirect calorimetry                         
measurements in DIO mice
Total water intake (ml), average O2 consumption (ml/kg0.75/hr), CO2 production (ml/kg0.75/hr),                   
RER (arbitrary unit) and heat production (kcal/hr) measured during the light and dark phase of a                             
24 hour light cycle using CLAMS metabolic cages. RER and heat production calculated using                         
equations 2.4.3.0.1. Data presented as mean ± sem, n=5­8/group. n.s=not significant. Yellow                     




FC mice showed less ambulatory activity at the onset of the dark phase of the light cycle                               
compared to FF mice, which was significant at 19:00 hr (Figure 3.8.3.0.5:A. p<0.001,                       
n=7­8/group). However, when comparing light and dark phase XAMB counts, the decrease in                       
activity was not significant (Figure 3.8.3.0.5:B. Table 3.8.3.0.6. n=7­8/group). Total ambulatory                   
movement was lower FC mice compared to FF mice, however again this was not significant.
ZTOT counts are also slightly decreased in FC mice compared to FF mice, again being most                             
obvious at the onset of the dark cycle, though not significant (Figure 3.8.3.0.5:B. n=7­8/group). A                           
comparison of ZTOT counts during light and dark phases of the light cycle show very little                             
difference in rearing activity (Figure 3.8.3.0.5:D. Table 3.8.3.0.6. n=7­8/group). Total vertical                   
movement over the 24 hour light cycle was also not significant between groups.
These was no significant difference in XTOT counts between groups, but with the difference in                           
XTOT counts between FC and FF mice being much smaller compared to XAMB counts (Figure                           
3.8.3.0.5:E. n=7­8/group). As above, maybe this suggest normal fat diet feeding mice (CC and                         
FC) make more finer movements compared to HFD feeding mice (CF and FF). No significant                           
difference between groups was observed during the light or dark phase of the light cycle, or                             




Figure {3.8.3.0.5} The effect of one week of normal fat feeding on activity of DIO mice                             
measured using CLAMS metabolic cages
A) Ambulatory activity counts (XAMB) over 24 hour light cycle; B) Total XAMB counts during light                             
phase, dark phase and entire light cycle; C) Rearing activity counts (ZTOT) over 24 hour light                             
cycle; D) Total ZTOT counts during light phase, dark phase and entire light cycle; E) All                             
movement along the horizontal plane (XTOT), including ambulatory and fine movements (such                     
as grooming) over 24 hour cycle; F) Total XTOT counts during light phase, dark phase and entire                               
light cycle. Shaded area on the graph represents the dark phase of the light cycle. Data                             





Light FF 5537.8 ± 1625.3 369.5 ± 67.0 6455.4 ± 1025.2
FC 2221.4 ± 455.9 310.4 ± 65.3 5833.7 ± 850.4
Dark FF 15842.5 ± 1987.0 2342.3 ± 377.0 20533.6 ± 1694.4
FC 12068.5 ± 3265.6 2593.3 ± 507.0 22769.4 ± 5434.3
Total FF 21380.3 ± 3425.9 2711.9 ± 416.0 26989.0 ± 2600.2
FC 14289.9 ± 3502.0 2903.7 ± 554.0 28603.1 ± 6037.2
Table {3.8.3.0.6} The effect of one week of high fat feeding on activity in lean mice
Total number of XAMB, ZTOT and XTOT counts during the light phase, dark phase and over a                               
whole 24 hour light cycle. Data presented as mean ± sem, n=7­8/group. Yellow highlight                         





To assess the effect of weight gain on stamina, an acute exercise study was used. This involved                               
measuring the total distance ran by mice upon placing them on a treadmill and increasing                           
treadmill speed until the point of exhaustion.
{3.9.1} Before diet swap
A detailed description of the effect of 6 weeks of HFD on stamina can be found in Section 4.10.1.                                   
Briefly, 6 weeks of HFD decreased running distance in mice compared to control mice, although                           
this did not reach significance (p=0.2227). No correlation was observed between running                     
distance, body weight, lean mass or fat mass.
{3.9.2} Weight gain
CF mice ran a shorter distance compared to CC mice, showing they have reduced stamina after                             
one week of high fat feeding, but this difference did not reach significance (Figure 3.9.2.0.1. CC:                             
1112 ± 97.79 m; CF: 861.3 ± 19.32 m. p=0.0604, n=5­7/group).
Unfortunately, due to the exclusion of 3 mice from the data analysis (due to running less than                               
200m), the mice used for this analysis did not show the significant difference in body weight                             
between CF and CC mice observed in all experiments presented elsewhere in this section                         
(Figure 3.9.2.0.2:A. CC: 30.79 ± 1.02 g; CF: 33.48 ± 0.91 g. p=0.0900, n=5­7/group).
For this reason also, there was no correlation between body weight and running distance in the                             
CF group (Figure 3.9.2.0.2:B. Table 3.9.2.0.3. n=5­7/group). Similarly, there was no correlation                     
observed between body weight and distance ran in CC mice, whereby heavier mice ran a                           
shorter distance (Figure 3.9.2.0.2:B. Table 3.9.2.0.3. n=5­7/group). Grouping CC and CF mice                     




Figure {3.9.2.0.1} The effect of one week of high fat feeding on distance ran on a                             
treadmill of lean mice
An acute exercise study was used to assess the maximum distance mice could run involuntarily                           
(m).




Figure {3.9.2.0.2} The effect of one week of high fat feeding on distance ran on a                             
treadmill of lean mice correlated with body weight
A) Body weight at the time of acute exercise study (g). Data presented as mean ± sem,                               
n=5­7/group. p=0.0900. Statistical analysis was performed using an unpaired t­test.
B) Correlation analysis between body weight and distance ran. Black line represents line of best                           
fit for correlation of all mice, regardless of diet group. n=12. Statistical analysis was performed                           
using Pearson’s correlation.
CC CF All
Pearson r ­0.3749 0.0050 0.4620
p value 0.4073 0.9937 0.1306
R2 0.1406 0.0002 0.2134
Table {3.9.2.0.3} The effect of one week of high fat feeding on distance ran on a treadmill                               
of lean mice correlated with body weight
Correlation analysis between body weight and distance ran. n=5­7/group, total n=12. Yellow                     




To assess whether a correlation existed between distance ran and fat or lean mass, an                           
EchoMRI whole adiposity MR scanner was used the day before treadmill measurements.
Lean mass was lower in CF mice compared to CC mice, but was not significant (Figure                             
3.9.2.0.5:A. Table 3.9.2.0.4. n=5­7/group). However, fat mass was significantly increased in CF                     
mice compared to CC mice (Figure 3.9.2.0.5:C. Table 3.9.2.0.4. n=5­7/group).
Upon normalisation to body weight at the time of the EchoMRI scan, percentage lean mass was                             
significantly reduced in CF mice compared to CC mice (Figure 3.9.2.0.5:B. Table 3.9.2.0.4.                       
n=5­7/group), whilst percentage fat mass was still significantly increased in CF mice compared                       
to CC mice (Figure 3.9.2.0.5:D. Table 3.9.2.0.4. n=5­7/group).
CC CF p value
Lean mass (g) 21.89 ± 0.38 20.63 ± 0.59 0.0888
Lean mass (%) 71.34 ± 1.35 61.57 ± 1.12 0.0004
Fat mass (g) 6.87 ± 0.66 10.59 ± 0.52 0.002
Fat mass (%) 22.07 ± 1.54 31.50 ± 0.37 0.0005
Table {3.9.2.0.4} The effect of one week of high fat feeding on lean mass and fat mass in                                 
lean mice




Figure {3.9.2.0.5} The effect of one week of high fat feeding on lean mass and fat mass in                                 
lean mice
A) Lean mass in grams (g); B) Lean mass as a percentage of body weight (%); C) Fat mass in                                     
grams (g); D) Fat mass as a percentage of body weight (%).




No correlation between distance ran to lean mass was observed in CC mice or CF mice. When                               
both CC and CF mice were grouped together, there was still no correlation between distance ran                             
and lean mass (Figure 3.9.2.0.6:A. Table 3.9.2.0.7:A. n=5­7/group).
When distance was correlated with percentage lean mass,again no correlation was observed in                       
CC mice or CF mice. However, there was a significant positive correlation between distance and                           
percentage lean mass when all mice were group together (Figure 3.9.2.0.6:B. Table 3.9.2.0.7:B.                       
n=5­7/group).
When comparing distance ran with fat mass, no significant correlation was observed in CC mice                           
or CF mice. When all mice were grouped together, there was a significant negative correlation                           
between distance ran and fat mass (Figure 3.9.2.0.6:C. Table 3.9.2.0.7:C. n=5­7/group).
When distance was correlated with percentage fat mass, CC mice and CF mice did not show a                               
significant correlation. Again, when all mice were groups together, there was a significant                       




Figure {3.9.2.0.6} The effect of one week of high fat feeding on correlation between                         
distance ran on a treadmill with lean mass and fat mass of lean mice
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           
percentage fat mass.





Pearson r ­0.3735 0.0054 0.1055
p value 0.4093 0.9931 0.7442
R2 0.1395 0.0002 0.0111
CC CF All
Pearson r 0.3440 ­0.0514 0.6016
p value 0.4499 0.9346 0.0385
R2 0.1184 0.0026 0.3619
CC CF All
Pearson r ­0.4793 ­0.8652 ­0.6502
p value 0.2765 0.9079 0.0221
R2 0.2297 0.0052 0.4228
CC CF All
Pearson r ­0.5142 0.3840 ­0.6893
p value 0.2377 0.5233 0.0131
R2 0.2644 0.1475 0.4752
Table {3.9.2.0.7} The effect of one week of high fat feeding on correlation between                         
distance ran on a treadmill with lean mass and fat mass of lean mice
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           
percentage fat mass.
Correlation analysis between body weight and distance ran. n=5­7/group, total n=12. Yellow                     





FC mice ran a significantly longer length of distance compared to FF mice, showing they have                             
reduced stamina after one week of normal fat feeding (Figure 3.9.3.0.1. FF: 649.4 ± 40.91 m;                             
FC: 1039 ± 83.26 m. p=0.0015, n=7/group).
FC mice showed a significantly lower body weight compared to FF mice showed decrease in                           
FC mouse body weight, consistent with the rest of the experiments in this section (Figure                           
3.9.3.0.2:A. FF: 41.09 ± 0.58 g; FC: 33.11 ± 1.33 g. p<0.0001, n=7/group).
Correlation between body weight and distance ran showed a significant negative correlation in                       
FC mice, whilst there was no correlation observed in FF mice. When all mice were grouped                             
together, a significant negative correlation between body weight and distance ran was observed                       
(Figure 3.9.3.0.2:B. Table 3.9.3.0.3. n=7/group).
Figure {3.9.3.0.1} The effect of one week of normal fat feeding on distance ran on a                             
treadmill of DIO mice
An acute exercise study was used to assess the maximum distance mice could run involuntarily                           
(m).




Figure {3.9.3.0.2} The effect of one week of normal fat feeding on distance ran on a                             
treadmill of DIO mice correlated with body weight
A) Body weight at the time of acute exercise study (g). Data presented as mean ± sem,                               
n=7/group. *** p<0.001. Statistical analysis was performed using an unpaired t­test.
B) Correlation analysis between body weight and distance ran. Black line represents line of best                           
fit for correlation of all mice, regardless of diet group. n =12. Statistical analysis was performed                             
using Pearson’s correlation.
FF FC All
Pearson r 0.5552 ­0.7703 ­0.7303
p value 0.1957 0.0427 0.0030
R2 0.3083 0.5934 0.5334
Table {3.9.3.0.3} The effect of one week of normal fat feeding on distance ran on a                             
treadmill of DIO mice correlated with body weight
Correlation analysis between body weight and distance ran. n=7/group, total n=14. Yellow                     




An EchoMRI whole adiposity MR scanner was used to assess lean and fat mass in these mice                               
to correlate these two measurements with distance ran.
Lean mass was lower in FC mice compared to FF mice, but was not significant (Figure                             
3.9.3.0.5:A. Table 3.9.3.0.4. n=7/group). However, fat mass was significantly lower in FC mice                       
compared to FF mice (Figure 3.9.3.0.5:C. Table 3.9.3.0.4. n=7/group).
Upon normalisation to body weight, percentage lean mass was significantly higher in FC mice                         
compared to FF mice (Figure 3.9.3.0.5:B. Table 3.9.3.0.4. n=7/group), whilst percentage fat                     
mass was still significantly lower in FC mice compared to FF mice (Figure 3.9.3.0.5:D. Table                           
3.9.3.0.4. n=7/group).
FF FC p value
Lean mass (g) 22.59 ± 0.53 21.25 ± 0.91 0.2254
Lean mass (%) 54.96 ± 0.83 62.38 ± 1.70 0.0021
Fat mass (g) 16.95 ± 0.38 11.46 ± 0.70 <0.0001
Fat mass (%) 41.26 ± 0.79 33.66 ± 1.80 0.0022
Table {3.9.3.0.4} The effect of one week of normal fat feeding on lean mass and fat mass                               
in DIO mice




Figure {3.9.3.0.5} The effect of one week of normal fat feeding on lean mass and fat mass                               
in DIO mice
A) Lean mass in grams (g); B) Lean mass as a percentage of body weight (%); C) Fat mass in                                     
grams (g); D) Fat mass as a percentage of body weight (%).




There was a significant negative correlation between distance ran to lean mass in FC mice,                           
whilst a trend showing a positive correlation was observed in FF mice. When all mice were                             
grouped together, there was also a significant negative correlation between distance ran and                       
lean mass (Figure 3.9.3.06:A. Table 3.9.3.0.7:A. n=7/group, total n=14).
When distance was correlated with percentage lean mass, there was a significant negative                       
correlation in FC mice, but a weak positive correlation in FF mice. A weak positive correlation                             
between distance ran and percentage lean mass was observed when all mice were grouped                         
together (Figure 3.9.3.06:B. Table 3.9.3.0.7:B. n=7/group, total n=14).
There was no correlation between fat mass and distance rain in FC or FF mice. When all mice                                 
were grouped together there was a significant negative correlation between fat mass and                       
distance ran (Figure 3.9.3.06:C. Table 3.9.3.0.7:C. n=7/group, total n=14).
When distance was correlated to percentage fat mass, FC mice showed a weak positive                         
correlation, whilst FF mice showed a weak negative correlation. However, when all mice were                         




Figure {3.9.3.0.6} The effect of one week of normal fat feeding on correlation between                         
distance ran on a treadmill with lean mass and fat mass of DIO mice
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           
percentage fat mass.





Pearson r 0.7081 ­0.9158 ­0.5564
p value 0.0750 0.0038 0.0388
R2 0.5014 0.8387 0.3096
FF FC All
Pearson r 0.5799 ­0.7043 0.3176
p value 0.1723 0.0773 0.2685
R2 0.3363 0.4960 0.1009
FF FC All
Pearson r ­0.0404 0.0146 ­0.6071
p value 0.9315 0.9752 0.0213
R2 0.0016 0.0002 0.3686
FF FC All
Pearson r ­0.4559 0.4314 ­0.3914
p value 0.2079 0.1861 0.1664
R2 0.2079 0.1861 0.1532
Table {3.9.3.0.7} The effect of one week of normal fat feeding on correlation between                         
distance ran on a treadmill with lean mass and fat mass of DIO mice
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           
percentage fat mass.
Correlation analysis between body weight and distance ran. n=7/group, total n=14. Yellow                     





Plasma was collected after 7 weeks of feeding from mice in a fed state to assess changes in                                 
metabolic hormones as a result of a rapid weight change. Metabolic hormones detected in this                           
assay include c­peptide, ghrelin, GIP, glucagon, insulin, leptin and resistin, and inflammatory                     
cytokines IL­6, MCP­1 and TNF­A.
{3.10.1} Before weight swap
A detailed description of the effects of 6 weeks of HFD on metabolic plasma hormones can be                               
found in Section 4.11.1. In summary, 6 weeks of HFD increased leptin and resistin plasma                           
concentration. Similarly, insulin, c­peptide and GIP plasma concentration was also increased                   
with 6 weeks of HFD. No significant changes were observed in glucagon or ghrelin plasma                           
concentration, or cytokine plasma concentration.
{3.10.2} Weight gain
Glucose and β­ketone concentration in the blood of fed mice were taken using a commercially                           
available glucose monitor. No difference in blood glucose concentration was detected in CF                       
mice compared to CC mice (Figure 3.10.2.0.1:A. Table 3.10.2.0.6. n=8/group). However, CF                     
mice showed a significant increase in blood β­ketone concentration compared to CC mice                       




Figure {3.10.2.0.1} The effect of one week of high fat feeding on blood glucose and                           
β­ketone concentration of lean mice
Blood samples from mice in a fed a state were used to assess A) blood glucose concentration                               




Increased plasma concentration of leptin and resistin were detected in plasma samples from CF                         
mice compared to CC mice (Figure 3.10.2.0.2:A­B. Table 3.10.2.0.6. n=7/group). This agrees                     
with 1H MRS above showing an increased level of adiposity in this CF mice compared to CC                               
mice (Section 3.4.2).
Figure {3.10.2.0.2} The effect of one week of high fat feeding on plasma leptin and                           
resistin concentration of lean mice
A) Leptin; B) Resistin.




An increase in insulin plasma concentration was observed in CF mice compared to CC mice,                           
however this increase was not significant (Figure 3.10.2.0.3:A. Table 3.10.2.0.6. n=6­7/group).                   
C­peptide, another hormone produced alongside insulin, was significantly increased in CF mice                     
compared to CC mice (Figure 3.10.2.0.3:B. Table 3.10.2.0.6. n=7/group). No noticeable                   
difference in GIP plasma concentration was detected between groups (Figure 3.10.2.0.3:C.                   
Table 3.10.2.0.6. n=7/group).
Figure {3.10.2.0.3} The effect of one week of high fat feeding on plasma insulin,                         
c­peptide and GIP concentration of lean mice
A) Insulin; B) C­peptide; C) GIP.




No significant differences in glucagon or ghrelin plasma concentration were detected between                     
groups (Figure 3.10.2.0.4:A­B. Table 3.10.2.0.6. n=7/group).
Figure {3.10.2.0.4} The effect of one week of high fat feeding on plasma glucagon and                           
ghrelin concentration of lean mice
A) Glucagon; B) Ghrelin




A significant increase in IL­6 plasma concentration was observed in CF mice compared to CC                           
mice (Figure 3.10.2.0.5:A. Table 3.10.2.0.6. n=5­7/group) whilst a trend towards an increase in                       
MCP­1 plasma concentration was also observed (Figure 3.10.2.0.5:B. Table 3.10.2.0.6.                 
n=5­7/group). No change in TNF­A was observed between groups (Figure 3.10.2.0.5:C. Table                     
3.10.2.0.6. n=5­7/group).
Figure {3.10.2.0.5} The effect of one week of high fat feeding on plasma inflammatory                         
cytokine concentration of lean mice
A) Interleukin 6 (IL­6); B) monocyte chemoattractant protein 1 (MCP­1); C) tumour necrosis                       
factor­alpha (TNF­A).





Glucose 10.0 ± 0.8 11.06 ± 0.8 0.3486
β­ketone 0.2 ± 0.1 0.4 ± 0.1 0.0057
Leptin 12630 ± 3442 27700 ± 5663 0.0422
Resistin 12550 ± 1603 46630 ± 6082 0.0002
Insulin 859.1 ± 161.7 1253 ± 231.1 0.2040
C­peptide 1979 ± 357.2 3495 ± 463.2 0.0236
GIP 117.1 ± 21.25 117.2 ± 12.38 0.9954
Glucagon 60.18 ± 6.416 73.40 ± 12.35 0.3645
Ghrelin 260.9 ± 52.93 281.1 ± 36.50 0.7592
IL­6 8.708 ± 1.28 17.61 ± 2.31 0.0066
MCP­1 52.37 ± 7.921 93.06 ± 24.25 0.0969
TNF­A 21.17 ± 5.054 22.43 ± 3.888 0.8501
Table {3.10.2.0.6} The effect of one week of high fat feeding on blood and plasma                           
measurements of lean mice
Blood samples from mice in a fed a state were used to assess blood glucose concentration and                               
blood β­ketone concentration (mmol/L). Plasma samples were used to assess metabolic                   
hormones and inflammatory cytokines (pg/mL).





FC mice had a significantly lower blood glucose concentration compared to FF mice (Figure                         
3.10.3.0.1:A. Table 3.10.3.0.6. n=8/group). A decrease in blood glucose concentration, both in                     
fasted and fed state, are associated with an improvement in insulin function. This agrees with                           
the trending improvement in glucose tolerance with the IPGTT results above (Section 3.7.3). No                         
significant difference was seen in blood β­ketone concentration between FC and FF mice,                       
however a clear trend towards a decrease in blood β­ketone concentration in FC mice was                           
observed compared to FF mice (Figure 3.10.3.0.1:B. Table 3.10.3.0.6. n=8/group), indicating a                     
possible decrease in fatty acid oxidation as a result of a decrease in fat intake due to diet                                 
change.
Figure {3.10.3.0.1} The effect of one week of normal fat feeding on blood glucose and                           
β­ketone concentration of DIO mice
Blood samples from mice in a fed a state were used to assess A) blood glucose concentration                               
and B) blood β­ketone concentration.




Decreased plasma concentration of leptin and resistin were detected in plasma samples from                       
FC mice compared to FF mice (Figure 3.10.3.0.2:A­B. Table 3.10.3.0.6. n=8/group). This agrees                       
with 1H MRS above showing a decreased level of adiposity in FC mice compared to FF mice                               
(Section 3.4.3).
Figure {3.10.3.0.2} The effect of one week of normal fat feeding on plasma leptin and                           
resistin concentration of DIO mice
A) Leptin; B) Resistin.




FC mice showed a significant decrease in insulin, c­peptide and GIP plasma concentration                       
compared to FF mice (Figure 3.10.3.0.3:A­C. Table 3.10.3.0.6. n=8/group). Alongside the results                     
from the IPGTT, this suggests insulin sensitivity has improved after one week of weight loss.
Figure {3.10.3.0.3} The effect of one week of normal fat feeding on plasma insulin,                         
c­peptide and GIP concentration of DIO mice
A) Insulin; B) C­peptide; C) GIP.




Similar to mice undergoing a rapid weight gain, no significant difference in glucagon or ghrelin                           
plasma concentration were detected between groups (Figure 3.10.3.0.4:A­B. Table 3.10.3.0.6.                 
n=8/group).
Figure {3.10.3.0.4} The effect of one week of normal fat feeding on plasma glucagon and                           
ghrelin concentration of DIO mice
A) Glucagon; B) Ghrelin.




A significant increase in IL­6 was observed in FC mice (Figure 3.10.3.0.5:A. Table 3.10.3.0.6.                         
p=0.0386, n=5­8/group). No change in MCP­1 or TNF­A was observed (Figure 3.10.3.0.5:B­C.                     
Table 3.10.3.0.6. MCP­1: p=0.8206; TNF­A: p=0.2809, n=5­8/group). Perhaps a rapid change in                     
weight, regardless of the direction of this change may induce a short term inflammatory                         
response.
Figure {3.10.3.0.5} The effect of one week of high fat feeding on plasma inflammatory                         
cytokine concentration of lean mice
A) Interleukin 6 (IL­6); B) monocyte chemoattractant protein 1 (MCP­1); C) tumour necrosis                       
factor­alpha (TNF­A).





Glucose 12.2 ± 0.8 8.3 ± 0.6 0.0021
β­ketone 0.4 ± 0.1 0.3 ± 0.1 0.2656
Leptin 38280 ± 4057 22870 ± 1422 0.0021
Resistin 36070 ± 5286 18460 ± 1837 0.0044
Insulin 3010 ± 255.8 2010 ± 244.9 0.0120
C­peptide 5451 ± 615.1 3714 ± 481.9 0.0392
GIP 128.4 ± 20.44 65.65 ± 6.728 0.0092
Glucagon 68.98 ± 13.61 58.65 ± 16.69 0.6423
Ghrelin 175.9 ± 16.72 156.7 ± 13.96 0.3897
IL­6 17.75 ± 3.485 32.36 ± 5.316 0.0386
MCP­1 41.78 ± 7.152 39.38 ± 7.595 0.8206
TNF­A 15.83 ± 1.822 18.79 ± 1.867 0.2809
Table {3.10.3.0.6} The effect of one week of normal fat feeding on blood and plasma                           
measurements of DIO mice
Blood samples from mice in a fed a state were used to assess blood glucose concentration and                               
blood β­ketone concentration (mmol/L). Plasma samples were used to assess metabolic                   
hormones and inflammatory cytokines (pg/mL). Data presented as mean ± sem. n=5­8/group.                     






Section 4.12.1 gives a detailed description of the effects of 6 weeks of HFD on organ mass. In                                 
summary, kidney weight was significantly increased, but this difference was lost when                     
normalised to body weight. Liver, heart and muscle showed a significant decrease as a                         
percentage of body weight compared to control mice. A trend towards a decreased in BAT as a                               
percentage of body weight was also observed.
{3.11.2} Weight gain
At the time of blood and tissue collection, body weight was significantly higher in CF mice                             
compared to CC mice (CC: 31.17 ± 0.79 g; CF: 35.88 ± 0.74 g. p=0.0016, n=7/group).
A significant increase in pancreas and kidney weight was observed in CF mice compared to CC                             
mice (Figure 3.11.2.0.1:C,D. Table 3.11.2.0.3. n=7/group). There was no significant difference                   
between groups in BAT, liver, heart and muscle weight (Figure 3.11.2.0.1:A,B,E,F. Table                     
3.11.2.0.3. n=7/group).
When normalised to body weight, there was no significant difference between the any of the                           
organs shown below as a percentage of body weight (Figure 3.11.2.0.3.A­F. Table 3.11.2.0.3.                       









Figure {3.11.2.0.2} Effect of one week of high fat feeding on organ weight as a                           
percentage of body weight of lean mice
A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle mass as                               





BAT (g) 0.1757 ± 0.0139 0.1688 ± 0.0196 0.7874
BAT (%) 0.5531 ± 0.0352 0.4732 ± 0.0485 0.4750
Liver (g) 1.358 ± 0.0820 1.468 ± 0.0494 0.2570
Liver (%) 4.273 ± 0.1661 4.184 ± 0.1972 0.7421
Pancreas (g) 0.2477 ± 0.0143 0.2857 ± 0.0053 0.0227
Pancreas (%) 0.7818 ± 0.0380 0.8120 ± 0.0152 0.4526
Kidneys (g) 0.3417 ± 0.0065 0.3855 ± 0.0151 0.0289
Kidneys (%) 1.081 ± 0.0255 1.093 ± 0.0267 0.7697
Heart (g) 0.1430 ± 0.0031 0.1448 ± 0.0042 0.7361
Heart (%) 0.4523 ± 0.0097 0.4124 ± 0.0164 0.0705
Muscle (g) 0.4634 ± 0.0279 0.4920 ± 0.0266 0.4750
Muscle (%) 1.462 ± 0.0776 1.396 ± 0.0722 0.5452
Table {3.11.2.0.3} Effect of one week of high fat feeding on organ weight in gram and as                               
a percentage of body weight of lean mice
Brown adipose tissue (BAT), liver, pancreas, kidneys, heart and muscle mass measured in                       
grams and expressed as a percentage of body weight. Yellow highlight indicates significance                       





At the time of blood and tissue collection, body weight was significantly lower in FC mice                             
compared to FF mice (FF: 41.42 ± 1.20 g; FC: 37.20 ± 1.02 g. p=0.0211, n=7/group).
A significant decrease in pancreas and kidney weight was observed in FC mice compared to FF                             
mice (Figure 3.11.3.0.1:C,D. Table 3.11.3.0.3. n=7/group). There was no significant difference                   
between groups in BAT, liver, heart and muscle weight, however a clear trend showing a                           
decrease in BAT and muscle weight was observed in FC mice compared to FF mice (Figure                             
3.11.3.0.1:A,B,E,F. Table 3.11.3.0.3. n=7/group).
When normalised to body weight, FC mice showed a significantly lower liver as a percentage of                             
body weight (Figure 3.11.3.0.2:A. Table 3.11.3.0.3. n=7/group). This indicates the size of the liver                         
is similar between the two groups, and did not reduce in size alongside body weight, unlike the                               
pancreas and kidneys (Figure 3.11.3.0.2:C,D. Table 3.11.3.0.3. n=7/group). As with organ weight                     
non­normalised, BAT as a percentage of body weight still shows a strong trend to being lower in                               
FC mice compared to FF mice (Figure 3.11.3.0.2:A. Table 3.11.3.0.3. n=7/group). There were no                         





A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle mass                             
measured in grams.




Figure {3.11.3.0.2} Effect of one week of normal fat feeding on organ weight as a                           
percentage of body weight of DIO mice
A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle mass as                               
a percentage of body weight.





BAT (g) 0.2990 ± 0.0298 0.2299 ± 0.0322 0.1479
BAT (%) 0.7222 ± 0.0710 0.6080 ± 0.0789 0.3122
Liver (g) 1.7620 ± 0.0730 1.696 ± 0.0557 0.4862
Liver (%) 4.247 ± 0.0665 4.562 ± 0.1008 0.0291
Pancreas (g) 0.3120 ± 0.0116 0.2608 ± 0.0152 0.0248
Pancreas (%) 0.7540 ± 0.0244 0.6998 ± 0.0357 0.2521
Kidneys (g) 0.4189 ± 0.0106 0.3721 ± 0.0149 0.0307
Kidneys (%) 1.013 ± 0.0186 1.001 ± 0.0318 0.7695
Heart (g) 0.1484 ± 0.0031 0.1475 ± 0.0063 0.9137
Heart (%) 0.3594 ± 0.0110 0.3970 ± 0.0156 0.0834
Muscle (g) 0.5319 ± 0.0453 0.4395 ± 0.0428 0.1670
Muscle (%) 1.2850 ± 0.1101 1.189 ± 0.1195 0.5717
Table {3.11.3.0.3} Effect of one week of normal fat feeding on organ weight in grams and                             
as a percentage of body weight of DIO mice
Brown adipose tissue (BAT), liver, pancreas, kidneys, heart and muscle mass measured in                       
grams and expressed as a percentage of body weight. Yellow highlight indicates significance                       




{3.12} The effect of rapid weight change on white adipose tissue                   
mass
{3.12.1} Before diet swap
A detailed description of the effects of 6 weeks of HFD on white adipose tissue mass can be                                 
found in Section 4.13.1. In summary, total white adipose tissue (WAT) and WAT from all depots                             
was significantly increased after 6 weeks of HFD. No significant difference in                     
internal:subcutaneous WAT ratio was observed, and not significant alterations in fat distribution                     
was observed.
{3.12.2} Weight gain
Total white adipose tissue (WAT) was extracted and subdivided into subcutaneous and internal                       
depots (sub and int WAT), Internal WAT was further subdivided into epididymal, retroperitoneal                       
and mesenteric depots (epi, ret and mes WAT respectively).
As a result of one week of high fat feeding, CF mice show an increase in the total amount of                                     
WAT (Figure 3.12.2.0.1:A. Table 3.12.2.0.2. n=7/group). When comparing each WAT depot,                   
there is a significantly higher mass of all types of WAT in CF mice compared to CC mice (Figure                                   
3.12.2.0.3:A­D. Table 3.12.2.0.2. n=7/group).
When WAT mass was normalised to body weight, total WAT mass remained significantly higher                         
in CF mice compared to CC mice (Figure 3.12.2.0.1:B. Table 3.12.2.0.2. n=7/group). However,                       
when each depot of WAT was normalised to body weight, only internal, epididymal and                         
mesenteric WAT remained significantly higher in CF mice compared to CC mice, whilst                       
subcutaneous and retroperitoneal WAT showed a trend towards an increase as a percentage of                         
body weight (Figure 3.12.2.0.4:A­D. Table 3.12.2.0.2. n=7/group). This suggests an increase in                     





A) Total white adipose tissue (WAT) in grams; B) Total WAT as a percentage of body weight.                               
Data presented as mean ± sem. n=7/group. * p<0.05. Statistical analysis was performed using                         
an unpaired t­test.
CC CF p value
Total WAT (g) 3.4680 ± 0.3343 4.900 ± 0.3427 0.0112
Total WAT (%) 11.02 ± 0.85 13.80 ± 0.65 0.0234
Sub WAT (g) 1.6270 ± 0.1672 2.241 ± 0.1837 0.0295
Sub WAT (%) 5.17 ± 0.43 6.30 ± 0.38 0.0709
Int WAT (g) 1.8410 ± 0.1760 2.6591 ± 0.1642 0.0053
Int WAT (%) 10.21 ± 0.36 8.89 ± 0.28 0.0134
Epi WAT (g) 1.0340 ± 0.1005 1.4410 ± 0.0843 0.0092
Epi WAT (%) 3.29 ± 0.27 4.07 ± 0.15 0.0248
Ret WAT (g) 0.3825 ± 0.0487 0.5389 ± 0.0346 0.0225
Ret WAT (%) 1.21 ± 0.14 1.44 ± 0.10 0.2056
Mes WAT (g) 0.4239 ± 0.0312 0.6797 ± 0.0534 0.0014
Mes WAT (%) 1.35 ± 0.07 1.91 ± 0.11 0.0013
Table {3.12.2.0.2} Effect of one week of high fat feeding on WAT of lean mice
Total WAT and depot­specific WAT. Measurements of WAT in grams and as a percentage of                           
body weight. Sub WAT: subcutaneous WAT; Int WAT: internal WAT; Epi: epididymal WAT; Ret                         
WAT: retroperitoneal WAT; Mes WAT: mesenteric WAT. Yellow highlight indicates significance                   





A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       




Figure {3.12.2.0.4} Effect of one week of high fat feeding on WAT mass as a percentage                             
of body weight of lean mice
A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. Measurements in percentage of body weight.




There was no significant difference between groups in the subcutaneous:internal WAT ratio                     
(Figure 3.12.2.0.5:A. CC: 1.138 ± 0.047; CF: 1.201 ± 0.036. p=0.3071, n=7/group).
A comparison of each depot as a percentage of total WAT shows the distribution of WAT. There                               
was no significant difference in distribution between groups, although there was a slight increase                         
in the percentage of mesenteric as a total of WAT, alongside a small decrease in the percentage                               
of subcutaneous in CF mice compared to CC mice (Figure 3.12.2.0.5:B. Table 3.13.2.0.6.                       
n=7/group).
Figure {3.12.2.0.5} Effect of one week of high fat feeding on WAT distribution of lean                           
mice
A) Internal:subcutaneous WAT ratio; B) Each WAT depot as a percentage of total WAT. Sub                           
WAT: subcutaneous WAT; Epi: epididymal WAT; Ret WAT: retroperitoneal WAT; Mes WAT:                     
mesenteric WAT. Data presented as mean ± sem. n=7/group. Significance p<0.05. Statistical                     
analysis was performed using an unpaired t­test.
CC (%) CF (%) p value
Sub WAT 46.91 ± 1.04 45.51 ± 0.76 0.2972
Epi WAT 29.86 ± 0.88 29.64 ± 0.90 0.8681
Ret WAT 10.77 ± 0.64 11.03 ± 0.23 0.7109
Mes WAT 12.46 ± 0.51 13.82 ± 0.41 0.0607
Table {3.12.2.0.6} Effect of one week of high fat feeding on WAT distribution of lean mice
Depot­specific WAT expressed as a percentage of total WAT. Sub WAT: subcutaneous WAT;                       
Epi: epididymal WAT; Ret WAT: retroperitoneal WAT; Mes WAT: mesenteric WAT. Yellow                     





As a result of one week of normal fat feeding, FC mice show a decrease in the total amount of                                     
WAT (Figure 3.12.3.0.1:A. Table 3.12.3.0.2. n=7/group). When comparing each WAT depot,                   
there is a significantly lower mass of all types of WAT in FC mice compared to FF mice (Figure                                   
3.12.3.0.3.A­D. Table 3.12.3.0.2. n=7/group).
When WAT mass was normalised to body weight, total WAT mass remained significantly lower                         
in FC mice compared to FF mice (Figure 3.12.3.0.4.B. Table 3.12.3.0.2. n=7/group). However,                       
when each depot of WAT was normalised to body weight, only subcutaneous and internal WAT                           
remained significantly lower in FC mice compared to FF mice, whilst epididymal, retroperitoneal                       
and mesenteric WAT showed a trend towards a decrease as a percentage of body weight                           
(Figure 3.12.3.0.4.A­D. Table 3.12.3.0.2. n=7/group). This suggests a decrease in subcutaneous                   
WAT is mostly responsible for the decrease in adiposity of CF mice compared to CC, and                             
subsequent decrease in body weight.
Figure {3.12.3.0.1} Effect of one week of normal fat feeding on total WAT mass of DIO                             
mice
A) Total white adipose tissue (WAT) in grams; B) Total WAT as a percentage of body weight.                               





Total WAT (g) 7.714 ± 0.5305 5.748 ± 0.2068 0.0037
Total WAT (%) 18.53 ± 0.77 15.45 ± 0.36 0.0028
Sub WAT (g) 3.463 ± 0.2647 2.437 ± 0.0975 0.0026
Sub WAT (%) 8.32 ± 0.45 6.57 ± 0.27 0.0052
Int WAT (g) 4.2510 ± 0.2792 3.3111 ± 0.1610 0.0116
Int WAT (%) 5.85 ± 0.46 7.50 ± 0.29 0.0103
Epi WAT (g) 2.359 ± 0.1084 1.912 ± 0.0893 0.0082
Epi WAT (%) 5.68 ± 0.13 5.14 ± 0.21 0.0616
Ret WAT (g) 0.8276 ± 0.0476 0.6623 ± 0.0409 0.0225
Ret WAT (%) 1.99 ± 0.06 1.77 ± 0.08 0.0547
Mes WAT (g) 1.064 ± 0.1361 0.7375 ± 0.0674 0.0454
Mes WAT (%) 2.54 ± 0.24 1.97 ± 0.15 0.0650
Table {3.12.3.0.2} Effect of one week of normal fat feeding on WAT of DIO mice
Total WAT and depot­specific WAT. Measurements of WAT in grams and as a percentage of                           
body weight. Sub WAT: subcutaneous WAT; Int WAT: internal WAT; Epi: epididymal WAT; Ret                         
WAT: retroperitoneal WAT; Mes WAT: mesenteric WAT. Yellow highlight indicates significance                   





A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       





A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. Measurements in percentage of body weight.




There was no significant difference between groups in the internal:subcutaneous WAT ratio                     
(Figure 3.12.3.0.5:A. FF: 1.237 ± 0.046; FC: 1.366 ± 0.069. p=0.1983, n=7/group)
A comparison of each depot as a percentage of total WAT shows the distribution of WAT. There                               
was no difference in distribution between groups, although there was a slight increase in the                           
percentage of epididymal as a total of WAT, alongside a small decrease in the percentage of                             
subcutaneous in FC mice compared to FF mice (Figure 3.12.3.0.5:B. Table 3.12.3.3.0.6.                     
n=7/group).
Figure {3.12.3.0.5} Effect of one week of normal fat feeding on WAT distribution of DIO                           
mice
A) Internal:subcutaneous WAT ratio; B) Each WAT depot as a percentage of total WAT. Sub                           
WAT: subcutaneous WAT; Epi: epididymal WAT; Ret WAT: retroperitoneal WAT; Mes WAT:                     
mesenteric WAT. Data presented as mean ± sem. n=7/group. Significance p<0.05. Statistical                     
analysis was performed using an unpaired t­test.
FF (%) FC (%) p value
Sub WAT 44.78 ± 0.88 42.48 ± 1.28 0.1789
Epi WAT 30.81 ± 0.72 33.30 ± 1.13 0.1026
Ret WAT 10.80 ± 0.37 11.54 ± 0.70 0.3911
Mes WAT 13.60 ± 0.91 12.68 ± 0.74 0.4433
Table {3.12.3.0.6} Effect of one week of normal fat feeding on WAT distribution of DIO                           
mice
Depot­specific WAT expressed as a percentage of total WAT. Sub WAT: subcutaneous WAT;                       
Epi: epididymal WAT; Ret WAT: retroperitoneal WAT; Mes WAT: mesenteric WAT. Yellow                     




{3.13} The effect of rapid weight change on neuronal gene                 
expression
To assess changes in neuronal function, RT­qPCR was used to assess changes in mRNA                         
expression in homeostatic and hedonic areas. These include the hypothalamus, VTA, NAc and                       
PFC. Hypothalamic genes assessed include NPY, POMC and AgRP. Changes in dopamine                     
gene expression were assessed using 6 dopamine­related genes: tyrosine hydroxylase (rate                   
limiting enzyme of dopamine production), D1 and D2 Receptors, DAT (dopamine reuptake                     
transporter), DARPP­32 (downstream intracellular marker of dopamine signalling) and COMT                 
(breakdown enzyme of dopamine. Leptin receptor and MC4R (melanocortin 4 receptor) were                     
also assessed as receptors that respond to external energy signals (leptin) and internally                       
produced satiety signals (alpha­MSH, product of POMC breakdown).
{3.13.1} Before diet swap
A detailed description of changes in neural gene expression as a result of 6 weeks of HFD can                                 
be found in Section 3.14.1. In summary, NPY mRNA expression was significantly higher in the                           
hypothalamus after 6 weeks of HFD, whilst no changes in AgRP or POMC mRNA expression                           
were observed between groups.
A significant increase in TH mRNA expression and a significant decreased in COMT mRNA                         
expression was observed in the hypothalamus of mice fed a HFD for 6 weeks. In the VTA, D1R,                                 
D2R and DAT mRNA expression was increased as a result of 6 weeks of HFD. In contrast, DAT                                 
mRNA expression was significantly reduced in the NAc and PFC in the same animals.
No significant differences in LepR mRNA expression were observed in the hypothalamus or VTA                         





With one week of weight gain, CF mice showed a significant fold decrease in the expression of                               
orexigenic neuropeptides NPY and AgRP (Figure 3.13.2.0.1:A­B. Table 3.13.2.0.4:A.               
n=5­8/group). POMC mRNA expression was significantly increased (Figure 3.13.2.0.1:C. Table                 
3.13.2.0.4:A. n=5­8/group), indicating a decreased drive to feed through decreased orexigenic                   
signalling and increased anorectic signalling.








An assessment of dopaminergic gene expression in the hypothalamus showed a significant                     
increase in DAT expression in CF mice compared to CC mice (Figure 3.13.2.0.2:A. Table                         
3.13.2.0.4:A. n=5­8/group). This indicates an increased reuptake of dopamine from the synapse,                     
which could reduce dopamine­induced neuronal activity. No other dopaminergic genes showed a                     
significant fold change in mRNA expression, although a slight decrease in TH was observed                         
(Figure 3.13.2.0.2:A. Table 3.13.2.0.4:A. n=5­8/group).
None of the reward areas assessed showed any significant change in neuronal activity between                         
groups (Figure 3.13.2.0.2:B­D. Table 3.13.2.0.4:B, 3.13.2.0.5:A­B. n=5­8/group). This indicates               
dopamine signalling may not be affected by short term weight gain induced by one week of high                               




Figure {3.13.2.0.2} The effect of one week of high fat feeding on dopamine­related gene                         
expression in the hypothalamus and reward areas of lean mice
A) Hypothalamus; B) VTA; C) NAc; D) PFC.
RT­qPCR was used to assess changes in dopamine­related gene expression. TH: tyrosine                     
hydroxylase; D1R: dopamine receptor D1A; D2R: dopamine receptor 2; DAT: dopamine active                     
transporter; DARPP: dopamine and cAMP­regulated neuronal phosphoprotein; COMT:             
Catechol­O­methyltransferase.




Both leptin receptors and MC4R gene expression were significantly increased in the                     
hypothalamus in CF mice compared to CC mice (Figure 3.13.2.0.3:A. Table 3.13.2.0.4:A.                     
n=5­8/group). This indicates the hypothalamus may be more sensitive to satiety signal, both                       
external and internal to the brain, which may lead to the changes in neuropeptide expression in                             
the hypothalamus seen above and lead to a decreased in feeding behaviour.
No difference in leptin receptor mRNA expression was observed between groups in the VTA                         
(Figure 3.13.2.0.3:B. Table 3.13.2.0.4:B. n=5­8/group).
Figure {3.13.2.0.3} The effect of one week of high fat feeding on leptin receptor gene                           
expression in the hypothalamus and VTA, and MC4R gene expression in the                     
hypothalamus of lean mice
A) Hypothalamus; B) VTA.
RT­qPCR was used to assess changes in leptin receptor (LepR) and melanocortin 4 receptor                         
(MC4R) gene expression.




Hypothalamus CC CF p value
NPY 1.03 ± 0.12  0.63 ± 0.05 0.0059
AgRP 1.04 ± 0.15 0.70 ± 0.068 0.0455
POMC 1.03 ± 0.11 2.17 ± 0.24 0.0022
TH 1.03 ± 0.12 0.84 ± 0.04 0.1165
D1R 1.01 ± 0.05 1.07 ± 0.08 0.5747
D2R 1.01 ± 0.04 1.04 ± 0.06 0.7058
DAT 1.00 ± 0.17 1.57 ± 0.15 0.0314
DARPP­32 1.02 ± 0.08 0.99 ± 0.07 0.7399
COMT 1.00 ± 0.02 1.00 ± 0.04 0.9988
LepR 1.01 ± 0.06 1.40 ± 0.08 0.0034
MC4R 1.00 ± 0.04 1.35 ± 0.12 0.0224
VTA CC CF p value
TH 1.05 ± 0.13 0.96 ± 0.16 0.7052
D1R 1.02 ± 0.08 1.13 ± 0.14 0.5189
D2R 1.06 ± 0.13 1.26 ± 0.16 0.3727
DAT 1.04 ± 0.15 0.96 ± 0.22 0.8232
DARPP­32 1.04 ± 0.13 1.03 ± 0.10 0.9866
COMT 1.00 ± 0.02 0.96 ± 0.03 0.3589
LepR 1.03 ± 0.10 0.89 ± 0.07 0.2633
Table {3.13.2.0.4} The effect of one week of high fat feeding on gene expression in the                             
hypothalamus and VTA of lean mice
A) Hypothalamus; B) VTA. NPY: Neuropeptide Y; AgRP: Agouti­related peptide; POMC:                   
Pro­opiomelanocortin; TH: tyrosine hydroxylase; D1R: dopamine receptor D1A; D2R: dopamine                 
receptor 2; DAT: dopamine active transporter; DARPP: dopamine and cAMP­regulated neuronal                   
phosphoprotein; COMT: Catechol­O­methyltransferase; LepR: leptin receptor; MC4R:           




NAc CC CF p value
D1R 1.01 ± 0.04 1.12 ± 0.07 0.1751
D2R 1.01 ± 0.06 1.21 ± 0.14 0.2563
DAT 1.04 ± 0.11 0.89 ± 0.17 0.4773
DARPP­32 1.01 ± 0.06 1.22 ± 0.14 0.2002
COMT 1.00 ± 0.03 1.04 ± 0.05 0.5540
PFC CC CF p value
D1R 1.01 ± 0.06 0.87 ± 0.07 0.1290
D2R 1.01 ± 0.05 0.90 ± 0.06 0.1749
DAT 1.07 ± 0.19 1.14 ± 0.21 0.8359
DARPP­32 1.01 ± 0.05 0.96 ± 0.09 0.6911
COMT 1.03 ± 0.03 1.04 ± 0.07 0.6439
Table {3.13.2.0.5} The effect of one week of high fat feeding on gene expression in the                             
NAc and PFC of lean mice
A) NAc; B) PFC.
D1R: dopamine receptor D1A; D2R: dopamine receptor 2; DAT: dopamine active transporter;                     
DARPP: dopamine and cAMP­regulated neuronal phosphoprotein; COMT:           
Catechol­O­methyltransferase.
Measurements in fold change (arbitrary units). Data presented as mean ± sem, n=5­8/group.                       





With one week of weight loss, FC mice showed a significant fold increase in the expression of                               
orexigenic neuropeptides NPY and AgRP (Figure 3.13.3.0.1:A­B. Table 3.13.3.0.4.A.               
n=5­8/group). No significant decrease in POMC mRNA expression was detected, indicating an                     
increased orexigenic drive with no concurrent decrease in anorectic response (Figure                   
3.13.3.0.1:C. Table 3.13.3.0.4:A. n=5­8/group).
Figure {3.13.3.0.1} The effect of one week of normal fat feeding on neuronal gene                         
expression in the hypothalamus of DIO mice
A) NPY; B) AgRP; C) POMC
RT­qPCR was used to assess hypothalamic neuropeptide expression. Measurements in fold                   




However, when assessing dopaminergic marker mRNA expression in the hypothalamus, none                   
of the markers assessed showed any significant change (Figure 3.13.3.0.2:A. Table                   
3.13.3.0.4:A. n=5­8/group). This may indicate dopamine has no direct effect on the changes in                         
hypothalamic gene expression observed above.
When assessing dopaminergic marker expression in the VTA however, a significant decrease in                       
TH expression was observed in FC mice compared to FF mice (Figure 3.13.3.0.2:B. Table                         
3.13.3.0.4:B. n=5­8/group), indicating a possible reduction in dopamine production. This in turn                     
could lead to less dopamine release to other areas VTA neurons project to, including the                           
hypothalamus, NAc and PFC. D2 receptor mRNA expression was also significantly decreased in                       
the VTA of FC mice compared to FF mice (Figure 3.13.3.0.2:B. Table 3.13.3.0.4:B.                       
n=5­8/group), indicating a decreased sensitivity of VTA neurons to dopamine. A trend showing                       
decreased DAT mRNA was observed in FC mice compared to FF mice.
In the NAc, a significant fold increase in DAT mRNA expression was observed in FC mice                             
(Figure 3.13.3.0.2:C. Table 3.13.3.0.5:A. n=5­8/group). An increase in DAT suggests an                   
increased rate of dopamine removal from the synaptic cleft which would reduce the level of                           
neuronal firing induced by dopamine. However, as the level of TH production in the VTA would                             
lead to a decrease in dopamine production, this result seems a little contradictory.
A significant decrease in COMT mRNA expression was observed in the PFC of FC mice                           
compared to FF mice (Figure 3.13.3.0.2:D. Table 3.13.3.0.5:B. n=5­8/group). This shows a                     
decrease in an enzyme that breaks down dopamine, therefore dopamine will be in the synapse                           
for longer However, a trend increasing DAT mRNA expression contradicts this suggestion and                       
matches the significant increase in DAT mRNA expression in the NAc, again possibly indicating                         




Figure {3.13.3.0.2} The effect of one week of normal fat feeding on dopamine­related                       
gene expression in the hypothalamus and reward areas of DIO mice
A) Hypothalamus; B) VTA; C) NAc; D) PFC.
RT­qPCR was used to assess changes in dopamine­related gene expression. TH: tyrosine                     
hydroxylase; D1R: dopamine receptor D1A; D2R: dopamine receptor 2; DAT: dopamine active                     
transporter; DARPP: dopamine and cAMP­regulated neuronal phosphoprotein; COMT:             
Catechol­O­methyltransferase.




There was no significant difference in leptin receptor or MC4R mRNA expression in the                         
hypothalamus between groups, although a trend showing a decrease in MC4R was observed in                         
FC mice compared to FF mice (Figure 3.13.3.0.3:A. Table 3.13.3.0.4:A. n=5­8/group).
Leptin receptor mRNA expression was significantly reduced in the VTA of FC mice compared to                           
FF mice, indicating VTA neurons may be less sensitive to leptin after weight loss (Figure                           
3.13.3.0.3:B. Table 3.13.3.0.4:B. n=5­8/group).
Figure {3.13.3.0.3} The effect of one week of normal fat feeding on leptin receptor gene                           
expression in the hypothalamus and VTA, and MC4R gene expression in the                     
hypothalamus of lean mice
A) Hypothalamus; B) VTA.
RT­qPCR was used to assess changes in leptin receptor (LepR) and melanocortin 4 receptor                         
(MC4R) gene expression.




Hypothalamus FF FC p value
NPY 1.00 ± 0.12 2.14 ± 0.24 0.0014
AgRP 1.07 ± 0.21 6.04 ± 0.30 <0.0001
POMC 1.05 ± 0.15 1.20 ± 0.16 0.5059
TH 1.06 ± 0.17 0.84 ± 0.05 0.2081
D1R 1.02 ± 0.07 0.98 ± 0.05 0.7308
D2R 1.01 ± 0.06 0.90 ± 0.05 0.1569
DAT 1.02 ± 0.12 1.02 ± 0.23 0.9846
DARPP­32 1.01 ± 0.05 1.03 ± 0.07 0.7925
COMT 1.00 ± 0.03 0.96 ± 0.02 0.2079
LepR 1.03 ± 0.09 0.97 ± 0.10 0.6940
MC4R 1.07 ± 0.15 0.93 ± 0.03 0.3606
VTA FF FC p value
TH 0.96 ± 0.10 0.68 ± 0.08 0.0487
D1R 1.01 ± 0.07 0.99 ± 0.10 0.8711
D2R 0.99 ± 0.10 0.65 ± 0.09 0.0240
DAT 1.12 ± 0.12 0.89 ± 0.15 0.2511
DARPP­32 1.01 ± 0.05 1.19 ± 0.07 0.0791
COMT 1.00 ± 0.03 1.02 ± 0.01 0.6540
LepR 1.01 ± 0.07 0.77 ± 0.063 0.0289
Table {3.13.3.0.4} The effect of one week of normal fat feeding on gene expression in                           
the hypothalamus and VTA of DIO mice
A) Hypothalamus; B) VTA. NPY: Neuropeptide Y; AgRP: Agouti­related peptide; POMC:                   
Pro­opiomelanocortin; TH: tyrosine hydroxylase; D1R: dopamine receptor D1A; D2R: dopamine                 
receptor 2; DAT: dopamine active transporter; DARPP: dopamine and cAMP­regulated neuronal                   
phosphoprotein; COMT: Catechol­O­methyltransferase; LepR: leptin receptor; MC4R:           




NAc FF FC p value
D1R 1.01 ± 0.06 1.10 ± 0.07 0.3709
D2R 1.02 ± 0.08 1.12 ± 0.06 0.3405
DAT 1.03 ± 0.10 1.48 ± 0.15 0.0269
DARPP­32 1.00 ± 0.03 1.14 ±  0.11 0.2433
COMT 1.01 ± 0.04 1.04 ± 0.04 0.5973
PFC FF FC p value
D1R 1.01 ± 0.06 1.03 ± 0.05 0.8530
D2R 1.02 ± 0.09 0.92 ± 0.12 0.5222
DAT 1.05 ± 0.17 1.51 ±  0.26 0.2014
DARPP­32 1.02 ± 0.08 1.04 ± 0.08 0.8301
COMT 1.00 ± 0.04 0.87 ± 0.03 0.0203
Table {3.13.3.0.5} The effect of one week of normal fat feeding on gene expression in                           
the NAc and PFC of DIO mice
A) NAc; B) PFC.
D1R: dopamine receptor D1A; D2R: dopamine receptor 2; DAT: dopamine active transporter;                     
DARPP: dopamine and cAMP­regulated neuronal phosphoprotein; COMT:           
Catechol­O­methyltransferase.
Measurements in fold change (arbitrary units). Data presented as mean ± sem, n=5­8/group.                       








The protocol for this experiment is described in Section 2.2. C57Bl6 male mice aged 8­10 weeks                             
of age were fed a control diet (10% kcal fat) or a high fat diet (60% kcal fat) for 6 weeks (groups                                         
C or Fa respectively).
After one week of high fat feeding, Fa mice were significantly heavier compared to C mice and                               
persisted for the entire 6 week feeding period (Figure 4.1.1.0.1. Table 4.1.3.0.2. Week 1­6:                         
p<0.001, n=44/group).
Figure {4.1.1.0.1} The effect of 6 weeks of high fat feeding on body weight
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet (C) or HFD (Fa) for 6 weeks.                                     




A comparison of weekly body weight change also shows Fa mice gained significantly more                         
weight every week during the 6 week feeding period compared to C mice (Figure 4.1.1.0.2:A                           
Table 4.1.3.0.6. p<0.001, n=44/group). When comparing percentage weight change, Fa mice                   
gained significantly more weight as a percentage of weight after the first week of feeding, and 3rd                               
and 4th week of feeding (Figure 4.1.1.0.2:B. Table 4.1.3.0.7. p<0.001, n=44/group).
Figure {4.1.1.0.2} The effect of 6 weeks of high fat feeding on weekly body weight                           
change
A) Body weight change in grams (g); B) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet (C) or HFD (Fa) for 6 weeks.                                     





The protocol for this experiment is described in Section 2.2. C57Bl6 male mice aged 8­10 weeks                             
of age were fed a control diet (10% kcal fat) or a high fat diet (60% kcal fat) for 6 weeks. Half of                                           
the mice fed the control diet continued to feed on the control diet (CC group), whilst the other half                                   
of the mice were swapped to the high fat diet (CFa group). Similarly, half the mice fed the high                                   
fat diet continued to feed on the high fat diet (FaFa group), whilst the other half of the mice were                                     
swapped to the normal fat control diet (FaC).
Comparing the body weight of the two control groups, CC and FaFa mice, FaFa mice were                             
significantly heavier from week 2 of feeding (Figure 4.1.2.0.1:A. Table 4.1.3.0.2. p<0.001,                     
n=28/group). FaFa mice continued to be significantly heavier for the remainder of the 12 week                           
experiment.
Mice swapped to a high fat diet for 6 weeks after 6 weeks of control diet feeding (CFa group)                                   
were significantly heavier after one week of high fat feeding compared to CC mice (Figure                           
4.1.2.0.1:B. Table 4.1.3.0.2. p<0.001, n=28/group). CFa mice remained significantly heavier                 
compared to CC mice for the remainder of the 12 week period.
A comparison of body weight between CFa mice to FaFa mice shows control fed CFa mice a                               
significantly lighter from week 2 to 6 compared to fat fed FaFa mice (Figure 4.1.3.0.1:D. Table                             
4.1.3.0.2. p<0.01­0.001, n=28/group). After swapping to the high fat diet at 6 weeks of the feeding                             
experiment, CFa mice were still significantly lighter than FaFa mice until week 10, 4 weeks after                             
swapping to the high fat diet. This contrasts slightly when comparing CFa mice to CC mice,                             
where only one week of high fat feeding was needed to significantly increase body weight in                             
these mice.
Comparing FaC mice to CC mice, the first 6 weeks of high fat feeding led FaC mice to weigh                                   
significantly more than CC mice from week 2 to 6 (Figure 4.1.3.0.1:C. Table 4.1.3.0.2. Week 2:                             
p<0.05; week 3­6: p<0.001, n=28/group). When swapping to the control diet from the high fat                           
diet, FaC were no longer significantly heavier compared to CC mice after two weeks (Figure                           




A comparison between the body weight of FaC and FaFa mice show after the first 6 weeks of                                 
comparable body weight, a significant decrease in body weight of FaC mice compared to FaFa                           
mice was observed one week after swapping to the control fat diet (Figure 4.1.3.0.1:E. Table                           
4.1.3.0.2. p<0.001, n=28/group). FaC mice were significantly lighter compared to FaFa mice until                       
week 12. This slightly differs to the extra week needed to reduce body weight in FaC mice to the                                   





C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 6 weeks (CC group) whilst the other                                   
half were fed a high fat diet for 6 weeks (CFa group). Similarly, half the mice continued to feed on                                     
the HFD for 6 weeks (FaFa group) whilst the other half were fed a control diet for 6 weeks (FaC                                     
group). Dotted lines represent when the diets were swapped, if applicable. Data presented as                         




A comparison of weekly body weight change showed FaFa mice gained a significant amount of                           
weight compared to CC mice from week 1 to 8, except for week 6 (Figure 4.1.2.0.2:A. Table                               
4.1.3.0.6. p<0.01­0.001, n=28/group). Similarly, when normalising weight gain to body weight,                   
FaFa mice had a higher percentage weight gain compared to CC mice from week 1 to 8, except                                 
for week 6 (Figure 4.1.2.0.2:B. Table 4.1.3.0.7. p<0.05, p<0.001, n=28/group), showing a                     
decrease in rate of body weight increase after longer term high fat feeding.
Figure {4.1.2.0.2} The effect of 12 weeks of high fat feeding on weekly body weight                           
change
A) Body weight change in grams (g); B) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem,                           




From week 1 to 6, weight gain in CFa mice was comparable to CC mice, both in terms of weight                                     
change in grams and percentage change (Figure 4.1.2.0.3:A. Table 4.1.3.0.6. n=28/group).                   
When swapped to the high fat diet, CFa mice gained a significant amount of weight compared to                               
CC mice each week after changing diet (Figure 4.1.2.0.3:A. Table 4.1.3.0.6. p<0.01­0.001,                     
n=28/group). When weight change was normalised to body weight, percentage weight increase                     
was also significantly higher in CFa mice from week 7 to 9 of feeding, 1 to 3 weeks after                                   
swapping to a high fat diet (Figure 4.1.2.0.3:B. Table 4.1.3.0.7. p<0.001, n=28). Percentage                       
increase was not significant week 10 and 12 weeks after feeding, but was significantly higher at                             
week 11 (p<0.05, n=28), showing a decrease in the rate of increase 4 weeks after swapping to                               
the high fat diet.
When comparing body weight change, weight gain in FaFa mice is significantly higher compared                         
to CFa mice during the first 6 weeks, similar to the comparison made between the two control                               
groups, CC and FaFa (Figure 4.1.2.0.3:C. Table 4.1.3.0.6. p<0.01­0.001, n=28). However, when                     
swapped to the high fat diet, CFa mice showed a significant increase in the amount of body                               
weight gained from week 7 to 12, except for week 11, with the greatest increase in body weight                                 
gained within the first week of swapping to a high fat diet (Figure 4.1.2.0.3:C. Table 4.1.3.0.6.                             
p<0.01­0.001, n=28/group). After normalising weight change to body weight, the percentage                   
weight gain in CFa mice was only significantly higher compared to FaFa mice during the first 3                               
weeks after swapping to a high fat diet, again indicating the first 3 weeks being critical to the                                 






C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. Half of                                     
the mice fed a control diet continued feeding on the control diet (CC group), whilst the other half                                 
were swapped to a HFD (CFa group) for 6 weeks, resulting in maintained weight gain. Similarly,                             
half of the mice fed a HFD continued to feed on the HFD (FaFa group).
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




Similar to the comparison between CC and FaFa mice, FaC gained significantly more weight                         
weekly between week 1 and 5 due to high fat feeding (Figure 4.1.2.0.4:A. Table 4.1.3.0.6.                           
p<0.01­0.001, n=28/group). Week 7 and 8, 1 and 2 weeks after swapping to the control diet, FaC                               
mice showed a significant decrease in body weight gain compared to CC mice, showing                         
significant weight loss (Figure 4.1.2.0.4:A. Table 4.1.3.0.6. p<0.001, n=28/group). This was also                     
true when comparing percentage weight change (Figure 4.1.2.0.4:B. Table 4.1.3.0.7. p<0.001,                   
n=28/group). There was no additional loss in body weight from week 9 of feeding, indicating                           
weight loss in the first two weeks of swapping to a control diet were sufficient to reduce and                                 
maintain this group to a control level of body weight and weight change seen in CC mice.
A comparison of body weight change shows body weight change between FaC and FaFa mice                           
is similar for the first 6 weeks when both feeding on a high fat diet (Figure 4.1.2.0.4:C. Table                                 
4.1.3.0.6). After swapping to a control diet, there was a significant decrease in body weight                           
change week 7 to 9 in FaC mice compared to FaFa mice (Figure 4.1.2.0.4:C. Table 4.1.3.0.6.                             
p<0.001, n=28/group). As a percentage of weight change, this was only significantly difference                       






C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. Half of                                     
the mice fed a HFD diet continued feeding on the HFD diet (FaFa group), whilst the other half                                 
were swapped to a control diet (FCa group) for 6 weeks, resulting in maintained weight loss.                             
Similarly, half of the mice fed a control diet continued to feed on the control diet (CC group).
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           





The protocol for this experiment is described in Section 2.2. C57Bl6 male mice aged 8­10 weeks                             
of age were fed a control diet (10% kcal fat) or a high fat diet (HFD, 60% kcal fat) for 6 weeks.                                         
Half of the mice fed the control diet continued to feed on the control diet (CCC group) for another                                   
12 weeks, whilst the other half of the mice were swapped to the HFD (CFaC group) for 6 weeks.                                   
After 6 weeks of HFD, CFaC mice were swapped back to the control diet for another 6 weeks.                                 
Similarly, half the mice fed the HFD for 6 weeks continued to feed on the HFD for a further 12                                     
weeks (FaFaFa group), whilst the other half of the mice were swapped to the normal fat control                               
diet for 6 weeks (FaCFa). After 6 weeks of control diet feeding, FaCFa mice were swapped back                               
to the HFD for 6 weeks. The total feeding time for these mice was 18 weeks.
Comparing the body weight of the two control groups, CCC and FaFaFa mice, FaFaFa mice                           
were significantly heavier from week 2 of feeding (Figure 4.1.3.0.1:A. Table 4.1.3.0.2. p<0.001,                       
n=28/group). FaFaFa mice continued to be significantly heavier for the remainder of the 18 week                           
experiment.
CFaC mice had similar body weights compared to CCC mice for the first 6 weeks of control diet                                 
feeding (Figure 4.1.3.0.1:B. Table 4.1.3.0.2. n=28/group). When swapped to the HFD at week 6,                         
CFaC were significantly heavier compared to CCC mice from week 7 to week 16, 4 weeks after                               
swapping back to the control diet at week 12 (Figure 4.1.3.0.1:B. Table 4.1.3.0.2. Week 7­15:                           
p>0.001; week 16: p<0.01, n=28/group). Body weight was no longer significantly different from                       
week 17 to 18, 5 to 6 weeks after swapping back to the control diet.
A comparison of body weight between CFaC mice to FaFaFa mice shows control fed CFaC                           
mice were significantly lighter from week 2 to 6 compared to FaFaFa mice (Figure 4.1.3.0.1:D.                           
Table 4.1.3.0.2. p<0.001, n=28/group). After swapping to a HFD at 6 weeks of the feeding                           
experiment, CFaC mice were still significantly lighter than FaFaFa mice until week 12, 6 weeks                           
after swapping to the HFD (Figure 4.1.3.0.1:D. Table 4.1.3.0.2. Week 7­10: p<0.001; week 11:                         
p<0.05, n=28/group). One week after swapping back to the control diet at week 12, CFaC mice                             




Weight cycled mice who finished on a period of weight gain, FaCFa, were significantly heavier                           
after one week of HFD compared to CCC mice, both at the start of the experiment and after the                                   
second swap at week 12 (Figure 4.1.3.0.1:C. Table 4.1.3.0.2. Week 1: p<0.05; Week 13:                         
p<0.001, n=28/group). FaCFa mice remained significantly heavier compared to CCC mice after                     
swapping to the control diet for a further 3 weeks, indicating weight gain, both initial and                             
repeated, is more rapid compared to weight loss.
Lastly, a comparison between the body weight of FaCFa and FaFaFa mice show after the first 6                               
weeks of comparable body weight, a significant decrease in body weight of FaCFa mice                         
compared to FaFaFa mice was observed one week after swapping to the control fat diet (Figure                             
4.1.3.0.1:E. Table 4.1.3.0.2. p<0.001, n=28/group). FaC mice were significantly lighter compared                   
to FaFaFa mice until week 12. After swapping back to the HFD at week 12, FaCFa mice                               





C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Dotted lines represent when the diets were swapped, if applicable.                           




Week CC (g) CFa (g) FaC (g) FaFa (g)
0 24.4 ± 0.4 24.7 ± 0.4 24.8 ± 0.4 24.8 ± 0.4
1 26.3 ± 0.4 26.6 ± 0.3 29.1 ± 0.4 28.8 ± 0.4
2 27.4 ± 0.4 27.8 ± 0.3 31.9 ± 0.5 31.3 ± 0.5
3 29.2 ± 0.4 29.3 ± 0.4 34.9 ± 0.6 34.2 ± 0.6
4 30.2 ± 0.4 30.2 ± 0.4 37.5 ± 0.6 37.0 ± 0.6
5 31.2 ± 0.5 31.4 ± 0.4 40.1 ± 0.7 39.5 ± 0.6
6 31.9 ± 0.6 32.0 ± 0.5 42.1 ± 0.7 41.8 ± 0.6
7 32.5 ± 0.6 36.1 ± 0.6 38.7 ± 0.7 43.7 ± 0.6
8 33.7 ± 0.6 38.8 ± 0.7 37.2 ± 0.7 45.0 ± 0.5
9 34.2 ± 0.7 41.3 ± 0.8 36.8 ± 0.6 46.1 ± 0.4
10 34.4 ± 0.7 42.7 ± 0.8 36.7 ± 0.6 46.5 ± 0.4
11 34.4 ± 0.7 44.2 ± 0.8 36.2 ± 0.6 47.0 ± 0.3
12 35.5 ± 0.7 45.5 ± 0.8 37.0 ± 0.6 47.5 ± 0.3
13 35.5 ± 0.7 42.1 ± 0.8 42.0 ± 0.6 47.5 ± 0.4
14 35.9 ± 0.7 41.0 ± 0.7 44.7 ± 0.6 47.9 ± 0.4
15 36.6 ± 0.8 40.3 ± 0.7 46.5 ± 0.5 48.1 ± 0.4
16 37.0 ± 0.8 40.1 ± 0.7 47.7 ± 0.5 48.4 ± 0.4
17 37.2 ± 0.8 39.4 ± 0.8 48.5 ± 0.6 48.6 ± 0.4
18 37.4 ± 0.9 39.2 ± 0.8 49.2 ± 0.6 48.9 ± 0.4
Table {4.1.3.0.2} The effect of a single weight cycle on body weight
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             




Comparing weekly body weight change, FaFaFa mice gained a significant amount of weight                       
compared to CCC mice from week 1 to 7 (Figure 4.1.3.0.3:A. Table 4.1.3.0.6. p<0.001,                         
n=28/group). From week 8, weight change was similar between both groups. Similarly, when                       
normalising weight gain to body weight, FaFaFa mice had a higher percentage weight gain                         
compared to CC mice from week 1 to 7 (Figure 4.1.3.0.3:B. Table 4.1.3.0.7. Week 1­2, 4­6:                             
p<0.001; week 3, 7: p<0.01, n=28/group). Again, from week 8 to week 18, percentage body                           
weight change was comparable between CCC and FaFaFa mice.
Figure {4.1.3.0.3} The effect of 18 weeks of high fat feeding on weekly body weight                           
change
A) Body weight change in grams (g); B) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 18 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem,                           




Body weight change was comparable between CCC and CFaC mice for the first 6 weeks of                             
control diet feeding. After swapping to the HFD at week 6, CFaC mice gained significantly more                             
weight from week 7 to 11, 1 and 5 weeks after swapping to the HFD (Figure 4.1.3.0.4:A. Table                                 
4.1.3.0.6. Week 7­11: p<0.001, n=28/group). Percentage weight change was also significantly                   
higher in CFaC mice compared to CCC mice from week 7 to 11 (Figure 4.1.3.0.4:B. Table                             
4.1.3.0.7. Week 7­9: p<0.001; week 10: p<0.01; week 11: p<0.05, n=28/group). After swapping                       
back to the control diet at week 12, CFaC mice lost a significant amount of weight compared to                                 
CCC mice from week 13 to 17 (excluding 16), 1 to 5 weeks after swapping back to the control                                   
diet (Figure 4.1.3.0.4:A. Table 4.1.3.0.6. Week 13­15: p<0.001; week 17: p<0.05, n=28/group).                     
Percentage weight change was only significantly decreased between week 13 to 15, 1 to 3                           
weeks of control diet feeding (Figure 4.1.3.0.4:B. Table 4.1.3.0.7. p<0.001, n=28/group).
When comparing body weight change, weight gain in FaFaFa mice was significantly higher                       
compared to CFaC mice for the first 6 weeks (Figure 4.1.3.0.4:C. Table 4.1.3.0.6. p<0.001,                         
n=28/group). However, when swapped to the HFD, CFaC mice showed a significant increase in                         
the amount of body weight gained compared to FaFaFa mice from week 7 to 12 with the                               
greatest increase in body weight gained within the first week of swapping to a HFD (Figure                             
4.1.3.0.4:C. Table 4.1.3.0.6. Week: 7­11: p<0.001; week 12: p<0.05, n=28/group). After                   
normalising weight change to body weight, the percentage weight gain in CFaC mice was only                           
significantly higher compared to FaFaFa mice from week 7 to 11, 1 to 5 weeks after swapping to                                 
the HFD (Figure 4.1.3.0.4:D. Table 4.1.3.0.7. Week 7­9: p<0.001; week 10: p<0.01; week 11:                         
p<0.05, n=28/group). When CFaC mice were swapped back to the control diet at week 12, they                             
lost a significant amount of weight compared to FaFaFa mice from week 13 to 17 (excluding                             
week 16), 1 to 5 weeks after swapping back to the control diet (Figure 4.1.3.0.4:D. Table                             
4.1.3.0.7. Week 13­14: p<0.001; week 15, 17: p<0.01, n=28/group). Percentage weight change                     




Figure {4.1.3.0.4} The effect of a single weight cycle ending with weight loss on weekly                           
body weight change
A+C) Body weight change in grams (g); B+D) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a high fat diet for 6 weeks, before swapping back to the control diet for 6                                     
weeks (CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks                             
(FaFaFa group). Dotted lines represent when the diets were swapped, if applicable. Data                       




From week 1 to 6, weight gain in FaCFa mice was significantly higher compared to CCC mice,                               
both in terms of weight change in grams and percentage change (Figure 4.1.3.0.5:A. Table                         
4.1.3.0.6. p<0.01­0.001, n=28/group). When swapped to the control diet at 6 weeks, FaCFa                       
mice lost a significant amount of weight compared to CCC mice from week 7 to 11 (excluding                               
week 10), 1 to 5 weeks after changing diet (Figure 4.1.3.0.5::A. Table 4.1.3.0.6. Week 7­9:                           
p<0.001; week 11: p<0.01, n=28/group). When weight change was normalised to body weight,                       
percentage weight decrease was also significantly lower in FaCFa mice from week 7 to 11                           
(excluding week 10), 1 to 5 weeks after swapping to a control diet (Figure 4.1.3.0.5:B. Table                             
4.1.3.0.7. Week 7­8: p<0.001; week 9: p<0.01: week 11: p<0.05, n=28/group). After swapping                       
back to the HFD at week 12, FaCFa mice once again gained a significant amount of weight                               
compared to CCC mice from week 13 to 16, 1 to 4 weeks after swapping back to a HFD (Figure                                     
4.1.3.0.5:A. Table 4.1.3.0.6. Week 13­15: p<0.001; week 16: p<0.05, n=28/group). Percentage                   
increase was significantly increased from week 13­15 in FaCFa mice compared to CCC mice                         
(Figure 4.1.3.0.5:B. Table 4.1.3.0.7. Week 13­14: p<0.001; week 15: p<0.05, n=28/group). From                     
week 16 to 18, percentage change in body weight was comparable between the two groups.
A comparison of body weight change shows both FaCFa and FaFaFa mice have a similar                           
change in body weight for the first 6 weeks when both feeding on a high fat diet (Figure                                 
4.1.3.0.5:C. Table 4.1.3.0.6. n=28/group). After swapping to a control diet, there was a significant                         
decrease in body weight from week 7 to 11 (excluding week 10) in FaCFa mice compared to                               
FaFaFa mice, 1 to 5 weeks after swapping to the control diet (Figure 4.1.3.0.5:C Table 4.1.3.0.6.                             
Week 7­9: p<0.001; week 11: p<0.01, n=28/group). Percentage of weight change was also                       
significantly decreased in FaCFa mice compared to FaFaFa mice from week 7 to 11 (excluding                           
week 10), 1 to 5 weeks after swapping to the control diet (Figure 4.1.3.0.5:D Table 4.1.3.0.7.                             
Week 7­9: p<0.001; week 11: p<0.05, n=28/group). Similar to the comparison to CCC mice,                         
FaCFa mice had a significant increase in weight gain from week 13 to 16 compared to FaFaFa                               
mice, 1 to 4 weeks after swapping back to the HFD at week 12 (Figure 4.1.3.0.5:C. Table                               
4.1.3.0.6. Week 13­15: p<0.001; week 16: p<0.01, n=28/group). Percentage weight change was                     
also significant increased in FaCFa mice compared to FaFaFa mice from week 13 to 15, 1 to 3                                 




Figure {4.1.3.0.5} The effect of a single weight cycle ending with weight gain on weekly                           
body weight change
A+C) Body weight change in grams (g); B+D) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the HFD diet for 12 weeks (FaFaFa group) whilst the                                 
other half were fed a control for 6 weeks, before swapping back to the HFD for 6 weeks (FaCFa                                   
group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa group).                             
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




Week CC (g) CFa (g) FaC (g) FaFa (g)
1 1.9 ± 0.2 1.85 ± 0.17 4.29 ± 0.25 3.95 ± 0.26
2 1.1 ± 0.1 1.20 ± 0.09 2.78 ± 0.23 2.51 ± 0.20
3 1.8 ± 0.2 1.54 ± 0.18 2.79 ± 0.16 2.92 ± 0.14
4 1.1 ± 0.2 0.90 ± 0.14 2.78 ± 0.16 2.86 ± 0.13
5 1.0 ± 0.2 1.24 ± 0.17 2.61 ± 0.15 2.47 ± 0.15
6 0.7 ± 0.2 0.57 ± 0.17 1.98 ± 0.11 2.27 ± 0.10
7 0.6 ± 0.2 4.11 ± 0.29 ­3.41 ± 0.22 1.93 ± 0.13
8 1.2 ± 0.2 2.74 ± 0.16 ­1.46 ± 0.24 1.29 ± 0.17
9 0.6 ± 0.1 2.48 ± 0.20 ­0.43 ± 0.10 1.11 ± 0.12
10 0.2 ± 0.1 1.34 ± 0.19 ­0.08 ± 0.13 0.37 ± 0.12
11 0.4 ± 0.2 1.56 ± 0.17 ­0.45 ± 0.27 0.48 ± 0.10
12 0.7 ± 0.2 1.28 ± 0.12 0.72 ± 0.24 0.52 ± 0.08
13 0.0 ± 0.2 ­3.42 ± 0.22 5.00 ± 0.23 0.01 ± 0.06
14 0.5 ± 0.2 ­1.13 ± 0.19 2.73 ± 0.23 0.41 ± 0.09
15 0.7 ± 0.2 ­0.71 ± 0.12 1.85 ± 0.17 0.16 ± 0.08
16 0.4 ± 0.1 ­0.20 ± 0.17 1.14 ± 0.17 0.29 ± 0.08
17 0.1 ± 0.1 ­0.68 ± 0.15 0.82 ± 0.14 0.22 ± 0.05
18 0.3 ± 0.1 ­0.15 ± 0.21 0.74 ± 0.13 0.32 ± 0.05
Table {4.1.3.0.6} The effect of a single weight cycle on weekly body weight change
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   




Week CC (%) CFa (%) FaC (%) FaFa (%)
1 8.14 ± 0.95 7.72 ± 0.79 17.50 ± 1.18 16.17 ± 1.11
2 4.19 ± 0.50 4.55 ± 0.35 9.49 ± 0.76 8.72 ± 0.68
3 6.59 ± 0.58 5.56 ± 0.66 8.71 ± 0.47 9.34 ± 0.45
4 3.48 ± 0.63 3.14 ± 0.49 8.05 ± 0.44 8.41 ± 0.39
5 3.19 ± 0.58 4.09 ± 0.56 6.96 ± 0.36 6.70 ± 0.40
6 2.06 ± 0.58 1.75 ± 0.52 4.97 ± 0.27 5.80 ± 0.27
7 1.89 ± 0.61 12.95 ± 1.01 ­8.11 ± 0.50 4.70 ± 0.35
8 3.75 ± 0.51 7.53 ± 0.38 ­3.67 ± 0.62 3.04 ± 0.40
9 1.64 ± 0.42 6.35 ± 0.51 ­1.11 ± 0.27 2.56 ± 0.32
10 0.65 ± 0.42 3.21 ± 0.46 ­0.20 ± 0.35 0.83 ± 0.28
11 1.23 ± 0.56 3.72 ± 0.42 ­1.16 ± 0.72 1.05 ± 0.22
12 2.00 ± 0.60 3.02 ± 0.33 2.03 ± 0.67 1.11 ± 0.16
13 ­0.11 ± 0.52 ­7.60 ± 0.51 13.78 ± 0.76 0.03 ± 0.12
14 1.31 ± 0.57 ­2.55 ± 0.42 6.59 ± 0.58 0.86 ± 0.20
15 1.91 ± 0.48 ­1.74 ± 0.30 4.23 ± 0.43 0.34 ± 0.17
16 1.02 ± 0.28 ­0.46 ± 0.42 2.49 ± 0.39 0.59 ± 0.15
17 0.31 ± 0.27 ­1.75 ± 0.38 1.69 ± 0.30 0.46 ± 0.10
18 0.69 ± 0.21 ­0.44 ± 0.57 1.50 ± 0.28 0.66 ± 0.11
Table {4.1.3.0.7} The effect of a single weight cycle on weekly percentage body weight                         
change
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             






For the first 6 weeks of feeding, food intake per cage of 4 mice was significantly lower for Fa                                   
mice compared to C mice (Figure 4.2.1.0.1:A. Table 4.2.3.0.4. p<0.001, n=39/group). When food                       
intake was normalised to the cage weight0.75, food intake was significantly lower for Fa mice                           
compared to C mice from week 1 to 6 (Figure 4.2.1.0.1:B. Table 4.2.3.0.5. p<0.001,                         
n=39/group).
Figure {4.2.1.0.1} The effect of six weeks high fat feeding on weekly food intake
A) Weekly food intake measured in grams per cage of 4 mice. B) Weekly food intake measured                               
in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. Data                                   




Similarly, a comparison of cumulative food intake showed Fa mice consumed significantly less                       
food over the 6 week period from week 2 to 6 (Figure 4.2.1.0.2:A. Table 4.2.3.0.9. p<0.001,                             
n=39/group). Cumulative food intake normalised to cage weight0.75 showed Fa mice consumed                     
significantly less food for the entire 6 weeks (Figure 4.2.1.0.2:B. Table 4.2.3.0.10. Week 1:                         
p<0.05; week 2­6: p<0.001, n=39/group).
Figure {4.2.1.0.2} The effect of six weeks high fat feeding on cumulative food intake
A) Cumulative food intake measured in grams per cage of 4 mice (g); B) Cumulative food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks.





A comparison between control groups from weeks 7 to 12 showed CC mice still consumed                           
more food compared to FaFa mice (Figure 4.2.2.0.1:A. Table 4.2.3.0.4. Week 7­11: p<0.001;                       
week 12: p<0.05 n=14/group). When food intake was normalised to cage weight0.75, food intake                         
was significantly higher in CC mice compared to FaFa mice from week 7 to 12 (Figure                             
4.2.2.0.1:B. Table 4.2.3.0.5. p<0.001, n=14/group).
Figure {4.2.2.0.1} The effect of 12 weeks high fat feeding on weekly food intake
A) Weekly food intake measured in grams per cage of 4 mice. B) Weekly food intake measured                               
in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Data                                   




After swapping to the HFD at week 6, food intake was significantly lower in CFa mice compared                               
to CC mice from week 7 to 12 (Figure 4.2.2.0.2:A. Table 4.2.3.0.4. Week 7: p<0.01; week 8­9:                               
p<0.05; week 10­12: p<0.001, n=14/group). However when food intake was normalised to cage                       
weight0.75, food intake from week 7 to 12 was significantly reduced in CFa mice compared to CC                               
mice (Figure 4.2.2.0.2:B. Table 4.2.3.0.5. Week 7: p<0.01; week 8­12: p<0.001, n=14/group).
From week 7 to 12, there was no significant difference in food intake between CFa and FaFa                               
mice, once CFa mice had swapped to a HFD at week 6 (Figure 4.2.2.0.2:A. Table 4.2.3.0.4.                             
n=14/group). A trend showing increased food intake in CFa compared to FaFa mice between                         
week 8 and 9 was observed. Analysis of food intake data normalised to cage weight0.75 showed                             
CFa mice consumed significantly more food compared to FaFa mice from week 7 to 9 (Figure                             
4.2.2.0.2:B. Table 4.2.3.0.5. p<0.001, n=14/group). No significant differences between CFa and                   
FaFa mice were observed from week 10 to 12.
After swapping to a control diet at week 6, FaC mice had a significant reduction in food intake                                 
compared to CC mice from week 7 to 8, 1 to 2 weeks after swapping diet (Figure 4.2.2.0.3:A.                                 
Table 4.2.3.0.4. p<0.001, n=14/group). From week 9 onwards, food intake was comparable                     
between the two groups. Upon normalisation, food intake was significantly lower in FaC mice                         
compared to CC mice from week 7 to 10 (Figure 4.2.2.0.3:B. Table 4.2.3.0.5. Week 7­8:                           
p<0.001; week 0: p<0.01; week 10: p<0.05, n=14/group).
Compared to FaFa mice, FaC mice showed a significantly reduced food intake at week 7, one                             
week after FaC mice swapped to the control diet (Figure 4.2.2.0.3:C. Table 4.2.3.0.4. p<0.01,                         
n=14/group). From week 9 to 10, food intake was significantly higher in FaC mice compared to                             
FaFa mice (Figure 4.2.2.0.3:C. Table 4.2.3.0.4. Week 9: p<0.01; week 10: p<0.05, n=14/group).                       
A trend was also apparent between week 11 to 12. These differences remained when food                           
intake was normalised to cage weight0.75, but food intake from week 9 to 12 was significantly                             





A + C) Weekly food intake measured in grams per cage of 4 mice. B + D) Weekly food intake                                     
measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight gain mice (CFa) were fed a control diet from 0 to 6 weeks,                                     
then a HFD from 6 to 12 weeks. Data presented as mean ± sem. Week 1­6: n=39/group; week                                 





A + C) Weekly food intake measured in grams per cage of 4 mice. B + D) Weekly food intake                                     
measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight loss mice (FaC) were fed a HFD from 0 to 6 weeks, then a                                       
control diet from 6 to 12 weeks. Data presented as mean ± sem. Week 1­6: n=39/group; week                               




Similar to the first 6 week feeding period (Figure 4.2.1.0.2), cumulative food intake was                         
significantly increased in CC mice compared to FaFa mice from week 8 to 12 (Figure                           
4.2.2.0.4:A. Table 4.2.3.0.9. Week 8: p<0.01; week 9­12: p<0.001, n=14/group). When                   
cumulative food intake was normalised, CC mice showed a significantly higher food intake from                         
week 7 to 12 (Figure 4.2.2.0.4:B.Table 4.2.3.0.10. Week 7: p<0.01; week 8­12: p<0.001,                       
n=14/group).
Figure {4.2.2.0.4} The effect of six weeks high fat feeding from week 7 to 12 on                             
cumulative food intake
A) Cumulative food intake measured in grams per cage of 4 mice. B) Cumulative food intake                             
measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Data                                   




A comparison of week 7 to 12 showed CFa mice consumed significantly less food from week 9                               
to 12 compared to CC mice (Figure 4.2.2.0.5:A. Table 4.2.3.0.9. Week 9: p<0.01; week 10­12:                           
p<0.001, n=14/group). When normalised to cage weight0.75, cumulative food intake was                   
significantly lower in CFa mice compared to CC mice from week 8 to 12 (Figure 4.2.2.0.5:B.                             
Table 4.2.3.0.10. Week 8­12: p<0.001, n=14/group).
Comparing CFa mice to FaFa showed no difference in cumulative food intake from week 7 to 12                               
(Figure 4.2.2.0.5:C. Table 4.2.2.0.9. n=14/group). However, when data was normalised, CFa                   
mice consumed significantly more food from week 8 to 12 (Figure 4.2.2.0.5:D.Table 4.2.2.0.10.                       
Week 8: p<0.01; week 9­11: p<0.001; week 12: p<0.01, n=14/group).
From week 7 to 12, FaC mice showed a significantly lower cumulative food intake compared to                             
CC mice (Figure 4.2.2.0.6:A. Table 4.2.2.0.9. Week 7: p<0.01; week 8­12: p<0.001, n=14/group).                       
Normalised data to cage weight0.75 showed cumulative food intake was significantly higher from                       
week 7 to 12 (Figure 4.2.2.0.6:B. Table 4.2.2.0.10. p<0.001, n=14/group).
There was no significant difference in cumulative food intake between FaC and FaFa mice                         
(Figure 4.2.2.0.6:C. Table 4.2.2.0.9. n=14/group). However, when cumulative food intake was                   




Figure {4.2.2.0.5} The effect of six weeks high fat feeding after normal fat feeding from                           
week seven to twelve on cumulative food intake
A + C) Cumulative food intake measured in grams per cage of 4 mice. B + D) Cumulative food                                   
intake measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight gain mice (CFa) were fed a control diet from 0 to 6 weeks,                                     




Figure {4.2.2.0.6} The effect of six weeks normal fat feeding after high fat fat feeding                           
from week seven to twelve on cumulative food intake
A + C) Cumulative food intake measured in grams per cage of 4 mice. B+ D) Cumulative food                                 
intake measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight loss mice (FaC) were fed a HFD from 0 to 6 weeks, then a                                       





A comparison between control groups showed CCC mice consumed more food between 13 to                         
18 weeks compared to FaFaFa mice, but this was not always significantly difference (Figure                         
4.2.3.0.1:A. Table 4.2.3.0.4. Week 13: p<0.05; week 15­16: p<0.05, n=7/group). When food                     
intake was normalised to cage weight0.75, food intake was significantly higher in CCC mice                         
compared to FaFaFa mice from week 13 to 18 (Figure 4.2.3.0.1:B. Table 4.2.3.0.5. p<0.001,                         
n=7/group).
Figure {4.2.3.0.1} The effect of six weeks high fat feeding from week thirteen to eighteen                           
on weekly food intake
A) Weekly food intake measured in grams per cage of 4 mice. B) Weekly food intake measured                               
in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 18 weeks. Data                                   




After swapping back to the control diet at week 12, CFaC mice showed a more similar food                               
intake compared to CCC mice from week 16 to 18 (Figure 4.2.3.0.2:A. Table 4.2.3.0.4.                         
n=7/group). Food intake from week 13 to 15 was slightly reduced in CFaC mice compared to                             
CCC mice, although not significant. When data was normalised, food intake was significantly                       
lower from week 13 to 15 in CFaC mice compared to CCC mice (Figure 4.2.3.0.2:B. Table                             
4.2.3.0.5. Week 13: p<0.001; week 14­15: p<0.01, n=7/group).
CFaC showed a noticeable increase in food intake compared to FaFaFa from week 16 to 18,                             
although this was not significant (Figure 4.2.3.0.2:C. Table 4.2.3.0.4. n=7/group). Food intake                     
was significantly increased in CFaC mice compared to FaFaFa mice when normalised to cage                         
weight0.75 (Figure 4.2.3.0.2:D. Table 4.2.3.0.5. Week 16­17: p<0.05; week 18: p<0.01,                   
n=7/group).
When FaCFa mice were swapped back to the HFD at week 12, food intake was increased at                               
week 13 and week 17 compared to CCC mice (Figure 4.2.3.0.3:A. Table 4.2.3.0.4. Week 13:                           
p<0.01; week 17: p<0.05, n=7/group). When food intake was normalised to cage weight0.75, food                         
intake was significantly decreased in FaCFa mice compared to CCC mice from week 15 to 18                             
(Figure 4.2.3.0.3:B. Table 4.2.3.0.5. Week 15­18: p<0.001, n=7/group).
Lastly, a comparison between FaCFa and FaFaFa mice showed food intake was significantly                       
higher in FaCFa mice between week 13 to 14 (Figure 4.2.3.0.3:C. Table 4.2.3.0.4. Week 13:                           
p<0.001; week 14: p<0.05, n=7/group). From week 15 to 18, food intake was similar between the                             
two groups. Both week 13 and 14 showed FaCFa mice consumed significantly more food when                           




Figure {4.2.3.0.2} The effect of a single weight cycle ending with weight loss on weekly                           
food intake
A + C) Weekly food intake measured in grams per cage of 4 mice. B + D) Weekly food intake                                     
measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight loss (CFaC) were fed a                               
control diet from 0 to 6 weeks, a HFD from 6 to 12 weeks and a control diet from 12 to 18 weeks.                                           




Figure {4.2.3.0.3} The effect of a single weight cycle ending with weight gain on weekly                           
food intake
A) Weekly food intake measured in grams per cage of 4 mice. B) Weekly food intake measured                               
in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight gain (FaCFa) were fed a                               
HFD from 0 to 6 weeks, a control diet from 6 to 12 weeks and a HFD from 12 to 18 weeks. Data                                           




Week CCC (g) CFaC (g) FaCFa (g) FaFaFa (g)
1 95.6 ± 3.0 96.5 ± 2.6 87.5 ± 2.3 86.5 ± 5.2
2 88.3 ± 6.0 90.4 ± 2.9 83.4 ± 7.3 80 ± 5.3
3 88.0 ± 2.6 89.9 ± 4.7 77.5 ± 3.4 78.1 ± 3.4
4 88.1 ± 1.8 89.7 ± 7.2 80.5 ± 3.2 76.6 ± 2.8
5 83.5 ± 2.2 89.3 ± 3.0 72.3 ± 2.5 74.5 ± 2.5
6 84.4 ± 2.9 89.8 ± 2.3 77.4 ± 2.7 78.6 ± 2.8
7 89.3 ± 3.3 79.7 ± 1.9 60.0 ± 2.8 77.5 ± 2.9
8 88.8 ± 3.2 81.1 ± 3.3 71.4 ± 3.6 72.0 ± 2.3
9 86.2 ± 2.5 79.8 ± 3.8 76.6 ± 2.5 67.4 ± 5.5
10 87.0 ± 2.5 72.0 ± 4.0 77.1 ± 2.1 70.2 ± 3.6
11 82.3 ± 4.4 65.6 ± 3.8 74.5 ± 2.1 69.9 ± 3.5
12 81.4 ± 1.4 67.8 ± 3.6 74.0 ± 3.2 70.5 ± 3.0
13 84.8 ± 1.8 75.8 ± 4.2 98.7 ± 5.2 72.3 ± 3.8
14 83.9 ± 2.0 78.8 ± 4.2 87.8 ± 3.7 74.5 ± 3.2
15 81.3 ± 3.5 73.6 ± 2.8 71.3 ± 2.1 67.8 ± 2.4
16 80.0 ± 3.1 78.3 ± 4.2 73.0 ± 2.4 67.8 ± 2.6
17 77.0 ± 2.2 77.2 ± 2.3 64.9 ± 2.2 67.5 ± 0.8
18 76.3 ± 1.8 76.7 ± 1.8 67.6 ± 3.7 65.8 ± 1.2
Table {4.2.3.0.4} The effect of a single weight cycle on weekly food intake
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Data presented as mean ± sem, n=28/group. Food intake measured                           




Week CCC (g/g0.75) CFaC (g/g0.75) FaCFa (g/g0.75) FaFaFa (g/g0.75)
1 3.09 ± 0.12 3.09 ± 0.09 2.79 ± 0.09 2.76 ± 0.16
2 2.68 ± 0.18 2.73 ± 0.08 2.34 ± 0.19 2.27 ± 0.14
3 2.60 ± 0.08 2.64 ± 0.16 2.05 ± 0.09 2.10 ± 0.11
4 2.48 ± 0.06 2.53 ± 0.22 2.00 ± 0.09 1.92 ± 0.09
5 2.29 ± 0.7 2.46 ± 0.10 1.69 ± 0.07 1.76 ± 0.07
6 2.26 ± 0.08 2.39 ± 0.05 1.72 ± 0.06 1.77 ± 0.06
7 2.36 ± 0.09 2.09 ± 0.04 1.29 ± 0.07 1.67 ± 0.08
8 2.31 ± 0.08 1.95 ± 0.07 1.63 ± 0.09 1.50 ± 0.05
9 2.18 ± 0.05 1.82 ± 0.11 1.80 ± 0.07 1.37 ± 0.11
10 2.17 ± 0.05 1.57 ± 0.09 1.83 ± 0.05 1.40 ± 0.08
11 2.05 ± 0.11 1.40 ± 0.09 1.77 ± 0.05 1.39 ± 0.07
12 2.01 ± 0.05 1.34 ± 0.07 1.78 ± 0.08 1.39 ± 0.06
13 2.06 ± 0.05 1.54 ± 0.10 2.34 ± 0.16 1.41 ± 0.08
14 2.04 ± 0.07 1.69 ± 0.10 1.89 ± 0.08 1.45 ± 0.05
15 1.96 ± 0.10 1.61 ± 0.07 1.46 ± 0.05 1.31 ± 0.04
16 1.90 ± 0.07 1.73 ± 0.09 1.45 ± 0.04 1.31 ± 0.04
17 1.82 ± 0.07 1.72 ± 0.05 1.27 ± 0.05 1.30 ± 0.02
18 1.80 ± 0.06 1.73 ± 0.03 1.30 ± 0.08 1.27 ± 0.02
Table {4.2.3.0.5} The effect of a single weight cycle on weekly food intake normalised to                           
total cage weight0.75
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Data presented as mean ± sem, n=28/group. Food intake measured                           




A comparison of cumulative food intake between CCC and FaFaFa mice from week 13 to 18                             
again shows CCC consumed significantly more food from week 15 to 18 (Figure 4.2.3.0.6:A.                         
Table 4.2.3.0.9. Week 15: p<0.01; week 16­18: p<0.001, n=7/group). Food intake normalised to                       
cage weight0.75 was significantly higher in CCC mice from week 14 to 18 (Figure 4.2.3.0.6:B.                           
Table 4.2.3.0.10. p<0.001, n=7/group).
Figure {4.2.3.0.6} The effect of six weeks high fat feeding from week thirteen to eighteen                           
on cumulative food intake
A) Cumulative food intake measured in grams per cage of 4 mice. B) Cumulative food intake                             
measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 18 weeks. Data                                   




After returning to the control diet, CFaC mice showed no difference in food intake compared to                             
CCC mice during the last 12 to 18 week period (Figure 4.2.3.0.7:A. Table 4.2.3.0.9. n=7/group).                           
However, when normalised to cage weight0.75, CFaC mice consumed significantly less food                     
compared to CCC mice from week 14 to 18 (Figure 4.2.3.0.7:B. Table 4.2.3.0.10. Week 14:                           
p<0.05; week 15: p<0.01; week 16­17: p<0.001; week 18: p<0.01, n=7/group).
Compared to FaFaFa mice, CFaC mice consumed significantly more food from week 17 to 18                           
(Figure 4.2.3.0.7:C. Table 4.2.3.0.9. Week 17: p<0.01; week 18: p<0.001, n=7/group). Food                     
intake normalised to cage weight0.75 was significantly higher from week 15 to 18 in CFaC mice                             
compared to FaFaFa mice (Figure 4.2.3.0.7:D. Table 4.2.3.0.10. Week 15: p<0.05; week 16­18:                       
p<0.001, n=7/group).
After swapping from the control diet back to the HFD at week 12, FaCFa mice showed no                               
significant difference in food intake compared to CCC mice (Figure 4.2.3.0.8:A. Table 4.2.3.0.9.                       
n=7/group). When normalised, FaCFa consumed significantly less food compared to CCC mice                     
from week 15 to 18 (Figure 4.2.3.0.8:B. Table 4.2.3.0.10. Week 15: p<0.05; week 16­18:                         
p<0.001, n=7/group).
FaCFa mice consumed significantly more food compared to FaFaFa mice from week 14 to 18                           
(Figure 4.2.3.0.8:C. Table 4.2.3.0.9. p<0.001, n=7/group). This significant difference remained                 




Figure {4.2.3.0.7} The effect of a single weight cycle ending with weight loss on                         
cumulative food intake
A) Cumulative food intake measured in grams per cage of 4 mice. B) Cumulative food intake                             
measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight loss (CFaC) were fed a                               
control diet from 0 to 6 weeks, a HFD from 6 to 12 weeks and a control diet from 12 to 18 weeks.                                           




Figure {4.2.3.0.8} The effect of a single weight cycle ending with weight gain on                         
cumulative food intake
A) Cumulative food intake measured in grams per cage of 4 mice. B) Cumulative food intake                             
measured in grams per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight gain (FaCFa) were fed a                               
HFD from 0 to 6 weeks, a control diet from 6 to 12 weeks and a HFD from 12 to 18 weeks. Data                                           




Week CCC (g) CFaC (g) FaCFa (g) FaFaFa (g)
1 95.6 ± 3.0 96.5 ± 2.6 87.5 ± 2.3 86.5 ± 5.2
2 183.9 ± 7.8 186.9 ± 3.9 170.9 ± 8.6 166.4 ± 8.6
3 271.9 ± 9.5 276.8 ± 5.9 248.4 ± 9.6 244.6 ± 7.5
4 360.0 ± 11.0 366.5 ± 12.3 329.0 ± 11.1 321.2 ± 7.6
5 443.9 ± 11.1 455.8 ± 12.0 401.3 ± 10.4 395.8 ± 8.6
6 527.9 ± 12.3 545.6 ± 11.2 478.7 ± 12.2 474.4 ± 10.5
7 89.3 ± 3.3 79.7 ± 1.9 60.0 ± 2.8 77.5 ± 2.9
8 178.2 ± 5.1 160.8 ± 3.6 131.4 ± 5.8 149.5 ± 3.5
9 264.3 ± 6.6 240.5 ± 4.0 208.0 ± 7.6 216.9 ± 5.1
10 351.3 ± 8.3 312.5 ± 4.5 285.1 ± 8.0 287.1 ± 6.9
11 433.6 ± 11.8 378.1 ± 3.8 359.5 ± 9.0 357.0 ± 8.2
12 515.0 ± 12.3 446.0 ± 4.1 433.6 ± 10.1 427.5 ± 10.5
13 84.8 ± 1.8 75.8 ± 4.2 98.7 ± 5.2 72.3 ± 3.8
14 168.7 ± 3.0 154.6 ± 5.9 186.6 ± 8.2 146.8 ± 4.5
15 250.1 ± 4.9 228.2 ± 7.9 257.9 ± 6.8 214.6 ± 6.0
16 330.1 ± 6.4 306.5 ± 11.0 331.0 ± 6.3 282.4 ± 7.6
17 407.1 ± 7.2 383.6 ± 11.5 395.9 ± 5.7 349.9 ± 7.8
18 483.4 ± 7.7 460.3 ± 11.8 463.5 ± 7.3 415.8 ± 7.7
Table {4.2.3.0.9} The effect of a single weight cycle on periodic cumulative food intake
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Data presented as mean ± sem, n=28/group. Food intake measured                           
in grams per cage of 4 mice. Green highlight indicates start of swap period. Data presented as                               




Week CCC (g/g0.75) CFaC (g/g0.75) FaCFa (g/g0.75) FaFaFa (g/g0.75)
1 3.09 ± 0.12 3.09 ± 0.09 2.79 ± 0.09 2.76 ± 0.16
2 5.60 ± 0.24 5.65 ± 0.11 4.81 ± 0.21 4.73 ± 0.20
3 8.03 ± 0.29 8.10 ± 0.21 6.54 ± 0.17 6.54 ± 0.12
4 10.13 ± 0.29 10.32 ± 0.40 8.14 ± 0.23 8.04 ± 0.13
5 12.16 ± 0.27 12.54 ± 0.41 9.38 ± 0.21 9.32 ± 0.16
6 14.14 ± .31 14.57 ± 0.46 10.64 ± 0.25 10.65 ± 0.19
7 2.36 ± 0.09 2.09 ± 0.04 1.29 ± 0.07 1.67 ± 0.08
8 4.64 ± 0.15 3.86 ± 0.06 3.01 ± 0.15 3.12 ± 0.10
9 6.69 ± 0.15 5.48 ± 0.11 4.89 ± 0.19 4.42 ± 0.13
10 8.78 ± 0.16 6.79 ± 0.12 6.76 ± 0.21 5.74 ± 0.17
11 10.79 ± 0.29 8.04 ± 0.16 8.54 ± 0.23 7.09 ± 0.19
12 12.70 ± 0.24 9.21 ± 0.13 10.39 ± 0.26 8.43 ± 0.23
13 2.06 ± 0.05 1.54 ± 0.10 2.34 ± 0.16 1.41 ± 0.08
14 4.11 ± 0.11 3.33 ± 0.17 4.01 ± 0.20 2.87 ± 0.08
15 6.03 ± 0.18 5.00 ± 0.22 5.29 ± 0.18 4.17 ± 0.10
16 7.85 ± 0.21 6.80 ± 0.29 6.57 ± 0.16 5.47 ± 0.12
17 9.61 ± 0.26 8.54 ± 0.30 7.72 ± 0.15 6.74 ± 0.12
18 11.39 ± 0.32 10.39 ± 0.32 8.93 ± 0.22 7.99 ± 0.11
Table {4.2.3.0.10} The effect of a single weight cycle on periodic cumulative food intake                         
normalised to total cage weight0.75
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Data presented as mean ± sem, n=28/group. Food intake measured                           
in grams per cage of 4 mice normalised to total cage weight0.75. Green highlight indicates start of                               






For the first 6 weeks of feeding, unlike food intake data presented above measured in grams,                             
calorie intake per cage of 4 mice was significantly higher for Fa mice compared to C mice from                                 
week 1 to 6 (Figure 4.3.1.0.1:A. Table 4.3.3.0.4. p<0.001, n=39/group). However, when calorie                       
intake was normalised to the cage weight0.75, calorie intake was only significantly higher from                         
week 1 to 4 for Fa mice compared to C mice (Figure 4.3.1.0.1:B. Table 4.3.3.0.5. Week 1­3:                               
p<0.001; week 4: p<0.05, n=39/group). Calorie intake reduced over the 6 week period for both                           
groups and the difference in calorie intake also became smaller over time.
Figure {4.3.1.0.1} The effect of six weeks high fat feeding from week one to six on                             
weekly calorie intake
A) Weekly calorie intake measured per cage of 4 mice. B) Weekly calorie intake measured per                             
cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. Data                                   




A comparison of cumulative calorie intake showed Fa mice consumed significantly more                     
calories over the 6 week period from week 1 (Figure 4.3.1.0.2:A. Table 4.3.3.0.9. p<0.001,                         
n=39/group). When cumulative calorie intake was normalised to cage weight0.75 , calorie intake                       
was also significantly higher in Fa mice compared to C mice from week 1 to 6 (Figure                               
4.3.1.0.2:B. Table 4.3.3.0.10. p<0.001, n=39/group).
Figure {4.3.1.0.2} The effect of six weeks high fat feeding from week one to six on                             
cumulative calorie intake
A) Cumulative calorie intake measured per cage of 4 mice. B) Cumulative calorie intake                         
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. Data                                   





From week 6 to 12, FaFa mice showed a significantly higher calorie intake compared to CC                             
mice (Figure 4.3.2.0.1:A. Table 4.3.3.0.4. Week 7: p<0.001; week 8: p<0.01; week 9­10: p<0.05;                         
week 11­12: p<0.001, n=14/group). When normalised to cage weight0.75, calorie intake was                     
slightly lower in FaFa mice compared to CC mice, although this was not significant (Figure                           
4.3.2.0.1:B. Table 4.3.3.0.5. n=14/group).
Figure {4.3.2.0.1} The effect of 12 weeks high fat feeding on weekly calorie intake
A) Weekly calorie intake measured per cage of 4 mice. B) Weekly calorie intake measured per                             
cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Data                                   




CFa mice showed a significant increase in calorie intake compared to CC mice from week 7 to                               
12 after swapping to a HFD at week 6 (Figure 4.3.2.0.2:A. Table 4.3.3.0.4. Week 7­9: p<0.001;                             
week 10­12: p<0.01, n=14/group). However, when calorie intake was normalised, only week 7 to                         
9 showed CFa mice had a significantly higher calorie intake compared to CC mice (Figure                           
4.3.2.0.2:B. Table 4.3.3.0.5. Week 7: p<0.001; week 8: p<0.01; week 9: p<0.05, n=14/group).
Compared to FaFa mice, CFa mice showed no significant difference in calorie intake (Figure                         
4.3.2.0.2:C. Table 4.3.3.0.4. n=14/group). Similar to the comparison with CC mice, calorie intake                       
normalised to cage weight0.75 was significantly higher in CFa mice compared to FaFa mice                         
between week 7 to 9, 1 to 3 weeks after swapping to the HFD (Figure 4.3.2.0.2:D. Table                               
4.3.3.0.5. p<0.001, n=14/group).
A comparison between FaC and CC mice showed calorie intake was significantly decreased                       
from week 7 to 8, 1 to 2 weeks after swapping to the control diet (Figure 4.3.2.0.3:A. Table                                 
4.3.3.0.4. p<0.001, n=14/group). From week 9 to 12, calorie intake between the two groups was                           
comparable. Normalised calorie intake data showed FaC mice had significantly lower calorie                     
intake compared to CC mice from week 7 to 9 (Figure 4.3.2.0.3:B. Table 4.3.3.0.5. Week 7­8:                             
p<0.001; week 9: p<0.05, n=14/group).
Similarly, calorie intake was significantly decreased in FaC mice compared to FaFa mice from                         
week 7 to 12 (Figure 4.3.2.0.3:C. Table 4.3.3.0.4. p<0.001, n=14/group). Upon normalisation,                     
calorie intake was only significantly reduced in FaC mice compared to FaFa mice between week                           
7 to 8, 1 to 2 weeks after FaC mice swapped to the control diet (Figure 4.3.2.0.3:D. Table                                 





A + C) Weekly calorie intake measured per cage of 4 mice. B + D) Weekly calorie intake                                 
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight gain mice (CFa) were fed a control diet from 0 to 6 weeks,                                     
then a HFD from 6 to 12 weeks. Data presented as mean ± sem. Week 1­6: n=39/group; week                                 





A + C) Weekly calorie intake measured per cage of 4 mice. B + D) Weekly calorie intake                                 
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight loss mice (FaC) were fed a HFD from 0 to 6 weeks, then a                                       
control diet from 6 to 12 weeks. Data presented as mean ± sem. Week 1­6: n=39/group; week                               




From week 8 to 12, FaFa mice showed a significantly higher cumulative calorie intake compared                           
to CC mice (Figure 4.3.2.0.4:A. Table 4.3.3.0.9. Week 8: p<0.01; week 9­12: p<0.001,                       
n=14/group). When normalised to cage weight0.75, calorie intake was significantly increased from                     
week 10 to 12 only (Figure 4.3.2.0.4:B. Table 4.3.3.0.10. Week 10: p<0.05; week 11­12: p<0.01,                           
n=14/group).
Figure {4.3.2.0.4} The effect of six weeks high fat feeding from week 7 to 12 on                             
cumulative calorie intake
A) Cumulative calorie intake measured per cage of 4 mice. B) Cumulative calorie intake                         
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Data                                   




CFa mice showed a significant increase in cumulative calorie intake compared to CC mice from                           
week 8 to 12 (Figure 4.3.2.0.5:A. Table 4.3.3.0.9. p<0.001, n=14/group). However, when                     
cumulative calorie intake was normalised, there was significant difference between the two                     
groups only from week 8 to 9 (Figure 4.3.2.0.5:B. Table 4.3.3.0.10. Week 8: p<0.05; week 9:                             
p<0.01, n=14/group).
Compared to FaFa mice, CFa mice showed a very similar cumulative calorie intake (Figure                         
4.3.2.0.5:C. Table 4.3.3.0.9. n=14/group). Cumulative calorie intake normalised to cage weight0.75                   
was significantly increased from week 8 to 12 (Figure 4.3.2.0.5:D. Table 4.3.3.0.10. p<0.001,                       
n=14/group).
A comparison between FaC and CC mice showed cumulative calorie intake was significantly                       
reduced from week 7 to 12 (Figure 4.3.2.0.6:A. Table 4.3.3.0.9. Week 7: p<0.05; week 8­12:                           
p<0.001, n=14/group). Normalised cumulative calorie intake data showed FaC mice had a                     
significantly lower cumulative calorie intake compared to CC mice for both week 7 to 12 (Figure                             
4.3.2.0.6:B. Table 4.3.3.0.10. p<0.001, n=14/group).
Similarly, cumulative calorie intake was significantly decreased in FaC mice compared to FaFa                       
mice from week 7 to 12 (Figure 4.3.2.0.6:C. Table 4.3.3.0.9. p<0.001, n=14/group). Upon                       




Figure {4.3.2.0.5} The effect of six weeks high fat feeding after normal fat feeding from                           
week seven to twelve on cumulative calorie intake
A + C) Cumulative calorie intake measured per cage of 4 mice. B + D) Cumulative calorie intake                                 
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight gain mice (CFa) were fed a control diet from 0 to 6 weeks,                                     
then a HFD from 6 to 12 weeks. Data presented as mean ± sem. n=14/group. * p<0.05, **                                 




Figure {4.3.2.0.6} The effect of six weeks normal fat feeding after high fat feeding from                           
week seven to twelve on cumulative calorie intake
A + C) Cumulative calorie intake measured per cage of 4 mice. B+ D) Cumulative calorie intake                               
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 12 weeks. Control groups were fed a                                 
control or HFD for 12 weeks. Weight loss mice (FaC) were fed a HFD from 0 to 6 weeks, then a                                       





From week 13 to 18, FaFaFa mice showed a significantly higher calorie intake compared to                           
CCC mice (Figure 4.3.3.0.1:A. Table 4.3.3.0.4. Week 13: p<0.01; week 14: p<0.001: week                       
15­16: p<0.05: week 17­18: p<0.01, n=7/group). When normalised to cage weight0.75, calorie                     
intake was again indistinguishable between the two groups (Figure 4.3.3.0.1:B. Table 4.3.3.0.4.                     
n=7/group).
Figure {4.3.3.0.1} The effect of 18 weeks high fat feeding on weekly calorie intake
A) Weekly calorie intake measured per cage of 4 mice. B) Weekly calorie intake measured per                             
cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 18 weeks. Data                                   
presented as mean ± sem. Week 1­6: n=39/group; week 7­12: n=14/group; week 13­18:                       




CFaC mice showed no significant difference in calorie intake compared to CCC mice after                         
swapping back to the control diet at week 12 (Figure 4.3.3.0.2:A. Table 4.3.3.0.4. n=7/group).                         
When calorie intake was normalised, week 13 to 15 showed CFaC mice consumed significantly                         
fewer calories compared to CCC mice (Figure 4.3.3.0.2:A. Table 4.3.3.0.5. Week 13: p<0.001;                       
week 14­15: p<0.05, n=7/group).
Compared to FaFaFa mice, CFaC mice showed a significantly lower calorie intake from week                         
13 to 18t after swapping back to the control diet at week 12 (Figure 4.3.3.0.2:C. Table 4.3.3.0.4.                               
Week 13­15: p<0.001; week 16­17: p<0.01; week 18: p<0.05, n=7/group). Calorie intake                     
normalised to cage weight0.75 was only significantly lower in CFaC mice compared to FaFaFa                         
mice between week 13 to 14 (Figure 4.3.3.0.2:D. Table 4.3.3.0.5. Week 13: p<0.01; week 14:                           
p<0.05, n=7/group).
A comparison between FaCFa and CCC mice showed calorie intake was significantly increased                       
from week 13 to 18, 1 to 6 weeks after swapping back to the HFD after 6 weeks of control diet                                       
feeding (Figure 4.3.3.0.3:A. Table 4.3.3.0.4. Week 13­14: p<0.001; week 15: p<0.01; week 16:                       
p<0.001; week 17: p<0.05; week 18: p<0.01, n=7/group). Normalised calorie intake data showed                       
FaCFa mice had significantly higher calorie intake compared to CCC mice from week 13 and 14                             
only (Figure 4.3.3.0.3:B. Table 4.3.3.0.5. p<0.001, n=7/group).
Similarly, calorie intake was significantly increased in FaCFa mice compared to FaFaFa mice                       
from week 13 to 14 (Figure 4.3.3.0.3:C. Table 4.3.3.0.4. Week 13: p<0.001; week 14: p<0.01,                           
n=7/group). Upon normalisation, calorie intake was still significantly reduced in FaCFa mice                     




Figure {4.3.3.0.2} The effect of a single weight cycle ending with weight loss on weekly                           
calorie intake
A + C) Weekly calorie intake measured per cage of 4 mice. B + D) Weekly calorie intake                                 
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight loss (CFaC) were fed a                               
control diet from 0 to 6 weeks, a HFD from 6 to 12 weeks and a control diet from 12 to 18 weeks.                                           
Data presented as mean ± sem. Week 1­6: n=39/group; week 7­12: n=14/group; week 13­18:                         




Figure {4.3.3.0.3} The effect of a single weight cycle ending with weight gain on weekly                           
calorie intake
A) Weekly calorie intake measured per cage of 4 mice. B) Weekly calorie intake measured per                             
cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight gain (FaCFa) were fed a                               
HFD from 0 to 6 weeks, a control diet from 6 to 12 weeks and a HFD from 12 to 18 weeks. Data                                           
presented as mean ± sem. Week 1­6: n=39/group; week 7­12: n=14/group; week 13­18:                       




Week CCC (kcal) CFaC (kcal) FaCFa (kcal) FaFaFa (kcal)
1 344.1 ± 10.8 347.5 ± 9.5 446.3 ± 11.9 441.0 ± 26.3
2 317.8 ± 21.5 325.4 ± 10.4 425.4 ± 37.0 407.9 ± 27.1
3 316.9 ± 9.5 323.5 ± 17.1 395.4 ± 17.3 398.5 ± 17.5
4 317.2 ± 6.6 323.0 ± 25.9 410.8 ± 16.3 390.9 ± 14.4
5 300.5 ± 7.7 321.6 ± 10.8 368.8 ± 12.6 380.2 ± 13.0
6 303.7 ± 10.6 323.3 ± 8.5 394.7 ± 13.8 400.9 ± 14.3
7 321.6 ± 12.0 406.3 ± 9.6 216.1 ± 10.1 395.2 ± 14.7
8 319.7 ± 11.3 413.7 ± 16.9 256.9 ± 12.9 367.3 ± 11.8
9 310.2 ± 9.0 406.8 ± 19.5 275.7 ± 9.1 343.9 ± 28.0
10 313.2 ± 9.1 367.0 ± 20.6 277.6 ± 7.7 358.1 ± 18.6
11 296.2 ± 15.9 334.8 ± 19.5 268.1 ± 7.5 356.3 ± 17.9
12 293.0 ± 5.2 345.9 ± 18.4 266.6 ± 11.5 359.4 ± 15.5
13 305.3 ± 6.5 273.0 ± 15.0 503.5 ± 26.4 368.8 ± 19.22
14 302.0 ± 7.0 283.6 ± 15.2 448.0 ± 18.7 379.8 ± 16.2
15 292.8 ± 12.6 264.9 ± 10.0 363.8 ± 10.9 345.8 ± 12.1
16 288.1 ± 11.0 281.8 ± 15.2 372.5 ± 12.3 345.9 ± 13.2
17 277.3 ± 8.0 277.8 ± 8.2 331.1 ± 11.3 344.3 ± 4.0
18 274.0 ± 6.6 276.0 ± 6.5 344.6 ± 19.0 335.8 ± 6.3
Table {4.3.3.0.4} The effect of a single weight cycle on weekly calorie intake
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Data presented as mean ± sem. Calorie intake measured per cage                             
of 4 mice. Week 1­6: n=39/group; week 7­12: n=14/group; week 13­18: n=7/group. * p<0.05, †                           




Week CCC (kcal/bw0.75) CFaC (kcal/bw0.75) FaCFa (kcal/bw0.75) FaFaFa (kcal/bw0.75)
1 11.12 ± 0.43 11.11 ± 0.33 14.21 ± 0.45 14.05 ± 0.83
2 9.66 ± 0.64 9.84 ± 0.29 11.96 ± 0.96 11.60 ± 0.70
3 9.35 ± 0.29 9.49 ± 0.58 10.43 ± 0.44 10.70 ± 0.57
4 8.93 ± 0.21 9.12 ± 0.77 10.20 ± 0.46 9.81 ± 0.46
5 8.25 ± 0.25 8.85 ± 0.36 8.64 ± 0.37 8.97 ± 0.34
6 8.13 ± 0.27 8.62 ± 0.19 8.78 ± 0.30 9.00 ± 0.33
7 8.49 ± 0.34 10.68 ± 0.18 4.65 ± 0.26 8.53 ± 0.41
8 8.32 ± 0.31 9.94 ± 0.37 5.88 ± 0.33 7.65 ± 0.26
9 7.85 ± 0.20 9.29 ± 0.54 6.49 ± 0.25 7.01 ± 0.58
10 7.82 ± 0.17 7.98 ± 0.47 6.58 ± 0.20 7.16 ± 0.39
11 7.37 ± 0.40 7.13 ± 0.48 6.37 ± 0.18 7.08 ± 0.37
12 7.24 ± 0.19 7.14 ± 0.37 6.39 ± 0.29 7.09 ± 0.32
13 7.43 ± 0.18 5.53 ± 0.36 11.94 ± 0.79 7.22 ± 0.39
14 7.36 ± 0.24 6.09 ± 0.36 9.62 ± 0.41 7.41 ± 0.27
15 7.07 ± 0.36 5.80 ± 0.26 7.46 ± 0.27 6.71 ± 0.21
16 6.85 ± 0.26 6.24 ± 0.32 7.39 ± 0.23 6.69 ± 0.22
17 6.55 ± 0.25 6.18 ± 0.16 6.46 ± 0.26 6.64 ± 0.09
18 6.47 ± 0.23 6.22 ± 0.10 6.64 ± 0.40 6.45 ± 0.11
Table {4.3.3.0.5} The effect of a single weight cycle on weekly calorie intake
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Data presented as mean ± sem. Weekly calorie intake measured                           
per cage of 4 mice normalised to total cage weight0.75. Week 1­6: n=39/group; week 7­12:                           




From week 14 to 18, FaFaFa mice showed a significantly higher cumulative calorie intake                         
compared to CCC mice (Figure 4.3.3.0.6:A. Table 4.3.3.0.9. Week 14: p<0.01; week 15­18:                       
p<0.001, n=7/group). When normalised to cage weight0.75, calorie intake was indistinguishable                   
between the two groups (Figure 4.3.3.0.6:B. Table 4.3.3.0.10. n=7/group).
Figure {4.3.3.0.6} The effect of six weeks high fat feeding from week thirteen to eighteen                           
on cumulative calorie intake
A) Cumulative calorie intake measured per cage of 4 mice. B) Cumulative calorie intake                         
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 18 weeks. Data                                   




CFaC mice showed no significant difference in cumulative calorie intake compared to CCC mice                         
from week 12 to 18 (Figure 4.3.3.0.7:A. Table 4.3.3.0.9. n=7/group). However, when cumulative                       
calorie intake was normalised, CFaC mice consumed significantly fewer calorie compare to                     
CCC mice from week 15 to 18 (Figure 4.3.3.0.7:B. Table 4.3.3.0.10. p<0.01, n=7/group).
Compared to FaFaFa mice, CFaC mice showed a significantly lower cumulative calorie intake                       
from week 14 to 18 (Figure 4.3.3.0.7:C. Table 4.3.3.0.9. p<0.001, n=7/group). Cumulative calorie                       
intake normalised to cage weight0.75 also showed CFaC consumed significantly fewer calories                     
from week 15 to 18 (Figure 4.3.3.0.7:D. Table 4.3.3.0.10. Week 15­16, 18: p<0.05; week 17:                           
p<0.01, n=7/group).
A comparison between FaCFa and CCC mice showed cumulative calorie intake was                     
significantly increased from week 12 to 18 (Figure 4.3.3.0.8:A. Table 4.3.3.0.9. p<0.001,                     
n=7/group). Normalised cumulative calorie intake data also showed FaCFa mice consumed                   
significantly more calories compared to CCC mice for both week 12 to 18 (Figure 4.3.3.0.8:B.                           
Table 4.3.3.0.10. p<0.001, n=7/group).
Cumulative calorie intake was significantly lower in FaCFa mice compared to FaFaFa mice from                         
week 7 to 18 (Figure 4.3.3.0.8:C. Table 4.3.3.0.9. p<0.001, n=7/group). Upon normalisation,                     




Figure {4.3.3.0.7} The effect of a single weight cycle ending with weight loss on                         
cumulative calorie intake
A) Cumulative calorie intake measured per cage of 4 mice. B) Cumulative calorie intake                         
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight loss (CFaC) were fed a                               
control diet from 0 to 6 weeks, a HFD from 6 to 12 weeks and a control diet from 12 to 18 weeks.                                           




Figure {4.3.3.0.8} The effect of a single weight cycle ending with weight gain on                         
cumulative calorie intake
A) Cumulative calorie intake measured per cage of 4 mice. B) Cumulative calorie intake                         
measured per cage of 4 mice normalised to total cage weight0.75.
C57Bl6 male mice aged 8­10 weeks of age were fed for 18 weeks. Control groups were fed a                                 
control or HFD for 18 weeks. Weight cycled mice ending with weight gain (FaCFa) were fed a                               
HFD from 0 to 6 weeks, a control diet from 6 to 12 weeks and a HFD from 12 to 18 weeks. Data                                           




Week CCC (kcal) CFaC (kcal) FaCFa (kcal) FaFaFa (kcal)
1 344.1 ± 10.8 347.5 ± 9.5 446.3 ± 11.9 441.0 ± 26.3
2 661.9 ± 28.0 672.9 ± 14.1 871.7 ± 44.1 848.9 ± 43.8
3 978.8 ± 34.3 996.4 ± 21.4 1267.1 ± 48.9 1247.4 ± 38.3
4 1296.0 ± 40.0 1319.3 ± 44.1 1677.8 ± 56.5 1638.3 ± 38.6
5 1596.5 ± 39.8 1640.9 ± 43.1 2046.6 ± 52.9 2018.4 ± 44.1
6 1900.3 ± 44.1 1964.3 ± 40.2 2441.4 ± 62.3 2419.4 ± 53.3
7 321.6 ± 12.0 406.3 ± 9.6 216.1 ± 10.1 395.2 ± 14.7
8 641.4 ± 18.2 819.9 ± 18.3 473.0 ± 20.8 762.5 ± 17.7
9 951.6 ± 23.9 1226.8 ± 20.2 748.6 ± 27.2 1106.3 ± 25.9
10 1264.8 ± 29.8 1593.8 ± 22.9 1026.2 ± 28.7 1464.4 ± 35.3
11 1561.0 ± 42.5 1928.5 ± 19.5 1294.3 ± 32.3 1820.8 ± 41.9
12 1854.0 ± 44.1 2274.5 ± 21.0 1560.9 ± 36.4 2180.2 ± 53.8
13 305.3 ± 6.5 273.0 ± 15.0 503.5 ± 26.4 368.8 ± 19.2
14 607.4 ± 10.8 556.6 ± 21.3 951.5 ± 41.9 748.6 ± 22.8
15 900.2 ± 17.7 821.4 ± 28.3 1315.4 ± 34.9 1094.4 ± 30.7
16 1188.3 ± 23.0 1103.2 ± 39.5 1687.9 ± 32.1 1440.2 ± 38.8
17 1465.6 ± 25.9 1381.0 ± 41.3 2019.0 ± 29.0 1784.6 ± 39.8
18 1740.3 ± 27.8 1657.0 ± 42.4 2363.6 ± 37.1 2120.4 ± 39.5
Table {4.3.3.0.9} The effect of a single weight cycle on periodic cumulative calorie intake
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 6 weeks. At this                                     
point, half the mice continued to feed on the control diet for 12 weeks (CCC group) whilst the                                 
other half were fed a HFD for 6 weeks, before swapping back to the control diet for 16 weeks                                   
(CFaC group). Similarly, half the mice continued to feed on the HFD for 12 weeks (FaFaFa                             
group) whilst the other half were fed a control diet for 6 weeks, before swapping back to the HFD                                   
for 6 weeks (FaCFa group). Data presented as mean ± sem, n=28/group. Calorie intake                         
measured in kcal per cage of 4 mice. Green highlight indicates start of swap period. Data                             




Week CCC  (kcal/bw0.75) CFaC (kcal/bw0.75) FaCFa (kcal/bw0.75) FaFaFa (kcal/bw0.75)
1 11.12 ± 0.43 11.11 ± 0.33 14.21 ± 0.45 14.05 ± 0.83
2 20.15 ± 0.86 20.35 ± 0.39 24.55 ± 1.07 24.14 ± 1.02
3 28.89 ± 1.05 29.17 ± 0.76 33.35 ± 0.89 33.34 ± 0.61
4 36.46 ± 1.06 37.13 ± 1.44 41.53 ± 1.15 40.98 ± 0.66
5 43.77 ± 0.97 45.13 ± 1.47 47.82 ± 1.05 47.55 ± 0.82
6 50.89 ± 1.11 52.46 ± 1.65 54.26 ± 1.25 54.30 ± 0.98
7 8.49 ± 0.34 10.68 ± 0.18 4.65 ± 0.26 8.53 ± 0.41
8 16.62 ± 0.53 19.89 ± 0.29 10.83 ± 0.55 15.89 ± 0.50
9 24.07 ± 0.53 27.93 ± 0.56 17.61 ± 0.69 22.55 ± 0.68
10 31.60 ± 0.56 34.65 ± 0.62 24.34 ± 0.74 29.29 ± 0.85
11 38.85 ± 1.06 40.98 ± 0.82 30.74 ± 0.82 36.18 ± 0.94
12 45.71 ± 0.86 46.99 ± 0.67 37.41 ± 0.93 42.99 ± 1.19
13 7.43 ± 0.18 5.53 ± 0.36 11.94 ± 0.79 7.22 ± 0.39
14 14.80 ± 0.38 11.97 ± 0.63 20.45 ± 1.01 14.63 ± 0.42
15 21.73 ± 0.63 18.0 ± 0.80 26.97 ± 0.93 21.24 ± 0.52
16 28.27 ± 0.76 24.48 ± 1.04 33.53 ± 0.79 27.88 ± 0.63
17 34.59 ± 0.92 30.75 ± 1.07 39.37 ± 0.79 34.40 ± 0.59
18 40.99 ± 1.14 37.39 ± 1.17 45.54 ± 1.11 40.73 ± 0.54














Mice were fasted overnight for 16­18 hours before assessing whole body and localised lipid                         
content using MRI and 1H MRS. Mice were anaesthetised with a 3% oxygen­isofluorane mix. The                           
mix was maintained at 1.5­2% according to respiration and body temperature monitoring during                       
the scan (SA Instruments Inc. USA). Mice were placed in a whole body birdcage coil and                             
scanned in a 4.7T Unity Inova MR scanner (Varian Inc, USA).
{4.4.1} Time point 1: 4 weeks of feeding, no diet swaps
Mice fed a HF diet for 4 weeks were significantly heavier compared to mice a control fat diet                                 
(Figure 4.4.1.0.1:A. C: 26.6 ± 0.6 g; Fa: 33.0 ± 0.6 g. p<0.0001, n=10/group).
Whole body 1H MRS showed mice fed a HF diet for 4 weeks had significantly higher percentage                               
adiposity compared to control fed mice (Figure 4.4.1.0.1:B. C: 11.20 ± 1.09 %; Fa: 28.90 ± 1.22                               
%. p<0.0001, n=10/group). This shows increased body weight is strongly associated with                     
increase whole body adiposity in C57Bl6 mice
Figure {4.4.1.0.1} The effect of four weeks of high fat feeding on adiposity
A) Body weight of mice at the time of the scan; B) Whole body adiposity measurements as                               





The HFD control group FaFa maintained a significantly higher body weight compared to the                         
control diet group CC (Figure 4.4.2.0.1:A. CC: 30.8 ± 1.1 g; FaFa: 41.2 ± 1.3 g. p<0.001,                               
n=10/group). CFa mice swapped to the HF diet after 6 weeks of control diet feeding were also                               
significantly heavier compared to CC mice and comparable body weights to FaFa mice (CFa:                         
41.4 ± 1.5 g. p<0.001, n=10/group). Conversely, FaC mice swapped to the control diet after 6                             
weeks of HF diet feeding were significantly lighter compared to FaFa mice and were                         
indistinguishable from CC mice (FaC: 32.2 ± 1.3 g. p<0.001, n=10/group).
FaFa mice maintained a significantly higher level of whole body adiposity compared to CC mice                           
(Figure 4.4.2.0.1:B. FaFa: 32.21 ± 1.04 %; CC: 17.35 ± 1.69 %. p<0.001, n=10/group).
CFa mice had significantly higher whole body adiposity compared to CC mice after 4 weeks of                             
HF feeding (Figure 4.4.2.0.1:B. CF: 35.55 ± 0.63 %. p<0.001, n=10/group). This measurement in                         
adiposity is comparable to 10 weeks of HF feeding in FaFa mice.
FaC mice had significantly higher whole body adiposity compared to CC mice, showing a lasting                           
effect of HF diet feeding that could be detecting using whole body MRS, but was not detected                               
using body weight measurement alone (Figure 4.4.2.0.1:B. FaC: 22.65 ± 1.57 %. p<0.05,                       
n=10/group).
FaC mice had significantly lower whole body adiposity compared to FaFa mice, showing 4                         
weeks of control feeding is sufficient in reducing whole body adiposity (Figure 4.4.2.0.1:B.                       
p<0.001, n=10/group). However, these mice still showed a trend towards increased whole body                       





A) Body weight of mice at the time of the scan; B) Whole body adiposity measurements as                               





FaFaFa mice were significantly heavier compared to the control group CCC (Figure 4.4.3.0.1:A.                       
CCC: 34.5 ± 1.1 g; 45.5 ± 0.6 g. p<0.001, n=10/group).
The weight cycled group FaCFa regained almost all of the weight lost during the control diet                             
feeding period and had comparable body weights to FaFaFa mice (Figure 4.4.3.0.1:A. FaCFa:                       
44.3 ± 0.5 g, n=10/group). FaCFa mice were also significantly heavier compared to CCC mice                           
(Figure 4.4.3.0.1:A. p<0.001, n=10/group).
Unlike body weight measurements from time point 1, this time point showed mice fed a HF diet                               
for 6 weeks, CFaC, did not return to body weight measurements observed in CCC mice after 4                               
weeks of control diet feeding (Figure 4.4.3.0.1:A. CFaC: 37.9 ± 0.8 g. p<0.05, n=10/group).                         
However, CFaC mice were significantly lighter compared to both FaCFa and FaFaFa mice                       
(Figure 4.4.3.0.1:A. Both p<0.001, n=10/group). This may be a result of reduced flexibility for                         
losing weight  that could occur with age.
Whole body adiposity measurements closely resemble body weight measurements taken at the                     
the time of the scan. The only discrepancy seen is between CCC and CFaC mice which shows                               
an increase whole body adiposity, but is not significant (Figure 4.4.3.0.1:B. CCC: 20.07 ± 2.60 %;                             
CFaC: 24.86 ± 1.34 %, n=10/group). This contrasts with CFaC mice being significantly heavier                         
compared to CCC mice, as shown previously (Figure 4.1.2.0.1:B). This appears to be due to a                             
gradual increase in whole body adiposity in control fed mice, which is probably due to ageing.
However, CCC and CFaC mice show significantly lower whole body adiposity compared to both                         
FaCFa and FaFaFa mice (Figure 4.4.3.0.1:BFaCFa: 35.92 ± 0.72 %; FaFaFa: 34.40 ± 0.61 %,                           
Both p<0.001, n=10/group). FaCFa and FaFaFa mice show no difference in whole body                       





A) Body weight of mice at the time of the scan; B) Whole body adiposity measurements as                               






Using localised 1H MRS, intrahepatic cellular lipid (IHCL) content was assessed in mice fed a HF                             
or control diet for 4 weeks. Unlike the increased whole body adiposity observed above, no                           
difference in IHCL was detected between HF and control diet fed mice at this time point (Figure                               
4.5.1.0.1. C: 15.50 ± 0.78 %; Fa: 14.50 ± 1.54 %. n=10/group).
Figure {4.5.1.0.1} The effect of four weeks of high fat feeding on IHCL content





After 10 weeks of HF feeding, FaFa mice show significantly higher IHCL content compared to                           
CC mice (Figure 4.5.2.0.1. CC: 18.00 ± 3.80 %; FaFa: 50.09 ± 3.58 %. p<0.001, n=10/group).
CFa mice also show a significantly higher IHCL content compared to CC mice (Figure 4.5.2.0.1.                           
CFa: 50.09 ± 3.58 %. p<0.001, n=10/group). Although IHCL content was not significantly different                         
between CFa and FaFa mice, it was noticeably lower.
FaC mice had significantly reduced IHCL content compared to FaFa and CFa mice (Figure                         
4.5.2.0.1. FaC: 31.00 ± 4.91 %. FaC­FaFa: p<0.001. FaC­CFa: p<0.05. n=10/group). IHCL                     
content was slightly higher in FaC mice compared to CC mice, but this was not a significant                               
difference.
At this time point, IHCL content more closely resembles whole body adiposity measurements                       
compared to time point 1. IHCL content also generally resembles body weight measurements at                         
this time point, unlike time point 1.
Figure {4.5.2.0.1} The effect of maintained weight loss and gain on IHCL content
IHCL content was assessed using localised 1H MRS. Data presented as mean ± sem, n=                           





After 16 weeks of feeding, FaFaFa mice had a significantly higher IHCL content compared to                           
CCC mice (Figure 4.5.3.0.1. CCC: 26.56 ± 3.31 %; FaFaFa: 102.91 ± 9.13 %. p<0.001,                           
n=10/group).
Both weight cycled groups showed a higher IHCL content compared to CCC, but only FaCFa                           
mice were significantly different (Figure 4.5.3.0.1. CFaC: 50.33 ± 4.03 %; FaCFa: 60.89 ± 6.02                           
%. FaCFa­CCC: p<0.05. n=10/group).
Unlike whole body adiposity and body weight measurements indicating adiposity is comparable                     
between the HF fed groups at time point 3, IHCL content measurements at time point 3 show                               
FaCFa mice have significantly lower IHCL content compared to FaFaFa mice. This could be due                           
to the fact there was no difference in IHCL content at 4 weeks before swapping from a HF diet to                                     
a control diet. Unlike whole body adiposity, which was high to start, reduced and then regained,                             
there was no fat to regain in the liver. This suggests short HF­control diet cycles could prevent                               
the accumulation of fat in the liver, which would normally only possible with maintained continual                           
HF feeding.
Figure {4.5.3.0.1} The effect of a single weight cycle on IHCL content
IHCL content was assessed was assessed using localised 1H MRS. Data presented as mean ±                           





Localised MRS was used to assess intramuscular cellular lipid (IMCL) content in each group of                           
mice at each time point. However, no significant differences were detected at any time point                           
(Figure 4.6.0.0.1. Table 4.6.0.0.2). A trend towards increased IMCL content was observed in HF                         
fed mice at time point 2 and 3. IMCL measurements were much more variable compared to                             
whole body and liver MRS, most likely due to the difficulty of placing the voxel on the muscle                                 
without possible interference from surrounding subcutaneous tissue.
Figure {4.6.0.0.1} The effect of a single weight cycle on IMCL content
A) Time point 1; B) Time point 2 and C) Time point 3. IMCL content was assessed was                                 
assessed using localised 1H MRS. Data presented as mean ± sem, n= 10/group. p>0.05 was an                             


































Using whole body MRI, segmentation analysis was performed on the images produced to                       
differentiate between white adipose tissue (WAT) depots, and therefore assess changes in WAT                       
distribution.
{4.7.1} Time point 1: 4 weeks of feeding, no diet swaps
4 weeks of high fat feeding significantly increased the amount of WAT in Fa mice compared to C                                 
mice (Figure 4.7.1.0.1:A. C: 5.38 ± 0.19 g; Fa: 10.11 ± 0.29 g. p<0.0001, n=10/group). This                             
remained true when normalising total WAT to body weight (C: 20.27 ± 1.01 %; Fa: 30.62 ± 0.54                                 
%. p<0.0001, n=10/group). This strongly matches the results obtained using whole body MRS                       
above (Figure 4.7.1.0.1:B).
Figure {4.7.1.0.1} The effect of four weeks of high fat feeding on total body WAT
A) Total body WAT measured in grams; B) Total body WAT as a percentage of body weight.                               




A comparison of subcutaneous WAT showed Fa mice had significantly more subcutaneous                     
WAT compared to C mice, both in total and as a percentage of body weight (Total: Figure                               
4.7.1.0.2:A. C: 3.15 ± 0.08 g; Fa: 5.53 ± 0.12 g. p<0.0001. Normalised: Figure 4.7.1.0.2:B. C:                             
11.82 ± 0.47 %; Fa: 16.79 ± 0.34 %. p<0.0001, n=10/group).
Figure {4.7.1.0.2} The effect of four weeks of high fat feeding on subcutaneous WAT
A) Subcutaneous WAT measured in grams; B) Subcutaneous WAT as a percentage of body                         




Assessment of internal WAT also showed Fa mice had significantly more internal WAT                       
compared to C mice, both in total and as a percentage of body weight (Total: Figure 4.7.1.0.3:A.                               
C: 2.24 ± 0.11 g; Fa: 4.58 ± 0.18 g. p<0.0001. Normalised: Figure 4.7.1.0.3:B. C: 8.45 ± 0.55 %;                                   
Fa: 13.83 ± 0.31 %. p<0.0001, n=10/group).
Figure {4.7.1.0.3} The effect of four weeks of high fat feeding on internal WAT
A) Internal WAT measured in grams; B) Subcutaneous WAT as a percentage of body weight.                           




Comparing the internal:subcutaneous WAT ratio indicates the relative distribution of WAT. Fa                     
mice showed a significantly higher internal:subcutaneous ratio compared to C mice, indicating 4                       
weeks of HF feeding increases the proportion of fat around the internal organs, as opposed to                             
being deposited under the skin (Figure 4.7.1.0.4. C: 0.709 ± 0.021; Fa: 0.825 ± 0.019. p=0.0008,                             
n=10/group).
Figure {4.7.1.0.4} The effect of four weeks of high fat feeding on internal:subcutaneous                       
WAT ratio





10 weeks of high fat feeding significantly increased the amount of WAT in FaFa mice compared                             
to CC mice (Figure 4.7.2.0.1:A. CC: 6.73 ± 0.48 g; FaFa: 13.08 ± 0.34 g. p<0.001, n=10/group).                               
This remained true when normalising total WAT to body weight (Figure 4.7.2.0.1:B. CC: 21.60 ±                           
1.17 %; FaFa: 31.91 ±  0.82 %. p<0.001, n=10/group).
CFa mice also had significantly more WAT compared to CC mice (Figure 4.7.2.0.1:A. CFa:                         
14.35 ± 0.85 g. p<0.001, n=10/group). This difference remained when normalising to body weight                         
(Figure 4.7.2.0.1:B. CFa: 34.80 ± 1.21 %. p<0.001, n=10/group). These results resemble those                       
produced using whole body MRS shown above (Figure 4.4.2.0.1:B). A trend showing an increase                         
in total WAT was observed in CFa mice compared to FaFa mice, however this difference was                             
not significant.
FaC mice had significantly less WAT compared to FaFa mice (Figure 4.7.2.0.1:A. FaC: 8.30 ±                           
0.67 g. p<0.001, n=10/group). Again, this significant difference remained when total WAT was                       
normalised to body weight (Figure 4.7.2.0.1:B. FaC: 25.12 ± 1.36 %. p<0.01, n=10/group). There                         
was no significant difference between FaC mice and CC mice, as was observed using whole                           
body MRS to assess adiposity, however a trend showing FaC mice had more total WAT was                             
observed.
Figure {4.7.2.0.1} The effect of maintained weight loss and gain on total body WAT
A) Total body WAT measured in grams; B) Total body WAT as a percentage of body weight.                               
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




A comparison of subcutaneous WAT shows FaFa mice had significantly more subcutaneous                     
WAT compared to CC mice, both in total and as a percentage of body weight (Total: Figure                               
4.7.2.0.2:A. CC:3.78 ± 0.23 g; FaFa: 7.57 ± 0.20 g. p<0.0001. Normalised: CC: Figure                         
4.7.2.0.2:B. 12.15 ± 0.54 %; FaFa: 18.48 ± 0.54 %. p<0.0001, n=10/group).
CFa mice also had significantly more subcutaneous WAT compared to CC mice, and had a                           
comparable amount to FaFa mice (Figure 4.7.2.0.2:A. CFa: 7.64 ± 0.46 g. p<0.001, n=10/group).                         
This difference remained when normalising to body weight (Figure 4.7.2.0.2:B. CFa: 18.53 ± 0.71                         
%. p<0.001, n=10/group).
FaC mice showed significantly less subcutaneous WAT compared to FaFa mice (Figure                     
4.7.2.0.2:A. FaC: 4.80 ± 0.34 g. p<0.001, n=10/group), which remained significant when                     
normalising to body weight (Figure 4.7.2.0.2:B. FaC: 14.57 ± 0.61 %. p<0.001, n=10/group).                       
Subcutaneous WAT showed a trend of increase subcutaneous WAT in FaC mice compared to                         
CC. This difference was significant when comparing subcutaneous WAT as a percentage of                       
body weight. This is similar to the results presented assessing whole body adiposity using whole                           
body MRS, again indicating 4 weeks of control fat feeding was not sufficient to reduce this                             
depot’s size.
Figure {4.7.2.0.2} The effect of maintained weight loss and gain on subcutaneous WAT
A) Subcutaneous WAT measured in grams; B) Subcutaneous WAT as a percentage of body                         
weight. Quantification of WAT was assessed using whole body MRI. Data presented as mean ±                           




FaFa mice had significantly more internal WAT compared to CC mice, both in total and as a                               
percentage of body weight (Total: Figure 4.7.2.0.3:A. CC: 2.95 ± 0.26 g; FaFa: 5.51 ± 0.20 g.                               
p<0.0001. Normalised: Figure 4.7.2.0.3:B. CC: 9.45 ± 0.66 %; FaFa: 13.43 ± 0.43 %. p<0.0001,                           
n=10/group).
CFa mice also had significantly more internal WAT compared to CC mice (Figure 4.7.2.0.3:A.                         
CFa: 6.71 ± 0.41 g. p<0.001, n=10/group). This difference remained when normalising to body                         
weight (Figure 4.7.2.0.3:B. CFa: 16.26 ± 0.59 %. p<0.001, n=10/group). A strong trend showing                         
an increased amount of internal WAT was observed in CFa mice compared to FaFa mice. This                             
difference was significant when comparing internal WAT as a percentage of body weight (Figure                         
4.7.2.0.3:B. p<0.05, n=10/group). This difference in internal WAT accounts for the trend in total                         
WAT showing an increased amount in CFa mice compared FaFa mice, as there is very little                             
difference in subcutaneous WAT content. This indicates short term HF feeding strongly affects                       
internal WAT content, and this in turn contributes to the rapid weight gain observed in these                             
mice.
FaC mice showed significantly less internal WAT compared to FaFa mice (Figure 4.7.2.0.3:A.                       
FaC: 3.50 ± 0.35 g. p<0.001, n=10/group), which remained significant when normalising to body                         
weight (Figure 4.7.2.0.3:B. FaC: 10.55 ± 0.81 %. p<0.05, n=10/group). Internal WAT showed a                         
small trend of increased subcutaneous WAT in FaC mice compared to CC. Unlike,                       
subcutaneous WAT, this difference was not significant when comparing subcutaneous WAT as                     





A) Internal WAT measured in grams; B) Internal WAT as a percentage of body weight.                           
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




A comparison of internal:subcutaneous ratios shows an increase the proportion of internal fat in                         
CFa mice compared to all other groups (Figure 4.7.2.0.4. CC: 0.77 ± 0.03; CFa: 0.88 ± 0.03;                               
FaC: 0.72 ± 0.03; FaFa: 0.73 ± 0.03. CC­CFa: p<0.05; CFa­FaC: p<0.01; CFa­FaFa: p<0.01,                         
n=10/group). This agrees with the conclusion that the increase in adiposity and body weight                         
observed in CFa mice is a result of an accumulation of internal WAT.
Figure {4.7.2.0.4} The effect of maintained weight loss and gain on internal:                     
subcutaneous WAT ratio
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           





16 weeks of high fat feeding significantly increased the amount of WAT in FaFaFa mice                           
compared to CCC mice (Figure 4.7.3.0.1:A CCC: 8.96 ± 0.88 g; FaFaFa: 14.26 ± 0.49 g.                             
p<0.001, n=10/group). This difference remained significant when normalising total WAT to body                     
weight (Figure 4.7.3.0.1:B. CCC: 25.50 ± 1.80 %; FaFa: 31.51 ± 0.72 %. p<0.01, n=10/group).
CFaC mice showed a reduced amount of total WAT compared to FaFaFa mice (Figure                         
4.7.3.0.1:A. CFaC: 10.30 ± 0.52 g. Total: p<0.001, n=10/group), however this reduction in total                         
WAT was not significant when normalised to body weight (Figure 4.7.3.0.1:B. CFaC: 27.21 ±                         
1.18 %. n=10/group). This may indicate weight loss in older mice is more difficult. CFaC mice                             
had a total WAT amount comparable to CCC mice (Figure 4.7.3.0.1:A. Similarly, there was also                           
no difference between CCC and CFaC mice when comparing total WAT as a percentage of                           
body weight (Figure 4.7.3.0.1:B). These results resemble those produced using whole body                     
MRS shown above (Figure 4.4.3.0.1:B), however neither of these methods represent the                     
significantly higher body weight observed in CFaC mice compared to CCC mice.
FaCFa mice had significantly more total WAT compared to CCC mice (Figure 4.7.3.0.1:A.                       
FaCFa: 16.03 ± 0.30 g. p<0.001, n=10/group). Again, this significant difference remained when                       
total WAT was normalised to body weight (Figure 4.7.3.0.1:B. FaCFa: 36.15 ± 0.60 %. p<0.001,                           
n=10/group), suggesting fat is easier to accumulate at this age compared to losing fat. There                           
was no significant difference between FaCFa and FaFaFa mice when comparing total WAT,                       
however a trend showing an increased amount of total WAT was observed in FaCFa mice                           
compared to FaFaFa. When normalised to body weight, this difference was significant (p<0.05,                       





A) Total body WAT measured in grams; B) Total body WAT as a percentage of body weight.                               
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




16 weeks of high fat feeding significantly increased the amount of subcutaneous WAT in FaFaFa                           
mice compared to CCC mice (Figure 4.7.3.0.2:A. CCC: 5.00 ± 0.47 g; FaFaFa: 8.65 ± 0.32 g.                               
p<0.001, n=10/group). This difference remained significant when normalising subcutaneous               
WAT to body weight (Figure 4.7.3.0.2:B. CCC: 14.26 ± 0.92 %; FaFaFa: 19.11 ± 0.48 %. p<0.01,                               
n=10/group).
CFaC mice showed a significantly reduced amount of subcutaneous WAT compared to FaFaFa                       
mice (Figure 4.7.3.0.2:A. CFaC: 5.93 ± 0.26 g. Total: p<0.001, n=10/group), which remained                       
significant when normalised to body weight (Figure 4.7.3.0.2:B. CFaC: 15.67 ± 0.58 %. p<0.01,                         
n=10/group).
There was no significant difference between CCC and CFaC mice when comparing                     
subcutaneous WAT mass and as a percentage of body weight (Figure 4.7.3.0.2:A­B).
FaCFa mice had significantly more subcutaneous WAT compared to CCC mice (Figure                     
4.7.3.0.2:A. FaCFa: 8.59 ± 0.16 g. p<0.001, n=10/group). Again, this significant difference                     
remained when subcutaneous WAT was normalised to body weight (Figure 4.7.3.0.2:B. FaCFa:                     
19.38 ± 0.34 %. p<0.001, n=10/group).
There was no significant difference between FaCFa and FaFaFa mice when comparing                     





A) Subcutaneous WAT measured in grams; B) Subcutaneous WAT as a percentage of body                         
weight. Quantification of WAT was assessed using whole body MRI. Data presented as mean ±                           




16 weeks of high fat feeding significantly increased the amount of internal WAT in FaFaFa mice                             
compared to CCC mice (Figure 4.7.3.0.3:A. CCC: 3.96 ± 0.44 g; FaFaFa: 5.61 ± 0.20 g. p<0.01,                               
n=10/group). However, this difference was no longer significant when normalising internal WAT                     
to body weight (Figure 4.7.3.0.3:B. CCC: 11.86 ± 0.85 %; FaFaFa: 12.40 ± 0.34 %. n=10/group).
CFaC mice showed a significantly reduced amount of internal WAT compared to FaFaFa mice                         
(Figure 4.7.3.0.3:A. CFaC: 4.37 ± 0.27 g. Total: p<0.05, n=10/group), but again this was no                           
longer significant when normalised to body weight (Figure 4.7.3.0.3:B. CFaC: 11.54 ± 0.63 %.                         
n=10/group). There was no significant difference between CCC and CFaC mice when                     
comparing internal WAT mass and as a percentage of body weight (Figure 4.7.3.0.3:A­B).
FaCFa mice had significantly more internal WAT compared to CCC mice (Figure 4.7.3.0.3:A.                       
FaCFa: 7.44 ± 0.21 g. p<0.001, n=10/group). This difference remained significant when internal                       
WAT was normalised to body weight (Figure 4.7.3.0.3:B. FaCFa: 16.78 ± 0.44 %. p<0.001,                         
n=10/group). Interestingly, there was a significant difference between FaCFa and FaFaFa mice                     
when comparing internal WAT mass (Figure 4.7.3.0.3:A. p<0.001, n=10/group). This difference                   
remained when normalising internal WAT amount to body weight (Figure 4.7.3.0.3:B. p<0.001,                     
n=10/group).
Figure {4.7.3.0.3} The effect of a single weight cycle on internal WAT
A) Internal WAT measured in grams; B) Internal WAT as a percentage of body weight.                           
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




Similarly to the internal WAT results presented above, the internal:subcutaneous ratio indicates                     
an increase internal adiposity in FaCFa mice compared to CCC and FaFaFa mice (Figure                         
4.7.3.0.4. CCC: 0.76 ± 0.04; FaCFa: 0.87 ± 0.02; FaFaFa: 0.65 ± 0.02. CCC­CFaC: p<0.05;                           
FaCFa­FaFaFa: p<0.05, n=10/group). A significantly smaller internal:subcutaneous WAT ratio is                 
observed in FaFaFa mice compared to CFaC mice, indicating long term HF feeding results in a                             
greater proportion of fat being stored in subcutaneous depots as opposed to the internal depots.
Figure {4.7.3.0.4} The effect of a single weight cycle on internal:subcutaneous WAT ratio
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           





To assess changes in glucose tolerance due to rapid weight changes, an intraperitoneal glucose                         
tolerance test (IPGTT) was performed. Mice were fasted overnight for 16­18 hours prior to the                           
IPGTT. Fasting glucose was determined with a commercially available glucose metre before                     
injecting a 2g/kg D­glucose bolus i.p. Blood glucose concentration was determined 15, 30, 60                         
and 120 minutes after the glucose injection.
{4.8.1} Time point 1: 5 weeks of feeding, no diet swaps
Mice fed a HF diet for 5 weeks were significantly heavier than mice fed a control diet for 6 weeks                                     
(Figure 4.8.1.0.1: A. C: 27.0 ± 0.7 g; Fa: 34.5 ± 0.7 g. p<0.0001, n=12/group).
Blood glucose concentration was significantly higher at all time points measured during the                       
IPGTT (Figure 4.8.1.0.1:B. Table 4.8.1.0.2. 0 mins: p<0.05; 15 mins: p<0.01; 30 mins: p<0.05;                         
60 mins: p<0.001; 120 mins: p<0.01, n=12/group). AUC measurements of glucose tolerance                     
showed mice fed a HF diet were significantly more glucose intolerant than mice fed a control                             





A) Body weight of mice at the time of the IPGTT; B) Blood glucose measurements during the                               
IPGTT measured in mmol/L. C) Area under the curve analysis of the IPGTT. Glucose tolerance                           
was assessed using an IPGTT. Data presented as mean ± sem, n=12/group. * p<0.05, **                           









Blood glucose measurements during the IPGTT measured in mmol/L. Data presented as mean                       





FaFa mice were significantly heavier than the control diet group, CC after 11 weeks of feeding on                               
their respective diets (Figure 4.8.2.0.1:A. CC: 31.9 ± 0.6 g; FaFa: 39.0 ± 1.1 g. p<0.001,                             
n=12/group). CFa mice swapped to a HF diet for 5 weeks after 6 weeks of control diet feeding                                 
were significantly heavier compared to the CC mice (Figure 4.8.2.0.1:A. CFa: 40.1 ± 1.6 g.                           
p<0.001, n=12/group) but were comparable to FaFa mice. Conversely, FaC mice swapped to a                         
control diet for 5 weeks after 6 weeks of HF diet feeding were significantly lighter than FaFa mice                                 
(Figure 4.8.2.0.1:A. FaC: 30.6 ± 1.1 g. p<0.001, n=12/group), but were comparable to CC mice.
Blood glucose concentration measurements were no longer significantly higher at all time points                       
during the IPGTT between CC and FaFa mice (Figure 4.8.2.0.1:B. Table 4.8.2.0.2). Blood                       
glucose concentration was higher at 30 minutes for FaFa mice compared to CC mice, but this                             
was not significant. Both 60 and 120 minute blood glucose measurements were significantly                       
higher in FaFa mice compared to CC mice (p<0.001, n=12/group). AUC measurements of                       
glucose tolerance still show an increased level of glucose intolerance in FaFa mice compared to                           
CC mice (Figure 4.8.2.0.1:C. CC: 1898 ± 129.9; FaFa: 2484 ± 129.3. p<0.05, n=12/group), as                           
observed above after 5 weeks of HF diet feeding (Section 4.8.1) .
After swapping to a HF diet for 5 weeks, CFa mice showed a higher blood glucose concentration                               
compared to CC mice at all points during the IPGTT, although this was only significant from                             
30­120 minutes (Figure 4.8.2.0.1:B. Table 4.8.2.0.2. 30 mins: p<0.01; 60­120 mins: p<0.001,                     
n=12/group). AUC measurements of glucose tolerance show CFa mice have an increased                     
glucose intolerance compared to CC mice (Figure 4.8.2.0.1:C. CFa: 2713 ± 79.7. p<0.001,                       
n=12/group). This indicates 5 weeks of HF feeding is sufficient to induce a degree of insulin                             
resistance. There was very little difference between blood glucose concentration measurements                   
during the IPGTT and the resulting AUC measurement of glucose tolerance between CFa and                         
FaFa mice. Again, this indicates 5 weeks of HF feeding is sufficient in inducing a similar profile of                                 
glucose tolerance as 11 weeks of HF feeding.
After swapping to a control diet for 5 weeks, FaC mice showed a lower blood glucose                             
concentration compared to FaFa mice at all points during the IPGTT, although this was only                           
significant from 30­120 minutes (Figure 4.8.2.0.1:B. Table 4.8.2.0.2. 30 mins: p<0.05. 60­120                     
349
The effects of a single weight cycle on metabolism and appetite           4. Results.
mins: p<0.001, n=12/group). AUC measurements of glucose tolerance show FaC mice have an                       
increased glucose tolerance compared to FaFa mice, indicating 5 weeks of control diet feeding                         
is sufficient in recovering insulin sensitivity (Figure 4.8.2.0.1:B. Table 4.8.2.0.2FaC: 1781 ± 155.1.                       
p<0.01, n=12/group). Similarly, comparing FaC and CC mice, there is very little difference in                         
blood glucose concentration measurements during the IPGTT and the resulting AUC                   
measurement of glucose tolerance. This indicates 5 weeks of control diet feeding after 6 weeks                           
of HF feeding is sufficient in returning previously overweight mice to a glucose tolerance profile                           
similar to mice fed a control diet for 11 weeks.
Figure {4.8.2.0.1} The effect of maintained weight loss and gain on glucose tolerance
A) Body weight of mice at the time of the IPGTT; B) Area under the curve (AUC) analysis of the                                     
IPGTT. Glucose tolerance was assessed using an IPGTT. Data presented as mean ± sem,                         
n=12/group. * p<0.05, ** p<0.01, *** p<0.001. Statistical analysis was performed using a                       
One­Way ANOVA with Tukey correction.
Time (mins) CC (mmol/L) CFa (mmol/L) FaC (mmol/L) FaFa (mmol/L)
0 8.4 ± 0.8 10.8 ± 0.7 6.8 ± 0.6 8.2 ± 0.8
15 19.8 ± 1.4 23.2 ± 0.7 18.4 ± 1.8 21.2 ± 1.2
30 20.1 ± 1.2 25.3 ± 0.6 18.7 ± 1.8 23.7 ± 1.1
60 16.7 ± 1.3 24.3 ± 0.9 15.7 ± 1.8 23.2 ± 1.3
120 11.3 ± 1.1 20.7 ± 1.1 11.0 ± 0.9 17.7 ± 1.5
Table {4.8.2.0.2} The effect of maintained weight loss and gain on glucose tolerance





Blood glucose measurements during the IPGTT measured in mmol/L. Glucose tolerance was                     
assessed using an IPGTT. Data presented as mean ± sem, n= 12/group. * p<0.05, ** p<0.01,                             





After 17 weeks of feeding, FaFaFa were significantly heavier than CCC mice (Figure 4.8.3.0.1:A.                         
CCC: 31.9 ± 1.3 g; FaFaFa: 45.6 ± 0.5 g. p<0.001, n=12/group). CFaC mice were still                             
significantly heavier than CCC mice (Figure 4.8.3.0.1:A. CFa: 35.3 ± 0.9 g. p<0.05, n=12/group)                         
but were also significantly lighter compared to FaFaFa mice (p<0.001, n=12/group). FaCFa mice                       
had regained a substantial amount of weight to make them significantly heavier than CCC mice                           
(Figure 4.8.3.0.1:A. FaC: 44.7 ± 0.7 g. p<0.001, n=12/group) and were no longer different from                           
FaFaFa mice.
Strangely, after 17 weeks of HF diet feeding, FaFaFa mice showed similar blood glucose                         
measurements as CCC mice fed a control diet for 17 weeks (Figure 4.8.3.0.3:A. Table                         
4.8.3.0.2). Fasting glucose was higher in FaFaFa mice, but this was not significant. These blood                           
glucose measurements resulted in a similar AUC measurement for the two control groups,                       
indicating there was no difference in glucose tolerance between mice fed a control diet or HF diet                               
for 17 weeks (Figure 4.8.3.0.1:B. CCC: 1792 ± 115.2; FaFaFa: 1985 ± 104.8. n=12/group).
Although the weight loss observed in CFaC was not quite sufficient to return these mice to body                               
weights observed in CCC mice, the blood glucose concentration measurements during the                     
IPGTT were indistinguishable (Figure 4.8.3.0.3:B. Table 4.8.3.0.2), as was the resulting AUC                     
measurement (Figure 4.8.3.0.1:B. CFaC: 1822 ± 79.3. n=12/group).
FaCFa mice showed an increased blood glucose concentration at all points during the IPGTT                         
compared to CCC mice, however this was only significant at 60 and 120 minutes (Figure                           
4.8.3.0.3.C. Table 4.8.3.0.2. 60 mins: p<0.01; 120 mins: p<0.001, n=12/group). The resulting                     
AUC measurement indicates these mice are again significantly more intolerant to glucose than                       
CCC mice (Figure 4.8.3.0.1:B. FaC: 2448 ± 95.1. p<0.001, n=12/group). However, due to the                         
unexpected blood glucose measurements observed in FaFaFa mice, FaFaFa mice were                   





A) Body weight of mice at the time of the IPGTT; B) Area under the curve analysis of the IPGTT.                                     
Glucose tolerance was assessed using an IPGTT. Data presented as mean ± sem, n=                         
12/group. * p<0.05, *** p<0.001. Statistical analysis was performed using a One­Way ANOVA                       
with Tukey correction.
Time (mins) CCC (mmol/L) CFaC (mmol/L) FaCFa (mmol/L) FaFaFa (mmol/L)
0 6.3 ± 0.4 6.7 ± 0.6 9.7 ± 0.3 9.7 ± 0.5
15 16.9 ± 0.8 17.5 ± 1.2 20.1 ± 0.8 19.5 ± 1.1
30 19.4 ± 1.1 19.8 ± 0.8 22.6 ± 0.8 19.6 ± 1.0
60 15.7 ± 1.1 15.9 ± 1.0 21.4 ± 1.3 16.7 ± 1.0
120 11.6 ± 1.4 11.6 ± 0.6 20.7 ± 1.4 14.3 ± 1.0
Table {4.8.3.0.2} The effect of a single weight cycle on glucose tolerance





Blood glucose measurements during the IPGTT measured in mmol/L. Glucose tolerance was                     
assessed using an IPGTT. Data presented as mean ± sem, n=12/group. * p<0.05, ** p<0.01, ***                             





Mice were housed individually in CLAMS metabolic cages to assess changes in food intake,                         
water intake, O2 consumption, CO2 production and movement.
{4.9.1} Time point 1: 6 weeks of feeding, no diet swaps
Water intake was measured during a full light cycle and showed an increase in water intake in C                                 
mice compared to Fa mice, which was significant during the last two hours of recording (Figure                             
4.9.1.0.1:A. p<0.05, n=7­8/group). Water intake was significantly higher during the lights phase                     
compared to Fa mice, and a trend was observed during the dark phase (Figure 4.9.1.0.1:B.                           
Table 4.9.1.0.4. Light: C: 0.5430 ± 0.1501 ml; Fa: 0.1833 ± 0.04244 ml. p=0.0293. Dark: C:                             
0.8094 ± 0.1553 ml; Fa: 0.5926 ± 0.0730 ml. p=0.2099. n=7­8/group).
Figure {4.9.1.0.1} The effect of 6 weeks of high fat feeding on cumulative water intake                           
measured using CLAMS metabolic cages
A) Total water intake during the light phase and dark phase of the light cycle; B) Water intake                                 
over a 24 hour light cycle. Water intake measured in mls using CLAMS metabolic cages.                           
Shaded area on the graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data                             




Oxygen consumption and carbon dioxide production show a slight reduction in both                     
measurements in Fa mice compared to C mice, although the difference between the two groups                           
reduced at the onset of the dark phase (Figure 4.9.1.0.2:A,C). O2 consumption was significantly                         
reduced during the light phase in Fa mice compared to C mice, whilst no significant difference                             
was seen during the dark phase between groups (Figure 4.9.1.0.2:B. Table 4.9.1.0.4. Light: C:                         
3449 ± 74.3 ml/kg0.75/hr; Fa: 3118 ± 66.86 ml/kg0.75/hr. p=0.0052. Dark: C: 3669 ± 97.02                           
ml/kg0.75/hr; Fa: 3533 ± 93.63 ml/kg0.75/hr. p=0.3293, n=8/group). Similarly, CO2 production was                     
significantly reduced in Fa mice compared to C mice during both the light and dark phase                             
(Figure 4.9.1.0.2:D. Table 4.9.1.0.4. Light: C: 2908 ± 82.86 ml/kg0.75/hr; Fa: 2311 ± 55.32                         
ml/kg0.75/hr. p<0.0001. Dark: 3206 ± 131.3 ml/kg0.75/hr; Fa: 2591 ± 70.28 ml/kg0.75/hr. p=0.0010.                       
n=8/group).
A significantly lower respiratory exchange ratio (RER) value was observed in Fa mice compared                         
to C mice during the whole 24 hour recording period (Figure 4.9.1.0.3:A. 13:00­06:00 hours :                           
p0.001; 07:00­11:00 hours: p<0.01, n=8/group). Similarly, a significant decrease in RER in Fa                       
mice compared to C mice was observed when comparing RER during the light and dark phase                             
of the light cycle (Figure 4.9.1.0.3:B. Table 4.9.1.0.4. Light: C: 0.8445 ± 0.0181; Fa: 0.7280 ±                             
0.0035. p<0.0001. Dark: C: 0.8749 ± 0.0236; Fa: 0.7312 ± 0.0037. p<0.0001, n=8/group).
Heat production was slightly elevated in Fa mice compared to C mice throughout, but this was                             
only significant shortly after the onset of the dark phase from 20:00 to 22:00 hours (Figure                             
4.9.1.0.3:C. 20:00­21:00 hours: p<0.001; 22:00 hours: p<0.01, n=8/group). Heat production was                   
significantly higher in Fa mice during the dark phase, whilst a trend was also apparent during the                               




Figure {4.9.1.0.2} The effect of 6 weeks of high fat feeding on O2 consumption and CO2                             
production measured using CLAMS metabolic cages
A) O2 consumption over 24 hour light cycle; B) O2 consumption during light phase and dark                             







Figure {4.9.1.0.3} The effect of 6 weeks of high fat feeding on RER and heat production                             
measured using CLAMS metabolic cages
A) Respiratory exchange ratio (RER) over 24 hour light cycle; B) RER during light phase and                             
dark phase of the light cycle; C) Heat production over 24 hour light cycle; D) Heat production                               
during light and dark phase of the light cycle.
Shaded area on the graph represents the dark phase of the light cycle. Data presented as mean                               





Water intake (ml) Light 0.543 ± 0.150 0.183 ± 0.042 <0.05
Dark 0.809 ± 0.155 0.593 ± 0.073 n.s
VO2 (ml/kg0.75/hr) Light 3449 ± 74.4 3118 ± 66.9 <0.01
Dark 3669 ± 97.0 3533 ± 93.6 n.s
VCO2 (ml/kg0.75/hr) Light 2908 ± 82.9 2311 ± 55.3 <0.001
Dark 3206 ± 131.3 2591 ± 70.3 <0.01
RER Light 0.8445 ± 0.0181 0.7280 ± 0.0035 <0.001
Dark 0.8749 ± 0.0236 0.7312 ± 0.0037 <0.001
Heat (kcal/hr) Light 0.5577 ± 0.0175 0.6080 ± 0.0182 n.s
Dark 0.5970 ± 0.0247 0.6925 ± 0.0190 <0.01
Table {4.9.1.0.4} The effect of 6 weeks of high fat feeding on indirect calorimetry                         
measurements
Total water intake (ml), average O2 consumption (ml/kg0.75/hr), CO2 production (ml/kg0.75/hr),                   
RER (arbitrary unit) and heat production (kcal/hr) measured during the light and dark phase of a                             
24 hour light cycle using CLAMS metabolic cages. RER and heat production calculated using                         
equations 2.4.3.0.1. Data presented as mean ± sem, n=7­8/group. n.s=not significant. Yellow                     




Movement was assessed using infrared beams, with a beam crossing given as one count of                           
movement. XAMB counts measured ambulatory activity on a horizontal axis. ZTOT counts                     
measured movement in the vertical axis, such as rearing. XTOT counts measure all movement                         
in the horizontal axis, including fine movements such as grooming. In all planes of movement,                           
counts increased in all groups initially at the onset of the dark phase of the light cycle at 19:00. A                                     
second peak was also observed between 05:00 to 07:00.
No significant difference in XAMB activity was observed between groups, although both groups                       
showed an increase in ambulatory activity at the onset of the dark phase of the light cycle (Figure                                 
4.9.1.0.5:A). No difference in total ambulatory activity during the light or dark cycle was observed                           
between groups, or during the whole 24 hour recording period (Figure 4.9.1.9.5:B. Table                       
4.9.1.0.6. Light: p=0.3785. Dark: p=0.7049. 24hr: 0.6267, n=8/group).
In contrast, ZTOT count analysis showed C mice were more active in this plane of movement                             
compared to Fa mice, which was significant from 22:00 to 24:00 hours (Figure 4.9.1.0.5:C.                         
p<0.01­0.001, n=8/group) Total vertical movement during the dark phase of the light cycle and                         
over the whole 24 hour light cycle was significantly increased in C mice compared to Fa mice                               
(Figure 4.9.1.0.5:D. Table 4.9.1.0.6. Light: p=0.1112. Dark: p=0.0089. 24hr: 0.0115, n=8/group).                   
This could be due to higher in water consumption in C mice compared to Fa mice, as rearing is                                   
required to drink in these cages.
These was no significant difference in XTOT counts, although C mice showed a higher XTOT                           
count compared to Fa mice at the onset of the dark phase (Figure 4.9.1.0.5:E). No significant                             
difference between groups was observed during the light or dark phase of the light cycle, or                             
when comparing total movement over the 24 hour light cycle (Figure 4.9.1.0.5:F. Table 4.9.1.0.6.                         
Light: p=0.0948. Dark: p=0.2095. 24hr: p=0.1469, n=8/group). A trend showing a decrease in                       




Figure {4.9.1.0.5} The effect of 6 weeks of high fat feeding on activity measured using                           
CLAMS metabolic cages
A) Ambulatory activity counts (XAMB) over 24 hour light cycle; B) Total XAMB counts during light                             
phase, dark phase and entire light cycle; C) Rearing activity counts (ZTOT) over 24 hour light                             
cycle; D) Total ZTOT counts during light phase, dark phase and entire light cycle; E) All                             
movement along the horizontal plane (XTOT), including ambulatory and fine movements (such                     
as grooming) over 24 hour cycle; F) Total XTOT counts during light phase, dark phase and entire                               
light cycle. Shaded area on the graph represents the dark phase of the light cycle. Data                             





Light C 3164 ± 485.9 687.0 ± 195.1 7798 ± 987.6
Fa 3862 ± 593.8 331.8 ± 74.77 5873 ± 423.1
Dark C 12850 ± 2345 4505 ± 970.1 24730 ± 3777
Fa 13830 ± 1714 1500 ± 196.7 19340 ± 1583
Total C 16020 ± 2494 5192 ± 1128 32530 ± 4340
Fa 17700 ± 2271 1831 ± 254.0 25220 ± 1959
Table {4.9.1.0.6} The effect of 6 weeks of high fat feeding on activity
Total number of XAMB, ZTOT and XTOT counts during the light phase, dark phase and over a                               
whole 24 hour light cycle. Data presented as mean ± sem, n=7­8/group. Yellow highlight                         





Cumulative water intake in CC mice was significantly higher compared to FaFa from 21:00 to                           
11:00 hours (Figure 4.9.2.0.1:B. 21:00­22:00 hrs: p<0.05; 24:00­01:00 hrs: p<0.01; 02:00­11:00                   
hr: p<0.001, n=7­8/group). Similarly, cumulative water intake was also significantly higher for CC                       
mice compared to CFa mice (Figure 4.9.2.0.2:C. CC­CFa: 23:00 hr: p<0.05; 24:00 hr: p<0.01;                         
01:00­11:00 hrs: p<0.001, n=7­8/group). CC mice showed a higher cumulative water intake after                       
24 hours compared to FaC mice (Figure 4.9.2.0.2:D. 11:00 hr: p<0.05, n=7­8/group).
FaC mice showed a significant increase in water intake compared to FaF mice from 04:00 to                             
011:00 hours (Figure 4.9.2.0.2:F. 04:00 hr: p<0.05; 05:00­06:00 hrs: p<0.01; 07:00­11:00 hr:                     
p<0.001, n=7­8/group). No significant difference in water intake was observed between CFa and                       
FaFa mice (Figure 4.9.2.0.2:E).
A comparison of water intake during the light and dark phase of the light cycle shows CC mice                                 
consume significantly more water compared to both CFa and FaFa mice (Figure 4.9.2.0.2:A.                       
Table 4.9.2.0.6. Light: CC­CFa: p<0.01; CC­FaFa: p<0.001. Dark: CC­CFa/FaFa: p<0.01,                 
n=7­8/group). A trend showing increased water intake in CC mice during the light and dark                           
phase of the light cycle was also observed compared to FaC mice. FaC mice also showed a                               




Figure {4.9.2.0.1} The effect of maintained weight change on cumulative water intake                     
measured using CLAMS metabolic cages
A) Total water intake during the light phase and dark phase of the light cycle; B­F) Water intake                                 
over a 24 hour light cycle. Water intake measured in mls using CLAMS metabolic cages.                           
Shaded area on the graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data                             




Oxygen consumption measurements showed no significant differences over the 24 hour light                     
cycle (Figure 4.9.2.0.2:B­F). However, control fed mice (CC and FaC) showed a higher rate of                           
O2 consumption compared to HF fed mice (CFa and FaFa) in general. CFa and FaFa O2                             
consumption was very similar over 24 hours, whereas FaC mice showed a slightly delayed                         
increase in O2 consumption associated with the onset of the dark phase compared to CC mice,                             
although no significant differences were observed (Figure 4.9.2.0.2:E).
O2 consumption was significantly higher in CC mice compared to both HF fed groups during the                             
light phase, whilst a trend was observed between FaC mice and HF fed mice (Figure 4.9.2.0.2:A.                             
Table 4.9.2.0.6. CC­CFa/FaFa: p<0.05, n=7­8/group). No significant difference between groups                 
was seen during the dark phase, but a trend showing an increase rate of O2 consumption in                               
control fed mice was observed compared to HF fed mice (Figure 4.9.2.0.2:A. Table 4.9.2.0.6).
Carbon dioxide production measurements showed CC mice had a higher rate of CO2 production                         
compared to CFa and FaFa mice (Figure 4.9.2.0.3:B,C. p<0.05­0.001, n=7­8/group). FaC mice                     
also showed a significantly higher rate of CO2 production compared to FaFa mice (Figure                         
4.9.2.0.3:F, p<0.05­0.001, n=7­8/group). CFa and FaFa mice showed a similar rate of CO2                       
production (Figure 4.9.2.0.3:E). FaC mice showed no significant differences in CO2 production                     
compared to CC mice, although a delayed increase in CO2 production was observed, similar to                           
O2 consumption measurements presented above (Figure 4.9.2.0.3:D).
CO2 production was significantly higher in both control fed groups compared to HF fed groups                           




Figure {4.9.2.0.2} The effect of maintained weight change on O2 consumption measured                     
using CLAMS metabolic cages
A) Average O2 consumption during the light phase and dark phase of the light cycle; B­F) O2                               
consumption over a 24 hour light cycle. O2 consumption measured in ml/kg0.75/hr using CLAMS                         
metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                           
(19:00­07:00 hrs). Data presented as mean ± sem, n=7­8/group. * p<0.05, ** or † p<0.01, *** or                               




Figure {4.9.2.0.3} The effect of maintained weight change on CO2 consumption measured                     
using CLAMS metabolic cages
A) Average CO2 consumption during the light phase and dark phase of the light cycle; B­F) CO2                               
consumption over a 24 hour light cycle. CO2 consumption measured in ml/kg0.75/hr using                       
CLAMS metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                             
(19:00­07:00 hrs). Data presented as mean ± sem, n=7­8/group. * p<0.05, ** or † p<0.01, *** or                               




RER values obtained from O2 consumption and CO2 production showed control fed mice had a                           
significantly higher RER compared to HF fed mice during the entire 24 hour period (Figure                           
4.9.2.0.4:B­F. All p<0.01, n=7­8/group). No significant differences in RER were observed                   
between CC and FaC mice, or between CFa and FaFa mice (Figure 4.9.2.0.4:D,E.                       
n=7­8/group).
A comparison between RER during the light and dark phase also reflected these differences                         
(Figure 4.9.2.0.4:A. Table 4.9.2.0.6. All p<0.001, n=7­8/group).
Heat production was slightly elevated in HF fed mice compared to control fed mice throughout,                           
although most of these readings were not significant (Figure 4.9.2.0.5:B­F. n=8/group). Heat                     
production was significantly higher in FaFa mice compared to CC mice at 24:00 hours and                           
between 03:00 to 05:00 hours (Figure 4.9.2.0.5:B. 24:00 hr: p<0.01; 03:00­05:00 hr: p<0.05,                       
n=7­8/group). In comparison to FaC mice, FaFa mice showed a higher level of heat production                           
from 19:00 to 20:00 hours, and at 04:00 hours (Figure 4.9.2.0.5:F. 19:00 hr: p<0.05; 20:00 hr:                             
p<0.01; 04:00 hr: p<0.05, n=7­8/group).
No significant differences in heat production were observed when separated into light and dark                         




Figure {4.9.2.0.4} The effect of maintained weight change on RER measured using                     
CLAMS metabolic cages
A) Average RER during the light phase and dark phase of the light cycle. B­F) RER over a 24                                   
hour light cycle. RER measured in arbitrary units using CLAMS metabolic cage measurements                       
of O2 consumption and CO2 production and equations 2.4.3.0.1. Shaded area on the graph                         
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             




Figure {4.9.2.0.5} The effect of maintained weight change on heat production measured                     
using CLAMS metabolic cages
A) Average heat production during the light phase and dark phase of the light cycle. B­F) Heat                               
production over a 24 hour light cycle. Heat production was measured in kcal/hr using CLAMS                           
metabolic cage measurements of O2 consumption and equations 2.4.3.0.1. Shaded area on the                       
graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ±                             




CC CFa FaC FaFa
Water intake
(ml)
Light 0.913 ± 0.170 0.308 ± 0.055 0.592 ± 0.090 0.173 ± 0.059
Dark 1.449 ± 0.256 0.516 ± 0.083 1.078 ± 0.081 0.587 ± 0.121
VO2 (ml/kg0.75/hr) Light 3578 ± 157.3 2997 ± 165.3 3469 ± 65.08 2992 ± 114
Dark 3784 ± 158 3302 ± 168.9 3734 ± 102.2 3338 ± 146.7
VCO2
(ml/kg0.75/hr)
Light 3217 ± 197.7 2161 ± 113.7 3056 ± 55.92 2159 ± 78.34
Dark 3452 ± 207.5 2390 ± 117.9 3375 ± 89.99 2450 ± 112.8
RER Light 0.893 ± 0.018 0.721 ± 0.005 0.879 ± 0.007 0.720 ± 0.004
Dark 0.907 ± 0.021 0.724 ± 0.006 0.904 ± 0.010 0.732 ± 0.005
Heat (kcal/hr) Light 0.620 ± 0.019 0.656 ± 0.026 0.603 ± 0.012 0.672 ± 0.023
Dark 0.656 ± 0.018 0.725 ± 0.026 0.652 ± 0.019 0.753 ± 0.027
Table {4.9.2.0.6} The effect of maintained weight change on indirect calorimetry                   
measurements
Total water intake (ml), average O2 consumption (ml/kg0.75/hr), CO2 production (ml/kg0.75/hr),                   
RER (arbitrary unit) and heat production (kcal/hr) measured during the light and dark phase of a                             




Measurements of ambulatory activity showed no significant difference between groups, except                   
between CC and FaC mice. CC mice showed an increase in XAMB counts compared to FaC                             
mice at the onset of the dark phase, which was significant at 20:00 (Figure 4.9.2.0.7:D. p<0.05,                             
n=7­8/group). CFa mice showed a noticeably higher number of XAMB counts compared to FaFa                         
mice at the onset of the dark phase, but this was not significant (Figure 4.9.2.0.7:E.                           
n=7­8/group).
A comparison of total XAMB counts during the light, dark and total 24 hour period also showed                               
significant differences between groups (Figure 4.9.2.0.7:A. Table 4.9.2.0.10). In general CFa                   
mice showed the highest number of XAMB counts, whilst FaC showed the lowest number of                           
XAMB counts (Figure 4.9.2.0.7:A. Table 4.9.2.0.10).
In contrast, ZTOT counts were significantly higher in CC mice compared to FaFa and CFa mice                             
during the dark phase of the light cycle (Figure 4.9.2.0.8:B,C. CC­CFa/FaFa: 20:00 hr: p<0.05;                         
23:00 hr: p<0.001. CC­CFa: 22:00 hr: p<0.01; CC­FaFa: 22:00 hr: p<0.001, n=7­8/group).                     
Similarly, FaC mice showed a significantly higher number of XTOT counts compared to FaFa                         
mice during the dark phase of the light cycle (Figure 4.9.2.0.8:F. 22:00­23:00 hrs: p<0.001; 24:00                           
hr: p<0.05; 01:00 hr: p<0.01, n=7­8/group). No differences in ZTOT counts were observed                       
between CC and FaC, or CFa and FaFa (Figure 4.9.2.0.8:D,E. n=7­8/group).
A comparison of ZTOT counts separated by phase of the light cycle show no significant                           
differences between groups during the light phase of the light cycle (Figure 4.9.2.0.8:A. Table                         
4.9.2.0.10). During the dark phase, both control fed groups had a significantly higher number of                           
ZTOT counts compared to FaFa mice (Figure 4.9.2.0.8:A. Table 4.9.2.0.10. CC­FaFa: p<0.05;                     
FaC­FaFa: p<0.01, n=7­8/group). FaC mice also had significantly more ZTOT counts compared                     
to CFa mice (Figure 4.9.2.0.8:A. Table 4.9.2.0.10. p<0.05, n=7­8/group). A trend showing CC                       
mice had increased ZTOT counts compared to HF fed mice was also observed. Total ZTOT                           
counts over the 24 hour recording period were significantly higher in FaC mice compared to CFA                             
and FaFa mice (Figure 4.9.2.0.8:A. Table 4.9.2.0.10. Both p<0.05, n=7­8/group). Again, a trend                       
between CC and HF fed mice was also observed (Figure 4.9.2.0.8:A. Table 4.9.2.0.10.                       
n=7­8/group).
A comparison of XTOT counts showed CC mice had significantly more counts at the onset of                             
the dark phase compared to FaFa mice (Figure 4.9.2.0.9:B. 20:00 hr: p<0.01, n=7­8/group). No                         
significant differences in XTOT counts were observed between CC and CFa mice, although                       
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there were generally higher number of XTOT counts in CC mice (Figure 4.9.2.0.9:C.                       
n=7­8/group). Interestingly, CC and FaC mice appear to have different XTOT peak times during                         
the dark phase. CC mice showed a significant number of XTOT counts at 20:00, whilst FaC                             
mice showed a significant number of XTOT counts at 22:00 (Figure 4.9.2.0.9:D. 20:00 hr:                         
p<0.001; 22:00 hr: p<0.01, n=7­8/group). This profile can also be seen with O2 consumption and                           
CO2 production measurements presented above (Figure 4.9.2.0.2­3). These was no significant                   
difference in XTOT counts between CFa and FaFa mice, although CFa mice showed more                         
XTOT counts compared to FaFa mice at the onset of the dark phase (Figure 4.9.2.0.9:E.                           
n=7­8/group).
No significant difference between groups was observed during the light or dark phase of the light                             
cycle, or when comparing total movement over the 24 hour light cycle (Figure 4.9.2.0.9:A. Table                           
4.9.2.0.10. n=7­8/group). A trend showing a higher number of XTOT counts by control fed mice                           




Figure {4.9.2.0.7} The effect of maintained weight change on ambulatory activity using                     
CLAMS metabolic cages
A) Total ambulatory activity (XAMB) counts during the light phase, dark phase and entire light                           
cycle. B­F) XAMB counts recorded per hour over a light cycle. Shaded area on the graph                             
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             




Figure {4.9.2.0.8} The effect of maintained weight change on rearing activity using                     
CLAMS metabolic cages
A) Total rearing activity (ZTOT) counts during the light phase, dark phase and entire light cycle.                             
B­F) ZTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           




Figure {4.9.2.0.9} The effect of maintained weight change on activity using CLAMS                     
metabolic cages
A) Total x axis activity (XTOT) counts during the light phase, dark phase and entire light cycle.                               
B­F) XTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           





Light CC 3362 ± 675.5 525.8 ± 74.88 8793 ± 1417
CFa 3550 ± 435 263.3 ± 53.9 5688 ± 611.4
FaC 2512 ± 259.1 562.5 ± 134.5 7428 ± 739
FaFa 3729 ± 580.3 332.5 ± 90.32 5810 ± 665.9
Dark CC 11491 ± 2362 3635 ± 681.5 22342 ± 4270
CFa 12216 ± 1645 1465 ± 261.8 17438 ± 1513
FaC 9376 ± 1358 4245 ± 847.1 22258 ± 3910
FaFa 10282 ± 1465 1271 ± 201.6 16700 ± 3708
Total CC 14853 ± 3005 4160 ± 692.6 31135 ± 5613
CFa 15766 ± 1879 1729 ± 262.6 23126 ± 1560
FaC 11889 ± 1543 4808 ± 975.8 29686 ± 4571
FaFa 14011 ± 1862 1604 ± 261.3 22510 ± 4168
Table {4.9.2.0.10}  The effect of maintained weight change on activity





As shown above, control fed mice showed an increased cumulative water intake compared to                         
HF fed mice (Figure 4.9.3.0.1:B­F. n=7­8/group). A significant increase in cumulative water                     
intake was observed in CFaC compared to FaFaFa mice during the last two hours of recording                             
(Figure 4.9.3.0.1:E. 10:00­11:00 hrs: p<0.05, n=7­8/group). Similarly, cumulative water intake                 
was noticeably higher for CCC mice compared to FaCFa mice, although this was not significant                           
(Figure 4.9.3.0.1:D. n=7­8/group).
A comparison of water intake during the light and dark phase of the light cycle showed no                               
significant differences between groups (Figure 4.9.3.0.1:A. Table 4.9.3.0.6. n=7­8/group). In                 
general, CFaC showed the largest cumulative water intake during both the light and dark phase                           




Figure {4.9.3.0.1} The effect of a single weight cycle on cumulative water intake                       
measured using CLAMS metabolic cages
A) Total water intake during the light phase and dark phase of the light cycle; B­F) Water intake                                 
over a 24 hour light cycle. Water intake measured in mls using CLAMS metabolic cages.                           
Shaded area on the graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data                             




Oxygen consumption measurements showed no significant differences between groups over                 
the 24 hour light cycle (Figure 4.9.3.0.2:B­F). Again, control fed mice (CCC and CFaC) showed                           
a higher rate of O2 consumption compared to HF fed mice (FaCFa and FaFaFa) (Figure                           
4.9.3.0.2:B,D,E. CCC and CFaC mice O2 consumption showed CCC mice had a higher rate of                           
O2 consumption (Figure 4.9.3.0.2:C), whilst FaCFa and FaFaFa mice showed a very similar rate                         
of CO2 consumption  (Figure 4.9.3.0.2:F).
No significant differences were observed between groups when O2 consumption was separated                     
into light and dark phase measurements (Figure 4.9.3.0.2:A. Table 4.9.3.0.6. n=7­8/ group). A                       
trend was seen whereby the length of HF feeding was negatively associated with O2                         
consumption.
Carbon dioxide production measurements showed control diet fed mice had a higher rate of CO2                           
production compared to HF fed mice (Figure 4.9.3.0.3:B,D,E. p<0.05­0.001, n=7­8/group). No                   
differences in CO2 production were seen within control fed groups or HFD fed groups (Figure                           
4.9.3.0.3:C,F. n=7­8/group).
Similarly, CO2 production was significantly higher in both control fed groups compared to HF fed                           




Figure {4.9.3.0.2} The effect of a single weight cycle on O2 consumption measured using                         
CLAMS metabolic cages
A) Average O2 consumption during the light phase and dark phase of the light cycle; B­F) O2                               
consumption over a 24 hour light cycle. O2 consumption measured in ml/kg0.75/hr using CLAMS                         
metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                           




Figure {4.9.3.0.3} The effect of a single weight cycle on CO2 consumption measured                       
using CLAMS metabolic cages
A) Average CO2 consumption during the light phase and dark phase of the light cycle; B­F) CO2                               
consumption over a 24 hour light cycle. CO2 consumption measured in ml/kg0.75/hr using                       
CLAMS metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                             
(19:00­07:00 hrs). * p<0.05, ** or † p<0.01; *** or ‡ p<0.001Data presented as mean ± sem,                               




RER values obtained from O2 consumption and CO2 production showed control fed mice had a                           
significantly higher RER compared to HF fed mice during the entire 24 hour period (Figure                           
4.9.3.0.4:B,D,E. All p<0.001, n=7­8/group). No significant differences in RER were observed                   
between CCC and CFaC mice, or between FaCFa and FaFaFa mice (Figure 4.9.3.0.4:C,F.                       
n=7­8/group).
A comparison between RER during the light and dark phase also reflected these differences                         
(Figure 4.9.3.0.4:A. Table 4.9.3.0.6. All p<0.001, n=7­8/group).
Heat production was slightly elevated in HF fed mice compared to control fed mice throughout,                           
although this was not significant (Figure 4.9.3.0.5:B,D,E. n=7­8/group). Heat production between                   
CCC and CFaC mice was comparable (Figure 4.9.3.0.5:C. n=7­8/group), whilst FaCFa mice                     
showed slightly higher heat production compared to FaFa mice during the dark phase (Figure                         
4.9.3.0.5:F. n=7­8/group).
No significant differences in heat production were observed when separated into light and dark                         




Figure {4.9.3.0.4} The effect of maintained weight change on RER measured using                     
CLAMS metabolic cages
A) Average RER during the light phase and dark phase of the light cycle. B­F) RER over a 24                                   
hour light cycle. RER measured in arbitrary units using CLAMS metabolic cage measurements                       
of O2 consumption and CO2 production and equations 2.4.3.0.1. Shaded area on the graph                         
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             




Figure {4.9.3.0.5} The effect of a single weight cycle on heat production measured using                         
CLAMS metabolic cages
A) Average heat production during the light phase and dark phase of the light cycle. B­F) Heat                               
production over a 24 hour light cycle. Heat production was measured in kcal/hr using CLAMS                           
metabolic cage measurements of O2 consumption and equations 2.4.3.0.1. Shaded area on the                       
graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ±                             

























VO2 (ml/kg0.75/hr) Light 3351 ± 83.62 3237 ± 91.47 3069 ± 81.76 3021 ± 117.6
Dark 3755 ± 109.7 3574 ± 96.77 3475 ± 122.2 3375 ± 119.9
VCO2
(ml/kg0.75/hr)
Light 2862 ± 91.7 2875 ± 82.17 2214 ± 60.46 2197 ± 87.85





































Table {4.9.3.0.6} The effect of a single weight cycle on indirect calorimetry                     
measurements
Total water intake (ml), average O2 consumption (ml/kg0.75/hr), CO2 production (ml/kg0.75/hr),                   
RER (arbitrary unit) and heat production (kcal/hr) measured during the light and dark phase of a                             




Measurements of ambulatory activity showed no significant difference between groups (Figure                   
4.9.3.0.7:B­F. n=7­8/group). A trend showed CFaC mice had lower XAMB counts compared to                       
both CCC and FaFaFa mice at the onset of the dark phase (Figure 4.9.3.0.7:B. n=7­8/group).                           
There was also a second peak in ambulatory activity in FaCFa mice compared to CCC mice at                               
01:00 (Figure 4.9.3.0.7:D. n=7­8/group).
Reduced ambulatory activity during the dark phase in CFaC mice could be observed when total                           
counts to other groups (Figure 4.9.3.0.7:A. Table 4.9.3.0.10. n=7­8/group). Total activity over 24                       
hours shows a trend for HF fed mice have an increased number of XAMB counts compared to                               
control fed mice (Figure 4.9.3.0.7:A. Table 4.9.3.0.10. n=7­8/group).
No significant differences in ZTOT counts were observed between groups over 24 hours (Figure                         
4.9.3.0.8:B­F. n=7­8/group). A trend showed CCC mice had more ZTOT counts compared to all                         
other groups, including control fed CFaC mice (Figure 4.9.3.0.8:C. n=7­8/group). CFaC mice                     
also showed increased ZTOT counts compared to FaFa mice after the onset of the dark phase                             
of the light cycle (Figure 4.9.3.0.8:E. n=7­8/group). No noticeable differences in ZTOT counts                       
were observed between FaCFa and FaFaFa mice (Figure 4.9.3.0.8:F. n=7­8/group).
A comparison of ZTOT counts separated by phase of the light cycle showed no significant                           
differences between groups during the light or dark phase of the light cycle or over the 24 hour                                 
recording period (Figure 4.9.3.0.8:A. Table 4.9.3.0.10). Again, a noticeable trend showed CCC                     
mice had more ZTOT counts during the dark phase compared to all other groups (Figure                           
4.9.3.0.8:A. Table 4.9.3.0.10. n=7­8/group). This resulted in a higher number of total ZTOT                       
counts during 24 hours. CFaC also showed a higher number of ZTOT counts during the dark                             




A comparison of XTOT counts showed no differences between groups over 24 hours of                         
recording (Figure 4.9.3.0.9:B­F. n=7­8/group). Similar to ZTOT counts, CCC mice showed a                     
trend towards an increase in XTOT counts compared to all other groups at the onset of the dark                                 
phase of the light cycle (Figure 4.9.3.0.9:B­D. n=7­8/group). XTOT counts were similar between                       
CFaC and FaFaFa mice, and FaCFa and FaFaFa mice (Figure 4.9.3.0.9:E,F. n=7­8/group).
No significant differences between groups were observed during the light or dark phase of the                           
light cycle, or when comparing total movement over the 24 hour light cycle (Figure 4.9.3.0.9:A.                           
Table 4.9.3.0.10. n=7­8/group). A trend showed a higher number of XTOT counts by CCC and                           
FaCFa mice compared to CFaC and FaFaFa mice during the light and dark phase of the light                               




Figure {4.9.3.0.7} The effect of a single weight cycle on ambulatory activity using CLAMS                         
metabolic cages
A) Total ambulatory activity (XAMB) counts during the light phase, dark phase and entire light                           
cycle. B­F) XAMB counts recorded per hour over a light cycle. Shaded area on the graph                             
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             




Figure {4.9.3.0.8} The effect of a single weight cycle on rearing activity using CLAMS                         
metabolic cages
A) Total rearing activity (ZTOT) counts during the light phase, dark phase and entire light cycle.                             
B­F) ZTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           




Figure {4.9.3.0.9} The effect of a single weight cycle on activity using CLAMS metabolic                         
cages
A) Total x axis activity (XTOT) counts during the light phase, dark phase and entire light cycle.                               
B­F) XTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           





Light CCC 2725 ± 419.9 609.7 ± 154.4 8438 ± 1076
CFaC 3018 ± 535.8 463.8 ± 147.9 7051 ± 861.7
FaCFa 4480 ± 662.1 307.7 ± 62.23 8274 ± 897.6
FaFaFa 3895 ± 511 398 ± 125.1 6358 ± 812.8
Dark CCC 12633 ± 2021 4072 ± 533.9 24310 ± 3312
CFaC 11315 ± 1415 3306 ± 686.2 22042 ± 2505
FaCFa 12862 ± 839.5 2339 ± 579.5 23274 ± 2002
FaFaFa 13589 ± 1691 2461 ± 662.7 20591 ± 1742
Total CCC 15359 ± 2312 4682 ± 671.7 32748 ± 4340
CFaC 14333 ± 1735 3770 ± 689.8 29093 ± 3063
FaCFa 17342 ± 1386 2647 ± 596.6 31548 ± 2650
FaFaFa 17484 ± 1890 2859 ± 715.4 26949 ± 2248
Table {4.9.3.0.10}  The effect of a single weight cycle on activity





To assess the effect of weight gain on stamina, an acute exercise study was used. This involved                               
measuring the total distance ran by mice upon placing them on a treadmill and increasing                           
treadmill speed until the point of exhaustion.
{4.10.1} Time point 1: 6 weeks of feeding, no diet swaps
Fa mice ran a shorter distance compared to C mice, but this difference was not significant                             
(Figure 4.10.1.0.1. C: 655.7 ± 81.2 m; Fa: 475.1 ± 110.9 m. p=0.2227, n=7­8/group).
Figure {4.10.1.0.1} The effect of 6 weeks of high fat feeding on distance ran on a                             
treadmill of lean mice
An acute exercise study was used to assess the maximum distance mice could run involuntarily                           




Body weight measurements between groups show as expected, Fa mice used for this analysis                         
were significantly heavier compared to C mice (Figure 4.10.1.0.2:A. C: 30.5 ± 0.9 g; Fa: 39.3 ±                               
1.2 g. p<0.0001,  n=7­8/group).
Correlation analysis was performed to assess the relationship between running distance and                     
body weight. There was no correlation within groups between body weight and running distance                         
(Figure 4.10.1.0.2:B. C: r=0.1819, p=0.6963, R2=0.03308; Fa: r=0.1880, p=0.6557, R2=0.03534).                 
When all mice were grouped together, there was still no correlation between body weight and                           
running distance (r=­0.1877, p=0.5028, R2=0.03525).
Figure {4.10.1.0.2} The effect of 6 weeks of high fat feeding on distance ran on a                             
treadmill correlated with body weight
A) Body weight at the time the of acute exercise study. Data presented as mean ± sem,                               
n=6­8/group. *** p<0.001. Statistical analysis was performed using an unpaired t­test.
B) Correlation analysis between body weight and distance ran. Black line represents line of best                           




To assess whether a correlation existed between distance ran and fat or lean mass, an                           
EchoMRI whole adiposity MR scanner was used the day before treadmill measurement.
Fa mice had significantly more lean mass compared to C mice (Figure 4.10.1.0.3:A. C: 20.14 ±                             
0.34 g; Fa: 21.73 ± 0.46 g. p=0.0187, n=7­8/group). However, upon normalisation to body weight,                           
percentage lean mass was significantly lower in Fa mice compared to C mice (Figure                         
4.10.1.0.3:B. C: 64.79 ± 1.10 %; Fa: 54.19 ± 1.11 %. p<0.0001, n=7­8/group).
Fat mass was significantly increased in Fa mice compared to C mice (Figure 4.10.1.0.3:C. C:                           
7.01 ± 0.60 g; Fa: 14.74 ± 0.86 g. p<0.0001, n=7­8/group). This significance remained when                           











There was no correlation between lean mass and distance ran in either group (C: r=0.1850,                           
p=0.6913, R2=0.0342, n=7; Fa: r=­0.0396, p=0.9258, R2=0.0016, n=8). This remained true when                     
performing correlation analysis on all mice grouped together (Figure 4.10.1.0.4:A. r=­0.1674,                   
p=0.5510, R2: 0.0280, n=15).
When distance was correlated with percentage lean mass, there was still no correlation with                         
distance ran in C mice (r=­0.1647, p=0.7242, R2=0.0271, n=7). A negative correlation between                       
percentage lean mass and distance ran was observed in Fa mice, opposite of what would be                             
expected (r=­0.5816, p=0.1304, R2=0.3383, n=8), although this was not significant. When all                     
mice were combined, there was still no correlation between percentage lean mass and distance                         
ran (Figure 4.10.1.0.4:B. r=0.1044, p=0.7112, R2=0.0109, n=15).
Both C and Fa mice showed a positive correlation between fat mass and distance ran, although                             
this was not significant (C: r=0.5882, p=0.1648, R2=0.3460, n=7; Fa: r=0.5310, p=0.1757, R2=                       
0.2820, n=8). Again, this was opposite of what would be expected. However, when mice were                           
grouped together, there was no correlation between fat mass and distance ran (Figure                       
4.10.1.0.4:C. r=­0.06751, p=0.8111, R2=0.0046, n=15).
A comparison between percentage fat mass and distance ran showed no correlation in C mice                           
(r=0.1814, p=0.6970, R2 0.03291, n=7). A positive trend showing a correlation between                     
percentage fat mass and distance was observed in Fa mice (r=0.5116, p=0.1949, R2= 0.2618,                         
n=8). Again, when all mice were grouped together there, no correlation was observed between                         




Figure {4.10.1.0.4} The effect of 6 weeks of high fat feeding on correlation between                         
distance ran on a treadmill with lean mass and fat mass
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           
percentage fat mass. Black line represents line of best fit for correlation of all mice, regardless of                               





FaFa mice ran a significantly shorter distance compared to CC and FaC mice (Figure                         
4.10.2.0.1. CC: 960.4 ± 49.9 m; FaC: 928.5 ± 68.0 m; FaFa: 630.2 ± 55.4 m. Both p<0.01,                                 
n=7­8/group). There was no significant difference between CFa and FaFa mice. Similarly, CFa                       
mice also ran a significantly shorter distance compare to both CC and FaC mice (Figure                           
4.10.2.0.1. CFa: 595.5 ± 40.1 m. Both p<0.001, n=7­8/group). No significant differences in                       
running distance was observed between CC and FaC mice.
Figure {4.10.2.0.1} The effect of maintained weight change on distance ran on a treadmill                         
of lean mice
An acute exercise study was used to assess the maximum distance mice could run involuntarily                           




Body weight measurements between groups show FaFa mice used for this analysis were                       
significantly heavier compared to CC and FaC mice (Figure 4.10.2.0.2:A. CC: 36.0 ± 1.4 g; FaC:                             
35.5 ± 1.0 g. FaFa: 45.3 ± 1.0 g. Both p<0.001, n=7­8/group). Similarly, CFa mice were                             
significantly heavier compared to CC mice and FaC mice (Figure 4.10.2.0.2:A. CFa: 45.1 ± 1.7                           
g. Both p<0.001, n=7­8/group).
No correlation FaC and FaFa mice was observed between body weight and running distance                         
(Figure 4.10.2.0.2:B. Table 4.10.2.0.3). However, a significant negative correlation between                 
running distance with body weight was observed in CC and CFa mice. When all mice were                             




Figure {4.10.2.0.2} The effect of maintained weight change on distance ran on a treadmill                         
correlated with body weight
A) Body weight at the time the of acute exercise study. Data presented as mean ± sem , n=7­8.                                   
*** p<0.001. Statistical analysis was performed using a One­Way ANOVA with Tukey correction.
B) Correlation analysis between body weight and distance ran. Black line represents line of best                           
fit for correlation of all mice, regardless of diet group. Statistical analysis was performed using                           
Pearson’s correlation. n=31.
CC CFa FaC FaFa All
Pearson r ­0.804 ­0.8076 0.2903 0.2341 ­0.6035
p value 0.0162 0.0153 0.4855 0.6134 0.0003
R2 0.6465 0.6522 0.08429 0.05478 0.3643
Table {4.10.2.0.3} The effect of maintained weight change on distance ran on a treadmill                         
correlated with body weight
Correlation analysis between body weight and distance ran. n=7­8/group, total n=31. Yellow                     





FaFaFa mice ran a significantly shorter distance compared to CCC and CFaC mice (Figure                         
4.10.3.0.1. CCC: 1029 ± 37.4 m; CFaC: 856.2 ± 39.1 m; FaFaFa: 453.5 ± 79.9 m. Both p<0.001,                                 
n=7­8/group). Similarly, FaCFa mice ran a significantly shorter distance compare to both CCC                       
and CFaC mice (Figure 4.10.3.0.1. FaCFa: 561.7 ± 81.0 m. CCC­FaCFa: p<0.001;                     
CFaC­FaCFa: p<0.05, n=7­8/group). No significant differences in running distance was                 
observed between FaFaFa and FaCFa mice, or CCC and CFaC mice. A trend showing a                           
decreased running distance was observed in CFaC mice compared to CCC mice.
Figure {4.10.3.0.1} The effect of a single weight cycle on distance ran on a treadmill of                             
lean mice
An acute exercise study was used to assess the maximum distance mice could run involuntarily                           




Body weight measurements between groups show FaFaFa mice used for this analysis were                       
significantly heavier compared to CCC mice (Figure 4.10.3.0.2:A. CCC: 35.6 ± 2.1 g; FaFaFa:                         
46.4 ± 0.6 g. p<0.001, n=7­8/group). FaFaFa mice were also significantly heavier compared to                         
CFaC mice (CFaC: 40.1 ± 1.2 g. p<0.05. n=7­8/group). Similarly, FaCFa mice were significantly                         
heavier compared to CCC mice and CFaC mice (Figure 4.10.3.0.2:A. FaCFa: 47.6 ± 1.4 g.                           
CCC­FaCFa: p<0.001; CFaC­FaCFa: p<0.01, n=7­8/group).
There was no correlation within groups between body weight and running distance (Figure                       
4.10.3.0.2:B. Table 4.10.3.0.3). A positive trend correlated running distance with body weight,                     
however this is contrary to what would be expected. When all mice were grouped together, there                             




Figure {4.10.3.0.2} The effect of a single weight cycle on distance ran on a treadmill                           
correlated with body weight
A) Body weight at the time the of acute exercise study. Data presented as mean ± sem,                               
n=7­8/group. *** p<0.001. Statistical analysis was performed using a One­Way ANOVA with                     
Tukey correction.
B) Correlation analysis between body weight and distance ran. Black line represents line of best                           
fit for correlation of all mice, regardless of diet group. Statistical analysis was performed using                           
Pearson’s correlation. n=29.
CCC CFaC FaCFa FaFaFa All
Pearson r ­0.2951 0.6512 ­0.4738 0.4412 ­0.6547
p value 0.5206 0.0803 0.2828 0.3218 0.0001
R2 0.0871 0.4241 0.2245 0.1946 0.4286
Table {4.10.3.0.3} The effect of single weight cycle on distance ran on a treadmill                         
correlated with body weight
Correlation analysis between body weight and distance ran. n=7­8/group, total n=29. Yellow                     




FaFaFa and FaCFa mice had significantly more lean mass compared to CCC mice (Figure                         
4.10.3.0.5:A. Table 4.10.3.0.4. Both p<0.05, n=7­8/group). However, upon normalisation to body                   
weight, percentage lean mass was significantly lower in FaFaFa and FaCFa mice compared to                         
CCC mice (Figure 4.10.3.0.5:B. Table 4.10.3.0.4. Both p<0.0001, n=7­8/group). Similarly, both                   
FaFaFa and FaCFa mice had significantly lower percentage lean mass compared to CFaC mice                         
(Figure 4.10.3.0.5:A. Table 4.10.3.0.4. Both p<0.001, n=7­8/group). No significant difference                 
existed between fat fed FaFaFa or FaCFa mice. However, CFaC mice also showed a                         
significantly lower percentage lean mass compared to CCC mice (Figure 4.10.3.0.5:B. Table                     
4.10.3.0.4. p<0.01, n=7­8/group).
Fat mass was significantly increased in FaFaFa and FaCFa mice compared to CCC mice                         
(Figure 4.10.3.0.5:C. Table 4.10.3.0.4. Both p<0.001, n=7­8/group). This significance remained                 
when comparing percentage fat mass between groups (Figure 4.10.3.0.5:D. Table 4.10.3.0.4.                   
Both p<0.001, n=7­8/group). FaFaFa and FaCFa mice also showed had significantly more fat                       
mass compared to CFaC mice (Figure 4.10.3.0.5:C. Table 4.10.3.0.4. Both p<0.001,                   
n=7­8/group), which remained significantly higher when normalised to body weight (Figure                   
4.10.3.0.5:D. Table 4.10.3.0.4. Both p<0.001, n=7­8/group). As with lean mass measurements,                   
there was a significant difference in fat mass and percentage fat mass between CFaC and CCC                             
mice, where fat content was increased in CFaC mice (Figure 4.10.3.0.5:C,D. Table 4.10.3.0.4.                       
p<0.01, n=7­8/group).
CC CFa FaC FaFa
Lean mass (g) 22.02 ± 0.72 23.40 ± 0.56 24.40 ± 0.61 24.73 ± 0.40
Lean mass (%) 59.61 ± 1.03 56.00 ± 0.36 51.53 ± 0.48 50.96 ± 0.57
Fat mass (g) 11.03 ± 0.73 14.02 ± 0.34 18.92 ± 0.47 19.29 ± 0.59
Fat mass (%) 29.31 ± 1.34 33.59 ± 0.69 39.71 ± 0.62 39.58 ± 0.66
Table {4.10.3.0.4} The effect of a single weight cycle on lean mass and fat mass assessed                             
using EchoMRI




Figure {4.10.3.0.5} The effect of three weight cycles on lean mass and fat mass assessed                           
using EchoMRI
A) Lean mass in grams; B) Lean mass as a percentage of body weight; C) Fat mass in grams;                                   
D) Fat mass as a percentage of body weight. Data presented as mean ± sem, n=7­8/group. *                               




There was no correlation between lean mass and distance ran in CFaC or FaFaFa mice (Figure                             
4.10.3.0.6:A. Table 4.10.3.0.7:A. CFaC: p=0.8227; FaFaFa: p=0.5052, n=7­8/group). CCC and                 
FaCFa mice showed a trend negatively correlating lean mass with running distance (Figure                       
4.10.3.0.6:A. Table 4.10.3.0.7:A. CCC: p=0.1021; FaCFa: p=0.1325, n=7/group). When all mice                   
were grouped together, a significant negative correlation between lean mass and distance ran                       
was observed (Figure 4.10.3.0.6:A. Table 4.10.3.0.7:A. p=0.0006, n=29).
When distance was correlated with percentage lean mass, there was still no correlation with                         
distance ran in CFaC mice (Figure 4.10.3.0.6:B. Table 4.10.3.0.7:B. p=0.9066, n=8). A trend was                         
now apparent negatively correlating percentage lean mass and running distance in FaFaFa mice                       
(Figure 4.10.3.0.6:B. Table 4.10.3.0.7:B. p=0.0951, n=7). No clear trend correlating percentage                   
lean mass and running distance was observed in CCC mice (Figure 4.10.3.0.6:B. Table                       
4.10.3.0.7:B. p=0.2445, n­7). FaCFa mice showed a trend positively correlating percentage lean                     
mass and distance ran (Figure 4.10.3.0.6:B. Table 4.10.3.0.7:B. p=0.1256, n=7). However, when                     
all mice were grouped together, a significant positive correlation between percentage lean mass                       
and running distance was observed, which would be expected (Figure 4.10.3.0.6:B. Table                     
4.10.3.0.7:B. p<0.0001, n=29).
CFaC mice showed a trend positively correlating fat mass with running distance (Figure                       
4.10.3.0.6:C. Table 4.10.3.0.7:C. p=0.0654, n=8), again an unexpected result, but did not reach                       
significance. The remaining groups showed no correlation between fat mass and running                     
distance (Figure 4.10.3.0.6:C. Table 4.10.3.0.7:C. CCC: p=0.3846; FaCFa: p=0.3051; FaFaFa:                 
p=0.6567, n=7/group). With all mice grouped together, a significant negative correlation was                     
observed between fat mass and running distance (Figure 4.10.3.0.6:C. Table 4.10.3.0.7:C.                   
p<0.0001, n=29), similar to the correlation observed between lean mass and running distance,                       
but which is more expected.
A comparison between percentage fat mass and distance ran showed no correlation in CCC,                         
CFaC or FaCFa mice (Figure 4.10.3.0.6:D. Table 4.10.3.0.7:D. CCC: p=0.2748; CFaC: p=5303;                     
FaCFa: 0.4055, n=7­8/group). An unexpected positive trend showing a correlation between                   
percentage fat mass and distance was observed in FaFaFa mice (Figure 4.10.3.0.6:D. Table                       
4.10.3.0.7:D. p=0.1623, n=7). When correlating percentage fat mass and running distance for all                       




Figure {4.10.3.0.6} The effect of a single weight cycle on correlation between distance                       
ran on a treadmill with lean mass and fat mass
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           
percentage fat mass. Black line represents line of best fit for correlation of all mice, regardless of                               




CCC CFaC FaCFa FaFaFa All
Pearson r ­0.6665 0.09512 ­0.6262 ­0.3055 ­0.5968
p value 0.1021 0.8227 0.1325 0.5052 0.0006
R2 0.4442 0.0090 0.3921 0.0934 0.3561
CCC CFaC FaCFa FaFaFa All
Pearson r ­0.5079 ­0.04992 0.6349 ­0.6766 0.7053
p value 0.2445 0.9066 0.1256 0.0951 <0.0001
R2 0.2580 0.0025 0.4030 0.4578 0.4974
CCC CFaC FaCFa FaFaFa All
Pearson r ­0.3919 0.6766 ­0.4549 0.2066 ­0.7235
p value 0.3846 0.0654 0.3051 0.6567 <0.0001
R2 0.1536 0.4578 0.2069 0.0427 0.5235
CCC CFaC FaCFa FaFaFa All
Pearson r 0.4807 ­0.2623 ­0.3762 0.591 ­0.6951
p value 0.2748 0.5303 0.4055 0.1623 P<0.0001
R2 0.2311 0.0688 0.1415 0.3493 0.4831
Table {4.10.3.0.7} The effect of a single weight cycle on correlation between distance ran                         
on a treadmill with lean mass and fat mass
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           





After 6, 12 and 18 weeks of feeding, fed glucose and ketone blood concentration measurements                           
were taken. Plasma was also collected at these time points to assess changes in metabolic                           
hormones as a result of diet swapping. Metabolic hormones detected in this assay include leptin,                           
resistin, insulin, c­peptide, GIP, glucagon, and inflammatory cytokines IL­6, MCP­1 and TNF­                     
alpha.
{4.11.1} Time point 1: 6 weeks of feeding, no diet swaps
There was no significant difference in fed blood glucose concentration fat fed Fa mice and C                             
mice, although an increased trend was observed in Fa mice (Figure 4.11.1.0.1:A. Table                       
4.11.1.0.6. p=0.1480, n=12/group). Similarly, blood β­ketone concentration was also not                 
significantly different between Fa mice and C mice (Figure 4.11.1.0.1:B. Table 4.11.1.0.6.                     
p=0.4640, n=12/group).
Figure {4.11.1.0.1} The effect of a 6 weeks of high fat feeding on blood glucose and                             
β­ketone concentration
A) Blood glucose concentration; B) Blood β­ketone concentration. Blood samples were taken                     




Increased plasma concentration of leptin and resistin were detected in plasma samples from Fa                         
mice compared to C (Figure 4.11.1.0.2:A,B. Table 4.11.1.0.6. Leptin: p<0.0001; resistin:                   
p=0.0002, n=8­10/group).
Figure {4.11.1.0.2} The effect of 6 weeks of high fat on plasma leptin and resistin                           
concentration
A) Leptin; B) resistin




A significant increase in insulin, c­peptide and GIP plasma concentration was observed in Fa                         
mice compared to all C mice (Figure 4.11.1.0.3. Table 4.11.1.0.6. Insulin: p=0.0047; c­peptide:                       
p=0.0007; GIP: p=0.0040, n=9­10/group).
Figure {4.11.1.0.3} The effect of 6 weeks of high fat feeding on plasma insulin, c­peptide                           
and GIP concentration




No significant differences in glucagon or ghrelin plasma concentration were detected between                     
groups (Figure 4.11.1.0.4:A,B. Table 4.11.1.0.6. Glucagon: p=0.3831; ghrelin: p=0.3996,               
n=9­10/group). A trend showed an increase in plasma glucagon with 6 weeks of HFD, whilst a                             
trend towards a decrease in plasma ghrelin was observed in this group.
Figure {4.11.1.0.4} The effect of 6 weeks of high fat feeding on plasma glucagon and                           
ghrelin concentration
A) Glucagon; B) Ghrelin




No significant differences in inflammatory cytokines in the plasma were detected between                     
groups (Figure 4.11.1.0.6:A­C. Table 4.11.1.0.6. IL­6: 0.4837; MCP­3: 0.9688; TNF­A: 0.8777,                   
n=5­8/group). A trend showing a decrease in IL­6 plasma concentration was observed in Fa                         
mice compared to C mice.
Figure {4.11.1.0.5} The effect of 6 weeks of high fat feeding on plasma cytokines
A) Interleukin 6 (IL­6); B) monocyte chemoattractant protein­1(MCP­1); C) tumour necrosis                   





Glucose 12.50 ± 0.64 13.9 ± 0.7 0.148
β­ketone 0.29 ± 0.06 0.35 ± 0.06 0.464
Leptin 9007 ± 2173 36170 ± 3675 <0.0001
Resistin 16180 ± 1818 33790 ± 3261 0.0002
Insulin 1012 ± 190.2 2965 ± 598.5 0.0047
C­peptide 2145 ± 263.3 4037 ± 387.0 0.0007
GIP 127.9 ± 27.08 338.9 ± 58.08 0.0040
Glucagon 25.36 ± 6.31 32.76 ± 5.20 0.3831
Ghrelin 269.8 ± 53.96 217.0 ± 28.78 0.3996
IL­6 35.74 ± 7.96 24.76 ± 10.66 0.4837
MCP­1 43.40 ± 5.752 43.70 ± 4.706 0.9688
TNF­A 8.833 ± 1.733 8.408 ± 2.110 0.8777
Table {4.11.1.0.6} The effect of 6 weeks of high fat feeding on blood and plasma                           
measurements
Blood samples from mice in a fed a state were used to assess blood glucose concentration and                               







After 12 weeks of HF feeding, fed blood glucose concentration was slightly higher between FaFa                           
mice and CC mice, although this was not a significant difference (Figure 4.11.2.0.1:A. Table                         
4.11.2.0.6. n=12/group). This trend was also apparent when FaFa mice were compared to CFa                         
and FaC mice. Fed blood β­ketone concentration was noticeably higher in FaFa mice and CFa                           
mice compared to CC and FaC mice, but again this difference was not significant. (Figure                           
4.11.2.0.1:A. Table 4.11.2.0.6. n=12/group).
Figure {4.11.2.0.1} The effect of maintained weight change on blood glucose and                     
β­ketone concentration
A) Blood glucose concentration; B) Blood β­ketone concentration. Blood samples were taken                     
from mice were in a fed a state using a commercially available glucose meter. Data presented                             




Mice on a HFD, CFa and FaFa mice, had a significantly higher plasma concentration of leptin                             
and resistin compared to control fed mice, CC and CFa mice. (Figure 4.11.2.0.2:A,B. Table                         
4.11.2.0.6. Leptin: CC/FaC­FaFa: p<0.001; CC­CFa: p<0.001; CFa­FaC: p<0.01. Resistin:               
CC/FaC­CFa: p<0.001; CC­FaFa: p<0.01; FaC­FaFa: p<0.001. n=9­10/group). A trend showing                 
an increased resistin plasma concentration was observed in CFa mice compared to FaFa mice,                         
although this was not significant.
Figure {4.11.2.0.2} The effect of maintained weight change on plasma leptin and resistin                       
concentration




A significant increase in insulin and c­peptide plasma concentration was observed in HFD mice                         
(CFa and FaFa) compared to control fed mice (CC and FaC) (Figure 4.11.2.0.3:A,B. Table                         
4.11.2.0.6. CC­FaFa: p<0.001; CC/FaC­CFa: p<0.01; Fac­FaFa: p<0.01. n=9­10/group). CFa               
mice showed a significantly higher GIP plasma concentration compared to CC and FaFa mice,                         
whilst a trend was observed compared to FaC (Figure 4.11.2.0.3:C. Table 4.11.2.0.6. CC­CFa:                       
p<0.01; CFa­FaFa: p<0.05. n=9­10/group).
Figure {4.11.2.0.3} The effect of maintained weight change on plasma insulin, c­peptide                     
and GIP concentration
A) Insulin; B) C­peptide; C) GIP. Data presented as mean ± sem. n=5­8/group. * p<0.05, **                             




No significant differences in glucagon plasma concentration were detected between groups                   
(Figure 4.11.2.0.4:A. Table 4.11.2.0.6. n=9­10/group). A significant decrease in ghrelin plasma                   
concentration was observed in FaFa mice compared to CC mice (Figure 4.11.2.0.4:B. Table                       
4.11.2.0.6. p<0.05. n=9­10/group). A trend showing a decrease in ghrelin plasma concentration                     
was also observed in FaFa mice compared to FaC mice. Similarly, CFa mice showed a trend                             
towards a decrease in ghrelin plasma concentration compared to CC and FaC mice.
Figure {4.11.2.0.4} The effect of maintained weight change on plasma glucagon and                     
ghrelin concentration
A) Glucagon; B) Ghrelin




No significant differences in inflammatory cytokines in the plasma were detected between                     
groups (Figure 4.11.2.0.5:A­C. Table 4.11.2.0.6. n=5­8/group). A noticeable trend showing an                   
increase in TNF­alpha plasma concentration was observed in CFa and FaFa mice compared to                         
CC and FaC mice.
Figure {4.11.2.0.5} The effect of maintained weight change on plasma cytokines
A) Interleukin 6 (IL­6); B) monocyte chemoattractant protein­1(MCP­1); C) tumour necrosis                   




CC CFa FaC FaFa
Glucose 10.0 ± 0.8 10.5 ± 0.6 10.8 ± 0.8 12.2 ± 0.6
β­ketone 0.24 ± 0.04 0.33 ± 0.06 0.26 ± 0.02 0.36 ± 0.05
Leptin 5485 ± 1097 29627 ± 4559 7292 ± 1692 32193 ± 5878
Resistin 12033 ± 1239 27913 ± 2771 10399 ± 1078 20252 ± 2689
Insulin 569.7 ± 80.5 3964 ± 861.1 901.3 ± 283.7 4512 ± 981.0
C­peptide 1664 ± 105.9 3988 ± 673.3 1482 ± 343.0 4599 ± 601.1
GIP 96.6 ± 13.2 449.5 ± 64.4 182.8 ± 84.5 219.5 ± 39.6
Glucagon 33.4 ± 12.0 35.2 ± 8.4 46.8 ± 11.5 41.0 ± 8.6
Ghrelin 331.4 ± 60.0 186.9 ± 32.3 277.0 ± 44.3 159.6 ± 18.0
IL­6 17.89 ± 6.51 12.47 ± 3.70 18.03 ± 3.70 17.74 ± 4.86
MCP­1 34.36 ± 10.59 36.95 ± 5.30 22.76 ± 3.98 51.15 ± 11.40
TNF­A 8.07 ± 2.65 22.87 ± 4.73 7.51 ± 3.20 21.08 ± 6.45
Table {4.11.2.0.6} The effect of maintained weight change on blood and plasma                     
measurements
Blood samples from mice in a fed a state were used to assess blood glucose concentration and                               





Glucose and β­ketone concentration in the blood of fed mice were taken using a commercially                           
available glucose monitor. No difference in blood glucose or β­ketone concentration was                     
detected between groups (Figure 4.11.3.0.1:A,B. Table 4.11.3.0.6. n=9­10/group).
Figure {4.11.3.0.1} The effect of a single weight cycle on blood glucose and β­ketone                         
concentration
A) Blood glucose concentration; B) Blood β­ketone concentration. Blood samples were taken                     
from mice were in a fed a state using a commercially available glucose meter. Data presented                             




Increased plasma concentration of leptin were detected in plasma samples from FaFaFa mice                       
compared to CCC mice and CFaC (Figure 4.11.3.0.2:A. Table 4.11.3.0.6. Both: p<0.01,                     
n=9­10/group). A trend of increase plasma leptin concentration was detected in FaCFa mice                       
compared to CCC mice, but was noticeably lower compared to FaFaFa mice. This contrasts                         
with MRI and 1H MRS data showing FaCFa mice have a similarly high fat content as FaFaFa                               
mice (Figure 4.4.3.0.1:B). However, plasma concentrations of resistin were significantly higher                   
FaCFa mice compared to CCC mice (Figure 4.11.3.0.2:B. Table 4.11.3.0.6. p<0.001,                   
n=9­10/group) and showed a trend towards increase plasma concentration compared to                   
FaFaFa mice. FaFaFa mice also showed a significantly higher plasma resistin concentration                     
compared to CCC mice (p<0.05, n=9­10/group), but only showed a trend in comparison to                         
CFaC mice.
Figure {4.11.3.0.2} The effect of a single weight cycle on plasma leptin and resistin                         
concentration
A) Leptin; B) resistin




An increase in insulin plasma concentration was observed in FaFaFa mice compared to all other                           
groups (Figure 4.11.3.0.3:A. Table 4.11.3.0.6. CCC and CFaC: p<0.001; FaCFa: p<0.01,                   
n=9­10/group). Considering this result along with measurements of glucose tolerance presented                   
above (Section 4.8.3), it is unusual that FaCFa mice do not have a significantly higher plasma                             
concentration of insulin compared to control diet fed groups CCC and CFaC, or that insulin                           
concentration was significantly lower compared to FaFaFa mice, who showed a seemingly                     
normal glucose tolerance. However, C­peptide plasma concentration was significantly higher in                   
FaCFa and FaFaFa mice compared to CCC and CFaC mice (Figure 4.11.3.0.3:B. Table                       
4.11.3.0.6. CCC­FaCFa/FaFaFa: p<0.001; CFaC­FaCFa/FaFaFa: p<0.001, n=9­10/group). No           
significant difference in GIP plasma concentration was detected between groups, however both                     




Figure {4.11.3.0.3} The effect of a single weight cycle on plasma insulin, c­peptide and                         
GIP concentration
A) Insulin; B) C­peptide; C) GIP. Data presented as mean ± sem. n=5­8/group. * p<0.05, **                             




No significant differences in glucagon plasma concentration were detected between groups                   
(Figure 4.11.3.0.4:A. Table 4.11.3.0.6. n=9­10/group). A trend was apparent between weight                   
cycle groups and FaFaFa mice compared to CCC mice showing an increase in glucagon                         
plasma concentration. A significant decrease in ghrelin plasma concentration was observed in                     
FaFaFa mice compared to CCC and CFaC mice (Figure 4.11.3.0.4:B. Table 4.11.3.0.6.                     
CCC­FaFaFa: p<0.01; CFaC­FaFaFa: p<0.05, n=9­10/group). A trend showing a decrease in                   
ghrelin plasma concentration was also observed between FaCFa mice and both CCC and                       
CFaC mice.
Figure {4.11.3.0.4} The effect of a single weight cycle on plasma glucagon and ghrelin                         
concentration
A) Glucagon; B) Ghrelin




No significant differences in inflammatory cytokines in the plasma were detected between                     
groups (Figure 4.11.3.0.5:A­C. Table 4.11.3.0.6. n=5­8/group). A noticeable trend showing an                   
increase in TNF­alpha plasma concentration was observed in CFaC mice compared to all other                         
groups.
Figure {4.11.3.0.5} The effect of a single weight cycle on plasma cytokines
A) Interleukin 6 (IL­6); B) monocyte chemoattractant protein­1(MCP­1); C) tumour necrosis                   




CCC CFaC FaCFa FaFaFa
Glucose 8.8 ± 0.7 9.1 ± 0.4 10.5 ± 0.6 9.1 ± 0.8
β­ketone 0.26 ± 0.04 0.26 ± 0.03 0.30 ± 0.03 0.29 ± 0.04
Leptin 9533 ± 2346 12901 ± 2964 25962 ± 4035 23822 ± 3169
Resistin 8255 ± 1079 11704 ± 1820 25338 ± 2914 18485 ± 3253
Insulin 1197 ± 285.8 1386 ± 262.9 2689 ± 374.5 3934 ± 264.7
C­peptide 2169 ± 332.6 2709 ± 451.4 5146 ± 792.1 5317 ± 163.7
GIP 152.4 ± 37.7 140.6 ± 39.2 258.3 ± 54.1 312.9 ± 60.0
Glucagon 21.69 ± 3.29 41.41 ± 10.50 52.91 ± 12.67 55.05 ± 16.55
Ghrelin 220.6 ± 26.7 204.3 ± 19.7 141.9 ± 23.2 112.2 ± 11.8
IL6 14.63 ± 3.85 13.54 ± 3.52 19.70 ± 1.82 15.75 ± 2.65
MCP1 59.94 ± 5.76 43.23 ± 7.95 66.59 ± 1.70 52.85 ± 7.32
TNF­A 10.27 ± 3.24 33.96 ± 9.09 12.68 ± 1.54 11.34 ± 4.8
Table {4.11.3.0.6} The effect of a single weight cycle on blood and plasma measurements
Blood samples from mice in a fed a state were used to assess blood glucose concentration and                               






After 6 weeks of HF feeding, Fa mice had significantly heavier kidneys compared to C mice                             
(Figure 4.12.1.0.1:D. Table 4.12.1.0.3:A. p=0.0042, n=12/group). There was a trend towards an                     
increase in pancreas mass in Fa mice compared to C mice (Figure 4.12.1.0.1:C. Table                         
4.12.1.0.3:A. p=0.1137, n=12/group). There were no significant differences in brown adipose                   
tissue (BAT), liver, heart or muscle mass (Figure 4.12.1.0.1:A,B,E,F. Table 4.12.1.0.3:A. BAT:                     
p=0.9905; liver: p=0.7835; heart: p=0.5797; muscle: p=0.9412, n=12/group).
When organ mass was normalised to body weight, there was no significant difference in kidneys                           
as a percentage of body weight (Figure 4.12.1.0.2:D. Table 4.12.1.0.3:B. p=0.3029, n=12/group).                     
No significant differences in organ as percentage of body weight were observed with BAT or                           
pancreas (Figure 4.12.1.0.2:A,C. Table 4.12.1.0.3:B. BAT: p=0.2023; pancreas: p=0.2158,               
n=12/group). Liver mass as a percentage of body weight was significantly lower in Fa mice                           





A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             




Figure {4.12.1.0.2} The effect of 6 weeks of high fat feeding on organ weight as a                             
percentage of body weight
A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             





BAT 0.2052 ± 0.0233 0.2048 ± 0.0163 0.9905
Liver 1.3540 ± 0.0614 1.3780 ± 0.0624 0.7835
Pancreas 0.1716 ± 0.0060 0.1933 ± 0.0118 0.1137
Kidneys 0.3236 ± 0.0111 0.3765 ± 0.0123 0.0042
Heart 0.1466 ± 0.0048 0.1504 ± 0.0048 0.5797
Muscle 0.4136 ± 0.0165 0.4112 ± 0.0281 0.9412
C (%) Fa (%) p value
BAT 0.71 ± 0.08 0.59 ± 0.05 0.2023
Liver 4.71 ± 0.15 3.96 ± 0.15 0.0020
Pancreas 0.60 ± 0.02 0.55 ± 0.03 0.2158
Kidneys 1.13 ± 0.03 1.08 ± 0.03 0.3029
Heart 0.51 ± 0.01 0.43 ± 0.01 0.0002








After 12 weeks of feeding, there was a significant increase in BAT, liver and kidney mass in FaFa                                 
mice compared to CC mice (Figure 4.12.2.0.1:A,B,D. Table 4.12.2.0.3:A. BAT: p<0.05; liver:                     
p<0.001; kidneys: p<0.01, n=10/group). FaFa mice also had significantly increased BAT, liver                     
and kidney mass compared to FaC mice (Figure 4.12.2.0.1:A,B,D. Table 4.12.2.0.3:A. BAT:                     
p<0.01; liver: p<0.001; kidneys: p<0.001, n=10/group). There was also a trend showing an                       
increase in pancreas mass in FaFa mice compared to FaC mice (Figure 4.12.2.0.1:C. Table                         
4.12.2.0.3:A. n=10/group). Additionally, liver mass was also significantly increased in FaFa mice                     
compared to CFa mice (Figure 4.12.2.0.1:B. Table 4.12.2.0.3. p<0.05, n=10/group). A trend                     
showing an increase in BAT mass was also apparent in CFa mice compared to CC mice                             
(Figure 4.12.2.0.1:A. Table 4.12.2.0.3:A. n=10/group). There were no significant differences in                   
pancreas, heart or muscle mass between groups (Figure 4.12.2.0.1:C,E,F. Table 4.12.2.0.3.                   
n=10/group).
Upon normalising organ mass to body weight, a significantly higher liver mass as a percentage                           
of body weight was still apparent in FaFa mice compared to all other groups (Figure                           
4.12.2.0.2:B. Table 4.12.2.0.3:B. CC­FaFa: p<0.01; CFa­FaFa: p<0.05; FaC­FaFa: p<0.01,               
n=10/group). Pancreas as a percentage of body weight was significantly higher compared to                       
CFa mice and a trend was also seen between CC and FaFa mice (Figure 4.12.2.0.2:C. Table                             
4.12.2.0.3:B. CC­CFa: p<0.05, n=10/group). Similarly, kidney weight was also significantly higher                   
in CC mice compared to CFa mice, with a trend apparent between CC and FaFa mice (Figure                               
4.12.2.0.2:D. Table 4.12.2.0.3:B. CC­CFa: p<0.01, n=10/group). Both heart and muscle mass                   
percentages were significantly higher in control fed mice (CC and FaC) compared to HF fed                           
mice (CFa and FaFa) (Figure 4.12.2.0.2:E,F. Table 4.12.2.0.3:B. Heart: CC­CFa: p<0.001;                   





A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             




Figure {4.12.2.0.2} The effect of maintained weight change on organ weight as a                       
percentage of body weight
A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             




CC (g) CFa (g) FaC (g) FaFa (g)
BAT 0.2237 ± 0.0275 0.2794 ± 0.0302 0.1979 ± 0.0222 0.3194 ± 0.0131
Liver 1.404 ± 0.1500 1.8910 ± 0.1180 1.2800 ± 0.1427 2.5930 ± 0.1867
Pancreas 0.2163 ± 0.0190 0.2065 ± 0.0134 0.1926 ± 0.0078 0.2246 ± 0.0104
Kidneys 0.3589 ± 0.0117 0.3910 ± 0.0153 0.3550 ± 0.0092 0.4364 ± 0.0152
Heart 0.1574 ± 0.0054 0.1605 ± 0.0060 0.1709 ± 0.0083 0.1583 ± 0.0063
Muscle 0.5139 ± 0.0315 0.4804 ± 0.0449 0.4982 ± 0.0250 0.4865 ± 0.0365
CC (%) CFa (%) FaC (%) FaFa (%)
BAT 0.67 ± 0.07 0.65 ± 0.07 0.61 ± 0.06 0.74 ± 0.03
Liver 4.19 ± 0.32 4.42 ± 0.22 3.98 ± 0.44 5.95 ± 0.34
Pancreas 0.67 ± 0.08 0.48 ± 0.03 0.60 ± 0.01 0.52 ± 0.02
Kidneys 1.10 ± 0.04 0.92 ± 0.02 1.12 ± 0.02 1.01 ± 0.04
Heart 0.48 ± 0.02 0.38 ± 0.01 0.53 ± 0.02 0.36 ± 0.01
Muscle 1.56 ± 0.06 1.13 ± 0.11 1.56 ± 0.07 1.12 ± 0.07
Table {4.12.2.0.3} The effect of maintained weight change on organ weight
A) Organ weight measured in grams; B) Organ weight expressed as a percentage of body                           





After 18 weeks of feeding, there was a significant increase in BAT, liver, pancreas and kidney                             
mass in FaFaFa mice compared to CCC mice (Figure 4.12.3.0.1:A­D. Table 4.12.3.0.3:A. BAT:                       
p<0.01; liver: p<0.001; pancreas: p<0.001; kidneys: p<0.001, n=10/group). This was also true                     
comparing FaCFa mice to CCC mice (Figure 4.12.3.0.1:A­D. Table 4.12.3.0.3:A. BAT: p<0.01;                     
liver: p<0.001; pancreas: p<0.05; kidneys: p<0.01, n=10/group). FaFaFa mice also showed a                     
significant increase in liver, pancreas and kidney mass compared to CFaC mice (Figure                       
4.12.3.0.1:B­D. Table 4.12.3.0.3:A. Liver: p<0.001; pancreas: p<0.001; kidneys: p<0.001,               
n=10/group). Liver and pancreas mass was significantly higher in FaCFa mice compared to                       
CFaC mice (Figure 4.12.3.0.1:B,C. Table 4.12.3.0.3:A. Liver: p<0.01; pancreas: p<0.05,                 
n=10/group). There were no significant differences in heart or muscle mass between groups                       
(Figure 4.12.3.0.1:E,F. Table 4.12.3.0.3:A. n=10/group).
Upon normalising organ mass to body weight, percentage liver mass in FaFa mice was still                           
significantly higher compared to CCC and CFaC mice (Figure 4.12.3.0.2:B. Table 4.12.3.0.3:B.                     
CCC­FaFaFa: p<0.01; CFaC­FaFaFa: p<0.001, n=10/group). This was not true when                 
comparing FaCFa mice to control fed groups as was observed above with liver mass, although                           
a trend was present (Figure 4.12.3.0.2:B. Table 4.12.3.0.3:B. n=10/group). FaCFa mice showed                     
a significantly lower kidney percentage of body weight compared to all other groups (Figure                         
4.12.3.0.2:D. Table 4.12.3.0.3:B. CCC­FaCFa: p<0.01; CFaC­FaCFa: p<0.05; FaCFa­FaFaFa:             
p<0.05, n=10/group). Unlike the observations presented above, no significant difference in BAT                     
or pancreas as a percentage of body weight were observed between groups (Figure                       
4.12.3.0.2:A,C. Table 4.12.3.0.3:B. n=10/group), although a trend showing CCC have lower a                     
lower BAT mass percentage compared to all other groups was observed. HF fed mice showed a                             
significantly lower heart mass as a percentage of body weight compared to control fed groups                           
(Figure 4.12.3.0.2:E. Table 4.12.3.0.3:B. CCC­FaCFa: p<0.001; CCC­FaFaFa: p<0.05;             
CFaC­FaCFa: p<0.01; CFaC­FaFaFa: p<0.05, n=10/group). Muscle mass percentages were               
significantly higher in CCC mice compared to FaCFa and FaFaFa mice, whilst CFaC mice                         
showed significantly higher muscle mass percentage compared to FaCFa mice only (Figure                     





A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             




Figure {4.12.3.0.2} The effect of a single weight cycle on organ weight as a percentage of                             
body weight
A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             




CCC (g) CFac (g) FaCFa (g) FaFaFa (g)
BAT 0.2704 ± 0.0478 0.3559 ± 0.0338 0.4691 ± 0.0253 0.4635 ± 0.0440
Liver 1.5360 ± 0.1244 1.6030 ± 0.0695 2.6051 ± 0.2711 2.9281 ± 0.1772
Pancreas 0.2397 ± 0.0091 0.2421 ± 0.0102 0.2906 ± 0.0118 0.3201 ± 0.0147
Kidneys 0.3646 ± 0.0167 0.3851 ± 0.0089 0.4367 ± 0.0183 0.4871 ± 0.0092
Heart 0.1599 ± 0.0065 0.1670 ± 0.0069 0.1661 ± 0.0052 0.1777 ± 0.0033
Muscle 0.5688 ± 0.0351 0.6105 ± 0.0321 0.5442 ± 0.0540 0.5968 ± 0.0272
CCC (%) CFac (%) FaCFa (%) FaFaFa (%)
BAT 0.74 ± 0.10 0.94 ± 0.08 0.96 ± 0.09 0.97 ± 0.05
Liver 4.35 ± 0.17 4.24 ± 0.15 5.33 ± 0.46 6.08 ± 0.29
Pancreas 0.69 ± 0.02 0.64 ± 0.03 0.60 ± 0.02 0.67 ± 0.03
Kidneys 1.05 ± 0.01 1.02 ± 0.03 0.90 ± 0.04 1.02 ± 0.02
Heart 0.46 ± 0.02 0.44 ± 0.02 0.34 ± 0.01 0.37 ± 0.01
Muscle 1.66 ± 0.12 1.62 ± 0.07 1.13 ± 0.11 1.25 ± 0.07
Table {4.12.3.0.3} The effect of a single weight cycle on organ weight
A) Organ weight measured in grams; B) Organ weight expressed as a percentage of body                           









After 6 weeks of HF feeding, Fa mice showed an increase in the total amount of WAT (Figure                                 
4.13.1.0.1:A. Table 4.13.1.0.4. p<0.0001, n=12/group). When WAT mass was normalised to                   
body weight, total WAT mass remained significantly higher in Fa mice compared to C mice                           
(Figure 4.13.1.0.1:B. Table 4.13.1.0.4. p<0.0001, n=12/group).
Figure {4.13.1.0.1} The effect of 6 weeks of high fat feeding on total WAT mass
A) Total white adipose tissue (WAT) in grams; B) Total WAT as a percentage of body weight.                               
Data presented as mean ± sem. n=8­10/group. *** p<0.001. Statistical analysis was performed                       
using an unpaired t­test.
A comparison of each WAT depot showed Fa mice had significantly more WAT in each depot                             
compared to C mice (Figure 4.13.1.0.2:A­E. Table 4.13.1.0.4. All WAT depots: p<0.0001,                     
n=12/group). Similarly, when each WAT depot mass was normalised to body weight, each Fa                         





A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       




Figure {4.13.1.0.3} The effect of 6 weeks of high fat feeding on WAT mass as a                             
percentage of body weight
A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       




C (g) C (%) Fa (g) Fa (%)
Total WAT 2.2990 ± 0.2427 7.99 ± 0.80 5.8030 ± 0.1923 16.74 ± 0.62
Sub WAT 0.9887 ± 0.1163 3.43 ± 0.39 2.6430 ± 0.1163 7.64 ± 0.44
Int WAT 1.310 ± 0.1396 4.56 ± 0.46 3.160 ± 0.0851 9.09 ± 0.22
Epi WAT 0.7500 ± 0.0973 2.61 ± 0.33 1.7450 ± 0.0814 5.02 ± 0.22
Ret WAT 0.2502 ± 0.0253 0.87 ± 0.08 0.6195 ± 0.0282 1.78 ± 0.07
Mes WAT 0.3102 ± 0.0297 1.08 ± 0.10 0.7959 ± 0.0556 2.29 ± 0.16
Figure {4.13.1.0.4} The effect of 6 weeks of high fat feeding on WAT mass
Total, subcutaneous WAT, internal WAT, epididymal WAT, retroperitoneal WAT and mesenteric                   




There was no significant difference between groups in the internal:subcutaneous WAT ratio                     
(Figure 4.13.1.0.5:A. C: 1.398 ± 0.103; Fa: 1.232 ± 0.070. p=0.1962, n=12/group).
A comparison of each depot as a percentage of total WAT shows the distribution of WAT. There                               
was no significant difference in distribution between groups (Figure 4.13.1.0.5:B. Table                   
4.13.1.0.6. n=12/group).
Figure {4.13.1.0.5} The effect of 6 weeks of high fat feeding on internal:subcutaneous                       
WAT ratio
Data presented as mean ± sem. n=8­10/group. Statistical analysis was performed using an                       
unpaired t­test.
C (%) Fa (%) p value
Sub WAT 42.76 ± 2.30 45.23 ± 1.27 0.3559
Epi WAT 32.40 ± 2.92 30.34 ± 1.50 0.5366
Ret WAT 11.02 ± 0.53 10.77 ± 0.55 0.7508
Mes WAT 13.83 ± 0.75 13.66 ± 0.79 0.8743
Table {4.13.1.0.6} The effect of 6 weeks of high fat feeding on WAT distribution





After 12 weeks of HF feeding, FaFa mice had significantly more total WAT compared to CC                             
mice and FaC mice (Figure 4.13.2.0.1:A. Table 4.13.2.0.4:A. Both p<0.001, n=10/group). CFa                     
mice also had significantly more WAT compared to CC and FaC mice, and showed a similar                             
amount compared to FaFa mice (Figure 4.13.2.0.1:A. Table 4.13.1.0.4:A. CC­CFa/FaC:                 
p<0.001, n=10/group). Similarly, there was no significant differences between CC and FaC mice                       
(Figure 4.13.2.0.1:A. Table 4.13.2.0.4:A. n=10/group).
These significant differences remained when total WAT was normalised to body weight (Figure                       
4.13.2.0.1:B. Table 4.13.2.0.4:B. CC/FaC­CFa/FaFa p<0.001, n=10/group).
Figure {4.13.2.0.1} The effect of maintained weight change on total WAT mass
A) Total white adipose tissue (WAT) in grams; B) Total WAT as a percentage of body weight.                               




A comparison of each WAT depot showed significant differences in subcutaneous, retroperineal                     
and mesenteric WAT mirrored differences in total WAT (Figure 4.13.2.0.2:A,D,E. Table                   
4.13.2.0.4:A. Sub, ret and mes WAT: all CC/FaC­CFa/FaFa p<0.001, n=10/group). However,                   
CFa mice showed a higher amount of internal WAT compared to FaFa mice (Figure                         
4.13.2.0.2:B. Table 4.13.2.0.4:A. p<0.05, n=10/group). Only CFa mice showed a significantly                   
epididymal WAT mass compared to CC and FaC mice, and was also significantly greater                         
compared to FaFa mice (Figure 4.13.2.0.2:C. Table 4.13.2.0.4:A. CFa­CC/FaC/FaFa: p<0.001,                 
n­10/group). CC, FaC and FaFa mice showed similar epididymal WAT mass.
Again, when each WAT depot mass was normalised to body weight, the differences observed                         
between groups comparing WAT mass by depot remained upon normalisation to body weight                       





A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. WAT measured in grams. Data presented as mean ± sem. n=8­10/group. *                         




Figure {4.13.2.0.3} The effect of maintained weight change on WAT mass as a percentage                         
of body weight
A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. WAT expressed as a percentage of body weight. Data presented as mean ±                           




CC (g) CFa (g) FaC (g) FaFa (g)
Total WAT 3.3420 ± 0.3550 7.8540 ± 0.3189 2.8980 ± 0.2854 7.1890 ± 0.2900
Sub WAT 1.3740 ± 0.1664 3.6940 ± 0.1825 1.2590 ± 0.0971 3.8350 ± 0.1496
Int WAT 1.9691 ± 0.2059 4.1611 ± 0.1913 1.6402 ± 0.1967 3.3543 ± 0.1929
Epi WAT 1.1680 ± 0.1203 2.0500 ± 0.1236 0.9258 ± 0.1231 1.1560 ± 0.1328
Ret WAT 0.4159 ± 0.0513 0.9208 ± 0.0662 0.3329 ± 0.0423 0.9396 ± 0.0530
Mes WAT 0.3844 ± 0.0381 1.1890 ± 0.0838 0.3811 ± 0.0423 1.2590 ± 0.0991
CC (%) CFa (%) FaC (%) FaFa (%)
Total WAT 10.00 ± 0.86 18.35 ± 0.37 9.02 ± 0.81 16.58 ± 0.44
Sub WAT 4.11 ± 0.42 8.62 ± 0.26 3.92 ± 0.26 8.87 ± 0.29
Int WAT 5.89 ± 0.49 9.73 ± 0.31 5.09 ± 0.58 7.72 ± 0.33
Epi WAT 3.50 ± 0.30 4.80 ± 0.26 2.89 ± 0.38 2.66 ± 0.28
Ret WAT 1.24 ± 0.12 2.16 ± 0.15 1.03 ± 0.11 2.18 ± 0.14







CC mice and FaC mice showed a significantly bigger internal:subcutaneous ratio compared to                       
FaFa mice (Figure 4.13.2.0.5. CC: 1.465 ± 0.087; FaC: 1.277 ± 0.085; FaFa: 0.8803 ± 0.050.                             
CC­FaFa: p<0.001; FaC­FaFa: p<0.01, n­10/group). This indicates a greater degree of internal                     
adiposity compared to subcutaneous WAT. CFa mice also showed a bigger internal                     
subcutaneous ratio compared to FaFa mice (Figure 4.13.2.0.5. CFa: 1.141 ± 0.055. p<0.05,                       
n=10/group).
Figure {4.13.2.0.5} The effect of maintained weight change on internal:subcutaneous                 
WAT ratio




Distribution analysis of each WAT depot as a percentage of total WAT showed FaFa mice had                             
significantly more WAT stored as subcutaneous WAT compared to CC and FaC mice (Figure                         
4.13.2.0.6:A. Table 4.13.2.0.7. Both p<0.001, n=10/group). CFa mice had significantly more                   
subcutaneous WAT as a percentage of total WAT compared to CC mice, but was still                           
significantly lower compared to FaFa mice (Figure 4.13.2.0.6:A. Table 4.13.2.0.7. Both p<0.05,                     
n=10/group).
FaFa mice showed significantly lower epididymal WAT as a percentage of total WAT compared                         
to all other groups, including CFa mice (Figure 4.13.2.0.6:B. Table 4.13.2.0.7. All p<0.001,                       
n=10/group). CFa mice also showed a significantly lower epididymal WAT percentage of total                       
WAT compared to CC mice (Figure 4.13.2.0.6:B. Table 4.13.2.0.7. p<0.001, n=10/group).
No significant differences in the percentage retroperitoneal WAT were observed between groups                     
(Figure 4.13.2.0.6:C. Table 4.13.2.0.7).
Mesenteric WAT as a percentage of total WAT was significantly higher in FaFa mice and CFa                             
mice compared to CC mice (Figure 4.13.2.0.6:D. Table 4.13.2.0.7. CC­CFa: p<0.01; CC­FaFa:                     
p<0.001, n=10/group). FaFa mice also had significantly more mesenteric WAT as a percentage                       
of total WAT compared to FaC mice (Figure 4.13.2.0.6:D. Table 4.13.2.0.7. p<0.001,                     








CC (%) CFa (%) FaC (%) FaFa (%)
Sub WAT 41.01 ± 1.37 47.01 ± 1.27 44.46 ± 1.64 53.51 ± 1.39
Epi WAT 35.11 ± 0.93 26.21 ± 1.52 31.27 ± 1.58 15.98 ± 1.64
Ret WAT 12.25 ± 0.59 11.74 ± 0.66 11.27 ± 0.57 13.16 ± 0.76
Mes WAT 11.63 ± 0.33 15.03 ± 0.63 13.00 ± 0.45 17.34 ± 0.91
Table {4.13.2.0.7} The effect of maintained weight change on WAT distribution





After 18 weeks of HF feeding, FaFaFa mice had significantly more total WAT compared to CCC                             
mice and CFaC mice (Figure 4.13.3.0.1:A. Table 4.13.3.0.4:A. Both p<0.001, n=10/group).                   
However, FaCFa mice had significantly more WAT compared to FaFaFa mice, and also both                         
control fed groups (Figure 4.13.3.0.1:A. Table 4.13.3.0.4:A. CCC/CFaC­FaCFa: p<0.001;               
FaCFa­FaFaFa: p<0.01, n=10/group). There was no significant difference between CCC and                   
CFaC mice (Figure 4.13.3.0.1:A. Table 4.13.3.0.4:A. n=10/group). These significant differences                 
remained when total WAT was normalised to body weight (Figure 4.13.3.0.1:B. Table                     
4.13.3.0.4:B. CCC­FaFaFa: p<0.001; CFaC­FaFaFa: p<0.05; CCC/CFaC­FaCFa: p<0.001;           
FaCFa­FaFaFa: p<0.01, n=10/group).
Figure {4.13.3.0.1} The effect of a single weight cycle on total WAT mass
A) Total white adipose tissue (WAT) in grams; B) Total WAT as a percentage of body weight.                               




A comparison of subcutaneous WAT mass showed HF fed mice had significantly more                       
subcutaneous WAT compared to control fed groups (Figure 4.13.3.0.2:A. Table 4.13.3.0.4:A. All                     
p<0.001, n=10/group). Unlike total WAT measurements, there was no significant difference                   
between FaCFa and FaFaFa mice between subcutaneous WAT mass. Internal WAT was                     
significantly increased in FaCFa mice compared to all other groups (Figure 4.13.3.0.2:B. Table                       
4.13.3.0.4:A. CCC/CFaC­FaCFa: p<0.001; CCC/FaCFa­FaFaFa: p<0.01; CFaC­FaFaFa:         
p<0.001.. No difference in internal WAT was observed between CCC, CFaC or FaFaFa mice                         
(Figure 4.13.3.0.2:B. Table: 4.13.3.0.4:A. CCC/FaFaFa­FaCFa: p<0.01; CFaC­FaCFa: p<0.001.             
n=10/group). Epididymal WAT mass was significantly higher in FaCFa mice compared to all                       
other groups (Figure 4.13.3.0.2:C. Table 4.13.3.0.4:A. CCC/FaFaFa­FaCFa: p<0.001;             
CFaC­FaCFa: p<0.001, n=10/group) and there was no significant differences between CCC,                   
CFaC and FaFaFa mice. Retroperitoneal and mesenteric WAT showed a similar pattern of                       
difference. FaFaFa mice had significantly more WAT in these two depots compared to CCC and                           
CFaC mice (Figure 4.13.3.0.2:D,E. Table 4.13.3.0.4:A. All p<0.001, n=10/group). There was no                     
significant difference between CCC and CFaC mice in these depots. However, FaCFa mice                       
showed significantly more mesenteric WAT compared to FaFaFa mice (Figure 4.13.3.0.2:E.                   
Table 4.13.3.0.4:A. p<0.001, n=10/group) and also showed a strong trend of increased                     
retroperitoneal WAT (Figure 4.13.3.0.2:D. Table 4.13.3.0.4:A. n=10/group). This indicates an                 
increase in internal fat and not subcutaneous fat in responsible for the increase in WAT in cycled                               
FaCFa mice compared to time matched chronic HF fed mice.
As shown in time point 1 and 2, these differences in WAT depot mass remained when                             
normalised to body weight (Figure 4.13.3.0.3:A­E. Table 4.13.3.0.4:B. Sub WAT:                 
CCC/CFaC­FaCFa/FaFaFa: all p<0.001. Int WAT: CCC/CFaC/FaFaFa­FaCFa: all p<0.001. Epi               
WAT: CCC/FaFaFa­FaCFa: p<0.01; CFaC­FaCFa: p<0.001. Ret WAT:           





A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. WAT measured in grams. Data presented as mean ± sem. n=8­10/group. *                         




Figure {4.13.3.0.3} The effect of a single weight cycle on WAT mass as a percentage of                             
body weight
A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. WAT expressed as a percentage of body weight. Data presented as mean ±                           




CCC (g) CFac (g) FaCFa (g) FaFaFa (g)
Total WAT 4.2130 ± 0.4419 4.9010 ± 0.3142 9.4430 ± 0.3240 7.7711 ± 0.2553
Sub WAT 1.8331 ± 0.2234 2.4810 ± 0.1936 4.6270 ± 0.1394 4.4540 ± 0.1519
Int WAT 2.3813 ± 0.2295 2.4191 ± 0.1342 4.8163 ± 0.2057 3.3162 ± 0.1286
Epi WAT 1.3700 ± 0.1149 1.1921 ± 0.0568 1.8792 ± 0.1463 1.1810 ± 0.0363
Ret WAT 0.4932 ± 0.0766 0.6055 ± 0.0580 1.4220 ± 0.0693 1.1620 ± 0.0969
Mes WAT 0.5166 ± 0.0674 0.6210 ± 0.0387 1.5140 ± 0.0749 0.9730 ± 0.0382
CCC (%) CFac (%) FaCFa (%) FaFaFa (%)
Total WAT 11.83 ± 0.06 12.90 ± 0.68 19.62 ± 0.81 16.17 ± 0.36
Sub WAT 5.12 ± 0.47 6.52 ± 0.46 9.61 ± 0.35 9.27 ± 0.23
Int WAT 6.72 ± 0.43 6.38 ± 0.27 10.01 ± 0.50 6.90 ± 0.21
Epi WAT 3.91 ± 0.27 3.15 ± 0.12 3.93 ± 0.35 2.47 ± 0.09
Ret WAT 1.37 ± 0.15 1.59 ± 0.13 2.94 ± 0.13 2.41 ± 0.18







CCC mice showed a significantly bigger internal:subcutaneous ratio compared to all other                     
groups (Figure 4.13.3.0.5. CCC: 1.373 ± 0.087; CFa: 1.026 ± 0.084; FaC: 1.040 ± 0.028; FaFa:                             
0.746 ± 0.023. CCC­CFaC/FaCFa: p<0.01; CCC­FaFaFa: p<0.001, n=10/group). CFaC mice                 
and FaCFa showed a similar internal subcutaneous ratio, whilst both groups had a significantly                         
higher ratio compared to FaFa mice (Figure 4.13.3.0.5. Both p<0.05, n=10/group).
Figure {4.13.3.0.5} The effect of a single weight cycle on internal:subcutaneous WAT                     
ratio




Distribution analysis of each WAT depot as a percentage of WAT showed FaFaFa mice have                           
significantly more of the WAT stored as subcutaneous WAT compared to all other groups                         
(Figure 4.13.3.0.6:A. Table 4.13.3.0.7. All p<0.001, n=10/group). CFaC mice FaCFa mice also                     
have significantly more WAT stored as subcutaneous WAT compared to CCC mice (Figure                       
4.13.3.0.6:A. Table 4.13.3.0.7. CCC­CFaC: p<0.001; CCC­FaCFa: p<0.01, n=10/group).
CCC mice had a higher percentage of epididymal WAT as a percentage of total WAT compared                             
to all other groups (Figure 4.13.3.0.6:B. Table 4.13.3.0.7. All p<0.001, n=10/group). FaCFa and                       
FaFaFa mice also showed significantly lower epididymal WAT as a percentage of total WAT                         
compared to CFaC mice (Figure 4.13.3.0.6:B. Table 4.13.3.0.7. CFaC­FaCFa: p<0.05;                 
CFaC­FaFaFa: p<0.001 n=10/group). A trend showing a decrease in epididymal WAT as a total                         
WAT percentage was observed in FaFaFa mice compared to FaCFa mice (Figure                     
4.13.3.0.6:B.Table 4.13.3.0.7. n=10/group).
Retroperitoneal WAT normalised to total WAT was significantly lower in CCC mice compared to                         
FaCFa and FaFaFa mice (Figure 4.13.3.0.6:C. Table 4.13.3.0.7. Both p<0.05, n=10/group).








CCC (%) CFac (%) FaCFa (%) FaFaFa (%)
Sub WAT 42.63 ± 1.49 49.98 ± 1.65 49.10 ± 0.65 57.35 ± 0.54
Epi WAT 33.46 ± 1.39 24.95 ± 1.39 19.75 ± 1.15 15.37 ± 0.72
Ret WAT 11.64 ± 0.83 12.26 ± 0.58 15.14 ± 0.80 14.76 ± 0.87
Mes WAT 12.27 ± 0.77 12.80 ± 0.45 16.01 ± 0.48 12.52 ± 0.23
Table {4.13.3.0.7} The effect of a single weight cycle on WAT distribution






To assess changes in neuronal function, RT­qPCR was used to assess changes in mRNA                         
expression in homeostatic and hedonic areas. These include the hypothalamus, VTA, NAc and                       
PFC. Hypothalamic genes assessed include NPY, POMC and AgRP. Changes in dopamine                     
gene expression were assessed using 6 dopamine­related genes: tyrosine hydroxylase (rate                   
limiting enzyme of dopamine production), D1 and D2 Receptors (D1R and D2R), DAT                       
(dopamine reuptake transporter), DARPP­32 (downstream intracellular marker of dopamine               
signalling) and COMT (breakdown enzyme of dopamine. Leptin receptor and melanocortin 4                     
receptor (LepR and MC4R) were also assessed as receptors that respond to external energy                         
signals (leptin) and internally produced satiety signals (alpha­MSH, product of POMC                   
breakdown).
{4.14.1} Time point 1: 6 weeks of feeding, no diet swaps
After 6 weeks of HF feeding, Fa mice showed a significant fold increase in the expression of                               
NPY (Figure 4.14.1.0.1:A. Table 4.14.1.0.4:A). There was a slight trend towards an increase in                         
AgRP mRNA expression in Fa mice compared to C mice, whilst there was no change in POMC                               
mRNA expression between the two groups (Figure 4.14.1.0.1:B,C. Table 4.14.1.0.4:A). This                   
suggests the over consumption of calorie in HF fed mice at 6 weeks of age could be a result of                                     




Figure {4.14.1.0.1} The effect of 6 weeks of high fat feeding on neuronal gene                         
expression in the hypothalamus
A) NPY; B) AgRP; C) POMC. RT­qPCR was used to assess hypothalamic neuropeptide                       




An assessment of dopaminergic gene expression in the hypothalamus showed a significant                     
increase in TH expression in Fa mice compared to C mice (Figure 4.14.1.0.2:A. Table                         
4.14.1.0.4:A), indicating an increased production of dopamine. A significant decrease in COMT                     
was observed in Fa mice compared to C mice, indicating a reduction in the production of one of                                 
the enzymes that breaks down dopamine. No other dopaminergic genes showed a significant                       
fold change in mRNA expression (Figure 4.14.1.0.2:A. Table 4.14.1.0.4:A).
In the VTA, the area of the brain responsible for the production of dopamine, a significant                             
increase in D1R, D2R and DAT mRNA expression was observed (Figure 4.14.1.0.2:B. Table                       
4.14.1.0.4:B). An increase in dopamine receptor expression would indicate VTA neurons are                     
more sensitive to dopamine. An increase in DAT expression suggests an increase rate of                         
reuptake of dopamine from the synapse, thereby reducing dopamine­induced signalling, which                   
may account for the change in dopamine receptor expression.
In both the NAc and PFC, reward centres that receive a substantial number of projections from                             
the VTA, a significant decrease in DAT mRNA expression was observed (Figure 4.14.1.0.2:C,D.                       




Figure {4.14.1.0.2} The effect of 6 weeks of high fat feeding on dopamine­related gene                         
expression in the hypothalamus and reward areas
A) Hypothalamus; B) VTA; C) NAc; D) PFC. RT­qPCR was used to assess changes in                           
dopamine­related gene expression. TH: tyrosine hydroxylase; D1R: dopamine receptor D1A;                 
D2R: dopamine receptor 2; DAT: dopamine active transporter; DARPP: dopamine and                   
cAMP­regulated neuronal phosphoprotein; COMT: Catechol­O­methyltransferase.       




There was no significant difference between groups in LepR mRNA expression in the                       
hypothalamus or VTA (Figure 4.14.1.0.3:A,B. Table 4.14.1.0.4:A,B). Similarly, no difference in                   
MC4R mRNA expression was observed in the hypothalamus (Figure 4.14.1.0.3:A. Table                   
4.14.1.0.4:A).
Figure {4.14.1.0.3} The effect of 6 weeks of high fat feeding on LepR gene expression in                             
the hypothalamus and VTA, and MC4R gene expression in the hypothalamus of lean mice
A) Hypothalamus; B) VTA. RT­qPCR was used to assess changes in leptin receptor (LepR) and                           
melanocortin 4 receptor (MC4R) gene expression. Measurements in fold change (arbitrary                   




Hypothalamus C Fa p value
NPY 1.06 ± 0.18 1.7 ± 0.19 0.0410
AgRP 1.04 ± 0.13 1.26 ± 0.24 0.4482
POMC 1.02 ± 0.09 1.01 ± 0.15 0.9804
TH 1.01 ± 0.08 1.31 ± 0.08 0.0341
D1R 1.01 ± 0.04 1.06 ± 0.03 0.3560
D2R 1.01 ± 0.05 1.02 ± 0.09 0.9631
DAT 1.04 ± 0.18 0.79 ± 0.16 0.4317
DARPP­32 1.04 ± 0.12 1.11 ± 0.13 0.6978
COMT 1.00 ± 0.04 0.84 ± 0.04 0.0171
LepR 1.02 ± 0.09 1.18 ± 0.07 0.2121
MC4R 1.02 ± 0.08 1.01 ± 0.06 0.8656
VTA C Fa p value
TH 1.01 ± 0.09 1.17 ± 0.11 0.3098
D1R 1.01 ± 0.05 1.33 ± 0.11 0.0203
D2R 1.03 ± 0.09 1.41 ± 0.13 0.0353
DAT 1.01 ± 0.06 1.65 ± 0.19 0.0149
DARPP­32 1.02 ± 0.08 1.18 ± 0.12 0.2583
COMT 1.01 ± 0.04 1.05 ± 0.06 0.6047
LepR 1.01 ± 0.06 1.02 ± 0.05 0.9391
Table {4.14.1.0.4} The effect of 6 weeks of high fat feeding on gene expression in the                             
hypothalamus and VTA
A) Hypothalamus; B) VTA. NPY: Neuropeptide Y; AgRP: Agouti­related peptide; POMC:                   
Pro­opiomelanocortin; TH: tyrosine hydroxylase; D1R: dopamine receptor D1A; D2R: dopamine                 
receptor 2; DAT: dopamine active transporter; DARPP: dopamine and cAMP­regulated neuronal                   
phosphoprotein; COMT: Catechol­O­methyltransferase; LepR: leptin receptor; MC4R:           
melanocortin 4 receptor. Measurements in fold change (arbitrary units). Data presented as mean                       




NAc C Fa p value
D1R 1.02 ± 0.09 1.10 ± 0.09 0.5404
D2R 1.03 ± 0.13 0.76 ± 0.10 0.1287
DAT 1.06 ± 0.17 0.29 ± 0.04 0.0002
DARPP­32 1.02 ± 0.09 1.07 ± 0.09 0.7508
COMT 1.01 ± 0.04 1.02 ± 0.05 0.8707
PFC C Fa p value
D1R 1.03 ± 0.09 0.88 ± 0.07 0.2511
D2R 1.03 ± 0.11 0.99 ± 0.07 0.7698
DAT 1.01 ± 0.05 0.50 ± 0.10 0.0023
DARPP­32 1.03 ± 0.10 1.03 ± 0.06 0.9992
COMT 1.00 ± 0.03 0.93 ± 0.05 0.2330
Table {4.14.1.0.5} The effect of 6 weeks of high fat feeding on gene expression in the                             
NAc and PFC
A) NAc; B) PFC. D1R: dopamine receptor D1A; D2R: dopamine receptor 2; DAT: dopamine                         
active transporter; DARPP: dopamine and cAMP­regulated neuronal phosphoprotein; COMT:               
Catechol­O­methyltransferase. Measurements in fold change (arbitrary units). Data presented               





After 12 weeks of HF feeding, FaFa mice showed no significant changes in orexigenic or                           
anorectic mRNA expression in the hypothalamus compared to CC mice (Figure 4.14.2.0.1:A­C.                     
Table 4.14.2.0.4:A).
Unlike the comparison between groups C and Fa at time point 1, a significant decrease in NPY                               
mRNA expression was observed in CFa mice compared to CC mice (Figure 4.14.2.0.1:A. Table                         
4.14.2.0.4:A. p<0.01, n=6­8/group). Also in contrast to time point 1, CFa mice show an increased                           
expression of POMC mRNA compared to CC mice, indicating a decreased neural drive to feed                           
(Figure 4.14.2.0.1:C. Table 4.14.2.0.4:A. p<0.05, n=6­8/group). In line with this indication, a trend                       
in AgRP mRNA expression was also observed in CFa mice (Figure 4.14.2.0.1:B. Table                       
4.14.2.0.4:A). These differences were also apparent when comparing CFa mice to FaFa mice                       
for expression of NPY, AgRP and POMC mRNA expression (Figure 4.14.2.0.1:A­C. Table                     
4.14.2.0.4:A. NPY: p<0.05; POMC: p<0.01, n=6­8/group).
FaC mice also showed a significant decrease in NPY expression compared to CC mice (Figure                           
4.14.2.0.1:A. Table 4.14.2.0.4:A. p<0.01, n=6­8/group). A trend towards an increase in POMC                     
expression was observed in FaC mice compared to CC mice, again indicating a decreased                         
neural drive to feed. However, a slight trend towards an increase in AgRP expression was                           
observed, contradicting this idea (Figure 4.14.2.0.1:B. Table 4.14.2.0.4:A). No significant                 
difference in NPY or AgRP mRNA expression was observed when comparing FaC mice to FaFa                           
mice, although again a trend towards a decrease in NPY mRNA expression and an increase in                             
AgRP mRNA expression was observed. A significant increase in POMC mRNA expression was                       




Figure {4.14.2.0.1} The effect of maintained weight change on neuronal gene expression                     
in the hypothalamus
A) NPY; B) AgRP; C) POMC. RT­qPCR was used to assess hypothalamic neuropeptide                       
expression. Measurements in fold change (arbitrary units). Data presented as mean ± sem,                       




No significant differences in dopamine marker expression in the hypothalamus were observed                     
between CC and FaFa mice (Figure 4.14.2.0.2:A. Table 4.14.2.0.4:A).
TH expression in the hypothalamus was significantly increased in CFa mice compared to CC                         
mice, indicating an increased production of dopamine (Figure 4.14.2.0.2:A. Table 4.14.2.0.4:A).                   
No other dopamine markers showed a significant difference between these groups. A                     
comparison between CFa and FaFa mice showed a significant increase in D2R and COMT                         
mRNA expression in the hypothalamus. A trend was also observed showing an increase in TH                           
expression in CFa mice compared to FaFa mice.
FaC mice showed a significant increase in DARPP­32 and COMT mRNA expression in the                         
hypothalamus compared to FaFa mice (Figure 4.14.2.0.2:A. Table 4.14.2.0.4:A).
In the VTA, DAT mRNA expression showed a trend towards a decrease in FaFa mice compared                             
to CC mice (Figure 4.14.2.0.2:B. Table 4.14.2.0.4:B). No other dopamine markers showed any                       
significant changes between groups (Figure 4.14.2.0.2:B. Table 4.14.2.0.4:B). This contrasts                 
with significant changes in D1R, D2R and DAT expression in the VTA after 6 weeks of HF                               
feeding, suggesting changes in dopamine signalling may vary with the duration of HF feeding.
DAT mRNA expression was significantly increased in CFa mice compared to CC mice (Figure                         
4.14.2.0.2:B. Table 4.14.2.0.4:B. p<0.05, n=6­8/group), similar to the results presented above                   
showing the same difference after 6 weeks of HF feeding (Figure 4.14.2.0.2:B. Table                       
4.14.2.0.4:B).
Interestingly, CFa mice also showed a significant increase in VTA DAT mRNA expression in                         
comparison to FaFa mice, again suggesting changes in dopamine signalling induced by HF                       
feeding do not necessarily remain constant (Figure 4.14.2.0.2:B. Table 4.14.2.0.4:B).
FaC mice also showed a significant increase in VTA DAT mRNA expression in comparison to                           
FaFa mice, whilst a trend was observed in comparison with CC mice (Figure 4.14.2.0.2:B. Table                           




Similar to the VTA, there were no significant differences in NAc and PFC dopamine marker                           
mRNA expression between CC and FaFa mice after 12 weeks of feeding (Figure 4.14.2.0.2:C,D.                         
Table 4.14.2.0.5:A,B). However, a trend towards an increase in DAT mRNA expression was                       
observed in FaFa mice compared to CC mice in both reward areas.
In both the NAc and PFC, a significant decrease in TH mRNA expression was observed in CFa                               
mice compared to CC mice (Figure 4.14.2.0.2:C,D. Table 4.14.2.0.5:A,B. NAc: p<0.01; PFC:                     
p<0.05, n=6­8/group). This was also true when comparing CFa mice to FaFa mice (Figure                         
4.14.2.0.2:C,D. Table 4.14.2.0.5:A,B. Both p<0.05, n=6­8/group). A trend towards an increase in                     
DAT mRNA expression was observed in the NAc of CFa mice compared to CC mice, but was                               
not observed in the PFC (Figure 4.14.2.0.2:C,D. Table 4.14.2.0.5:A,B). No other differences in                       
dopamine marker mRNA expression was observed in the NAc. In the PFC however, a trend                           
towards in decrease in D2R expression was observed in CFa mice compared to CC mice,                           




Figure {4.14.2.0.2} The effect of maintained weight change on dopamine­related gene                   
expression in the hypothalamus and reward areas
A) Hypothalamus; B) VTA; C) NAc; D) PFC. RT­qPCR was used to assess changes in                           
dopamine­related gene expression. TH: tyrosine hydroxylase; D1R: dopamine receptor D1A;                 
D2R: dopamine receptor 2; DAT: dopamine active transporter; DARPP: dopamine and                   
cAMP­regulated neuronal phosphoprotein; COMT: Catechol­O­methyltransferase.       
Measurements in fold change (arbitrary units). Data presented as mean ± sem, n=5­8/group. *                         




LepR expression and MC4R expression showed no significant changes between CC and FaFa                       
mice in the hypothalamus (Figure 4.14.2.0.3:A. Table 4.14.2.0.4:A). Similarly, no significant                   
differences in these receptors were observed between CFa mice and CC or FaFa mice,                         
although an increased trend was present.
In contrast, FaC mice showed a significant increase in hypothalamic LepR mRNA expression in                         
comparison to CC and FaFa mice (Figure 4.14.2.0.3:A. Table 4.14.2.0.4:A. Both p<0.001,                     
n=6­8/group), possibly indicating hypothalamic neurons are more sensitive to leptin in mice who                       
have lost weight. No significant difference in MC4R expression was observed FaC and CC or                           
FaFa mice (Figure 4.14.2.0.3:A. Table 4.14.2.0.4:A).
In contrast to the hypothalamus, FaFa mice showed a significant decrease in LepR mRNA                         
expression in the VTA compared to CC mice (Figure 4.14.2.0.3:B. Table 4.14.2.0.4:B. p<0.001,                       
n=6­8/group). A trend towards an increase in LepR mRNA expression was observed between                       
CFa mice and CC mice, whilst this difference was significant compared to FaFa mice (Figure                           
4.14.2.0.3:B. Table 4.14.2.0.4:B. p<0.001, n=6­8/group). This suggests an increase in leptin                   
sensitivity in VTA neurons. Similarly, a slight trend toward an increase in LepR expression was                           




Figure {4.14.2.0.3} The effect of maintained weight change on LepR gene expression in                       
the hypothalamus and VTA, and MC4R gene expression in the hypothalamus of lean mice
A) Hypothalamus; B) VTA. RT­qPCR was used to assess changes in leptin receptor (LepR) and                           
melanocortin 4 receptor (MC4R) gene expression. Measurements in fold change (arbitrary                   




Hypothalamus CC CFa FaC FaFa
NPY 1.03 ± 0.12 1.51 ± 0.16 1.15 ± 0.07 1.12 ± 0.10
AgRP 1.02 ± 0.07 1.26 ± 0.09 1.13 ± 0.05 0.85 ± 0.09
POMC 1.01 ± 0.07 1.05 ± 0.08 0.94 ± 0.05 0.86 ± 0.05
TH 1.08 ± 0.24 0.96 ± 0.09 1.17 ± 0.16 0.98 ± 0.18
D1R 1.04 ± 0.13 1.10 ± 0.10 1.45 ± 0.17 0.68 ± 0.05
D2R 1.01 ± 0.07 1.16 ± 0.03 1.13 ± 0.03 0.88 ± 0.02
DAT 1.05 ± 0.15 1.55 ± 0.16 2.37 ± 0.17 1.00 ± 0.12
DARPP­32 1.05 ± 0.14 1.38 ± 0.18 1.40 ± 0.11 1.18 ± 0.09
COMT 1.07 ± 0.20 0.38 ± 0.05 0.52 ± 0.09 0.81 ± 0.08
LepR 1.01 ± 0.05 2.04 ± 0.31 1.53 ± 0.28 0.58 ± 0.18
MC4R 1.15 ± 0.32 0.50 ± 0.17 1.50 ± 0.25 0.97 ± 0.14
VTA CC CFa FaC FaFa
TH 1.02 ± 0.11 1.36 ± 0.16 1.31 ± 0.11 0.95 ± 0.14
D1R 1.01 ± 0.07 1.34 ± 0.06 1.51 ± 0.18 1.18 ± 0.12
D2R 1.01 ± 0.06 1.29 ± 0.10 1.05 ± 0.06 0.79 ± 0.15
DAT 1.04 ± 0.14 2.02 ± 0.28 1.69 ± 0.19 0.47 ± 0.10
DARPP­32 1.01 ± 0.06 1.11 ± 0.14 1.10 ± 0.11 0.96 ± 0.14
COMT 1.00 ± 0.04 1.13 ± 0.03 1.13 ± 0.04 1.00 ± 0.04
LepR 1.01 ± 0.07 1.31 ± 0.14 1.25 ± 0.11 0.60 ± 0.60
Table {4.14.2.0.4} The effect of maintained weight change on gene expression in the                       
hypothalamus and VTA
A) Hypothalamus; B) VTA. NPY: Neuropeptide Y; AgRP: Agouti­related peptide; POMC:                   
Pro­opiomelanocortin; TH: tyrosine hydroxylase; D1R: dopamine receptor D1A; D2R: dopamine                 
receptor 2; DAT: dopamine active transporter; DARPP: dopamine and cAMP­regulated neuronal                   
phosphoprotein; COMT: Catechol­O­methyltransferase; LepR: leptin receptor; MC4R:           
melanocortin 4 receptor. Measurements in fold change (arbitrary units). Data presented as mean                       




NAc CC CFa FaC FaFa
D1R 1.01 ± 0.05 0.73 ± 0.04 0.72 ± 0.04 0.97 ± 0.07
D2R 1.03 ± 0.10 1.03 ± 0.06 1.06 ± 0.10 1.02 ± 0.10
DAT 1.02 ± 0.09 1.79 ± 0.24 2.11 ± 0.26 1.42 ± 0.12
DARPP­32 1.02 ± 0.10 0.80 ± 0.04 0.82 ± 0.10 0.80 ± 0.13
COMT 1.00 ± 0.03 0.93 ± 0.06 1.09 ± 0.05 0.98 ± 0.03
PFC CC CFa FaC FaFa
D1R 1.01 ± 0.06 0.78 ± 0.06 0.64 ± 0.07 1.01 ± 0.03
D2R 1.02 ± 0.08 0.72 ± 0.03 0.91 ± 0.15 1.14 ± 0.07
DAT 1.02 ± 0.12 1.25 ± 0.14 2.84 ± 0.24 1.47 ± 0.14
DARPP­32 1.04 ± 0.14 0.82 ± 0.06 0.80 ± 0.03 0.72 ± 0.07
COMT 1.00 ± 0.03 1.03 ± 0.04 1.05 ± 0.03 0.98 ± 0.02
Table {4.14.2.0.5} The effect of maintained weight change on gene expression in the NAc                         
and PFC
A) NAc; B) PFC. D1R: dopamine receptor D1A; D2R: dopamine receptor 2; DAT: dopamine                         
active transporter; DARPP: dopamine and cAMP­regulated neuronal phosphoprotein; COMT:               
Catechol­O­methyltransferase. Measurements in fold change (arbitrary units). Data presented               





After 18 weeks of HF feeding, there remained no difference in orexigenic or anorexigenic mRNA                           
expression between FaFaFa mice and CCC mice in the hypothalamus (Figure 4.14.2.0.1:A­C.                     
Table 4.14.3.0.4:A).
Unlike the comparisons between the diet swap groups and control group at time point 2, there                             
was no significant differences in neuropeptide expression between any of the groups at time                         
point 3 (Figure 4.14.2.0.1:A­C. Table 4.14.3.0.4:A).
Figure {4.14.3.0.1} The effect of a single weight cycle on neuronal gene expression in                         
the hypothalamus
A) NPY; B) AgRP; C) POMC. RT­qPCR was used to assess hypothalamic neuropeptide                       




Similarly, no significant differences in hypothalamic dopamine marker mRNA expression was                   
observed between any of the groups (Figure 4.14.2.0.2:A. Table 4.14.3.0.4:A). However, a trend                       
showing an increase in COMT mRNA expression was observed in all groups in comparison to                           
CCC mice.
In the VTA, FaFaFa mice showed a similar profile of dopamine mRNA expression similar to that                             
shown in the VTA after 6 weeks of HF feeding shown above at time point 1 (Figure 4.14.1.0.2:B).                                 
TH, D2R and DAT mRNA expression were significantly higher in FaFaFa mice compared to                         
CCC mice (Figure 4.14.2.0.2:B. Table 4.14.3.0.4:B. All p<0.05, n=6­8/group).
CFaC mice showed a significant decrease in VTA D1R mRNA expression compared to CCC                         
mice (Figure 4.14.2.0.2:B. Table 4.14.3.0.4:B p<0.01, n=6­8/group). However, a trend towards                   
an increase in D2R mRNA expression was also observed simultaneously. A significant increase                       
in COMT mRNA expression was also observed in CFaC mice compared to CCC mice (Figure                           
4.14.2.0.2:B. Table 4.14.3.0.4:B. p<0.001, n=6­8/group). Similarly, this increase was also                 
significant when comparing to FaFaFa mice (Figure 4.14.2.0.2:B. Table 4.14.3.0.4:B p<0.01,                   
n=6­8/group). FaFaFa mice also had significantly higher DAT mRNA expression compared to                     
CFaC mice (Figure 4.14.2.0.2:B. Table 4.14.3.0.4:B. p<0.001, n=6­8/ group). Trends showing an                     
increase in VTA TH and D2R mRNA expression was observed in FaFaFa mice compared to                           
CFaC mice.
FaCFa mice showed a significant increase in DARPP­32 and COMT mRNA expression                     
compared to CCC mice in the VTA (Figure 4.14.2.0.2:B. Table 4.14.3.0.4:B. DARPP­32: p<0.05;                       
COMT: p<0.001, n=6­8/group). A comparison with FaFaFa mice showed FaFaFa mice had                     
significantly higher TH mRNA expression compared to FaCFa mice (Figure 4.14.2.0.2:B. Table                     
4.14.3.0.4:B. p<0.05, n=6­8/group). Similarly, VTA D2R and DAT mRNA expression was                   




In the NAc, no significant differences in dopamine marker mRNA expression were observed                       
between any groups (Figure 4.14.2.0.2:C. Table 4.14.3.0.5:A). A trend showing a decrease in                       
DAT mRNA expression in all groups compared to CCC mice as observed. Similarly, there was                           
no significant difference in D1R, DAT or COMT mRNA expression between groups (Figure                       
4.14.2.0.2:C. Table 4.14.3.0.5:A. A trend towards an increase in DARPP­32 expression was                     
observed in CFaC and FaCFa mice compared to CCC mice.
Both CFaC and FaCFa mice showed a significant increase in PFC D1R expression compared                         
to CCC mice (Figure 4.14.2.0.2:D. Table 4.14.3.0.5:B. CFaC: p<0.01; FaCFa: p<0.05,                   




Figure {4.14.3.0.2} The effect of a single weight cycle on dopamine­related gene                     
expression in the hypothalamus and reward areas
A) Hypothalamus; B) VTA; C) NAc; D) PFC. RT­qPCR was used to assess changes in                           
dopamine­related gene expression. TH: tyrosine hydroxylase; D1R: dopamine receptor D1A;                 
D2R: dopamine receptor 2; DAT: dopamine active transporter; DARPP: dopamine and                   
cAMP­regulated neuronal phosphoprotein; COMT: Catechol­O­methyltransferase.       
Measurements in fold change (arbitrary units). Data presented as mean ± sem, n=5­8/group. *                         




No significant differences in hypothalamic LepR or MC4R mRNA expression were observed                     
between groups (Figure 4.14.2.0.3:A. Table 4.14.3.0.4:A).
In the VTA, LepR mRNA expression was significantly increased compared to CFaC and FacFa                         
mice (Figure 4.14.2.0.3:B. Table 4.14.3.0.4:B. CFaC: p<0.01; FaCFa: p<0.05, n=6­8/group). A                   
trend towards an increase in LepR mRNA expression was also observed in comparison to CCC                           
mice.
Figure {4.14.3.0.3} The effect of a single weight cycle on LepR gene expression in the                           
hypothalamus and VTA, and MC4R gene expression in the hypothalamus of lean mice
A) Hypothalamus; B) VTA. RT­qPCR was used to assess changes in leptin receptor (LepR) and                           
melanocortin 4 receptor (MC4R) gene expression. Measurements in fold change (arbitrary                   




Hypothalamus CCC CFaC FaCFa FaFaFa
NPY 1.02 ± 0.10 1.28 ± 0.16 0.91 ± 0.12 0.83 ± 0.11
AgRP 1.02 ± 0.11 1.20 ± 0.14 0.75 ± 0.08 0.79 ± 0.14
POMC 1.01 ± 0.07 1.12 ± 0.07 0.99 ± 0.12 0.91 ± 0.10
TH 1.02 ± 0.09 1.17 ± 0.08 1.08 ± 0.06 1.11 ± 0.10
D1R 1.01 ± 0.06 1.18 ± 0.13 1.15 ± 0.06 1.14 ± 0.14
D2R 1.01 ± 0.06 1.10 ± 0.10 1.10 ± 0.12 1.16 ± 0.06
DAT 1.03 ± 0.12 1.03 ± 0.18 0.82 ± 0.16 0.98 ± 0.19
DARPP­32 1.06 ± 0.15 1.22 ± 0.24 1.35 ± 0.24 1.22 ± 0.20
COMT 1.01 ± 0.05 1.49 ± 0.19 1.39 ± 0.10 1.50 ± 0.20
LepR 1.03 ± 0.15 1.35 ± 0.20 1.14 ± 0.18 1.19 ± 0.15
MC4R 1.01 ± 0.07 1.43 ± 0.12 1.15 ± 0.13 1.50 ± 0.15
VTA CCC CFaC FaCFa FaFaFa
TH 1.08 ± 0.14 1.38 ± 0.25 1.19 ± 0.21 2.06 ± 0.21
D1R 1.05 ± 0.15 0.51 ± 0.06 0.65 ± 0.11 0.81 ± 0.09
D2R 1.01 ± 0.07 1.61 ± 0.27 1.07 ± 0.19 1.98 ± 0.17
DAT 1.03 ± 0.12 1.07 ± 0.23 0.91 ± 0.23 2.00 ± 0.29
DARPP­32 1.01 ± 0.07 1.03 ± 0.09 1.47 ± 0.21 0.88 ± 0.18
COMT 1.02 ± 0.08 1.73 ± 0.10 1.87 ± 0.22 1.10 ± 0.07
LepR 1.02 ± 0.11 0.78 ± 0.09 0.97 ± 0.12 1.44 ± 0.12
Table {4.14.3.0.4} The effect of a single weight cycle on gene expression in the                         
hypothalamus and VTA
A) Hypothalamus; B) VTA. NPY: Neuropeptide Y; AgRP: Agouti­related peptide; POMC:                   
Pro­opiomelanocortin; TH: tyrosine hydroxylase; D1R: dopamine receptor D1A; D2R: dopamine                 
receptor 2; DAT: dopamine active transporter; DARPP: dopamine and cAMP­regulated neuronal                   
phosphoprotein; COMT: Catechol­O­methyltransferase; LepR: leptin receptor; MC4R:           
melanocortin 4 receptor. Measurements in fold change (arbitrary units). Data presented as mean                       




NAc CCC CFaC FaCFa FaFaFa
D1R 0.99 ± 0.12 0.77 ± 0.11 0.91 ± 0.09 0.84 ± 0.08
D2R 0.97 ± 0.11 0.79 ± 0.12 0.83 ± 0.09 0.96 ± 0.10
DAT 0.92 ± 0.07 0.65 ± 0.13 0.58 ± 0.13 0.64 ± 0.16
DARPP­32 0.97 ± 0.13 0.76 ± 0.09 0.94 ± 0.16 1.15 ± 0.19
COMT 1.03 ± 0.09 0.97 ± 0.07 1.02 ± 0.09 1.08 ± 0.11
PFC CCC CFaC FaCFa FaFaFa
D1R 1.02 ± 0.08 1.19 ± 0.07 1.15 ± 0.21 1.15 ± 0.13
D2R 1.04 ± 0.13 1.70 ± 0.11 1.56 ± 0.13 1.41 ± 0.14
DAT 1.07 ± 0.16 1.15 ± 0.24 0.88 ± 0.15 1.17 ± 0.24
DARPP­32 1.04 ± 0.13 1.36 ± 0.25 1.61 ± 0.13 1.16 ± 0.18
COMT 1.03 ± 0.09 0.95 ± 0.06 1.19 ± 0.16 0.88 ± 0.04
Table {4.14.3.0.5} The effect of a single weight cycle on gene expression in the NAc and                             
PFC
A) NAc; B) PFC. D1R: dopamine receptor D1A; D2R: dopamine receptor 2; DAT: dopamine                         
active transporter; DARPP: dopamine and cAMP­regulated neuronal phosphoprotein; COMT:               
Catechol­O­methyltransferase. Measurements in fold change (arbitrary units). Data presented               








The protocol for this experiment is described in Section 2.3. C57Bl6 male mice aged 8­10 weeks                             
of age were fed a control diet (10% kcal fat) or a high fat diet (HFD, 60% kcal fat) for 4 weeks.                                         
Half of the mice fed the control diet continued to feed on the control diet for a further 8 weeks (CT                                       
group), whilst the other half of the mice were swapped to the HFD. The mice then returned to the                                   
control diet after 4 weeks of HFD feeding (CFC group). Similarly, half the mice fed the high fat                                 
diet continued to feed on the high fat diet for a further 8 weeks (FT group), whilst the other half of                                       
the mice were swapped to the normal fat control diet for 4 weeks. After this, mice were swapped                                 
back to the HFD for another 4 weeks (FCF group). In total, diet swapping groups will have had                                 
one complete weight cycle over 12 weeks of feeding.
Comparing the body weight of the two control groups, CT and FT mice, FT mice were                             
significantly heavier from week 2 of feeding (Figure 5.1.1.0.1:A. Table 5.1.2.0.2. p<0.001,                     
n=52/group). FT mice continued to be significantly heavier for the remainder of the 12 week                           
experiment.
CFC mice had similar body weights compared to CT mice for the first 4 weeks of control diet                                 
feeding (Figure 5.1.1.0.1:B. Table 5.1.2.0.2. n=52/group). When swapped to the HFD at week 4,                         
CFC were significantly heavier compared to CT mice from week 5 to week 8, 1 to 4 weeks after                                   
swapping back to the HFD (Figure 5.1.1.0.1:B. Table 5.1.2.0.2. Week 5: p<0.05; week 6­8:                         
p<0.001, n=52/group). After swapping back to the control diet at week 8, CFC mice no longer                             
had a significantly higher body weight compared to CT mice.
In comparison to FT mice, CFC mice were significantly lighter from week 1 to 4 when feeding on                                 
a control diet (Figure 5.1.1.0.1:D. Table 5.1.2.0.2. Week 1: p<0.01; week 2­4: p<0.001,                       
n=52/group). When swapping to the HFD, CFC gained weight but were still significantly lighter                         
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compared to FT mice throughout the 4 week period of HF feeding (Figure 5.1.1.0.1:D. Table                           
5.1.2.0.2. p<0.001, n=52/group). As expected, this difference persisted once CFC mice returned                     
to the control diet at week 8 (Figure 5.1.1.0.1:D]. Table 5.1.2.02. p<0.001, n=52/group).
A comparison of body weight between FCF mice and CT mice showed FCF mice were                           
significantly heavier from week 2 to 4 during the first period of HF feeding (Figure 5.1.1.0.1:C.                             
Table 5.1.2.0.2. Week 2: p<0.01; week 3­4: p<0.001, n=52/group). After swapping to the control                         
diet at week 4, FCF mice were still significantly heavier one week after the diet swap compared                               
to CT mice. From week 6 to 8, FCF mice and CT mice were not significantly different in terms of                                     
body weight measurements (Figure 5.1.1.0.1:C. Table 5.1.2.0.2. Week 5: p<0.01, n=52/group).                   
When the diet was swapped back to a HFD, FCF mice were once again significantly heavier                             
compared to CT mice from week 9 to 12, 1 to 4 weeks after swapping diet (Figure 5.1.1.0.1:C.                                 
Table 5.1.2.0.2. Week 9­12: p<0.001, n=52/group).
FCF mice and FT mice showed comparable body weights during the first 4 weeks of HF feeding.                               
From week 5 to 8, FCF mice were significantly lighter compared to FT mice, 1 to 4 weeks after                                   
swapping to the control diet (Figure 5.1.1.0.1:E. Table 5.1.2.0.2. p<0.001, n=52/group). Upon                     
swapping back to the HFD, FCF mice still showed a significantly lower body weight compared to                             





C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group) whilst the other                                   
half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4 weeks                                     
(CFC group). Similarly, half the mice continued to feed on the HFD for 8 weeks (FT group) whilst                                 
the other half were fed a control diet for 4 weeks, before swapping back to the HFD for 4 weeks                                     
(FCF group). Dotted lines represent when the diets were swapped, if applicable. Data presented                         




A comparison of weekly body weight change showed FT mice gained a significant amount of                           
weight compared to CT mice from week 1 to 8, and at week 10 (Figure 5.1.1.0.2:A. Table                               
5.1.2.0.6. Week 1­8: p<0.001; week 10: p<0.001, n=52/group). There was a general decrease in                         
body weight gain over the 12 week feeding period, particularly in FT mice.
Similarly, normalisation of weight change to body weight also showed an increased percentage                       
weight gain in FT mice compared to CT mice, except at week 8 (Figure 5.1.1.0.2:B. Table                             
5.1.2.0.7. Week 1­3: p<0.001; week 4: p<0.05; week 5: p<0.001; week 6: p<0.01; week 7:                           
p<0.001; week 10: p<0.05, n=52/group).
Figure {5.1.1.0.2} The effect of 12 weeks of high fat feeding on weekly body weight                           
change
A) Body weight change in grams (g); B) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem,                           




Body weight change was comparable between CT mice and CFC mice for the first 4 weeks of                               
control diet feeding. After swapping to the HFD at week 4, CFC mice gained significantly more                             
weight from week 5 to 8, 1 to 4 weeks after swapping to the HFD (Figure 5.1.1.0.3.A. Table                                 
5.1.2.0.6. Week 5­8: p<0.001, n=52/group). After swapping to the control diet at week 8, CFC                           
mice showed significant weight loss compared to CT mice from week 9 to 12, 1 to 4 weeks after                                   
the diet swap (Figure 5.1.1.0.3.A. Table 5.1.2.0.6. Week 9­10: p<0.001; week 11: p<0.01; week                         
12: p<0.001, n=52/group).
These results were also replicated when assessing percentage weight change (Figure                   
5.1.1.0.3.B. Table 5.1.2.0.7. Week 5­7: p<0.001; week 8: p<0.01; week 9­10: p<0.001; week 11:                         
p<0.01; week 12: p<0.001, n=52/group).
A comparison of body weight change between CFC mice and FT mice showed CFC mice                           
gained significantly less weight from week 1 to 4 of control fat feeding (Figure 5.1.1.0.3.C. Table                             
5.1.2.0.6. p<0.001, n=52/group). After swapping to the HFD at week 4, CFC mice showed a                           
significantly higher body weight gain at week 5, after which, weight change was comparable                         
between CFC mice and FT mice (Figure 5.1.1.0.3.C. Table 5.1.2.0.6. Week 5: p<0.001,                       
n=52/group). When swapping back to the control diet at week 8, CFC mice showed significant                           
weight loss compared to FT mice from week 9 to 12 (Figure 5.1.1.0.3.C. Table 5.1.2.0.6.                           
p<0.001, n=52/group).
Again, these difference were replicated when comparing percentage body weight change, except                     
CFC mice also showed a significantly higher percentage weight gain compared to FT mice at                           




Figure {5.1.1.0.3} The effect of a single weight cycle ending with weight loss on weekly                           
body weight change
A+C) Body weight change in grams (g); B+D) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group) whilst the other                                   
half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4 weeks                                     
(CFC group). Similarly, half the mice continued to feed on the HFD for 8 weeks (FT group).                               
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




A comparison of body weight change between FCF mice and CT mice showed FCF mice had a                               
significantly higher body weight gain compared to CF mice from week to 1 to 4 (Figure                             
5.1.1.0.4.A. Table 5.1.2.0.6. Week 1­3: p<0.001; week 4: p<0.05, n=52/group). After swapping to                       
the control diet at week 4. FCF mice lost a significant amount of weight from week 5 to 6, 1 to 2                                         
weeks after swapping diets. From week 7 to 8, body weight change in FCF mice was                             
comparable to CT mice (Figure 5.1.1.0.4.A. Table 5.1.2.0.6. Week 5­6: p<0.001, n=52/group).                     
After swapping back to the HFD at week 8, there was a significant increase in body weight from                                 
week 8 to 12 in FCF mice compared to CT mice (Figure 5.1.1.0.4.A. Table 5.1.2.0.6. Week 9­12:                               
p<0.001, n=52/group).
When comparing percentage weight change, differences between the two groups were similar.                     
However, percentage weight change did not show a significant difference between CT and FCF                         
mice at week 4 or week 12, unlike weight change differences measured in grams (Figure                           
5.1.1.0.4.B. Table 5.1.2.0.6. Week 1­3: p<0.001; week 5­6: p<0.001; week 9­11: p<0.001,                     
n=52/group).
From week 1 to 4, weight gain between FCF mice and FT mice was comparable during HF                               
feeding. When FCF mice were swapped to the control diet at 4 weeks, FCF mice lost a                               
significant amount of weight compared to FT mice from week 5 to 8 (Figure 5.1.1.0.4.C. Table                             
5.1.2.0.6. Week 5­8: p<0.001, n=52/group). When swapping back to the HFD at week 8, FCF                           
mice gained a significant amount of weight compared to week 9 to 12 compared to FT mice                               
(Figure 5.1.1.0.4.C. Table 5.1.2.0.6. p<0.001, n=52/group).
These results were replicated when comparing changes in percentage weight change between                     




Figure {5.1.1.0.4} The effect of a single weight cycle ending with weight gain on weekly                           
body weight change
A+C) Body weight change in grams (g); B+D) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group). Similarly, half                                 
the mice continued to feed on the HFD for 8 weeks (FT group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks (FCF group).. Dotted                               
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem,                           





The protocol for this experiment is described in Section 2.3. C57Bl6 male mice aged 8­10 weeks                             
of age were fed a control diet (10% kcal fat) or a high fat diet (60% kcal fat) for 4 weeks. Half of                                           
the mice fed the control diet continued to feed on the control diet for a further 24 weeks (LTC                                   
group), whilst the other half of the mice were swapped to the high fat diet. The mice returned to                                   
the control diet after 4 weeks of HFD feeding (LTFC group). The diet was swapped a further 4                                 
times with the full experiment time lasting 28 weeks. Similarly, half the mice fed the high fat diet                                 
continued to feed on the high fat diet for a further 24 weeks (LTF group), whilst the other half of                                     
the mice were swapped to the normal fat control diet for 4 weeks. After this, mice were swapped                                 
back to the HFD for another 4 weeks (LTFC group).The diet was swapped a further 4 times with                                 
the full experiment time lasting 28 weeks. In total, diet swapping groups will have had three                             
complete weight cycles over 28 weeks of feeding.
Comparing the body weight of the two control groups, LTC and LTF mice, LTF mice were                             
significantly heavier from week 2 to 28 of HF feeding (Figure 5.1.2.0.1:A. Table 5.1.2.0.2.                         
p<0.001, n=28/group).
As seen above, body weight was significantly heavier in LTCF mice when swapped to the HFD                             
compared to LTC mice. The first time LTCF mice swapped to the HFD, body weight was                             
significantly higher within a week and remained so until the last week of HF feeding. After which,                               
body weight was not significantly different within a week of swapping back to the control diet.                             
(Figure 5.1.2.0.1:B. Table 5.1.2.0.2. Week 5: p<0.05; week 6­8: p<0.001, n=52/group). Upon                     
swapping back to the HFD at week 12, body weight was significantly higher 2 weeks after                             
swapping diet rather than 1. Again this lasted to the end of the HFD feeding period at week 16                                   
(Figure 5.1.2.0.1:B. Table 5.1.2.0.2. Week 14: p<0.05; week 15­16: p<0.001, n=28/group). The                     
third time these mice were swapped to a HFD, again body weight wasn’t significantly higher until                             
the second week of HF feeding. However, after swapping back the control diet at week 24, body                               
weight remained significantly higher for another week, unlike during the first and second                       




In comparison to LTF mice, LTCF mice were always significantly lighter during the first weight                           
cycle from weeks 2 to 12 (Figure 5.1.2.0.1:D. Table 5.1.2.0.2. Week 2: p<0.01; week 3­12:                           
p<0.001, n=52/group). However, during the second weight gain period, LTCF mice were not                       
significantly different in body weight compared to LTF mice at week 16, the 4th week after                             
changing to the HFD (Figure 5.1.2.0.1:D. Table 5.1.2.0.2. Week 12­14: p<0.001; week 15:                       
p<0.05, n=28/group). Again, body weight was significantly lower one week after swapping back                       
to the control diet (Figure 5.1.2.0.1:D. Table 5.1.2.0.2. Week 16­20: p<0.001, n=28/group). When                       
swapping to the HFD for the third time, LTCF mice were only significantly lighter from week 20 to                                 
22, but did not show a significant difference in body weight from week 23 to 24 (Figure                               
5.1.2.0.1:D. Table 5.1.2.0.2. Week 20­22: p<0.001, n=28/group). After swapping back to the                     




A comparison of body weight between LTFC mice and LTC mice showed LTFC mice were                           
significantly heavier after 2 weeks of HF feeding during the first HF feeding period from week 1 to                                 
4. Subsequent increases in body weight when placed back on the HFD showed body weight was                             
significantly higher within a week (Figure 5.1.2.0.1:C .Table 5.1.2.0.2. Week 9: p<0.001; week 17:                         
p<0.01; week 25: p<0.001. Week 1­12: n=52/group; week 13­28: n=28/group). Body weight was                       
significantly higher for the remainder of those HF feeding periods (Figure 5.1.2.0.1:C. Table                       
5.1.2.0.2. All p<0.001. Week 1­12: n=52/group; week 13­28: n=28/group). Upon moving the the                       
control diet, LTFC mice showed a significantly higher body weight one week after each diet                           
swap, and was not significantly different compared to LTC mice within 2 weeks of swapping to                             
the control diet (Figure 5.1.2.0.1:C]. Table 5.1.2.0.2. Week 5: p<0.01; week 13: p<0.05; week 21:                           
p<0.01. Week 1­12: n=52/group; week 13­28: n=28/group).
LTFC mice and LTF mice showed comparable body weights during the first 4 weeks of HF                             
feeding. Body weight was significantly lower from week 5 to 18 in LTFC mice compared to LTF                               
mice, showing LTFC mice did not recover their body weight to a HF control level after the first                                 
period of weight loss from week 4 to 8 (Figure 5.1.2.0.1:E. Table 5.1.2.0.2. Week 5­11: p<0.001;                             
week 12: p<0.01; week 13­17: p<0.001; week 18: p<0.05. Week 1­12: n=52/group; week 13­28:                         
n=28/group). However, during recovery from the second period of weight loss (weeks 12 to 16),                           
body weight was no longer significantly different 3 weeks after returning to the HFD at week 16.                               
Body weight was significantly reduced again on week after swapping to the control diet at week                             
20 (Figure 5.1.2.0.1:E. Table 5.1.2.0.2. Week 21­24: p<0.001, n=28/group). Upon returning to the                       
HFD at week 24, body weight was no longer significantly different 2 weeks after the diet swap, as                                 





C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group) whilst the                                 
other half were fed a control diet for 4 weeks, before swapping back to the HFD for 4 weeks.                                   
Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTFC group).                             
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




Week LTC (g) LTCF (g) LTFC (g) LTF (g)
0 22.77 ± 0.30 22.59 ± 0.31 23.29 ± 0.33 23.28 ± 0.31
1 23.80 ± 0.37 23.45 ± 0.36 26.10 ± 0.39 26.26 ± 0.41
2 24.84 ± 0.45 24.28 ± 0.38 27.99 ± 0.41 28.07 ± 0.48
3 25.64 ± 0.59 25.59 ± 0.43 30.35 ± 0.44 30.23 ± 0.53
4 27.03 ± 0.63 26.68 ± 0.43 32.41 ± 0.45 32.45 ± 0.54
5 27.93 ± 0.61 30.43 ± 0.48 30.75 ± 0.46 34.52 ± 0.57
6 28.67 ± 0.59 32.13 ± 0.51 30.05 ± 0.43 36.36 ± 0.60
7 29.11 ± 0.60 34.56 ± 0.54 30.23 ± 0.43 38.29 ± 0.64
8 29.99 ± 0.61 36.41 ± 0.58 30.71 ± 0.44 40.04 ± 0.66
9 30.77 ± 0.68 32.91 ± 0.50 35.47 ± 0.51 41.00 ± 0.68
10 31.27 ± 0.72 32.25 ± 0.54 37.80 ± 0.59 42.40 ± 0.69
11 31.70 ± 0.75 31.92 ± 0.52 39.74 ± 0.63 43.40 ± 0.70
12 32.30 ± 0.74 31.63 ± 0.5 41.04 ± 0.68 43.96 ± 0.70
13 32.63 ± 1.26 36.44 ± 0.74 37.48 ± 0.91 43.91 ± 0.85
14 33.39 ± 1.22 38.09 ± 0.78 36.32 ± 0.92 44.32 ± 0.81
15 33.65 ± 1.26 40.20 ± 0.75 35.49 ± 0.84 44.51 ± 0.84
16 34.04 ± 1.23 41.25 ± 0.83 35.05 ± 0.82 44.73 ± 0.83
17 34.16 ± 1.23 38.10 ± 0.80 39.17 ± 0.92 44.78 ± 0.80
18 34.27 ± 1.23 36.95 ± 0.85 41.02 ± 0.92 45.38 ± 0.90
19 34.70 ± 1.18 35.98 ± 0.85 42.68 ± 0.96 45.74 ± 0.88
20 34.88 ± 1.19 35.52 ± 0.86 43.76 ± 0.98 46.12 ± 0.93
21 35.21 ± 1.23 39.36 ± 0.91 40.86 ± 1.04 46.43 ± 0.94
22 35.58 ± 1.19 40.95 ± 0.87 39.59 ± 1.04 46.98 ± 0.93
23 35.70 ± 1.20 42.90 ± 0.89 38.85 ± 0.97 46.79 ± 0.97
24 35.91 ± 1.20 44.04 ± 0.95 38.61 ± 0.92 47.11 ± 0.97
25 36.14 ± 1.20 41.06 ± 0.94 42.94 ± 1.07 47.04 ± 1.04
26 36.52 ± 1.19 39.84 ± 0.95 44.20 ± 1.05 47.28 ± 1.08
27 36.59 ± 1.15 38.73 ± 0.91 44.65 ± 1.01 46.94 ± 0.98




C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group) whilst the                                 
other half were fed a control diet for 4 weeks, before swapping back to the HFD for 4 weeks.                                   




A comparison of weekly body weight change showed, unlike increased body weight gain during                         
the first 10 weeks of HF feeding, no subsequent changes in body weight change were observed                             
between LTF mice and LTC mice, except at week 13 (Figure 5.1.2.0.3:A. Table 5.1.2.0.6. Week                           
13: p<0.05, n=28/group). Body weight change was comparable between the two groups from                       
week 14 to 28.
This was also true upon normalising weight change to body weight (Figure 5.1.2.0.3.B. Table                         
5.1.2.0.7. Week 13: p<0.05, n=28/group).
Figure {5.1.2.0.3} The effect of 28 weeks of high fat feeding on weekly body weight                           
change
A) Body weight change in grams (g); B) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 28 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




Similar to the differences in body weight change discussed above between CT and CFC from                           
week 1 to 12, LTCF mice showed significant increases in body weight during the first 3 weeks of                                 
the second HF feeding period (week 13 to 16) and during the entire third HF feeding period (week                                 
21 to 24) (Figure 5.1.2.0.4:A. Table 5.1.2.0.6. Week 13: p<0.001; week 14: p<0.01; week 15:                           
p<0.001; week 21­23: p<0.001; week 24: p<0.05, n=28/group). Also similar to the first weight                         
cycle, there was a significant weight loss 1 to 3 weeks after swapping back to the control diet in                                   
LTCF mice compared to LTC mice (Figure 5.1.2.0.4:A. Table 5.1.2.0.6. Week 17­19: p<0.001;                       
week 25­27: p<0.001, n=28/group). The only difference in these subsequent weight regains                     
compared to the first weight regain was LTCF mice still showed a significantly lower weight                           
change 4 weeks after feeding on the control diet, compared to 3 weeks.
Similarly, these differences were replicated when comparing differences in percentage weight                   
change between LTC mice and LTCF mice (Figure 5.1.2.0.4:B. Table 5.1.2.0.7. Week 13:                       




In comparison to LTF mice, LTCF mice showed significant weight loss for 4 weeks upon                           
swapping back to a control diet during the second period of weight loss from week 17 to 20,                                 
similar to the first period of weight loss between week 9 to 12, both 4 weeks in total. However,                                   
the final weight loss between week 25 to 28 only showed significant weight loss for 3 weeks,                               
from week 25 to 27 (Figure 5.1.2.0.4.C. Table 5.1.2.0.6. Week 17­19: p<0.001; week 20: p<0.01;                           
week 25­26: p<0.001; week 27: p<0.05, n=28/group). During the first weight gain period from                         
week 5 to 8, only week 5 showed a significant increase in body weight gain in LTCF mice                                 
compared to LTF mice, 1 week after swapping to the HFD. This is probably due to LTF mice                                 
showing a high level of weight gain during the first 8 weeks of HF feeding. Subsequent weight                               
gains from week 13 to 16 and week 21 to 24 show a significantly higher weight gain during the                                   
entire 4 weeks of HF feeding in LTCF mice compared to LTF mice (Figure 5.1.2.0.4:C. Table                             
5.1.2.0.6. Week 13­15: p<0.001; week 16: p<0.05; week 21­23: p<0.001; week 24: p<0.05,                       
n=28/group).
These results were, again, closely replicated when comparing percentage weight change                   
between the two groups. The only difference observed was percentage weight change was not                         
significantly higher in LTCF mice at week 24 compared to LTF mice, whilst body weight change                             
measured in grams showed this was a significant difference (Figure 5.1.2.0.4:D. Table 5.1.2.0.7.                       




Figure {5.1.2.0.4} The effect of three weight cycles ending with weight loss on weekly                         
body weight change
A+C) Body weight change in grams (g); B+D) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group). Dotted                               
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




A comparison of body weight change between LTFC mice and LTC mice showed LTFC mice                           
had a significantly higher body weight gain compared to LTC mice for 4 weeks during the first 3                                 
HFD feeding periods (Figure 5.1.2.0.5:A. Table 5.1.2.0.6. Week 1­3: p<0.001; week 4: p<0.05;                       
week 8­11: p<0.001; week 12: p<0.01; week 17­19: p<0.001; week 20: p<0.01. Week 1­12:                         
n=52/group; week 13­28: n=28/group). However, the 4th HFD feeding period showed a                     
significant weight gain in LTFC mice compared to LTC mice only during the first 2 weeks (Figure                               
5.1.2.0.5:A. Table 5.1.2.0.6. Week 25: p<0.001; week 26: p<0.01, n=28/group).The first weight                     
loss period for LTFC mice (week 5­8) showed LTFC mice had significantly lower weight change                           
compared to LTC mice from week 5 to 6. Subsequent weight loss periods showed a significant                             
reduction in body weight for the first 4 weeks in the second weight loss period (week 13 to 16),                                   
and during the first 3 weeks during the third weight loss period (week 21 to 24) (Figure                               
5.1.2.0.5:A. Table 5.1.2.0.6. Week 13­15: p<0.001; week 16: p<0.05; week 21­22: p<0.001; week                       
23: p<0.01, n=28/group).
A comparison of percentage body weight change showed similar results to those presented                       
comparing difference in body weight change measured in grams. Unlike the significant difference                       
observed between groups at week 12 and 25, percentage body weight change did not show                           
these differences to be significant. However, all other significant differences observed when                     
comparing body weight change were also observed when comparing percentage body weight                     
change (Figure 5.1.2.0.5:B. Table 5.1.2.0.7. Week 13­15: p<0.001; week 16: p<0.01; week                     




A comparison of body weight change between LTFC mice and LTF mice showed, similar to the                             
comparisons made for one weight cycle, LTFC mice lost a significant amount of weight 1 week                             
after swapping to the control diet. During the first weight loss, body weight change was                           
significantly lower during the entire 4 weeks of control feeding. During the second weight loss,                           
weight change was only significant for 3 weeks, whilst during the third weight loss period, this                             
was only significant for 2 weeks (Figure 5.1.2.0.5:C. Table 5.1.2.0.6. Week 13­15: p<0.001; week                         
21­22: p<0.001, n=28/group). Similarly, weight regain during week 8­12 was significantly higher                     
in LTFC mice compared to LTF mice throughout. Subsequent weight regain periods show                       
weight change was only significantly higher during the first 3 weeks, rather than 4 weeks of HF                               
feeding (Figure 5.1.2.0.5:C. Table 5.1.2.0.6. Week 17­19: p<0.001; week 25­26: p<0.001; week                     
27: p<0.05, n=28/group).
A comparison of percentage weight change between LTFC mice and LTF mice showed all                         
significant difference show when comparing body weight change in grams, except at week 27.                         
This was shown to not be a significant difference between the two groups when comparing                           
percentage body weight change (Figure 5.1.2.0.5:D. Table 5.1.2.0.7. Week 13­14: p<0.001;                   




Figure {5.1.2.0.5} The effect of three weight cycles ending with weight gain on weekly                         
body weight change
A+C) Body weight change in grams (g); B+D) Percentage body weight change (%).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Dotted lines represent                           
when the diets were swapped, if applicable. Data presented as mean ± sem. Week 1­12:                           




Week LTC (g) LTCF (g) LTFC (g) LTF (g)
1 1.03 ± 0.12 0.86 ± 0.09 2.81 ± 0.13 2.97 ± 0.18
2 1.04 ± 0.12 0.83 ± 0.07 1.90 ± 0.10 1.81 ± 0.14
3 0.80 ± 0.17 1.31 ± 0.14 2.35 ± 0.11 2.16 ± 0.11
4 1.39 ± 0.14 1.09 ± 0.07 2.06 ± 0.11 2.22 ± 0.16
5 0.90 ± 0.19 3.74 ± 0.16 ­1.66 ± 0.14 2.09 ± 0.15
6 0.74 ± 0.10 1.70 ± 0.20 ­0.70 ± 0.09 1.83 ± 0.16
7 0.43 ± 0.12 2.43 ± 0.11 0.18 ± 0.10 1.93 ± 0.19
8 0.88 ± 0.11 1.85 ± 0.12 0.48 ± 0.21 1.75 ± 0.11
9 0.78 ± 0.17 ­3.50 ± 0.21 4.76 ± 0.25 0.96 ± 0.16
10 0.49 ± 0.14 ­0.66 ± 0.14 2.33 ± 0.14 1.40 ± 0.19
11 0.44 ± 0.11 ­0.33 ± 0.09 1.94 ± 0.14 1.00 ± 0.11
12 0.59 ± 0.13 ­0.29 ± 0.11 1.30 ± 0.14 0.55 ± 0.08
13 0.07 ± 0.18 4.53 ± 0.19 ­3.60 ± 0.32 0.85 ± 0.15
14 0.76 ± 0.16 1.66 ± 0.14 ­1.16 ± 0.18 0.42 ± 0.09
15 0.27 ± 0.12 2.11 ± 0.13 ­0.84 ± 0.23 0.19 ± 0.09
16 0.38 ± 0.17 1.05 ± 0.17 ­0.43 ± 0.14 0.22 ± 0.10
17 0.13 ± 0.17 ­3.15 ± 0.23 4.11 ± 0.18 0.04 ± 0.17
18 0.11 ± 0.15 ­1.15 ± 0.17 1.85 ± 0.15 0.60 ± 0.17
19 0.43 ± 0.12 ­0.97 ± 0.16 1.65 ± 0.15 0.36 ± 0.12
20 0.18 ± 0.13 ­0.46 ± 0.18 1.09 ± 0.21 0.38 ± 0.13
21 0.34 ± 0.16 3.84 ± 0.18 ­2.90 ± 0.37 0.30 ± 0.10
22 0.36 ± 0.11 1.59 ± 0.13 ­1.27 ± 0.16 0.56 ± 0.09
23 0.13 ± 0.05 1.95 ± 0.15 ­0.75 ± 0.14 ­0.19 ± 0.11
24 0.20 ± 0.08 1.13 ± 0.15 ­0.24 ± 0.18 0.32 ± 0.09
25 0.23 ± 0.08 ­2.98 ± 0.31 4.33 ± 0.24 ­0.07 ± 0.27
26 0.38 ± 0.09 ­1.22 ± 0.23 1.26 ± 0.12 0.24 ± 0.14
27 0.07 ± 0.11 ­1.11 ± 0.23 0.45 ± 0.15 ­0.35 ± 0.15




C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group) whilst the                                 
other half were fed a control diet for 4 weeks, before swapping back to the HFD for 4 weeks.                                   




Week LTC (%) LTCF (%) LTFC (%) LTF (%)
1 4.38 ± 0.51 3.75 ± 0.36 12.04 ± 0.50 12.70 ± 0.77
2 4.22 ± 0.47 3.52 ± 0.29 7.34 ± 0.39 6.82 ± 0.47
3 2.80 ± 0.71 5.37 ± 0.52 8.47 ± 0.38 7.71 ± 0.36
4 5.48 ± 0.51 4.36 ± 0.29 6.88 ± 0.39 7.49 ± 0.54
5 3.62 ± 0.67 14.16 ± 0.61 ­5.16 ± 0.45 6.51 ± 0.48
6 2.83 ± 0.37 5.68 ± 0.64 ­2.21 ± 0.29 5.36 ± 0.46
7 1.52 ± 0.40 7.66 ± 0.36 0.65 ± 0.31 5.34 ± 0.53
8 3.11 ± 0.38 5.33 ± 0.31 1.71 ± 0.78 4.61 ± 0.29
9 2.51 ± 0.52 ­9.50 ± 0.51 15.64 ± 0.83 2.40 ± 0.39
10 1.52 ± 0.43 ­2.10 ± 0.44 6.49 ± 0.34 3.50 ± 0.47
11 1.36 ± 0.34 ­0.95 ± 0.30 5.13 ± 0.38 2.39 ± 0.27
12 1.99 ± 0.42 ­0.93 ± 0.35 3.24 ± 0.35 1.30 ± 0.20
13 ­0.02 ± 0.55 14.46 ± 0.75 ­8.85 ± 0.85 2.04 ± 0.36
14 2.56 ± 0.56 4.57 ± 0.41 ­3.15 ± 0.53 1.02 ± 0.23
15 0.75 ± 0.41 5.65 ± 0.41 ­2.12 ± 0.6 0.37 ± 0.21
16 1.27 ± 0.58 2.55 ± 0.42 ­1.16 ± 0.44 0.53 ± 0.23
17 0.41 ± 0.51 ­7.63 ± 0.57 11.76 ± 0.48 0.14 ± 0.34
18 0.35 ± 0.51 ­3.12 ± 0.54 4.82 ± 0.42 1.26 ± 0.38
19 1.41 ± 0.39 ­2.62 ± 0.42 4.05 ± 0.38 0.86 ± 0.28
20 0.52 ± 0.39 ­1.28 ± 0.49 2.60 ± 0.48 0.79 ± 0.29
21 0.89 ± 0.47 10.92 ± 0.53 ­6.72 ± 0.95 0.66 ± 0.22
22 1.18 ± 0.35 4.18 ± 0.41 ­3.17 ± 0.44 1.23 ± 0.20
23 0.35 ± 0.17 4.81 ± 0.41 ­1.75 ± 0.37 ­0.44 ± 0.24
24 0.58 ± 0.22 2.61 ± 0.35 ­0.48 ± 0.55 0.70 ± 0.20
25 0.66 ± 0..22 ­6.77 ± 0.71 11.18 ± 0.54 ­0.21 ± 0.58
26 1.10 ± 0.24 ­3.02 ± 0.62 3.04 ± 0.35 0.47 ± 0.28
27 0.30 ± 0.31 ­2.70 ± 0.57 1.13 ± 0.38 ­0.59 ± 0.33
28 ­0.70 ± 0.50 ­0.94 ± 0.75 1.11 ± 0.31 ­0.12 ± 0.36
508
The Effects of Multiple Weight Cycles on Metabolism and Appetite                                            5. Results
Table {5.1.2.0.7} The effect of three weight cycles on weekly percentage body weight                       
change
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group) whilst the                                 
other half were fed a control diet for 4 weeks, before swapping back to the HFD for 4 weeks.                                   






A comparison between FT mice and CT mice showed CT mice consumed more food compared                           
to FT mice, although this was not always significant (Figure 5.2.1.01:A. Table 5.2.2.0.4. Week                         
2­3: p<0.001; week 5: p<0.01; week 6: p<0.05; week 7: p<0.01; week 8­9: p<0.001; week 11:                             
p<0.01, n=13/group).
When food intake was normalised to cage weight0.75, food intake was significantly higher in CT                           
mice compared to FT mice from week 1 to 12 (Figure 5.2.1.0.1:B. Table 5.2.2.0.5. Week 1:                             
p<0.05; week 2: p<0.01; week 3­12: p<0.001, n=13/group).
Figure {5.2.1.0.1} The effect of 12 weeks of high fat feeding on weekly food intake
A) Weekly food intake measured in grams per cage of 4 mice (g); B) Weekly food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem. n=                             




Food intake was comparable between CT mice and CFC mice whilst both were feeding on the                             
control diet. After swapping to the HFD at week 4, food intake was significantly lower in CFC                               
mice compared to CT mice from week 5 to 8 (Figure 5.2.1.0.2:A. Table 5.2.2.0.4. Week 5:                             
p<0.001; week 6­7: p<0.05; week 8: p<0.001, n=13/group). However, when CFC mice returned                       
back to the control diet at week 8, food intake was still significantly reduced compared to CT                               
mice from week 9 to 11 (Figure 5.2.1.0.2:A. Table 5.2.2.0.4. Week 9­10: p<0.001; week 11:                           
p<0.01, n=13/group). At week 12, food intake was still lower in CFC mice compared to CT mice,                               
although this was not significantly different.
Food intake normalised to cage weight0.75 showed the same significant differences observed                     
when comparing food intake measured in grams (Figure 5.2.1.0.2:B. Table 5.2.2.0.5. Week 5­10                       
p<0.001; week 11: p<0.01, n=13/group).
A comparison between CFC mice and FT mice showed, like CT mice, food intake was higher in                               
CFC mice, although this was only significant from week 3 to 4 (Figure 5.2.1.0.2:C. Table                           
5.2.2.0.4. Week 3: p<0.001; week 4: p<0.01, n=13/group). When swapped to the HFD at week 4,                             
CFC mice showed no difference in food intake compared to FT mice. When CFC mice were                             
swapped back to the control diet at week 8, a decrease in food intake was observed at week 9                                   
and 10, although this was not significantly different compared to FT mice (Figure 5.2.1.0.2:C.                         
Table 5.2.2.0.4. n=13/group).
Analysis of food intake data normalised to cage weight0.75 showed, again similar to CT mice,                           
CFC mice consumed significantly more food compared to FT mice from week 1 to 4 (Figure                             
5.2.2.0.1:D. Table 5.2.2.0.5. p<0.001, n=13/group). No significant differences between CFC and                   
FT mice were observed in food intake normalised to cage weight0.75 from week 5 to 8 whilst CFC                                 
mice were feeding on the HFD. Also, there were no significant differences in food intake data                             
normalised to cage weight0.75 between CFC mice and FT mice when CFC mice were swapped                           




Figure {5.2.1.0.2} The effect of a single weight cycle ending with weight loss on weekly                           
food intake
A+C) Weekly food intake measured in grams per cage of 4 mice (g); B+D) Weekly food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group) whilst the other                                   
half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4 weeks                                     
(CFC group). Similarly, half the mice continued to feed on the HFD for 8 weeks (FT group).                               
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




Food intake between FCF mice and CT mice showed, similar to FT mice, FCF mice consumed                             
less food compared to CT mice during the first 4 weeks of HF feeding, which was significant                               
between week 2 and 3 (Figure 5.2.1.0.3:A. Table 5.2.2.0.4. p<0.05, n=13/group). When FCF                       
mice were swapped to the control diet at week 4, food intake was significantly lower in FCF mice                                 
compared to CT mice from week 5 to 6, and at week 8, with the biggest decrease in food intake                                     
observed one week after swapping to the control diet (Figure 5.2.1.0.3:A. Table 5.2.2.0.4. Week                         
5: p<0.001; week 6: p<0.01; week 8: p<0.08, n=13/group). At week 8 when FCF mice were                             
swapped back to the HFD, an increase in food intake was observed in FCF mice at week 9,                                 
although this was not significant. From week 10 to 12, food intake was lower in FCF mice                               
compared to CT mice, which was significantly lower at week 12 (Figure 5.2.1.0.3:A. Table                         
5.2.2.0.4. p<0.05, n=13/group).
Upon normalisation to cage weight0.75, again similar to FT mice, food intake was significantly                         
lower whilst FCF mice were feeding on a HFD compared to CT mice (Figure 5.2.1.0.3:B. Table                             
5.2.2.0.4. Week 1: p<0.01; week 2­4: p<0.001, n=13/group). Replicating the results presented                     
measured in grams, food intake normalised to cage weight0.75 also showed FCF mice                       
consumed less food when moved to the control diet at week 4, which was significant from week                               
5 to 6, and at week 8 (Figure 5.2.1.0.3:B .Table 5.2.2.0.4. Week 5­6: p<0.001; week 8: p<0.01,                               
n=13/group). The peak in food intake observed in FCF mice the week after moving back to the                               
HFD was comparable to food intake consumed by CT mice when comparing food intake                         
normalised to cage weight0.75. From week 10 to 12, food intake was again significantly lower in                             




In comparison to FT mice, FCF mice showed a similar level of food intake whilst feeding on the                                 
HFD. When swapped to the control diet at week 4, FCF mice showed a significant decrease in                               
food intake one week after swapping diet, whilst 3 to 4 weeks after, food intake was slightly                               
increase compared to FT mice (Figure 5.2.1.0.3:C. Table 5.2.2.0.4. Week 5: p<0.01,                     
n=13/group). When moved back to the HFD at week 8, FCF mice showed a significant increase                             
in food intake at week 9 compared to FT mice (Figure 5.2.1.0.3:C. Table 5.2.2.0.4. p<0.001,                           
n=13/group). Week 10 to 12 showed comparable food intake between the two groups.
When food intake was normalised to cage weight0.75, the significant decrease observed in food                         
intake at week 5 was not significant between the two groups, although a noticeable decrease in                             
food intake normalised to cage weight0.75 was observed (Figure 5.2.1.0.3:D. Table 5.2.2.0.4.                     
n=13/group). However, the slight increase in food intake observed above was significantly higher                       
in FCF mice from week 6 to 8, 2 to 4 weeks after swapping to the control diet, compared to FT                                       
mice (Figure 5.2.1.0.3:D. Table 5.2.2.0.4. Week 6­8: p<0.001, n=13/group). Again, a significant                     
increase in food intake normalised to cage weight was observed in FCF mice compared to FT                             




Figure {5.2.1.0.3} The effect of a single weight cycle ending with weight gain on weekly                           
food intake
A+C) Weekly food intake measured in grams per cage of 4 mice (g); B+D) Weekly food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group). Similarly, half                                 
the mice continued to feed on the HFD for 8 weeks (FT group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks (FCF group). Dotted lines                                 
represent when the diets were swapped, if applicable. Data presented as mean ± sem.                         




An assessment of cumulative food intake for 4 week feeding periods show CT mice consumed                           
significantly more food compared to FT mice from week 3 to 4 during the first 4 weeks period                                 
(Figure 5.2.1.0.4:A. Table 5.2.2.0.9. Week 3: p<0.01; week 4: p<0.001, n=13/group). The next                       
two 4 week periods showed cumulative food intake increased from the 2nd to 4th week from the                               
start of the feeding period (week 4 and 8) (Figure 5.2.1.0.4:A. Table 5.2.2.0.9. Week 6: p<0.01;                             
week 7­8: p<0.001; week 10: p<0.01; week 11­12: p<0.001, n=13/group).
Similarly, when cumulative food intake was normalised to cage weight0.75, CT mice showed a                         
significantly higher food intake from week 3 to 4, but then also from the 1st to 4th week for both                                     
subsequent 4 week feeding periods (Figure 5.2.1.0.4:B]. Table 5.2.2.0.10. Week 3­4: p<0.01;                     
week 5­8: p<0.001; week 9: p<0.05; week 10­12: p<0.001, n=13/group).
Figure {5.2.1.0.4} The effect of 12 weeks of high fat feeding on cumulative food intake                           
for 4 week periods
A) Cumulative food intake measured in grams per cage of 4 mice (g); B) Cumulative food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




Cumulative food intake was comparable during the first 4 weeks of control feeding between CT                           
mice and CFC mice. After swapping to the HFD, CFC mice showed a significantly lower                           
cumulative food intake from week 6 to 8 compared to CT mice, 2 to 4 weeks after swapping                                 
diets (Figure 5.2.1.0.5:A. Table 5.2.2.0.9. Week 6: p<0.01; week 7­8: p<0.001, n=13/group). After                       
swapping back to the control diet at week 8, cumulative food intake was significantly decreased                           
in CFC mice compared to CT mice from week 9 to 12 (Figure 5.2.1.0.5:A. Table 5.2.2.0.9. Week                               
9: p<0.01; week 10­12: p<0.001, n=13/group).
A comparison between CT mice and CFC mice assessing cumulative food intake normalised to                         
cage weight0.75 also showed the significant differences observed when assessing cumulative                   
food intake measured in grams (Figure 5.2.1.0.5:B. Table 5.2.2.0.10. Week 6­8; p<0.001; week                       
9: p<0.05; week 10­12: p<0.001, n=13/group).
During the first 4 weeks feeding on a control diet, CFC mice showed a significantly higher                             
cumulative food intake compared to FT mice from week 3 to 4 (Figure 5.2.1.0.5:C. Table                           
5.2.2.0.9. p<0.001, n=13/group). After swapping diets at week 4 to a HFD, no significant                         
difference in food intake was observed between CFC mice and FT mice. However, once                         
swapping back to the control diet at week 8, cumulative food intake was slightly lower in CFC                               
mice compared to FT mice, although this was not significant (Figure 5.2.1.0.5:C. Table 5.2.2.0.9.                         
n=13/group).
When normalised to cage weight0.75, food intake was significantly higher in CFC mice compared                         
to FT mice from week 2 to 4, similar to CT mice (Figure 5.2.1.0.5:D. Table 5.2.2.0.10. Week 2:                                 
p<0.05; week 3­4: p<0.001, n=13/group). 4 weeks after swapping to the HFD, cumulative food                         
intake normalised to cage weight0.75 was significantly higher in CFC mice compared to FT mice                           
(Figure 5.2.1.0.5:D. Table 5.2.2.0.10. p<0.05, n=13/group). No significant difference in                 
cumulative food intake normalised to cage weight0.75 was observed from week 9 to 12 in CFC                             




Figure {5.2.1.0.5} The effect of a single weight cycle ending with weight loss on                         
cumulative food intake for 4 week periods
A+C) Cumulative food intake measured in grams per cage of 4 mice (g); B+D) Cumulative food                             
intake measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group) whilst the other                                   
half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4 weeks                                     
(CFC group). Similarly, half the mice continued to feed on the HFD for 8 weeks (FT group).                               
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




Cumulative food intake was significantly lower in FCF mice compared to CT mice from week 2                             
to 4 whilst feeding on a HFD (Figure 5.2.1.0.6:A. Table 5.2.2.0.9. Week 2: p<0.005; week 3­4:                             
p<0.001, n=13/group). After swapping to the control diet, FCF mice showed a significantly lower                         
cumulative food intake from week 5 to 8 compared to CT mice, 1 to 4 weeks after swapping                                 
diets (Figure 5.2.1.0.6:A. Table 5.2.2.0.9. Week 5: p<0.01; week 6­8: p<0.001, n=13/group). After                       
swapping back to the HFD at week 8, no significant differences in cumulative food intake were                             
observed between CT mice and FCF mice (Figure 5.2.1.0.6:A. Table 5.2.2.0.9. n=13/group).
A comparison between CT mice and FCF mice assessing cumulative food intake normalised to                         
cage weight0.75 also showed most of the significant differences observed when assessing                     
cumulative food intake measured in grams. However, food intake at week 5 was not significant                           
when normalised to cage weight0.75, whilst cumulative food intake was significantly lower in FCF                         
mice compared to CT mice at week 12, 4 weeks after swapping back to the HFD (Figure                               
5.2.1.0.6:B. Table 5.2.2.0.10. Week 2; p<0.01; week 3­4: p<0.001; week 6­8: p<0.001; week 12:                         
p<0.01, n=13/group).
During the first 4 week period of feeding on a HFD, cumulative food intake was comparable                             
between FCF mice and FT mice. After swapping to a control diet at week 4, no subsequent                               
change in cumulative food intake was observed. After swapping back to the HFD at week 8,                             
cumulative food intake was significantly higher in FCF mice compared to FT mice from week 10                             
to 12, 2 to 4 weeks after swapping diet (Figure 5.2.1.0.6:C. Table 5.2.2.0.9. Week 10: p<0.01;                             
week 11­12: p<0.001, n=13/group).
Similarly, when food intake was normalised to cage weight0.75, no significant differences between                       
FCF mice and FT mice were observed between week 1 to 8. However, after swapping to the                               
HFD at week 8, cumulative food intake normalised to cage weight0.75 was significantly higher in                           




Figure {5.2.1.0.6} The effect of a single weight cycle ending with weight gain on                         
cumulative food intake for 4 week periods
A+C) Cumulative food intake measured in grams per cage of 4 mice (g).;B+D) Cumulative food                           
intake measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group). Similarly, half                                 
the mice continued to feed on the HFD for 8 weeks (FT group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks (FCF group). Dotted lines                                 
represent when the diets were swapped, if applicable. Data presented as mean ± sem.                         





No further significant changes in food intake were observed from week 13 to 28 between LTC                             
mice and LTF mice, although similar to the first weight cycle from week 1 to 12, food intake in                                   
CT mice was noticeably higher compared to LTF mice (Figure 5.2.2.0.1:A. Table 5.2.2.0.4.                       
n=7/group).
Again, when food intake was normalised to cage weight0.75, food intake was significantly higher in                           
LTC mice compared to LTF for the entire duration of the experiment (Figure 5.2.2.0.1:B. Table                           
5.2.2.0.5. Week 13­25: p<0.001; week 26: p<0.01; week 27: p<0.05; week 28: p<0.01,                       
n=7/group).
Figure {5.2.2.0.1} The effect of 28 weeks of high fat feeding on weekly food intake
A) Weekly food intake measured in grams per cage of 4 mice (g); B) Weekly food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 28 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




After returning to the HFD for second time at week 12, LTCF mice showed an increase in food                                 
intake compared to LTC mice, although this was not significant. The third time swapping to a                             
HFD at week 20 however showed although food intake increased in LTCF mice, it was not                             
higher compared to LTC mice (Figure 5.2.2.0.2:A. Table 5.2.2.0.4. n=7/group). After the initial                       
significant decrease in food intake upon returning to a control diet after HF feeding observed from                             
week 8 to 12, food intake in LTCF mice similarly decreased at week 16, although this was not                                 
significantly lower compared to LTC mice. At week 24, food intake remained low but did not                             
decrease further due to control diet feeding (Figure 5.2.2.0.2:A. Table 5.2.2.0.4. n=7/group).
Food intake normalised to cage weight0.75 showed the food intake was never significantly higher                         
in LTCF mice compared to LTC after feeding a HFD at week 12 and 20. However, food intake                                 
normalised to cage weight0.75 showed after the initial increase in food intake from returning to                           
HFD (week 12 and 20), the 2nd to the 4th week showed a significant decrease in food intake in                                   
LTCF mice compared to LTC mice (Figure 5.2.2.0.2:B. Table 5.2.2.0.5. Week 14: p<0.01; week                         
15: p<0.05; week 16: p<0.001; week 22­23: p<0.05; week 24: p<0.001, n=7/group). significant                       
differences observed when comparing food intake measured in grams (Figure 5.2.2.0.2:B. Table                     
5.2.2.0.5. Week 5­10 p<0.001; week 11: p<0.01, n=13/group). Similarly, when LTCF mice                     
returned to feeding on a control diet at week 16, food intake remained significantly lower from                             
week 17 to 19, 1 to 3 weeks after swapping back to control feeding compared to LTC mice,                                 
similar to that observed during the first control diet refeeding period from week 8 to 12 (Figure                               
5.2.2.0.2:B. Table 5.2.2.0.5. Week 16­17: p<0.001; week 18: p<0.05, n=7/group). However, the                     
third period of control diet refeeding from week 24 to 28 showed food intake normalised to cage                               
weight0.75 was only significantly lower for one week after the diet swap in LTCF mice, although                             




In comparison to LTF mice, LTCF mice showed a significantly higher food intake one week after                             
refeeding on the HFD at week 12 (Figure 5.2.2.0.2:C. Table 5.2.2.0.4. p<0.001, n=7/group). One                         
week after HFD refeeding at week 20, food intake was also increased in LTCF mice compared                             
to LTF mice, although this instance was not significantly higher. Similar to week 8 to 12, food                               
intake was lower at week 17 in LTCF mice compared to LTF mice swapping back to the control                                 
diet at week 16, although this was not significant (Figure 5.2.2.0.2:C. Table 5.2.2.0.4. n=7/group).                         
No such trend was observed after swapping back to the control diet at week 24.
Food intake normalised to cage weight0.75 showed the increase in food intake at week 13 due to                               
HFD refeeding was also significant in LTCF mice compared to LTF mice (Figure 5.2.2.0.2:D.                         
Table 5.2.2.0.5. p<0.001, n=7/group). Similar to the increase in food intake in LTCF at the end of                               
the 4 week period of control diet feeding from week 8 to 12, normalised food intake increased                               
from week 16 to 20, where at week 20, food intake normalised to cage weight0.75 was                             
significantly higher at week 20 in LTCF mice compared to LTF mice (Figure 5.2.2.0.2:D. Table                           




Figure {5.2.2.0.2} The effect of three weight cycles ending with weight loss on weekly                         
food intake
A+C) Weekly food intake measured in grams per cage of 4 mice (g); B+D) Weekly food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group). Dotted                               
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




After returning to the control diet for a second time at week 12, LTFC mice showed a decrease                                 
in food intake compared to LTC mice, which was significant at week 14, 2 weeks after swapping                               
diet (Figure 5.2.2.0.3:A. Table 5.2.2.0.4. p<0.05, n=7/group). The third time swapping to a control                         
diet at week 20, LTFC mice showed again food intake decreased, which was significant at week                             
21 compared to LTC mice, 1 week after swapping diet (Figure 5.2.2.0.3:A. Table 5.2.2.0.4.                         
p<0.05, n=7/group). Food intake started to increase in LTFC mice compared to LTC from week                           
21 to 24, although food intake was always lower in LTFC mice compared to LTC mice. Food                               
intake initially increased one week after refeeding with HFD at week 16 and 24, although food                             
intake was not significantly higher in LTFC mice compared to LTC mice . Food intake then                             
decreased from 2 to 4 weeks after HFD refeeding, although again, this difference was not                           
significant (Figure 5.2.2.0.3:A. Table 5.2.2.0.4. n=7/group).
Food intake normalised to cage weight0.75 showed, similar to the first instance of control diet                           
feeding between week 4 to 8, food intake was significantly lower from week 13 to 15, 1 to 3                                   
weeks after control diet feeding, and from week 21 to 22, 1 to 2 weeks after control diet feeding                                   
(Figure 5.2.2.0.3:B. Table 5.2.2.0.5. Week 13­14: p<0.001; week 15: p<0.05; week 21­22:                     
p<0.001, n=7/group). Similar to food intake analysis, normalised food intake increased upon HFD                       
feeding at week 16 and 24, 1 week afterwards in LTFC compared to LTC mice, although again                               
this was not a significant difference. After the first week of HFD refeeding at week 16 and 24,                                 
food intake was reduced from week 18 to 20, and from week 26 to 28. This was significantly                                 




After returning to the control diet at week 12 and 20, LTFC mice showed a slight decrease in                                 
food intake compared to LTF mice, although this was not significant (Figure 5.2.2.0.3:C. Table                         
5.2.2.0.4. n=7/group). Other than the initial significant decrease in food intake in LTFC mice                         
observed during the first period of control diet feeding (week 5 to 8), no significant decrease in                               
food intake in LTFC mice were observed compared to LTF mice. No noticeable difference in                           
food intake was observed during the second control diet feeding period between 12 to 16 weeks,                             
whilst food intake increased in LTFC mice compared to LTF during the third control diet feeding                             
period (week 20­24) from week 23 to 24 (Figure 5.2.2.0.3:C. Table 5.2.2.0.4. n=7/group). Similar                         
to the first HFD refeeding period between week 9 and 12, food intake was significantly increased                             
in LTFC mice compared to LTF mice at week 17, after refeeding at week 16 (Figure 5.2.2.0.3:C.                               
Table 5.2.2.0.4. p<0.01, n=7/group). The third instance of HFD feeding also showed LTFC mice                         
had an increase in food intake one week after HFD feeding (week 24), although this was not                               
significant compared to LTF mice (Figure 5.2.2.0.3:C. Table 5.2.2.0.4. n=7/group).
Food intake normalised to cage weight0.75 showed the food intake was not significantly altered                         
upon feeding a control diet after week 12 and 20, similar to the first instance of control feeding at                                   
week 4 (Figure 5.2.2.0.4:D. Table 5.2.2.0.5. n=7/group). Additionally, no noticeable difference in                     
food intake was observed during these control diet feeding periods. The increase in food intake                           
noted from week 23 to 24 in LTFC mice compared to LTF mice was significantly higher when                               
comparing food intake normalised to cage weight0.75 (Figure 5.2.2.0.4:D. Table 5.2.2.0.5. Week                     
23­24: p<0.05, n=7/group). Similar to food intake analysis, normalised food intake increased                     
upon HFD feeding at week 16 and 24 in LTFC compared to LTF mice. Food intake normalised to                                 
cage weight0.75 was significantly higher from week 17 to 18 during the second HFD refeeding                           
period (week 17­20), whilst food intake was significantly higher at week 25 after the third HFD                             




Figure {5.2.2.0.3} The effect of three weight cycles ending with weight gain on weekly                         
food intake
A+C) Weekly food intake measured in grams per cage of 4 mice (g); B+D) Weekly food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Dotted lines represent                           
when the diets were swapped, if applicable. Data presented as mean ± sem. n=13/group. *                           




Week LTC (g) LTCF (g) LTFC (g) LTF (g)
1 80.7 ± 2.1 82.5 ± 2.3 71.7 ± 1.5 74.4 ± 1.7
2 81.5 ± 1.9 80.4 ± 1.5 70.4 ± 1.8 75.2 ± 1.9
3 83.9 ± 2.8 84.9 ± 2.4 72.8 ± 1.4 70.2 ± 2.3
4 86.7 ± 1.8 84.0 ± 1.6 71.2 ± 2.3 70.8 ± 1.6
5 86.0 ± 2.1 72.1 ± 2.5 59.9 ± 2.5 72.7 ± 1.6
6 83.6 ± 2.6 72.7 ± 1.9 71.9 ± 2.1 72.4 ± 3.3
7 82.4 ± 3.2 72.6 ± 3.1 75.6 ± 2.0 70.6 ± 2.9
8 86.0 ± 2.9 67.9 ± 2.2 74.5 ± 3.2 68.7 ± 2.3
9 84.7 ± 2.7 62.1 ± 2.8 92.9 ± 2.6 69.4 ± 2.3
10 79.2 ± 2.2 59.7 ± 5.1 73.7 ± 2.1 69.4 ± 1.5
11 81.5 ± 2.5 69.7 ± 2.2 71.7 ± 1.8 69.6 ± 1.6
12 81.9 ± 2.4 77.2 ± 3.8 71.7 ± 1.9 72.1 ± 2.0
13 79.9 ± 3.7 91.1 ± 6.4 65.8 ± 3.6 69.4 ± 2.0
14 83.8 ± 5.3 71.8 ± 2.2 65.6 ± 1.3 67.8 ± 1.7
15 79.3 ± 4.5 69.3 ± 3.2 66.6 ± 4.0 66.5 ± 2.3
16 79.8 ± 6.0 65.3 ± 4.9 70.6 ± 4.1 72.0 ± 5.2
17 79.0 ± 8.2 61.7 ± 4.6 90.1 ± 5.4 70.1 ± 4.2
18 83.5 ± 5.0 68.7 ± 6.8 77.1 ± 2.7 67.0 ± 3.9
19 87.6 ± 3.6 76.8 ± 1.9 75.0 ± 2.9 72.5 ± 2.5
20 91.0 ± 4.8 82.3 ± 5.3 76.5 ± 3.3 73.5 ± 4.4
21 83.6 ± 7.0 83.4 ± 4.6 64.2 ± 3.3 69.3 ± 4.3
22 85.0 ± 2.6 75.4 ± 3.7 69.6 ± 2.2 70.3 ± 4.1
23 80.7 ± 3.9 71.5 ± 2.5 76.9 ± 2.8 69.0 ± 3.1
24 85.7 ± 3.6 74.1 ± 3.3 79.3 ± 5.5 71.1 ± 3.0
25 85.3 ± 1.6 73.5 ± 4.3 88.8 ± 4.5 74.3 ± 3.2
26 80.5 ± 3.4 74.0 ± 5.8 78.0 ± 4.3 72.9 ± 4.8
27 78.8 ± 7.3 71.7 ± 5.4 74.6 ± 2.5 74.0 ± 3.3





C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Data presented as mean                             




Week LTC (g/g0.75) LTCF (g/g0.75) LTFC (g/g0.75) LTF (g/g0.75)
1 2.71 ± 0.06 2.79 ± 0.09 2.32 ± 0.07 2.37 ± 0.07
2 2.64 ± 0.06 2.65 ± 0.06 2.11 ± 0.04 2.25 ± 0.07
3 2.64 ± 0.08 2.71 ± 0.10 2.06 ± 0.05 2.00 ± 0.09
4 2.69 ± 0.10 2.60 ± 0.09 1.91 ± 0.07 1.91 ± 0.08
5 2.57 ± 0.09 2.07 ± 0.07 1.59 ± 0.05 1.86 ± 0.07
6 2.42 ± 0.06 1.95 ± 0.07 1.97 ± 0.08 1.78 ± 0.10
7 2.35 ± 0.07 1.87 ± 0.09 2.09 ± 0.06 1.67 ± 0.07
8 2.42 ± 0.08 1.66 ± 0.06 2.05 ± 0.08 1.56 ± 0.05
9 2.33 ± 0.04 1.55 ± 0.07 2.41 ± 0.08 1.53 ± 0.06
10 2.15 ± 0.06 1.55 ± 0.13 1.76 ± 0.05 1.51 ± 0.05
11 2.19 ± 0.06 1.83 ± 0.06 1.65 ± 0.04 1.48 ± 0.05
12 2.18 ± 0.07 2.05 ± 0.08 1.60 ± 0.05 1.51 ± 0.05
13 2.09 ± 0.11 2.41 ± 0.16 1.44 ± 0.08 1.47 ± 0.05
14 2.21 ± 0.19 1.72 ± 0.07 1.54 ± 0.04 1.41 ± 0.06
15 2.02 ± 0.05 1.60 ± 0.08 1.60 ± 0.10 1.38 ± 0.06
16 2.01 ± 0.06 1.44 ± 0.09 1.71 ± 0.08 1.48 ± 0.08
17 1.97 ± 0.13 1.34 ± 0.09 2.20 ± 0.09 1.43 ± 0.06
18 2.10 ± 0.09 1.58 ± 0.14 1.75 ± 0.08 1.37 ± 0.06
19 2.20 ± 0.08 1.82 ± 0.06 1.64 ± 0.08 1.47 ± 0.06
20 2.26 ± 0.07 1.97 ± 0.09 1.62 ± 0.06 1.48 ± 0.07
21 2.06 ± 0.13 2.03 ± 0.11 1.35 ± 0.11 1.39 ± 0.10
22 2.10 ± 0.09 1.72 ± 0.13 1.54 ± 0.09 1.40 ± 0.08
23 1.97 ± 0.06 1.57 ± 0.04 1.74 ± 0.09 1.37 ± 0.07
24 2.09 ± 0.10 1.57 ± 0.08 1.81 ± 0.13 1.41 ± 0.07
25 2.08 ± 0.10 1.51 ± 0.05 2.02 ± 0.06 1.47 ± 0.08
26 1.94 ± 0.07 1.60 ± 0.09 1.64 ± 0.07 1.44 ± 0.08
27 1.88 ± 0.14 1.61 ± 0.13 1.55 ± 0.05 1.45 ± 0.05
28 1.91 ± 0.07 1.60 ± 0.04 1.46 ± 0.10 1.40 ± 0.08
530
The Effects of Multiple Weight Cycles on Metabolism and Appetite                                            5. Results
Table {5.2.2.0.5} The effect of three weight cycles on weekly food intake normalised to                         
cage weight0.75.
Weekly food intake measured in grams per cage of 4 mice normalised to total cage weight0.75                             
(g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Data presented as mean                             




An assessment of cumulative food intake for from week 13 to 28 also show a similar pattern of                                 
difference as seen when assessing a single weight cycle from week 1 to 12 (Figure 5.2.1.0.4:A.                             
Table 5.2.2.0.9. n=13/group). Cumulative food intake was significantly increased in LTC mice                     
compared to LTF mice from the 3rd to 4th week of each 4 week feeding period, except from                                 
week 24 to 28, where a trend towards increased food intake was observed (Figure 5.2.2.0.6:A.                           
Table 5.2.2.0.9. Week 15: p<0.05; week 16: p<0.001; week 19: p<0.01; week 20: p<0.001; week                           
23: p<0.01; week 24: p<0.001, n=7/group).
Similarly, when cumulative food intake was normalised to cage weight0.75, CT mice showed a                         
significantly higher food intake from the 2nd to 4th week of each 4 week feeding period, including                               
week 24 to 28 (Figure 5.2.2.0.6:B. Table 5.2.2.0.10. Week 14­16: p<0.001; week 18­20: p<0.001;                         
week 22­24: p<0.001; week 26­28: p<0.001, n=7/group).
Figure {5.2.2.0.6} The effect of 28 weeks of high fat feeding on cumulative food intake                           
for 4 week periods
A) Cumulative food intake measured in grams per cage of 4 mice (g); B) Cumulative food intake                               
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 28 weeks.                                 
Cumulative food intake presented from week 13 to 28. Dotted lines represent when the diets                           




Cumulative food intake analysis showed no significant differences between LTCF mice and LTC                       
mice during further periods of HFD feeding in LTCF mice (week 13 to 16, and week 21 to 24).                                   
However, upon control diet feeding between week 17 to 20 and week 25 to 28, cumulative food                               
intake was decreased in LTCF mice compared to LTC mice, which was significant between                         
week 19 to 20, and at week 28 (Figure 5.2.2.0.7:A. Table 5.2.2.0.9. Week 19: p<0.01; week 20:                               
p<0.001; week 28: p<0.05, n=7/group).
Similarly, normalised cumulative food intake showed no differences between week 13 to 16 and                         
week 21 to 24 whilst LTCF mice were feeding on a HFD. Between week 17 to 20 and week 25 to                                       
28, cumulative food intake normalised to cage weight was significantly reduced in LTCF mice                         
compared to LTC mice 2 to 4 weeks after swapping diets (Figure 5.2.2.0.7:B. Table 5.2.2.0.10.                           
Week 18­20: p<0.001; week 26: p<0.01; week 27­28: p<0.001, n=7/group).
No significant differences in cumulative food intake were observed from week 13 to 28 between                           
LTCF mice and LTF mice (Figure 5.2.2.0.7:C. Table 5.2.2.0.9. n=7/group). However, LTCF mice                       
showed a noticeably higher cumulative food intake compared to LTF mice whilst feeding on a                           
HFD from week 12 to 16, and week 20 to 24.
When normalised to cage weight0.75, food intake was significantly higher in LTCF mice                       
compared to LTF mice from week 13 to 16, and from week 22 to 24, whilst LTCF mice were                                   
feeding on a HFD (Figure 5.2.2.0.7:D. Table 5.2.2.0.10. Week 13: p<0.05; week 14­16: p<0.001;                         
week 22­24: p<0.001, n=7/group). No significant difference in cumulative food intake normalised                     




Figure {5.2.2.0.7} The effect of three weight cycles ending with weight loss on                       
cumulative food intake for 4 week periods
A+C) Cumulative food intake measured in grams per cage of 4 mice (g); B+D) Cumulative food                             
intake measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group).                             
Cumulative food intake presented from week 13 to 28. Dotted lines represent when the diets                           




Cumulative food intake analysis showed no significant differences between LTFC mice and LTC                       
mice during further periods of HFD feeding in LTFC mice (week 17 to 20, and week 25 to 28).                                   
However, upon control diet feeding between week 13 to 16, and week 21 to 24, cumulative food                               
intake was decreased in LTFC mice compared to LTC mice, which was significant between                         
week 15 to 16, and between week 22 to 24 (Figure 5.2.2.0.8:A. Table 5.2.2.0.9. Week 15:                             
p<0.01; week 16: p<0.001; week 22­23: p<0.05; week 24: p<0.01, n=7/group).
Similarly, normalised cumulative food intake showed no differences between week 17 to 20 and                         
week 25 to 28 whilst LTCF mice were feeding on a HFD. Between week 13 to 16 and week 21 to                                       
24, cumulative food intake normalised to cage weight was significantly reduced in LTFC mice                         
compared to LTC mice 2 to 4 weeks after swapping diets, similar to the result presented                             
comparing cumulative food intake measured in grams (Figure 5.2.2.0.8:B. Table 5.2.2.0.10.                   
Week 13­16; p<0.001; week 21­24; p<0.001, n=7/group).
No significant differences in cumulative food intake were observed between LTFC mice and LTF                         
mice from week 13 to 16, or between week 21 to 24 whilst LTFC mice were feeding on a control                                     
diet. Cumulative food intake was increased in LTFC mice whilst feeding on a HFD compared to                             
LTF mice, but this was only a significant difference at week 20, 4 weeks after swapping to the                                 
HFD (Figure 5.2.2.0.8:C. Table 5.2.2.0.9. p<0.05, n=7/group).
When normalised to cage weight0.75, food intake was significantly higher in LTFC mice                       
compared to LTF mice from week 18 to 20, and from week 26 to 29, 2 to 4 weeks after LTFC                                       
mice swapped to a HFD (Figure 5.2.2.0.8:D. Table 5.2.2.0.10. Week 18­20: p<0.001; week 26:                         
p<0.01; week 27­28: p<0.001, n=7/group). No significant difference in cumulative food intake                     




Figure {5.2.2.0.8} The effect of three weight cycles ending with weight gain on                       
cumulative food intake for 4 week periods
A+C) Cumulative food intake measured in grams per cage of 4 mice (g); B+D) Cumulative food                             
intake measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Cumulative food intake                           
presented from week 13 to 28. Dotted lines represent when the diets were swapped, if                           




Week LTC (g) LTCF LTFC LTF
1 80.7 ± 2.1 82.5 ± 2.3 71.7 ± 1.5 74.4 ± 1.7
2 162.2 ± 3.5 162.9 ± 3.6 142.1 ± 2.7 149.6 ± 2.6
3 246.1 ± 5.9 247.8 ± 5.7 214.9 ± 3.6 219.8 ± 3.7
4 332.8 ± 7.0 331.7 ± 6.6 286.1 ± 4.5 290.6 ± 4.1
5 86.0 ± 2.1 72.1 ± 2.5 59.9 ± 2.5 72.7 ± 1.6
6 169.5 ± 4.1 144.8 ± 3.7 131.8 ± 4.2 145.1 ± 3.4
7 252.0 ± 6.9 217.4 ± 5.6 207.4 ± 5.0 215.8 ± 5.2
8 338.0 ± 9.1 285.2 ± 6.9 281.9 ± 7.4 284.4 ± 6.2
9 84.7 ± 2.7 62.1 ± 2.8 92.9 ± 2.6 69.4 ± 2.3
10 163.9 ± 3.7 121.8 ± 5.9 166.6 ± 3.8 138.7 ± 2.7
11 245.4 ± 5.4 191.5 ± 6.9 238.3 ± 5.2 208.3 ± 3.4
12 327.3 ± 6.8 268.7 ± 7.3 310.0 ± 5.8 280.4 ± 4.8
13 79.9 ± 3.7 91.1 ± 6.4 65.8 ± 3.6 69.4 ± 2.0
14 163.6 ± 8.6 162.9 ± 6.5 131.3 ± 3.2 137.2 ± 2.0
15 242.9 ± 10.2 232.1 ± 8.0 197.9 ± 6.1 203.7 ± 2.9
16 322.7 ± 14.9 297.4 ± 7.4 268.5 ± 5.8 275.8 ± 5.0
17 79.0 ± 8.2 61.7 ± 4.6 90.1 ± 5.4 70.1 ± 4.2
18 162.5 ± 11.6 130.4 ± 10.0 167.1 ± 6.0 137.1 ± 6.9
19 250.1 ± 14.5 207.1 ± 9.6 242.1 ± 5.9 209.6 ± 7.4
20 341.0 ± 18.6 289.4 ± 14.2 318.6 ± 6.9 283.1 ± 10.4
21 83.6 ± 7.0 83.4 ± 4.6 64.2 ± 3.3 69.3 ± 4.3
22 168.6 ± 7.3 158.8 ± 4.4 133.8 ± 5.0 139.5 ± 3.0
23 249.3 ± 9.7 230.3 ± 3.9 210.7 ± 5.1 208.5 ± 4.3
24 335.1 ± 12.2 304.4 ± 5.6 290.1 ± 7.0 279.6 ± 4.9
25 85.3 ± 1.6 73.5 ± 4.3 88.8 ± 4.5 74.3 ± 3.2
26 165.8 ± 4.2 147.4 ± 9.4 166.8 ± 7.3 147.2 ± 5.7
27 244.6 ± 11.1 219.1 ± 12.5 241.4 ± 9.1 221.2 ± 8.8
28 324.5 ± 13.2 289.1 ± 14.4 312.4 ± 10.8 291.9 ± 9.8




C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Cumulative food intake                           
measured in grams per cage of 4 mice (g). Data presented as mean ± sem. Week 1­12:                               




Week LTC (g/g0.75) LTCF (g/g0.75) LTFC (g/g0.75) LTF (g/g0.75)
1 2.71 ± 0.06 2.79 ± 0.09 2.32 ± 0.07 2.37 ± 0.07
2 5.45 ± 0.13 5.57 ± 0.17 4.59 ± 0.13 4.76 ± 0.13
3 8.09 ± 0.17 8.22 ± 0.23 6.66 ± 0.16 6.85 ± 0.22
4 10.69 ± 0.09 10.87 ± 0.34 8.62 ± 0.20 8.82 ± 0.28
5 2.57 ± 0.09 2.07 ± 0.07 1.59 ± 0.05 1.86 ± 0.07
6 5.11 ± 0.17 4.09 ± 0.14 3.33 ± 0.12 3.68 ± 0.15
7 7.49 ± 0.23 6.00 ± 0.20 5.36 ± 0.11 5.41 ± 0.20
8 9.87 ± 0.25 7.82 ± 0.26 7.39 ± 0.14 7.05 ± 0.24
9 2.33 ± 0.04 1.55 ± 0.07 2.41 ± 0.08 1.53 ± 0.06
10 4.60 ± 0.08 3.18 ± 0.16 4.53 ± 0.21 3.04 ± 0.12
11 6.73 ± 0.10 4.72 ± 0.22 6.25 ± 0.25 4.55 ± 0.14
12 8.91 ± 0.14 6.62 ± 0.25 7.88 ± 0.29 6.04 ± 0.19
13 2.09 ± 0.11 2.41 ± 0.16 1.44 ± 0.08 1.47 ± 0.05
14 4.19 ± 0.22 4.81 ± 0.32 2.87 ± 0.16 2.93 ± 0.09
15 6.40 ± 0.41 6.53 ± 0.32 4.41 ± 0.15 4.35 ± 0.12
16 8.43 ± 0.41 8.13 ± 0.35 6.01 ± 0.22 5.72 ± 0.17
17 1.97 ± 0.13 1.34 ± 0.09 2.20 ± 0.09 1.43 ± 0.06
18 3.93 ± 0.25 2.68 ± 0.19 4.40 ± 0.17 2.86 ± 0.12
19 6.04 ± 0.22 4.27 ± 0.28 6.15 ± 0.15 4.22 ± 0.14
20 8.24 ± 0.24 6.08 ± 0.26 7.80 ± 0.09 5.70 ± 0.14
21 2.06 ± 0.13 2.03 ± 0.11 1.35 ± 0.11 1.39 ± 0.10
22 4.12 ± 0.26 4.07 ± 0.22 2.70 ± 0.21 2.79 ± 0.19
23 6.22 ± 0.22 5.79 ± 0.28 4.24 ± 0.30 4.19 ± 0.17
24 8.19 ± 0.19 7.36 ± 0.29 5.98 ± 0.35 5.55 ± 0.22
25 2.08 ± 0.10 1.51 ± 0.05 2.02 ± 0.06 1.47 ± 0.08
26 4.16 ± 0.19 3.03 ± 0.09 4.05 ± 0.12 2.94 ± 0.16
27 6.10 ± 0.24 4.63 ± 0.16 5.69 ± 0.12 4.38 ± 0.18
28 7.98 ± 0.33 6.24 ± 0.23 7.24 ± 0.12 5.83 ± 0.22




C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Cumulative food intake                           
measured in grams per cage of 4 mice normalised to total cage weight0.75 (g/g0.75). Data                           
presented as mean ± sem. Week 1­12: n=13/group; week 13­28: n=7/group. Green highlight                       






A comparison between FT mice and CT mice showed FT mice consumed significantly more                         
calories compared to CT mice from week 1 to 12, excluding week 8 (Figure 5.3.1.0.1:A. Table                             
5.3.2.0.4. Week: 1­2: p<0.001; week 3: p<0.01; week 4: p<0.05; week 5­7: p<0.001; week 9:                           
p<0.05; week 10­12: p<0.001, n=13/group).
However, when calorie intake was normalised to cage weight0.75, calorie intake was significantly                       
higher in FT mice compared to CT mice from week 1 to 2 (Figure 5.3.1.0.1:B. Table 5.3.2.0.5.                               
p<0.001, n=13/group). Apart from an increase in calorie intake at week 8 in CT mice, calorie                             
intake normalised to cage weight0.75 between the two groups was comparable from week 3 to                           
12.
Figure {5.3.1.0.1} The effect of 12 weeks of high fat feeding on weekly calorie intake
A) Weekly calorie intake per cage of 4 mice (kcal); B) Weekly calorie intake per cage of 4 mice                                   
normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




Calorie intake was comparable between CT mice and CFC mice whilst both were feeding on the                             
control diet. After swapping to the HFD at week 4, calorie intake was significantly higher in CFC                               
mice compared to CT mice from week 5 to 7 (Figure 5.3.1.0.2:A. Table 5.3.2.0.4. p<0.001,                           
n=13/group). However, when CFC mice returned back to the control diet at week 8, calorie                           
intake was significantly reduced compared to CT mice from week 9 to 10 . Calorie intake did not                                 
return to a comparable level until week 12.
Calorie intake normalised to cage weight0.75 did not show a significant increase in calorie intake                           
upon CFC mice moving to the HFD compared to CT mice, although a trend was apparent                             
between week 5 to 7. The significant decrease in calorie intake observed between week 9 to 10                               
was still evident when comparing calorie intake normalised to cage weight0.75 in CFC mice                         
compared to CT mice (Figure 5.3.1.0.2:B. Table 5.3.2.0.5. p<0.001, n=13/group).
A comparison between CFC mice and FT mice showed, similar to CT mice, calorie intake was                             
significantly lower in CFC mice compared to FT mice from week 1 to 4 (Figure 5.3.1.0.2:C.                             
Table 5.3.2.0.4. p<0.001, n=13/group). When swapped to the HFD at week 4, CFC mice showed                           
no difference in calorie intake compared to FT mice. When CFC mice were swapped back to the                               
control diet at week 8, a significant decrease in calorie intake was observed from week 9 to 12                                 
(Figure 5.3.1.0.2:D .Table 5.3.2.0.4. p<0.001, n=13/group).
Analysis of calorie intake data normalised to cage weight0.75 showed CFC mice consumed                       
significantly fewer calories compared to FT mice from week 1 to 2, similar to CT mice (Figure                               
5.3.1.0.2:D. Table 5.3.2.0.5. Week 1: p<0.01; week 2: p<0.001, n=13/group). Similar to the                       
comparison made with CT mice, normalised calorie intake was higher in CFC mice compared to                           
FT mice from week 5 to 8, although this was not significantly higher. Upon moving back to the                                 
control diet, again similar to the comparison with CT mice, calorie intake normalised to cage                           




Figure {5.3.1.0.2} The effect of a single weight cycle ending with weight loss on weekly                           
calorie intake
A+C) Weekly calorie intake per cage of 4 mice (kcal); B+D) Weekly calorie intake per cage of 4                                 
mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group) whilst the other                                   
half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4 weeks                                     
(CFC group). Similarly, half the mice continued to feed on the HFD for 8 weeks (FT group).                               
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




Calorie intake between FCF mice and CT mice showed, similar to FT mice, FCF mice                           
consumed significantly more calories compared to CT mice during the first 4 weeks of HF                           
feeding (Figure 5.3.1.0.3:A. Table 5.3.2.0.4. Week 1­3: p<0.001; week 4: p<0.01, n=13/group).                     
When FCF mice were swapped to the control diet at week 4, calorie intake was significantly                             
lower in FCF mice compared to CT mice from week 5 to 6 (Figure 5.3.1.0.3:A. Table 5.3.2.0.4.                               
Week 5: p<0.001; week 6: p<0.05, n=13/group). When FCF mice were swapped back to the                           
HFD at week 8, an increase in calorie intake was observed in FCF mice from week 9 to 12.
Upon normalisation to cage weight0.75, calorie intake was significantly higher in FCF mice                       
compared to CT mice only at week 1 (Figure 5.3.1.0.3:B. Table 5.3.2.0.5. p<0.05, n=13/group).                         
FCF mice consumed significantly less calories normalised to cage weight0.75 one week after                       
moving to the control diet compared to CT mice, rather than 2 weeks as shown when comparing                               
calorie intake. The peak in calorie intake observed in FCF mice one week after moving back to                               
the HFD was still observed when comparing calorie intake normalised to cage weight0.75,                       
although this significant difference did not remain from week 10 to 12, as observed previously                           
when comparing calorie intake between FCF mice and CT mice (Figure 5.3.1.0.3:B. Table                       
5.3.2.0.5. p<0.001, n=13/group).
In comparison to FT mice, FCF mice showed a comparable calorie intake whilst feeding on the                             
HFD. When swapped to the control diet, FCF mice showed a significant decrease in calorie                           
intake compared to FT mice from week 5 to 8, 1 to 4 weeks after swapping diet (Figure                                 
5.3.1.0.3:C. Table 5.3.2.0.4. p<0.001, n=13/group). When moved back to the HFD at week 8,                         
FCF mice showed a significant increase in calorie intake at week 9 compared to FT mice, whilst                               
calorie intake was comparable from week 10 to 12.
When calorie intake was normalised to cage weight0.75, FCF mice showed a significant                       
decrease in calorie compared to FT mice from week 9 to 10 only, whilst calorie intake                             
measurements showed a significant decrease during the entire control feeding period from week                       
5 to 8 (Figure 5.3.1.0.3:D. Table 5.3.2.0.5. Week 5: p<0.001; week 6: p<0.05, n=13/group).                         
Similar to calorie intake, FCF mice showed a significant increase in calorie intake normalised to                           
cage weight0.75 at week 9 compared to FT mice, 1 week after swapping back to the HFD, whilst                                 




Figure {5.3.1.0.3} The effect of a single weight cycle ending with weight gain on weekly                           
calorie intake
A+C) Weekly calorie intake per cage of 4 mice (kcal); B+D) Weekly calorie intake per cage of 4                                 
mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group). Similarly, half                                 
the mice continued to feed on the HFD for 8 weeks (FT group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks (FCF group). Dotted lines                                 
represent when the diets were swapped, if applicable. Data presented as mean ± sem.                         




An assessment of cumulative calorie intake for 4 week feeding period showed FT mice                         
consumed significantly more calories compared to CT mice from the 2nd week to 4th week                           
during all three 4 week periods (Figure 5.3.1.0.4:A. Table 5.3.2.0.9. Week 2­4: p<0.001; week 6:                           
p<0.06; week 7­8: p<0.001; week 10: p<0.05; week 11­12: p<0.001, n=13/group).
However, when cumulative calorie intake was normalised to cage weight0.75, FT mice showed a                         
significantly higher cumulative calorie intake from week 3 to 4 (Figure 5.3.1.0.4:B. Table                       
5.3.2.0.10. Week 3: p<0.04; week 4: p<0.01, n=13/group). Subsequent 4 week feeding periods                       
showed no significant difference in calorie intake normalised to cage weight0.75.
Figure {5.3.1.0.4} The effect of 12 weeks of high fat feeding on cumulative calorie intake                           
for 4 week periods
A) Cumulative calorie intake per cage of 4 mice (kcal). B) Cumulative calorie intake per cage of 4                                 
mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 12 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




Cumulative calorie intake was comparable during the first 4 weeks of control feeding between                         
CT mice and CFC mice. After swapping to the HFD, CFC mice showed a significantly higher                             
cumulative calorie intake from week 6 to 8 compared to CT mice, 2 to 4 weeks after swapping                                 
diets (Figure 5.3.1.0.5:A. Table 5.3.2.0.9. Week 6: p<0.05; week 7­8: p<0.001, n=13/group). After                       
swapping back to the control diet at week 8, cumulative calorie intake was significantly                         
decreased in CFC mice compared to CT mice from week 10 to 12.
A comparison between CT mice and CFC mice assessing cumulative calorie intake normalised                       
to cage weight0.75 showed no significant difference between CFC mice and CT mice whilst CFC                           
mice were feeding on the HFD from week 5 to 8, although calorie intake normalised to cage                               
weight0.75 was slightly higher in CFC mice compared to FT mice. Similar to calorie intake                           
measurements, calorie intake normalised to cage weight0.75 was significantly lower in CFC mice                       
compared to CT mice from week 10 to 12 (Figure 5.3.1.0.5:B. Table 5.3.2.0.10. p<0.001,                         
n=13/group).
During the first 4 weeks period feeding on the control diet, CFC mice showed a significantly                             
lower cumulative calorie intake compared to FT mice from week 2 to 4 (Figure 5.3.1.0.5:C. Table                             
5.3.2.0.9. p<0.001, n=13/group). After swapping diets to a HFD at week 4, no significant                         
difference in calorie intake was observed between CFC mice and FT mice. Once swapping back                           
to the control diet at week 8, cumulative calorie intake was significantly lower in CFC mice                             
compared to FT mice from week 9 to 12 (Figure 5.3.1.0.5:C. Table 5.3.2.0.9. Week 9: p<0.01;                             
week 10­12: p<0.001, n=13/group).
When normalised to cage weight0.75, calorie intake was significantly lower in CFC mice                       
compared to FT mice from week 2 to 4 (Figure 5.3.1.0.5:D. Table 5.3.2.0.10. Week 2: p<0.05;                             
week 3: p<0.01; week 4: p<0.001, n=13/group). No difference between CFC mice and FT mice                           
was observed between week 5 to 9 when comparing calorie intake normalised to cage                         
weight0.75. When swapping back to the control diet at work 8, CFC mice showed a significantly                             
lower calorie intake normalised to cage weight0.75 compared to FT mice from week 10 to 12                             




Figure {5.3.1.0.5} The effect of a single weight cycle ending with weight loss on                         
cumulative calorie intake for 4 week periods
A+C) Cumulative calorie intake per cage of 4 mice (kcal); B+D) Cumulative calorie intake per                           
cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group) whilst the other                                   
half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4 weeks                                     
(CFC group). Similarly, half the mice continued to feed on the HFD for 8 weeks (FT group).                               
Dotted lines represent when the diets were swapped, if applicable. Data presented as mean ±                           




Cumulative calorie intake was significantly higher in FCF mice compared to CT mice from week                           
2 to 4 whilst feeding on a HFD (Figure 5.3.1.0.6:A. Table 5.3.2.0.9. Week 2: p<0.001; week 3­4:                               
p<0.001, n=13/group). After swapping to the control diet, FCF mice showed a significantly lower                         
cumulative calorie intake from week 6 to 8 compared to CT mice, 2 to 4 weeks after swapping                                 
diets (Figure 5.3.1.0.6:A. Table 5.3.2.0.9. Week 6­7: p<0.01; week 8: p<0.001, n=13/group). After                       
swapping back to the HFD at week 8, FCF showed a significantly higher cumulative calorie                           
intake compared to CT mice from week 9 to 12 (Figure 5.3.1.0.6:A. Table 5.3.2.0.9. p<0.001,                           
n=13/group).
A comparison between CT mice and FCF mice assessing cumulative food intake normalised to                         
cage weight0.75 showed a significant increase in FCF mice at week 4 compared to CT mice.                             
When swapped to the control diet at week 4, FCF mice showed a significantly lower calorie                             
intake normalised to cage weight0.75 from week 6 to 8 (Figure 5.3.1.0.6:B. Table 5.3.2.0.10. Week                           
6: p<0.05; week 7: p<0.01; week 8: p<0.001, n=13/group). Upon swapping back to the HFD at                             
week 8, FCF mice showed a significant increase in cumulative calorie intake normalised to cage                           
weight0.75 from week 11 to 12.
During the first 4 week period of feeding on a HFD, cumulative calorie intake was comparable                             
between FCF mice and FT mice. After swapping to a control diet at week 4,calorie intake was                               
significantly decreased in FCF mice compared to FT mice from week 5 to 8 (Figure 5.3.1.0.6:C.                             
Table 5.3.2.0.9. Week 5: p<0.01; week 6­8: p<0.001, n=13/group). After swapping back to the                         
HFD at week 8, cumulative calorie intake was significantly higher in FCF mice compared to FT                             
mice from week 9 to 12 (Figure 5.3.1.0.6:C. Table 5.3.2.0.9. Week 9: p<0.05; week 10­11:                           
p<0.01; week 12: p<0.001, n=13/group).
Similarly, when food intake was normalised to cage weight0.75, no significant differences between                       
FCF mice and FT mice were observed between week 1 to 4. From week 6 to 8, FCF mice                                   
showed a significantly lower cumulative calorie intake compared to FT mice , 2 to 4 weeks after                               
swapping to the control diet (Figure 5.3.1.0.6:D. Table 5.3.2.0.10. Week 6: p<0.01; week 7­8:                         
p<0.001, n=13/group). After swapping back to the HFD at week 8, cumulative calorie intake                         
normalised to cage weight0.75 was significantly higher in FCF mice compared to FT mice from                           




Figure {5.3.1.0.6} The effect of a single weight cycle ending with weight gain on                         
cumulative calorie intake for 4 week periods
A+C) Cumulative calorie intake per cage of 4 mice (kcal); B+D) Cumulative calorie intake per                           
cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 8 weeks (CT group). Similarly, half                                 
the mice continued to feed on the HFD for 8 weeks (FT group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks (FCF group). Dotted lines                                 
represent when the diets were swapped, if applicable. Data presented as mean ± sem.                         





A comparison between LTF mice and LTC mice showed LTF mice consumed more calories                         
compared to LTC mice from week 13 to 28, although this was rarely significantly different (Figure                             
5.3.2.0.1:A. Table 5.3.2.0.4. Week 16: p<0.05; week 25: p<0.05; week 7: p<0.01, n=7/group).





C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 28 weeks. Dotted                                   
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem. n=                             




Similar to the first instance of HF feeding from week 5 to 8, LTCF mice showed a significant                                 
increase in calorie intake after swapping to the HFD at week 12 and 20. This increase was                               
significant at week 13, 1 week after swapping diets, and week 21 to 22, week 1 to 2 after                                   
swapping to a HFD a week 20 (Figure 5.3.2.0.2:A. Table 5.3.2.0.4. Week 13: p<0.001; week 21:                             
p<0.001; week 22: p<0.05, n=7/group). Unlike the first instance of weight loss after a feeding of a                               
HFD (week 9 to 12), calorie intake did not show a significant decreased in LTCF mice compared                               
to LTC mice, although a trend showing a decreased calorie intake was observed.
Calorie intake normalised to cage weight0.75 showed calorie intake was significantly higher in                       
LTCF mice compared to LTC at week 13, 1 week after HFD refeeding at week 12, although the                                 
third instance of HFD feeding between week 21 and 24 did not show a significant increase in                               
calorie intake normalised to cage weight0.75 in LTCF mice compared to LTC mice, although a                           
trend was observed (Figure 5.3.2.0.2:B. Table 5.3.2.0.5. Week 13: p<0.001, n=7/group). In                     
comparison to calorie intake, where no significant differences in calorie intake were observed                       
from week 13 to 28 between groups when LTCF mice were fed a control diet, a significant                               
decrease in calorie intake normalised to cage weight0.75 was observed in LTCF mice compared                         




In comparison to LTF mice, LTCF mice showed a significantly lower calorie intake after                         
swapping back to the control diet, as described in detail above from week 1 to 12 (Figure                               
5.3.1.0.3:C). Subsequent decreases in calorie intake observed in LTCF mice compared to LTF                       
mice occured for the full 4 week duration of control diet feeding, again similar to the first instance                                 
of control feeding after a period of HFD feeding (week 9 to 12) (Figure 5.3.2.0.2:C. Table                             
5.3.2.0.4. Week 17: p<0.001; week 18­19: p<0.01; week 20: p<0.05; week 25­28: p<0.001,                       
n=7/group). Unlike the first instance of HF feeding experienced by LTCF mice from week 5 to 8,                               
where no significant difference in calorie intake was observed between groups, a significant                       
increase in calorie intake was observed at week 13 in LTCF mice compared to LTF mice (Figure                               
5.3.1.0.3:C. Table 5.3.2.0.4. p<0.001, n=7/group). However, when LTCF mice were fed the HFD                       
a third time at week 20, there was no subsequent significant increase in calorie intake in LTCF                               
mice, although a trend was observed compared to LTF mice.
Food intake normalised to cage weight0.75 showed the increase in calorie intake at week 13 and                             
week 21 was significantly higher in LTCF mice compared to LTF mice, unlike just week 21 as                               
observed when comparing calorie intake (Figure 5.3.1.0.3:D. Table 5.3.2.0.5. Week 13: p<0.001;                     
week 21: p<0.01, n=7/group). Similar to the decrease in calorie intake normalised to cage                         
weight0.75 in LTCF at week 9 to 10 due to swapping back to a control diet, normalised calorie                                 
intake was not significantly reduced in LTCF mice for the whole 4 week period of control diet                               
feeding. Week 17 showed a significant decrease in calorie intake normalised to cage weight0.75                         
in LTCF mice compared to LTF mice, whilst no significant decrease was observed at week 25,                             




Figure {5.3.2.0.2} The effect of three weight cycles ending with weight loss on weekly                         
calorie intake
A+C) Weekly calorie intake per cage of 4 mice (kcal); B+D) Weekly calorie intake per cage of 4                                 
mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group). Dotted                               
lines represent when the diets were swapped, if applicable. Data presented as mean ± sem.                           




After returning to the control diet for second time at week 12, LTFC mice showed a decrease in                                 
calorie intake compared to LTC mice,although this was not significant. Similarly, the third time                         
LTFC mice swapped to a control diet at week 20 showed a trend towards a decrease in calorie                                 
intake in LTFC mice compared to LTC mice. Similar to the first instance of HFD refeeding from                               
week 9 to 12, calorie intake was higher in LTFC mice compared to LTC mice from week 17 to                                   
20, and week 25 to 28, although this was not always significantly higher (Figure 5.3.2.0.3:A.                           
Table 5.3.2.0.4. Week 17: p<0.001; week 18: p<0.01; week 25­26: p<0.001; week 27: p<0.01,                         
n=7/group).
Calorie intake normalised to cage weight0.75 showed calorie intake was not significantly reduced                       
due to control diet feeding between week 13 to 16 in LTFC mice compared to LTC mice, but was                                   
significant at week 21, 1 week after swapping to the control diet at week 20 in LTFC mice, similar                                   
to that observed during the first period of control diet feeding from week 5 to 8 (Figure                               
5.3.2.0.3:B. Table 5.3.2.0.5. Week 21: p<0.05, n=7/group). Calorie intake normalised to cage                     
weight0.75 showed when LTFC mice were refed the HFD a second time between week 17 to 20,                               
normalised calorie intake was significantly increased for one week at week 17 in LTFC mice                           
compared to LTC mice, whilst a trend was observed the third time HFD refeeding at week 25                               
(Figure 5.3.2.0.3:B. Table 5.3.2.0.5. Week 17: p<0.001, n=7/group).
After returning to the control diet at week 12 and 20, LTFC mice showed a decrease in calorie                                 
intake compared to LTF mice, which was significant from week 13 to 16 and between week 21                               
to 24, similar to the first instance of control diet feeding between week 5 to 12. (Figure                               
5.3.2.0.3:C. Table 5.3.2.0.4. Week 13­14: p<0.001; week 15: p<0.01; week 16: p<0.001; week                       
21­22: p<0.001; week 23­24: p<0.05, n=7/group). Upon refeeding on a HFD at week 16 and 24,                             
calorie intake increase in LTFC mice compared to LTF mice 1 week after refeeding, similar to                             
the increase in calorie intake observe at week 9. However, this increased calorie intake was only                             
significant at week 17 in LTFC mice compared to LTF mice (Figure 5.3.2.0.3:C. Table 5.3.2.0.4.                           
p<0.001, n=7/group).
Calorie intake normalised to cage weight0.75 showed no significant reduction in calorie intake in                         
LTFC mice compared to LTF mice at during week 13 to 16, or week 21 to 24. LTFC mice                                   
showed a significant increase in calorie intake normalised to cage weight0.75 compared to LTF                         




Figure {5.3.2.0.3} The effect of three weight cycles ending with weight gain on weekly                         
calorie intake
A+C) Weekly calorie intake per cage of 4 mice (kcal); B+D) Weekly calorie intake per cage of 4                                 
mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Dotted lines represent                           
when the diets were swapped, if applicable. Data presented as mean ± sem. n=13/group. *                           




Week LTC (kcal) LTCF (kcal) LTFC (kcal) LTF (kcal)
1 290.6 ± 7.7 297.0 ± 8.1 365.7 ± 7.7 379.6 ± 8.7
2 293.2 ± 6.9 289.4 ± 5.4 358.9 ± 9.0 383.4 ± 9.5
3 302.0 ± 10.2 305.6 ± 8.8 371.4 ± 7.3 357.9 ± 11.5
4 312.1 ± 6.5 302.2 ± 5.8 363.1 ± 11.5 361.1 ± 8.2
5 309.4 ± 7.6 367.6 ± 13.0 215.7 ± 9.0 370.6 ± 8.2
6 300.9 ± 9.4 371.0 ± 9.7 258.9 ± 11.1 369.5 ± 17.0
7 296.8 ± 11.4 370.1 ± 15.8 272.1 ± 7.4 360.3 ± 114.7
8 309.7 ± 10.5 346.1 ± 11.1 268.1 ± 11.6 350.3 ± 11.8
9 305.0 ± 9.7 223.6 ± 9.9 474.0 ± 13.2 353.7 ± 11.9
10 285.0 ± 7.8 214.9 ± 18.4 375.7 ± 10.8 353.8 ± 7.7
11 293.5 ± 9.0 250.8 ± 7.8 365.8 ± 9.2 354.8 ± 8.2
12 294.7 ± 8.4 278.1 ± 13.8 365.7 ± 9.8 367.6 ± 10.1
13 287.5 ± 13.5 464.5 ± 32.7 236.7 ± 13.1 353.9 ± 10.1
14 301.5 ± 19.1 366.1 ± 11.3 236.0 ± 4.8 345.9 ± 8.5
15 285.4 ± 16.1 353.2 ± 16.4 239.8 ± 14.6 339.1 ± 11.9
16 287.2 ± 21.7 333.1 ± 25.0 254.1 ± 14.9 367.4 ± 26.7
17 284.5 ± 29.4 222.1 ± 16.7 459.4 ± 27.4 357.3 ± 21.6
18 300.7 ± 17.9 247.3 ± 24.5 393.0 ± 13.6 341.9 ± 19.8
19 315.2 ± 12.8 276.4 ± 7.0 382.5 ± 15.0 369.9 ± 12.6
20 327.5 ± 17.4 296.3 ± 19.1 390.2 ± 16.7 374.9 ± 22.4
21 301.0 ± 25.3 425.3 ± 23.4 231.2 ± 11.8 353.2 ± 22.2
22 306.1 ± 9.2 384.4 ± 18.8 250.6 ± 7.9 358.4 ± 21.1
23 290.5 ± 13.9 364.9 ± 12.7 276.8 ± 10.2 351.8 ± 15.8
24 308.6 ± 12.9 377.8 ± 16.9 285.6 ± 19.7 362.5 ± 15.1
25 307.1 ± 5.9 264.4 ± 15.5 453.1 ± 22.8 379.1 ± 16.2
26 290.0 ± 12.1 266.2 ± 20.9 397.7 ± 21.7 371.8 ± 24.6
27 283.6 ± 26.1 258.1 ± 19.6 380.5 ± 12.8 377.2 ± 17.0
28 287.4 ± 9.3 251.8 ± 7.8 361.8 ± 22.7 360.9 ± 17.5
Table {5.3.2.0.4} The effect of three weight cycles on weekly calorie intake
Weekly calorie intake per cage of 4 mice (kcal)C57Bl6 male mice aged 8­10 weeks of age were                               
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fed a control diet or HFD for 4 weeks. At this point, half the mice continued to feed on the control                                       
diet for 24 weeks (LTC group). Similarly, half the mice continued to feed on the HFD for 24                                 
weeks (LTF group), whilst the other half were fed a control diet for 4 weeks, before swapping                               
back to the HFD for 4 weeks. Diets were swapped for a further 4 times, resulting in 3 complete                                   




Week LTC (kcal/g0.75) LTCF (kcal/g0.75) LTFC (kcal/g0.75) LTF (kcal/g0.75)
1 9.59 ± 0.22 9.90 ± 0.27 11.00 ± 0.34 11.6 ± 0.26
2 9.40 ± 0.22 9.40 ± 0.19 10.21 ± 0.28 11.17 ± 0.33
3 9.46 ± 0.26 9.57 ± 0.34 9.95 ± 0.27 9.89 ± 0.43
4 9.46 ± 0.31 9.17 ± 0.28 9.26 ± 0.36 9.46 ± 0.33
5 9.13 ± 0.28 9.81 ± 0.36 6.00 ± 0.20 9.00 ± 0.27
6 8.66 ± 0.23 9.55 ± 0.37 7.41 ± 0.42 8.68 ± 0.51
7 8.43 ± 0.26 9.01 ± 0.47 7.76 ± 0.36 8.11 ± 0.39
8 8.61 ± 0.25 8.09 ± 0.32 7.52 ± 0.38 7.62 ± 0.30
9 8.31 ± 0.15 5.78 ± 0.27 11.31 ± 0.41 7.77 ± 0.33
10 7.72 ± 0.24 5.61 ± 0.46 8.54 ± 0.28 7.59 ± 0.27
11 7.85 ± 0.20 6.63 ± 0.21 8.01 ± 0.24 7.47 ± 0.25
12 7.78 ± 0.22 7.36 ± 0.27 7.84 ± 0.28 7.66 ± 0.24
13 7.55 ± 0.44 10.60 ± 0.81 5.85 ± 0.39 7.03 ± 0.33
14 7.80 ± 0.62 8.12 ± 0.47 6.02 ± 0.46 6.82 ± 0.32
15 7.25 ± 0.18 7.51 ± 0.49 6.21 ± 0.53 6.67 ± 0.35
16 7.19 ± 0.24 6.96 ± 0.59 6.58 ± 0.41 7.17 ± 0.51
17 7.05 ± 0.43 5.12 ± 0.36 9.95 ± 0.68 7.28 ± 0.34
18 7.54 ± 0.30 5.82 ± 0.50 8.23 ± 0.45 6.90 ± 0.30
19 7.85 ± 0.28 6.68 ± 0.20 7.77 ± 0.42 7.47 ± 0.30
20 8.10 ± 0.26 7.18 ± 0.31 7.79 ± 0.45 7.50 ± 0.37
21 7.36 ± 0.46 9.17 ± 0.58 5.45 ± 0.55 6.75 ± 0.54
22 7.50 ± 0.31 8.09 ± 0.61 6.08 ± 0.67 6.77 ± 0.47
23 7.06 ± 0.22 7.39 ± 0.39 6.77 ± 0.65 6.68 ± 0.44
24 7.50 ± 0.34 7.44 ± 0.21 6.95 ± 0.64 6.82 ± 0.34
25 7.45 ± 0.35 5.75 ± 0.20 9.15 ± 0.51 7.52 ± 0.42
26 6.94 ± 0.25 5.91 ± 0.35 7.88 ± 0.51 7.29 ± 0.40
27 6.74 ± 0.52 5.93 ± 0.49 7.48 ± 0.38 7.45 ± 0.27
28 6.92 ± 0.27 5.79 ± 0.13 7.02 ± 0.45 7.16 ± 0.40





C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Data presented as mean                             




Analysis of cumulative calorie intake for from week 13 to 28 also show a similar pattern of                               
difference as seen when assessing a single weight cycle from week 1 to 12 (Figure 5.3.1.0.6:A).                             
Cumulative calorie intake was increased in LTF mice compared to LTC mice, but was only                           
significant at week 20, and at week 27 to 28 (Figure 5.3.2.0.6:A. Table 5.3.2.0.9. Week 20:                             
p<0.05; week 17: p<0.01; week 28: p<0.001, n=7/group).
As shown with cumulative calorie analysis between week 1 to 12, cumulative calorie intake                         
normalised to cage weight0.75, was not significantly different in any four of the 4 week periods                             
from week 13 to 28 (Figure 5.3.2.0.6:B. Table 5.3.2.0.10. n=7/group).
Figure {5.3.2.0.6} The effect of 28 weeks of high fat feeding on cumulative calorie intake                           
for 4 week periods
A) Cumulative calorie intake per cage of 4 mice (kcal). B) Cumulative calorie intake per cage of 4                                 
mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 28 weeks.                                 
Cumulative food intake presented from week 13 to 28. Dotted lines represent when the diets                           




Cumulative calorie intake analysis showed no significant differences between LTCF mice and                     
LTC mice during further periods of control feeding in LTCF mice, although a trend was observed                             
showing a higher calorie intake in LTC mice (week 17 to 20, and week 25 to 28). However, upon                                   
HFD feeding between week 13 to 16 and week 21 to 24, cumulative calorie intake was increased                               
in LTCF mice compared to LTC mice, which was significant between week 14 to 16, and                             
between week 23 to 24 (Figure 5.3.2.0.7:A. Table 5.3.2.0.9. Week 14: p<0.05; week 15: p<0.01;                           
week 16: p<0.001; week 23: p<0.05; week 24: p<0.001, n=7/group).
However, normalised cumulative calorie intake did not show the same significant differences                     
observed with cumulative calorie intake. Week 13 showed a significantly increased calorie intake                       
in LTCF mice compared to LTC, whilst the rest of the 4 week feeding period only showed a trend                                   
towards an increased cumulative calorie intake normalised to cage weight. This was also true                         
between week 21 to 24, with no significant difference in cumulative calorie intake normalised to                           
cage weight0.75 observed between groups (Figure 5.3.2.0.7:B. Table 5.3.2.0.10. Week 13:                   
p<0.001, n=7/group). Also in contrast, the trend observed showing a reduced cumulative calorie                       
intake in LTCF mice compared to LTC mice during periods of control diet feeding were                           
significant from week 19 to 20, and at week 28 when data was normalised to cage weight0.75                               




No significant differences in cumulative calorie intake were observed when LTCF mice were                       
feeding on a HFD between week 13 to 16, and between week 21 to 24 in comparison to LTF                                   
mice. However, a trend was apparent showing an increased cumulative calorie intake in LTCF                         
mice compared to LTF mice during the periods of HF feeding (Figure 5.3.2.0.7:C. Table                         
5.3.2.0.9. n=7/group). In contrast, when LTCF mice were feeding on a control diet, cumulative                         
calorie intake was significantly lower compared to LTF mice from the 2nd to the 4th week of                               
feeding a control diet (Figure 5.3.2.0.7:C. Table 5.3.2.0.9. Week 18: p<0.01; week 19­20:                       
p<0.001; week 26: p<0.05; week 27­28: p<0.001, n=7/group).
When normalised to cage weight0.75, cumulative calorie intake was significantly higher in LTCF                       
mice compared to LTF mice from week 14 to 16, and from week 23 to 24, whilst LTCF mice                                   
were feeding on a HFD (Figure 5.3.2.0.7:D. Table 5.3.2.0.10. Week 14: p<0.01; week 15­16:                         
p<0.001; week 23­24: p<0.05, n=7/group). During periods of control diet feeding, LTCF mice                       
showed a significantly lower cumulative calorie intake normalised to cage weight0.75 from week                       




Figure {5.3.2.0.7} The effect of three weight cycles ending with weight loss on                       
cumulative calorie intake for 4 week periods
A+C) Cumulative calorie intake per cage of 4 mice (kcal); B+D) Cumulative calorie intake per                           
cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group) whilst the                                 
other half were fed a high fat diet for 4 weeks, before swapping back to the control diet for 4                                     
weeks. Diets were swapped for a further 4 times, resulting in 3 complete weight cycles (LTCF                             
group). Similarly, half the mice continued to feed on the HFD for 24 weeks (LTF group).                             
Cumulative food intake presented from week 13 to 28. Dotted lines represent when the diets                           




Cumulative calorie intake analysis showed no significant differences between LTFC mice and                     
LTC mice during further periods of control diet feeding in LTFC mice (week 13 to 16, and week                                 
21 to 24), although a trend was observed showing decreased calorie intake in LTFC mice                           
compared to LTC mice (Figure 5.3.2.0.8:A. Table 5.3.2.0.9. n=7/group). However, upon                   
refeeding on a HFD between week 17 to 20 and week 25 to 28, cumulative calorie intake was                                 
increased in LTFC mice compared to LTC mice, which was significant between week 18 to 20,                             
and between week 26 to 28 (Figure 5.3.2.0.8:A. Table 5.3.2.0.9. Week 18: p<0.05; week 19­20:                           
p<0.001; week 26: p<0.05; week 27­28: p<0.001, n=7/group).
Normalised cumulative calorie intake a significantly lower calorie intake in LTFC mice during                       
control diet feeding compared to LTC mice between week 15 to 16, and at week 24 (Figure                               
5.3.2.0.8:B. Table 5.3.2.0.10. Week 15: p<0.05; week 16: p<0.01; week 24: p<0.05, n=7/group).                       
No significant differences in cumulative calorie intake normalised to cage weight0.75 was                     
observed whilst LTFC mice were feeding on a HFD between week 17 to 20, and week 25 to 28,                                   
although a trend showing increased calorie intake in LTFC mice was observed compared to LTC                           
mice.
No significant differences in cumulative calorie intake were observed between LTFC mice and                       
LTF mice from week 17 to 20, or between week 25 to 28 whilst LTFC mice were feeding on a                                     
HFD, although a trend showing increased calorie intake in LTFC mice was observed between                         
week 18 to 20. Cumulative calorie intake was decreased in LTFC mice whilst feeding on a                             
control diet compared to LTF mice, which was significant from week 15 to 16, and between                             
week 23 to 24 (Figure 5.3.2.0.8:C. Table 5.3.2.0.9. Week 15: p<0.01; week 16: p<0.001; week                           
23: p<0.05; week 26: p<0.001, n=7/group).
When normalised to cage weight0.75, cumulative calorie intake was significantly higher in LTFC                       
mice compared to LTF mice from week 18 to 20,but not during the last HF feeding period from                                 
week 25 to 28 (Figure 5.3.2.0.8:D. Table 5.3.2.0.10. Week 18­19: p<0.05; week 20: p<0.01,                         
n=7/group). No significant difference in cumulative calorie intake normalised to cage weight0.75                     
was observed from week 13 to 16, or between week 21 to 24 whilst LTFC mice were feeding on                                   




Figure {5.3.2.0.8} The effect of three weight cycles ending with weight gain on                       
cumulative calorie intake for 4 week periods
A+C) Cumulative calorie intake per cage of 4 mice (kcal); B+D) Cumulative calorie intake per                           
cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75).
C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Cumulative food intake                           
presented from week 13 to 28. Dotted lines represent when the diets were swapped, if                           




Week LTC (kcal) LTCF LTFC LTF
1 290.6 ± 7.7 297.0 ± 8.1 357.3 ± 11.2 379.6 ± 8.7
2 583.8 ± 12.8 586.4 ± 12.8 708.2 ± 21.5 763.0 ± 13.3
3 885.8 ± 21.1 892.0 ± 20.4 1070.7 ± 29.8 1120.9 ± 19.1
4 1198.0 ± 25.1 1194.2 ± 23.9 1424.9 ± 37.8 1482.0 ± 20.8
5 309.4 ± 7.6 360.0 ± 16.3 221.3 ± 8.5 361.7 ± 10.4
6 610.4 ± 14.8 723.0 ± 27.0 488.7 ± 18.6 724.1 ± 25.4
7 907.2 ± 24.9 1085.3 ± 40.8 769.5 ± 26.3 1077.1 ± 38.9
8 1216.8 ± 32.7 1424.2 ± 52.0 1046.7 ± 40.2 1419.8 ± 49.1
9 305.0 ± 9.7 223.6 ± 9.9 463.3 ± 17.1 353.7 ± 11.9
10 590.0 ± 13.3 438.5 ± 21.3 830.8 ± 27.8 707.5 ± 13.9
11 883.6 ± 19.3 689.3 ± 24.7 1188.5 ± 39.0 1062.3 ± 17.1
12 1178.2 ± 24.4 967.3 ± 26.1 1546.3 ± 48.1 1429.9 ± 24.3
13 287.5 ± 13.5 446.2 ± 39.7 248.9 ± 13.7 339.5 ± 19.0
14 589.0 ± 30.9 797.5 ± 51.7 498.7 ± 22.0 670.7 ± 31.7
15 874.3 ± 36.6 1136.5 ± 69.4 752.1 ± 37.7 995.4 ± 46.4
16 1161.5 ± 53.8 1458.9 ± 86.2 1019.4 ± 42.5 1348.4 ± 67.2
17 284.5 ± 29.4 222.1 ± 16.7 444.1 ± 38.3 357.3 ± 21.6
18 585.1 ± 41.8 469.3 ± 36.1 821.0 ± 55.0 699.2 ± 35.2
19 900.4 ± 52.2 745.7 ± 34.5 1187.4 ± 70.0 1069.1 ± 37.5
20 1227.9 ± 67.1 1042.0 ± 51.0 1562.4 ± 89.1 1444.0 ± 53.2
21 301.0 ± 25.3 407.8 ± 30.0 244.7 ± 17.3 338.9 ± 27.4
22 607.1 ± 26.1 774.7 ± 38.1 511.4 ± 37.0 682.4 ± 35.4
23 897.6 ± 35.0 1125.8 ± 54.8 805.4 ± 54.3 1019.8 ± 52.6
24 1206.2 ± 43.9 1485.6 ± 66.4 1107.3 ± 70.4 1366.2 ± 65.5
25 307.1 ± 5.9 264.4 ± 15.5 436.9 ± 33.8 379.1 ± 16.2
26 597.0 ± 15.0 530.7 ± 33.7 820.4 ± 60.0 750.8 ± 29.0
27 880.6 ± 39.9 788.8 ± 45.2 1185.9 ± 80.8 1128.0 ± 45.0
28 1168.0 ± 47.6 1040.6 ± 52.0 1530.9 ± 96.3 1488.9 ± 50.0




C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Cumulative calorie intake                           
per cage of 4 mice (kcal). Data presented as mean ± sem. Week 1­12: n=13/group; week 13­28:                               




Week LTC (kcal/g0.75) LTCF (kcal/g0.75) LTFC (kcal/g0.75) LTF (kcal/g0.75)
1 9.59 ± 0.22 9.90 ± 0.27 11.00 ± 0.34 11.61 ± 0.26
2 18.99 ± 0.37 19.29 ± 0.44 21.22 ± 0.55 22.78 ± 0.48
3 28.45 ± 0.56 28.86 ± 0.76 31.17± 0.79 32.67 ± 0.82
4 37.92 ± 0.79 38.03 ± 0.98 40.43 ± 1.00 42.14 ± 1.08
5 9.13 ± 0.28 9.81 ± 0.36 6.00 ± 0.20 9.00 ± 0.27
6 17.79 ± 0.44 19.36 ± 0.66 13.41 ± 0.53 17.68 ± 0.66
7 26.22 ± 0.63 28.37 ± 0.99 21.16 ± 0.81 25.79 ± 0.94
8 34.83 ± 0.80 36.47 ± 1.24 28.69 ± 1.14 33.41 ± 1.15
9 8.31 ± 0.15 5.78 ± 0.27 11.31 ± 0.41 7.77 ± 0.33
10 16.03 ± 0.27 11.39 ± 0.52 19.85 ± 0.59 15.36 ± 0.49
11 23.87 ± 0.40 18.02 ± 0.61 27.86 ± 0.80 22.84 ± 0.68
12 31.65 ± 0.53 25.37 ± 0.53 35.70 ± 0.99 30.49 ± 0.87
13 7.55 ± 0.44 10.60 ± 0.81 5.85 ± 0.39 7.03 ± 0.33
14 15.35 ± 1.05 18.72 ± 1.07 11.87 ± 0.75 13.86 ± 0.56
15 22.60 ± 10.6 26.22 ± 1.44 18.08 ± 1.23 20.53 ± 0.85
16 29.79 ± 1.02 33.18 ± 1.66 24.66 ± 1.44 27.70 ± 1.03
17 7.05 ± 0.43 5.12 ± 0.36 9.95 ± 0.68 7.28 ± 0.34
18 14.59 ± 0.43 10.94 ± 0.74 18.18 ± 0.95 14.19 ± 0.45
19 22.44 ± 0.52 17.62 ± 0.67 25.94 ± 1.17 21.66 ± 0.45
20 30.54 ± 0.64 24.79 ± 0.88 33.73 ± 1.46 29.15 ± 0.64
21 7.36 ± 0.46 9.17 ± 0.58 5.45 ± 0.55 6.75 ± 0.54
22 14.86 ± 0.37 17.26 ± 0.95 11.53 ± 1.20 13.52 ± 0.65
23 21.93 ± 0.36 24.65 ± 1.20 18.30 ± 1.78 20.20 ± 1.00
24 29.43 ± 0.65 32.09 ± 1.29 25.25 ± 2.29 27.02 ± 1.22
25 7.45 ± 0.35 5.75 ± 0.20 9.15 ± 0.51 7.52 ± 0.42
26 14.39 ± 0.53 11.66 ± 0.47 17.03 ± 0.90 14.81 ± 0.58
27 21.14 ± 0.87 17.59 ± 0.80 24.51 ± 1.23 22.26 ± 0.82
28 28.06 ± 1.10 23.38 ± 0.88 31.53 ± 1.44 29.42 ± 0.99




C57Bl6 male mice aged 8­10 weeks of age were fed a control diet or HFD for 4 weeks. At this                                     
point, half the mice continued to feed on the control diet for 24 weeks (LTC group). Similarly, half                                 
the mice continued to feed on the HFD for 24 weeks (LTF group), whilst the other half were fed a                                     
control diet for 4 weeks, before swapping back to the HFD for 4 weeks. Diets were swapped for                                 
a further 4 times, resulting in 3 complete weight cycles (LTFC group). Cumulative calorie intake                           
per cage of 4 mice normalised to total cage weight0.75 (kcal/g0.75). Data presented as mean ±                             
sem. Week 1­12: n=13/group; week 13­28: n=7/group. Green highlight indicates beginning of 4                       






FT mice were significantly heavier compared to CT mice when whole body adiposity was                         
assessed (Figure 5.4.1.0.1:A. CT: 26.40 ± 1.48 g; FT: 38.66 ± 1.89 g. p<0.001, n=10/group).                           
CFC mice showed a trend for a slightly higher body weight compared to CT mice, but this was                                 
not significant. CFC mice were also significantly lighter compared to FT mice (Figure 5.4.1.0.1:A.                         
CFC: 28.64 ± 0.67 g. CFC­FT: p<0.001, n=10/group). FCF mice were significantly heavier                       
compared to CT mice, but were not significantly different compared to FT mice (Figure                         
5.4.1.0.1:A. FCF: 35.67 ± 1.28 g. CT­FCF: p<0.001, n=10/group). However, a trend could be                         
observed showing slightly lower body weight in FCF mice compared to FT mice.
As expected, FT mice showed a significantly higher level of whole body adiposity compared to                           
CT mice (Figure 5.4.1.0.1:B. CT: 16.00 ± 2.38 %; FT: 33.18 ± 1.62 %. p<0.001, n=10/group).
CFC mice showed no significant difference in whole body adiposity measurements compared to                       
CT mice, although a noticeable trend showing an increase in whole body adiposity was observed                           
(Figure 5.4.1.0.1:B. CFC: 19.71 ± 2.24 %. n=10/group). Both a slight increase in body weight and                             
whole body adiposity indicate a possible lasting effect from HF feeding, although not a significant                           
effect.
Similar to body weight, CFC mice had significantly lower whole body adiposity compared to FT                           
mice (Figure 5.4.1.0.1:B. p<0.001, n=10/group).
FCF mice had a significantly higher whole body adiposity compared to CT mice, also                         
represented by a higher body weight (Figure 5.4.1.0.1:B. FCF: 29.38 ± 2.11 %. p<0.001,                         
n=10/group).
No significant difference in whole adiposity measurements were observed between FCF mice                     





A) Body weight of mice at the time of the scan. B) Whole body adiposity measurements as                               





LTF mice maintained a higher body weight compared to LTC mice after 27 weeks of feeding                             
when whole body adiposity was assessed (Figure 5.4.2.0.1:A. LTC: 32.74 ± 1.84 g; LTF: 43.74 ±                             
2.03 g. p<0.001, n=10/group). LTCF mice showed a trend for a slightly higher body weight                           
compared to LTC mice, but this was not significant. LTCF mice were also significantly lighter                           
compared to FT mice (Figure 5.4.2.0.1:A. CFC: 35.85 ± 1.29 g. CFC­FT: p<0.01, n=10/group).                         
LTFC mice were significantly heavier compared to LTC mice, but were not significantly different                         
compared to FT mice (Figure 5.4.2.0.1:A. FCF: 41.17 ± 1.56 g. CT­FCF: p<0.01, n=10/group).                         
Again, a trend could be observed showing slightly lower body weight in FCF mice compared to                             
FT mice. Also of note is LTCF and LTFC mice were no longer significantly different to one                               
another, unlike at time point 2 (Figure 5.4.1.0.1:A. Time point 1: p<0.001, n=10/group).
LTF mice still showed a significantly higher level of whole body adiposity compared to LTC mice                             
(Figure 5.4.2.0.1:B. CT: 26.76 ± 2.18 %; FT: 38.33 ± 0.68 %. p<0.001, n=10/group).
LTCF mice showed a significantly higher whole body adiposity compared to LTC mice (Figure                         
5.4.2.0.1:B. LTCF: 32.44 ± 0.89 %. p<0.05, n=10/group). This contrasts with observed body                       
weight measurements at this time, which show no significant difference between the two                       
groups.
However, LTCF mice still showed a significantly lower whole body adiposity compared to LTF                         
mice, which is similar to body weight measurements (Figure 5.4.2.0.1:B. p<0.01, n=10/group).
LTFC mice had a significantly higher whole body adiposity compared to LTC mice (Figure                         
5.4.2.0.1:B. FCF: 36.44 ± 0.75 %. p<0.001, n=10/group).
Again, no significant difference in whole adiposity measurements were observed between LTFC                     
mice and FT mice, although a slight trend was observed showing LTFC mice had lower whole                             





A) Body weight of mice at the time of the scan. B) Whole body adiposity measurements as                               






After 11 weeks of HF feeding, FT mice showed a significantly higher IHCL content compared to                             
CT mice (Figure 5.5.1.0.1. CT: 25.50 ± 3.46 %; FT: 52.00 ± 9.26 %. p<0.01, n=10/group).
CFC mice did not show any significant difference in IHCL content compared to CT mice (Figure                             
5.5.1.0.1. CFC: 19.50 ± 2.65 %. n=10/group). CFC mice also showed a significantly lower IHCL                           
content compared to FT mice (Figure 5.5.1.0.1. p<0.001, n=10/group).
FCF mice showed no significant difference in IHCL content compared to CT mice (Figure                         
5.5.1.0.1. FCF: 23.29 ± 4.05 %, n=10/group). Similar to both CT and CFC groups, FCF mice had                               
significantly lower IHCL content compared to FT mice (Figure 5.5.1.0.1. p<0.01, n=10/group).
Figure {5.5.1.0.1} The effect of a single weight cycle on IHCL content
IHCL content was assessed was assessed using localised 1H MRS. Data presented as mean ±                           





After 27 weeks of HF feeding, LTF mice showed a significantly higher IHCL content compared to                             
LTC mice (Figure 5.5.2.0.1. LTC: 39.00 ±7.15 %; LTF: 80.56 ± 6.76 %. p<0.001, n=10/group).
LTCF mice did not show any significant difference in IHCL content compared to LTC mice                           
(Figure 5.5.2.0.1. LTCF: 35.80 ± 5.34 %. n=10/group). Again, LTCF mice showed a significantly                         
lower IHCL content compared to LTF mice (Figure 5.5.2.0.1. p<0.001, n=10/group).
LTFC mice showed no significant difference in IHCL content compared to LTC mice (Figure                         
5.5.2.0.1. FCF: 52.38 ± 7.07 %, n=10/group). However, a trend was observed showing a higher                           
IHCL content in LTFC mice compared to LTC and LTCF mice. Similar to time point 1, LTFC                               
mice still showed a significantly lower IHCL content compared to LTF mice (Figure 5.5.2.0.1.                         
p<0.05, n=10/group).
Figure {5.5.2.0.1} The effect of three weight cycles on IHCL content
IHCL content was assessed was assessed using localised 1H MRS. Data presented as mean ±                           




{5.6} The Effect of Multiple Weight Cycles on Adipose Tissue                 
Content and Distribution
{5.6.1} Time point 1: 11 weeks of feeding, 1 weight cycle
11 weeks of HF feeding significantly increased the amount of WAT in FT mice compared to CT                               
mice (Figure 5.6.1.0.1:A. CT: 6.184 ± 0.815 g; FT: 13.400 ± 0.962 g. p<0.001, n=10/group). This                             
difference remained significant when normalising total WAT to body weight (Figure 5.6.1.0.1:B.                     
CT: 22.70 ± 1.87 %; FT: 34.46 ± 1.27 %. p<0.001, n=10/group).
CFC mice showed a similar amount of total WAT compared to CT mice (Figure 5.6.1.0.1:A.                           
CFC: 6.664 ± 0.570 g. n=10/group). Similarly, percentage of total WAT for CFC mice was                           
comparable to CT mice (Figure 5.6.1.0.1:B. CFC: 23.25 ± 1.88 %. n=10/group).
In comparison to FT mice, CFC mice had significantly less total WAT, both measured in grams                             
and as a percentage of body weight (Figure 5.6.1.1.A+B. Both p<0.001, n=10/group).
FCF mice had significantly more total WAT compared to CT mice (Figure 5.6.1.0.1:A. FCF:                         
11.000 ± 1.046 g. p<0.01, n=10/group). Again, this significant difference remained when total                       
WAT was normalised to body weight (Figure 5.6.1.0.1:B. FCF: 30.01 ± 1.89 %. p<0.05,                         
n=10/group).
There was no significant difference between FCF mice and FT mice when comparing total WAT,                           
however a trend showing a lower amount of total WAT was observed in FCF mice (Figure                             
5.6.1.0.1:A. n=10/group). When normalised to body weight, this difference was also not                     





A) Total body WAT measured in grams B) Total body WAT as a percentage of body weight.                               
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




11 weeks of HF feeding significantly increased the amount of subcutaneous WAT in FT mice                           
compared to CT mice (Figure 5.6.1.0.2:A. CT: 3.655 ± 0.395 g; FT: 7.595 ± 0.508 g. p<0.001,                               
n=10/group). This difference remained significant when normalising subcutaneous WAT to body                   
weight (Figure 5.6.1.0.2:B. CT: 13.54 ± 0.81 %; FT: 19.62 ± 0.78 %. p<0.001, n=10/group).
CFC mice showed no significant difference in subcutaneous WAT compared to CT mice (Figure                         
5.6.1.2.A. CFC: 4.004 ± 0.304 g. n=10/group), which was also true remained when normalised to                           
body weight (Figure 5.6.1.0.2:B. CFC: 13.96 ± 0.95 %. n=10/group).
CFC mice had significantly less subcutaneous WAT compared to FT mice (Figure 5.6.1.0.2:A.                       
p<0.001, n=10/group). Again, this difference remained when comparing subcutaneous WAT as                   
a percentage of body weight (Figure 5.6.1.0.2:B. p<0.001, n=10/group).
FCF mice had significantly more subcutaneous WAT compared to CT mice (Figure 5.6.1.0.2:A.                       
FCF: 5.971 ± 0.490 g. p<0.01, n=10/group). However, when normalised to body weight, there                         
was no significant difference in percentage subcutaneous WAT between CT mice and FCF                       
mice (Figure 5.6.1.0.2:B. FCF: 16.38 ± 1.01 %. n=10/group), although a trend was apparent.
There was no significant difference between FCF and FT mice when comparing subcutaneous                       
WAT mass, although a strong trend showing a reduced subcutaneous WAT mass was                       





A) Subcutaneous WAT measured in grams (g); B) Subcutaneous WAT as a percentage of body                           
weight (%).
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




Internal WAT mass was significantly increased in FT mice compared to CT mice after 11 weeks                             
of HF feeding (Figure 5.6.1.0.3:A. CT: 2.530 ± 0.426 g; FT: 5.807 ± 0.492 g. p<0.001,                             
n=10/group). Similarly, internal WAT normalised to body weight was significantly increased in FT                       
mice compared to CT mice (Figure 5.6.1.0.3:B. CT: 9.16 ± 1.09 %; FT: 14.84 ± 0.73 %.                               
n=10/group).
CFC mice showed no significant difference in internal fat mass compared to CT mice (Figure                           
5.6.1.0.3:A. CFC: 2.659 ± 0.281 g. n=10), which was still present when comparing percentage                         
internal WAT (Figure 5.6.1.0.3:A. CFC: 9.29 ± 0.97 %. n=10/group).
CFC mice had significantly less internal WAT compared to FT mice (Figure 5.6.1.0.3:A. p<0.05,                         
n=10/group). This difference remained when normalising internal WAT to body weight (Figure                     
5.6.1.0.3:A. p<0.01, n=10/group).
FCF mice had significantly more internal WAT compared to CT mice (Figure 5.6.1.0.3:A. FCF:                         
5.031 ± 0.597 g. p<0.01, n=10/group). This difference remained significant when internal WAT                       
was normalised to body weight (Figure 5.6.1.0.3:B. FaCFa: 13.63 ± 1.1 %. p<0.05, n=10/group).
No significant difference in internal WAT mass was observed between FCF and FT mice,                         
although a trend showing lower internal WAT in FCF mice was observed (Figure 5.6.1.0.3:A.                         





A) Internal WAT measured in grams B) Internal WAT as a percentage of body weight.                           
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




An assessment of internal:subcutaneous WAT ratio indicates a significant increase in internal                     
adiposity in FCF mice compared to both CT and CFC mice (Figure 5.6.1.0.4. CT: 0.658 ± 0.040;                               
CFC: 0.654 ± 0.034; FCF: 0.836 ± 0.054. Both p<0.05, n=10/group).
FT mice also showed a trend towards a higher internal:subcutaneous WAT ratio compared to                         
CT and CFC mice, although this was not a significant difference (Figure 5.6.1.0.4. FT: 0.764 ±                             
0.043. n=10/group). FCF mice showed a slightly higher internal:subcutaneous WAT ratio                   
compared to FT mice, although again this was not significant.
Figure {5.6.1.0.3} The effect of a single weight cycle on internal:subcutaneous WAT ratio
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           





27 weeks of HF feeding significantly increased the amount of WAT in LTF mice compared to                             
LTC mice (Figure 5.6.2.0.1:A. LTC: 9.236 ± 0.740 g; LTF: 14.581 ± 0.643 g. p<0.001,                           
n=10/group). This difference remained significant when normalising total WAT to body weight                     
(Figure 5.6.2.0.1:B. LTC: 28.11 ± 1.41 %; LTF: 34.37 ± 0.66 %. p<0.001, n=10/group).
LTCF mice showed no significant difference in total WAT compared to LTC mice, although a                           
noticeable trend showing an increase total amount of WAT was present (Figure 5.6.2.0.1:A.                       
LTCF: 11.110 ± 0.485 g. n=10/group). Similarly, percentage of total WAT for LTCF mice was not                             
significantly higher than LTC mice, and the trend observed was smaller compared to the                         
comparison made between total amount of WAT in grams (Figure 5.6.2.0.1:B. LTCF: 31.03 ±                         
0.91 %. n=10/group).
In comparison to LTF mice, LTCF mice had significantly less total WAT when comparing                         
measurements in grams (Figure 5.6.2.0.1:A. p<0.01, n=10/group). However, a comparison                 
between LTCF and LTF % total body WAT showed no significant difference between the two                           
groups (Figure 5.6.2.0.1:B. n=10/group).
LTFC mice had significantly more total WAT compared to CT mice (Figure 5.6.2.0.1:A. FCF:                         
13.140 ± 0.592 g. p<0.001, n=10/group). When normalised to body weight, the percentage of                         
total body WAT was also significantly higher, although the difference was reduced (Figure                       
5.6.2.0.1:B. FCF: 31.88 ± 0.67 %. p<0.05, n=10/group).
There was no significant difference between LTFC mice and LTF mice when comparing total                         
WAT, however a trend showing a lower amount of total WAT was observed in LTFC mice                             
(Figure 5.6.2.0.1:A. n=10/group). When normalised to body weight, this difference was also not                       





A) Total body WAT measured in grams B) Total body WAT as a percentage of body weight.                               
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           




After 27 weeks of HF feeding, LTF mice showed a significantly increased amount of                         
subcutaneous WAT compared to LTC mice (Figure 5.6.2.0.2:A. LTC: 5.208 ± 0.379 g; LTF:                         
8.731 ± 0.279 g. p<0.001, n=10/group). Again, this difference remained significant when                     
normalising subcutaneous WAT to body weight (Figure 5.6.2.0.2:B. LTC: 15.90 ± 0.73 %; FT:                         
20.64 ± 0.30 %. p<0.001, n=10/group).
LTCF mice showed had significantly more subcutaneous WAT compared to LTC mice (Figure                       
5.6.2.0.2:A. LTCF: 6.680 ± 0.259 g. p<0.01, n=10/group). Upon normalising to body weight,                       
LTCF mice still showed an increased percentage of subcutaneous WAT compared to LTC mice                         
(Figure 5.6.2.0.2:B. LTCF: 18.69 ± 0.56 %. n=10/group).
LTCF mice had significantly less subcutaneous WAT compared to LTF mice (Figure 5.6.2.0.2:A.                       
p<0.001, n=10/group). However, this difference was not significant when comparing                 
subcutaneous WAT as a percentage of body weight (Figure 5.6.2.0.2:B. n=10/group).
LTFC mice had significantly more subcutaneous WAT compared to LTC mice (Figure                     
5.6.2.0.2:A. LTFC: 7.561 ± 0.299 g. p<0.001, n=10/group). When normalised to body weight,                       
there were still a significant difference in percentage subcutaneous WAT between LTFC mice                       
and LTC mice (Figure 5.6.2.0.2:B. LTFC: 18.39 ± 0.40 %. n=10/group).
Unlike time point 1, there was a significant difference between LTFC and LTF mice when                           
comparing subcutaneous WAT mass, showing an increased mass in LTF mice (Figure                     





A) Subcutaneous WAT measured in grams B) Subcutaneous WAT as a percentage of body                         
weight. Quantification of WAT was assessed using whole body MRI. Data presented as mean ±                           




Internal WAT mass was significantly increased in LTF mice compared to LTC mice after 27                           
weeks of HF feeding (Figure 5.6.2.0.3:A. LTC: 4.029 ± 0.365 g; LTF: 5.848 ± 0.427 g. p<0.01,                               
n=10/group). However, when internal WAT was normalised to body weight, no significant                     
difference was observed between LTC and LTF mice, although a slight trend was observed                         
(Figure 5.6.2.0.3:B. LTC: 12.21 ± 0.72 %; LTF: 13.73 ± 0.66 %. n=10/group). This is in contrast                               
to both total WAT measurements and subcutaneous WAT measurements shown above.
LTCF mice had significantly more internal WAT compared to LTC mice (Figure 5.6.2.0.3:A.                       
LTCF: 4.434 ± 0.241 g. n=10/group). Similar to LTC and LTF, no significant differences were                           
observed between LTCF mice and LTC mice when assessing difference in internal WAT                       
percentage (Figure 5.6.2.0.3:B. CFC: 12.34 ± 0.43 %. n=10/group).
LTCF mice had significantly less internal WAT compared to FT mice (Figure 5.6.2.0.3:A. p<0.05,                         
n=10/group), although this significance did not remain when comparing internal WAT percentage                     
between the two groups (Figure 5.6.2.0.3:B. n=10/group).
LTFC mice had significantly more internal WAT compared to CT mice (Figure 5.6.2.0.3:A. LTFC:                         
5.576 ± 0.305 g. p<0.05, n=10/group). Again, no significant difference in internal WAT                       
percentage was observed between LTFC mice and LTC mice (Figure 5.6.2.0.3:B. LTFC: 13.49                       
± 0.38 %. n=10/group).
No significant difference in internal WAT mass was observed between LTFC and FT mice,                         
although a trend showing lower internal WAT in FCF mice was observed (Figure 5.6.2.0.3:A.                         





A) Subcutaneous WAT measured in grams B) Subcutaneous WAT as a percentage of body                         
weight. Quantification of WAT was assessed using whole body MRI. Data presented as mean ±                           




An assessment of internal:subcutaneous WAT ratio indicates a significant increase in internal                     
adiposity in LTC mice compared to both LTCF and LTF mice (Figure 5.6.2.04. LTC: 0.765 ±                             
0.021; LTCF: 0.662 ± 0.018; LTFC: 0.667 ± 0.037. Both p<0.05, n=10/group).
Interestingly, LTFC mice also showed a internal:subcutaneous WAT ratio comparable to LTC                     
mice (Figure 5.6.2.0.4. LTFC: 0.735 ± 0.018. n=10/group). A trend was also observed showing a                           
higher internal:subcutaneous WAT ratio compared to LTF and LTCF mice, indicating multiple                     
weight cycled mice ending with weight gain have more internal adiposity compared to chronic                         
HFD.
Figure {5.6.2.0.4} The effect of three weight cycles on internal:subcutaneous WAT ratio
Quantification of WAT was assessed using whole body MRI. Data presented as mean ± sem,                           






FT mice were significantly heavier than the control diet group, CT after 11 weeks of feeding                             
(Figure 5.7.1.0.1:A. CT: 25.78 ± 1.02 g; FT: 38.20 ± 1.78 g. p<0.001, n=10/group). CFC mice                             
showed no difference in body weight compared to CT mice, but were significantly lighter                         
compared to FCF and FT mice (Figure 5.7.1.0.1:A. CFC: 29.14 ± 0.65 g. FCF: 35.54 ± 1.13 g.                                 
CFC­FCF: p<0.01; CFC­FT: p<0.001, n=10/group). Conversely, FCF mice showed no                 
difference in body weight measurements compared to FT mice, but were significantly heavier                       
compared to CT, as well as CFC mice (Figure 5.7.1.0.1:A. CT­FCF: p<0.001, n=10/group).
Blood glucose concentration measurements were significantly higher in FT mice prior to the                       
start of the IPGTT compared to CT mice, as well as 60 and 120 minutes after a glucose injection                                   
(Figure 5.7.1.0.3:A. Table 5.7.1.0.2. 0 mins: p<0.05; 60­120 mins: p<0.001, n=10/group). AUC                     
measurements of glucose tolerance showed FT mice were significantly more glucose intolerant                     
compared to CT mice after 12 weeks of HF feeding (Figure 5.7.1.0.1:B. Table 5.7.1.0.2. CT:                           
1439 ± 66.1 mmol/L x 120 mins; FT: 2036 ± 86.5 mmol/L x 120 mins. p<0.001, n=10/group).                               
This indicates 12 weeks of HF feeding is sufficient in inducing a degree of insulin resistance.
After a single weight cycle ending with a period of weight loss, CFC mice showed no significant                               
differences in blood glucose concentration compared to CT mice before or during the IPGTT                         
(Figure 5.7.1.0.3:B. Table 5.7.1.0.2. n=10/group). Similarly, AUC calculations showed no                 
significant difference in glucose tolerance between these two groups, indicating weight cycling                     
had no significant effect on glucose tolerance (Figure 5.7.1.0.1:B. CFC: 1512 ± 76.0 mmol/L x                           
120 mins. n=10/group).
A comparison between CFC mice and FT mice showed CFC mice had a significantly lower                           
blood glucose concentration during the IPGTT, except for 15 minutes after the glucose injection                         
(Figure 5.7.1.0.3:D. Table 5.7.1.0.2. 0 mins: p<0.05; 30­60 mins: p<0.01; 120 mins: p<0.001,                       




FCF mice showed significantly higher blood glucose concentration measurements compared to                   
CT mice 60 and 120 minutes after a glucose injection (Figure 5.7.1.0.3:C. Table 5.7.1.0.2.                         
60­120 mins: p<0.001, n­10/group). Blood glucose concentrations were higher compared to CT                     
mice before and 15 to 30 minutes after a glucose injection, but this was not significantly different.                               
An AUC measurement showed these mice were significantly more glucose intolerant compared                     
to CT mice (Figure 5.7.1.0.1:B. FCF: 1986 ± 77.7 mmol/L  x 120 mins. p<0.001, n=10/group).
However, FCF mice showed no significant difference in blood glucose concentration                   
measurements compared to FT mice throughout the IPGTT (Figure 5.7.1.0.3:E. Table 5.7.1.0.2.                     
n=10/group). Similarly, AUC assessment showed no difference in glucose tolerance between                   





A) Body weight of mice at the time of the intraperitoneal glucose tolerance test (IPGTT). Body                             
weight measure in grams. B) Area under the curve (AUC) analysis of blood glucose                         
concentration measurements during the IPGTT. AUC measure in mmol/L x 120 mins. Data                       
presented as mean ± sem, n=10/group. ** p<0.01, *** p<0.001. Statistical analysis was                       
performed using a One­Way ANOVA with Tukey correction.
Time (mins) CT (mmol/L) CFC (mmol/L) FCF (mmol/L) FT (mmol/L)
0 5.0 ± 0.2 5.0 ± 0.3 6.8 ± 0.2 8.2 ± 0.4
15 14.9 ± 0.8 14.3 ± 0.7 17.6 ± 0.6 15.7 ± 0.8
30 15.7 ± 0.7 14.5 ± 0.6 18.3 ± 0.6 18.2 ± 0.7
60 12.4 ± 0.8 14.2 ± 1.0 18.2 ± 1.1 18.0 ± 1.0
120 8.8 ± 0.7 9.8 ± 1.0 14.6 ± 1.3 17.4 ± 0.9
Table {5.7.1.0.2} The effect of a single weight cycle on glucose tolerance
Blood glucose measurements during the IPGTT, measured in mmol/L. Data presented as mean                       





Blood glucose measurements during the IPGTT, measured in mmol/L. Data presented as mean                       





LTF mice were significantly heavier than LTC 27 weeks of feeding (Figure 5.7.2.0.1:A. LTC:                         
32.41 ± 1.67 g; LTF: 41.37 ± 1.71 g. p<0.05, n=10/group). LTCF mice showed no significant                             
difference in body weight compared to CT mice, but also LTCF did not show any significant                             
difference compared to LTF (Figure 5.7.2.0.1:A. LTCF: 37.16 ± 2.23 g. n=10/group). Conversely,                       
LTFC mice showed no difference in body weight measurements compared to LTF mice, and                         
showed a significant difference compared to LTCF mice (Figure 5.7.2.0.1:A. LTFC: 41.02 ± 2.05                         
g. p<0.05, n=10/group).
Blood glucose concentration measurements showed no significant differences between LTC                 
and LTF mice during the IPGTT (Figure 5.7.2.0.3:A. Table 5.7.2.0.2. n=10/group). AUC                     
measurements of glucose tolerance also showed LTF mice had a similar level of glucose                         
tolerance compared to LTC mice, as assessed by calculating AUC from the IPGTT blood                         
glucose concentrations (Figure 5.7.2.0.1:B. LTC: 1966 ± 119.8 mmol/L x 120 mins; LTF: 2004 ±                           
134.4 mmol/L x 120 mins, n=10/group).
LTCF mice showed no significant differences in blood glucose concentration compared to LTC                       
mice before or during the IPGTT (Figure 5.7.2.0.3:B. Table 5.7.2.0.2. n=10/group). Similarly, AUC                       
calculations showed no significant difference in glucose tolerance between these two groups                     
(Figure 5.7.2.0.1:B. LTCF: 1956 ± 128.4 mmol/L x 120 mins. n=10/group).
Similarly, LTCF mice showed no difference in blood glucose concentrations during the IPGTT                       
compared to LTF mice (Figure 5.7.2.0.3:D. Table 5.7.2.0.2. n=10/group). LTCF mice had a                       
glucose tolerance level compared to LTF, as shown when comparing AUC values (Figure                       
5.7.2.0.1:B. n=10/group).
LTFC mice showed significantly higher blood glucose concentration measurements during the                   
IPGTT compared to LTC mice, but only 15 and 30 minutes after a glucose injection (Figure                             
5.7.2.0.3:C. Table 5.7.2.0.2. 15­30 mins: p<0.05, n­10/group). Blood glucose concentrations                 
remained higher during the rest of the IPGTT compared to LTC mice, but these measurements                           
were not significant. AUC measurements showed LTFC mice were not significantly more                     




Similarly, LTFC mice showed a significantly higher blood glucose concentration 30 minutes after                       
a glucose injection compared to LTF mice (Figure 5.7.2.0.3:E. Table 5.7.2.0.2. p<0.05,                     
n=10/group). Again, blood glucose concentration was slightly higher in LTFC mice compared to                       
LTF mice throughout the IPGTT. AUC assessment showed no significant difference in glucose                       





A) Body weight of mice at the time of the intraperitoneal glucose tolerance test (IPGTT). Body                             
weight measure in grams. B) Area under the curve (AUC) analysis of blood glucose                         
concentration measurements during the IPGTT. AUC measure in mmol/L x 120 mins. Data                       
presented as mean ± sem, n=10/group. ** p<0.01, *** p<0.001. Statistical analysis was                       
performed using a One­Way ANOVA with Tukey correction.
Time (mins) CT (mmol/L) CFC (mmol/L) FCF (mmol/L) FT (mmol/L)
0 5.0 ± 0.2 5.0 ± 0.3 6.8 ± 0.2 8.2 ± 0.4
15 14.9 ± 0.8 14.3 ± 0.7 17.6 ± 0.6 15.7 ± 0.8
30 15.7 ± 0.7 14.5 ± 0.6 18.3 ± 0.6 18.2 ± 0.7
60 12.4 ± 0.8 14.2 ± 1.0 18.2 ± 1.1 18.0 ± 1.0
120 8.8 ± 0.7 9.8 ± 1.0 14.6 ± 1.3 17.4 ± 0.9
Table {5.7.2.0.2} The effect of three weight cycles on glucose tolerance
Blood glucose measurements during the IPGTT, measured in mmol/L. Data presented as mean                       





Blood glucose measurements during the IPGTT, measured in mmol/L. Data presented as mean                       








Both control fed groups, CT and CFC, showed an increased cumulative water intake compared                         
to both FCF and FT groups (Figure 5.8.1.0.1:B,D,E. n=7­8/group). A significant increase in                       
cumulative water intake was observed in CT compared to FT mice from 01:00 to 11:00 (Figure                             
5.8.1.0.1:B. 01:00­02:00 hrs: p<0.05; 03:00­04:00 hrs: p<0.01; 05:00­11:00 hrs: p<0.001,                 
n=7­8/group). Similarly, cumulative water intake was noticeably higher for CT mice compared to                       
FCF mice from 24:00 to 11:00 (Figure 5.8.1.0.1:D. 24:00­01:00 hr: p<0.05; 02:00­03:00 hrs:                       
p<0.01; 04:00­11:00 hrs, n=7­8/group). CFC mice also showed an increased cumulative water                     
intake compared FT mice from 24:00 to 11:00 (Figure 5.8.1.0.1:E. 24:00­01:00 hrs: p<0.05;                       
02:00­03:00 hrs: p<0.01; 04:00­11:00 hrs: p<0.001, n=7­8/group). No differences in cumulative                   
water intake were observed between CT and CFC mice or between FCF and FT mice (Figure                             
5.8.1.0.1:C,F. n=7­8/group).
A comparison of water intake during the light phase of the light cycle showed CT mice                             
consumed significantly more water compared to FCF and FT mice (Figure 5.8.1.0.1:A. Table                       
5.8.1.0.6. CT­FCF: p<0.001. CT­FT: p<0.01, n=7­8/group). Similarly, CFC mice showed a                   
significantly higher water intake during the light phase compared to FCF mice (Figure                       
5.8.1.0.1:A. Table 5.8.1.0.6. p<0.05, n=7­8/group). A strong trend was observed showing an                     
increased water intake in CFC mice compared to FT mice, but a trend also showing a                             
decreased water intake during the light phase was observed in CFC mice compared to CT mice                             
(Figure 5.8.1.0.1:A. Table 5.8.1.0.6. n=7­8/group).
Both CT and CFC mice showed a significantly higher water intake during the dark phase                           
compared to both FCF and FT mice (Figure 5.8.1.0.1:A. Table 5.8.1.0.6. All p<0.05,                       
n=7­8/group). No differences were observed between CT and CFC or FCF and FT mice during                           





A) Total water intake during the light phase and dark phase of the light cycle. B­F) Water intake                                 
over a 24 hour light cycle. Water intake measured in mls using CLAMS metabolic cages.                           
Shaded area on the graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data                             




Oxygen (O2) consumption measurements showed CT and CFC mice had an increased rate of                         
O2 consumption compared to FCF and FT mice over 24 hours, although generally this was not                             
significant (Figure 5.8.1.0.2:B,D,E. CFC­FT: p<0.05; all other comparisons p>0.05,               
n=7­8/group). No observable differences in O2 consumption were observed between CFC and                     
CT mice (Figure 5.8.1.0.2:C. n=7­8/group). However, FCF mice showed a noticeable increase in                       
O2 consumption at the onset of the dark phase (19:00­21:00 hrs) of the light cycle compared to                               
FT mice, showing a difference in the rate of O2 consumption caused by a single weight cycle                               
(Figure 5.8.1.0.2:F. n=7­8/group).
A significant difference in the rate of O2 consumption was observed during the light phase in CT                               
and CFC mice compared to FCF and FT mice (Figure 5.8.1.0.2:A. Table 5.8.1.0.6. All p<0.05,                           
n=7­8/group). No significant differences were observed during the dark phase of the light cycle,                         
although a trend between both CT and CFC mice, and FCF and FT mice was observed (Figure                               
5.8.1.0.2:A. Table 5.8.1.0.6. n=7­8/group). No differences were observed as a result of a single                         
weight cycle on the rate of O2 consumption when divided into the light and dark phase of the light                                   
cycle.
Carbon dioxide (CO2) production measurements showed CT and CFC mice had a higher rate of                           
CO2 production compared to FCF and FT mice (Figure 5.8.1.0.3:B,D,E. p<0.05­0.001,                   
n=7­8/group). No differences in CO2 production were seen between CT and CFC mice, or                         
between FCF and FT mice (Figure 5.8.1.0.3:C,F. n=7­8/group). Similar to O2 consumption                     
measurements, FCF showed an increased rate of CO2 production at the onset of the dark phase                             
of the light cycle compared to FT mice, although this was not significant (Figure. n=7­8/group).
Similarly, CO2 production was significantly higher in both CT and CFC mice compared to FCF                           





A) Average O2 consumption during the light phase and dark phase of the light cycle. B­F) O2                               
consumption over a 24 hour light cycle. O2 consumption measured in ml/kg0.75/hr using CLAMS                         
metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                           
(19:00­07:00 hrs). Data presented as mean ± sem, n=7­8/group. * p<0.05, ** or † p<0.01, *** or                               





A) Average CO2 production during the light phase and dark phase of the light cycle. B­F) CO2                               
production over a 24 hour light cycle. CO2 production measured in ml/kg0.75/hr using CLAMS                         
metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                           
(19:00­07:00 hrs). Data presented as mean ± sem, n=7­8/group. * p<0.05, ** or † p<0.01, *** or                               




The respiratory exchange ratios (RER) obtained from O2 consumption and CO2 production                     
showed CT and CFC mice had a significantly higher RER compared to both FCF and FT mice                               
during the entire 24 hour period (Figure 5.8.1.0.4:B,D,E. CT­FCF/FT: p<0.001; CFC­FT:                   
12:00­33:00 hrs: p<0.001; 34:00 hr: p<0.01; 35:00 hr: p<0.001, n=7­8/group). No significant                     
differences in RER were observed between CT mice and CFC mice, or between FCF mice and                             
LTF mice (Figure 5.8.1.0.4:C,F. n=7­8/group), indicating a single weight cycle did not affect RER                         
measurements.
A comparison between RER during the light and dark phase also reflected these differences                         
(Figure 5.8.1.0.4:A. Table 5.8.1.0.6. All p<0.001, n=7­8/group).
Heat production was slightly elevated in FCF and FT mice compared to CT and CFC mice                             
throughout the 24 hour light cycle, but generally these measurements were not significantly                       
different from each other (Figure 5.8.1.0.5:B,D,E. CT­FT: 24 hr: p<0.01; 04:00 hr: p<0.05.                       
CT­FCF: 21:00 hr: p<0.05, n=7­8/group). Heat production between CT and CFC mice was                       
comparable, as was heat production between FCF and FT mice (Figure 5.8.1.0.5:C,E.                     
n=7­8/group).
No significant differences in heat production were observed during the light phase of the light                           
cycle. FT mice showed a significantly higher level of heat production during the dark phase                           
compared to CT mice (Figure 5.8.1.0.5:A. Table 5.8.1.0.6. p<0.05, n=7­8/group). A trend was                       
also apparent showing weight cycled mice had a higher level of heat production compared CT                           
mice, FCF mice having a higher level of heat production compared to CFC mice (Figure                           





A) Average RER during the light phase and dark phase of the light cycle. B­F) RER over a 24                                   
hour light cycle. RER measured in arbitrary units using CLAMS metabolic cage measurements                       
of O2 consumption and CO2 production and equations 2.4.3.0.1. Shaded area on the graph                         
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             





A) Average heat production during the light phase and dark phase of the light cycle. B­F) Heat                               
production over a 24 hour light cycle. Heat production was measured in kcal/hr using CLAMS                           
metabolic cage measurements of O2 consumption and equations 2.4.3.0.1. Shaded area on the                       
graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ±                             




CT CFC FCF FT
Water intake Light 0.913 ± 0.170 0.646 ± 0.124 0.150 ± 0.027 0.207 ± 0.069
Dark 1.449 ± 0.256 1.451 ± 0.195 0.615 ± 0.117 0.587 ± 0.121
VO2 (ml/kg0.75/hr) Light 3578 ± 157.3 3550 ± 182.3 2989 ± 83.9 2992 ± 114.0
Dark 3784 ± 158.0 3911 ± 223.4 3400 ± 101.5 3338 ± 146.7
VCO2
(ml/kg0.75/hr)
Light 3217 ± 197.7 3208 ± 234.8 2161 ± 56.2 2159 ± 78.3
Dark 3452 ± 107.5 3572 ± 247.4 2458 ± 77.0 2450 ± 112.8
RER Light 0.893 ± 0.018 0.896 ± 0.022 0.716 ± 0.004 0.720 ± 0.004
Dark 0.907 ± 0.021 0.910 ± 0.021 0.722 ± 0.004 0.732 ± 0.005
Heat (kcal/hr) Light 0.620 ± 0.018 0.624 ± 0.019 0.636 ± 0.013 0.672 ± 0.022
Dark 0.656 ± 0.018 0.686 ± 0.025 0.725 ± 0.027 0.753 ± 0.026
Table {5.8.1.0.6} The effect of a single weight cycle on indirect calorimetry                     
measurements
Total water intake (ml), average O2 consumption (ml/kg0.75/hr), CO2 production (ml/kg0.75/hr),                   
RER (arbitrary unit) and heat production (kcal/hr) measured during the light and dark phase of a                             
24 hour light cycle using CLAMS metabolic cages. RER and heat production calculated using                         




Movement was assessed using infrared beams, with a beam crossing given as one count of                           
movement. XAMB counts measured ambulatory activity on a horizontal axis. ZTOT counts                     
measured movement in the vertical axis, such as rearing. XTOT counts measure all movement                         
in the horizontal axis, including fine movements such as grooming. In all planes of movement,                           
counts increased in all groups initially at the onset of the dark phase of the light cycle at 19:00. A                                     
second peak was also observed between 02:00 to 07:00.
Measurements of ambulatory activity showed a large peak in activity in CT mice at the onset of                               
the dark phase that was significant compared to FT mice (Figure 5.8.1.0.7:B. p<0.001,                       
n=7­8/group). This was also noticeably higher compared to CFC mice (Figure 5.8.1.0.7:C.                     
n=7­8/group). However, this peak in XAMB counts at the onset of the dark phase was not                             
significant compared to FCF mice, who also showed a significantly higher number of XAMB                         
counts compared to CT mice at 21:00 (Figure 5.8.1.0.7:D. p<0.05, n=7­8/group). This increase                       
in activity in FCF mice was also significantly higher compared to FT mice (Figure 5.8.1.0.7:F.                           
p<0.001, n=7­8/group). There was no noticeable difference in XAMB counts during the first half                         
of the dark phase between CFC and FT mice, however FT mice showed a higher number of                               
counts during the second peak of activity observable during the last half of the dark phase                             
(Figure 5.8.1.0.7:C. n=7­8/group).
No significant differences were observed between groups when XAMB counts were separated                     
into light and dark phases of the light cycle (Figure 5.8.1.0.7:A. Table 5.8.1.0.10. n=7­8/group). In                           
both instances, FCF mice showed the highest number of XAMB counts out of the four groups.                             
Similarly, FCF mice showed the highest number of total XAMB counts during 24 hours, whilst                           





A) Total ambulatory activity (XAMB) counts during the light phase, dark phase and entire light                           
cycle. B­F) XAMB counts recorded per hour over a light cycle. Shaded area on the graph                             
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             




CT mice showed a significant increase in ZTOT counts during the first half of the dark phase                               
compared to FCF and FT mice (Figure 5.8.1.0.8:B,D. CT­FT: 20:00 hr: p<0.001; 21:00 hr:                         
p<0.05; 23:00 hr: p<0.001. CT­FCF: 20:00 hr: p<0.001; 23:00 hr: p<0.01, n=7­8/group). No                       
noticeable differences in ZTOT counts were observed between CT and CFC mice (Figure                       
5.8.1.0.8:C. n=7­8/group). CFC mice also showed a significant increase in ZTOT counts during                       
the first half of the dark phase compared to FT mice (Figure 5.8.1.0.8:E. 20:00 hr: p<0.01;                             
21:00­22:00 hrs: p<0.001; 23:00 hr: p<0.01, n=7­8/group). No significant differences between                   
FCF and FT mice were observed with regards to ZTOT counts, although there was a greater                             
number of counts during the peak at the onset of the dark phase in FCF mice compared to FT                                   
mice (Figure 5.8.1.0.8:F. n=7­8/group).
A comparison of ZTOT counts separated by phase of the light cycle showed no significant                           
differences between groups during the light phase of the light cycle (Figure 5.1.9.0.8:A. Table                         
5.8.1.0.10). During the dark phase, CT and CFC mice had a significantly higher number of ZTOT                             
counts compared to both FCF and FT mice (Figure 5.8.1.0.8:A. Table 5.8.1.0.10. CT­FCF/FT:                       
p<0.01. CFC­FCF: p<0.01, CFC­FT: p<0.001, n=7­8/group). This resulted in a significantly                   
higher number of total ZTOT counts during 24 hours in CT and CFC mice compared to FCF and                                 





A) Total rearing activity (ZTOT) counts during the light phase, dark phase and entire light cycle.                             
B­F) ZTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           




A comparison of XTOT counts showed CT mice had significantly more counts at the onset of                             
the dark phase compared to FT mice (Figure 5.8.1.0.9:A. 19:00 hr: p<0.01; 20:00 hr: p<0.001,                           
n=7­8/group). No significant differences in XTOT counts were observed between CT and FCF                       
mice (Figure 5.8.1.0.9:D. n=7­8/group). FCF mice also showed significantly more XTOT counts                     
at the onset of the dark phase compared to FT mice (Figure 5.8.1.0.9:F. 20:00 hr: p<0.05; 21:00                               
hr: p<0.001, n=7­8/group). CT mice also showed an increased number of XTOT counts at the                           
beginning of the dark phase compared to CFC mice (Figure 5.8.1.0.9:C. 20:00 hr: p<0.01,                         
n=7­8/group). No significant difference in XTOT counts was observed between CFC and FT                       
mice, although a trend was apparent showing an increased number of counts in CFC mice                           
compared to FT mice (Figure 5.8.1.0.9:E. n=7­8/group).
No significant differences between groups was observed during the light or dark phase of the                           
light cycle, or when comparing total movement over the 24 hour light cycle (Figure 5.8.1.0.9:A.                           
Table 5.8.1.0.10. n=7­8/group). A trend showing a higher number of XTOT counts in CT, CFC                           





A) Total x axis activity (XTOT) counts during the light phase, dark phase and entire light cycle.                               
B­F) XTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           





Light CT 2834 ± 499.6 528.8 ± 86.4 7859 ± 1262.0
CFC 2169 ± 381.9 418.7 ± 80.4 6364 ± 979.3
FCF 4199 ± 579.3 268.5 ± 41.9 6744 ± 560.2
FT 3729 ± 580.3 332.5 ± 90.3 5372 ± 579.2
Dark CT 9853 ± 2014 3009 ± 312.4 19245 ± 3479.0
CFC 10642 ± 2104 3316 ± 398.1 18678 ± 2362
FCF 12330 ± 1204 1509 ± 245.8 19383 ± 919.2
FT 10282 ± 1465 1271 ± 201.6 13154 ± 1251
Total CT 12688 ± 2465 3538 ± 350.6 27105 ± 4623
CFC 11084 ± 1746 3735 ± 447.3 25042 ± 3236
FCF 16529 ± 1568 1777 ± 266.8 26127 ± 828.0
FT 14011 ± 1862 1604 ± 261.3 18527 ± 1416
Table {5.8.1.0.10}  The effect of a single weight cycle on activity
Total number of XAMB, ZTOT and XTOT counts during the light phase, dark phase and over a                               





Both control fed groups, LTC and LTCF, showed an increased cumulative water intake                       
compared to both FCF and FT groups (Figure 5.8.2.0.1:B,D,E. n=6­7/group), with the most                       
noticeable difference observed between LTCF mice and LTF mice. However, no significant                     
differences in cumulative water intake was observed.
A comparison of water intake during the light phase of the light cycle showed no significant                             
differences between groups (Figure 5.8.2.0.1:A. Table 5.8.2.0.6. n=6­7/group). As observed over                   
the 24 hour light cycle, LTC mice and LTCF mice consumed more water during the light phase                               





A) Total water intake during the light phase and dark phase of the light cycle. B­F) Water intake                                 
over a 24 hour light cycle. Water intake measured in mls using CLAMS metabolic cages.                           
Shaded area on the graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data                             




No significant differences in oxygen (O2) consumption were observed over 24 hours between                       
groups (Figure 5.8.2.0.2:B­F. n=6­7/group). LTC mice showed a slight increase in the rate of O2                           
consumption compared to LTFC mice and LTF mice over 24 hours. Also, LTCF mice showed a                             
slight increase in the rate of O2 consumption compared to LTF mice.
A comparison between the average rate of O2 consumption during the light phase showed no                           
significant differences between groups. (Figure 5.8.2.0.2:A. Table 5.8.2.0.6. n=6­7/group). A                 
trend was observed showing an increase in O2 consumption in LTC mice and LTCF mice                           
compared to LTFC mice and LTF mice during the light phase of the light cycle (Figure                             
5.8.2.0.2:A. Table 5.8.2.0.6. n=6­7/group). This trend was also apparent during the dark phase of                         
the light cycle.
Carbon dioxide (CO2) production measurements also showed LTC mice had a higher rate of                         
CO2 production compared to LTF mice and LTFC mice during a 24 hour light cycle, which was                               
occasionally significantly higher (Figure 5.8.2.0.3:B,D. LTC­LTF: 17:00­18:00 hrs: p<0.05; 19:00                 
hr: p<0.01; 02:00 hr: p<0.01; 03:00 hr: p<0.05; 06:00 hr: p<0.05. LTC­LTFC: 17:00 hr: p<0.05;                           
19:00 hr: p<0.001; 06:00 hr: p<0.01, n=6­7/group). Similarly, LTCF mice showed an increase                       
rate of CO2 production compared to LTF mice, which was significant at various points (Figure                           
5.8.2.0.3:E. 13:00­14:00 hrs: p<0.05; 15:00­16:00 hrs: p<0.01; 17:00 hr: p<0.05; 22:00­24:00 hrs:                     
p<0.01; 01:00 hr: p<0.05; 02:00 hr: p<0.01; 06:00 hr: p<0.05, n=6­7/group). No significant                       
differences in CO2 production were observed between LTC mice and LTCF mice, or between                         
LTFC mice and LTF mice (Figure 5.8.2.0.6:C,F. n=6­7/group).
CO2 production was significantly higher in both LTC mice and LTCF mice compared to LTFC                           





A) Average O2 consumption during the light phase and dark phase of the light cycle. B­F) O2                               
consumption over a 24 hour light cycle. O2 consumption measured in ml/kg0.75/hr using CLAMS                         
metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                           





A) Average CO2 consumption during the light phase and dark phase of the light cycle. B­F) CO2                               
consumption over a 24 hour light cycle. CO2 consumption measured in ml/kg0.75/hr using CLAMS                         
metabolic cages. Shaded area on the graph represents the dark phase of the light cycle                           
(19:00­07:00 hrs). Data presented as mean ± sem, n=6­7/group. * p<0.05, ** or † p<0.01, *** or                               




RER values obtained from O2 consumption and CO2 production showed LTC mice and LTCF                         
mice had a higher RER compared to both FCF and FT mice during the entire 24 hour period.                                 
This was significant during the dark phase and at some points during the light phase of the light                                 
cycle (Figure 5.8.2.0.4:B,D,E. p<0.05­p<0.001, n=6­7/group). No significant differences in RER                 
were observed between LTC mice and LTCF mice, or between LTFC mice and LTF mice                           
(Figure 5.8.2.0.4:C,F. n=7­8/group). However, a noticeable decrease in RER was observed in                     
LTC mice during the dark phase compared to LTCF mice (Figure 5.8.2.0.4:C. n=6­7/group).
A comparison between RER during the light and dark phase also reflected these differences                         
(Figure 5.8.2.0.4:A. Table 5.8.2.0.6. Light: LTC­LTFC/LTF: p<0.01; LTCF­LTFC/LTF: p<0.05.               
Dark: all p<0.001, n=6­7/group).
Heat production was elevated in LTF mice compared to LTC mice, particularly during the dark                           
phase (Figure 5.8.2.0.5:B. n=6­7/group). Although these measurements were not significantly                 
different, LTF mice showed a significant increase in heat production compared to LTCF mice at                           
the onset of the dark phase, and a second peak was observed during the latter half of the dark                                   
phase (Figure 5.8.2.0.5:E. 19:00­20:00 hrs: p<0.001; 21:00 hr: p<0.01; 05:00 hr: p<0.05,                     
n=6­7/group). LTFC mice showed no significant difference in heat production compared to LTC                       
mice, although a slight increase was observed during the first few hours of the dark phase                             
(Figure 5.8.2.0.5:D. n=6­7/group). However, in comparison to LTF mice, LTFC mice showed a                       
lower level of heat production, which was significant at 19:00 hr (Figure 5.8.2.0.5:F. p<0.05,                         
n=6­7/group). No significant differences in heat production were observed between LTC mice                     
and LTCF mice, although LTC mice showed a trend towards an increased rate of heat                           
production compared to LTCF mice, especially during the onset of the dark phase (Figure                         
5.8.2.0.5:C. n=6­7/group).
No significant differences in average heat production were observed during the light phase or                         
dark phase of the light cycle (Figure 5.8.2.0.5:A. Table 5.8.2.0.6. n=6­7/group). As observed with                         
24 hours of measurements, LTF mice showed the highest rate of heat production during both                           





A) Average RER during the light phase and dark phase of the light cycle. B­F) RER over a 24                                   
hour light cycle. RER measured in arbitrary units using CLAMS metabolic cage measurements                       
of O2 consumption and CO2 production and equations 2.4.3.0.1. Shaded area on the graph                         
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             





A) Average heat production during the light phase and dark phase of the light cycle. B­F) Heat                               
production over a 24 hour light cycle. Heat production was measured in kcal/hr using CLAMS                           
metabolic cage measurements of O2 consumption and equations 2.4.3.0.1. Shaded area on the                       
graph represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ±                             




LTC LTCF LTFC LTF
Water intake Light 0.547 ± 0.081 0.679 ± 0.105 0.383 ± 0.072 0.448 ± 0.047
Dark 1.279 ± 0.180 1.364 ± 0.160 1.177 ± 0.121 1.143 ± 0.164
VO2
(ml/kg0.75/hr) Light 3201 ± 101.7 3237 ± 82.8 2951 ± 69.1 2964 ± 137.4
Dark 3613 ± 134.3 3599 ± 119.1 3502 ± 123.2 3519 ± 172.1
VCO2
(ml/kg0.75/hr) Light 2714 ± 142.2 2803 ± 95.8 2170 ± 51.7 2184 ± 98.8
Dark 3160 ± 174.2 3235 ± 80.2 2610 ± 103 2593 ± 121.9
RER Light 0.844 ± 0.026 0.863 ± 0.021 0.734 ± 0.005 0.735 ± 0.005
Dark 0.870 ± 0.026 0.899 ± 0.014 0.743 ± 0.005 0.736 ± 0.005
Heat (kcal/hr) Light 0.663 ± 0.017 0.628 ± 0.026 0.657 ± 0.022 0.706 ± 0.015
Dark 0.758 ± 0.027 0.703 ± 0.025 0.784 ± 0.042 0.842 ± 0.030
Table {5.8.2.0.6} The effect of three weight cycles on indirect calorimetry measurements
Total water intake (ml), average O2 consumption (ml/kg0.75/hr), CO2 production (ml/kg0.75/hr),                   
RER (arbitrary unit) and heat production (kcal/hr) measured during the light and dark phase of a                             
24 hour light cycle using CLAMS metabolic cages. RER and heat production calculated using                         




Measurements of ambulatory activity showed a peak in activity in LTC mice at the onset of the                               
dark phase compared to FT mice, although this was not significant (Figure 5.8.2.0.7:B.                       
n=6­7/group). However, compared to LTCF and LTFC mice, this differences in XAMB activity                       
was comparable. Both LTCF and LTFC mice showed a slightly increased number of XAMB                         
counts compared to LTF mice at the onset of the dark phase of the light cycle (Figure                               
5.8.2.0.7:C.F. n=6­7/group). No significant differences in XAMB counts were observed between                   
groups during the 24 hour light cycle.
No significant differences were observed between groups when XAMB counts were separated                     
into light and dark phases of the light cycle (Figure 5.8.2.0.7:A. Table 5.8.2.0.10 n=6­7/group).                         
LTFC mice showed the highest number of XAMB counts during the light phase and in total. LTF                               
mice had the lowest XAMB counts during the light phase, which was similarly low in LTCF mice,                               





A) Total ambulatory activity (XAMB) counts during the light phase, dark phase and entire light                           
cycle. B­F) XAMB counts recorded per hour over a light cycle. Shaded area on the graph                             
represents the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                             




LTC mice showed a significant increase in ZTOT counts at 20:00 hr compared to all other                             
groups (Figure 5.8.2.0.8:B,C,D. LTC­LTFC/LTF: p<0.001; LTC­LTCF p<0.05, n=6­7/group). In               
comparison to LTF mice, ZTOT counts at other points during the 24 hour light cycle did not show                                 
any noticeable differences in ZTOT counts (Figure 5.8.2.0.8:B. n=6­7/group). LTC mice showed                     
a significantly higher number of ZTOT counts compared to LTFC mice also at 21:00 hr (Figure                             
5.8.2.0.8:D. p<0.01, n=6­7/group). After this, ZTOT counts were comparable between the two                     
groups. Compared to LTCF mice, LTC mice had a significantly lower number of ZTOT counts at                             
22:00 hr, and counts remained higher during the rest of the first half of the dark phase (Figure                                 
5.8.2.0.8:C. p<0.01, n=6­7/group). A noticeable peak in rearing activity was observed in LTC                       
mice at 05:00 hr compared to LTCF mice. No significant differences were observed between                         
LTCF mice and LTF mice, although ZTOT counts were noticeably higher in LTCF mice (Figure                           
5.8.2.0.8:E. n=6­7/group). LTF mice showed no significant difference in ZTOT counts compared                     
to LTFC mice, although LTF mice had a higher number of counts during the onset of the dark                                 
phase compared to LTFC mice (Figure 5.8.2.0.8:F. n=6­7/group).
A comparison of ZTOT counts separated by phase of the light cycle showed no significant                           
differences between groups during either phase of the light cycle (Figure 5.8.2.0.8:A. Table                       
5.8.2.0.10. n=6­7/group). In total, LTCF mice showed the most ZTOT counts, which seem to                         
arise from the large number of ZTOT counts during the dark phase. During the light phase, LTC                               
mice showed the highest number of XTOT counts compared to other groups. This resulted in a                             
similar number of total ZTOT counts over the whole 24 hour light cycle. LTFC mice showed a                               
higher number of ZTOT counts compared to LTCF and LTF mice, but the lowest number of                             





A) Total rearing activity (ZTOT) counts during the light phase, dark phase and entire light cycle.                             
B­F) ZTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           




A comparison of XTOT counts showed LTC mice had more counts at the onset of the dark                               
phase compared to LTFC mice and LTF mice, although this was only significantly different                         
compared to LTFC mice (Figure 5.8.2.0.9:B,D. 19:00 hr: p<0.05, n=6­7/group). Similarly, LTCF                     
mice also showed a significantly higher number of XTOT counts at the onset of the dark phase                               
compared to LTF mice (Figure 5.8.2.0.9:E. 20:00 hr: p<0.05, n=6­7/group). No significant                     
differences in XTOT counts were observed between LTC mice and LTCF mice, although an                         
increased number of counts was observed in LTCF mice between 23:00 to 01:00 hrs. (Figure                           
5.8.2.0.9:C. n=6­7/group). No significant differences in XTOT counts were observed between                   
LTFC mice and LTF mice during the 24 hour light cycle (Figure 5.8.2.0.9:F. n=6­7/group).
No significant differences between groups was observed during the light or dark phase of the                           
light cycle, or when comparing total movement over the 24 hour light cycle (Figure 5.8.2.0.9:A.                           
Table 5.8.2.0.10. n=6­7/group). A trend showed LTCF mice had a higher number of XTOT                         
counts compared to other groups during the whole 24 hour light cycle and during the dark phase.                               
Total number of XTOT counts during the light cycle were comparable between LTC, LTFC and                           
LTF mice. LTF mice showed a trend towards and increase number of XTOT counts during the                             





A) Total x axis activity (XTOT) counts during the light phase, dark phase and entire light cycle.                               
B­F) XTOT counts recorded per hour over a light cycle. Shaded area on the graph represents                             
the dark phase of the light cycle (19:00­07:00 hrs). Data presented as mean ± sem,                           





Light CT 7321 ± 1839 974.6 ± 418.9 11775 ± 3347
CFC 3945 ± 1224 228.9 ± 35.2 7351 ± 1907
FCF 9426 ± 3637 638.3 ± 199.0 10546 ± 3563
FT 3643 ± 320.1 306.6 ± 76.1 6493 ± 809.9
Dark CT 10947 ± 1493 2725 ± 486.4 17383 ± 2482
CFC 14205 ± 3279 3588 ± 870.1 27030 ± 5268
FCF 12063 ± 1660 1452 ± 149.3 16563 ± 924.7
FT 13917 ± 746.9 2626 ± 419.3 21837 ± 3086
Total CT 18269 ± 1746 3699 ± 351.3 29158 ± 3661
CFC 18151 ± 4240 3817 ± 884.1 34381 ± 6641
FCF 21489 ± 5027 2090 ± 305.1 27109 ± 3848
FT 17560 ± 850.8 2933 ± 388.5 28329 ± 3841
Table {5.8.2.0.10} The effect of three weight cycles on activity
Total number of XAMB, ZTOT and XTOT counts during the light phase, dark phase and over a                               






FT mice and FCF mice ran a significantly shorter distance compared to both CT and CFC mice                               
(Figure 5.9.1.0.1. CT: 1005.0 ± 25.8 m; CFC: 1090.0 ± 66.4 m; FCF: 636.3 ± 53.1; FT: 630.2 ±                                   
55.4 m. All p<0.001, n=6­8/group). There was no significant difference in running distance                       
between CT mice and CFC mice. Similarly, no significant difference in running distance was                         
observed between FCF mice and FT mice.
Figure {5.9.1.0.1} The effect of a single weight cycle on distance ran on a treadmill
An acute exercise study was used to assess the maximum distance mice could run                         




Body weight measurements between groups showed both FCF mice and FT mice used for this                           
analysis were significantly heavier compared to CT mice and CFC mice (Figure 5.9.1.0.2:A. CT:                         
34.36 ± 1.27 g; CFC: 34.53 ± 0.93 g; FCF: 43.93 ± 1.07 g; FT: 47.14 ± 1.50 g. All p<0.001,                                       
n=6­8/group).
When correlating body weight to running distance for each group, no significant correlation was                         
observed (Figure 5.9.1.0.2:B. Table 5.9.1.0.3. n=6­8/group). However, a trend was observed in                     
CT and FT showing a negative correlation between body weight and distance ran (Figure                         
5.9.1.0.2:B. Table 5.9.1.0.3. CT: p=0.0612; FT: p=0.0629. n=6­8/group).




Figure {5.9.1.0.2} The effect of a single weight cycle on distance ran on a treadmill                           
correlated with body weight
A) Body weight at the time the of acute exercise study. Data presented as mean ± sem , n=6­8.                                   
*** p<0.001. Statistical analysis was performed using a One­Way ANOVA with Tukey correction.
B) Correlation analysis between body weight and distance ran. Black line represents line of best                           
fit for correlation of all mice, regardless of diet group. Statistical analysis was performed using                           
Pearson’s correlation.
CT CFC FCF FT All
Pearson r ­0.7325 ­0.1713 0.1563 ­0.7294 ­0.8168
p value 0.0612 0.6850 0.7675 0.0629 <0.0001
R2 0.5365 0.0294 0.0244 0.5320 0.6672
Table {5.9.1.0.3} The effect of a single weight cycle on distance ran on a treadmill                           
correlated with body weight





No significant difference was observed in LTF mice in terms of running distance on a treadmill                             
compared to any group. However, a noticeable trend showed LTF mice ran a shorter distance                           
compared to LTC mice and LTCF mice (Figure 5.9.2.0.1. LTC: 901.3 ± 77.1 m; LTCF: 836.6 ±                               
100.8 m; LTF: 640.8 ± 46.5 m. n=6­7/group). LTFC mice showed significantly shorter running                         
distance compared to both LTC and LTCF mice (Figure 5.9.2.0.1. LTFC: 539.8 ± 61.9 m.                           
LTC­LTFC: p<0.01; LTCF­LTFC: p<0.05, n=6­7/group). Similarly, LTFC mice showed a shorter                   
running distance compared to LTF mice, although this difference was not significant.
Figure {5.9.2.0.1} The effect of three weight cycles on distance ran on a treadmill
An acute exercise study was used to assess the maximum distance mice could run                         




Body weight measurements between groups showed LTFC mice and LTF mice used for this                         
analysis were significantly heavier compared to LTC mice and LTCF mice (Figure 5.9.2.0.2:A.                       
LTC: 40.76 ± 1.21 g; LTCF: 39.70 ± 1.38 g; LTFC: 46.11 ± 0.84 g; LTF: 47.15 ± 1.12 g.                                     
LTC­LTFC/LTF: p<0.01; LTCF­LTFC: p<0.01; LTCF­LTF: p<0.001, n=6­7/group). No difference               
in body weight measurements were observed between LTC mice and LTCF mice, or between                         
LTFC mice and LTF mice.
When correlating body weight to running distance for each group, a significant negative                       
correlation was observed in LTC and LTCF mice only (Figure 5.9.2.0.2:B. Table 5.9.2.0.3. LTC:                         
p=0.0310; LTCF: p=0.0067, n=6­7/group). No significant correlation was observed between body                   
weight and running distance within LTFC mice or LTF mice (Figure 5.9.2.0.2:B. Table 5.9.2.0.3.                         
n=6­7/group).




Figure {5.9.2.0.2} The effect of three weight cycles on distance ran on a treadmill                         
correlated with body weight
A) Body weight at the time the of acute exercise study. Data presented as mean ± sem ,                                 
n=6­7/group. *** p<0.001. Statistical analysis was performed using a One­Way ANOVA with                     
Tukey correction.
B) Correlation analysis between body weight and distance ran. Black line represents line of best                           
fit for correlation of all mice, regardless of diet group. n=26 Statistical analysis was performed                           
using Pearson’s correlation.
LTC LTCF LTFC LTF All
Person r ­0.7994 ­0.9325 0.1233 0.02332 ­0.7217
p value 0.0310 0.0067 0.7923 0.9650 <0.0001
R2 0.6391 0.8695 0.0152 0.0005 0.5208
Table {5.9.2.0.3} The effect of three weight cycles on distance ran on a treadmill                         
correlated with body weight
Correlation analysis between body weight and distance ran. n=6­7/group, total n=26. Yellow                     




To assess whether a correlation existed between distance ran and fat or lean mass, an                           
EchoMRI whole adiposity MR scanner was used the day before treadmill measurement.
LTF mice had significantly more lean mass compared to LTCF mice, but not compared to LTC                             
mice (Figure 5.9.2.0.5:A. Table 5.9.2.0.4. p<0.05, n=6­7/group). LTFC mice also showed no                     
significant difference in lean mass compared to LTC mice or LTCF mice. However, upon                         
normalisation to body weight, percentage lean mass was significantly lower in LTF mice and                         
LTFC mice compared to both LTC mice and LTCF mice (Figure 5.9.2.0.5:B. Table 5.9.2.0.4.                         
LTC­LTFC/LTF: p<0.001; LTCF­LTFC: p<0.05; LTCF­LTF: p<0.001, n=6­7/group). No             
significant difference existed between fat fed LTFC mice and LTF mice, or between LTC mice                           
and LTCF mice.
Fat mass was significantly increased in LTF mice and LTFC mice compared to LTC mice and                             
LTCF mice (Figure 5.9.2.0.5:C. Table 5.9.2.0.4. All p<0.001, n=6­7/group). This significance                   
remained when comparing percentage fat mass between groups (Figure 5.9.2.0.5:D. Table                   




Figure {5.9.2.0.4} The effect of three weight cycles on lean mass and fat mass assessed                           
using EchoMRI
A) Lean mass in grams; B) Lean mass as a percentage of body weight; C) Fat mass in grams;                                   
D) Fat mass as a percentage of body weight. Data presented as mean ± sem, n=6­7/group. *                               




LTC LTCF LTFC LTF
Lean mass (g) 24.10 ± 0.45 22.39 ± 0.60 23.35 ± 0.50 24.73 ± 0.61
Lean mass (%) 60.55 ± 1.33 57.55 ± 1.04 50.43 ± 0.78 52.40 ± 1.25
Fat mass (g) 11.92 ± 0.86 12.49 ± 0.79 19.04 ± 0.43 18.20 ± 0.81
Fat mass (%) 29.66 ± 1.53 31.93 ± 1.15 41.12 ± 0.69 38.46 ± 1.04
Table {5.9.2.0.5} The effect of three weight cycles on lean mass and fat mass assessed                           
using EchoMRI




No significant correlation was observed between lean mass and distance ran in any of the                           
groups (Figure 5.9.2.0.6:A. Table 5.9.2.0.7:A. n=6­7/group). Similarly, when all mice were                   
grouped together, there was still no significant correlation between lean mass and distance ran                         
(Figure 5.9.2.0.6:A. Table 5.9.2.0.7:A. p=0.3309, n=26).
When distance was correlated with percentage lean mass, there was a significant positive                       
correlation in LTC mice (Figure 5.9.2.0.6:B. Table 5.9.2.0.7:B. p=0.0054, n=7). However, none of                       
the other groups showed a significant correlation between percentage lean mass and distance                       
ran (Figure 5.9.2.0.6:B. Table 5.9.2.0.7:B. n=6­7/group). When all mice were grouped together, a                       
significant positive correlation between percentage lean mass and running distance was                   
observed (Figure 5.9.2.0.6:B. Table 5.9.2.0.7:B. p<0.0001, n=26).
Correlation analysis between fat mass and distance ran showed LTC mice and LTCF mice had                           
a significant negative correlation (Figure 5.9.2.0.6:C. Table 5.9.2.0.7:C. LTC: p=0.0021; LTCF:                   
p=0.0052, n=6­7/group). Again, no significant correlation was observed in LTFC mice or LTF                       
mice between fat mass and distance ran (Figure 5.9.2.0.6:C. Table 5.9.2.0.7:C. n=6­7/group).                     
With all mice grouped together, a significant negative correlation was observed between fat                       
mass and running distance (Figure 5.9.2.0.6:C. Table 5.9.2.0.7:C. p<0.0001, n=26).
A comparison between percentage fat mass and distance ran showed no significant correlation                       
in LTCF, LTFC or LTF mice (Figure 5.9.2.0.6:D. Table 5.9.2.0.7:D. n=6­7/group). LTC mice                       
showed a significant negative correlation between percentage fat mass and distance ran (Figure                       
5.9.2.0.6:D. Table 5.9.2.0.7:D. p=0.001, n=7). Again, when correlating percentage fat mass and                     




Figure {5.9.2.0.6} The effect of three weight cycles on correlation between distance ran                       
on a treadmill with lean mass and fat mass
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           
percentage fat mass. Black line represents line of best fit for correlation of all mice, regardless of                               




LTC LTCF LTFC LTF All
Pearson r ­0.06634 ­0.6794 ­0.09969 0.1426 ­0.1986
p value 0.8876 0.1377 0.8316 0.7876 0.3309
R2 0.004401 0.4616 0.009939 0.02033 0.03943
LTC LTCF LTFC LTF All
Pearson r 0.9027 0.6787 ­0.2671 0.3404 0.7538
p value 0.0054 0.1383 0.5626 0.5091 <0.0001
R2 0.8149 0.4606 0.07133 0.1159 0.5682
LTC LTCF LTFC LTF All
Pearson r ­0.934 ­0.9402 0.379 ­0.3642 ­0.7877
p value 0.0021 0.0052 0.4018 0.4778 <0.0001
R2 0.8724 0.8841 0.1436 0.1327 0.6205
LTC LTCF LTFC LTF All
Pearson r ­0.9513 ­0.7633 0.3444 ­0.4563 ­0.7933
p value 0.001 0.0774 0.4493 0.363 <0.0001
R2 0.9049 0.5827 0.1186 0.2083 0.6293
Table {5.9.2.0.7} The effect of three weight cycles on correlation between distance ran                       
on a treadmill with lean mass and fat mass
A) Distance ran correlated with lean mass in grams; B) Distance ran correlated with percentage                           
lean mass; C) Distance ran correlated with fat mass in grams; D) Distance correlated with                           






At the time of blood collection and organ extraction, both HF fed groups FCF mice and FT mice                                 
were significantly heavier compared to CT mice and CFC mice (CT: 29.53 ± 1.53 g; CFC: 30.59                               
± 1.32; FCF: 40.30 ± 1.34 g; FT: 41.20 ± 1.78 g. CT/CFC­FCF/FT: p<0.001, n=8­10/group). No                             
significant differences were observed between CT mice and CFC mice, or between FCF mice                         
and FT mice.
After 12 weeks of HF feeding, fed blood glucose concentration was significantly higher between                         
CT mice and FCF mice (Figure 5.10.1.0.1:A. Table 5.10.1.0.6. p<0.05, n=8­10/group). Similarly,                     
FCF mice had a higher blood glucose concentration compared to CFC and FT mice, although                           
this was not a significant difference (Figure 5.10.1.0.1:A. Table 5.10.1.0.6. n=8­10/group).
Fed blood ketone concentration was noticeably higher in FT mice compared to other groups, but                           
again these differences were not significant (Figure 5.10.1.0.1:B. Table 5.10.1.0.6.                 
n=8­10/group).
Figure {5.10.1.0.1} The effect of a single weight cycle on blood glucose and β­ketone                         
concentration
A) Blood glucose concentration; B) Blood β­ketone concentration. Blood samples were taken                     
from mice were in a fed a state using a commercially available glucose meter. Data presented                             




Both HF fed groups, FCF and FT, showed a significantly higher leptin and resistin plasma                           
concentration compared to both control fed groups, CT and CFC (Figure 5.10.1.0.2:A,B. Table                       
5.10.1.0.6. Leptin: CT/CFC­FCF/FT: p<0.001. Resistin: CT­FCF/FT: p<0.01; CFC­FCF/FT:             
p<0.001. n=8­10/group).
Figure {5.10.1.0.2} The effect of a single weight cycle on plasma leptin and resistin                         
concentration




FT mice had a significantly higher insulin plasma concentration compared to CT and CFC mice                           
(Figure 5.10.1.0.3:A. Table 5.10.1.0.6. CT­FT: p<0.001; CFC­FT: p<0.05. n=8­10/group). FCF                 
mice showed a decreased insulin plasma concentration compared to FT mice, although this                       
was not significant (Figure 5.10.1.0.3:A. Table 5.10.1.0.6. n=8­10/group). However, FCF showed                   
a significantly higher insulin plasma concentration compared to CT mice and a trend compared                         
to CFC mice (Figure 5.10.1.0.3:A. Table 5.10.1.0.6. CT­FCF: p<0.05. n=8­10/group). CFC mice                     
showed a trend towards an increased insulin plasma concentration compared to CT mice, but                         
did not reach significance (Figure 5.10.1.0.3:A. Table 5.10.1.0.6. n=8­10/group).
C­peptide plasma concentration showed an increased trend with increased HFD exposure.                   
However, only FT mice showed an increased plasma c­peptide concentration compared to CT                       
mice (Figure 5.10.1.0.3:B. Table 5.10.1.0.6. p<0.01. n=8­10/group).
GIP plasma concentration was significantly higher in FT mice compared to CT mice (Figure                         
5.10.1.0.3:C. Table 5.10.1.0.6. p<0.001, n=8­10/group). Interestingly, FCF mice showed a                 
significantly lower GIP plasma concentration compared to FT mice, whilst CFC mice showed a                         




Figure {5.10.1.0.3} The effect of a single weight cycle on plasma insulin, c­peptide and                         
GIP concentration
A) Insulin; B) c­peptide; C) GIP. Data presented as mean ± sem. n=8­10/group. * p<0.05, **                             




No significant difference in glucagon plasma concentration was observed between groups                   
(Figure 5.10.1.0.4:A. Table 5.10.1.0.6. n=8­10/group).
CT mice showed a significantly higher ghrelin plasma concentration compared to all other                       
groups (Figure 5.10.1.0.4:B. Table 5.10.1.0:6. CT­CFC: p<0.01; CT­FCF/FT: p<0.001).
Figure {5.10.1.0.4} The effect of a single weight cycle on plasma glucagon and ghrelin                         
concentration




IL­6 plasma concentration was significantly higher in CT mice compared to CFC mice (Figure                         
5.10.1.0.5:A. Table 5.10.1.0.6. p<0.05, n=5­8/group). Similarly, IL­6 plasma concentration was                 
higher in CT mice compared to FCF and FT mice, although this trend was not significant (Figure                               
5.10.1.0.5:A. Table 5.10.1.0.6. n=5­8/group).
CT mice also showed a significantly higher MCP­1 plasma concentration compared to FT mice                         
(Figure 5.10.1.0.5:B. Table 5.10.1.0.6. p<0.05, n=5­8/group). A trend was also observed showing                     
a higher MCP­1 plasma concentration in CT mice compared to CFC and FCF mice. Similarly,                           
CFC mice showed a higher MCP­1 plasma concentration compared to FCF and FT mice,                         
although this was not significant. This indicated increased exposure to control diet increased                       
MCP­1 plasma concentration.
TNF­A plasma concentration was not significantly different between groups. CFC mice showed                     





A) Interleukin 6 (IL­6); B) monocyte chemoattractant protein­1(MCP­1); C) tumour necrosis                   




CT CFC FCF FT
Glucose 8.79 ± 0.48 9.58 ± 0.71 11.53 ± 0.48 9.80 ± 0.76
β­ketone 0.33 ± 0.07 0.29 ± 0.03 0.31 ± 0.03 0.40 ± 0.06
Leptin 10727 ± 2155 4813 ± 525 30990 ± 3407 30931 ± 2352
Resistin 12839 ± 746 11887 ± 714 26197 ± 1561 21928 ± 2661
Insulin 1185 ± 161 2390 ± 509 3734 ± 917 5053 ± 710
C­peptide 3122 ± 304.2 4060 ± 493.5 4829 ± 491.2 5229 ± 325.7
GIP 48.59 ± 12.81 151.70 ± 26.93 97.63 ± 18.92 181.80 ± 19.23
Glucagon 38.39 ± 8.98 31.00 ± 3.41 51.97 ± 9.38 49.26 ± 8.29
Ghrelin 280.3 ± 18.4 190.1 ± 9.6 151.2 ± 13.6 152.0 ± 18.7
IL­6 33.80 ± 5.07 11.63 ± 1.42 18.88 ± 4.30 19.89 ± 4.65
MCP­1 122.80 ± 32.16 94.61 ± 18.20 64.18 ± 13.07 53.57 ± 4.75
TNF­A 13.78 ± 2.57 21.73 ± 3.82 15.68 ± 3.22 13.15 ± 1.70
Table {5.10.1.0.6} The effect of a single weight cycle on blood and plasma measurements
Blood samples from mice in a fed a state were used to assess blood glucose concentration and                               
blood β­ketone concentration (mmol/L). Plasma samples were used to assess metabolic                   





At the time of blood collection and organ extraction, both HF fed groups LTFC mice and LTF                               
mice were significantly heavier compared to LTC mice and LTCF mice (LTC: 35.10 ± 1.59 g;                             
LTCF: 38.35 ± 1.28 g; LTFC: 45.95 ± 1.60 g; LTF: 46.98 ± 2.07 g. LTC­LTFC/LTF: p<0.001;                               
LTCF­LTFC/LTF: p<0.01, n=8­10/group). No significant differences were observed between CT                 
mice and CFC mice, or between FCF mice and FT mice, although a trend showing an increased                               
body weight in LTCF mice compared to LTC mice was observed.
No significant differences in fed blood glucose concentration was observed between groups after                       
28 weeks of feeding (Figure 5.10.2.0.1:A. Table 5.10.2.0.6. n=8­10/group). A trend was observed                       
showing decreased blood glucose concentration in LTCF mice and LTF mice compared to LTC                         
mice and LTFC mice.
Fed blood ketone concentration was noticeably higher in LTFC mice compared to other groups,                         
but again these differences were not significant (Figure 5.10.2.0.1:B. Table 5.10.2.0.6.                   
n=8­10/group).
Figure {5.10.2.0.1} The effect of a three weight cycles on blood glucose and β­ketone                         
concentration
A) Blood glucose concentration; B) Blood β­ketone concentration. Blood samples were taken                     
from mice were in a fed a state using a commercially available glucose meter. Data presented                             




Both HF fed groups, LTFC and LTF, showed a significantly higher leptin plasma concentration                         
compared to both control fed groups, LTC and LTCF (Figure 5.10.2.0.2:A. Table 5.10.2.0.6.                       
LTC­LTFC/LTF: p<0.001; LTCF­LTFC: p<0.01; LTCF­LTF: p<0.05. n=8­10/group).
LTFC mice showed a significantly higher resistin plasma concentration compared to LTC and                       
LTCF mice (Figure 5.10.2.0.2:A. Table 5.10.2.0.6. LTC­LTFC: p<0.05; LTCF­LTFC: p<0.01.                 
n=8­10/group). LTF mice also showed a trend towards increase resistin plasma concentration                     
compared to both control fed mice, although this difference was not significant (Figure                       
5.10.2.0.2:B. Table 5.10.2.0.6. n=8­10/group). Interestingly, LTFC mice showed a trend towards                   
an increased resistin plasma concentration compared to LTF mice, although this did not reach                         
significance.
Figure {5.10.2.0.2} The effect of three weight cycles on plasma leptin and resistin                       
concentration




Mice feeding on a HFD, LTFC and LTF mice, had a significantly higher insulin plasma                           
concentration compared to control fed mice, LTC and LTCF mice (Figure 5.10.2.0.3:A. Table                       
5.10.2.0.6. LTC­LTFC/LTF: p<0.01; LTCF­LTFC/LTF: p<0.05. n=8­10/group).
C­peptide plasma concentration showed an increased trend with increased HFD exposure.                   
However, only LTF mice showed an increased plasma c­peptide concentration compared to                     
LTC mice (Figure 5.10.2.0.3:B. Table 5.10.2.0.6. p<0.05. n=8­10/group).
GIP plasma concentration was significantly higher in LTFC and LTF mice compared to LTC and                           
LTCF mice, similar to insulin plasma concentration (Figure 5.10.2.0.3:C. Table 5.10.2.0.6.                   
LTC/LTCF­LTFC: p<0.05; LTC/LTCF­LTF: p<0.01, n=8­10/group).
Figure {5.10.2.0.3} The effect of three weight cycles on plasma insulin, c­peptide and GIP                         
concentration
A) Insulin; B) c­peptide; C) GIP. Data presented as mean ± sem. n=8­10/group. * p<0.05, **                             




No significant difference in glucagon plasma concentration was observed between groups                   
(Figure 5.10.2.0.4:A. Table 5.10.2.0.6. n=8­10/group).
LTC and LTCF mice showed a significantly higher ghrelin plasma concentration compared to                       
LTF mice (Figure 5.10.2.0.4:B. Table 5.10.2.0.6. LTC/LTCF: p<0.05. n=8­10/group). Similarly,                 
both control­fed groups showed an increased ghrelin plasma concentration compared to LTFC                     
mice, although this did not reach significance (Figure 5.10.2.0.4:B. Table 5.10.2.0.6.                   
n=8­10/group).
Figure {5.10.2.0.4} The effect of three weight cycles on plasma glucagon and ghrelin                       
concentration




IL­6 plasma concentration was significantly higher in LTC mice compared to all other groups                         
(Figure 5.10.2.0.5:A. Table 5.10.2.0.6. LTC­LTCF/LTFC: p<0.001; LTC­LTF: p<0.01,             
n=5­8/group).
No significant differences in MCP­1 plasma concentration was observed between groups (Figure                     
5.10.2.0.5:B. Table 5.10.2.0.6. n=5­8/group).
TNF­A plasma concentration was not significantly different between groups. However, a                   
decreased trend was observed with increased exposure to HFD (Figure 5.10.2.0.5:B. Table                     
5.10.2.0.6. n=5­8/group)
Figure {5.10.2.0.5} The effect of three weight cycles on plasma cytokines concentration
A) Interleukin 6 (IL­6); B) monocyte chemoattractant protein­1(MCP­1); C) tumour necrosis                   




LTC LTCF LTFC LTF
Glucose 10.53 ± 0.63 9.30 ± 0.59 10.59 ± 0.49 9.78 ± 0.24
β­ketone  0.29 ± 0.07 0.32 ± 0.03 0.41 ± 0.04 0.31 ± 0.04
Leptin 18970 ± 4044 25794 ± 3246 44342 ± 3947 40062 ± 2446
Resistin 12231 ± 2298 11239 ± 1334 18569 ± 1075 15934 ± 1098
Insulin 1612 ± 296 2484 ± 941 5805 ± 741 5718 ± 876
C­peptide 3141 ± 260.4 3026 ± 361.3 4244 ± 205.1 4447 ± 407.6
GIP 90.63 ± 23.22 96.54 ± 14.47 219.20 ± 34.71 249.32 ± 44.22
Glucagon 40.97 ± 10.90 41.41 ± 8.25 45.36 ± 6.66 51.87 ± 10.81
Ghrelin 212.4 ± 23.8 230.6 ± 15.0 167.3 ± 24.1 123.2 ± 24.7
IL­6 34.74 ± 2.34 14.54 ± 3.37 14.67 ± 2.22 20.17 ± 3.00
MCP­1 48.64 ± 8.01 42.46 ± 7.28 42.14 ± 3.95 57.07 ± 10.09
TNF­A 17.34 ± 4.99 12.66 ± 4.03 12.23 ± 1.57 9.66 ± 1.58
Table {5.10.2.0.6} The effect of three weight cycles on blood and plasma measurements
Blood samples from mice in a fed a state were used to assess blood glucose concentration and                               
blood β­ketone concentration (mmol/L). Plasma samples were used to assess metabolic                   






After 12 weeks of HF feeding, FT mice had significantly more brown adipose tissue (BAT) and a                               
heavier liver compared to CT mice (Figure 5.11.1.0.2:A,B. Table 5.11.1.0.1. BAT: p<0.05. Liver:                       
p<0.01, n=8­10/group). A trend was observed showing an increase in pancreas weight in FT                         
mice compared to CT mice (Figure 5.11.1.0.2:C. Table 5.11.1.0.1. n=8­10/group).
CFC mice showed significantly lower liver weight compared to FT mice (Figure 5.11.1.0.2:B.                       
Table 5.11.1.0.1. p<0.01, n=8­10/group). Kidney weight was also significantly lower in CFC mice                       
compared to FCF mice (Figure 5.11.1.0.2:D. Table 5.11.1.0.1. n=8­10/group). No significant                   
differences in organ weight were observed between CFC and CT mice (Figure 5.11.1.0.2:A­F.                       
Table 5.11.1.0.1. n=8­10/group).
FCF mice had significantly more BAT compared to CT mice (Figure 5.11.1.0.2:A. Table                       
5.11.1.0.1. p<0.05, n=8­10/group). Kidney weight was significantly increased in comparison to                   
CT mice (Figure 5.11.1.0.2:D. Table 5.11.1.0.1. p<0.01, n=8­10/group). Similar to FT mice, FCF                       
mice showed a trend towards an increase in pancreas weight compared to CT and CFC mice                             
(Figure 5.11.1.0.2:C. Table 5.11.1.0.1. n=8­10/group). FCF mice showed a trend towards a                     
lower liver weight compared to FT mice, although this was not significant (Figure 5.11.1.0.2:B.                         
Table 5.11.1.0.1. n=8­10/group). No significant differences were observed between FCF mice                   
and FT mice for any of the organs measured.
Between all groups, no significant differences were observed in pancreas, heart and muscle                       
tissue (Figure 5.11.1.0.2:C,E,F. Table 5.11.1.0.1. n=8­10/group). As noted above, trends were                   





A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             




CT (g) CFC (g) FCF (g) FT (g)
BAT 0.1735 ± 0.0150 0.2047 ± 0.0278 0.2964 ± 0.0200 0.2895 ± 0.0324
Liver 1.3322 ± 0.0427 1.3941 ± 0.0684 1.6490 ± 0.0921 2.0291 ± 0.1917
Pancreas 0.1687 ± 0.0183 0.2036 ± 0.0236 0.2547 ± 0.0263 0.2352 ± 0.0237
Kidneys 0.3269 ± 0.0214 0.3300 ± 0.0125 0.4089 ± 0.0167 0.3718 ± 0.0141
Heart 0.1452 ± 0.0104 0.1408 ± 0.0048 0.1566 ± 0.0069 0.1557 ± 0.0065
Muscle 0.5140 ± 0.0394 0.4865 ± 0.0597 0.4724 ± 0.0476 0.5581 ± 0.0538
Table {5.11.1.0.2} The effect of a single weight cycle on organ weight




When normalised to body weight, FT mice showed no significant difference compared to CT                         
mice in BAT or liver weight (Figure 5.11.1.0.4:A,B. Table 5.11.1.0.3. n=8­10/group). Similarly, no                       
noticeable trend was observed in pancreas weight (Figure 5.11.1.0.4:C. Table 5.11.1.0.3.                   
n=8­10/group). FT mice showed significantly lower kidney and heart weight as a percentage of                         
body weight compared to CT mice (Figure 5.11.1.0.4:D,E. Table 5.11.1.0.3. Kidney: p<0.01.                     
Heart: p<0.001, n=8­10/group). A trend showing a decrease in muscle normalised to body                       
weight was also observed in FT mice compared to CT mice (Figure 5.11.1.0.4:F. Table                         
5.11.1.0.3. n=8­10/group).
CFC mice showed no significant difference compared to CT mice when for any organ                         
normalised to body weight (Figure 5.11.1.0.4:A­F. Table 5.11.10..3. n=8­10/group). In                 
comparison to FT mice, CFC mice showed a significantly higher kidney and heart as a                           
percentage of body weight (Figure 5.11.1.0.4:D,E. Table 5.11.1.0.3. Kidney: p<0.05. Heart:                   
p<0.001, n=8­10/group).
No significant difference was seen between FCF mice and any other group in BAT, liver,                           
pancreas or kidney as a percentage of body weight (Figure 5.11.1.0.4:C,D. Table 5.11.1.0.3.                       
n=8­10/group). A trend showing reduced kidney percentage was observed in FCF mice                     
compared to CT mice. Similar to FT mice, FCF mice a significantly reduced heart percentage                           
compared to CT and CFC mice (Figure 5.11.1.0.4:E. Table 5.11.1.0.3. n=8­10/group). towards                     
an increase in pancreas weight compared to CT and CFC mice (Figure 5.11.1.0.4:C. Table                         
5.11.1.0.3. n=8­10/group).
There was no significant difference in muscle as a percentage of body weight (Figure                         




Figure {5.11.1.0.3} The effect of a single weight cycle on organ weight as a percentage of                             
body weight
A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             
weight in grams normalised to body weight in grams. Data presented as mean ± sem.                           




CT (%) CFC (%) FCF (%) FT (%)
BAT 0.651 ± 0.057 0.675 ± 0.093 0.745 ± 0.063 0.711 ± 0.079
Liver 4.602 ± 0.152 4.589 ± 0.233 4.097 ± 0.185 4.880 ± 0.315
Pancreas 0.604 ± 0.041 0.673 ± 0.079 0.629 ± 0.062 0.569 ± 0.052
Kidneys 1.124 ± 0.044 1.088 ± 0.045 1.015 ± 0.029 0.911 ± 0.041
Heart 0.501 ± 0.010 0.464 ± 0.016 0.388 ± 0.010 0.379 ± 0.010
Muscle 1.722 ± 0.127 1.595 ± 0.189 1.196 ± 0.144 1.371 ± 0.138
Table {5.11.1.0.4} The effect of a single weight cycle on organ weight as a percentage of                             
body weight





After 28 weeks of HF feeding, no significant difference was observed between LTF mice and                           
LTC mice in BAT tissue (Figure 5.11.2.0.2:A. Table 5.11.2.0.1. n=8­10/group). Liver and kidney                       
weight was significantly increased in LTF mice compared to LTC mice (Figure 5.11.2.0.2:B,D.                       
Table 5.11.2.0.1. p<0.001, n=8­10/group). A trend was observed showing a reduced muscle                     
weight in LTF mice compared to LTC mice (Figure 5.11.2.0.2:F. Table 5.11.2.0.1. n=8­10/group).                       
No significant differences were observed in pancreas or heart weight between LTC and LTF                         
mice (Figure 5.11.2.0.2:C,E. Table 5.11.2.0.1. n=8­10/group).
LTCF mice showed significantly lower liver weight compared to LTFC and LTF mice (Figure                         
5.11.2.0.2:B. Table 5.11.2.0.1. LTCF­LTFC: p<0.001. LTCF­LTF: p<0.001, n=8­10/group).             
Similarly, a trend was also apparent showing a lower kidney weight in LTCF mice compared to                             
LTFC and LTF mice (Figure 5.11.2.0.2:D. Table 5.11.2.0.1. n=8­10/group). No significant                   
differences were observed in pancreas or heart weight in LTCF mice compared to any other                           
group (Figure 5.11.2.0.2:C,E. Table 5.11.2.0.1. n=8­10/group). Muscle weight was lower in LTCF                     
mice compared to LTC and LTFC mice, although this difference was not significant (Figure                         
5.11.2.0.2:F. Table 5.11.2.0.1. n=8­10/group).
LTFC mice showed a trend towards an increase in BAT compared to all other groups (Figure                             
5.11.2.0.2:A. Table 5.11.2.0.1. n=8­10/group). Similar to LTF mice, LTFC mice showed a                     
significantly higher liver weight compared to LTC and LTCF mice (Figure 5.11.2.0.2:B. Table                       
5.11.2.0.1. Both p<0.01, n=8­10/group). However, LTFC mice still had significantly lighter livers                     
compared to LTF mice (Figure 5.11.2.0.2:B. Table 5.11.2.0.1. p<0.01, n=8­10/group). Kidney                   
weight was also significantly increased in comparison to LTC mice, and a trend was also                           
apparent compared to LTCF mice (Figure 5.11.2.0.2:D. Table 5.11.2.0.1. p<0.05, n=8­10/group).                   
No significant differences were observed in LTFC mice compared to other groups in pancreas or                           
heart weight (Figure 5.11.2.0.2:C,E. Table 5.11.2.0.1. n=8­10/group). Muscle weight in LTFC                   





A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             




LTC (g) LTCF (g) LTFC (g) LTF (g)
BAT 0.4295 ± 0.0562 0.3799 ± 0.0324 0.4921 ± 0.0840 0.4222 ± 0.0212
Liver 1.6561 ± 0.0846 1.8420 ± 0.1096 2.5041 ± 0.1124 3.1734 ± 0.2123
Pancreas 0.2528 ± 0.0191 0.2802 ± 0.0120 0.2901 ± 0.0129 0.3021 ± 0.0140
Kidneys 0.3586 ± 0.0156 0.3974 ± 0.0121 0.4506 ± 0.0134 0.4692 ± 0.0327
Heart 0.1504 ± 0.0067 0.1516 ± 0.0053 0.1645 ± 0.0046 0.1695 ± 0.0111
Muscle 0.5859 ± 0.0790 0.4772 ± 0.0471 0.5968 ± 0.0575 0.5244 ± 0.0349
Figure {5.11.2.0.2} The effect of three weight cycles on organ weight




No significant difference was observed between LTF mice and LTC mice in BAT tissue, however                           
an observable trend showed LTF mice had less BAT as a percentage of the body compared to                               
LTC mice (Figure 5.11.2.0.4:A. Table 5.11.2.0.3. n=8­10/group). Similarly, muscle weight as a                     
percentage of body weight was significantly reduced in LTF mice compared to LTC mice (Figure                           
5.11.2.0.4:F. Table 5.11.2.0.3. p<0.05, n=8­10/group). No significant differences were observed                 
between LTF and LTC mice in pancreas, kidney or heart weight as a percentage of body weight,                               
although a slight decrease in pancreas and heart weight was observed in LTF mice (Figure                           
5.11.2.0.4:C,D,E. Table 5.11.2.0.3. n=8­10/group). Liver weight as a percentage of body weight                     
was still significantly higher in LTF mice compared to LTC mice (Figure 5.11.2.0.4:B. Table                         
5.11.2.0.3. p<0.001, n=8­10/group).
LTCF mice showed significantly lower percentage liver weight compared to LTF mice (Figure                       
5.11.2.0.4:B. Table 5.11.2.0.3. p<0.001, n=8­10/group). A noticeable decrease in BAT and                   
muscle weight as a percentage of body weight was observed in LTCF mice compared to LTC,                             
showing a comparable measurement to LTF mice (Figure 5.11.2.0.4:A. Table 5.11.2.0.3.                   
n=8­10/group). As with LTF mice, there was a slight decrease in pancreas and heart weight as a                               
percentage of body weight in LTCF mice compared to LTC mice (Figure 5.11.2.0.4:C,E. Table                         
5.11.2.0.3. n=8­10/group).
LTFC mice showed similar BAT percentage compared to LTC, which was was slightly higher                         
compared to both LTCF and LTF mice (Figure 5.11.2.0.4:A. Table 5.11.2.0.3. n=8­10/group).                     
LTF mice had a significantly higher liver weight as a percentage of body weight compared to                             
LTFC mice, wihch was a similar measurement compared to LTC and LTCF mice (Figure                         
5.11.2.0.4:B. Table 5.11.2.0.3. p<0.01, n=8­10/group). No trend was observed in kidney weight                     
compared to all groups (Figure 5.11.2.0.4:D. Table 5.11.2.0.3. n=8­10/group). Similar to LTF                     
mice, LTFC mice showed a slight decrease in pancreas and heart weight as a percentage of                             
body weight (Figure 5.11.2.0.4:C,E. Table 5.11.2.0.3. n=8­10/group). As shown with LTCF mice                     




LTC (%) LTCF (%) LTFC (%) LTF (%)
BAT 1.21 ± 0.12 0.99 ± 0.07 1.10 ± 0.02 0.92 ± 0.07
Liver 4.74 ± 0.21 4.80 ± 0.22 5.47 ± 0.22 6.74 ± 0.31
Pancreas 0.73 ± 0.06 0.73 ± 0.04 0.64 ± 0.03 0.65 ± 0.04
Kidneys 1.02 ± 0.03 1.04 ± 0.02 0.99 ± 0.10 1.01 ± 0.06
Heart 0.43 ± 0.02 0.40 ± 0.02 0.36 ± 0.01 0.36 ± 0.02
Muscle 1.65 ± 0.20 1.24 ± 0.11 1.28 ± 0.09 1.13 ± 0.08
Table {5.11.2.0.3} The effect of three weight cycles on organ weight as a percentage of                           
body weight




Figure {5.11.2.0.4} The effect of three weight cycles on organ weight as a percentage of                           
body weight
A) Brown adipose tissue (BAT); B) liver; C) pancreas; D) kidneys; E) heart; F) muscle. Organ                             
weight in grams normalised to body weight in grams. Data presented as mean ± sem.                           










After 12 weeks of HF feeding, FT mice had significantly more total WAT compared to CT mice                               
and CFC mice (Figure 5.12.1.0.1:A. Table 5.12.1.0.4:A. Both p<0.001, n=8­10/group). Similarly,                   
FCF mice had significantly more total WAT compared to both CT and CFC mice (Figure                           
5.12.1.0.1:A. Table 5.12.1.0.4:A. Both p<0.001, n=8­10/group). No significant differences were                 
observed between CT mice and CFC mice, or between FCF mice and FT mice (Figure                           
5.12.1.0.1:A. Table 5.12.1.0.4:A. n=8­10/group).
These significant differences remained when total WAT was normalised to body weight (Figure                       
5.12.1.0.1:B. Table 5.12.1.0.4:B. All p<0.001, n=8­10/group).
Figure {5.12.1.0.1} The effect of a single weight cycle on total WAT mass
A) Total white adipose tissue (WAT) in grams; B) Total WAT as a percentage of body weight.                               




A comparison of each WAT depot showed FT mice had significantly more WAT in                         
subcutaneous, internal, retroperitoneal and mesenteric depots compared to CT mice (Figure                   
5.12.1.0.2:A,C,D. Table 5.12.1.0.4:A. All p<0.001, n=8­10/group). However, FT mice did not have                     
significantly more epididymal WAT compared to CT, although a slight trend was observed                       
(Figure 5.12.1.0.2:B. Table 5.12.1.0.4:A. n=8­10/group).
Similar to CT mice, CFC mice had significantly less WAT compared to FT mice in                           
subcutaneous, internal, retroperitoneal and mesenteric depots (Figure 5.12.1.0.2:A­D. Table               
5.12.1.0.4:A. All p<0.001, n=8­10/group). In addition, FCF mice also showed significantly more                     
epididymal WAT compared to CFC mice, as well as the other WAT depots (Figure                         
5.12.1.0.2:A­E. Table 5.12.1.0.4:A. All p<0.001, n=8­10/group). No difference in WAT weight was                     
observed in CFC mice compared to CT mice in any of the WAT depots measured (Figure                             
5.12.1.0.2:A­E. Table 5.12.1.0.4:A. n=8­10/group).
FCF mice had significantly more WAT in all depots, including epididymal, compared to CT mice                           
(Figure 5.12.1.0.2:A­E. Table 5.12.1.0.4:A. All p<0.001, n=8­10/group). Retroperitoneal and               
mesenteric WAT was comparable between FCF mice and FT mice (Figure 5.12.1.0.2:C,D.                     
Table 5.12.1.0.4:A. n=8­10/group). However, FCF mice showed a significantly higher epididymal                   
WAT weight compared to FT mice (Figure 5.12.1.0.2:C. Table 5.12.1.0.4:A. p<0.01,                   
n=8­10/group). A trend was also observed showing a lower subcutaneous weight in FCF mice                         
compared to FT mice (Figure 5.12.1.0.2:A. Table 5.12.1.0.4:A. n=8­10/group). A trend was also                       
observed showing increased internal WAT compared to FT mice (Figure 5.12.1.0.2:B. Table                     
5.12.1.0.4:A).
When each WAT depot mass was normalised to body weight, the differences observed between                         
groups comparing WAT mass by depot remained (Figure 5.12.1.0.3:A­E. Table 5.12.1.0.4:B.                   





A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. WAT measured in grams. Data presented as mean ± sem. n=8­10/group. **                         




Figure {5.12.1.0.3} The effect of a single weight cycle on WAT mass as a percentage of                             
body weight
A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
Mesenteric WAT. WAT normalised to body weight (%). Data presented as mean ± sem.                         




CT (g) CFC (g) FCF (g) FT (g)
Total WAT 2.8690 ± 0.3868 3.1381 ± 0.3967 7.7874 ± 0.2917 7.7192 ± 0.4546
Sub WAT 1.2612 ± 0.1867 1.5983 ± 0.2003 3.5472 ± 0.0874 4.2891 ± 0.2597
Int WAT 1.4682 ± 0.1928 1.5390 ± 0.2005 4.2423 ± 0.2323 3.4311 ± 0.2339
Epi WAT 0.8845 ± 0.1165 0.9069 ± 0.1002 2.2910 ± 0.2005 1.4781 ± 0.1677
Ret WAT 0.2601 ± 0.0361 0.2794 ± 0.0565 0.7970 ± 0.0665 0.8080 ± 0.0699
Mes WAT 0.3230 ± 0.0492 0.3532 ± 0.0572 1.1520 ± 0.0789 1.1430 ± 0.1108
CT (%) CFC (%) FCF (%) FT (%)
Total WAT 10.03 ± 1.27 10.14 ± 0.98 19.32 ± 0.29 18.67 ± 0.54
Sub WAT 4.87 ± 0.66 5.17 ± 0.51 8.85 ± 0.27 10.39 ± 0.38
Int WAT 5.16 ± 0.67 4.97 ± 0.49 10.47 ± 0.27 8.28 ± 0.35
Epi WAT 3.10 ± 0.38 2.93 ± 0.21 5.62 ± 0.37 3.59 ± 0.39
Ret WAT 0.92 ± 0.13 0.90 ± 0.16 1.96 ± 0.12 1.94 ± 0.10
Mes WAT 1.14 ± 0.18 1.15 ± 0.16 2.89 ± 0.22 2.75 ± 0.19
Figure {5.12.1.0.4} The effect of a single weight cycle on WAT mass
A) WAT measured in grams; B) WAT weight normalised to body weight (%). Data presented as                             




CT mice and FCF mice showed a significantly bigger internal:subcutaneous ratio compared to                       
FT mice (Figure 5.12.1.0.5. CT: 1.076 ± 0.103; FCF: 1.194 ± 0.054; FT: 0.805 ± 0.047. CT­FT:                               
p<0.05; FCF­FT: p<0.001, n=8­10/group). This indicates a greater degree of internal adiposity                     
compared to subcutaneous WAT. CFC mice showed a slightly high internal:subcutaneous WAT                     
ratio compared to FT mice, but also showed a slightly lower ratio compared to both CT mice and                                 
FCF mice (Figure 5.12.1.0.5. CFC: 0.980 ± 0.064. n=8­10/group).
Figure {5.12.1.0.5} The effect of a single weight cycle on internal:subcutaneous WAT                     
ratio




Distribution analysis of each WAT depot as a percentage of total WAT showed FT mice had                             
significantly more WAT stored as subcutaneous WAT compared to CT and FCF mice (Figure                         
5.12.1.0.6:A. Table 5.12.1.0.7. CT­FT: p<0.05; FCF­FT: p<0.001, n=8­10/group). CFC mice had                   
did not show a significant difference in subcutaneous WAT compared to CT mice or FT mice,                             
although a clear trend showing CFC mice had less WAT stored subcutaneously compared to FT                           
mice (Figure 5.12.1.0.6:A. Table 5.12.1.0.7. n=8­10/group).
FT mice showed significantly lower epididymal WAT as a percentage of total WAT compared to                           
all other groups (Figure 5.12.1.0.6:B. Table 5.12.1.0.7. CT/CFC­FT: p<0.001; FCF­FT: p<0.01,                   
n=8­10/group). Epididymal WAT as a percentage of total WAT was comparable between CT,                       
CFC and FCF mice (Figure 5.12.1.0.6:B. Table 5.12.1.0.7. n=8­10/group).
No significant differences were observed between groups when assessing retroperitoneal WAT                   
as a percentage of total WAT (Figure 5.12.1.0.6:C. Table 5.12.1.0.7. n=8­10/group). A trend was                         
observed showing FCF nad FT mice had slightly more retroperitoneal WAT compared to CT and                           
CFC mice.
Mesenteric WAT as a percentage of total WAT was significantly higher in FCF mice compared                           
to CFC mice only (Figure 5.12.1.0.6:D. Table 5.12.1.0.7. p<0.05, n=8­10/group). A trend was                       
apparent in FCF mice compared to CT mice showing an increased percentage of mesenteric                         





A) Subcutaneous WAT; B) Epididymal WAT; C) Retroperitoneal WAT D) Mesenteric WAT as a                         




CT (%) CFC (%) FCF (%) FT (%)
Total Sub WAT 49.17 ± 2.13 50.88 ± 1.46 45.81 ± 1.17 55.68 ± 1.38
Total Epi WAT 30.43 ± 0.91 29.82 ± 1.72 29.09 ± 1.80 19.24 ± 2.16
Total Ret WAT 8.85 ± 0.63 8.30 ± 0.87 10.12 ± 0.58 10.44 ± 0.57
Total Mes WAT 11.54 ± 1.13 11.00 ± 1.03 14.98 ± 1.15 14.64 ± 0.78
Table {5.12.1.0.7} The effect of a single weight cycle on WAT distribution





After 28 weeks of HF feeding, LTF mice still had significantly more total WAT compared to LTC                               
mice and LTCF mice (Figure 5.12.2.0.1:A. Table 5.12.2.0.4:A. LTC­LTF: p<0.001. LTCF­LTF:                   
p<0.01, n=8­10/group). Similarly, LTFC mice had significantly more total WAT compared to both                       
LTC and LTCF mice (Figure 5.12.2.0.1:A. Table 5.12.2.0.4:A. Both p<0.001, n=8­10/group). A                     
slight trend was observed in LTCF mice showing an increase total WAT weight compared to                           
LTC mice, although this was not significant (Figure 5.12.2.0.1:A. Table 5.12.2.0.4:A.                   
n=8­10/group). No significant differences were observed between LTFC mice and LTF mice                     
(Figure 5.12.2.0.1:A. Table 5.12.2.0.4:A. n=8­10/group).
When total WAT was normalised to body weight, LTF mice still showed significantly more total                           
WAT compared to LTC mice, although the difference between LTF and LTCF mice was no                           
longer significantly different (Figure 5.12.2.0.1:B. Table 5.12.2.0.4:B. LTC­LTF: p<0.01,               
n=8­10/group). LTFC mice still had significantly more total WAT compared to LTC mice and                         
LTCF mice when weight was normalised to body weight (Figure 5.12.2.0.1:B. Table 5.12.2.0.4:B.                       
Both p<0.001, n=8­10/group). A trend was also apparent showing an increase in total WAT as a                             





A) Total white adipose tissue (WAT) in grams; B) Total WAT as a percentage of body weight.                               




A comparison of each WAT depot showed LTF mice had significantly more WAT in                         
subcutaneous, internal, retroperitoneal and mesenteric depots compared to LTC mice (Figure                   
5.12.2.0.2:A,B,D,E. Table 5.12.2.0.4:A. Sub, Int, Ret WAT: p<0.001; Mes WAT: p<0.01,                   
n=8­10/group). Similar to time point 1, LTF mice did not have significantly different epididymal                         
WAT compared to LTC mice (Figure 5.12.2.0.2:C. Table 5.12.2.0.4:A. n=8­10/group).
Similar to LTF mice, LTCF mice had significantly less WAT compared to FT mice in                           
subcutaneous and retroperitoneal depots (Figure 5.12.2.0.2:A,D. Table 5.12.2.0.4:A. Both               
p<0.001, n=8­10/group). However, mesenteric WAT weight did not differ significantly between                   
LTCF and LTF mice, although a slight trend was observed showing more mesenteric WAT in                           
LTF mice (Figure 5.12.2.0.2:E. Table 5.12.2.0.4:A. n=8­10/group). No significant differences                 
were observed between LTC and LTCF mice for any WAT depot, although trends showing                         
increased WAT in LTCF mice were observed in subcutaneous, retroperitoneal and mesenteric                     
WAT depots (Figure 5.12.2.0.2:A,D,E. Table 5.12.2.0.4:A. n=8­10/group).
LTFC mice had significantly more WAT in subcutaneous, internal, retroperitoneal and                   
mesenteric WAT depots compared to LTC mice (Figure 5.12.2.0.2:A,B,D,E. Table 5.12.2.0.4:A.                   
All p<0.001, n=8­10/group). A trend was also observed showing increase epididymal WAT in                       
LTFC mice compared to LTC mice (Figure 5.12.2.0.2:C. Table 5.12.2.0.4:A. n=8­10/group).                   
These differences were also observed between LTCF and LTFC mice (Figure 5.12.2.0.2:A­E.                     
Table 5.12.2.0.4:A. Sub WAT: p<0.01; Int, Ret and Mes WAT: p<0.001, n=8­10/group). In                       
comparison to LTF mice, LTFC mice showed no significant difference in subcutaneous or                       
retroperitoneal WAT weight (Figure 5.12.2.0.2:A,D. Table 5.12.2.0.4:A. n=8­10/group). However,               
LTFC mice had significantly more epididymal and mesenteric WAT compared to LTF mice                       
(Figure 5.12.2.0.2:C,E. Table 5.12.2.0.4:A. Epi WAT: p<0.05; Mes WAT: p<0.01, n=8­10/group).                   





A) Subcutaneous WAT; B) epididymal WAT; C) retroperitoneal WAT; D) Mesenteric WAT. WAT                       




When each WAT depot mass was normalised to body weight, the differences observed between                         
groups comparing subcutaneous and retroperitoneal WAT weight by depot remained (Figure                   
5.12.2.0.3:A,D,E. Table 5.12.2.0.4:B. Sub WAT: LTC­LTFC/FT: p<0.001; LTCF­LTFC/LTF:             
p<0.05. Ret WAT: LTC/LTCF­LTFC/LTF: p<0.001, n=8­10/group). LTF mice showed               
significantly lower epididymal WAT as a percentage of body weight compared to LTC mice and                           
LTFC mice (Figure 5.12.2.0.3.C. Table 5.12.2.0.4.B. Both p<0.01, n=8­10/group). LTF mice also                     
showed significantly less internal WAT as a percentage of body weight (Figure 5.12.2.0.4:B.                       
Table 5.12.2.0.4.B. p<0.001, n=8­10/group). A trend was also observed showing decreased                   
epididymal WAT in LTF mice compared to LTCF mice. Mesenteric WAT as a percentage of                           




Figure {5.12.2.0.3} The effect of three weight cycles on WAT mass as a percentage of                           
body weight
A) Subcutaneous WAT; B) internal WAT; C) epididymal WAT; D) retroperitoneal WAT; E)                       
mesenteric WAT. WAT normalised to body weight (%). Data presented as mean ± sem.                         




LTC (g) LTCF (g) LTFC (g) LTF (g)
Total WAT 5.0411 ± 0.4362 6.0401 ± 0.2029 8.9154 ± 0.4809 8.3052 ± 0.6502
Sub WAT 2.4571 ± 0.2750 3.2232 ± 0.1268 4.6160 ± 0.2521 4.8081 ± 0.3818
Int WAT 2.5850 ± 0.2096 2.8171 ± 0.1188 4.2990 ± 0.2499 3.4971 ± 0.2801
Epi WAT 1.4210 ± 0.1480 1.3082 ± 0.0957 1.7171 ± 0.1672 1.2031 ± 0.1108
Ret WAT 0.5630 ± 0.0534 0.7615 ± 0.0402 1.2950 ± 0.0563 1.3461 ± 0.1479
Mes WAT 0.6004 ± 0.0489 0.7480 ± 0.0251 1.2880 ± 0.0794 0.9488 ± 0.0673
LTC (%) LTCF (%) LTFC (%) LTF (%)
Total WAT 14.30 ± 0.89 15.77 ± 0.28 19.30 ± 0.49 17.55 ± 0.73
Sub WAT 6.97 ± 0.67 8.43 ± 0.27 10.01 ± 0.31 10.17 ± 0.48
Int WAT 7.33 ± 0.39 7.34 ± 0.19 9.30 ± 0.27 7.38 ± 0.30
Epi WAT 4.03 ± 0.33 3.40 ± 0.21 3.67 ± 0.25 2.54 ± 0.16
Ret WAT 1.59 ± 0.11 1.99 ± 0.09 2.84 ± 0.13 2.82 ± 0.20
Mes WAT 1.70 ± 0.09 1.96 ± 0.05 2.79 ± 0.11 2.02 ± 0.11
Table {5.12.2.0.4} The effect of three weight cycles on WAT mass
A) WAT measured in grams (g); B) WAT weight normalised to body weight (%). Data presented                             




LTC mice had a significantly bigger internal:subcutaneous ratio compared to LTCF mice and                       
LTF mice (Figure 5.12.2.0.5. LTC: 1.097 ± 0.090; LTFC: 0.881 ± 0.041; LTF: 0.731 ± 0.024.                             
LTC­LTCF: p<0.05; LTC­LTF: p<0.001, n=8­10/group). LTF mice showed the lowest                 
internal:subcutaneous WAT ratio out of all groups, also showing a significantly lower ratio                       
compared to LTFC mice (Figure 5.12.2.0.5. LTFC: 0.934 ± 0.030. p<0.05, n=8­10/group). A                       
trend was also observed showing LTF mice had a lower ratio compared to LTCF mice (Figure                             
5.12.2.0.5. n=8­10/group).
Figure {5.12.2.0.5} The effect of three weight cycles on internal:subcutaneous WAT ratio




Distribution analysis of each WAT depot as a percentage of total WAT showed LTF mice had                             
significantly more WAT stored as subcutaneous WAT compared to LTC and LTFC mice (Figure                         
5.12.2.0.6:A. Table 5.12.2.0.7. LTC­LTF: p<0.001; LTFC­LTF: p<0.01, n=8­10/group). A trend                 
was also observed showing LTCF mice had lower a lower percentage of WAT stored as                           
subcutaneous WAT compared to LTF mice (Figure 5.12.2.0.6:A. Table 5.12.2.0.7.                 
n=8­10/group). However, LTCF mice showed a significantly higher percentage of subcutaneous                   
WAT compared to LTC mice (Figure 5.12.2.0.6:A. Table 5.12.2.0.7. p<0.05, n=8­10/group).
LTC mice showed the highest proportion of epididymal WAT compared to all other groups                         
(Figure 5.12.2.0.6:B. Table 5.12.2.0.7. LTC­LTCF: p<0.01; LTC­LTFC/LTF: p<0.001,             
n=8­10/group). LTF mice also had significantly less epididymal WAT compared to LTCF mice,                       
whilst a trend was observed showing reduced epididymal WAT compared to LTFC mice (Figure                         
5.12.2.0.6:B. Table 5.12.2.0.7. n=8­10/group). In general, the longer the mice spent feeding on                       
HFD, the lower the proportion of WAT was stored as epididymal WAT.
LTF mice showed a significantly higher proportion of retroperitoneal WAT compared to LTC                       
mice and LTCF mice (Figure 5.12.2.0.6:C. Table 5.12.2.0.7. LTC­LTF: p<0.001; LTCF­LTF:                   
p<0.05, n=8­10/group). LTFC mice also had significantly more retroperitoneal WAT compared to                     
LTC mice, and a trend was observed showing increased retroperitoneal WAT in LTFC mice                         
compared to LTCF mice. Similar to epididymal WAT distribution, a trend was observed in                         
retroperitoneal WAT distribution according the length of time spent feeding on a HFD, although                         
this was a positive trend. (Figure 5.12.2.0.6:C. Table 5.12.2.0.7. n=8­10/group).
Mesenteric WAT as a percentage of total WAT was significantly higher in LTFC mice compared                           
to all other groups (Figure 5.12.2.0.6:D. Table 5.12.2.0.7. LTC­LTFC: p<0.01; LTCF­LTFC:                   
p<0.05; LTFC­LTF: p<0.001, n=8­10/group). No noticeable differences in mesenteric WAT                 





A) Subcutaneous WAT; B) Epididymal WAT; C) Retroperitoneal WAT D) Mesenteric WAT as a                         
percentage of total WAT (%) . Data presented as mean ± sem. n=8­10/group. * p<0.05, **                   




LTC (%) LTCF (%) LTFC (%) LTF (%)
Sub WAT 48.24 ± 2.18 53.39 ± 1.17 51.82 ± 0.77 57.87 ± 0.82
Epi WAT 28.61 ± 2.22 21.57 ± 1.32 18.90 ± 1.05 14.49 ± 0.75
Ret WAT 11.19 ± 0.52 12.61 ± 0.55 14.85 ± 0.90 16.00 ± 0.77
Mes WAT 11.97 ± 0.33 12.43 ± 0.35 14.43 ± 0.35 11.65 ± 0.70
Table {5.12.2.0.7} The effect of three weight cycles on WAT distribution






In this thesis I investigated the phenotypic and central neural changes in a murine model                           
associated with rapid (1 week) and prolonged (4­6 weeks) weight change, as well as weight                           
cycling. Phenotypic assessment included body weight, food intake, body composition, glucose                   
tolerance, metabolic hormones and energy expenditure. The hypothalamus and reward areas of                     
the brain, including the VTA, NAc and PFC were assessed for changes in homeostatic and                           
dopaminergic gene markers.
Rapid weight change was induced by altering diet composition (10% vs 60% kcal fat), which                           
effectively increased or decreased body weight and calorie intake within one week. Whole body                         
adiposity measurements also showed significant alterations in response to rapid weight change,                     
but no alterations in liver fat were observed. Similarly, no significant changes in glucose                         
tolerance were observed. Metabolic hormones changed in accordance to rapid weight change,                     
including changes in adiposity hormones and insulin­related hormones. Indirect calorimetry                 
showed RER changed in response to changes in dietary fat intake, and a decrease in physical                             
activity was also observed after rapid weight change. A forced exercise experiment showed                       
rapid weight change altered stamina.
Significant changes in orexigenic signalling were observed with rapid weight gain/loss, whilst an                       
increase in anorexigenic signalling was observed with rapid weight gain. Limited changes in                       
dopaminergic signalling were observed with rapid weight gain, whilst rapid weight loss reduced                       
TH and D2R mRNA expression in the VTA, and reduced DAT expression in the NAc and PFC.                               




Similarly, body weight and calorie intake were most altered one week after swapping diets during                           
weight cycling. Changes in calorie intake were present usually 1­2 weeks after altering diet                         
before normalising to a respective control level. Body weight changes matched respective                     
controls within 1­4 weeks of swapping diets. With weight cycling, whole body adiposity showed                         
current diet heavily influenced adiposity, with a residual effect of previous HF feeding in weight                           
loss mice. However, weight cycled mice did not show the same level of liver adiposity as chronic                               
HF fed mice, although total adiposity was the same. MRI analysis indicated this was due to an                               
increase in internal adiposity. Additionally, prolonged weight loss (6 week interval) showed mice                       
with increased liver fat compared to controls, but this was not observed with shorter weight cycle                             
periods (4 week interval). Initially, chronic HFD induced glucose intolerance (5­12 weeks), which                       
was maintained in FaCFa but not in CFaC weight cycling groups. However, after 18 weeks of                             
feeding, chronic HF mice showed a similar glucose tolerance compared to controls, and by 27                           
weeks of HFD no differences were observed between groups, regardless of diet or weight                         
cycling. Metabolic hormones changed according to current HF feeding, including changes in                     
adiposity hormones and insulin­related hormones, although weight cycled mice showed lower                   
plasma insulin concentration. No changes in indirect calorimetry or exercise were observed with                       
weight cycling, with current diet being the dominant effect on calorimetry measurements.
Weight cycling had no effect on homeostatic gene expression (NPY, AgRP, POMC), but this                         
may have been confounded by age, as chronic HF mice showed a progressive decrease in                           
signalling over time. Differences in VTA dopaminergic gene expression were observed with                     
weight cycling. This included decreased TH, D2R and DAT mRNA expression compared to                       
chronic HF fed mice, but reduced D1R expression compared to controls. Both weight cycled                         
mice showed increased COMT expression compared to control and chronic HF mice. No                       
differences in dopaminergic gene expression were observed in the hypothalamus or NAc.                     
Increased D2R mRNA expression was observed in the PFC of weight cycled mice compared to                           





Previous work has shown weight loss induced by swapping to a low calorie diet without                           
additional restriction leads to a significant decrease in body weight within one week [MacLean et                           
al., 2004]. Furthermore, MacLean et al. reported a decrease in energy intake after swapping to a                             
normal fat diet. A high calorie diet has been shown to increase weight gain within 24 hours,                               
which is persistent through to 21 days [Bjursell et al., 2007]. This was in part due to an increase                                   
in feeding efficiency. Interestingly, acute HFD increased calorie intake within 24 hours, but was                         
reduced from 2 days to a week, before normalising to a chow level from 2­3 weeks after initial                                 
HF feeding.
Swapping to a high calorie diet increases total fat mass within 1 day and persists with chronic                               
feeding, although no changes in lean mass were observed [Bjursell et al., 2007]. In humans, it                             
has been reported that an increase in calorie intake due to glucose or fructose supplementation                           
was sufficient to increase fat content in the liver within 7 days [Sock et al., 2010]. Weight loss                                 
induced by changing to a normal fat diet showed a decrease in fat mass after two weeks                               
[MacLean et al., 2004]. A human study showed that weight reduction through low calorie diet                           
significantly reduced liver triglycerides [Browning et al., 2011]. short­term HFD in healthy humans                       
has been reported to increase fasting hepatic glucose production, but showed no changes in                         
overall glucose tolerance [Brøns et al., 2009; Jiang et al., 2009]. Other studies have shown a                             
decrease in glucose tolerance with short­term HFD, with one study reporting changes in as little                           
as 56 hours [Pehleman et al., 2005; Numao et al., 2012; Winzell & Ahrén, 2004]. Changes in                               
metabolic hormones, including adiponectin, leptin, GIP and GLP­1 have also been observed with                       
short­term HFD [Brøns et al., 2009; Bjursell et al., 2007; Numao et al., 2012]. Both fasting and                               
short­term low fat diet after HF feeding showed an increase in ghrelin concentration and a                           
decrease in PYY concentration [Huang et al., 2008; Li et al., 2011]. Control diet feeding in a                               
murine model of DIO reported a nonsignificant decrease in glucose intolerance after                     
approximately 3 weeks of normal fat diet feeding compared to chronic HFD, whilst the addition of                             
calorie restriction was sufficient to significantly improve glucose tolerance [Briggs et al., 2013].                       
Moreover, acute moderate weight loss in obese humans showed no effect on glucose tolerance                         
[Joseph et al., 2001]. Apoptosis induced in adipose tissue showed a rapid improvement in                         
glucose tolerance, indicating the rate at which fat content can be reduced may limit changes in                             
glucose homeostasis [Kim et al,. 2012].
Limited data is available regarding the effect of weight change and locomotor activity. Bjursell et                           
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al. reported locomotor activity to decreased with high calorie feeding in mice within 72 hours of                             
feeding, which was also observed at 7 days and 21 days of feeding. This was found to correlate                                 
with a decrease in energy expenditure [Bjursell et al., 2007]. A rapid change in respiratory                           
exchange ratio (RER) was shown in response to HFD or chow diet [Bjursell et al., 2007; Bruss                               
et al., 2010].
In response to an energy deficit, an increase in orexigenic signalling and a decrease in                           
anorexigenic signalling is observed in the hypothalamus, which is particularly pronounced after                     
an acute change, such as fasting [Bjursell et al., 2007; Mizuno et al., 1999]. Acute exposure to                               
palatable food increases dopamine signalling in the brain [Hajnal et al., 2002; Liang et al., 2006;                             
Avena et al., 2006]. However, the responses of dopaminergic signalling is less well                       
characterised in response to short­term changes in diet. One study showed no effect of                         
short­term HFD exposure on dopamine release or receptor gene expression in the                     
hypothalamus [de Leeuw van Weenen et al., 2009]. Similarly, no difference in dopamine                       
concentration was detected after 48 hours of high calorie diet in any reward areas [Bjursell et al.,                               
2007].
Previous studies have reported weight cycling both hinders future weight loss and has no effects                           
[Brownell et al., 1986; Mason et al., 2012]. A study by List et al. showed weight cycled mice                                 
repeatedly increased and decreased calorie intake according to HFD or control diet feeding,                       
respectively [List et al., 2012]. In particular, calorie intake during normal fat feeding was lower                           
compared to chronic control mice. There have been mixed results reported on the effects of                           
weight cycling on adiposity and body composition. Some of these studies show changes in                         
percentage lean mass or an increase in visceral adiposity [Keys et al., 1950; Rodin et al., 1990;                               
Guagnano et al., 1999; Guagnano et al., 2000; Byrne et al., 2003; Wallner et al., 2004; Lee et al.,                                   
2010; Beavers et al., 2011]. However, a large number of studies have shown weight cycling has                             
no effect on adiposity or fat distribution [Gray et al., 1988; Jebb et al., 1991; Hainer et al., 1992;                                   
Prentice et al 1992; Wadden et al., 1992; van der Kooy et al., 1993; Rebuffé­Serive et al., 1994;                                 
Wadden et al., 1996; Zamboni et al., 1996; Heitmann et al., 2002; Lien et al., 2009;                             
Bosy­Westphal et al., 2013; Mason et al, 2013]. HFD has been shown to increase liver fat, which                               
can be reduced by weight loss and reduces the incidence of steatosis [Sato et al., 2007; Vitola et                                 




No effect on glucose tolerance has been observed as a result of reported weight cycling in a                               
human study [Podar et al., 1996]. Similarly, no effect has been reported on glucose tolerance                           
and metabolic hormones in weight cycled mice beyond those corresponding to the changes in                         
fat content of the current diet [List et al., 2012]. Although a decrease in glucose tolerance is                               
generally associated with HFD, studies have shown chronic HFD shows a paradoxical                     
improvement in glucose tolerance compared to short/mid­term HFD [Sumiyoshi et al., 2006].
Previous work has shown weight cycling does not have an effect on RER [Wadden et al., 1996].                               
However, weight cycling may be a result of changes in energy efficiency after weight loss which                             
encourages weight regain [MacLean et al., 2004; MacLean et al., 2006; MacLean et al., 2009].
Few studies have been conducted assessing the long­term effects of weight cycling on neural                         
appetite control, although changes in neural signalling in response to weight loss and weight gain                           
have been assessed. Previous studies have shown that acute feeding studies (weight gain/loss)                       
lead to significant changes in hypothalamic signalling [Sainsbury & Zhang, 2010]. However, with                       
chronic HFD, some of these changes are disrupted [Stricker­Krongrad et al., 1998; Lin et al.,                           
2000; Kohsaka et al., 2007; Bouret et al., 2008; Briggs et al., 2010]. This has been suggested to                                 
be in part a result of resistance of these neurons to external signals, such as leptin or ghrelin                                 
[White et al., 2009; Briggs et al., 2010]. With regards to changes in dopamine signalling, a large                               
number of studies have assessed the effects of chronic HFD and DIO [Huang et al., 2005;                             
Huang et al., 2006; Geiger et al., 2009; Vucetic et al., 2012]. Many of these studies, both clinical                                 
and preclinical, show obesity is associated with a decrease in dopaminergic signalling in reward                         
areas, building on the premise that obesity in part is due to a “reward deficit” [Kenny, 2011;                               
Ziauddeen et al., 2012]. Similarly, food deprivation has been shown to reduce dopamine release                         





In my current study I chose 4 and 6 weeks weight changing periods, as this would be sufficient                                 
to induce significant changes in body weight. Previous work has reported that simply swapping                         
diets from a HFD to a normal fat diet is an extremely successful method for returning animals to                                 
a control level after 8 and 16 weeks of feeding in C57Bl/6 mice [Barbosa­da­Silva et al., 2012;                               
Parekh et al., 1998]. However, Guo et al. showed that 7 weeks of HFD was sufficient to maintain                                 
a higher body weight for a further 12 weeks compared to control mice after weight loss induced                               
by swapping to a chow diet, indicating long periods of HF feeding can impinge on future weight                               
loss [Guo et al., 2009]. It is important to note that a variable between obesity­related experiments                             
is the age at which the animals starts feeding. Whilst Guo et al. started feeding mice at 14                                 
weeks of age, Parekh et al. started feeding mice at 4 weeks of age, and Barbosa­da­Silva et al.                                 
used mice aged 12 weeks of age. The mice used in my study were fed from 8­10 weeks age. I                                     
chose this age as the animals are in ‘early adulthood/adolescent’, to focus on adulthood obesity                           
and avoid potential confounding factors arising from early life programming. Little is known about                         
the potential effects of the starting age of the feeding cycle on the final outcome, since age may                                 
influence metabolic flexibility.
In a study that used a similar paradigm as my 4 week weight cycling experiment, List et al.                                 
reported that 4 week cycles of HFD and chow diet feeding lead to weight cycled mice that fail to                                   
attain the body weight observed in chronic HF fed mice. This occurred during the first weight                             
cycle of my experiment, but weight cycled mice began to catch up in body weight compared to                               
chronic HF fed animals in the subsequent two cycles (See Section 5.1). Interestingly, weight                         
cycled animals with a feeding interval of 6 weeks showed sufficient weight recovery to match                           
chronic HF fed mice within 2 weeks (See Section 4.1). This could be because after 4 weeks of                                 
feeding, animals were still at the steepest part of weight gain, whilst by week 6 of HFD, the mice                                   
were closer to the plateau of weight gain. It should also be noted that mice were fed from 4                                   
weeks of age, which is a period of rapid growth, regardless of diet. With no “moving target”,                               
weight regain in cycled mice reaches a chronic HF level in a shorter period of time. With regards                                 
to weight loss, cycled mice (both 4 and 6 week cycle intervals) achieved significant weight loss                             
compared to chronic control fed mice, although body weight was slightly elevated after three                         




My results show that changes in calorie intake increased upon HF feeding, and usually                         
normalised after one week. Upon normal fat feeding, mice previously fed a HFD showed a                           
significant decrease in calorie intake compared to control mice. This occurred repeatedly with                       
weight cycling, although the difference in calorie intake reduced with repetition. These findings                       
are similar to those presented by List et al., although their results indicated no changes in calorie                               
intake between HF fed mice and weight cycled mice when feeding on a HFD. This may be in part                                   
because their data was not normalised to body weight, so does not take into account the relative                               
increase in calorie intake compared to body weight. My data was normalised to body weight                           
raised to the power 0.75, commonly known as the “metabolic body mass” [Tschöp et al., 2011].                             
Furthermore, my results also show that swapping to a HFD increased feeding efficiency (FE)                         
compared to both control and chronic HF fed mice, whilst swapping to a control diet reduced FE                               
compared to control and chronic HF fed mice. Barbosa­da­Silva et al. have found that HFD                           
increased FE, whilst control diet decreased FE, but FE was not significantly different between                         
weight cycled mice and their respective control group [Barbosa­da­Silva et al., 2012]. However,                       
the swap period for my weight cycling experiment was smaller compared to their study, which                           
was a 2 month cycle period. A longer period of weight maintenance may be responsible for                             
alteration in FE.
{6.4} The Effects of Weight Cycling on Fat Content and Body                   
Composition
Studies assessing the effect of weight cycling on adiposity and fat distribution have produced                         
mixed results. Fat distribution has been shown to be altered by weight cycling [Keys et al., 1950;                               
Reed et al., 1988; Rodin et al., 1990; Jen et al., 1995; Ernsberger et al., 1996; Guagnano et al.,                                   
1999; Guagnano et al., 2000; Sea et al., 2000; Byrne et al., 2003; Wallner et al., 2004; Lee et al.,                                     
2010; Beavers et al., 2011]. Similarly, studies looking at changes in fat distribution have reported                           
no change with weight cycling [Gray et al., 1988; Graham et al., 1990; Wheeler et al., 1990; Jebb                                 
et al., 1991; Hainer et al., 1992; Prentice et al 1992; Wadden et al., 1992; van der Kooy et al.,                                     
1993; Rebuffé­Serive et al., 1994; Lu et al., 1995; Lim et al., 1996; Wadden et al., 1996; Zamboni                                 
et al., 1996; Chen et al., 1997; Lauer et al., 1999; Pellizzon et al., 2000; Heitmann et al., 2002;                                   
Lien et al., 2009; Bosy­Westphal et al., 2013; Mason et al, 2013].
In my weight cycling studies no alteration in total fat content were observed, although residual                           
effects of HF feeding were observed after weight loss. Weight cycling did lead to altered fat                             
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distribution, whereby weight cycling increased internal adiposity compared to chronic HFD. This                     
is in agreement with some of the published human studies [Rodin et al., 1990; Wallner et al.,                               
2004; Mason et al., 2013]. It should be noted that many of these studies assessed the effects of                                 
a reported history of weight cycling, rather than a controlled weight cycling intervention, so it is                             
difficult to determine the extent and period of cycling that any of these cohorts may have                             
undertaken [Rodin et al., 1990; Wadden et al., 1992; Rebuffé­Serive et al., 1994; Guagnano et                           
al., 1999; Guagnano et al., 2000; Wallner et al., 2004; Lee et al., 2010; Mason et al., 2013]. Many                                   
animal studies on the other hand have not reported changes in fat distribution, which is similar to                               
a large number of clinical studies [Brownell et al., 1986; Hill et al., 1987; Gray et al., 1988; Hill et                                     
al., 1987; Hill et al., 1988; Graham et al., 1990; Wheeler et al., 1990; Lu et al., 1995; Lauer et al.,                                       
1999; Pellizzon et al., 2000]. This discrepancy may be a result of study design. This is highly                               
variable in clinical trials, many of which assess differences based on reported weight cycling                         
history, whilst intervention studies vary in type of diet, length of intervention, follow up period, and                             
if any exercise is used in conjunction with the diet change [Keys et al., 1950; Jebb et al., 1991;                                   
Hainer et al., 1992; van der Kooy et al., 1993; Wadden et al., 1996; Zamboni et al., 1996; Byrne et                                     
al., 2003; Lien et al., 2009; Beavers et al., 2011; Bosy­Westphal et al., 2013]. Similarly, study                             
design varied between animal studies. For example, a number of studies did not have fixed                           
periods of cycling, instead diet was swapped when animals reached a certain weight or lost a                             
certain percentage of body weight [Brownell et al., 1986; Gray et al., 1988; Jen et al., 1995; Lu et                                   
al., 1995]. This means there was no period of weight maintenance, but a constant change in                             
weight, both gain and loss. Another confounding issue when comparing between animal diet                       
studies is the types of diets used to induce weight gain, discussed in more detail below (Section                               
6.8).
Ideally, excess fat is stored as subcutaneous white adipose tissue. However, a large excess will                           
overcome the maximal capacity for fat storage in subcutaneous depots and “overflow”, leading                       
to an increase in internal adipose depots, such as the retroperitoneal or mesenteric depots. A                           
further increase can lead to fat deposition in internal organs (ectopic fat), such as the muscle or                               
liver [McLaughlin et al., 2007; Kursawe et al., 2010; Carobbio et al., 2011]. Increased internal and                             
ectopic fat is associated with metabolic syndrome [Bjørndal et al., 2011; Perseghin, 2011; Byrne,                         
2012]. Previous studies have shown fat depots respond differently to an energy deficit and                         
indicate a preferential loss of fat from visceral depots compared to subcutaneous stores [Palou                         
et al., 2009; Palou et al., 2010; Singh et al., 2012]. This may also indicate a difference in depot                                   
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flexibility in response to large fluctuations in circulating fatty acids, either in response to                         
consumption of a diet with a very high fat content or a swap to a severe reduction in dietary fat                                     
intake [Bjørndal et al., 2011]. In my study, chronic HFD lead to the progression of fat deposition in                                 
adipose tissue, both external and internal fat, and fat in the liver. However weight cycling                           
prevented fat accumulation in the liver, with no significant effect on total fat. Moreover, the rapid                             
increase in fat maximally fills subcutaneous depots with the excess being stored in the internal                           
cavity. Strikingly, this resulted in an increase in internal adiposity, but a lower liver fat content.                             
This is probably due to continuous exposure to fat being required to induce hepatic lipid                           
accumulation. Interestingly, during the 6 week periods of weight loss, liver fat content did not                           
decrease, although total body fat was reduced. Weight cycling with 4 week cycle intervals                         
showed no difference in liver fat compared to control fed mice. Again chronic HFD significantly                           
increased liver adiposity compared to all other groups. This indicates the length of each cycle                           
could contribute to lipid deposition in the liver. Many studies have shown a decrease in liver fat                               
with weight loss [Colles et al., 2006; Browning et al., 2011; Edholm et al., 2011]. However, few                               
studies have assessed the effects of weight cycling on liver adiposity. Bosy­Westphal et al.                         
observed an increase in liver mass, but did not investigate fat content. However, it was                           
suggested this may not be due to a rise in liver fat, due to a concurrent improvement of glucose                                   
metabolism [Bosy­Westphal et al., 2013]. Weight cycling has been shown to reduce unsaturated                       
fatty acid content in the liver, and shifted the ratio of unsaturated and saturated fatty acids                             
towards increased saturated fatty acids during refeeding after prolonged fasting. However, liver                     
fat content was not assessed [Chen et al., 2005]. Another study which used a lipophilic toxin to                               
assess changes in fat distribution upon fasting and refeeding showed an increase in toxin                         
accumulation with fasting and refeeding, which suggests increased liver fat deposition with                     
weight cycling. This was confirmed by extracting liver fat in vitro [Jandacek et al., 2005].                           
Jandacek et al. induced weight cycling by a 55% reduction in calorie intake from ad libitum                             
access to a 40% kcal fat diet with a cycle period of 5 days after an initial 15 day period of HF                                         
feeding. In contrast, my study induced weight cycling by swapping from a 60% kcal fat diet to a                                 
10% kcal fat diet.
One reason for a lack of change in liver adiposity upon weight loss in 6 week cycled mice could                                   
be a result of rapid breakdown of WAT, resulting in an increase in circulating triglycerides. These                             
are used for metabolism to provide energy, given the sudden development of a large energy                           
deficit. In some instances, this release of triglycerides may exceed the body's capacity to rapidly                           
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metabolise the fatty acids, leading to an excess. As the liver is a site of major β­oxidation, much                                 
of the excess fatty acids could accumulate in the liver, leading to an increase in liver triglyceride                               
content. This is observed with acute energy deficit, during fasting between 6­24 hours [Lin 2005;                           
Nishikawa 2008; Palou et al., 2008]. However, due to the extremely large concentration of                         
circulating fatty acids, a large amount of fat may accumulate in the liver and a percentage of this                                 
may remain during weight maintenance. Surprisingly this does not occur with my weight cycled                         
mice with a shorter cycling interval (4 weeks), as the energy deficit is smaller due to the animal                                 
having a lesser degree of obesity compared to the longer feeding interval. This could lead to a                               
lower concentration of circulating fatty acids, which the liver is more able to metabolise and                           
attenuates the increase in liver fat. This ability to remove circulating fatty acids and liver fat may                               
decrease over time, as mice weight cycled three times with a 4 week cycle interval showed a                               
trend towards an increase in liver fat compared to controls.
An increase in internal adiposity as opposed to liver adiposity may only occur when there are                             
large energy deficits. This was induced in my experiment using a very HFD which causes rapid                             
weight gain and can be attributed to an increase in fat mass. A large negative energy balance                               
was induced by swapping to a lower calorie, normal fat diet. Additionally, even with ad libitum                             
access to this diet, calorie intake was significantly reduced even compared to control fed mice.                           
These large fluctuations in energy state may have altered fat metabolism differentially in fat                         
depots, whereby subcutaneous WAT has a fixed maximum capacity, leading to excess fat being                         
stored elsewhere. As fat accumulation in the liver requires longer exposure to HFD before fat                           
accumulates in the organ, the excess fat is stored in the internal adipose depot, thereby weight                             
cycling increases internal adiposity, but prevents lipid accumulation in the liver.
{6.5} The Effects of Weight Cycling on Glucose Tolerance and                 
Metabolic Hormones
Studies have previously shown a decrease in glucose tolerance with obesity and HFD [Winzell,                         
M. S., & Ahrén, 2004]. This has commonly been associated with visceral and ectopic adiposity,                           
particularly in the liver [Gabriely et al., 2002; Kirchhoff et al., 2007]. However, numerous                         
phenotypic responses to a HFD are observed within C57Bl/6 mice, including lean but diabetic                         
mice or lipodystrophic models [Burcelin et al., 2002; Asterholm et al., 2007]. My results show a                             
significant decrease in glucose tolerance in the absence of changes in liver adiposity after 5­6                           
weeks of HFD. Additionally, all of these mice showed an increase in total, subcutaneous and                           
internal WAT, and an increase internal:subcutaneous WAT ratio. This suggests internal adiposity                     
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may be an independent risk factor for reduced glucose tolerance. However, the                     
internal:subcutaneous WAT ratio does not always correlate with decreased glucose tolerance.                   
For example, as shown in Section 4.7.2, CFa mice have an increased internal:subcutaneous                       
WAT ratio whilst FaFa mice do not, but both groups showed a decrease in glucose tolerance.                             
Interestingly FaFa mice show a higher liver adiposity compared to all other groups, suggesting                         
an increase in adiposity in either depot may modulate glucose intolerance.
As mentioned above, the results obtained from the present study show mice fed a HFD for 12                               
weeks have decreased glucose tolerance compared to control mice, but by 18 weeks of feeding,                           
glucose tolerance was similar between these groups. However, weight cycled mice ending on                       
weight gain (FaCFa) showed a significantly decreased glucose tolerance compared to all                     
groups, even though the total amount of time feeding on a HFD was shorter than chronic HF fed                                 
mice. Sumiyoshi et al. has previously shown that chronic HFD in mice decreased glucose                         
tolerance after 10 weeks of HFD, but normalised to control fed levels after 30 and 55 weeks                               
[Sumiyoshi et al., 2006]. Additionally, this difference in glucose tolerance did not appear to be an                             
effect of age in these mice, similar to the control mice presented in my experiments. This study                               
also showed a high sucrose diet caused persistent glucose intolerance, suggesting the                     
macronutrient composition of the diet could influence glucose tolerance, and is not solely                       
determined by weight gain. Again, this indicates the importance of the type of diet used for                             
obesity experiments. In direct comparison to my weight cycling experiment, List et al. showed                         
after 8 weight cycles with each feeding interval lasting 4 weeks, significant differences in glucose                           
tolerance were still observed whereby HF fed mice showed a decrease in glucose tolerance                         
compared to control fed mice, regardless of weight cycling. This experiment also used a 60% fat                             
diet with C57Bl/6, but control animals were fed a chow diet rather than a purified control diet.                               
Additionally, animals were fed from 4 weeks of age. Although body weight measurements of                         
control mice in their study were similar to those observed in my experiment, whole body                           
adiposity (as assessed using EchoMRI) was higher in my mice at 27 weeks of feeding (29.6%                             
vs 12.6% fat). Adiposity between HF fed mice was comparable (my experiment: 38.6%; List et                           
al.: 39.3%). Differences between these studies may arise from the fact that the control groups                           
were fed slightly different diets. List et a.l used a chow diet as a ‘control’ diet, whilst I used a                                     
purified control diet that matched in composition to other macronutrients in the HFD. Differences                         
in glycemic index, due to the presence of resistant starch present in fibre, are known to influence                               
fat deposition and glucose tolerance, even if body weights are comparable [Liljeberg et al., 1999;                           
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Nilsson et al., 2008; So et al., 2007]. This may explain the differences in body composition and                               
glucose tolerance between studies, despite similar body weight. Another study assessing a                     
single weight cycle in C57Bl/6 mice, where a single cycle period of 2 months was used, showed                               
weight cycled mice returned to a chow diet had reduced glucose tolerance compared to chronic                           
chow fed mice [Barbosa­da­Silva et al., 2012]. This could indicate the length of HFD feeding and                             
cycle time may determine whether a dysfunctional metabolism can be recovered. Both studies                       
showed chronic HF fed mice were still glucose intolerant compared to control fed mice, whilst no                             
difference in glucose tolerance was observed in my experiment from 18 weeks onwards of HF                           
feeding compared to controls. Again, Barbosa­da­Silva et al. also used a chow diet as a control,                             
rather than a purified control diet.
Another possible confounding factor that may help to explain differences between my results and                         
those showing rapid changes in glucose tolerance with HF feeding may be related to the fasting                             
time for the glucose tolerance test. For example, no difference was detected with one week of                             
HF feeding in my experiment, whilst others have demonstrated a significant decrease in glucose                         
tolerance within one week/9­10 days of 60% fat diet feeding [Winzell & Ahrén, 2004; Raher et al.,                               
2008]. In both of these studies, a much reduced fasting time was used before the glucose                             
tolerance test (4­6 hours) compared to my study (overnight fast, 16­18 hours). An evaluation of                           
the glucose tolerance test assessing the different variables within the protocol showed a fasting                         
time of 6 hours produces a larger difference in glucose tolerance compared to an extended                           
fasting period [Andrikopoulos et al., 2008]. In fact, 8 weeks of HFD showed no effect on glucose                               
tolerance after an overnight fast (18 hours), whilst a 6 hour fast showed a significant decrease in                               
glucose tolerance. Additionally, List et al. conducted a glucose tolerance test after a 12 hour fast,                             
rather than 16­18 hour fast, whilst Barbosa­da­Silva et al. only fasted mice for 6 hours, indicating                             
fasting length could also contribute towards the difference in results.
Metabolic hormones in plasma were assessed in fed mice at the end of their respective feeding                             
periods. Although the results from the glucose tolerance tests did not always indicate changes in                           
glucose tolerance as a result of HFD, alterations in hormones associated with glucose                       
homeostasis were observed. A significant decrease in insulin, C­peptide and GIP was observed                       
after 1 week of weight loss, whilst one week of weight gain significantly increased C­peptide                           
plasma concentration, and a trend in insulin concentration was also observed. Similarly,                     
circulating insulin, C­peptide and GIP varied according to diet, indicating these hormones                     
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fluctuate with changes in fat mass. These fluctuations have also been observed previously [List                         
et al., 2012]. Both internal and liver fat have been shown to contribute to insulin resistance,                             
although liver fat may have a bigger influence on insulin sensitivity [Stefan et al., 2008; Fabbrini et                               
al., 2009; Kantartzis et al., 2010; Neeland et al., 2012]. No difference in insulin or associated                             
hormones were observed between weight cycled mice on a HFD and chronic HF fed mice,                           
which may not be expected if insulin resistance is more associated with internal adiposity or liver                             
adiposity. Weight cycled mice showed increased internal adiposity, whilst chronic HF mice                     
showed increased liver fat. Perhaps because the degree of fat deposition in each area was very                             
large, this was sufficient to induce hyperinsulinemia in both groups.
A previous study has shown a correlation between leptin and resistin with insulin resistance, with                           
the strongest relationship between leptin and insulin resistance [Silha et al., 2003]. Another study                         
showed no relationship between resistin and insulin resistance, which was also unaffected by                       
leptin [Lee et al., 2003]. Although the relationship between leptin and obesity is well documented,                           
disagreement over the alterations in resistin concentration in response to obesity still exists,                       
even though resistin was originally identified as a hormone which induced insulin resistance                       
[Steppan et al., 2001; Burcelin., 2008; Gharibeh et al., 2010; Schwartz et al., 2011]. My results                             
show both leptin and resistin plasma concentration changes according to fat mass, with no                         
additional effect of weight cycling. This is in agreement with List et al., where plasma hormones                             
were assessed after 8 weight cycles, indicating this pattern of expression is still dependent on                           
the diet being consumed at the time of assessment [List et al., 2012]. In addition, resistin is                               
classified as an inflammatory adipokine [Rondinone, 2006]. A previous study assessing single                     
weight cycling on adipokine expression showed no effect of weight cycling on circulating leptin                         
and resistin concentration, but observed an increase in other inflammatory adipokines in                     
circulating plasma, such as IL­6, TNF­A and MCP­1 in all mice exposed to a HFD, which                             
persisted with control diet feeding [Barbosa­da­Silva et al., 2012]. However, these results were                       
not observed with multiple weight cycles. In fact, weight cycling appeared to decrease IL­6                         
circulating in the plasma compared to both controls and chronic HF fed mice [List et al 2012]. My                                 
results also showed a single weight cycle and three weight cycles decreased circulating IL­6                         
when cycled at 4 week intervals compared to control mice. TNF­A was increased after a single                             




Consistently, HFD reduced the circulating concentration of active ghrelin in the plasma,                     
regardless of weight cycling. My results agree with previous results showing obesity reduces                       
circulating ghrelin concentration [Tschöp et al., 2001; Shiiya et al., 2002]. My results showed no                           
difference in circulating ghrelin with rapid weight change. This is surprising, as weight loss is                           
commonly associated with increased ghrelin release [Hansen et al., 2002; Faraj et al., 2003;                         
Leidy et al., 2004]. A potential reason for the lack of observed change may be due to the fact that                                     
ghrelin plasma levels were assessed in the fed state. Plasma ghrelin is frequently assessed in                           
the fasted state, which increases ghrelin secretion. I assessed plasma ghrelin in the fed state to                             
determine basal circulating ghrelin. It would be interesting to determine ghrelin plasma                     
concentration in weight cycling mice in the fasted state to determine if they are more sensitive to                               
an energy deficit than their control counterparts.
{6.6} The Effects of Weight Cycling on Energy expenditure and                 
Motor Activity
Indirect calorimetry is a useful tool for assessing changes in energy expenditure, by measuring                         
changes in oxygen consumption and carbon dioxide production. Six weeks of HFD lead to a                           
significant increase in energy expenditure, as measured as heat production, compared to control                       
fed mice. However, this only trended at later time points. Importantly, no changes in energy                           
expenditure were observed with weight loss at any time point. Similarly, no significant changes in                           
energy expenditure were observed with weight cycling. No significant differences in energy                     
expenditure were observed with rapid weight gain or loss. Previous work has shown a decrease                           
in energy expenditure and a relative increase in energy efficiency with weight loss, which in turn                             
can drive weight regain [MacLean et al., 2011]. The reason for a lack of change in energy                               
expenditure in my data is unclear, but may be related to the sensitivity of the method used                               
during this study. The method used by MacLean and colleagues account not only for changes in                             
body heat but also for loss of nitrogen in the urine, thereby giving a more accurate assessment                               
of metabolic rate [MacLean et al., 2004]. These measurements also accounted for energy intake                         
adjusted for energy loss through feces, again giving a more accurate assessment of energy                         
expenditure. Unfortunately, the equipment used in my experiments did not allow for collection of                         
urine and feces.
A direct relationship between HFD or obesity on activity has not been well documented, as a                             
decrease in activity is not necessarily a result of obesity, but would contribute to the development                             
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of obesity due to a decrease in energy expenditure. For example, Levine et al. has shown the                               
amount of time spent seated was longer in obese individuals than their lean counterparts, which                           
persisted after weight loss, suggesting reduced physical activity may be a key driving force for                           
weight gain [Levine et al., 2005]. Hormonal signals and neuropeptides of energy status have                         
been shown to alter locomotor activity [Castañeda et al., 2005]. For example, ob/ob mice                         
showed reduced locomotor activity, which contributes to the obese phenotype. Treatment with                     
leptin increased spontaneous motor activity independent of changes in body weight, but                     
decreased food anticipatory activity [Ribeiro et al., 2011]. This suggests resistance to hormonal                       
signals, such as leptin, insulin or ghrelin not only reduces their effect on food intake, but also                               
physical activity. Furthermore, mice exposed to a western diet showed reduced locomotor                     
activity and this reduction in physical activity largely contributed to early weight gain [Bjursell et                           
al., 2008]. Similarly, 7 and 19 weeks of HFD reduced ambulatory activity [Guo et al., 2009].                             
However, Brownlow et al. showed no change in motor activity as a result of one month of HFD                                 
[Brownlow et al., 1996]. Calorie restriction on the other hand has previously been shown to                           
increase physical activity, which could be part of a food seeking behaviour [Chen et al., 2005].                             
Another study suggested that the effect of weight loss on physical activity is a relative decline in                               
non­resting energy expenditure, as the physical activity required to move the body becomes less                         
energy intensive as the total body weight to move is reduced. This effectively reduces energy                           
expenditure and increases energy conservation, and could be viewed as a relative reduction in                         
physical energy expenditure [MacLean et al., 2011].
Weight cycling has previously been shown to have no effect on free­running in rats as assessed                             
with wheel running [Archambault et al., 1989]. My results indicate swapping to both a HFD and                             
control diet decreases free­moving activity, as assessed with infra­red beam crosses. Swapping                     
to a HFD decreased rearing activity, which may be a result of a trend towards a decrease in                                 
water intake. However, swapping to a HFD decreased ambulatory activity, which may be an                         
energy conservation strategy. Differences in ambulatory activity were not observed with weight                     
maintenance. Weight cycling was shown to have no effect of locomotor activity. The greatest                         
difference in locomotor activity was observed in rearing activity, whereby control fed mice                       
showed increased rearing activity compared to HF fed mice, regardless of weight cycling. Again,                         
this may be a result of increased water intake in control fed mice compared to HF fed mice.
There appear to be no studies that have assessed the effects of weight cycling on endurance                             
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capacity. One group has shown short­term HFD significantly reduced endurance capacity in                     
lean rats and humans, with the suggestion HFD increases respiratory uncoupling [Murray et al.,                         
2009; Edwards et al., 2009]. My study showed HFD, regardless of weight cycling, reduced                         
endurance capacity (as assessed with forced exercise on a treadmill), which was assumed to                         
be a result of an increase in fat content. Further work will be needed to assess whether changes                                 






The roles of NPY, AgRP and POMC have been extensively characterised, particularly with                       
regards to the acute effects of feeding. NPY/AgRP neurons stimulate food intake, whilst POMC                         
neurons stimulate satiety and decrease food intake [Sainsbury & Zhang, 2010]. Additionally,                     
these neurons interact with one another to regulate food intake [Hansen et al., 2002]. Two                           
candidate receptors were chosen to assess possible changes in sensitivity of the hypothalamus                       
to external signals. Leptin receptors are abundantly expressed throughout the hypothalamus and                     
have been shown to be expressed in NPY/AgRP and POMC neurons. Leptin stimulates POMC                         
neurons, whilst NPY/AgRP neurons are inhibited by leptin [Cowley et al., 2001; Myers et al.,                           
2008]. Melanocortin 4 receptors (MC4R) are activated by α­MSH, a peptide produced by the                         
cleavage of POMC. These receptors are found predominantly in the hypothalamus and activation                       
of these receptors increases satiety and decreases food intake [Kishi et al, 2003; Garfield et al.,                             
2009].
With rapid weight gain, my results show that HFD significantly reduces NPY and AgRP mRNA                           
expression, whilst significantly increasing POMC mRNA expression. This is expected, as a large                       
increase in calorie intake would activate satiety mechanisms, which aim to reduce food intake.                         
This includes decreasing orexigenic signalling and increasing anorexigenic signalling.               
Ziotopoulou et al. have previously shown a decrease in NPY and AgRP mRNA expression after 2                             
days of HFD, however after 1­2 weeks of HFD, NPY and AgRP expression were no longer                             
significantly altered compared to controls, whilst POMC expression was only increased after 2                       
weeks of HFD [Ziotopoulou et al., 2000]. In contrast, a high calorie western diet, which consisted                             
of 40% fat from milk fat and corn oil, and a mixture of corn starch, sucrose and maltodextrin                                 
reduced NPY and AgRP mRNA expression in the hypothalamus after 48 hours of feeding. This                           
decrease in mRNA expression persisted until 21 days of feeding [Bjursell et al., 2008]. Wang et                             
al. used a HFD with a high saturated fat content and showed a decrease in NPY and AgRP                                 
mRNA expression from 1 week of feeding, but no difference in POMC expression after 1, 7 or 11                                 
weeks [Wang et al., 2002]. This discrepancy may arise from differences in dietary composition,                         
where Ziotopoulou et al. used a 42% fat diet using milk fat as the main source. Wang et al. used                                     
a 58% fat diet using an equal combination of lard and safflower oil. Bjursell et al. used a similar                                   
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diet as Ziotopoulou et al. diet, but the diet also contained corn oil, which may result in a different                                   
effect on hypothalamic gene expression. Although both diets had a high sugar content, the age at                             
which the study started differed. Ziotopoulou et al. fed mice from 3 weeks of age whilst Bjursell et                                 
al. fed mice from 8 weeks of age. This appears to suggest once again that the age of initiation of                                     
the study may have a profound effect on the outcome. Similarly, Giraudo et al. showed that with                               
a 58% fat diet, there was no effect on NPY mRNA expression in the hypothalamus after a week,                                 
whilst a 77% fat diet significantly decreased NPY mRNA expression. However, in this study fat                           
was derived from vegetable shortening [Giraudo et al., 1994]. Demonstration of the effects of                         
HFD on NPY expression in rat hypothalamus showed a decrease in NPY expression was only                           
observed from week 9 onward of feeding, although this “HFD” was only 30% fat, but with added                               
“cafeteria­type” foods, such as cake and noodles [Hansen et al., 2004]. This indicates the                         
importance of diet selection for obesity studies, which is highly variable within the literature and                           
will be discussed below in more detail. Taken together, my findings with those of previous                           
studies show that orexigenic neurotransmitters in the hypothalamus decrease in response to                     
short­term exposure to HFD.
Both LepR and MC4R mRNA expression was increased in the hypothalamus in response to an                           
increase in energy intake in my study, again indicating an increased sensitivity in anorexigenic                         
signalling. However, a number of studies have shown a decrease or no effect in LepR mRNA                             
expression with one week of HFD, again the difference probably being a result of the type of diet                                 
used [Wang et al., 2002; Lin et al., 2000]. Previous studies do however support my findings,                             
showing an increase in MC4R expression in response to HFD exposure in the PVN and VMH                             
[Butler et al., 2001; Archer et al., 2005; Huang et al., 2003a]. This represents an increase in                               
anorexigenic signalling in response to a HFD in order to maintain energy homeostasis, by                         
altering sensitivity to the signal.
My results assessing the effects of rapid weight loss induced by swapping to a control diet after                               
6 weeks of HFD showed an increase in NPY and AgRP mRNA expression, but no change in                               
POMC mRNA expression. No difference in LepR or MC4R mRNA expression was observed. An                         
increase in orexigenic signalling in response to an energy deficit has been observed previously                         
[Sainsbury & Zhang, 2010]. Most studies have also shown a decrease in POMC signalling in                           




The effects of chronic HFD were assessed on hypothalamic signalling. After 6 weeks of HFD,                           
NPY mRNA expression was significantly increased, whilst no significant differences were                   
observed in AgRP or POMC mRNA expression. The increase in NPY mRNA expression could                         
be a result of leptin resistance. At 12 and 18 weeks of HFD no significant alterations in NPY,                                 
AgRP or POMC mRNA expression were observed in the hypothalamus. No changes in either                         
LepR or MC4R mRNA expression were observed at any time point of the experiment. These                           
findings confirm previous studies that have shown feeding on a HFD for 8 weeks onwards                           
decreases NPY content, which tends to decrease with increasing feeding period [Lin et al., 2000;                           
Beck et al., 2006]. However, other studies have shown that DIO animals have increased LepR                           
expression in the hypothalamus, indicating the possible development of leptin resistance in                     
hypothalamic neurons [Huang et al., 2003b; Huang et al., 2004]. Chronic HFD has previously                         
been shown to increase MC4R expression in the VMH [Huang et al., 2003a]. Perhaps no change                             
in MC4R mRNA expression was observed in my study because the whole hypothalamus was                         
assessed, rather than individual nuclei.
In contrast, significant changes were observed in my study with maintained weight loss or weight                           
gain. Maintained weight gain showed a significant decrease in NPY mRNA expression and a                         
trend towards decreased AgRP mRNA expression, indicating a decrease in appetite in response                       
to maintained weight gain. In conjunction with this, an increase in POMC mRNA expression was                           
also observed. This is similar to the rapid swap results presented above, showing a decrease in                             
orexigenic signaling and an increase in anorexigenic signalling.
My results showed maintained weight loss lead to a significant decrease in NPY mRNA                         
expression compared to controls, and a trend compared to chronic HFD mice. A trend showing                           
increased POMC mRNA expression was observed compared to controls, and was significant                     
compared to chronic HFD mice, indicating maintained weight loss decreased appetite. This                     
contrasts to the results presented above showing an increase in orexigenic signalling and                       
seems paradoxical given these animals have undergone a loss of energy. This could be due to                             
habituation to a new set point, where energy demands are controlled to maintain the new weight.                             
Indeed, food intake is initially lower after weight loss but normalises during weight maintenance.                         
There was also a significant increase in LepR mRNA expression in the hypothalamus. Because                         
total hypothalamic activity was assessed, it is unknown which neurons show altered LepR                       
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mRNA expression. Leptin receptors are expressed in all neuronal subtypes in the hypothalamus                       
and have opposing effects in NPY/AgRP and POMC/CART neurons [Cowley et al., 2001; Myers                         
et al., 2008]. In agreement with my results, a previous study has shown an increase in LepR                               
expression with fasting [Mitchell et al., 2009]. Additionally, assessing the effects of fasting in the                           
hypothalamus showed an increase in LepR, which could further be assigned to NPY­expressing                       
neurons, whilst POMC neurons did not show a change in LepR expression in response to                           
fasting [Baskin et al., 1998; Baskin et al., 1999]. In agreement with this, an overexpression of                             
LepR expression in POMC neurons increases the susceptibility to obesity, suggesting a change                       
in LepR mRNA expression in my results are not colocalised with POMC neurons, as these mice                             
have undergone weight loss [Gamber et al., 2012].
After a single weight cycle (6 week intervals), my results showed no difference in homeostatic                           
gene expression between groups. A slight increase in NPY and AgRP mRNA expression was                         
observed in weight cycled mice after weight loss. Chronic HFD has previously been shown to                           
have no effect on NPY or POMC mRNA expression, although a decrease in AgRP mRNA                           
expression was reported [Yu et al., 2009]. Other studies have shown a decrease in NPY                           
expression with prolonged HFD, although no differences were observed between moderate and                     
chronic HFD. A potential explanation for these effects may be related to hormone resistance                         
within these neurons; however hormonal resistance would result in no difference in neuronal                       
signalling compared to controls, rather than a lack of further alterations in neuronal signalling.                         
Previous work has shown resistance to metabolic hormones, including leptin and ghrelin, could                       
contribute to the lack of response to obesity [White et al., 2009; Briggs et al., 2010]. This                               
effectively resets the system to a new “set point”, whereby a deviation from the obese state to                               
the previous “normal” weight is perceived as severe energy deficiency, and contributes to weight                         
regain. Interestingly, results from my single weight cycle, which involves frequent weight                     
fluctuation and could prevent the development of resistance mechanisms associated with                   
chronic feeding, also show no change in homeostatic signalling. This may suggest that                       
regardless of diet or dietary cycling as all groups have increased sufficiently in body weight and                             
have new ‘set­points’ may be triggered in each group, even though they may have significantly                           





Tyrosine hydroxylase (TH) is the rate­limiting enzyme involved in the production of dopamine and                         
TH mRNA is expressed in the midbrain and hypothalamus [Daubner et al., 2011]. D1 and D2                             
receptors are expressed in the hypothalamus and reward areas. DAT, a transporter involved in                         
removing dopamine for the synapse, is also expressed in these areas of the brain and is partly                               
responsible for terminating dopaminergic signalling [Beaulieu & Gainetdinov, 2011; Torres et al.,                     
2003]. DARPP­32 is a downstream intracellular transcription factor within the dopamine                   
signalling pathway [Svenningsson et al., 2000]. COMT is an enzyme involved in the degradation                         
of dopamine and is another mechanism that reduces dopamine signalling [Myöhänen et al.,                       
2010; Tong et al., 2013].
VTA dopamine neurons have been shown to express LepR, and some of these                       
LepR­expressing dopamine neurons project to other reward areas, such as the NAc and PFC                         
[Fulton et al., 2006; Hommel et al., 2006; Morton et al., 2009]. MC4Rs are found predominantly in                               
the hypothalamus, although some studies have shown these receptors are also expressed in                       
the VTA. For example, transgenic overexpression of POMC has been shown to protect against                         
obesity when overexpressed in the VTA [Alvaro et al., 1996; Leriche et al., 2007; Andino et al.,                               
2011].
{6.7.2.1} Hypothalamus
Reports on the role of dopamine signalling within the hypothalamus are inconsistent. Acute                       
peripheral administration of D1 and D2 receptor agonists have been shown to reduce food intake                           
and NPY mRNA expression in the hypothalamus [Kuo et al., 2002]. Similarly, coadministration of                         
dopamine and NPY results in reduced NPY­induced feeding [Gillard et al., 1993]. In contrast,                         
administration of a D1R/D2R agonist in streptozotocin diabetic rats showed an attenuated                     
decrease in food intake and NPY mRNA expression. This response was restored with                       
coadministration of insulin [Kuo et al., 2006]. Closer analysis of changes in dopamine signalling                         
in the hypothalamus shows dopamine has different roles in the VMH and LH. Dopamine levels in                             
the LH increase in response to a meal and normalise upon meal termination [Meguid et al., 1995;                               
Yang et al., 1996]. Both acute and persistent dopamine administration in the LH decreased food                           
intake [Meguid et al., 1995; Yang et al., 1996; Giannakopoulos et al, 1998]. Dopamine release in                             
the LH was higher in obese rats compared to lean rats. This observation has led to the                               
suggestion that a higher threshold level of dopamine concentration has to be reached in order to                             
terminate a meal [Meguid et al., 2000]. The VMH showed a different dopaminergic response                         
compared to the LH, where fasting increased dopamine levels, which decreased upon feeding in                         
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the obese state [Meguid et al., 1997]. Changes in dopamine levels fluctuated with meal size,                           
which suggests the VMH is involved in meal number. Dopamine injection into the VMH increased                           
meal size, but decreased meal number [Meguid et al., 2000].
Studies assessing the effects of HFD on dopaminergic signalling in the hypothalamus also show                         
conflicting results. Chronic HF feeding (12 weeks onwards) has been shown to increase TH and                           
DAT mRNA expression in the hypothalamus [Huang et al., 2005; Lee et al., 2010; Vucetic et al.,                               
2012]. However, another study showed a decrease in TH mRNA expression within the VMH after                           
8 weeks of HF feeding, whilst another study showed 4 weeks of HFD had no effect on                               
dopaminergic signalling in the hypothalamus [Li et al., 2009; de Leeuw van Weenen et al., 2009].                             
Other than differences in the feeding time, there are also differences between age of feeding,                           
with some studies starting soon after weaning and others during mature adulthood [Lee et al.,                           
2010; Vucetic et al., 2012; Li et al., 2009; de Leeuw van Weenen et al., 2009].
Rapid weight gain in my study (1 week of HFD) lead to an increase in DAT mRNA expression                                 
and a trend towards a decrease in TH mRNA expression in the hypothalamus. This indicates a                             
decrease in dopamine signalling, primarily through an increase in dopamine reuptake. This is                       
consistent with the documented decrease in dopamine signalling within the hypothalamus                   
following HFD [Li et al., 2009]. Concurrently, a decrease in orexigenic signalling and an increase                           
in anorexigenic signalling were observed. Together these results suggest that dopamine acts as                       
an anorexigenic signal in the hypothalamus. Rapid weight loss induced by swapping to a control                           
diet for a week (after 6 weeks of HFD) showed a trend towards a decrease in TH mRNA                                 
expression but no other changes in dopaminergic gene expression. As a concurrent significant                       
increase in NPY and AgRP mRNA expression was observed, this suggests dopaminergic                     
signalling within the hypothalamus does not play a dominant role with regards to rapid weight                           
loss.
Previous work has shown that 4 weeks of HFD did not alter dopamine expression, although                           
other markers of obesity were observed, such as insulin resistance [de Leeuw van Weenen et                           
al., 2009]. In my study, 6 weeks of HFD showed an increase in TH mRNA expression and a                                 
decrease in COMT mRNA expression. Additionally, a decrease in DAT mRNA expression was                       
observed, although it did not reach significance. This indicates an increase in dopamine                       
signalling with short­term HFD, but a decrease in dopamine signalling was observed with acute                         
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HFD. Other studies have shown a decrease or no effect in dopamine signalling with HFD [de                             
Leeuw van Weenen et al., 2009]. Previous work has suggested an increase in dopaminergic                         
signalling within the hypothalamus with HFD [Meguid et al., 2000; Vucetic et al., 2012]. A                           
concurrent increase in NPY mRNA expression seems to agree with this suggestion. However,                       
12 and 18 weeks of HFD showed no significant differences in dopaminergic gene expression in                           
the hypothalamus. An increase in COMT mRNA expression was observed although again this                       
did not reach significance. These results would seem to correlate with a lack of change in the                               
homeostatic neuropeptides (with the exception of decreased NPY mRNA expression after 12                     
weeks of feeding), although a lack of change in hypothalamic dopaminergic gene expression                       
does not agree with previous work [Vucetic et al., 2012]. In this instance however, the mice were                               
treated at an earlier age, which may have an impact on the results. A comparable study by                               
Huang et al., using mice aged 12 weeks (adult), showed 20 weeks of HFD lead to dopaminergic                               
changes, however this study only assessed changes in the VMH, whilst in my study I looked at                               
the hypothalamus as a whole. This may have masked regional variation in gene expression                         
[Huang et al., 2005]. Indeed, regional variation in dopaminergic signalling is known to occur, such                           
as the different roles of the LH and VMH in dopamine­related feeding behaviour [Meguid et al.,                             
2010].
Prolonged weight gain, achieved with 6 weeks of HFD after 6 weeks of control diet, showed a                               
significant increase in TH mRNA expression compared to controls and a trend compared to                         
chronic HFD fed mice and prolonged weight loss mice. D2R and COMT mRNA expression was                           
significantly higher compared to chronic HF mice, with a trend observed compared to controls.                         
Prolonged weight loss showed an increase in DARPP­32 mRNA expression compared to                     
chronic HFD mice, and a trend compared to controls and prolonged weight gain mice. Similar to                             
prolonged weight gain, prolonged weight loss mice also showed an increase in COMT mRNA                         
expression compared to chronic HF mice. This suggests prolonged weight gain results in an                         
increase in dopamine signalling which may lead to a compensatory increase in degradation                       
enzymes in order to normalise dopamine signalling. With prolonged weight loss, we observed a                         
surprisingly high expression of downstream transcription factor of dopamine receptor                 
stimulation. However, this appears to take place in the absence of increased dopamine                       
production or increased receptor number and changes in food intake, which would be expected                         
to increase if increased dopamine signalling in the hypothalamus was observed. This change in                         
DARPP­32 mRNA expression could be a result of other changes such as altered BDNF                         
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expression, or changes in other intracellular pathways, such as Akt or CDK5/p53, which in the                           
hypothalamus has been shown to be important in appetite regulation [Ivkovic et al., 1999; Bogush                           
et al., 2007].
A single weight cycle showed no changes in hypothalamic dopaminergic gene expression in                       
mice ending with weight loss or weight gain. Similar to mice fed a HFD for 18 weeks, a trend                                   
showing an increase in COMT mRNA expression was observed compared to control mice.                       
These results match closely with the lack of changes in NPY, AgRP and POMC gene                           
expression, which together results in normalisation of food intake and weight change.
{6.7.2.2} Reward areas
In recent years the “reward deficit” hypothesis has gained support, where obesity is considered                         
to partially arise from a decrease in dopaminergic signalling; mainly a decrease in D2 receptor                           
availability in reward areas, which leads to overeating to compensate. Many studies have                       
assessed the effects of chronic HFD on dopamine signalling in animals, or in established obesity                           
in humans [Vucetic & Reyes, 2010; Kenny, 2011; Ziauddeen et al., 2012]. In my study I assessed                               
the effects of HFD (short, medium and long­term) on dopaminergic gene expression in reward                         
areas (VTA, Nac and PFC). I also assessed the effects of rapid and prolonged weight change on                               
these parameters. At this point, it is worth highlighting that body weights were significantly altered                           
due to diet changes compared to their respective control group, including after only 1 week of                             
feeding.
Rapid weight gain (1 week of HFD) showed no changes in dopaminergic gene expression in the                             
VTA, NAc or PFC. Bjuersell et al. assessed the effects of 48 hours of western diet feeding and                                 
also showed no changes in dopamine levels in the VTA, S.Nigra, NAc or PFC [Bjuersell et al.,                               
2008]. This suggests that dopamine signalling in reward areas does not play a significant role in                             
food intake and body weight gain.
Rapid weight loss (1 week of control diet after 6 weeks of HFD) resulted in a significant decrease                                 
in TH and D2R mRNA expression in the VTA. The observed changes in TH mRNA expression                             
may be a result of a decrease in reward, due to moving from a palatable diet to a non­palatable                                   
diet, which reduced dopamine production. A decrease in D2R may reflect a mechanism to                         
reduce self­inhibition by reducing auto­receptor activity, thus attempting to normalise dopamine                   




Both the NAc and PFC show a decrease in DAT mRNA expression, which was significant in the                               
NAc. Additionally, a decrease in COMT mRNA production was observed in the PFC. This                         
suggests projection areas of dopamine neurons reduce the removal of dopamine, perhaps due                       
to a decrease in TH mRNA expression in the VTA, suggesting a compensatory change in                           
response to reduced dopamine signalling. Together, this suggests decreased reward signalling,                   
resulting from a decrease in TH mRNA expression as a result of switching to a unpalatable diet,                               
as indicated by the decrease food intake. In response, mechanisms to reduce the breakdown of                           
dopamine and self­inhibition are observed. A previous study showed knockdown of DAT results                       
in increased dopamine concentration throughout the brain, which results in increased food intake                       
[Peciña et al., 2003].
My results showed 6 weeks of HFD increased D1R, D2R and DAT mRNA expression in the                             
VTA. However both projection areas, the NAc and PFC, showed a significant decrease in DAT                           
mRNA expression. A decrease in DAT mRNA expression in the NAc and PFC may indicate a                             
compensatory attempt to decrease dopamine release, due to increased DAT mRNA expression                     
in the VTA. In a previous study, VTA levels of dopamine but not NAc levels of dopamine were                                 
shown to be changed in ob/ob mice [Roseberry et al., 2007]. This suggests differential regulation                           
of dopamine in various CNS compartments. After 12 weeks of HFD, my results showed a trend                             
towards a decrease in VTA DAT mRNA expression, whilst 18 weeks of HFD significantly                         
increased DAT mRNA expression in the VTA. Additionally, the VTA showed a significant increase                         
in TH and D2R mRNA expression after 18 weeks of HFD, but not after 12 weeks. This indicates                                 
a possible time dependent response, where 6 and 18 weeks of HFD increased dopaminergic                         
gene expression, whilst 12 weeks of HFD reduced DAT mRNA expression. However, as these                         
genes play different roles within the dopamine signalling pathway, it is difficult to accurately                         
delineate the end result from these changes. For example, increased dopamine receptor                     
expression would indicate an increase in sensitivity in these neurons to dopamine, but a                         
concurrent increase in DAT expression suggests increased removal of dopamine, thereby                   
reducing dopamine signalling. One example of this was shown by Cone et al., whereby 6 weeks                             
of HFD reduced dopamine reuptake, as assessed by fast­scan cyclic voltammetry. This showed                       
an increase in dopamine concentration in the ventral striatum, but no change in DAT protein                           
expression was observed [Cone et al., 2013]. Other techniques would need to be used to                           
produce a more meaningful conclusion of these gene changes, such as immunohistochemistry                     
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or chromatography to assess dopamine peptide levels. No significant changes in dopaminergic                     
gene expression were observed in the NAc or PFC. However, another study assessing the                         
effects of prolonged HFD feeding showed a decrease in D1R and DARPP­32 mRNA expression                         
in the NAc and PFC, suggesting decreased sensitivity to dopamine and a reduction in                         
dopamine­induced activity [Vucetic et al., 2012]
Prolonged weight gain (6 weeks control diet, 6 weeks HFD) showed an increase in DAT mRNA                             
expression in the VTA compared to both control mice and chronic HF fed mice, with no change                               
in TH mRNA expression. A decrease in D1R mRNA expression was observed in the NAc and                             
PFC compared to controls and chronic HF mice. A decrease in PFC D2R mRNA expression                           
was observed compared to chronic HF mice and a trend compared to controls. This contrasts to                             
the lack of change observed above with rapid weight gain. Additionally this contrasts to another                           
study assessing 8 weeks of HFD, showing a decrease in TH mRNA expression in the VTA and                               
S.Nigra [Li et al., 2009]. The increase in DAT expression appears to suggest a decrease in                             
dopaminergic signalling, which may be a compensatory reaction to the HFD in order to reduce                           
further weight gain. The change in D1R and D2R mRNA expression observed appears to                         
confirm this effect by driving the system to a lower reward from the HFD.
Prolonged weight loss (6 weeks HFD, 6 week control diet) resulted in an increase in VTA DAT                               
mRNA expression compared to chronic HF mice, whilst a trend was present compared to                         
controls, with no changes in TH mRNA expression. Similar to prolonged weight gain, a decrease                           
in D1R mRNA expression was observed in the NAc, whilst an increase in DAT mRNA                           
expression was observed compared to controls and a trend compared to chronic HF mice. The                           
PFC also showed these differences in gene expression. Lindblom et al. showed chronic food                         
restriction also increased DAT (and TH) mRNA expression in the VTA, along with a trend                           
showing an increase in D2R mRNA expression. A decrease in D1R and D2R mRNA expression                           
was also reported in the CPu [Lindblom et al., 2006]. South et al. have shown that swapping                               
back to control diet after 20 days of HFD lead to no change in D2R and DAT mRNA expression,                                   
after HFD induced an increase in D2R mRNA in the CPu and the shell of the NAc, but a                                   
decrease in DAT mRNA expression in the CPu [South et al., 2008]. In contrast, swapping to a                               
normal fat diet for 6 weeks after 8 weeks of HFD was shown to increase TH mRNA expression                                 
in the VTA and S.Nigra [Li et al., 2009]. Although a significant decrease in calorie intake took                               
place during the initial phase of the weight loss, this quickly normalised, suggesting a habituation                           
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to the control diet. This habituation coincided with the observed changes in DAT mRNA                         
expression, which have been shown to modulate appetite.
My results showed weight cycling ending with a HFD or a control diet generally showed a similar                               
dopaminergic mRNA expression. Within the VTA, no differences in TH or DAT mRNA expression                         
compared to control mice were observed, whilst mRNA expression was significantly lower                     
compared to chronic HF mice. Both weight cycled mice showed a decrease in VTA D1R mRNA                             
expression compared to controls, which was significantly lower in CFaC mice. Weight cycled                       
mice showed an increase in COMT mRNA expression compared to control mice and chronic HF                           
mice. Differences between weight cycled mice were observed when comparing D2R and                     
DARPP­32 mRNA expression. Weight cycled mice ending with control diet feeding showed an                       
increase in D2R mRNA expression compared to controls and FaCFa mice, but no difference                         
compared to chronic HF mice. Weight cycled mice ending with HFD showed an increase in                           
DARPP­32 mRNA expression compared to chronic HF mice, and a trend compared to control                         
mice and CFaC mice. No clear pattern of response appears to emerge from the weight cycling                             
experiment, probably reflecting the complexity of the reward centre pathways and the need to                         
determine protein expression levels in these brain areas.
My results show rapid weight gain caused no alterations in LepR mRNA expression in the VTA.                             
Rapid weight loss significantly decreased LepR mRNA expression. Previous work has shown                     
leptin reduces the firing rate in dopamine neurons and direct infusion of leptin into the VTA                             
reduces food intake [Hommel et al., 2006; Bruijnzeel et al., 2011]. Furthermore, LepR                       
knockdown in the VTA increased food intake and sensitivity to palatable food [Hommel et al.,                           
2006]. Other studies have shown food restriction increases the reward properties of food and                         
drugs [Fulton et al., 2000; Stuber et al., 2002; Domingos et al., 2011]. The effects of fasting on                                 
dopamine neuron firing and food reward can be reversed with leptin administration, whilst leptin                         
has been shown to reduce conditioned place preference using HFD [Fulton et al., 2000;                         
Domingos et al., 2011; Figlewicz et al., 2004]. Additionally, leptin infusion into the VTA increases                           
the threshold for self­stimulation indicating a reduction in reward perception [Bruijnzeel et al.,                       
2011]. Therefore, it seems a downregulation in LepR during energy deficit would reduce the                         
sensitivity of dopamine neurons to leptin, therefore reduce leptin­induced inhibition of dopamine                     
neurons and enhance the rewarding properties of food and increase food intake. However, my                         
result show a decrease in TH mRNA expression. This is consistent with Leinninger et al.                           
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showing ob/ob mice have decreased TH expression in the VTA [Leinninger et al., 2009]. Perhaps                           
this could be due to the lack of palatability of the control diet. A taste preference test would show                                   
whether there is an increased sensitivity to rewarding foods after weight loss.
I observed no significant changes in VTA LepR mRNA expression after 6 weeks of HFD, whilst a                               
significant decrease in LepR mRNA expression was observed after 12 weeks of HFD. After 18                           
weeks of HFD, a reversal in LepR mRNA expression was seen in the VTA, where a trend of                                 
increased expression was observed. This could indicate the development of a new “set­point” in                         
body weight, whereby chronic HFD more closely resembles LepR gene expression after                     
short­term HFD, compared to mid­term HFD. This could be in part due to the development of                             
leptin resistance, whereby prolonged hyperleptinemia attenuates the neural response to leptin. At                     
12 weeks of HFD, a reduction in LepR mRNA expression may be a mechanism to reduce                             
overstimulation by leptin, which may be ineffective with further leptin exposure and result in a                           
lack of change in LepR mRNA expression. Matheny et al. have previously demonstrated leptin                         
resistance can develop in the VTA, as well as the hypothalamus [Matheny et al., 2011].                           
Additionally, this group also showed overexpression of leptin in the VTA increased STAT3                       
phosphorylation in the VTA and arcuate nucleus, whilst overexpression in the arcuate nucleus                       
did not alter VTA leptin signalling. This indicates leptin signalling in the VTA can also affect                             
signalling in the arcuate nucleus [Scarpace et al., 2012]. However, this study did not assess                           
changes in leptin receptor activity, but rather a downstream factor of leptin signalling to assess                           
the development of leptin resistance. This does not elucidate the mechanisms involved in the                         
development of VTA leptin resistance, such as inhibition of SOCS3 and PTP1B [Reed et al.,                           
2010; White et al., 2009]. Another study showed a decrease in LepR protein expression in the                             
VTA after 6 weeks of HFD, as well as a decrease in TH and DAT expression [Teegarden et al.,                                   
2008]. My results report the opposite change in dopaminergic VTA gene expression, whereby a                         
slight increase in TH mRNA expression and a significant increase in DAT mRNA expression was                           
observed, with no concurrent alteration in LepR mRNA expression.
Prolonged weight gain and loss showed an increase in LepR mRNA expression compared to 12                           
weeks of HFD, whilst a trend was observed compared to control mice. In both cases, this shows                               
a relative higher sensitivity to leptin compared to chronic HFD, which could indicate a                         
compensatory decrease in LepR mRNA expression to reduce overstimulation of these neurons                     
by leptin. Weight cycling, regardless of diet, showed no difference in LepR mRNA expression                         
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compared to control mice, although both groups showed a decreasing trend in LepR mRNA                         
expression. CFaC mice showed a significantly lower LepR mRNA expression compared to                     
chronic HFD and a trend was observed in FaCFa mice.
Having assessed the changes in dopaminergic gene expression, no clear conclusion can be                       
drawn from these results. As discussed in Section 1.2.5.4, Wang et al. reported a negative                           
correlation between BMI and D2R availability in the striatum [Wang et al., 2001]. Many studies                           
have built upon this data to propose the “reward deficit” hypothesis, suggesting a deficiency in                           
dopamine signalling leads to overeating and obesity. Although there are conflicting results in the                         
literature based on clinical studies, much of the data produced from animal studies seems to                           
support this hypothesis [Vucetic et al., 2010; Kenny et al., 2011; Ziauddeen et al., 2012].                           
However, my results do not support the reward deficit hypothesis. In fact, 18 weeks of HFD was                               
sufficient to induce a significantly higher body weight and fat mass compared to controls, but                           
showed an increase in D2R and TH mRNA expression in the VTA. This suggests an increase in                               
dopamine signalling with obesity, rather than a decrease. No changes in dopaminergic gene                       
expression were observed in the projection areas of the VTA with 18 weeks of HF feeding. These                               
differences were not observed after 12 weeks of feeding but more closely resembled those                         
observed after 6 weeks of HFD, showing changes in dopaminergic gene expression is not just a                             
gradual change in one direction, but shows differential expression according to the time spent                         
feeding on a HFD. This may be a result of producing a new set point for body weight. When                                   
considering the validity of the reward deficit hypothesis, overeating according to body weight                       





Obesity is a disease state which has exponentially increased over recent years due to a radical                             
change in diet and a reduction in the need to spend energy to achieve everyday tasks.                             
Epidemiological studies provide an important insight into the development and effects of obesity                       
within the population, but do not test directly the causes of obesity. Clinical studies present the                             
opportunity to assess directly measures of obesity, perhaps with an intervention. However,                     
clinical studies frequently require large numbers of subjects, due to the highly diverse genetic                         
variation within a population. It is very difficult to generate and maintain a cohort of subjects with                               
similar characteristics. With regards to weight cycling, this could include variation in the number                         
of cycles, the severity of weight loss and gain, the length of weight maintenance periods, types of                               
diets consumed and exercise. Interventional studies are difficult to perform in human studies,                       
due to the moral implications of perhaps inducing a harmful condition. Additionally, molecular                       
quantification is frequently limited to plasma analysis, which does not always indicate the                       
tissue­specific molecular changes underlying a phenotype. Biopsies can be taken, but are                     
extremely painful and cause long­term scarring, thereby reducing the willingness of subjects to                       
participate in the study. However, commonly used non­invasive clinical tools such as MRI, MRS                         
and PET can illustrate changes in a wide variety of experimental variables, including changes in                           
fat distribution, metabolites and neural activity.
However, to more definitively understand the mechanisms underlying obesity and metabolism,                   
other experimental models must be used. The most common animal model is the rodent, mostly                           
rats or mice. This thesis used C57Bl/6 mice exclusively, which are frequently used in obesity                           
experiments [Collins et al., 2004]. Additionally, the C57Bl/6 mouse was selected to have its                         
genome sequenced over other mouse models, adding to the popularity of this model for possible                           
genetic manipulation [Battey et al., 1999; Mouse Genome Sequencing Consortium, 2002].                   
Unfortunately, not only is the C57Bl/6 mice highly susceptible to developing obesity with                       
obesogenic diets, but also whilst maintained in control conditions. This results in control animals                         
also being unhealthy and leads to questions on the validity of results produced [Martin et al.,                             
2010]. Ideally, laboratory conditions should provide more space and stimulation for animals,                     
including different types of bedding that allow burrowing and exercise devices. In this regard it                           
has been shown that environmental enrichment alone can protect against obesity, with one                       
study suggesting this occurs by elevating brain BDNF [Cao et al., 2011]. However, due to costs                             
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and the desire to easily standardise between experiments, mice are left with little to do but feed                               
on unlimited food and perhaps overgroom or fight with their cage mates. This does not                           
accurately reflect the variety of environmental stimulation within a human population and adds to                         
the unsuitability of this model to study human obesity. As my study involved feeding animals for                             
extended periods of time, the effects of weight cycling or chronic obesity could certainly be                           
masked by the possible development of obese­traits in control animals. Additionally, using an                       
inbred strain reduces genetic variation, but does not accurately represent the large genetic                       
variation within the population. Similarly, it should be noted there is a large difference between                           
strains in response to HFD [Montgomery et al., 2013]. Even a very short­term stimulus like                           
fasting exhibit strain differences in liver adiposity [Nishikawa et al., 2008; Lin et al., 2005].                           
Perhaps a variety of strains should be assessed when studying obesity to fully comprehend the                           
variety of phenotypes and mechanisms that may exist within a human population [Svenson et al.,                           
2007].
Another major criticism towards obesity experiments, particularly in mouse studies, is the variety                       
of diets used to induce obesity. These include purified HFDs of various fat percentages, use of                             
different types of fat, use of “western diets” which consist of moderate fat and sugar, or                             
“cafeteria or junk food’ diets, usually consisting of a purified diet plus a number of “human” foods,                               
such as bacon, chocolate, cheese and cookies [Hansen et al., 2004; Johnson & Kenny, 2010].                           
Cafeteria diets more accurately represent an unhealthy human diet, but lack control over                       
macronutrient composition and introduce other elements to feeding, including variety and                   
novelty. Additionally, extreme HFDs, such as the 60% fat diet used in my studies, are commonly                             
used to rapidly induce obesity but represent an extreme that is unlikely to be observed in a                               
human population. In hindsight, a “western diet”, may have been more appropriate to use. It is                             
less extreme than a 60% fat diet (usually about 45% fat) and also includes a higher sucrose                               
content, which more accurately represents an unhealthy human diet without the added variety of                         
different types of food. It would be interesting to compare results between these two diets in the                               
future. Additionally, variation in the types of control diet used is frequently observed, with many                           
using a standard chow diet as a control. However, chow diets are usually unmatched to the test                               
diet used and frequently contain more fibre than test diets. A popular purified control diet for the                               
60% fat diet (TD.6414) is a 10% fat diet (TD.6416), but is relatively high in sucrose. This in turn                                   
could contribute to the development of metabolic dysfunction. My study used a reduced sucrose                         
content which matched the amount present in my test diet, whilst the rest of the carbohydrate                             
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content was provided by corn starch (TD.00806). However, even readily metabolised                   
carbohydrate could contribute to metabolic dysfunction, suggesting even though chow diet may                     
not perfectly match test diets for a number of macronutrients, it may be the most suitable diet for                                 
maintaining a healthy, lean animal. A good study to conduct would be to assess the effects of                               
commonly used control diets to determine which is most suitable for control animals for obesity                           
studies.
Although calorie content and it’s source was considered when choosing the diets used in my                           
study, the palatability of the diet was not. From my results assessing food intake, moving from a                               
HFD to a control diet showed a reduction in calorie content, as predicted. However, there was                             
also a reduction in food intake alone compared to control animals, showing a bigger reduction in                             
food intake than one might expect. This may be a result of the palatability of the diet. Not only                                   
would this reduce food intake, but may be unpleasant and impact upon taste and reward                           
signalling in the brain separate from the reduction in calorie intake. A taste preference test would                             
be able to determine the palatability of the diet and would allow this variable to be taken into                                 
account when considering the results.
A study by Domingos et al. controlled for this variable by comparing the rewarding properties of                             
sugar as a nutrient separate from it’s taste element by using an artificial sweetener [Domingos et                             
al., 2011]. However, it would be difficult to perform a long­term study that is able to control for                                 
changes in the rewarding properties of diet taste, particularly when fat is the variable in question.                             
Currently, an artificial fat taste that has no calorie content is not available, compared to artificial                             
sweeteners such as sucralose or aspartame. Therefore, it is difficult to separate the fat calorie                           
from the fat taste.
Another variation that can be introduced in animal studies is the age at which the experiment                             
starts. The effects of HFD exposure during pregnancy has shown long­term changes in offspring                         
which favour the development of obesity and metabolic syndrome in later life. Although the                         
nervous system of the mouse develops rapidly in early life, studies in mice have shown                           
exposure to a HFD at weaning for only a week can influence adult diet preference and increased                               
NAc expression of DARPP­32 and ΔFosB [Teegarden et al., 2009]. Similarly, exposure to                       
sucrose or sweet food during the first week after weaning increased preference for these foods                           
in later life [Sato et al., 1991; Silveira et al., 2008]. Early exposure to nicotine resulted in a                                 
decrease in the reward response to cocaine in adult life [Kelley & Rowan, 2004]. Human studies                             
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have shown children exposed to different dietary stimuli can alter preference in later years [Kern                           
et al., 1993; Liam & Mannella, 2002]. Therefore, a large number of studies which begin feeding                             
soon after weaning could be introducing early life programming effects [List et al., 2012; Vucetic                           
et al., 2012]. My study started with mice aged 8­10 weeks, the equivalent of late adolescence in                               
humans. Perhaps a more suitable age to start feeding experiments would be at 3 months of age,                               
which is equivalent to mature adults, thereby being a more precise model of adulthood obesity                           
[Harrison Lab, The Jackson Laboratory, 2011]. I started a study to assess the effect of 18 weeks                               
of HFD from weaning at 3 weeks of age to compare to my results feeding mice for 18 weeks                                   
from 8 weeks of age. Unfortunately, a large number of mice fed a control diet from weaning                               
showed liver abnormalities, which resulted in growth retardation. I would like to repeat this                         
experiment to assess the effects of HF feeding from weaning compared to young and mature                           
adult HF feeding, although the reasons for the growth abnormalities need to be determined first.                           
Perhaps the purified control diet I used was not suitable for feeding mice from early age.
Although MRI is recognised as a useful tool for longitudinal studies, the stress caused by the                             
procedure through use of anaesthesia and fasting may influence the long­term results of the                         
experiment. Initially, the same animals used for molecular analysis had undergone at least one                         
procedure which required fasting (MRI or IPGTT). In fact, one could say undergoing an overnight                           
fast, the equivalent of foregoing food during the day for humans, could introduce a mini weight                             
cycle. Assessing multiple characteristics of a phenotype is obviously the optimal condition if the                         
act of testing had a minimal effect on the individual, and more closely mirrors experiments                           
conducted in the the clinic. Additionally short­term interventions, such as my rapid weight change                         
study, would be seriously affected by an overnight fast occurring at the time of a diet swap,                               
introducing more variability within the results. Therefore for this study, separate groups of mice                         
were used for each experiment. However this means a change in fat distribution could not be                             
directly correlated to neural changes, as these procedures would occur in separate animals.                       
Instead, separate observations in the same model were collated to produce a story. Due to the                             
reduced variability of using an inbred strain, an assumption of genetic similarity is possible to a                             
certain extent, unlike in human studies. However, even mice age­ and weight­matched upon                       
arrival can show differences in glucose tolerance, whole body and liver adiposity, as observed in                           
our lab. For this reason, more recent studies in our group have adopted assessing adiposity at                             
baseline and measuring the the difference over time, rather than taking endpoint scans. This                         
considers the differences in starting measurements. In the future, I would use separate batches                         
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of animals for each procedure, thereby reducing the possible effects of fasting and stress on                           
other parameters.
As stated above, fasting animals and performing measurements repeatedly would probably                   
induce stress. Similarly, swapping diets could also induce stress, which could induce long­term                       
changes, particularly if the diet swaps are frequent. To test the effects of stress on both                             
changing diets and performing phenotypic measurements, stress signals could be measured in                     
the blood or feces, such as corticosterone or nucleic acid metabolites in the urine [Kalliokoski et                             
al., 2013].
The majority of statistical analyses in this thesis were conducted using t­tests or ANOVAs. This                           
type of statistical test relies heavily on the test design and needs to be considered when drafting                               
a potential experiment to fully determine the variable being measured and controlling for it                         
accordingly, such as age­matching or early life programming.
This sort of analysis is common in studies involving animals, where the tests can be highly                             
restrictive and interventional. This differs from clinical studies, which more frequently rely on                       
correlation analysis. This is understandable given the nature of clinical studies compared to                       
animal studies from an ethical perspective. However, as shown in my study assessing the                         
relationship between phenotype and distance ran on a treadmill, it was difficult to delineate a                           
meaningful result from this analysis and required a large number of subjects to reduce the                           
variation within groups.
On one hand, this is a useful test in showing that my stimulus was very much overwhelmed by                                 
variation within my group. It also calls into question whether there is real correlation when a very                               
large sample size is required to dampen this variation, as is frequently required in clinical trials.                             
However, it is also an interesting result in itself and highlights the fact that obesity and diet                               
studies produce highly variable results due to obesity being a whole system condition.
To test the relationship between diet swaps and length of swaps, a mathematical model could                           
be developed to produce a list of scenarios that would produce specific phenotypes. Using this                           
sort of model, it would be interesting to see how predictable phenotypic changes are in response                             
to diet swapping variation. For example, you could predict the feeding time at which fatty liver                             
develops and how this condition would be affected by the number of diet swaps.
Finally, although rodent models have proved to be useful tools in delineating the mechanisms                         
underlying obesity, it is difficult to ascribe distinctly human behaviours to a mouse, with particular                           
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reference to the study of reward, addiction and cognition. Other disparities between human and                         
animal models include the assessment of Alzheimer's disease, psychiatric disorders and                   
developmental disorders [Preuss, 2006; Lynch, 2009; Chadman et al., 2009; Craley, 2012]. A                       
recent review assessing the reward deficit hypothesis suggests the disparity between animal                     
data and clinical studies results is partially due to the rigid and extreme diet regimes used for                               
animal studies of obesity and reward [Ziauddeen et al., 2012]. Therefore, results produced from                         
these studies should be interpreted with caution.
{6.9} Future work
My experiments and other work have indicated the possible effects of cycle time on determining                           
the long­term effects on affecting long­term health [Barbosa­da­Silva et al., 2012; Parekh et al.,                         
1998; List et al., 2012]. I would like to expand on my single weight cycle consisting of 6 weeks                                   
interval to further cycles. Further studies on cycle interval could determine how long HF feeding                           
can be tolerated before weight loss no longer reverses the detrimental effects of HFD.
Having observed differences in lipid accumulation in the liver and alterations in fat distribution, the                           
next step would be to assess the molecular changes that may underlie this phenotype. This                           
includes assessing changes in lipolysis and lipogenesis in fat depots, which may indicate                       
depot­specific rates of lipid turnover that contribute towards altered fat distribution. I would like to                           
assess changes in gene and protein expression in markers involved with lipogenesis, lipolysis                       
and fatty acid oxidation in the liver and WAT depots [Westerbacka et al., 2007; Kohjima et al.,                               
2007; Palou et al., 2009]. Changes in the rate at which the liver is able to metabolise excess fatty                                   
acids, either caused by an increase in dietary fat or a rapid release into the circulation as a result                                   
of adipose tissue breakdown in response to weight loss, could differentially alter lipid deposition                         
in the liver and offer an explanation to altered body composition with weight cycling.
Insulin resistance is a common problem associated with obesity and can contribute to a blunted                           
response by organs, such as the liver and adipose tissue, to effectively respond to the energy                             
state of the body. Changes in the insulin signalling pathway could be determined by assessing                           
the IRS proteins, the PI3K pathway and the ERK1/2 pathway [Samuel & Shulman, 2012].                         
Additionally, leptin resistance can also exacerbate obesity. A change in expression in a number                         
of intracellular markers have been suggested to induce leptin resistance [Myers et al., 2008]. It                           




RT­qPCR has proved itself to be useful tool in assessing changes in gene expression in a                             
number of different tissues and biological models. However, there is a danger of making                         
definitive statements on the end results of gene expression without actually assessing them.                       
Previous work has shown alterations in gene expression can occur without concurrent changes                       
in protein expression, indicating gene expression does not always equate with changes in the                         
product [Vogel & Marcotte, 2012]. For this reason, protein analysis should be performed to                         
assess the effects of altered gene expression. A gold standard of neural research in rodent                           
models is to use immunohistochemistry. This is more time consuming than RT­qPCR and                       
usually only allows the assessment of one protein per slice, where a colocalisation of your                           
protein of interest and a marker of neuronal activation (commonly cFos) indicates the increase                         
protein expression in response to a stimulus. An added advantage of using a histological                         
technique is the ability to differentiate with ease between nuclei in the brain, such as the arcuate                               
nucleus or the shell and core of the NAc. This is possible with RT­qPCR, but requires either                               
micropuncture in fresh tissue or laser capture dissection in fixed tissue, both of which require                           
considerable skill and time. Another useful tool to assess changes in neurotransmitter                     
concentration directly is using microdialysis and chromatography [de Leeuw van Weenen et al.,                       
2009; Narayanaswami et al., 2012]. This technique also requires considerable skill, but does                       
yield data accurately reflecting protein concentration in vivo. Alternatively, neuropeptide secretion                   
can be assessed by using neural explants ex vivo [Enriori et al., 2007].
Recent advances have shown epigenetic modifications have an important role in altering gene                       
expression [Slomko et al., 2012; Youngson & Morris, 2013]. Although epigenetic research with                       
regards to obesity is still in its infancy, several groups have indicated changes in methylation in                             
response to both early life programming and adult HF feeding [Vucetic et al., 2010b; Sandovici et                             
al., 2011; Vucetic et al., 2012]. It would be interesting to assess how flexible these epigenetic                             
modifications are once the body has been exposed to HFD, or whether a persistent change in                             
methylation of various genes may contribute to weight gain.
Changes in behaviour in response to weight cycling and weight change were assessed in this                           
study by assessing motor activity in CLAMS cages and maximal exercise using forced exercise                         
on a treadmill. Long­term changes in spontaneous activity would be useful to study with changes                           
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in body weight, particularly if assessed in a normal home cage rather than the much reduced                             
size of the CLAMS cage. Other future work I would like to undertake would assess changes in                               
diet preference with weight cycling or weight loss. This could correlate well with clinical studies                           
showing increased preference for different types of food depending on energy state, which in                         
turn could cause the selection of food which favours weight regain [Doucet et al., 2000;                           
Cameron et al., 2008; Goldstone et al., 2009; Sumithran et al., 2011].
{6.10} Conclusion
In this thesis, I showed swapping to a control diet was an effective method of reducing body                               
weight and appears to be mediated by a reduction in food intake. Similarly, a 60% kcal fat diet                                 
was sufficient in increasing body weight after an initial increase in food intake.
Total adiposity was shown to be highly responsive to diet swapping. However, weight cycling                         
appeared to alter fat distribution, where cycling increased internal adiposity, whilst chronic HFD                       
resulted in an increase in liver adiposity.
Glucose tolerance was similarly affected by HF feeding, however no difference in glucose                       
tolerance was observed between groups after an extended period of feeding. This may be                         
related to an extended fasting time used for the test.
Indirect calorimetry did not show any significant differences in energy production. Rearing activity                       
appeared to increase when feeding on a control diet, which correlated with an increase in water                             
intake. However, differences in motor activity were not observed after extended periods of                       
feeding. Forced exercise showed an increase in fat mass reduced endurance capacity with no                         
additional effect of weight cycling.
Analysis of metabolic hormones appeared to fluctuate with diet, again with no additional effect of                           
weight cycling.
Neural gene expression showed rapid weight change had profound effects on NPY, AgRP and                         
POMC mRNA expression to counteract the effects of weight fluctuation. These changes                     
became less pronounced with prolonged feeding, indeed showing no differences in expression                     
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after 18 weeks of feeding. This may indicate these neurons become resistant to hormone                         
signals of satiety. Changes in dopaminergic gene expression did not show a consistent pattern                         
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